



---

## Uploaded to VFC Website

▶▶ **November 2012** ◀◀

---

This Document has been provided to you courtesy of Veterans-For-Change!

Feel free to pass to any veteran who might be able to use this information!

For thousands more files like this and hundreds of links to useful information, and hundreds of "Frequently Asked Questions, please go to:

[Veterans-For-Change](#)

---

*Veterans-For-Change is a 501(c)(3) Non-Profit Corporation  
Tax ID #27-3820181*

***If Veteran's don't help Veteran's, who will?***

We appreciate all donations to continue to provide information and services to Veterans and their families.

[https://www.paypal.com/cgi-bin/webscr?cmd=\\_s-xclick&hosted\\_button\\_id=WGT2M5UTB9A78](https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=WGT2M5UTB9A78)

---

**Note:**

VFC is not liable for source information in this document, it is merely provided as a courtesy to our members.



Item Number 05513



**Not Scanned**

Author

**Corporate Author** U.S. Environmental Protection Agency (EPA), Office of

**Report/Article Title** Health Assessment Document for Polychlorinated  
Dibenzo-p-Dioxins: Final Report

**Journal/Book Title**

**Year** 1985

**Month/Day** September 1

Color



**Number of Images** 612

**Description Notes**

Research and Development



# Health Assessment Document for Polychlorinated Dibenzo-p-Dioxins



Health Assessment Document  
for  
**Polychlorinated  
Dibenzo-p-Dioxins**

U.S. ENVIRONMENTAL PROTECTION AGENCY  
Office of **Research** and Development  
Office of Health and Environmental Assessment  
Environmental Criteria and Assessment Office  
Cincinnati, **Ohio** 45268

#### NOTICE

**This** document has been reviewed in accordance **with** U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute **endorsement** or recommendation for use.

## PREFACE

The Office of Health and **Environmental** Assessment has prepared **this Health Assessment Document** on **polychlorinated** dibenzo-2-dioxins at the request of the Office of **Air** Quality Planning and Standards.

In the development of **this** assessment document, the scientific literature has been inventoried, key studies have been evaluated, and summary and conclusions have been prepared such that the **toxicity** of polychlorinated **dibenzo-p-dioxins** is **qualitatively** and where possible, quantitatively, identified. Observed effect levels and dose-response relationships are discussed where appropriate in order to identify the critical effect and to place adverse health responses in perspective **with** observed environmental levels.

**This** document was reviewed by a panel of expert scientists during the peer review workshop held at the Cincinnati Convention/Exposition Center, Cincinnati, OH, on July 27, 28 and 29, 1983. The Environmental Health Committee and the Environmental Effects, Fate and Transport Committee of the U.S. **EPA's** Science Advisory Board **independently** reviewed the document in a public session.

## AUTHORS, CONTRIBUTORS AND REVIEWERS

The EPA Office of Health and Environmental Assessment (OHEA) was responsible for the preparation of **this** draft health assessment document. The OHEA Environmental Criteria and Assessment Office (**ECAO-Cincinnati**) had overall responsibility for coordination and direction of the document preparation and production effort (Dr. Debdas **Mukerjee**, Project Manager, Dr. **Jerry F. Stara**, Director, **ECAO-Cincinnati**). The following individuals contributed substantially to portions of various chapters of the document and their assistance is greatly appreciated.

Dr. **Dipak K. Basu**  
**Life** and Environmental  
Sciences Division  
Syracuse Research Corporation  
Syracuse, NY

Dr. Debdas Mukerjee  
Environmental Criteria and  
Assessment Office  
U.S. **Environmental** Protection Agency  
Cincinnati, OH

Dr. **Michael W. Neal**  
**Life** and Environmental  
Sciences Division  
Syracuse Research Corporation  
**Syracuse, NY**

Dr. James R. Olson  
Department of Pharmacology  
and Therapeutics  
School of Medicine  
State University of New York  
at Buffalo  
Buffalo, NY

Dr. Shane Que Hee  
**Kettering** Laboratories  
Department of Environmental Health  
University of Cincinnati Medical School  
Cincinnati, OH

Dr. Stephen H. Safe  
Department of Physiology and  
Pharmacology  
College of Veterinary Medicine  
Texas **A&M** University  
**College Station, TX**

Dr. Marvin A. **Schneiderman**  
Bethesda, MD

The OHEA Carcinogen Assessment Group (CAG) was responsible for preparation of the sections on **carcinogenicity**. Participating members of CAG are listed below and the authors for the Carcinogenicity Chapter are indicated by an asterisk.

Roy E. Albert, M.D. (Chairman)  
Elizabeth L. Anderson, Ph.D.  
Larry D. Anderson, Ph.D.  
Steven Bayard, Ph.D.\*  
David L. **Bayliss**, M.S.\*  
Chao W. Chen, Ph.D.  
Herman J. Glbb, B.S., **M.P.H.**  
Bernard H. **Haberman**, D.V.M., M.S.

**Charalingayya B. Hiremath, Ph.D.\***  
James W. Holder, Ph.D.  
Robert E. McGaughy, Ph.D.  
Jean C. **Parker**, Ph.D.  
**Charles H. Rls**, M.S., **P.E.**  
Dharm V. Singh, D.V.M., Ph.D.  
Todd W. Thorslund, Sc.D.

The following Individuals were asked to review **this** document and earlier drafts of **this** document:

|                                       |   |
|---------------------------------------|---|
| <b>Dr.</b> Bernard H. <b>Haberman</b> | U.S. EPA Carcinogen Assessment Group              |
| Or. Franklin L. <b>Mink</b>           | U.S. EPA ECAO-Cincinnati                          |
| Dr. Charles H. <b>Nauman</b>          | U.S. EPA Exposure Assessment Group                |
| Dr. Sheila L. <b>Rosenthal</b>        | U.S. EPA Reproductive Effects Assessment<br>Group |
| Dr. William E. Pepelko                | U.S. EPA <b>ECAO-Cincinnati</b>                   |
| <b>W.</b> Bruce <b>Petrano</b>        | U.S. EPA ECAO-Cincinnati                          |
| David J. <b>Reisman</b>               | U.S. EPA ECAO-Cincinnati                          |
| John L. <b>Schaum</b>                 | U.S. EPA Exposure Assessment Group                |

The following members of the ECAO-Cincinnati Technical Services Staff were responsible for document production:

|                          |                        |
|--------------------------|------------------------|
| Patricia A. <b>Daunt</b> | Judith A. <b>Olsen</b> |
| <b>Erma</b> R. Durden    | Bette L. Zwyer         |



POLYCHLORINATED **DIBENZO-p-DIOXINS** PEER **REVIEW** PANEL MEMBERS  
July 27, 28 and 29, 1983 Cincinnati, Ohio

Co-Chairmen: Dr. Debdas **Mukerjee**, ECAO-Cincinnati  
Dr. Jerry F. Stara, ECAO-Cincinnati

MEMBERS

Dr. Roy Albert  
Institute of Environmental Medicine  
New York University Medical Center

Dr. Donald G. Barnes  
Office of Pesticides and Toxic  
Substances  
U.S. Environmental Protection Agency

Dr. **K.** Diane Courtney  
Health Effects Research Laboratory  
Research **Triangle** Park  
U.S. Environmental Protection Agency

Dr. Frederick Coulston  
White Sands Research Center

Dr. David Firestone  
Food and Drug Administration

Dr. S. Garattini  
Institute di Recerche  
**Farmacologic "Mario Negri"**  
Milan, Italy

Dr. Dolores Graham  
Health Effects Research Laboratory  
Research Triangle Park  
U.S. Environmental Protection Agency

Dr. Richard **Griesemer**  
Biology Division  
Oak Ridge National Laboratory

Dr. Lennart Hardell  
University Hospital  
Umea, Sweden

Dr. Robert Harless  
Environmental Monitoring Systems  
Laboratory, Research Triangle Park  
U.S. Environmental Protection Agency

Dr. Rolf Hartung  
University of Michigan

Dr. **Alistair W.M.** Hay  
University of Leeds  
Leeds, United Kingdom

Dr. Otto **Hutzinger**  
University of Amsterdam  
Amsterdam, The Netherlands

Dr. R.D. **Kimbrough**  
Centers for Disease Control

Dr. Richard J. **Kociba**  
Dow Chemical Company

Dr. Frederick **Kopfler**  
Health Effects Research Laboratory  
Cincinnati  
U.S. **Environmental** Protection Agency

Dr. Marvin Legator  
University of Texas Medical Branch

Dr. Ruth **Lillis**  
Mt. Sinai School of Medicine

Dr. Prab D. **Lotlikar**  
Temple University School of Medicine

**Dr. Fumio Matsumura**  
Michigan State University

Dr. E. McConnell  
National Institute of Environmental  
Health Sciences

Dr. **W.P.** McNulty  
Oregon Regional Primate Research  
Center

Dr. Robert **Miller**  
National Cancer Institute

Dr. **James** R. Olson  
State University of New York  
at Buffalo

Dr. Francesco Pocchiarl  
**Instituto Super iore dl Sanita**  
**Rome, Italy**

Dr. Shane Que Hee  
University of Cincinnati **Medical**  
Center

Dr. **Christoffer** Rappe  
University of **Umea**, Sweden

Dr. Stephen H. Safe  
Texas **A&M** University

Dr. Marvin **Schneiderman**  
Environmental Law Institute

Larry **Silbart**  
National Wildlife Federation

Dr. Ellen **Silbergeld**  
Environmental Defense Fund

Dr. David Stalling  
Columbia National Fisheries Research  
Laboratory

Dr. Lewis **Thibodeaux**  
University of Arkansas

Dr. Thomas **Tiernan**  
Wright State University

SCIENCE ADVISORY BOARD

**Environmental** Health Committee

Chairmen: Dr. Herschel E. Griffin, San Diego State **University**, San Diego, CA

MEMBERS

Dr. Seymour Abrahamson  
University of Wisconsin  
Madison, **WI**

Dr. Marvin Kuschner  
State University of New York  
Stony Brook, NY

Dr. Morton Corn  
The John Hopkins University  
Baltimore, MD

Dr. D. Warner North  
Decision Focus Inc.  
Los Altos, CA

Dr. Ronald D. Hood  
University of Alabama  
Tuscaloosa, AL

Dr. Bernard Weiss  
University of Rochester  
Rochester, NY

**Dr. John Doull**  
University of Kansas Medical Center  
Kansas **City**, KS

Dr. Ronald Wyzga  
Electric Power Institute  
Palo Alto, CA

COUNSULTANT

**Dr. Stephen H. Safe**  
Texas **A&M** University  
College Station, TX

**Dr. William Lowrance**  
Rockefeller University  
New **York**, NY

Environmental Effects, Transport and Fate **Committee**, Dioxin Subcommittee

Dr. Robert Huggett  
Institute of Marine Science  
College of William and Mary  
Gloucester Point, VA

Dr. John Laseter  
**Enviro-Health** Systems, Inc.  
New Orleans, LA

## TABLE OF CONTENTS

|  | Page       |
|--|------------|
| 1. INTRODUCTION . . . . .  | 1-1        |
| 2. SUMMARY <b>AND</b> CONCLUSIONS . . . . .  | 2-1        |
| 2.1. SUMMARY . . . . .   | 2-1        |
| 2.2. CONCLUSIONS . . . . .   | 2-7        |
| 2.3. <b>NEEDS</b> FOR FUTURE RESEARCH . . . . .  | 2-8        |
| 3. PHYSICAL AND CHEMICAL PROPERTIES/ANALYTICAL METHODOLOGY . . . . .                                       | 3-1        |
| 3.1. INTRODUCTION . . . . .  | 3-1        |
| 3.2. PHYSICAL AND CHEMICAL PROPERTIES . . . . .  | <b>3-1</b> |
| 3.2.1. Chemical Formula and Synonyms . . . . .   | <b>3-1</b> |
| 3.2.2. Physical Properties . . . . .   | 3-3        |
| 3.2.3. Chemical Properties . . . . .   | 3-5        |
| 3.3. ANALYTICAL METHODOLOGY . . . . .  | <b>3-5</b> |
| <b>3.3.1. General</b> Procedure for the <b>Analysis</b> of PCDDs . . . . .                                 | 3-7        |
| 3.3.2. Analysis of PCDDs in Specific Environmental Media . . . . .   | 3-20       |
| 3.3.3. Bioanalysis of PCDDs . . . . .  | 3-30       |
| 3.3.4. Critique of Sampling and Chemical Analysis . . . . .  | 3-30       |
| 3.4. SUMMARY . . . . .   | 3-34       |
| 4. <b>PRODUCTION, USE, SYNTHESIS, ENVIRONMENTAL SOURCES AND ENVIRONMENTAL LEVELS.</b> . . . .              | 4-1        |
| <b>4.1. PRODUCTION AND USE.</b> . . . .  | <b>4-1</b> |
| 4.2. SYNTHESIS . . . . .   | <b>4-1</b> |
| 4.2.1. Reaction of <b>Dichlorocatechol</b> Salts with <b>1,2,4,5-Tetrachlorobenzenes</b> in DMSO . . . . . | 4-1        |
| 4.2.2. Substitution Reaction . . . . .   | 4-2        |
| 4.2.3. <b>Photoproduction</b> . . . . .  | 4-2        |
| 4.2.4. <b>Ullmann</b> Condensation Reactions . . . . .   | 4-2        |
| 4.2.5. <b>Pyrolysis</b> of <b>Chlorophenates</b> . . . . .   | 4-4        |
| 4.2.6. Conversion Through Nitration . . . . .  | 4-4        |
| 4.3. ENVIRONMENTAL SOURCES . . . . .   | 4-5        |
| <b>4.3.1. Manufacturing Processes.</b> . . . .   | 4-5        |
| 4.3.2. <b>Municipal</b> Incinerators . . . . .   | 4-14       |
| 4.3.3. Other Combustion Processes . . . . .  | 4-15       |
| 4.3.4. Chemical Dump Sites . . . . .   | 4-17       |
| 4.3.5. Photochemical Process . . . . .   | 4-17       |
| 4.4. RELATIONSHIP BETWEEN SOURCES AND CONTAMINATION IN ENVIRONMENTAL MATRICES . . . . .                    | 4-18       |

TABLE OF CONTENTS (cont.)

|  | <u>Page</u> |
|--|-------------|
| 4.5. ENVIRONMENTAL LEVELS . . . . .                                    | 4-18        |
| 4.5.1. Water . . . . .   | 4-20        |
| 4.5.2. <b>Air</b> . . . . .  | 4-21        |
| 4.5.3. <b>Soil</b> . . . . .   | 4-25        |
| 4.5.4. Foods and Biological Samples . . . . .                          | 4-28        |
| 4.6. EXPOSURE . . . . .  | 4-32        |
| 4.7. SUMMARY . . . . .   | 4-38        |
| 5. ENVIRONMENTAL FATE AND TRANSPORT PROCESSES . . . . .                | 5-1         |
| 5.1. FATE . . . . .  | 5-1         |
| 5.1.1. Water . . . . .   | 5-1         |
| 5.1.2. Air . . . . .   | 5-6         |
| 5.1.3. <b>Soil</b> . . . . .   | 5-7         |
| 5.1.4. Food . . . . .  | 5-11        |
| 5.2. TRANSPORT . . . . .   | 5-12        |
| 5.2.1. Water . . . . .   | 5-12        |
| 5.2.2. Air . . . . .   | 5-13        |
| 5.2.3. <b>Soil</b> . . . . .   | 5-14        |
| 5.3. BIOACCUMULATION/BIOCONCENTRATION . . . . .                        | 5-15        |
| 5.4. SUMMARY . . . . .   | 5-18        |
| 6. ECOLOGICAL EFFECTS . . . . .  | 6-1         |
| 6.1. EFFECTS ON ORGANISMS . . . . .                                    | 6-1         |
| <b>6.1.1. Aquatic Life Toxicology</b> . . . . .                        | 6-1         |
| 6.2. TISSUE RESIDUES . . . . .   | 6-8         |
| 6.3. ECOSYSTEM EFFECTS . . . . .                                       | 6-14        |
| 6.4. SUMMARY . . . . .   | 6-19        |
| 7. COMPOUND DISPOSITION AND RELEVANT <b>PHARMACOKINETICS</b> . . . . . | 7-1         |
| 7.1. ABSORPTION . . . . .  | 7-1         |
| 7.1.1. Absorption from the Gastrointestinal Tract . . . . .            | 7-1         |
| 7.1.2. Absorption Through the <b>Skin</b> . . . . .                    | 7-6         |
| 7.2. DISTRIBUTION . . . . .  | 7-7         |
| 7.3. METABOLISM . . . . .  | 7-12        |
| 7.4. ELIMINATION . . . . .   | 7-16        |
| 7.5. SUMMARY . . . . .   | 7-20        |

TABLE OF CONTENTS (cont.)

|   | <u>Page</u> |
|---|-------------|
| 8. TOXICOLOGY: ACUTE, SUBCHRONIC AND CHRONIC . . . . .                                  | 8-1         |
| <b>8.1. EXPERIMENTAL ANIMALS.</b> . . . . .   | 8-1         |
| <b>8.1.1. Acute.</b> . . . . .  | 8-1         |
| <b>8.1.2. Subchronic</b> . . . . .  | 8-44        |
| 8.1.3. Chronic. . . . .   | 8-50        |
| 8.2. HUMAN. . . . .   | 8-60        |
| 8.2.1. Acute Exposure . . . . .   | 8-60        |
| 8.2.2. Chronic Studies. . . . .   | 8-65        |
| 8.3. MECHANISM OF TOXICITY. . . . .   | 8-69        |
| <b>8.3.1. Receptor-Mediated Toxicity.</b> . . . . .                                     | <b>8-70</b> |
| 8.3.2. Metabolism . . . . .   | 8-78        |
| 8.3.3. Vitamin A Depletion. . . . .   | 8-80        |
| 8.3.4. <b>Lipid</b> Peroxidation . . . . .  | 8-81        |
| 8.3.5. Endocrine Imbalance. . . . .   | 8-82        |
| 8.4. SUMMARY. . . . .   | 8-84        |
| 8.4.1. Experimental Animal Data. . . . .  | 8-84        |
| 8.4.2. Human Data. . . . .  | 8-88        |
| 8.4.3. Mechanisms of <b>Toxicity</b> . . . . .  | 8-88        |
| 9. TERATOGENICITY AND OTHER REPRODUCTIVE EFFECTS. . . . .                               | 9-1         |
| 9.1. STUDIES ON EXPERIMENTAL MAMMALS. . . . .   | 9-1         |
| 9.1.1. <b>2,3,7,8-TCDD</b> Administered as a Contaminant of<br>Other Chemicals. . . . . | 9-1         |
| 9.1.2. 2,3,7,8-TCDD Studies <b>in Mice</b> . . . . .                                    | 9-6         |
| 9.1.3. 2,3,7,8-TCDD Studies in Rats. . . . .  | 9-13        |
| 9.1.4. 2,3,7,8-TCDD Studies in Rabbits and Ferrets . . . . .                            | 9-18        |
| <b>9.1.5.</b> 2,3,7,8-TCDD Studies in <b>Nonhuman</b> Primates. . . . .                 | 9-20        |
| 9.1.6. Studies in Chickens. . . . .   | 9-22        |
| 9.1.7. Studies of the <b>Teratogenic</b> and Reproductive<br>Effects of HxCDD. . . . .  | 9-23        |
| 9.2. STUDIES ON HUMAN POPULATIONS. . . . .  | 9-23        |
| 9.3. OTHER REPRODUCTIVE EFFECTS. . . . .  | 9-34        |
| 9.4. SUMMARY. . . . .   | 9-35        |

TABLE OF CONTENTS (cont.)

|   | Page          |
|---|---------------|
| 10. MUTAGENICITY AND OTHER INDICATIONS OF GENOTOXICITY . . . . .  | 10-1          |
| 10.1. RELEVANT STUDIES. . . . .   | 10-1          |
| <b>10.1.1. Assays In Microorganisms.</b> . . . . .  | 10-1          |
| 10.1.2. Interactions <b>with</b> Nucleic Acids. . . . .   | 10-7          |
| 10.1.3. <b>Cytogenetic</b> Effects of <b>2,3,7,8-TCDD</b> . . . . .   | 10-8          |
| 10.2. SUMMARY. . . . .  | 10-13         |
| 11. CARCINOGENICITY. . . . .  | 11-1          |
| <b>11.1. ANIMAL STUDIES.</b> . . . . .  | 11-1          |
| 11.1.1. Studies Using 2,3,7,8-TCDD. . . . .   | 11-1          |
| <b>11.1.2. Studies Using HxCDD.</b> . . . . .   | 11-39         |
| 11.1.3. Summary of Animal <b>Carcinogenicity</b> . . . . .  | 11-51         |
| 11.2. CASE REPORTS AND EPIDEMIOLOGICAL STUDIES. . . . .   | 11-60         |
| 11.2.1. Case Reports. . . . .   | 11-60         |
| 11.2.2. Epidemiologic Studies. . . . .  | 11-64         |
| 11.2.3. Summary of Case Reports and <b>Epidemiologic</b> Studies . . . . .  | 11-108        |
| <b>11.3. QUANTITATIVE ESTIMATION OF RISKS OF EXPOSURE TO</b><br><b>2,3,7,8-TCDD and HxCDDs.</b> . . . . .   | 11-109        |
| 11.3.1. Introduction . . . . .  | 11-109        |
| 11.3.2. Procedures for the Determination of Incremental<br><b>Unit</b> from Animal Data and Description of the<br><b>Low-Dose</b> Animal Extrapolation Model. . . . . | 11-110        |
| 11.3.3. Selection of Data. . . . .  | <b>11-112</b> |
| 11.3.4. Calculation of Human Equivalent Dosages for<br><b>Animal-to-Man</b> Extrapolation . . . . .   | 11-112        |
| 11.3.5. Alternative Methodological Approaches . . . . .   | 11-113        |
| 11.3.6. Interpretation of Quantitative Estimates. . . . .   | 11-114        |
| 11.3.7. Incremental <b>Unit Risk</b> Estimates for 2,3,7,8-TCDD<br><b>via</b> the <b>Oral</b> and Inhalation Routes. . . . .  | 11-115        |
| 11.3.8. Incremental <b>Unit Risk</b> Estimates for HxCDDs<br><b>(1,2,3,6,7,8 and 1,2,3,7,8,9) via</b> the Oral<br>and Inhalation Routes. . . . .                      | 11-119        |
| 11.3.9. Relative Potency. . . . .   | <b>11-125</b> |
| 11.4. SUMMARY AND CONCLUSIONS. . . . .  | 11-131        |
| <b>11.4.1. Summary.</b> . . . . .   | <b>11-131</b> |
| 11.4.2. Conclusions. . . . .  | 11-138        |

TABLE OF CONTENTS (cont.)

|  | <u>Page</u>  |
|--|--------------|
| 12. <b>SYNERGISM AND ANTAGONISM</b> . . . . .                      | 12-1         |
| 12.1. CHEMICAL CARCINOGENS . . . . .                               | <b>12-1</b>  |
| 12.2. NON-CARCINOGENIC CHEMICALS . . . . .                         | 12-1         |
| 12.3. SUMMARY . . . . .  | 12-2         |
| 13. REGULATIONS AND STANDARDS . . . . .                            | 13-1         |
| 13.1. WATER . . . . .  | 13-1         |
| 13.2. AIR . . . . .  | 13-1         |
| 13.3. FOOD . . . . .   | 13-1         |
| 13.4. SUMMARY . . . . .  | 13-2         |
| 14. EFFECTS OF MAJOR CONCERN AND HEALTH HAZARD ASSESSMENT. . . . . | 14-1         |
| 14.1. PRINCIPAL EFFECTS. . . . .                                   | 14-2         |
| <b>14.1.1. Toxicity</b> . . . . .                                  | <b>14-2</b>  |
| <b>14.1.2. Mutagenicity</b> . . . . .                              | <b>14-7</b>  |
| 14.2. SENSITIVE POPULATIONS. . . . .                               | 14-7         |
| 14.3. FACTORS INFLUENCING HEALTH HAZARD ASSESSMENT. . . . .        | 14-8         |
| <b>14.4. QUALITATIVE HEALTH HAZARD ASSESSMENT.</b> . . . . .       | <b>14-9</b>  |
| 14.4.1. Animal Toxicity Data . . . . .                             | 14-10        |
| <b>14.4.2. Animal Carcinogenicity</b> . . . . .                    | <b>14-11</b> |
| 15. <b>REFERENCES</b> . . . . .                                    | 15-1         |
| APPENDIX A . . . . .   | <b>A-1</b>   |
| APPENDIX B . . . . .   | <b>B-1</b>   |
| APPENDIX C . . . . .   | <b>C-1</b>   |
| APPENDIX D . . . . .   | <b>D-1</b>   |



LIST OF TABLES

| <u>No.</u> | <u>Title</u>  | <u>Page</u> |
|------------|---|-------------|
| 3-1        | Physical Properties of a Few Selected <b>Polychlorinated Dioxins</b> . . . . .  | 3-4         |
| 3-2        | A Few Estimated Physical Parameters of Chlorinated <b>Dibenzo-p-dioxins</b> . . . . .   | 3-6         |
| 3-3        | Potential Interferences in the Determination of TCDDs at <b>m/e</b> Values of 319.8966 and 321.8936. . . . .  | 3-12        |
| 3-4        | Some Packed and Capillary Columns Used for the Analysis of PCDDs. . . . .   | 3-14        |
| 3-5        | The Detection Limit, Resolution and Ions Monitored by a Few Mass <b>Spectrometric</b> Systems for the Determination of TCDDs . . .                      | 3-17        |
| 3-6        | Some Published Method Validation Data for 2,3,7,8-TCDD Recovered from Fortified Matrices and Determined by GC/MS . . .                                  | 3-31        |
| 4-1        | Levels of Tetra-, Penta- and <b>Hexa-chlorodibenzo-p-dioxins</b> Reported in Chlorophenols and a Few Pesticides Originating from Chlorophenols. . . . . | 4-7         |
| 4-2        | Locations of Companies that have been Major Producers and Formulators of Chlorophenols and Their Derivatives. . . . .                                   | 4-10        |
| 4-3        | Levels of TCDD in Soils and Sediments from Different Locations. . . . .   | 4-26        |
| 4-4        | Predicted BCFs from Calculated and Measured Values of <b>K<sub>ow</sub></b> . . .   | 4-36        |
| 4-5        | Measured <b>Bioaccumulation</b> Factor for 2,3,7,8-TCDD in Freshwater Aquatic Organisms. . . . .  | 4-37        |
| <b>5-1</b> | Bioconcentration Factor of TCDD for <b>Several</b> Aquatic Organisms. . . . .   | 5-16        |
| 6-1        | Effect of Acute Exposure to 2,3,7,8-TCDD on Aquatic Animals . . .   | 6-2         |
| 6-2        | Effects of Chronic or <b>Subchronic</b> Exposure to 2,3,7,8-TCDD on Aquatic Animals. . . . .  | 6-5         |
| 6-3        | Levels of <b>2,3,7,8-TCDDs</b> in Fish and Shellfish . . . . .  | 6-10        |
| 6-4        | TCDD Levels in Wildlife. . . . .  | <b>6-15</b> |
| 7-1        | <b>Gastrointestinal</b> Absorption of 2,3,7,8-TCDD. . . . .   | 7-2         |
| 7-2        | Liver <b>Accumulation</b> of 2,3,7,8-TCDD in Guinea <b>Pigs</b> 30 Days after a Single <b>Intragastric</b> Exposure to 2,3,7,8-TCDD. . . . .            | 7-4         |

LIST OF TABLES (cont.)

| <u>No.</u> | <u>Title</u>   | <u>Page</u>  |
|------------|--|--------------|
| 7-3        | Distribution of <b>2,3,7,8-TCDD</b> . . . . .  | 7-8          |
| 7-4        | <b>Elimination</b> of <b>2,3,7,8-TCDD</b> . . . . .  | 7-17         |
| 8-1        | <b>Lethal</b> Doses of <b>2,3,7,8-TCDD</b> Following Acute Exposure . . . . .  | 8-2          |
| 8-2        | Toxic Responses Following Exposure to <b>2,3,7,8-TCDD</b> :<br>Species Differences. . . . .  | 8-11         |
| 8-3        | Estimated Single Oral <b>LD<sub>50</sub></b> - 30 Values for PCDDs. . . . .  | 8-12         |
| 8-4        | <b>Immunological</b> Effects of 2,3,7,8-TCDD in Animals. . . . .   | 8-28         |
| 8-5        | Effects of Chronic Exposure to 2,3,7,8-TCDD on Laboratory<br>Rodents. . . . .  | 8-52         |
| 9-1        | Studies on the Potential <b>Teratogenic</b> Effects of 2,3,7,8-TCDD<br>Contaminated <b>2,4,5-T</b> . . . . .   | 9-2          |
| 9-2        | Studies on the Potential Teratogenic Effect of 2,3,7,8-TCDD . . . . .  | 9-7          |
| 10-1       | The Results of <b>Mutagenicity</b> Assays for 2,3,7,8-TCDD in<br><b>Salmonella typhimurium</b> . . . . .   | 10-2         |
| 11-1       | 2,3,7,8-TCDD Intake and <b>Mortality</b> in Male Sprague-Dawley<br>Rats. . . . .   | <b>11-3</b>  |
| 11-2       | Benign and Malignant Tumors in Rats Ingesting 2,3,7,8-TCDD. . . . .  | 11-5         |
| 11-3       | Liver Tumors in Rats Ingesting 2,3,7,8-TCDD. . . . .   | 11-6         |
| 11-4       | <b>Hepatocellular</b> Carcinomas and Hepatocellular <b>Hyperplastic</b><br>Nodules in Female Sprague-Dawley Rats Maintained on Diets<br>Containing 2,3,7,8-TCDD. . . . .             | <b>11-9</b>  |
| 11-5       | Tumor Incidence in Female Rats Fed Diets Containing<br>2,3,7,8-TCDD. . . . .   | <b>11-10</b> |
| 11-6       | Tumor Incidence in Male Rats Fed Diets Containing<br>2,3,7,8-TCDD. . . . .   | 11-11        |
| 11-7       | Dow 2,3,7,8-TCDD Oral Rat Study by Dr. <b>Kociba, With</b><br>Dr. <b>Squire's</b> Review (8/15/80) Sprague-Dawley Female Rats -<br>Spartan <b>Substrain</b> (2 years). . . . .       | 11-13        |
| 11-8       | Dow <b>2,3,7,8-TCDD</b> Oral Rat Study by Dr. Kociba, <b>With</b><br>Dr. <b>Squire's</b> Review (8/15/80) Sprague-Dawley Male Rats -<br>Spartan Substrain ( <b>2</b> years). . . . . | 11-14        |

## LIST OF TABLES (cont.)

| <u>No.</u>   | <u>Title</u>  | <u>Page</u>  |
|--------------|---|--------------|
| 11-9         | Incidence of Primary Tumors in <b>Male</b> Rats Administered <b>2,3,7,8-TCDD</b> by Gavage. . . . .   | 11-16        |
| <b>11-10</b> | Incidence of Primary Tumors in <b>Female</b> Rats Administered <b>2,3,7,8-TCDD</b> by <b>Gavage</b> . . . . .   | 11-17        |
| 11-11        | Cumulative Data on Tumor Incidence. . . . .   | 11-18        |
| <b>11-12</b> | Incidence of Primary Tumors in Male <b>Mice</b> Administered <b>2,3,7,8-TCDD</b> by Gavage. . . . .   | 11-22        |
| 11-13        | Incidence of Primary Tumors in Female <b>Mice</b> Administered <b>2,3,7,8-TCDD</b> by Gavage. . . . .   | 11-23        |
| 11-14        | Promoting Effect of <b>2,3,7,8-TCDD</b> on <b>Hepatocarcinogenesis</b> by a Single Dose of Diethylnitrosamine (DEN) and Partial Hepatectomy (PH). . . . .   | 11-24        |
| <b>11-15</b> | Incidence of Primary Tumors in <b>Mice</b> Administered <b>2,3,7,8-TCDD</b> or <b>2,3,7,8-TCDD</b> Following DMBA by Dermal Application. . . . .  | <b>11-28</b> |
| 11-16        | Effects of <b>Intraperitoneal</b> Administration of <b>2,3,7,8-TCDD</b> on <b>3-MC-Initiated</b> Subcutaneous Tumors. . . . .   | 11-31        |
| 11-17        | Effect of <b>Intraperitoneal</b> or Subcutaneous Administration of <b>2,3,7,8-TCDD</b> Given 2 Days Before or Simultaneous <b>With</b> Subcutaneous Administration of <b>3-MC</b> on <b>Tumorigenesis</b> in <b>D2 Mice</b> . . . . . | <b>11-32</b> |
| 11-18        | Incidence of Tumors in <b>Mice</b> Treated <b>With</b> <b>3-MC</b> and <b>With</b> <b>3-MC</b> and <b>2,3,7,8-TCDD</b> . . . . .  | <b>11-34</b> |
| 11-19        | Liver Tumor Incidences in Male and Female Osborne-Mendel Rats Administered HxCDD for 104 Weeks. . . . .   | 11-41        |
| 11-20        | Liver Tumor Incidences in Female Osborne-Mendel Rats Administered HxCDD by Gavage for 104 Weeks. . . . .  | 11-43        |
| 11-21        | Liver Tumor Incidences in <b>Male</b> and Female B6C3F1 <b>Mice</b> Administered HxCDD by Gavage for 104 Weeks. . . . .   | 11-44        |
| 11-22        | Liver Tumor Response for HxCDD ( <b>Observed</b> ) and TCDD Contaminant (Calculated). . . . .   | 11-46        |
| 11-23        | <b>Carcinogenicity Bioassays</b> of <b>2,3,7,8-TCDD</b> and HxCDD by Dermal <b>Application</b> to <b>Mice</b> . . . . .   | 11-49        |

LIST OF TABLES (cont.)

| <u>No.</u> | <u>Title</u>   | <u>Page</u>   |
|------------|--|---------------|
| 11-24      | <b>Carcinogenicity Bioassays</b> of PCDD Administration by the Oral and Dermal Route . . . . .   | 11-52         |
| 11-25      | Distribution of Tumor Types in Two Case-Controls Studies of Soft-Tissue Sarcoma . . . . .  | 11-67         |
| 11-26      | Exposure Frequencies in Two Case-Control Studies of Soft-Tissue Sarcoma . . . . .  | <b>11-68</b>  |
| 11-27      | Relative Risks of Soft-Tissue Sarcoma in Relation to Exposure to <b>Phenoxyacetic</b> Acids and <b>Chlorophenols</b> in Two Case-Control Studies . . . . .         | <b>11-70</b>  |
| 11-28      | Distribution of <b>Histological</b> Types of Soft-Tissue Sarcomas . . . . .  | 11-75         |
| 11-29      | Midland County Soft and Connective Tissue Cancer <b>Deaths</b> 1960-1981. . . . .  | <b>11-84</b>  |
| 11-30      | Other Occupations (Minus Forestry/Agriculture). . . . .  | 11-95         |
| 11-31      | Other Occupations (Minus <b>Forestry/Agriculture/Woodworkers</b> . . . . .   | 11-96         |
| 11-32      | Analysis of Stomach Cancer Mortality in a Group of West German Factory Workers Exposed to <b>2,3,7,8-TCDD</b> . . . . .  | 11-101        |
| 11-33      | <b>Reanalysis</b> of Stomach Cancer Mortality in a Group of West German Factory Workers Exposed to 2,3,7,8-TCDD . . . . .  | 11-103        |
| 11-34      | Stomach Cancer Mortality in Three Studies of Workers Exposed to Phenoxyacetic Acid Herbicides and/or 2,3,7,8-TCDD. . . . .   | 11-105        |
| 11-35      | NTP HxCDD (Gavage) <b>Bioassay</b> . <b>Osborne-Mendel</b> Rats (2 years) Incidences of <b>Neoplastic</b> Nodules and <b>Hepatocellular</b> Carcinomas. . . . .    | 11-120        |
| 11-36      | NTP HxCDD ( <b>Gavage</b> ) Bioassay. B6C3F1 <b>Mice</b> (104 weeks) Incidences of Adenomas Nodules and Hepatocellular Carcinomas. . . . .                         | <b>11-123</b> |
| 11-37      | <b>Relative</b> Carcinogenic Potencies Among 55 <b>Chemicals</b> Evaluated by the Carcinogen Assessment Group as Suspect Human Carcinogens. . . . .                | 11-128        |
| 14-1       | No-Observed-Effect Levels and Low-Observed-Effect Levels Obtained from <b>Subchronic</b> and Chronic Oral <b>Toxicity</b> Studies of <b>2,3,7,8-TCDD</b> . . . . . | 14-3          |

LIST OF TABLES (cont.)

| <u>No.</u> | <u>Title</u>  | <u>Page</u>  |
|------------|---|--------------|
| 14-2       | No-Observed-Effect Levels and Low-Observed-Effect Levels<br>Obtained from <b>Subchronic</b> and Chronic Oral <b>Toxicity</b><br>Studies of HxCOD. . . . . | 14-5         |
| 14-3       | <b>Carcinogenicity Bioassays</b> of <b>2,3,7,8-TCDD</b> . . . . .   | <b>14-12</b> |
| 14-4       | CardnogenlcHy Bloassays of a 1:2 Mixture of 1,2,3,6,7,8-<br>and <b>1,2,3,7,8,9-HxCDD</b> . . . . .  | <b>14-16</b> |

LIST OF FIGURES

| <u>No.</u> | <u>Title</u>  | <u>Page</u> |
|------------|---|-------------|
| 4-1        | <b>Ullmann</b> Condensation Reactions . . . . .   | 4-3         |
| 4-2        | Possible Potential Relationship Between Various Sources<br>of PCDDs and the Environmental Matrices <b>where</b> PCDDs have<br>been Detected . . . . .           | <b>4-19</b> |
| 11-1       | Time-Dependent Inhibition by <b>2,3,7,8-TCDD</b> of Tumor<br>Initiation . . . . .   | 11-37       |
| 11-2       | Histogram Representing the Frequency Distribution of the<br>Potency Indices of 55 Suspect Carcinogens Evaluated by<br>the Carcinogen Assessment Group . . . . . | 11-127      |

LIST OF ABBREVIATIONS

|                  |   |
|------------------|---|
| <b>ADI</b>       | Acceptable dally Intake   |
| AHH              | <b>Aryl</b> hydroxycarbon <b>hydroxylase</b>                        |
| bw               | Body weight   |
| BCF              | <b>Bioconcentration</b> factor                                      |
| BromoPeCDD       | <b>Bromopentachlorodibenzo-p-dioxin</b>                             |
| DCDD             | <b>Dichlorodibenzo-p-dioxin</b>                                     |
| <b>DMSO</b>      | <b>Dimethylsulfoxide</b>  |
| DNA              | <b>Deoxyribonucleic</b> add   |
| EC/6C            | Electron capture/gas <b>chromatography</b>                          |
| <b>ED50</b>      | Median effective dose   |
| <b>FEL</b>       | Frank effect level  |
| <b>GC/MS</b>     | Gas <b>chromatography/mass spectrometry</b>                         |
| <b>GC/SIM/MS</b> | Gas <b>chromatography/specific</b> lon monitoring/mass spectrometry |
| HPLC             | <b>High</b> performance liquid chromatography                       |
| HRGC             | <b>High</b> resolution gas chromatography                           |
| <b>HRMS</b>      | <b>High resolution</b> mass spectrometry                            |
| HxCDDs           | Hexachloro derivatives of <b>dibenzo-p-dioxins</b>                  |
| <b>LC50</b>      | Concentration lethal to <b>50%</b> of recipients                    |
| <b>LD50</b>      | Dose lethal to 5054 of recipients                                   |
| LOAEL            | Lowest-observed-adverse-effect level                                |
| <b>LRMS</b>      | Low resolution mass spectrometry                                    |
| MFO              | <b>Mixed</b> function <b>oxidase</b>                                |
| <b>NICI</b>      | Negative lon chemical Ionlzation                                    |
| NOAEL            | No-observed-adverse-effect <b>level</b>                             |
| NOEL             | No-observed-effect level  |

LIST OF ABBREVIATIONS (cont.)

|                |   |
|----------------|---|
| OCDD           | Octachlorinated <b>dibenzo-p-dioxins</b>            |
| PCDDs          | <b>All polychlorinated dibenzo-p-dioxins</b>        |
| PCP            | <b>Pentachlorophenol</b>                            |
| PeCDDs         | Pentachloro derivatives of <b>dibenzo-p-dioxins</b> |
| ppb            | Parts per <b>billion</b>                            |
| ppm            | Parts per million                                   |
| Ppt            | Parts per <b>trillion</b>                           |
| RBC            | Red blood cells                                     |
| RNA            | <b>Ribonucleic acid</b>                             |
| SA             | Satellite association                               |
| TCDDs          | Tetrachloro derivatives of <b>dibenzo-p-dioxins</b> |
| <b>TricDD</b>  | <b>Trichlorodibenzo-p-dioxin</b>                    |
| <b>2,4,5-T</b> | <b>2,4,5-Trichlorophenoxyacetic acid</b>            |
| TWA            | Time-weighted average                               |
| <b>UV</b>      | Ultraviolet   |
| <b>WCOT</b>    | <b>Wall-coated</b> open tubular                     |



## 1. INTRODUCTION

**Dioxins** are a class of compounds that contain the **dibenzo-p-dioxin** nucleus. In chlorinated dioxins, the **dibenzo-p-dioxin** nucleus is substituted **with** chlorine at different positions of the fused benzene rings. Depending on the number and position of chlorine substitution, 75 congeners are possible for the chlorinated dioxins. **This** document deals **with** the most toxic chlorinated dioxins, namely, **2,3,7,8-tetrachloro-, 1,2,3,7,8-pentachloro-, 1,2,3,6,7,8-hexachloro-** and **1,2,3,7,8,9-hexachlorodibenzo-p-dioxin**. Of these four congeners, the **2,3,7,8-tetrachlorodibenzo-p-dioxin** has been studied extensively and is often described in both popular and technical literature as "**TCDD**" or simply "**dioxin**."

A few documents exist at the present **time** that deal **with** selected aspects of **polychlorinated** dibenzo-p-dioxins in the environmental media. **This** document, however, has been prepared to provide a comprehensive multimedia assessment of the analytical methodologies, environmental levels and ecological and health effects of the four **chlorinated** dioxins. The **following** acronyms **will** hereafter be used when discussing the **polychlorinated dibenzo-p-dioxins**:

| PCDDs                    | Polychlorinated dibenzo-p-dioxins             |
|--------------------------|---|
| <b>2,3,7,8-TCDD</b>      | <b>2,3,7,8-Tetrachlorodibenzo-p-dioxin</b>    |
| <b>1,2,3,7,8-PeCDD</b>   | <b>1,2,3,7,8-Pentachlorodibenzo-p-dioxin</b>  |
| <b>1,2,3,6,7,8-HxCDD</b> | <b>1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin</b> |
| <b>1,2,3,7,8,9-HxCDD</b> | <b>1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin</b> |

## 2. SUMMARY AND CONCLUSIONS

### 2.1. SUMMARY

**Polychlorinated dibenzo-p-dioxins** are a **class** of **chlorinated tricyclic** aromatic hydrocarbons consisting of two benzene rings connected by a **pair** of oxygen atoms. According to the position and number of chlorine atoms it is possible to form 75 different congeners of chlorinated **dioxins**. The word "**dioxins**" is often used to refer to **this** class of compounds, especially **with** respect to the highly toxic and environmentally widely distributed **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)**. **This** class of compounds is rather stable toward heat, acids and alkalis. The solubility of **2,3,7,8-TCDD** in water is 0.2  $\mu\text{g}/\text{l}$ . **This isomer** and the three other PCDDs discussed in **this** document are soluble in certain aromatic and aliphatic solvents. The PCDDs are chemically relatively stable and start to decompose at temperatures **>500°C**; the percent of decomposition depends upon the residence **time** in the **high** temperature zone and the proportion of oxygen in the heated zone.

The commonly used method for the determination of these compounds in different samples consists of solvent extraction, followed by **sulfuric** acid and base washes to remove **lipids** and other impurities from the solvent extract. The extract is then subjected to two liquid **chromatographic** clean-up procedures. The **cleaned-up** extract is finally analyzed for the PCDDs by the gas **chromatographic-mass spectrometric** methods. Despite the specialized methods used for the determination of PCDDs, the results of analysis at very low levels (possibly <9 ppt in biological **matrices**) can be questionable unless special precautions, including addition of internal standard, are made.

None of the PCDDs are either commercially manufactured or have any known use. They are produced as unwanted contaminants primarily during the

manufacture of **chlorophenols** and their derivatives. The primary sources of PCDD contamination in the environment result from the Industrial manufacture of chlorophenols and their derivatives and the subsequent disposal of wastes from these Industries. Municipal Incineration may also produce some **envi-**ronmental emission of PCDDs. From the available data, **it** is difficult to ascertain the comparative Importance of these three sources in contributing to environmental emissions. The **1,2,3,7,8-PeCDD** found in environmental samples has only been reported in emissions from Incinerators.

The **monitoring** data to date **indicate** that the maximum level of PCDDs is **likely** to be found **in soil** and drainage sediment samples near chlorophenol **manufacturing** Industries and chemical waste disposal sites. **With** the exception of air near certain contaminated sites, only very limited attempts have been made to determine the level of PCDDs **in air** samples. In the United States, the highest levels are reported at certain hazardous waste sites and **in fish** and **wildlife** tissue from areas contaminated **with 2,3,7,8-TCDD**.

The environmental fates of the four PCDDs are not known **with** certainty. Most of the **investigations** in **this** field have been conducted **with 2,3,7,8-TCDD**, and the conclusions regarding the environmental fate of the other three PCDDs have been drawn by analogy. Few data exist in the literature that would indicate significant chemical and biological transformation of these compounds in atmospheric, aquatic or **soil** media. The **role** of photo-**chemical** transformation **in** determining the fates of these chemicals **in** various ambient media is not known **with** certainty, but the PCDDs are susceptible to photochemical reactions in the presence of hydrogen donors. In the **aquatic media**, a substantial proportion of the PCDDs may be present in the sediment-sorbed state or **in** the biota. In the atmosphere, the PCDDs are expected to be present in the vapor-phase and particulate-sorbed states.

The atmospheric transport of these compounds can be predicted from dispersion modeling equations. In the case of the accidental release of 2,3,7,8-TCDF at Seveso, Italy, **it** has been estimated from laboratory experiments that **2,3,7,8-TCDF** deposition from **air** to **soil** follows an exponential decay pattern along the downward **wind** direction. The most probable transport mechanisms of the PCDFs from soils are transport to the atmosphere by contaminated dust particles, direct volatilization from the surface or near surface zones (**≤5** cm), and transport to surface water by eroded **soil**.

Both the calculated and the experimental results show that the PCDFs **will** concentrate in sediments and biota present in aquatic media. It has been shown by static test procedures that, depending on the species, the **bioconcentration** factor (BCF) for 2,3,7,8-TCDF **in fish** ranges from **~2000-30,000**. The **U.S. EPA's** best estimate of the BCF for 2,3,7,8-TCDF is 5000 (U.S. EPA, 1984).

In mammals, 2,3,7,8-TCDF is readily absorbed through the gastrointestinal tract, and absorption through intact **skin** has also been reported. Absorption may decrease dramatically if 2,3,7,8-TCDF is adsorbed to **particulate** matter such as activated carbon or **soil**. After absorption, 2,3,7,8-TCDF is distributed to tissues **high** in **lipid** content; however, **in** many species, the liver **is** a major storage **site**. **Metabolism** of 2,3,7,8-TCDF occurs slowly, **with** the polar metabolites excreted in the urine and feces. **Unmetabolized** 2,3,7,8-TCDF can be eliminated in the feces and **in** the **milk**. It **is** metabolized by the P-450 monooxygenase system through a reactive **epoxide** intermediate. The metabolism of 2,3,7,8-TCDF seems to be a detoxification process resulting **in** the production of metabolites that are less toxic than the parent compound. Available scientific data supports the contention that the toxic response to 2,3,7,8-TCDF exposure is mediated through **cytosolic** Ah-receptor **site** binding.

The PCODs discussed in **this** document are among some of the most toxic compounds known, **with** the lowest  $LD_{50}$  level for **male guinea pigs**, the most sensitive species, being 0.6  $\mu\text{g}/\text{kg}$  for **2,3,7,8-TCDD**. The other congeners are somewhat less toxic; however, the  $LD_{50}$  values are still in the  $\mu\text{g}/\text{kg}$  range. Although **2,3,7,8-TCDD** is highly toxic in all species tested, there are large species differences in sensitivity, **with** the  $LD_{50}$  for hamsters being 1157-5051  $\mu\text{g}/\text{kg}$ . The characteristic signs and symptoms of lethal poisoning are severe weight loss and **thymic** atrophy. Death usually occurs many days after the exposure. In rats, rabbits and **mice**, 2,3,7,8-TCDD produces an acute **liver injury** that is not observed in either monkeys, hamsters or guinea **pigs**. In **mice**, the immune response is also suppressed. After **subchronic** or chronic exposure to 2,3,7,8-TCDD in rats or **mice**, the liver appears to be the most severely affected organ, although systemic hemorrhage, edema and suppressed thymic activity are also observed. The limited data available for the other PCDDs indicate that these chemicals produce the same symptoms as **2,3,7,8-TCDD** in a given species; however, the doses required are higher.

Humans have been exposed to herbicides and other chlorinated chemicals containing 2,3,7,8-TCDD as a contaminant. The symptoms of **toxicity** in many cases are similar to those observed in animals, **with** exposure leading to altered **liver** function and **lipid** metabolism, **porphyria** cutanea tarda, **neurotoxicity** and pathologic changes **in hematologic** parameters. In addition, exposure of humans to 2,3,7,8-TCDD produces **skin** lesions such as chloracne and **hyperpigmentation**. Although some signs such as chloracne are attributed to the PCDDs, the other signs of toxicity may arise, at least **in part**, from the other chemical of which PCDDs are a minor contaminant.

Animal studies have demonstrated that 2,3,7,8-TCDD is **teratogenic** and **fetotoxic** in rats, **mice**, rabbits and ferrets; and **fetotoxic** in monkeys.

Exposure to **2,3,7,8-TCDD** in **mice** produces facial **clefts**, while exposure in rats results in edema, hemorrhage and kidney anomalies; rabbits have a higher Incidence of extra **ribs**. In rats a reduction in the gestation **index**, decreased fetal weight, Increased **liver-to-body** weight ratio and Increased Incidence of dilated renal pelvis in the offspring has been observed. Certain human epidemiology studies have shown positive associations with exposure to chemicals contaminated with 2,3,7,8-TCDD and birth defects and abortions, while others have not.

There is a limited data base with conflicting evidence for 2,3,7,8-TCDD's **mutagenic** potential; therefore, the available evidence is judged to be Inconclusive. There are no studies in the published literature regarding the **mutagenicity** of HxCDD or any other congeners of PCDD.

There is evidence from chronic animal cancer **bioassay** studies that 2,3,7,8-TCDD and HxCDD are **probable** human carcinogens. There are no chronic cancer bioassay studies available that evaluate the carcinogenic potential for other PCDDs. The **available** data for 2,3,7,8-TCDD and HxCDD come from gavage and feeding studies, there being no studies available for Inhalation exposure. The **epidemiologic** evidence for the **carcinogenicity** of 2,3,7,8-TCDD alone is Inadequate, while the evidence for **phenoxyacetic** herbicides and/or **chlorophenols** with 2,3,7,8-TCDD as an Impurity is limited. There have been no **epidemiologic** evaluations, as yet, for HxCDD as the sole compound of concern.

A number of chronic animal cancer **bioassays** show that 2,3,7,8-TCDD is an animal carcinogen. In rats, oral exposure to 2,3,7,8-TCDD resulted in an Increased Incidence of **hepatocellular** carcinomas, **squamous** cell carcinomas of the tongue and hard palate/nasal **turbinates**, and squamous cell carcinomas of the lung. In both male and female **mice**, Increased Incidences of **liver**

tumors were observed. A mixture of the two **isomers** of HxCDD, discussed **in this** document has been tested for carcinogenicity and shows increased incidences of liver tumors in rats and **mice**. **Also, 2,3,7,8-TCDD** has produced **fibrosarcomas** at the **site** of application after dermal administration, although there was no significant increase in dermal tumors when the mixture of HxCDDs was tested. Since both compounds produce statistically significant increased incidences of tumors in two species of animals, there is sufficient evidence, according to the Interim EPA weight-of-evidence classification criteria, to conclude that both 2,3,7,8-TCDD and HxCDD are animal carcinogens. 2,3,7,8-TCDD has been shown to be a promoter as well as an initiator in rodent test systems. Evidence is available from **epidemiologic** studies that implicate exposure to herbicides contaminated **with** 2,3,7,8-TCDD **with** a significantly elevated **risk** of soft tissue sarcomas and to a lesser extent non-Hodgkin's **lymphomas**; however, the exposures to 2,3,7,8-TCDD were always compounded **with** exposures to the herbicide chemicals.

Assuming that 2,3,7,8-TCDD and HxCDD are carcinogenic in humans, upper bound incremental **unit** cancer risks have been estimated for both ingestion and inhalation exposure. The **unit** risks have been estimated using a multi-stage extrapolation model that is linear at low doses. Available metabolism and pharmacokinetic data are insufficient to alter typically used assumptions for estimating the human equivalent dose. Since incidence data exist only for oral studies in animal test systems, the inhalation **risk** estimates are based upon the cancer potency derived from the oral studies along **with** appropriate conversion assumptions.

Using data from a feeding study **with** female rats the upper limit incremental cancer **risk** for 2,3,7,8-TCDD is estimated to be  $1.56 \times 10^{-2}$  per ng/kg/day. The upper limit estimate of incremental cancer **risk** is

$4.5 \times 10^{-5}$  for a continuous **lifetime** exposure to **1 ng/l** of 2,3,7,8-TCDD in drinking water and  $3.3 \times 10^{-5}$  for a continuous **lifetime** exposure to **1 pg/m<sup>3</sup>** of 2,3,7,8-TCDD in ambient air.

Using data from an **ingestion** study with female rats and male **mice**, the cancer potency for HxCDD is estimated to be  $6.2 \times 10^{-5}$  per ng/kg/day. The upper limit estimate of Incremental cancer **risk** is  $1.8 \times 10^{-4}$  for a continuous lifetime exposure to **1 ng/l** of HxCDD in drinking water and  $1.3 \times 10^{-6}$  for a continuous lifetime exposure to **1 pg/m<sup>3</sup>** of HxCDD in ambient air.

## 2.2. CONCLUSIONS

The PCDDs, 2,3,7,8-TCDD, **1,2,3,7,8-PeCDD**, 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDD, are highly toxic following acute exposure. All animal species administered **high** levels of these compounds developed weight loss and **thymic** atrophy. In some species **liver** damage, edema, **hair** loss and **immunosuppression** were also observed. Chronic **toxicity** studies have been conducted only on **2,3,7,8-TCDD** and a mixture of the two **isomers** of HxCDD. In these studies, the primary **nonneoplastic** lesion was fatty and **necrotic** change in the **liver**.

In the species studied, the fetus has been shown to be highly sensitive to the toxic effects of 2,3,7,8-TCDD. In rats the **fetotoxicity** observed included hemorrhage, edema and kidney anomalies, while in **mice** the predominant lesions were cleft palate and kidney anomalies. The lowest reported exposure in rats, 1 ng/kg, produced a significant (by some analyses but not others) effect on the fetus, and was similar to the LOAEL observed in chronic studies.

Evidence from oral animal cancer **bioassays** is "sufficient" (according to EPA and IARC criteria) to conclude that 2,3,7,8-TCDD and a mixture of the two isomers of HxCDD are animal carcinogens. 2,3,7,8-TCDD has increased the



Incidence of a variety of tumors, including hepatocellular tumors in rats and mice, while the mixture of HxCDD tested increased the incidence of hepatocellular tumors in both sexes of rats and mice. The available epidemiologic evidence for the carcinogenicity of 2,3,7,8-TCDD alone is inadequate and there have been no epidemiologic evaluations, as yet, for HxCDD as the sole compound of concern. Considering the animal evidence together with the epidemiologic data, the overall weight-of-evidence classification for 2,3,7,8-TCDD using EPA's Interim classification scheme is category B2 meaning that 2,3,7,8-TCDD should be regarded as a "probable" human carcinogen. The overall weight-of-evidence classification for HxCDD is also category B2 meaning that it should be regarded as a "probable" human carcinogen. In terms of low dose potency, 2,3,7,8-TCDD and the HxCDD mixture are the two most potent carcinogens evaluated by the EPA's Carcinogen Assessment Group. Epidemiologic studies of workers exposed to chemicals contaminated with 2,3,7,8-TCDD such as 2,4,5-trichlorophenoxyacetic acid and 2,4,5-trichlorophenol have produced positive findings that are suggestive of an elevated risk of cancer in humans. These epidemiologic findings are not inconsistent with the premise that 2,3,7,8-TCDD is probably carcinogenic for humans. There are no chronic studies available regarding the carcinogenicity of 1,2,3,7,8-PeCDD.

### 2.3. NEEDS FOR FUTURE RESEARCH


- The basic physical properties such as water solubilities and vapor pressures of the PeCDDs and HxCDDs need to be determined. These parameters are important in predicting the environmental fate of these compounds.
- New analytical methodologies must be established to determine the low levels of these compounds in environmental matrices without ambiguity.
- More monitoring data, particularly in air and aquatic media as well as in vegetables grown near urban incinerators, should be developed by a diversity of research groups.

- **Isotopically labeled** Internal standard compounds ( $^{14}\text{C}$  or  $^{13}\text{C}$ ) should be prepared for PeCDDs and HxCDDs.
- More research efforts should be directed to determining the environmental fate of the PeCDDs and HxCDDs. The determination of the fate of these chemicals **with** respect to the possibility of photochemical transformations in different environmental matrices needs special attention.
- Pharmacokinetic studies should be conducted to demonstrate more clearly the degree of absorption of the PCDDs by **all** routes. In **particular**, studies are needed on respiratory absorption and on PCDDs adsorbed to environmental media.
- Although a number of studies demonstrate that **2,3,7,8-TCDD is** a teratogen, the other congeners should be tested for **teratogenic** potential.
- There is no information on the effects of chronic exposure to **1,2,3,7,8-PeCDD**, and studies should be conducted to determine both the toxic effects of **this** compound and its carcinogenic **potential**.
- Further epidemiology data on the effects in human **populations** exposed to PCDDs might assist in determining which effects observed in animals are also present in humans. In these studies, careful **quantitation** of PCDD levels in humans and industrial hygiene samples might provide dose-response data necessary for **health** assessment.
- **Bioavailability** studies from contaminated **soil**, fly ash, etc., are needed.
- **Mechanism-of-action** studies should be conducted to determine the fundamental mode of action of the PCDDs.
- New destruction methods should be investigated in order to provide feasible methods for decontaminating environmental sites where PCDDs have been detected.
- Determination of BCF for all these most toxic PCDDs in state-of-the-art test systems.

### 3. PHYSICAL AND CHEMICAL PROPERTIES/ANALYTICAL METHODOLOGY

#### 3.1. INTRODUCTION

**Dibenzo-p-dioxin** is a derivative of the basic chemical structure **p-dioxane**. The structure of **dibenzo-p-dioxin** and the conventional numbering system used for defining **substituent** positions are shown below:




A number of **substituents** including **nitro**, **amino**, **alkyl**, alkoxy and halogen can be introduced at the different positions of the two benzene rings. Most environmental interest in substituted **dibenzo-p-dioxins** and most studies of **this** family of compounds have centered on chlorinated **dibenzo-p-dioxins** that are loosely referred to as "**dioxins**." Theoretically, there are 75 different congeners of **chlorinated dibenzo-p-dioxins**. In **this** document, only four **polychlorinated dibenzo-p-dioxins**, namely **2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD)**, **1,2,3,7,8-pentachlorodibenzo-p-dioxin (1,2,3,7,8-PeCDD)**, **1,2,3,6,7,8-hexachlorodibenzo-p-dioxin (1,2,3,6,7,8-HxCDD)** and **1,2,3,7,8,9-hexachlorodibenzo-p-dioxin (1,2,3,7,8,9-HxCDD)** will be discussed.

#### 3.2. PHYSICAL AND CHEMICAL PROPERTIES

##### 3.2.1. Chemical Formula and Synonyms.


##### **2,3,7,8-Tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD)**



**Chem. Abstr. Name:** 2,3,7,8-tetrachlorodibenzo[b,e](1,4)-dioxin

**Synonyms:** Dioxin; TCDBD; TCDD; 2,3,7,8-tetrachlorodibenzodioxin, 2,3,7,8-tetrachlorodibenzo-1,4-dioxin.


**1,2,3,7,8-Pentachlorodibenzo-p-dioxin (1,2,3,7,8-PeCDD)**



**Chem. Abstr. Name:** 1,2,3,7,8-Pentachlorodibenzo[b,e](1,4)dioxin

**Synonym:** 1,2,3,7,8-Pentachlorodibenzodioxin


**1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin (1,2,3,6,7,8-HxCDD)**



**Chem. Abstr. Name:** 1,2,3,6,7,8-Hexachlorodibenzo[b,e](1,4)dioxin

**Synonym:** 1,2,3,6,7,8-Hexachlorodibenzodioxin

**1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin (1,2,3,7,8,9-HxCDD)**



**Chem. Abstr. Name:** 1,2,3,7,8,9-Hexachlorodibenzo[b,e](1,4)dioxin

**Synonym:** 1,2,3,7,8,9-Hexachlorodibenzodioxin

3.2.2. Physical Properties. The physical properties of the four **polychlorinated dioxins** are given in Table 3-1. Although the physical properties of **1,2,3,7,8-PeCDD**, **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD** have not been well studied, these properties have been more intensively studied for **2,3,7,8-TCDD**. **2,3,7,8-TCDD** is **lipophilic**, exhibiting a higher degree of solubility in fats and **oils** than in water. The solubility of 2,3,7,8-TCDD in various solvents (at unspecified **temperatures**) is as follows (**Crummett and Stehl**, 1973):

| <u>Solvent</u>    | <u>Solubility (ppm)</u> |
|-------------------|-------------------------|
| water             | $2 \times 10^{-4}$      |
| lard oil          | 44                      |
| benzene           | 570                     |
| o-dichlorobenzene | <b>1400</b>             |
| chloroform        | 370                     |
| acetone           | 110                     |
| <b>n-octanol</b>  | 50                      |
| methanol          | 10                      |

The solubilities of HxCDD (**isomer** unspecified) in benzene and toluene are 1600 and 1800 **ppm**, respectively (U.S. EPA, 1978). The known solubility data (NRCC, 1981a) suggest that while the lower congeners (e.g., di-CDD and tri-CDD) are more soluble in **aliphatic** solvents (e.g., acetone, **methanol**), the higher **homologues** are more soluble in aromatic hydrocarbon **solvents**. However, the solubilities of both lower and higher homologues of **polychlorinated dioxins** may be comparable in chlorinated aliphatic hydrocarbons, namely chloroform.

Because of the  $\pi \rightarrow \pi^*$  transitions the **polychlorinated dioxins** have two absorption maxima in the near **UV** region. The absorption coefficients **resulting** from **this** transition at longer wavelengths are presented in Table 3-1. The partition coefficient of 2,3,7,8-TCDD in a **hexane** water system was estimated to be 1000 (temperature unspecified) (**Matsumura and Benzet**,

TABLE 3-1

## Physical Properties of a Few Selected Polychlorinated Dioxins

| Compound          | CAS Reg. No. | Molecular formula   | Molecular Weight | Description       | Melting Point (°C) | $\lambda_{max}^a$ (chloroform) (nm) | $\epsilon^{1b}$ | Reference              |
|-------------------|--------------|---|------------------|-------------------|--------------------|-------------------------------------|-----------------|------------------------|
| 2,3,7,8-TCDD      | 1746-01-6    | C <sub>12</sub> H <sub>4</sub> Cl <sub>4</sub> O <sub>2</sub> | 321.9            | colorless needles | 305-306            | 310                                 | 173.6           | Pohland and Yang, 1972 |
| 1,2,3,7,8-PeCDD   | 40321-76-4   | C <sub>12</sub> H <sub>3</sub> Cl <sub>5</sub> O <sub>2</sub> | 356.5            | NA                | 240-241            | 308                                 | 171.4           | Gray et al., 1976      |
| 1,2,3,6,7,8-HxCDD | 57653-85-7   | C <sub>12</sub> H <sub>2</sub> Cl <sub>6</sub> O <sub>2</sub> | 390.9            | NA                | 285-286            | 316                                 | 152             | Gray et al., 1975      |
| 1,2,3,7,8,9-HxCDD | 19408-74-3   | C <sub>12</sub> H <sub>2</sub> Cl <sub>6</sub> O <sub>2</sub> | 390.9            | NA                | 243-244            | 317                                 | 104             | Gray et al., 1975      |

<sup>a</sup>This is the wavelength of maximum absorption.

<sup>b</sup>This is the absorption coefficient for a 1% chloroform solution of substrate in 1 cm cell at the  $\lambda_{max}$ . To convert this to the molar absorption coefficient (M<sup>-1</sup> cm<sup>-1</sup>), multiply by one-tenth of the molecular weight.

NA . Not available

1973). **Values** for other physical properties for these compounds have been estimated from various correlation equations and are given **in** Table 3-2.

The **infrared, mass, phosphorescence, and nuclear magnetic spectra** of **2,3,7,8-TCDD** are available from various sources (**Mahle** and Shadoff, 1982; Pohland and Yang, 1972; Chen, 1973; Kende and Wade, 1973). The mass spectra of the three other PCDDs are also available (Mahle and Shadoff, 1982; Gray et al., 1975, 1976). The response ratios of electron Impact (**EI**) and negative chemical ionization (NCI) and fragmentation of 11 of the **TCDD isomers** have been reported by Rappe et al. (1983a). These spectra, **particularly** the mass spectra, are very useful in identifying the various homologues/isomers of the PCDDs, but they **give limited** information for the **identification** of particular isomers.

3.2.3. Chemical Properties. All four PCDDs are rather stable toward heat, acids and alkalis, although heat treatment **with** alkali (under conditions similar to alkaline extraction of tissue) completely destroys octa-CDD (**Albro**, 1979). These compounds begin to decompose at **500°C**, and at a temperature of **800°C**, virtually complete degradation of 2,3,7,8-TCDD occurs within 21 seconds (**Stehl** et al., 1973). The PCDDs are susceptible to photodegradation **in** the presence of UV light. They also undergo **photoreductive dechlorination** in the presence of an effective hydrogen donor. Gamma radiation degrades 2,3,7,8-TCDD in organic **solvents** (**Fanello** et al., 1978).

### 3.3. ANALYTICAL **METHODOLOGY**

Several publications on the analytical methods for the determination of PCDD levels **in** different media are available. The analytical methodologies for the separation of the different isomers of PCDDs are difficult and expensive. Many investigators, particularly the earlier ones, failed to characterize the individual isomers and it is not always clear whether a

TABLE 3-2

A Few Estimated Physical Parameters of Chlorinated **Dibenzo-p-Dioxins**<sup>a</sup>

| Parameter  | <b>2,3,7,8-TCDD</b>   | <b>PeCDD<sup>b</sup></b> | <b>HxCDD<sup>b</sup></b> |
|--|---|--------------------------|--------------------------|
| Vapor pressure (mm of Hg)<br>at 25°C and 1 atmosphere              | 1.7 x 10 <sup>-6</sup><br>1 x 10 <sup>-6c</sup>   | NA                       | NA                       |
| Octanol/water partition<br>coefficient at 25°C                     | 1.4 x 10 <sup>6</sup><br>6.9 x 10 <sup>6c</sup><br>1.9 x 10 <sup>7d</sup><br>1.4 x 10 <sup>6e</sup> | 7 x 10 <sup>6</sup>      | 4.2 x 10 <sup>7</sup>    |
| <b>Sorption</b> partition<br>coefficient ( <b>K<sub>oc</sub></b> ) | 9.9 x 10 <sup>5</sup><br>3.3 x 10 <sup>6c</sup>   | 5 x 10 <sup>6</sup>      | 3 x 10 <sup>7</sup>      |
| Water solubility (ppb)<br>at 25°C                                  | <b>0.2<sup>f</sup></b>  | 0.04                     | 0.008                    |

<sup>a</sup>**Source:** NRCC, 1981a (unless otherwise stated), based on vapor pressure data (**Firestone**, 1977a) and the octanol/water partition coefficient value (**Kenaga**, 1980)

<sup>b</sup>**These** are estimated values for nonspecific **isomers**

<sup>c</sup>**Mabey et al.**, 1981

<sup>d</sup>**U.S.** EPA, 1984

<sup>e</sup>**This is** a measured value (**Neely**, 1979)

<sup>f</sup>**This is** the experimental value (**Crummett and Stehl**, 1973)

NA = Not available



specific **isomer** or a mixture of **isomers** was responsible for the observed effect(s). However, analytical methods for detecting specific Isomers at low ppt levels are now available for human samples (**Crummett**, 1983). In the case of TCDDs, the specific Isomer **2,3,7,8-TCDD** has been more thoroughly studied than any of Us other Isomers because of Us **high toxicity**. It **is** not the purpose of **this** section to review the various analytical methodologies available for **PCDDs**. Such reviews of recent analytical methods have been done in a Canadian document (NRCC, **1981b**), a U.S. EPA (**1980a**) report and by **Tiernan** (1983). Instead, **this** section **will** attempt to point out the various problems that may be encountered in the analysis of these compounds and provide a critique of a few typical analytical methods available for PCDDs.

3.3.1. General Procedure for the Analysis of PCODs. The analysis of PCDDs can be broadly divided **into** three basic steps (sample preparation, sample cleanup and sample analysis). The description of each of these steps **with** the associated difficulties that may be encountered are discussed below.

**3.3.1.1. SAMPLE PREPARATION** - In **this** step, the sample is homogenized or digested and extracted **with** a suitable **solvent** or a solvent mixture to remove the bulk of the **sample** matrix and to transfer the PCDD residue **into** the solvent(s). Both the selection of the proper solvent(s) and the method of extraction can be critical in obtaining a satisfactory recovery of PCDDs from the sample matrix. A number of solvents including hexane, hexane-acetone, benzene, **toluene**, **chloroform** and methylene chloride generally have been used for extracting PCDDs from sample matrix (**Kooke et al.**, 1981; Harless et **al.**, 1980; Van Ness et **al.**, **1980**). If the sample does not contain water, as is the case **with** fly ash and atmospheric **particulate** samples, either benzene or toluene appears to be the desirable solvent

(Kooke et al., 1981). Toluene should be preferred over **benzene, however,** because of **its lower toxicity.** For the extraction of PCDDs from aquatic **media,** a solvent leading to **high** partition coefficient should be selected. No systematic study, however, has been done on the **extractability** of these compounds from aquatic media by different solvents.

The **lipid** content of different tissues may also influence the amount and the nature of extraction **solvent.** For example, **chloroform-methanol is** effective for serum and plasma, but it produces emulsion **with milk** containing higher **lipid (Albro, 1979).**

In other sample matrices that contain **high** amounts of water, such as tissues and food samples, the water may alter the extractability of a solvent. For example, although acetone may be a good solvent for **soil** extraction, the admixture of a small amount of water decreases the solubility of the substrate so that **it** cannot be used directly for animal tissues. **Mixtures** of polar and nonpolar solvents such as benzene-methanol may separate **into** two phases in the presence of 2% water, resulting in non-reproducible extraction (Albro, 1979).

Samples that may contain PCDDs bound to the matrices, such as tissue, food, **soil** and sediment, may require acid/base digestion procedures to release the bound substrate **into** the extraction media. The acid/base extraction is normally done **with** concentrated acid or an alcoholic base (**Tosine, 1981; Harless et al., 1980).** Kooke et al. (1981) reported highest extraction efficiencies by acid treatment of fly ash before extraction. The increase in efficiency was hypothesized to be due to opening of some of the pores **in** the fly ash structure, thus making the **solvent** more accessible to the sorbed PCDDs. **Refluxing with** alkaline potassium hydroxide, however, may cause decomposition of the higher **polychlorinated dioxins** and oxidation

of some products (Hass and Friesen, 1979; Albro, 1979). A **neutral** extraction system is reported to circumvent the possibility of **this** loss and has been used by several authors (O'Keefe et al., 1978; Harless et al., 1980).

The extraction efficiency may also depend on the method of extraction. The extraction efficiencies of PCODs by **simple** shaking, Ultrasonication and **soxhlet** extraction were studied by a few Investigators (Kooke et al., 1981; Chess and Gross, 1980). **While** Chess and Gross (1980) reported no significant improvement in extraction efficiencies of PCODs from fly ash by **sonication** or soxhlet extraction, Kooke et al. (1981) found soxhlet extraction to be a better procedure than the other two methods. Similarly, Albro (1979) reported that the nature of the sample matrix influences the effectiveness of extraction. Thus, **while** it may be possible to extract liver in a **Teflon-glass homogenizer**, brain tissues may require a **blender**, and **skin** a **powerful** disintegrator such as the Polytron for the extraction of residues.

3.3.1.2. **SAMPLE CLEANUP** - The sample cleanup procedure normally consists of three **essential** steps. A fourth step is usually required if an **isomer** specific **identification** and quantification is required. The first step in the **cleanup** procedure consists of the **removal** of **lipids** from the extracted sample matrix. The **lipid** cleanup can be achieved by two routes, **namely**, solvent extraction or reaction **with** an acid or a base. The use of solvents such as hexane, hexane-acetone, chloroform, chloroform-methanol and petroleum ether (NRCC, 1981b) is common. The use of nonpolar **solvents** (hexane or  $CCl_4$ ) gives **excellent** results when **lipids** consist primarily of **triglycerides** and/or **phospholipids**. When the **lipid** consists of cholesterol esters, however, **sulfuric acid** treatment gives a better result than **non-polar solvent** extraction (Albro, 1979). **Similarly**, base wash of the organic phase may remove interfering **lipids** and other materials through **saponification**, hydrolysis or degradation. However, acid wash is more commonly used

than **base** wash presumably because of the probability of decomposition (**Albro, 1979**) and oxidation (**Hass and Friesen, 1979**) of sample components as a result of base wash. The **possibility** of decomposition of higher PCDDs by the base may be the reason for its less frequent use. It should be mentioned that some Investigators used **chromatographic** columns such as silica gel containing **sulfuric acid** for the acid/base cleanup step. Instead of washing off the **lipids** by simple shaking (**Lamparski et al., 1979; Fanelli et al., 1980a; Langhorst and Shadoff, 1980; Buser, 1978; DiDomenico et al., 1980a**).

The second step in the **cleanup** procedure consists of **removal** of common impurities such as pesticide residues from the PCDDs. Liquid chromatography **with** alumina, **Florisil**, silica, foam **charcoal** or carbon dispersed on glass fibers has been used for **this** purpose (Harless et al., 1980; **Mitchum et al., 1980; Chess and Gross, 1980; Buser, 1978; Tiernan et al., 1980; Stalling et al., 1983; Buser and Rappe, 1983**). A few Investigators have used **AgNO<sub>3</sub>-impregnated silica gel columns** (Lamparski et al., 1979; **Tosine, 1981; Langhorst and Shadoff, 1980**). The **AgNO<sub>3</sub>/silica** column system is claimed to be effective in the removal of DDE, chlorinated **aliphatics** and **sulfides**.

There is a difference between the various alumina columns (Lamparski et al., 1979; **Harless et al., 1980**). The separation of PCDDs from PCBs may be accomplished **with** acidic, neutral and basic alumina; most authors have provided no reason for choosing one over the other. However, it has been shown by Albro (1979) that acidic alumina may be better than basic alumina, which in turn may be better than neutral alumina for the separation of residual **lipids** from the PCDDs in the sample extracts.

The third step in the cleanup procedure is used solely as an additional cleanup of contaminants and has been used by a few Investigators (Langhorst and Shadoff, 1980; Lamparski et al., 1979; Mitchum et al., 1980). The removal of these additional Impurities has been obtained by using HPLC with both normal and reversed phase packing materials. Recently, Phillipson and Puma (1980) reported that chlorinated methoxybiphenyls in fish extract could coelute with TCODs through an alumina-Florisil cleanup sequence and Interfere with the determination of TCODs. A few compounds that may Interfere with the determination of TCOD at m/e values of 319.8966 and 321.8936 are given in Table 3-3.

The additional cleanup step using the HPLC separation procedure may be essential for the unequivocal separation of Impurities that may Interfere with the MS analysis of PCDDs.

The fourth and final cleanup step consists of the separation of PCODs into several different fractions by means of chromatographic techniques. Both liquid chromatography with alumina columns (Hass et al., 1978; Albro and Corbett, 1977) and HPLC with normal and reverse phases have been used (Tosine, 1981; Ryan and Pilon, 1980; Langhorst and Shadoff, 1980; Mitchum et al., 1980). The separation of PCDDs using HRGC is necessary for the unequivocal separation of 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD and 1,2,3,7,8,9-HxCDD from the other congeners. Buser and Rappe (1983) have shown that this separation can be achieved using a 55 m Silar column. The unequivocal separation of 2,3,7,8-TCDD from other isomers has been accomplished by a combination of reverse phase and normal phase HPLC, and packed column GLC by Langhorst and Shadoff (1980). The cleanup procedure used by most of the other Investigators has failed to demonstrate this unequivocal separation of all the TCDD Isomers. The various cleanup and analysis procedures have been compared by Brumley et al. (1981).

TABLE 3-3

## Potential Interferences in the Determination of TC00s at m/e Values of 319.8966 and 321.8936\*

| Compound                             | Molecular Formula              | Interfering Ion            | m/e              | Resolution for Separation |
|--------------------------------------|--------------------------------|----------------------------|------------------|---------------------------|
| Heptachlorobiphenyls                 | $C_{12}H_3^{35}Cl_7$           | $M^+ - 2^{35}Cl$           | <b>321.8678</b>  | 12476                     |
| Nonachlorobiphenyls                  | $C_{12}H^{35}Cl_9$             | $M^+ - 4^{35}Cl$           | 319.8521         | 7189                      |
|                                      | $C_{12}H^{35}Cl_8^{37}Cl$      | $M^+ - 3^{35}Cl - ^{37}Cl$ | <b>321.8491</b>  | 7233                      |
| Tetrachloromethoxy biphenyls         | $C_{13}H_8^{35}Cl_4O$          | $M^+$                      | <b>319.9329</b>  | 8805                      |
|                                      | $C_{13}H_8^{35}Cl_3^{37}ClO$   | $M^+$                      | 321.9299         | 8848                      |
| Tetrachlorobenzyl-phenyl ethers      | $C_{13}H_8^{35}Cl_4O$          | $M^+$                      | <b>319.9329</b>  | 8813                      |
|                                      | $C_{13}H_8^{35}Cl_3^{37}ClO$   | $M^+$                      | 321.9300         | 8843                      |
| 3-12 Pentachlorobenzyl-phenyl ethers | $C_{13}H_7^{35}Cl_4^{37}ClO$   | $M^+ - H^{35}Cl$           | 319.9143         | 18043                     |
|                                      | $C_{13}H_7^{35}Cl_3^{37}Cl_2O$ | $M^+ - H^{35}Cl$           | <b>321.91138</b> | 18104                     |
| DDT (4 Isomers)                      | $C_{14}H_9^{35}Cl_3^{37}Cl_2$  | $M^+ - H^{35}Cl$           | 319.9321         | 9006                      |
|                                      | $C_{14}H_9^{35}Cl_2^{37}Cl_3$  | $M^+ - H^{35}Cl$           | 321.92917        | 9050                      |
| DDE (4 Isomers)                      | $C_{14}H_8^{35}Cl_2^{37}Cl_2$  | $M^+$                      | <b>319.9321</b>  | 9011                      |
|                                      | $C_{14}H_8^{35}Cl^{37}Cl_3$    | $M^+$                      | 321.92916        | 9052                      |
| Hydroxytetrachloro-dibenzofurans     | $C_{12}H_4Cl_4O_2$             | $M^+$                      | 319.8966         | NR                        |
|                                      |                                |                            | 321.8936         | NR                        |
| Tetrachlorophenyl-benzoquinones      | $C_{12}H_4Cl_4O_2$             | $M^+$                      | 319.8966         | NR                        |
|                                      |                                |                            | 321.8936         | NR                        |
| Tetrachloroxanthenes                 | $C_{13}H_6O^{35}Cl_3^{37}Cl$   | $M^+$                      | 319.9143         | 18043                     |
|                                      | $C_{13}H_6O^{35}Cl_2^{37}Cl_2$ | $M^+$                      | 321.9114         | 18104                     |

\*Source: NRCC, 1981b

NR = Not resolved by MS

The **cleanup** of the samples through liquid **chromatography with** subsequent quantification of PCDDs requires concentration of the sample solution. Evaporation to dryness by an Inert gas stream appears to be an accepted procedure for concentrating the TCDD solutions. If the concentration procedure is not **properly controlled**, it can introduce error in two different ways. It has been shown by **Lamparski et al.** (1979) that concentration of sample solution **with prepurified** nitrogen can introduce severe contamination. Therefore, further purification of the gas stream **with** a series of traps containing 10% **Aptezon L** plus 10% each **micronized** Carbopack B and Amoco **PX-21** on 60/80 Chromosorb **W-AW**, 13 x molecular sieve, 20% **H<sub>2</sub>SO<sub>4</sub>** on Blo-S11 A, and **Carbosieve** 8S were required. Secondly, **O'Keefe et al.** (1982) have demonstrated that significant losses of **2,3,7,8-TCDD** occur when nitrogen evaporation to dryness is done at temperatures >50°C.

**3.3.1.3. SAMPLE ANALYSIS** - The final analysis of PCDDs is almost **exclusively** performed by **GC/MS**. **Although** some of the earlier Investigators (**Lamparski et al.**, 1978; **Firestone**, 1977b) used GC **with** electron capture detection, it does not have the sensitivity for complex samples containing low levels (<10 ng **kg<sup>-1</sup>**) of PCDDs (**Hass and Friesen**, 1979).

The final separation procedure for PCDD analysis uses GC **with** packed or capillary columns. A typical **list** of packed and capillary columns used for the analysis of PCDDs is given in Table 3-4. Capillary columns are preferable over packed columns because they provide better separation of components **in** a complex mixture than packed columns. There are other advantages of capillary columns, **namely**, that the narrow band width of the separated components enhances MS sensitivity, and the **capillary** columns **with** their **low** bleed rates enhance MS sensitivity by keeping the background contamination low. A disadvantage of the capillary columns relative to the packed columns

TABLE 3-4

Some Packed and Capillary Columns Used for the Analysis of PCDDs

| <b>PACKED COLUMNS</b>   |   |
|---|---|
| 1.8 m x 2 mm <b>i.d.</b> , 354 <b>Dexsil 300</b>  | Van Ness et <b>al.</b> , 1980           |
| 0.6-2 m x 2.5 mm <b>i.d.</b> , 3X <b>OV-1</b> , 3X <b>OV-17</b> ,<br>3X <b>OV-61</b> , 2X <b>OV-101</b> | <b>DiDomenico</b> et <b>al.</b> , 1980a |
| <b>1.8</b> m x 2 mm <b>i.d.</b> , 3X <b>OV-7</b>  | <b>Tiernan</b> et <b>al.</b> , 1980     |
| 2 m x 2 mm <b>i.d.</b> , 3X <b>OV-210</b>   | Parker et <b>al.</b> , 1980             |
| 2 m x 2 mm <b>i.d.</b> specially packed 0.2X carbon<br>wax 20 M (Aue packing)                           | <b>Eiceman</b> et <b>al.</b> , 1981     |
| 2 m x 2 mm <b>i.d.</b> , 0.6X <b>OV-17</b> /0.4X <b>Poly S179</b>                                       | Langhorst and Shadoff, 1980             |
| 2 m x 4 mm <b>i.d.</b> , 1.2X <b>Silar 10C</b>  | Firestone et <b>al.</b> , 1979          |
| 1.8 m x 2 mm <b>i.d.</b> , 5X <b>SE-30</b>  | Baughman and <b>Meselson</b> , 1973     |
| <b>CAPILLARY COLUMNS</b>  |   |
| 18 m x 0.3 mm <b>i.d.</b> , <b>OV-61 WCOT</b>   | Buser, 1975                             |
| 22 m x 0.3 mm <b>i.d.</b> , <b>OV-17, 101, Silar 10C</b>  | Buser, 1976                             |
| 50 m x 0.36 mm <b>i.d.</b> , <b>OV-17 WCOT</b>  | Buser and Rappe, 1978                   |
| 30 m x (i.d. not given), <b>SE-30 WCOT</b>  | Harless and Oswald, 1978                |
| 30 m x 0.25 mm <b>i.d.</b> , <b>OV-101 WCOT</b>   | Harless and Lewis. 1980a                |
| 30 m x 0.25 mm <b>i.d.</b> , <b>SE-30 WCOT</b>  | Harless et <b>al.</b> , 1980            |
| 20 m, <b>SP-2100 SCOT</b>   | <b>Mitchum</b> et <b>al.</b> , 1980     |
| 25 m x 0.2 mm <b>i.d.</b> , quartz, methyl <b>silicone</b><br><b>WCOT</b>                               | Norstrom et <b>al.</b> , 1982           |
| 30 m x 0.5 mm <b>i.d.</b> , <b>glass, 60/40 w/w OV-17/<br/>Poly S-179</b>                               | <b>Nestrick</b> et <b>al.</b> , 1980    |
| 50 m x 0.25 mm <b>i.d.</b> , glass <b>Silar 10C</b>   | Buser and Rappe, 1980                   |
| 55 m x 0.37 mm <b>i.d.</b> , <b>glas OV-17</b>  | Buser and Rappe, 1980                   |
| 55 m x 0.40 mm <b>i.d.</b> , glass <b>OV-101</b>  | Buser and Rappe, 1980                   |
| 60 m x 0.26 mm <b>i.d.</b> , <b>Supelco SP-2330</b>   | Rappe et <b>al.</b> , 1983b             |
| 50 m x 0.4 mm <b>i.d.</b> , <b>OV-101 fused silica</b>  | Tiernan, 1983                           |
| 60 m <b>OV-101 WCOT (i.d. unspecified)</b>  | Van Ness et <b>al.</b> , 1980           |



Is the **problem** of easy overload in the presence of other coextracted Impurities. One group of researchers (**Langhorst and Shadoff, 1980**) has used a packed column for the **unequivocal** determination of 2,3,7,8-TCDD in the presence of 21 other **isomers**. However, **this** determination was possible because of the prior separation of components through **fractionation** by HPLC **with** a combination of a reverse phase Zorbax ODS column and a normal phase silica column. DiDomenico et al. (1980a) also found **low** resolution GC suitable for the analysis of ppt levels of TCDDs in **environmental** samples, provided the **samples** are **adequately** precleaned. Although the analysis of environmental samples from the Seveso accident by DiDomenico et al. (1980a) may not have required HRGC column because no other Isomers were expected to have been formed (Buser, 1978), a packed column may not be satisfactory for the unequivocal determination of **2,3,7,8-TCDD** in the presence of Interference from other TCDD Isomers (Hummel and Shadoff, 1980).

The separation of 2,3,7,8-TCDD from **all** the other 21 Isomers **is difficult** even **with capillary** columns. A combination of **OV-101** and **OV-17** glass capillary columns of 20-30 m length and 0.35-0.37 mm i.d. was required for unequivocal separation of 2,3,7,8-TCDD from the other 21 Isomers of TCDD (Buser, 1978). However, a Silar **10C** glass capillary column of 55 m length and 0.25 mm **i.d.**, and **with** a theoretical plate number of 192,000, provided almost unambiguous separation of 2,3,7,8-TCDD from **its** other Isomers (Buser and Rappe, 1980). Other capillary columns known to separate 2,3,7,8-TCDD from the other TCDD Isomers **include** SP-2340, SP-2330 and S1lov (**Tiernan, 1983**). A 50 m **length** of a Silar **10C capillary** column has been recommended by the U.S. EPA (1982a) for the determination of 2,3,7,8-TCDD in municipal and Industrial wastewaters. The same column can also be used for the unequivocal separation of **1,2,3,7,8-PeCDD** and **1,2,3,6,7,8-** and **1,2,3,7,8,9-HxCDD** from the less toxic congeners.

As previously mentioned, MS is used almost exclusively for the detection and quantification of PCDDs. Basically, three MS techniques (LRMS, HRMS and NICI) have been used. A few different MS systems used for the determination of TCDDs are shown in Table 3-5. It is obvious from Table 3-5 that electron impact ionization in the low resolution mode (resolution <8000, 10X valley) has been the most widely applied MS method used for the determination of TCDDs.

The electron-impact mass spectra of PCDDs show strong molecular ions ( $M^+$ ). Fragmentation occurs through the loss of CO and Cl radicals. Major ions are at  $M^+-63$  ( $M^+-COCl$ ) and  $M^+-126$  ( $M^+-2COCl$ ). Doubly charged molecular ions ( $M^{2+}$ ) and minor fragmentation ions occur at  $M^+-35$  ( $M^+-Cl$ ),  $M^+-70$  ( $M^+-2Cl$ ) and  $M^+-98$  ( $M^+-COCl-Cl$ ). The usual characteristic ion clusterings caused by the chlorine isotopes are also observed. Based on molecular ions and fragmentation pattern, PCDDs can be distinguished from other chlorinated pollutants. However, this requires monitoring multiple ions. The ions that are commonly monitored for 2,3,7,8-TCDD are  $M^+$  and its chlorine isotope clusters, that is, 320 ( $^{35}Cl_4$  CDD), 322 ( $^{35}Cl_3^{37}Cl$  CDD) and 324 ( $^{35}Cl_2^{37}Cl_2$  CDD). In some instances, fragment ions at 257 ( $320-CO^{35}Cl$ ), 259 ( $322-CO^{35}Cl$ ) and 194 ( $320-2CO^{35}Cl$ ) are also monitored. The intensity ratios in the mass spectrometric peaks that are due to chlorine isotope proportions in native TCDD can be used for assessing the degree of interference and confirming the identity of the TCDDs. Thus, the relative peak intensities of pure 2,3,7,8-TCDD at 320:322:324 are expected to be 77:100:49 (NRCC, 1981a). The response for the ion at 257 is ~30% of the response for the ion at 322 (Glaser et al., 1981). Sometimes internal standards containing ( $C_{12}H_4^{37}Cl_4O_2$ ) or ( $^{13}C_{12}H_4^{35}Cl_4O_2$ ) used for TCDD analysis give prominent ion peaks at 328 and 332, respectively. The primary

TABLE 3-5

The Detection Limit, Resolution and Ions Monitored by a Few Mass Spectrometric Systems for the Determination of TCDDs<sup>a</sup>

| Ionization Method and Reference | TCDD Limit of Detection (pg) | M/ΔM <sup>b</sup> | m/e Values Monitored for TCDD |     |     |     |     |     |     |     |     |
|---------------------------------|------------------------------|-------------------|-------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|
|                                 |                              |                   | 320                           | 322 | 324 | 326 | 328 | 332 | 259 | 257 | 194 |
| <u>ELECTRON IMPACT</u>          |                              |                   |                               |     |     |     |     |     |     |     |     |
| Baughman and Meselson, 1973     | 5                            | 10,000            | +                             | +   |     |     |     | +   |     |     | +   |
| Crummett and Stehl, 1973        | 6                            | 600               | +                             | +   | +   |     |     |     |     |     |     |
| Hummel, 1977                    | 5-10                         | 400               | +                             | +   |     |     |     | +   |     |     |     |
| Hummel, 1977                    | <b>5-10</b>                  | 3,000             | +                             | +   |     |     |     | +   |     |     |     |
| Mahle et al., 1977              | 5                            | NR                | +                             | +   |     |     |     | +   |     |     |     |
| Adamoli et al., 1978            | 50                           | <b>unit</b>       | +                             | +   | +   |     |     |     |     |     |     |
| Adamoli et al., 1978            | 50                           | <b>unit</b>       | +                             | +   | +   |     |     |     |     |     |     |
| O'Keefe et al., 1978            | NR                           | 10,000            | +                             | +   |     |     |     | +   |     |     |     |
| DiDomenico et al., 1980a        | 20                           | <b>unit</b>       | +                             | +   | +   |     |     |     |     |     |     |
| Buser and Rappe, 1980           |                              | <b>unit</b>       | +                             | +   | +   |     |     |     |     |     |     |
| Cavallaro et al., 1980a         | 40-80                        | <b>unit</b>       | +                             | +   | +   |     |     | +   |     |     |     |
| Chess and Gross, 1980           | 50                           | 2,000             | +                             | +   |     |     |     |     |     | +   | +   |
| Fanelli et al., 1980a           | 250                          | 400               | +                             | +   |     |     |     |     |     |     |     |
| Harless et al., 1980            | 5-10                         | 9,000             | +                             | +   |     | +   | +   |     |     | +   | +   |
| Langhorst and Shadoff, 1980     | 5                            | 1,000             | +                             | +   |     |     |     |     | +   |     |     |
| Lamparski and Nestricks, 1980   | 40-60                        | <b>unit</b>       | +                             | +   | +   |     |     |     | +   |     |     |

TABLE 3-5 (cont.)

| Ionization Method and Reference | TCDD Limit of Detection (pg) | M/ΔM <sup>b</sup> | m/e Values Monitored for TCDD  |     |     |     |     |     |     |     |     |   |
|---------------------------------|------------------------------|-------------------|--|-----|-----|-----|-----|-----|-----|-----|-----|---|
|                                 |                              |                   | 320  | 322 | 324 | 326 | 328 | 332 | 259 | 257 | 194 |   |
| Norstrom et al., 1982           | 5-10 <sup>c</sup>            | unit              | +  | +   | +   |     |     |     |     | f   |     | + |
| Tosine, 1981                    | 10 <sup>c</sup>              | unit              | +  | +   | 4   |     |     |     |     | +   |     |   |
| Ryan and Pilon, 1980            | 10 <sup>c</sup>              | 1,000             |  | +   |     |     |     |     |     |     |     |   |
| Tlernan et al., 1980            | 1 <sup>d</sup>               | 350               | +  | +   |     |     |     |     |     |     |     |   |
| Tlernan et al., 1980            | 100 <sup>c</sup>             | 12,500            | +  | +   |     | +   |     | +   |     |     |     |   |
| <u>CHEMICAL IONIZATION</u>      |                              |                   |  |     |     |     |     |     |     |     |     |   |
| Hass et al., 1978               | 50-500                       | unit              | 323 for <b>MNCI<sup>e</sup></b> , 252 and 276 for <b>MONCI<sup>f</sup></b> , 176 for <b>ONCI<sup>g</sup></b> |     |     |     |     |     |     |     |     |   |
| Mitchum et al., 1980            | 10                           | NR                | -176 from 320, -182 from 332 by <b>ONIAPCI<sup>h</sup></b>   |     |     |     |     |     |     |     |     |   |

<sup>a</sup> Source: NRCC, 1981a

<sup>b</sup> resolution of mass

<sup>c</sup> ng.kg<sup>-1</sup>

<sup>d</sup> μg.kg<sup>-1</sup>

<sup>e</sup> methane negative chemical ionization

<sup>f</sup> methane-oxygen negative ion chemical ionization

<sup>g</sup> oxygen negative ion chemical ionization

<sup>h</sup> oxygen negative ion atmospheric pressure chemical ionization

NR = Not reported

**M<sup>+</sup> ions** for PeCDDs and HxCODs are 356 and 390. If exact masses are used, the **normal** ion masses at 320, 322, 328, 257 and 259 **will** correspond to 319.8965, 321.8936, 327.8847, 256.9327 and 258.9298, respectively. Thus, **HRMS with appropriate resolution** in most cases may positively identify **2,3,7,8-TCDD** when the **sample cleanup** is not specific (**Humme**) and **Shadoff**, 1980). However, an **unequivocal identification** and quantification of **2,3,7,8-TCDD** in the presence of **its isomers will still** require HPLC **fractionation** or HRGC separation as described earlier.

The following criteria have been outlined by Harless et al. (1980) for confirmation of 2,3,7,8-TCDD residues:

1. Correct GC retention **time** for 2,3,7,8-TCDD.
2. Correct Isotope ratio for the **molecular ions** 320 and 322.
3. Correct **simultaneous** response for the **molecular ions** 320, 322 and 328.
4. Correct responses for the co-injection of sample fortified **with <sup>13</sup>C<sub>1</sub>-TCDD** and 2,3,7,8-TCDD standard.
5. Intensity of molecular **ions** 320 and 322 must be **>2.5** times the noise level.

**Supplemental** criteria that **Harless et al.** (1980) suggested for highly contaminated extracts are:

1. COCl loss Indicative of TCDD structure.
2. GC/MS peak-matching analysis of molecular **ions** 320 and 322 **in real time** to confirm the 2,3,7,8-TCDD elemental composition.

Although the limit of detection for TCDD is about the same on both HRMS and LRMS (**Crummett, 1983**), the advantage of HRMS over LRMS for PCDD analysis **is** that the former technique requires far less time-consuming cleanup steps than those required for LRMS although **this** is dependent on the nature of the

sample. **With** the use of properly selected analytical techniques, the PCDDs can be determined down to sub ppt levels (**Crummett**, 1983).

The use of chemical ionization techniques has received **limited** application for the Individual TCDD **isomers**. Other methods not requiring coupling GC **with** MS have also been used for PCODs. For example, the method of direct probe and specific ion monitoring ( $M^+ \rightarrow M_1^+ + COCl$ ) based on the concept of MS-MS was used for the analysis of TCDD (Chess and Gross, 1980). Although the method had comparable specificity to **GC-HRMS**, the precision of the method was not as good.

3.3.2. Analysis of PCDDs in Specific Environmental Media. Although the general procedure for the analysis of PCDDs levels has been discussed in Section **3.3.1.**, the detailed **analytical** procedures depend on the type of medium. For **this** document, the environmental media have been divided **into** four classes, namely, water, **air**, **soil** and biological media, and the techniques used for the sampling and analysis of PCDDs in each medium have been discussed individually.

#### 3.3.2.1. WATER -

3.3.2.1.1. Sampling Method - Two types of sampling methods can be used for collecting aqueous samples for PCDDs. In the first method, no preconcentration of the samples during collection **is** made. Grab samples are collected **in** clean (detergent washed, rinsed **with** acetone or methylene chloride, and dried) amber glass bottles of 1 **l** or 1 quart capacity fitted **with** screw caps **lined with** Teflon or **aluminum foil** (U.S. EPA, 1982a). If aluminum **foil is** used as a **liner**, **it** should be washed **with** acetone and the dull **side** should face the sample to avoid sample contamination (**Albro**, 1979). Automatic samplers can also be used for collecting flow proportional composite samples in amber glass bottles (U.S. EPA, 1982a). The sample

containers must be kept refrigerated at 4°C and protected from light during compositing. The grab or the composite-samples should be protected from light and be kept at 4°C during shipment. All samples must be extracted within 7 days and completely **analyzed** within 40 days of extraction (U.S. EPA, 1982a).

The **preconcentrative** method of sample collection was used by **DiDomenico et al.** (1980a). In **this method**, 2-20  $\mu$  of water was allowed to pass through a 12 cm x 1.5 cm i.d. XAD-2 column at a rate of 60 ml/minute. The XAD-2 columns containing the PCDOs should be protected from light and kept at 4°C during transportation and storage.

3.3.2.1.2. Analysis -- Most of the methods found in the **literature** described **2,3,7,8-TCDD** analysis. Instead of other PCDD analyses in aqueous samples. The methods used for the analysis of **2,3,7,8-TCDD** can be used also for the analysis of the other PCDDs. However, the recovery of the individual PCDDs should be established **with** added Internal standards.

An appropriate volume of water (depending on the desired detection limit) **with** added Internal standard of either  $^{13}\text{C}_{12}$  or  $^{37}\text{Cl}_4$  **2,3,7,8-TCDD** in the amount of 2.5-25 ng (Harless et al., 1980; U.S. EPA, 1982a) can be extracted **with** hexane (**DiDomenico et al.**, 1980a), **methylene** chlorine (U.S. EPA, 1982a; **Harless et al.**, 1980) or petroleum ether (Van Ness et al., 1980). **Judging** from the recovery data (U.S. EPA, 1982a; **DiDomenico et al.**, 1980a; **Harless et al.**, 1980) methylene chloride appears to be a better **solvent**.

The extract containing 2,3,7,8-TCDD was cleaned by **acid** and base wash (Harless et al., 1980; U.S. EPA, 1980b; Van Ness et al., 1980) and further cleaned by liquid chromatography **with** alumina column (Harless et al., 1980; Van Ness et al., 1980). However, U.S. EPA (1982a) recommends another

cleanup step using silica gel liquid chromatography, which may be necessary for **wastewater** but may be unnecessary for drinking water and clean surface water samples. The final separation and analysis was performed by low **resolution GC-HRMS** (Van Ness et al., 1980; Harless et al., 1980) or **high resolution GC-HRMS** or **LRMS** (U.S. EPA, 1982a). If an **unequivocal** Identification of **2,3,7,8-TCDD** is required, the U.S. EPA (1982a) method seems to be most appropriate since it recommends using a 50 m Silar **10C** capillary column and **multiple** ion monitoring MS mode that is known to unequivocally identify and quantify 2,3,7,8-TCDD in the presence of its other **isomers** (Buser and Rappe, 1980). Harless et al. (1980) reported that TCDD in water can be accurately determined to as low a concentration as 0.03 ppt.

#### 3.3.2.2. AIR --

3.3.2.2.1. Sampling Method - Monitoring of PCDDs from point sources of emission and ambient atmospheric level requires development of sample collection methods from both sources. The available published work suggests that the PCDDs are associated **primarily with particulate** matters (NRCC, 1981b).

For the collection of **air** samples from hot point sources, namely exhaust from an Incinerator, a number of commercially available sampling probe and sampling trains are available. Most incorporate filters to isolate the particles and a subsequent device to trap gaseous **organics** from the exhaust. For PCDDs, glass fiber filters of proper pore **size** are generally used (NRCC, 1981b). The filter should be maintained at a temperature of **>100°C** to prevent condensation of water. PCDDs that may escape the glass filters may be collected in a **polyurethane** foam or **XAD-2** trap maintained at room temperature. The **sampling** must be performed in an **isokinetic** manner to ensure representative sampling. To permit evaluation, the efficiency of the



**collection** method must be documented. The sampling **methodology** for point sources is in a developmental stage (NRCC, 1981b) and more work is needed in **this** area. The recommendations for sample collection procedure given above follow the general U.S. EPA procedure for collection of **air** samples from hot point sources. A modified U.S. EPA Method 5 **sampling** train (Federal Register, 1971) consisting of a **filtering unit**, a condenser **unit**, a resin cartridge **unit** and a series of impingers have been used by Stanley et al. (1982) to collect PCDOs in **flue** gas samples from utility boilers.

The collection of PCDDs in ambient atmospheric samples has been achieved by both dustfall jars and **high volume samplers** (DiDomenico et al., 1980b). Dustfall jars were constructed from 10 **l** glass **vessels** topped **with** metal **gridded** funnels **with** a collecting cross section of about 0.11 m<sup>2</sup>. The top of the funnels were about the human breathing level from the ground. The **grid** allowed particles <500 **µm** to be **collected**. Samples were collected for 1 month or the **time** required for the vessel to be **filled with meteoric** water and dust. At the end of the sampling **time**, the liquid phase was separated from the particles by filtration and the two phases were analyzed separately.

The **high** volume sampling was performed **with high** volume samplers equipped **with** A and E glass fiber filters at a flow rate of 1.5 m<sup>3</sup>/minute (DiDomenico et al., 1980b). The **sampling** duration was about **160** hours. The whole sampling **unit** was assembled **into** a protective container. The efficiency of sample collection by either of the above methods was not established. The **high** volume sampling can lead to stripping of PCDDs from the filter. A backup filter consisting of **polyurethane** foam plug may be used to prevent **this** anticipated **loss**. **Particulate** and vapor phase **TCDD** was also

collected by **polyurethane foam filters** (U.S. EPA, 1982b; Nash and **Beall**, 1980). The collection efficiency **with this** system was determined to be 86% by Nash and Beall (1980).

3.3.2.2.2. Analysis -- The analysis of PCDDs in the particulate matter begins **with** an extraction process. As has been shown in Section **3.3.1.1.**, the best extraction efficiency **is** obtained **with** dilute HCl pretreated particles, followed by Soxhlet extraction **with** benzene or toluene. Liberti and Brocco (1981) found that xylene was a better solvent than toluene, while **Cutie** (1981) found that o-dichlorobenzene may be better than any of the other solvents. Various extraction procedures for combustion effluent samples have been described by Taylor et al. (1983).

Several methods are available for sample cleanup before analysis. [Basically, the methods used for the analysis of fly ash can be used for particulate matter (Liberti and Brocco, 1981; **Eiceman et al.**, 1980; **Tiernan**, 1983; **Buser et al.**, 1978)]. In one analytical procedure, **Lamparski** and **Nestrick** (1980) added internal standards of **<sup>13</sup>C-2,3,7,8-TCDD**, **<sup>13</sup>C-1,2,3,4,7,8-HxCDD** and **<sup>13</sup>C-OCDD** to the particulate extract. The extract was cleaned **with acid** and base washes. Next, the extract was cleaned by liquid **chromatography with AgNO<sub>3</sub>/silica** column and basic alumina column, followed by cleanup and sample **fractionation with** an RP-HPLC (Zorbax ODS) and a normal phase HPLC (silica) method. The final analysis was performed **with** low resolution **GC-LRMS**. This method provided an unequivocal identification of **isomers** and permitted analysis of a minimum concentration of 110 ppt of **2,3,7,8-TCDD** in **electrostatically** precipitated fly ash from a municipal burner.

In another method (Rappe et al., 1983b; Buser and Rappe, 1983), the sample (soot or Kleenex tissue from wipe tests) was spiked with 1-5 ng of 2,3,7,8-<sup>13</sup>C<sub>12</sub>-TCDD, 2,3,7,8-<sup>37</sup>C<sub>14</sub>-TCDF (tetrachlorodibenzofuran) and <sup>37</sup>C<sub>8</sub>-OCDD and treated with 1 M hydrochloric acid. The PCDDs and PCDFs in the washed and dried sample were extracted with toluene in a Soxhlet extractor and the extract was subjected to column chromatography on silica gel and basic alumina column. The methylene chloride-n-hexane (1:1) fraction from the second column containing PCDDs and PCDFs was subjected to HRGC/MS analysis. A 55 m x 0.26 mm i.d. Silar column was found to be suitable for the isomeric separation of all 22 isomers of TCDD.

### 3.3.2.3. SOIL -

3.3.2.3.1. Sampling Method - Since similar analytical methods are used for both soil and sediments, this subsection describes the sampling and analytical methods for these two sample types.

Whenever possible, the sites for soil samples should be chosen in open areas away from physical obstacles. If the soil is suspected to be contaminated because of fallout from a point source, sampling sites should be established in a grid over a topographical map of the suspected area. Soil samples may be collected by inserting a 0.5 m long and 7 cm i.d. steel cylinder into the soil to a depth of 7 cm and then retracting the soil and the cylinder system. The earth core should be removed and stored in sealed plastic bags (DiDomenico et al., 1980c). The bags should be cooled to 4°C during transportation.

To determine the distribution of PCDDs in soil, samples can be taken from the vertical faces of dug trenches of a maximum depth of 2 m. Suitable steel core cylinders can be inserted horizontally into the trench face from bottom to top. The individual samples collected in this fashion should be

stored in plastic bags at 4°C during transportation them. The details of the **soil** sampling procedure have been described by **DiDomenico et al. (1980a,c)**.

Although no sampling procedure for the collection of sediment samples for PCDD analysis **is available**, the accepted method (U.S. EPA, 1979a) for the collection of bottom sediments should be adequate in **this** case. Clam-type or similar dredge samplers, such as Peterson, **Shipek** or Hopper samplers, can be used to collect sediment sample. Core samplers can also be used for collecting bottom sediments. The collected samples should be stored in glass containers **with teflon-lined** screw caps, and stored at 4°C during transportation.

3.3.2.3.2. Analysis - Several methods are available for the analysis of PCDDs in **soil** samples (Chess and Gross, 1980; Van Ness et al., 1980; Buser, 1978; Buser and Rappe, 1980; Harless et al., 1980). Although most of these methods have been used for the analysis of **2,3,7,8-TCDD**, they are applicable for other PCDDs. The methods used for the analysis of **soil** can also be used **with** very **little** modifications for the analysis of sediments.

The first step in the analysis is the extraction of PCDDs from the **soil with** a suitable solvent or a solvent mixture. A number of solvents including hexane-acetone (1:1), methylene chloride (Buser and Rappe, 1980), aqueous **KOH/ethanol** (Harless et al., 1980), benzene (Chess and Gross, 1980), petroleum ether (Van Ness et al., 1980), and a number of extraction methods including simple shaking (Van Ness et al., 1980; Buser and Rappe, 1980), **refluxing** (Harless et al., 1980), **sonication** and soxhlet extraction (Chess and Gross, 1980), have been used. However, Chess and Gross (1980) demonstrated that, in **soil**, the results obtained by simple stirring **with** 1:1 hexane/acetone and the more extensive sonication or soxhlet extraction **with** benzene are consistent.

The cleanup procedure for the extract generally consists of an acid and base **wash**, liquid **chromatography** on silica and alumina columns or two alumina **columns**, and final analysis by **HRGC-LRMS** or **HRGC-HRMS** (Harless et al., 1980; Buser and Rappe, 1980). If an unequivocal Identification and quantification of **2,3,7,8-TCDD** is required, the 55 m Silar **10C** capillary column used by Buser and Rappe (1980) or the 60 m **SP-2330** fused silica column (Rappe et al., 1983b) is **preferable** to the 30 m SE-30 **capillary** column used by Harless et al. (1980). The **HRMS** technique used by Harless et al. (1980) is expected to provide a better **resolution** of components than the **LRMS**. The method of Harless et al. (1980) was suitable for the determination of ppt levels of TCDD in soils.

3.3.2.4. **BIOLOGICAL MEDIA** - In **this** section, the sampling and analysis of PCODs **in** a number of media, namely, blood, urine, **fish**, egg, gelatin, liver, **milk**, cream, lean and adipose tissue, grain, grass, **leaves**, vegetables and sawdust, **will** be discussed in general.

3.3.2.4.1. **Sampling Methods** - **Only** a limited systematic study has been performed on the methods of sample collection for the different **biological** media. A review of available literature reveals certain facts that **should** be considered during **sample** collection. The concentration of PCDDs in blood is ~2-3 orders of magnitude **lower** than their concentrations **in** adipose tissue (Firestone et al., 1979). There is **also** evidence in several species that the **accumulation** of TCDD in liver tissue is higher than **in** adipose tissue (Section 7.2.). Liver is also preferable because its **lipid** content is lower than adipose tissue (samples **with high lipid** content are more difficult to extract and clean up). One of the most convenient sampling media that does not require sacrificing or surgically removing the tissue is **milk**. Because of the **high lipid** content of **milk**, PCDDs are expected to be accumulated in **this** medium (Langhorst and Shadoff, 1980).

The dry solid samples, such as **rice** grain, grass, vegetables and sawdust can be **collected** in **polyethylene** bags. Samples should be frozen in dry ice during transportation and should be stored in a freezer (**-18°C**) until analyzed (Jensen et al., 1983). However, **it** has been reported that tissue samples stored in linear **polyethylene** bottles sorbed **~2%** of added **<sup>14</sup>C-DDT** overnight and the sorbed DDT could not be washed out from the bottle (**Albro**, 1979). Similar absorption of **2,3,7,8-TCDD** on **polyethylene** bags or bottles may take place. The collection of samples **in clean** glass Jars sealed **with** screw caps lined **with** Teflon or acetone-washed aluminum **foil** (dull **side** down) is preferable (Brumley et al., 1981). The sample should be transported at 4°C and frozen until analysis.

3.3.2.4.2. Analysis - Numerous analytical methods are available for the analysis of samples in **this** category (NRCC, 1981a; **Crummett**, 1983; Rappe et al., 1984; Smith et al., 1984). The acid/base and neutral extractions procedures are available. Neutral extraction procedures are preferred over acid/base procedures since the latter may decompose the higher PCDDs. The analytical methods for the determination of PCDDs **in** three typical media, namely, **fish** and lean tissue, adipose tissue, and **milk**, **will** be discussed here. In choosing the **analytical** methods, the results of the study of Brumley et al. (1981) have been given due **considera- tion**.

Fish and other lean tissue samples should be ground to obtain a homogeneous sample. The homogenized sample should be blended **with** anhydrous sodium sulfate until a free-flowing powder **is** obtained. The mixture should be packed **into** a glass column and extracted **with methylene** chloride. The extract should be first cleaned through a dual-column system of silica, concentrated **sulfuric** acid **in** silica, and sodium hydroxide in silica, followed by a second dual-column system of silver nitrate on silica and

basic alumina. The PCDD fractions should then be cleaned up by normal phase silica HPLC, followed by reverse-phase (Zorbax-ODS) HPLC. **This** extraction and clean-up method is a combination of procedures employed by **Huckins et al. (1978)** and **Lamparski et al. (1979)**, and is expected to provide a better method for the analysis of PCDDs in lean tissue samples.

Recently, an **interlaboratory** round robin study to estimate the reliability of data on the determination of **2,3,7,8-TCDD** levels in **fish** and other aquatic species was conducted (Ryan et al., 1983). No significant differences in the determined concentration of **2,3,7,8-TCDD** in these species occurred from methods differing in the use of digestion or extraction technique, **HRMS** or **LRMS**, and **isomer** specific or nonspecific separation. The relative standard deviations in three **fish** samples analyzed by seven laboratories varied between 14 and **25%**. **This** study indicated the necessity for the use of an internal standard to obtain precise results.

Thawed adipose tissue samples should be ground **with** anhydrous sodium sulfate (8 g **Na<sub>2</sub>SO<sub>4</sub>**/g fat) **in** a mortar and pestle to remove excess moisture. The homogenized sample **should** be extracted **with chloroform-methanol** (2:1) in a blender. The **methanol** should be removed from the extract by adding aqueous **KCl**. The chloroform layer should then be subjected to the clean-up procedures. For the cleanup of the chloroform extract, the method described for lean tissue should be followed. The extraction and clean-up method described **is** a combination of procedures employed by Hass et al. (1978) and Lamparski et al. (1979). However, hexane-acetone (1:2) was used by Ryan and Williams (1983) in extracting 2,3,7,8-TCDD from human adipose tissue.

The **milk** samples should be mixed **with** sodium oxalate and **ethanol** and the solution extracted **with** ethyl **ether-hexane** (1:1.4). The ether-hexane extract should be dissolved in hexane and the clean-up procedure described

for **lean** tissue should be followed. For the extraction and clean-up **method**, a combination of procedures employed by **O'Keefe et al.** (1978) and **Lamparski et al.** (1979) may be employed.

3.3.3. Bioanalysis of PCDDs. There are currently three methods for the **bioanalysis** of PCDDs, namely, **radioimmunoassay** (**Albro et al.**, 1979; **McKinney et al.**, 1981), AHH Induction assay (**Bradlaw and Casterline**, 1979) and a cytosol receptor assay (**Hutzinger et al.**, 1981; Sawyer et al., 1983). All of these methods are in the developmental stage and are **neither** specific for PCDDs nor are sensitive enough at low levels. The advantages of these methods are that they are inexpensive and quick compared **with** chemical analytical methods. Therefore, these methods have some potential for **high** volume screening of samples for the presence of PCDDs, but should not be used as substitutes for chemical analysis.

3.3.4. Critique of Sampling and Chemical Analysis. The greatest weaknesses that persist in the determination of PCDD levels in environmental samples are the lack of data for validating the accuracy of sample collection, transportation and storage procedures. The lack of representativeness of samples during collection, loss of sample by **sorption** on container walls or photodecomposition during transportation and storage, and **contami-** nation of the sample by collection equipment or sample containers can all cause errors, particularly in samples **with** very low residue levels. However, no comprehensive study has been done to provide enough guidance **in** the sampling **procedures**.

There are several possible points of weakness in the analytical methods as well. Although some validation data are available for the overall recovery of **2,3,7,8-TCDD** in fortified matrices, these data, as shown in Table 3-6, may not represent the true recoveries, since **it** is difficult if



TABLE 3-6

Some Published Method Validation Data for 2,3,7,8-TCDD Recovered from Fortified Matrices and Determined by GC/MS

| m/e Values                   | Matrix          | TCDD Level of Fortification, ng/kg <sup>-1</sup> |  | Number of Replicates | Mean X Recovery with S.D.  |                    | Reference                    |
|------------------------------|-----------------|--|--|----------------------|----------------------------|--------------------|------------------------------|
|                              |                 | Native   | Isotope<br><sup>14</sup> C, ( <sup>13</sup> C <sup>1</sup> ) |                      | Native                     | Isotopes           |                              |
| 320. 322. <b>335</b>         | human milk      | 2.6  | 166  | 8                    | <b>25 + 7</b>              | <b>37 + 19</b>     | Langhorst and Shadoff, 1980  |
| 320. 322. 324                | soil            | NA   | 100*   | 6                    | NA                         | 87 ± 15            | Hummel, 1977                 |
| 320. 322. 324                | soil            | 10   | NA   | 28                   | <b>87 ± 17</b>             | NA                 | D'Domenico et al., 1980a     |
| 320. 322. 324.<br>335        | soil            | 50   | <b>16</b>  | 8                    | 99.2 ± 5                   | 59.8               | Lamparski and Westrick, 1980 |
| 320. 322. 328                | fish, liver     | 0-125  | 1000*  | 17                   | <b>±15<sup>c</sup></b>     | B6 ± 15            | Harless et al., 1980         |
| 320. 322. <b>328</b>         | human milk      | 0-5  | <b>250<sup>a</sup></b>                                       | <b>13</b>            | <b>±38<sup>c</sup></b>     | 68                 | Harless et al., 1980         |
| 320. 322. 328                | water, sediment | 0.01-1000  | 250*   | 14                   | <b>±16<sup>c</sup></b>     | 87                 | Harless et al., 1980         |
| 320. 322. 328.<br>329        | water, sediment | 0.7-65   | 66   | 1?                   | <b>85-100<br/>(±8-±17)</b> | 71-87<br>(±12-±21) | O'Keefe et al., 1978         |
| 320. 322. 328                | water, sediment | 2  | NA   | 3                    | <b>83.3</b>                | NA                 | Mahle et al., 1977           |
| 320. 322. 328                | water, sediment | NA   | 625*   | 4                    | NA                         | 64                 | Mahle et al., 1977           |
| <b>320.</b> 322. 328.<br>329 | bovine feed     | 13-200   | <b>390-1000</b>  | 16                   | 80-100<br>(±5-±18)         | 77-105<br>(±9-±18) | O'Keefe et al., 1978         |
| 320. 322. 328                | liver           | 20   | 1000   | 9                    | <b>34 ± 7</b>              | <b>27 ± 5</b>      | Baughman and Meselson, 1973  |

to  
Co

TABLE 3-6 (cont.)

| m/e Values    | Matrix  | TCDD Level of Fortification, ng/kg <sup>-1</sup> |                       | Number of Replicates | Mean X Recovery with S.D.               |          | Reference                  |
|---------------|---------|--|-----------------------|----------------------|---|----------|----------------------------|
|               |         | Native   | Isotope<br>14C, (14C) |                      | Native                                  | Isotopes |                            |
| 320, 322, 324 | carrots | 0.5-1.0  | NA                    | 20                   | 64.5-66.6<br>(+18.9-+25.5) <sup>b</sup> | NA       | Cavallaro<br>et al., 1980b |
| 320, 322, 324 | beets   | 0.5-1.0  | NA                    | 20                   | 60.8-79.8<br>(+17-+17.7) <sup>d</sup>   | NA       | Cavallaro<br>et al., 1980b |
| 320, 322, 324 | spinach | 0.5-1.0  | NA                    | 20                   | 46.6-67.7<br>(+14.2-+24.7) <sup>d</sup> | NA       | Cavallaro<br>et al., 1980b |

<sup>a</sup>Indicates publishing author's recovery data was converted from ng to ppt or from ppt to X.

<sup>b</sup>Plus Indicates fortified with Isotope but amount not specified clearly.

<sup>c</sup>These data Indicate the Mean X accuracy for TCDD obtained with quality assurance samples.

<sup>d</sup>Number in the bracket represents the X variation experienced; unclear as to how calculations were made.

NA . Not added; SD = Standard deviation

not Impossible to Incorporate the Internal standard In the same **physical/** chemical form In the sample matrix as the PCDDs. **This** situation weakens the reliability of much of the analytical data on PCDD levels In various matrices.

The recovery of the overall analytical procedures Is normally done by measuring the recovery of Internal standards such as **<sup>14</sup>C<sub>14</sub>-TCDD** and **<sup>13</sup>C-TCDD**. **Methods** that used Internal standards that exceeded the native TCDD by 50-2500 times are at best questionable. Also, the recovery data based on one Internal standard to correct for another congener or another **isomer**, such as **1,2,3,4-TCDD** for OCDD or **2,3,7,8-TCDD**, may be questionable In **view** of the fact that recovery and response factors may vary between congeners and **isomers**. **This** could cause serious problems **with** the determined detection limits.

Despite some rigorous criteria (**Harless et al.**, 1980) that may be used for positive Identification of **2,3,7,8-TCDD** (assuming that the GC column resolves **2,3,7,8-TCDD** from other TCDDs), **false** positive results have been obtained under certain conditions. A collaborative study conducted by the U.S. EPA exemplifies **this** point. Of the total of 20 **unspiked** samples In **this** study, 10 gave false positive **results** (**Crummett**, 1980). In a recent method validation study by the U.S. EPA (**Gross et al.**, 1981), 2,3,7,8-TCDD levels <9 ppt could not be detected **with** accuracy. Clearly, there Is a need for more exhaustive examination for potential Interferences that may cause false positive results.

Another **major** factor limiting the research In the field Is the shortage or lack of availability of Individual Isomers. Unless the authentic compounds are available, analytical data developed for one Isomer on the basis of the response factor of another Isomer **will** remain **largely** questionable.

#### 3.4. SUMMARY

The solubility of **2,3,7,8-TCDD** in water is 0.2  $\mu\text{g/l}$ . This congener and the other three PCDDs are more soluble in aromatic solvents than aliphatic solvents. The PCDDs are relatively stable in the environment and they start to decompose at temperatures **>500°C**.

The general method for the determination of these compounds in different sample matrices consists of a solvent extraction procedure to transfer the PCDD residue **into** the solvent(s), followed by **H<sub>2</sub>SO<sub>4</sub>** and base washes to remove the excess **lipid** and other Impurities from the solvent extract. The extract is then subjected to two liquid **chromatographic** clean-up procedures. The cleaned up extract is finally analyzed for the PCDDs by a GC/MS method. All the possible GC/MS **combinations**, namely, **HRGC-LRMS**, **LRGC-LRMS**, **LRGC-HRMS** and **HRGC-HRMS**, have been used. However, if an unequivocal Identification and quantification of several specific **isomers** is required, two methods are suitable. One involves a 55 m Silar **10C** glass capillary or a 60 m SP-2330 fused silica column in combination **with** LRMS. Another method using RP-HPLC and normal phase HPLC separation in combination **with** LRMS has been found to be satisfactory.

#### 4. PRODUCTION, USE, SYNTHESIS, ENVIRONMENTAL SOURCES

##### AND ENVIRONMENTAL LEVELS


#### 4.1. PRODUCTION AND USE

PCDDs including the four compounds discussed in **this** document are not commercially produced. Rather, these compounds are formed as trace amounts of unwanted Impurities in the manufacture of other chemicals, primarily chlorophenols and their derivatives. There is no known technical use for the PCDDs (Rappe et al., 1979). The amount of total PCDDs entering the Canadian environment/year has been speculated to be ~3300 pounds and **75%** of **this** amount has been estimated to be due to OCDD alone (NRCC, 1981a).


#### 4.2. SYNTHESIS

Although the PCDDs are not commercially produced, some of these compounds have been synthesized according to reactions discussed below (U.S. EPA, 1980a).


4.2.1. Reaction of Dichlorocatechol Salts with 1,2,4,5-Tetrachlorobenzenes in DMSO. **This** general reaction has been used to synthesize 2,3,7,8-TCDD according to the reaction scheme shown below:



The yield of 2,3,7,8-TCDD by **this** reaction is low (Kende et al., 1974). A better method is the reaction of **o**-dichlorocatechol with 3-nitro-2,5,6-trichlorobenzene as shown below (Gray et al., 1976):



4.2.2. Substitution Reaction. The following substitution reactions have been used for the synthesis of 2,3,7,8-TCDD:



The yield of 2,3,7,8-TCDD by **this** reaction has been reported to be low (U.S. EPA, 1980a). However, when the **chlorination** of the **unsubstituted dibenzo-p-dioxin** was conducted without the **FeCl<sub>3</sub>**, the yield of 2,3,7,8-TCDD was reported to be 40-50X (U.S. EPA, 1980a). The substitution of **dibenzo-p-dioxin with 2,3-dichlorodibenzo-p-dioxin** in the presence of **FeCl<sub>3</sub>** and Iodine, on the other hand, reportedly also produced a **high yield (41%)** of 2,3,7,8-TCDD (**Kende et al.**, 1974).

4.2.3. **Photoproduction.** Small amounts of mixtures of lower PCDDs have been produced by the UV Irradiation of OCDD (Buser, 1979). For **example**, a mixture of **tri-**, penta-, hexa- and hepta-CDD has been produced by **this method**.

4.2.4. **Ullmann** Condensation Reactions. The condensation reactions as shown in Figure 4-1 have been used for the synthesis of tetra- and hexa-CDD.

The yield of the desired products by the condensation reactions are not always satisfactory because of other competing reactions. Examples of some of these competing reactions are condensation **with** Cl atoms meta to a hydroxyl group, condensation of Cl atoms para to the hydroxyl group, **dechlorination** reactions, and Smiles rearrangement (U.S. EPA, 1980a). Although the best conditions for **dioxin** formation are unknown, it has been speculated that a temperature of **180-400°C**, a pressure of **>1** atmosphere





FIGURE 4-1

Ullmann Condensation Reactions

(necessary to retain some precursor compounds in the liquid state to permit **dioxin formation**), and the presence of some catalyst provide the most suitable conditions for dioxin formation (U.S. EPA, 1980a). However, some of the catalysts, namely, Cu, Fe, **Al-salts** and **I<sub>2</sub>**, may encourage competing reactions, thereby reducing the yield of the desired product(s) (U.S. EPA, 1980a).

4.2.5. **Pyrolysis of Chlorophenates.** All 22 TCDD isomers have been synthetically prepared from different Chlorophenates (**di-**, **tri-** and **tetra-**) using a simple **pyrolysis** procedure (Buser and Rappe, 1980). Pyrolyses of these Chlorophenates were conducted by placing 1 **mg** of the Chlorophenates in a glass reaction tube plugged **with** glass wool and alumina. They were heated for 30-60 minutes at 300°C. The yields of the TCODs have been reported to be in the **µg** range (Buser and Rappe, 1980).

4.2.6. Conversion Through Nitration. It has recently been shown by Oliver and Ruth (1983) that **1,2,3,6,7,8-hexachlorodibenzo-p-dioxin** can be **selectively** prepared from two synthetic routes each consisting of **dinitration** of a **tetrachlorodibenzo-p-dioxin**, followed by reduction and a **Sandmeyer** reaction as shown below:



The recovery of **1,2,3,6,7,8-HxCDD** was **excellent** by **this** method.




#### 4.3. ENVIRONMENTAL SOURCES

The sources of PCDDs and particularly **2,3,7,8-TCDD**, **1,2,3,7,8-PeCDD**, **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD** in the environment can be broadly divided into five categories, namely, manufacturing processes, municipal incinerations, other combustion processes, chemical disposal sites and photochemical processes. The last source may not significantly contribute to PCDD contamination in the environment. Each of these categories is discussed individually in the following subsections.

4.3.1. Manufacturing Processes. PCDDs are generally produced during the production of chlorinated phenols, during the production of chemicals utilizing the chlorophenols (i.e., **2,4,5-T** and **2,4-D**) and in various Industrial Incinerators where materials containing chlorinated phenol and polychlorinated diphenyl ethers are incinerated.

4.3.1.1. PRODUCTION OF CHLOROPHENOLS - PCDDs are formed as by-products during the manufacture of chlorophenols. Chlorophenols are produced by two processes, the chlorination of phenols and the alkaline hydrolysis of the appropriate chlorobenzenes. Hypothetically, both processes can lead to the formation of PCDDs according to the mechanism depicted below (U.S. EPA, 1980a):



Similarly, HxCDOs are formed during the manufacture of tetrachlorophenols by the above reaction process. PCDDs are also expected to be formed during the hydrolytic production of polychlorinated benzenes. The amounts of PCDDs in commercial chlorophenols vary according to manufacturing process and conditions. The levels of TCDDs, PeCDDs and HxCDDs found in different chlorophenols have been shown in Table 4-1. It can be seen from Table 4-1 that the specific isomers of the TCDDs, PeCDDs and HxCDDs have not always been identified in the products. However, 2,3,7,8-TCDD has been identified in commercial trichlorophenols (Table 4-1). On the other hand, 2,3,7,8-TCDD is not produced in the manufacture of PCP (Buser and Rappe, 1978). The main HxCDD isomers produced during the manufacture of PCP are 1,2,4,6,7,9-, 1,2,3,6,8,9- and 1,2,3,6,7,8-HxCDD present in a ratio of 1:4:5 (Buser, 1979). However, the composition and quantities of PCDDs in PCP may vary widely from batch to batch and manufacturer to manufacturer, depending on the manufacturing processes.

The annual world production of chlorophenols is estimated to be ~150,000 tons (Rappe et al., 1979). U.S. production figures for di- and tetrachlorophenols are not available. However, the 1977 estimated figures indicate that the annual production capacity for PCP in the United States was 53 million pounds (U.S. EPA, 1980a). Canadians manufacture ~4000 tons of chlorophenols annually with the total release inventory to the environment estimated at >1365 tons/year (Environmental Canada, 1984). The chlorophenols are used as fungicides, herbicides, slimicides, bactericides and intermediates in the production of chlorinated phenoxy acid herbicides in agriculture and forestry. The antiseptic, hexachlorophene, is also prepared from 2,4,5-trichlorophenol (Rappe et al., 1979). Therefore, the use or presence of contaminated chlorophenols in facilities such as chlorophenol

TABLE 4-1

## Levels of Tetra-, Penta- and Hexa-chlorodibenzo-p-dioxins Reported in Chlorophenols and a Few Pesticides Originating from Chlorophenols

| Compound                           | Chlorodibenzo-p-dioxin (-CDD) level, ppm            |        |         | No. Contam. <sup>a</sup><br>No. Tested | Reference   |
|------------------------------------|---|--------|---------|--|---|
|                                    | Tetra-  | Penta- | Hexa-   |  |   |
| o-Chlorophenol                     | ND  | ND     | ND      | 0/1                                    | Firestone<br>et al., 1972<br>Anonymous, 1979  |
|                                    | 0.037 <sup>b</sup>                                  | NR     | NR      | several<br>samples                     |   |
| 2,4-Dichlorophenol                 | ND  | ND     | NO      | 0/1                                    | Firestone<br>et al., 1972   |
| 2,6-Dichlorophenol                 | ND  | ND     | ND      | 0/1                                    | Firestone<br>et al., 1972   |
| 2,4,5-TCP <sup>c</sup>             | ND-6.2 (2,3,7,8-) <sup>d</sup><br>ND-0.3 (1,3,6,8-) | ND-1.5 | ND      | 3/4                                    | Firestone<br>et al., 1972   |
| 2,4,6-TCP                          | 49 (1,3,6,8-)                                       | ND     | ND      | 1/1                                    | Firestone<br>et al., 1972   |
| 2,4,5-TCP (Na salt)                | 1.40 (2,3,7,8-)                                     | ND     | ND      | 1/2                                    | Firestone<br>et al., 1972   |
| TCP (unspecified)                  | ND  | NR     | ND-<10  | 4/6                                    | Woolson et al.,<br>1972   |
| 2,3,4,6-Tetrachlorophenol          | ND  | ND     | ND-29   | 2/3                                    | Firestone<br>et al., 1972<br>Rappe et al.,<br>1978<br>Buser, 1975   |
|                                    | 0.7   | 5.2    | 9.6     | NA                                     |   |
|                                    | NR  | NR     | 6       | 1/1                                    |   |
| Tetrachlorophenol<br>(unspecified) | ND  | NR     | ND-<100 | 3/3                                    | Woolson et al.,<br>1972   |
| PCP <sup>e</sup>                   | ND  | ND     | 0.17-39 | 6/6                                    | Firestone<br>et al., 1972<br>Woolson et al.,<br>1972<br>Buser, 1975<br>AMPI, 1977<br>Villaneuva<br>et al., 1973<br>Buser and<br>Bosshardt, 1976 |
|                                    | NO  | NR     | ND-<100 | 10/11                                  |   |
|                                    | NR  | NR     | 9       | 1/1                                    |   |
|                                    | NO  | NR     | 9-27    | several<br>samples                     |   |
|                                    | ND  | NR     | 0.02-42 | 2/2                                    |   |
|                                    | ND  | ND     | 0.03-10 | 12/13                                  |   |

TABLE 4-1 (cont.)

| Compound  | Chlorodibenzo-p-dioxin (-CDD) level, ppm       |                |               | No. Contam. <sup>a</sup><br>No. Tested | Reference   |
|---|--|----------------|---------------|--|---|
|   | Tetra-   | Penta-         | Hexa-         |  |   |
| PCP (cont.)   | NR   | NR             | ND-2          | several<br>samples                     | Dow, 1978   |
| PCP (Na salt)   | ND   | ND             | 14-20         | 2/2                                    | Firestone<br>et al., 1972<br>Buser and<br>Bosshardt, 1976 |
|   | 0.06-0.4                                       | <b>ND-0.08</b> | <b>ND-6.8</b> | 6/6                                    |   |
| 2,4-D (-DB, -DP) <sup>f</sup>   | ND   | ND             | ND-<10        | 1/28                                   | <b>Woolson et al.,</b><br>1972                            |
| <b>2,4-D and 2,4,5-T mixtures</b><br>(formulated products)  | ND   | ND             | ND            | 0/10                                   | <b>Norstrom</b><br>et al., 1979                           |
| 2,4-D (acid, esters, and<br>amines)   | <b>ND-8.739</b> (1,3,6,8-/<br>1,3,7,9-)        | NR             | NR            | 28/58                                  | Cochrane<br>et al., 1981                                  |
| 2,4-D (add. esters, and<br>amines)  | <b>D</b> (1,3,6,8-)                            | NR             | NR            | 2/30                                   | Thomas, <b>1980a;</b><br><b>Harless,</b> 1981             |
| <b>2,4,5-T<sup>h</sup></b>  | <b>ND-&lt;100</b>                              | NR             | ND-<100       | 23/42                                  | Woolson et al.,<br>1972                                   |
| <b>2,4,5-T</b> (acid, esters, and<br>formulated products)   | 0.010-0.080<br>( <b>2,3,7,8-</b> )             | NR             | NR            | 12/30                                  | ACP, 1980   |
| <b>Silvex<sup>o</sup></b>   | <b>ND-&lt;10</b>                               | NR             | ND            | 1/7                                    | <b>Woolson et al.,</b><br>1972                            |
| Agent Orange (1:1 mixture<br>of butyl esters of 2,4-D<br>and 2,4,5-T)   | <b>1.98<sup>i</sup></b><br>( <b>2,3,7,8-</b> ) | NR             | NR            | 490/490                                | Young, <b>1983</b>  |
| Agent Purple ( <b>5:3:2</b> mixture<br>of <b>n-butyl</b> 2,4-D, <b>n-butyl</b><br><b>2,4,5-T</b> and <b>iso-butyl 2,4,5-T</b> ) | <b>32.8<sup>i</sup></b><br>( <b>2,3,7,8-</b> ) | NR             | NR            | NR                                     | Young, 1983   |

<sup>a</sup>These are the ratios of the number of samples contaminated with any chlorodioxins to the number of samples tested.

<sup>b</sup>2,3,7,8-isomer detected but not quantified

<sup>c</sup>TCP: trichlorophenol

<sup>d</sup>These indicate specific dioxin concentrations.

<sup>e</sup>PCP: pentachlorophenol

<sup>f</sup>These are dichlorophenoxy-acetic, -butyric acid and -proplonic acid.

<sup>g</sup>The isomers could not be separated.

<sup>h</sup>This is 2,4,5-trichlorophenoxy acetic acid.

<sup>i</sup>This is an average value.

ND = Not detected; NR = Not reported; 0 = detected; NA = Not available

and pesticide/herbicide plants, cooling towers, pulp and paper Industry, Incinerators and disposal sites are potential exposure areas for PCDDs (Josephson, 1983).

The locations of current and former producers and **formulators** of chlorophenols are presented in Table 4-2. The inclusion of the **locations** of the former producers has been **judged** necessary for the identification of past sources of contamination that may present an environmental hazard in the future (**i.e.**, airborne contaminated dust particles) because **of** the environmental persistence of **2,3,7,8-TCDD** (Chapter 5).

**4.3.1.2. PRODUCTION OF CHLOROPHENOL DERIVATIVES** – PCDDs have been detected also as contaminants produced during the manufacture of commonly used chlorophenol derivatives, such as **2,4-D**, **2,4,5-T** and hexachlorophene by mechanisms hypothesized to be similar to those discussed in the case of chlorophenols. The amounts of **1,3,6,8-** and **1,3,7,9-TCDD in commercial iso-octyl-**, mixed butyl- and propylene glycol butyl ether ester of **2,4,-D** varied from nondetectable to 8.7 mg/kg (Cochrane et al., 1981). Agent Orange, which is a 1:1 mixture of the butyl esters of 2,4-D and 2,4,5-T, has been shown to contain 2,3,7,8-TCDD in quantities in the range of 0.1-47 **µg/g** (Rappe et al., 1979). The 2,3,7,8-TCDD impurity in Agent Orange has been shown to originate from 2,4,5-T. The mean levels of 2,3,7,8-TCDD in Agent Orange and Agent **Purple (50% n-butyl 2,4-D, 30% n-butyl 2,4,5-T and 20% isobutyl 2,4,5-T)** preparations used in the **1960s** were shown to be **1.98** and **32.8 ppm, respectively** (Young, 1983). Efforts were made during the 1970s to control and minimize the formation of 2,3,7,8-TCDD and, at the present **time**, all the producers **claim** that their products contain **<0.1 µg/g** of 2,3,7,8-TCDD (Rappe et al., 1979).



TABLE 4-2 (cont.)

| Chemical   | Producer  |
|--|---|
| <b>2,4,5-T (cont.)</b>                                       | <b>Rorer-Amchem</b> , St. Joseph, MO<br>Jacksonville, AR<br><b>Thompson Chemical</b> , St. Louis, MO<br>Union Carbide Corp., Fremont, CA<br>St. Joseph, MO<br><b>Ambler</b> , PA<br>Vertac, Inc., Jacksonville, AR  |
| <b>2,4,5-T derivatives</b><br><b>Silvex esters and salts</b> | Dow Chemical U.S.A., Midland, MI<br>Hercules, Inc., <b>Jacksonville</b> , AR<br>North American Phillips Corp., Kansas <b>City, KS</b><br>*Rivdale Chemical Co., Chicago Hts., <b>IL</b><br>Vertac, Inc., Jacksonville, AR<br>*Oow <b>Chemical</b> U.S.A., Midland, MI<br>*Dow Chemical U.S.A., Midland, MI<br><b>Givaudan</b> Corp., Clifton, NJ  |
| Ronnel<br>Erbon<br>Hexachlorophene                           |   |
| <b>2,4,5-TCP and salts</b>                                   | <b>Diamond</b> Shamrock Corp., Cleveland, OH<br>Dow Chemical, U.S.A., Midland, MI<br><b>GAF Corp.</b> , Linden, NJ<br>Hercules, Inc., Jacksonville, AR<br>Hooker Chemical, Niagara Falls, NY<br>Merck and Co., <b>Inc.</b> , Rahway, NJ<br><b>Nalco</b> Chemical Co., Chicago, IL<br>North Eastern Pharmaceuticals, Verona, MO<br>Roberts <b>Chemical</b> , Inc., <b>Nitro, WV</b><br><b>Rhodia</b> , Inc., Monmouth Junction, NJ<br>Vertac, Inc., Jacksonville, AR |
| 2,3,4,6-Tetrachlorophenol                                    | Dow Chemical U.S.A., Midland, MI<br>Sanford <b>Chemical</b> , Port <b>Neches, TX</b>  |
| PCP and salts  | J.H. Baxter and Co., San Mateo, CA<br>Dow Chemical U.S.A., Midland, MI<br>ICC Industries, Inc., Dover, OH<br>Monsanto Co., <b>Sauget</b> , IL<br>Nalco Chemical Co., Chicago, IL<br>*Relchhold <b>Chemical</b> , Inc., <b>Tacoma, WA</b><br>Sanford Chemical, Port Neches, TX<br>*Vulcan <b>Materials</b> Co., Wichita, KS  |

<sup>a</sup>Sources: U.S. EPA, 1980a; SRI, 1982; USITC, 1982

<sup>b</sup>Company names indicated with an asterisk are the major producers of chlorophenols and their derivatives at the present time.

As can be seen from Table 4-1, **2,4-D, 2,4,5-T** and their formulated products may contain other PCDOs **in** addition to TCODs. It has also been reported that Agent Orange and 2,4,5-T samples used during the Vietnam conflict contain other PCDDs at levels **similar** to that of **2,3,7,8-TCDD**. Agent Orange and European 2,4,5-T formulations from the 1960s, on the other hand, may contain primarily 2,3,7,8-TCDD and **only** minor amounts of other PCDDs (Rappe et al., 1979). The average **2,3,7,8-TCDD** contents in Agent Orange and Agent Purple given in Table 4-1 refer to these materials manufactured in the 1960s.

**Hexachlorophene** is prepared from the same starting **material** as 2,4,5-T, namely, **1,2,4,5-tetrachlorobenzene**. Because of additional purification, however, the level of 2,3,7,8-TCDD in **this** product has been reported to be **<0.03 µg/g** (Rappe et al., 1979).

The **locations** of current and former producers of chlorophenol derivatives have been shown **in** Table 4-2.

4.3.1.3. CONTAMINATED **MANUFACTURING** EQUIPMENT -- Production trains are often used for the production of chemicals whose manufacture necessitates the use of similar process equipment. In the manufacture of chemicals on a production train previously contaminated **with** PCDDs, both the products and waste generated can be contaminated **with** PCDDs. Thus, the manufacture of 2,4-D, which otherwise was not expected to be contaminated **with** 2,3,7,8-TCDD, **did** indeed contain 2,3,7,8-TCDD because the equipment used had been employed previously to produce 2,4,5-T, and the equipment remained contaminated **with** 2,3,7,8-TCDD (Federal Register, 1980a).



4.3.1.4. DIPHENYL ETHER HERBICIDES – The presence of TCDDs, PeCDDs and HxCDDs as contaminants **in diphenyl** ether herbicides was reported by **Yamagishi et al. (1981)**. The source of PCDDs **in** these herbicides was speculated to be the **trichlorophenol** used in their production. The concentrations of the two **major** Impurities, TCDDs and PeCDDs, in commercial formulations were **~150** and 30 ppm, respectively. The **isomeric** distribution of TCDDs showed that the **major** components were **1,3,6,8-** and **1,3,7,9-isomers**. The **isomer** 2,3,7,8-TCDD was not detected in the commercial products.

4.3.1.5. INCINERATION OF SELECTED INDUSTRIAL WASTES – The combustion of a variety of chlorinated hydrocarbons has been shown to produce PCDDs (**Tiernan et al., 1982a**). The formation of PCDDs would likely occur in Incinerators operating at 750-900°C; **chlorophenols** are probably the precursors of PCDD formation. At temperatures >1200-1400°C and residence **time** of <1 second, PCDDs are **likely** to decompose and these compounds are not expected to form (Junk and Richard, 1981). From kinetic and **thermodynamical** considerations, Shaub and Tsang (1983) estimated that **99.99%** gas phase dissociation of **tetrachlorodibenzo-p-dioxins** at **727°C** may require ~15 minutes, while the same decomposition at 977°C may require <1 second.

In an Industrial boiler in the United States where PCP was known to have been burned, Rappe et al. (1983b) reported ~5 ppm PCDDs in the bottom and **baghouse** ash. More than **90%** of the PCDDs were lower chlorinated congeners than OCDD and only a small **amount** of 2,3,7,8-TCDD was detected. Soot **analysis** of a recent transformer **fire** in **Binghamton, NY**, in February, 1981, revealed that 2,3,7,8-TCDD (0.6 ppm) and **1,2,3,7,8-PeCDD** (2.5 ppm) were the dominating **isomers** of the PCDDs formed (Buser and **Rappe, 1983; Rappe et al., 1983b**). The origin of the PCDDs was **probably** the chlorobenzenes **in** the transformer **oil** (**Buser, 1979**). The analysis of **wipe** tests from a garage

adjacent to **this site did** reveal the presence of PCDDs before cleaning the garage. Following the **cleanup**, no contamination was found (Tiernan et al., 1982b; Tiernan, 1983). Therefore, it is important to recognize the possibility of production of PCDDs and PCDFs in fires involving PCB and chlorobenzene transformers.

4.3.2. Municipal Incinerators. PCDDs have been detected both in the fly ash and **air particulate** matter from municipal incinerators by several investigators in Canada, Europe and the United States. The particulate matter forming the emissions (**air particulates**) has a 10-fold greater concentration of PCDDs than the precipitated material (fly ash) (Lustenhouwer et al., 1980). The concentration of **total** TCDDs, PeCDDs and HxCDDs in the fly ash from a variety of municipal incinerators in Canada, Europe and the United States have been studied by several authors (Eiceman et al., 1979, 1980; Nestrick et al., 1982; Karasek et al., 1982; Bumb et al., 1980; Buser and Bosshardt, 1978; Tiernan et al., 1982a; Taylor et al., 1983). The TCDD **isomer** known to be the most toxic (**i.e., 2,3,7,8-TCDD**) was either not detected or detected at a low level. The quantities emitted in incinerators vary, probably because of differing efficiencies, and since few **municipal** incinerators have been **reliably** characterized for PCDD/PCDF emissions over extended **time** intervals, the data base is still inadequate. Whereas Bumb et al. (1980) and Buser and Rappe (1980) detected 0.4 ng/g of 2,3,7,8-TCDD in the fly ash from a United States municipal incinerator, the U.S. EPA concluded that emissions from **five** municipal waste **combustors did** not present a public health hazard for residents living in the immediate vicinity (CEQ, 1981). Evaluation of stack emissions of PCDDs have to be based on the amount of **dioxins** in both the flue gas condensate followed by an effective absorption or adsorption step (Ballschmiter et al., 1984). PCDDs have been

detected in the emissions of some municipal waste Incinerators in Europe (Glzzl et al., 1982; Benfenati et al., 1983; Taylor et al., 1983; Olie et al., 1982, 1983; Lustenhouwer et al., 1980; Barnes, 1983). Observations on PCDD emissions from an Industrial boiler have been discussed in Section 4.3.1.5. (Rappe et al., 1983b).

In a study of municipal fly ash conducted between a single Incinerator in the United States and one in Europe, Lamparski and Nestricks (1980) detected at least 14 of the 22 possible TCDD isomers. Although the ratio of isomers to the total present were similar in both fly ashes, their absolute amounts varied by a factor  $\geq 10$ . It has been demonstrated by Rappe et al. (1979) that minor amounts of the highly toxic PCDD congeners, 1,2,3,7,8-PeCDD, 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD, are also formed in municipal Incinerators.

4.3.3. Other Combustion Processes. Scientists from Dow Chemical Co. (Dow, 1978) reported the detection of PCDDs in particulate matter from most combustion sources. These findings led to a hypothesis which suggested that PCDDs may be formed in trace amounts from chemical reactions during the combustion of many chlorinated hydrocarbons (Bumb et al., 1980; Crummett et al., 1981). These Investigators detected PCDDs including TCDDs and HxCDDs in particulate matter from municipal and Industrial Incinerators, in mufflers from diesel truck and passenger vehicles, from home wood-burning fireplaces and from soot and cigarette smoke. Since the trace chemistries of fire hypothesis was presented, several Investigators have attempted to test it. Tiernan (1982) reported the detection of 0.65 ppb TCDD in soot from a wood-burning fireplace. Although there is general agreement regarding the production of PCDDs from the burning of wood with additional HCl and from Incinerators burning chlorinated products or wastes (Tiernan et al.,

1982a, **Tiernan, 1983**), production from the combustion of coal and hydrocarbons (such as occurs in gas **burners**, and auto and truck engines) has not been confirmed (NRCC, **1981a**). For **example**, Rappe et al. (**1979**) concluded from their **pyrolysis** experiments that PCDDs are produced by the burning of very specific **chemicals**, such as chlorinated phenols, **polychlorinated benzenes** and **polychlorinated diphenyl** ethers. Wood pregated **with** these compounds might produce PCDDs during Incineration and the history of wood to be burned in fireplaces is often unknown. Junk and Richard (1981) and **Kimble** and Gross (1980) failed to measure TCDD above the detection limits of 1 or 1.2 ppt, **respectively**, from their **analysis** of one fly ash sample from stack emissions of a low sulfur and **high-ash** coal burning power plant. Recent Investigations (**Halley et al., 1983**; Stanley et al., **1982**) also failed to detect (detection limit: flue gas, 100-700 **pg/m<sup>3</sup>**; fly ash, 10-70 pg/g) PCDD **homologues** in any sample from four coal-fired power plants. Independent confirmation of "trace chemistries of **fire**" as proposed by Dow, U.S.A., is not yet available.

Czuczwa and **Hites** (1984) and Czuczwa et al. (1984, 1985) analyzed for the PCDDs and PCDFs in sediments from the Great Lakes including the sediment core from Skiskiwit Lake of **Isle Royale** in northern Lake Superior. The sediment that came from Skiskiwit Lake was used because **it** received only atmospheric inputs. In all cases the authors detected the flux of PCDDs and PCDFs, which began at about 1940. When **this** "1940 horizon" was compared **with** combustion trends in the last century, the authors found evidence that the combustion of synthetic chlorinated organic chemicals is the primary source of PCDDs and PCDFs. Furthermore, the authors responded that the flux of PCDDs and PCDFs to three Swiss lakes, where combustion has been extensive during the last century, increased only after the development of the

**chlorinated organic chemical** Industry. The authors also addressed the debate regarding **2,3,7,8-TCDD in coal** fly ash. Reaffirming similar findings, no **2,3,7,8-TCDD** was found above a detection limit of 100 ppt. These results strongly suggest that coal combustion is not a significant source of **2,3,7,8-TCDD** contamination to the environment.

4.3.4. Chemical Dump Sites. At present, other potential sources of PCODs are chemicals known to be contaminated **with** PCDDs but withdrawn from use and awaiting disposal, and disposal sites where chemical wastes containing PCDDs have been dumped. It has been estimated that **~11,600** metric ton/year of hazardous wastes are produced in the manufacture of chlorophenols and **~79,000** metric ton/year are produced in the manufacture of phenoxy compounds (Jett, **1982**). Process wastes from the manufacture of chlorophenols and phenoxy compounds are **landfilled**, or injected **into** deep-well. Treatment wastes are frequently subjected to on-site impoundment (Jett, 1982). Recent Canadian environmental data indicate that 2,3,7,8-TCDD may be leaking **into** the Great Lakes from toxic dump sites (Hallett, 1984).

4.3.5. Photochemical Process. Photochemical processes can also lead to formation of PCDDs. For example, the **dimerization** of **chlorophenols** to OCDD has been studied by Crosby and **Wong** (1976). **Lamparski et al.** (1980) also reported that photolysis of PCP-treated woods may lead to the formation of PCDDs. **Similarly**, photochemical **cyclization** of **predioxins** (chlorinated **2-phenoxyphenols**, precursors of PCDDs) can also produce PCDDs. Since predioxins are common impurities (1-5%) in commercial chlorophenols, exposure of chlorophenols containing those impurities to light may produce PCDDs (**Nilsson et al.**, 1974).

Another **photochemical** process of **potential environmental** importance is the formation of highly toxic TCDD and PCDD congeners from the **dechlori-**

nation of higher PCDDs. However, photolysis of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9HxCDD produced only 13% of the toxic 1,2,3,7,8-PeCDD and no 2,3,7,8-TCDD (Kim et al., 1975), while the photolysis of octa-CDD was shown to produce mainly 1,4,6,9-TCDD, 1,2,4,6,9-PeCDD and 1,2,4,6,7,8-HxCDD. Consequently, it was concluded that the most toxic isomers are not likely to be formed from the photolysis of the higher PCODs (Buser and Rappe, 1978).

Formation of tetra- and pentachlorodibenzo-p-dioxins has been observed by the photolysis of 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDDs (Buser, 1979). There seems to be a preferential dechlorination of the HxCDDs occurring at the lateral positions flanked on both sides by adjacent chlorines (Choudhry and Hutzinger, 1984). However, formation of trace amounts of 2,3,7,8-TCDD were also observed from the photolysis of the above two isomers of HxCDDs (Buser, 1979).

#### 4.4. RELATIONSHIP BETWEEN SOURCES AND CONTAMINATION IN ENVIRONMENTAL MATRICES

The potential relationship between various sources of PCDDs and the environmental matrices where these compounds have been detected (NRCC, 1981a) is depicted in Figure 4-2, which has been modified from the original reference to indicate the possible inhalation exposures from these sources.

#### 4.5. ENVIRONMENTAL LEVELS

The detection of PCDD residues, particularly the residue of the four toxic PCDDs under discussion, in various environmental matrices is indicative of the potential impact that the various sources could have on the environment. However, the monitoring efforts for the determination of the levels of these compounds in the environment are extremely limited for several reasons. The primary reasons are the nonavailability of standardized sampling methods and the specialized analytical techniques that must be used for the determination of traces of these difficult to separate compounds in




FIGURE 4-2

Possible Potential Relationship Between Various Sources of PCDDs and the **Environmental** Matrices **Where** PCDDs have been Detected

Source: Modified from NRCC, 1981a

the presence of a **large** number of Interfering compounds. **Measurable** quantities of these compounds have been detected **in** the environment under special circumstances, that is, after accidents in factories producing **chlorophenols** and their derivatives, in the environment after certain herbicide use, and in the environment near certain **dumpsites**. In other words, the current available data demonstrate that the major sources of **PCDDs** in the environment are those associated **with** the production, use and disposal of chlorophenols and their derivatives. **Choudhary** (1983) in a review paper provided a list for some of the potential **workplaces** where occupational exposure to PCDDs may occur. It should also be recognized that most of the environmental monitoring investigations measured **2,3,7,8-TCDD** levels, whereas monitoring data for other PCDDs are even more **limited**. **With** these limitations in mind, the levels of **2,3,7,8-TCDD**, **1,2,3,7,8-PeCDD**, **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD** in various environmental media have been presented in the following subsections.

4.5.1. Water. NAS (1977) reported that no 2,3,7,8-TCDD has ever been detected in drinking water using methods **with** limits of detection in the ppt range. Other PCDDs including PeCDD and HxCDD have not been detected in drinking water. However, TCDD, including the **2,3,7,8-isomer**, has been reported in aqueous industrial effluent samples and leachates from hazardous waste disposal sites. For example, Van Ness et al. (1980) analyzed eight effluents from a **trichlorophenol** manufacturing plant **site** and detected TCDD in two of these effluents (detection limit 10-30 pg/g). The concentrations of TCDD in the two samples **with** detectable TCDD concentrations were 17 and **100** pg/g. Although the specific **isomer** was not routinely separated, the authors concluded from their study that a significant portion of the TCDD was apparently the 2,3,7,8-isomer.



The **analysis** of leachate samples from two waste disposal sites for the analysis of TCDD have also been reported. In one study, 23 water samples analyzed by Wright State University Inside and outside of a waste disposal **site** near Jacksonville, AR (containing wastes from **2,4-D** and **2,4,5-T** manufacture) were found to contain **2,3,7,8-TCDD** (Thibodeaux, 1983). The concentration of 2,3,7,8-TCDD in these samples averaged 14 ppt **with** a concentration range of none detected to 47 ppb. In another study (U.S. EPA, 1982b), two untreated leachate samples collected from the Love Canal, NY, chemical dump **site** showed a concentration of 1.56 ppb (1560 ppt) for 2,3,7,8-TCDD. The treated leachate (samples taken after remedial steps were installed to minimize PCDD-leaching **possibility**), on the other hand, showed no detectable level of 2,3,7,8-TCDD (detection limit 5-10 ppt). 2,3,7,8-TCDD was not detected in any of the groundwater samples analyzed.

Shadoff et al. (1977) analyzed for 2,3,7,8-TCDD in two **locations** exposed annually to 2,4,5-T. These locations were an Impoundment from the drainage of a watershed in Texas where 2,4,5-T had been used for several years for brush control and from a pond in Arkansas used as a reservoir for irrigating **rice** fields treated **with** 2,4,5-T. Two water samples from each location **failed** to show any detectable **level** of 2,3,7,8-TCDD at a detection limit of 0.1-0.2 ppt.

4.5.2. Air. One possible source of PCDDs in the atmosphere **is** the field spraying of the herbicide 2,4,5-T. The spraying of 2,4,5-T containing 2,3,7,8-TCDD impurity may lead to a concomitant exposure to 2,3,7,8-TCDD. However, the measurement of **air** concentration at any particular **time** after spraying may not be a representative sample because of spray drift to non-target sites and the intermittent nature of spray application. From **micro-**agroecosystem chamber and field studies, Nash and **Beall** (1980) determined

the atmospheric concentration of **2,3,7,8-TCDD** at various times after the application of **emulsified** and granular **Silvex** (1.3-2.0 kg/ha **Silvex**) containing 44 ppb to 15 **ppm** TCDD Impurity. Using **tritiated 2,3,7,8-TCDD**, these authors found that atmospheric concentrations of **2,3,7,8-TCDD** decreased **with time** either at an exponential rate (granular formulation) or at a log log rate (emulsifiable formulation) in chambers. The **emulsifiable** formulation **resulted** in **considerably** higher TCDD concentrations (**~1000-fold** or more) **in air** than in granular formulation **initially**, but **with time** (200 days) approached the concentrations in **air** similar to the granular formulation (10 fg/m<sup>3</sup>; fg = 10<sup>-15</sup> g). In a small field trial, **with** a nonshaded plot, TCDD concentrations **in air** from the application of 2 kg/ha of emulsifiable **Silvex** containing 15 ppm TCDD were about twice (620 **fg/m<sup>3</sup>**) that of a shaded plot (270 **fg/m<sup>3</sup>**) on the treatment day, but only **~33%** of the amount from the shaded **plot** on the second day. **Presumably, this** was a **result** of the lesser quantities (**<50%**) of TCDD remaining on the grass for volatilization during the second day.

Air filter samples collected from Elizabeth, **NJ**, after an Industrial **fire** on April 22, 1980, were analyzed for TCDD by Harvan et al. (1981). Collision-induced-dissociation mass-analyzed ion kinetic energy **spectrometry** was used for the confirmation of the presence of TCDD. Of the **nine** samples analyzed by these authors, one contained 20 pg of TCDD, four contained <9 pg of **TCDD**, and four others probably contained 5-12 pg of TCDD. However, the concentration of TCDD in the **air** cannot be given for these samples because the **air** volumes corresponding to the filters analyzed were not specified by the Investigators.

The atmospheric concentrations of TCDD near two hazardous waste sites have been monitored. In one study, U.S. EPA (1982b) failed to detect

(detection limit 1-20 ppt) any **2,3,7,8-TCDD** in the atmosphere at the Love Canal, NY, area. In another study of a waste disposal **site** near Jacksonville, AR, an average concentration of **1100** ppt of TCDD in two **air particulate** samples collected near the disposal **site** was reported (**Thibodeaux**, 1983).

The levels of 2,3,7,8-TCDD in atmospheric dust were monitored in the Seveso, Italy, area between 1977 and 1979. The concentrations of 2,3,7,8-TCDD were found to be in the range of 0.06-2.1 ng/g of dust with dustfall Jars as sample collection technique and 0.17-0.50 ng/g of dust with high volume sampler as sample collection technique (**DiDomenico et al.**, 1980b). The accident in Seveso released only 2,3,7,8-TCDD, while most other environmental sources may produce a mixture of PCDDs.

Another source of atmospheric emission of PCDDs is Incineration (**Glz1 et al.**, 1982; **Benfenati et al.**, 1983; Taylor et al., 1983; **Ol1e et al.**, 1982, 1983; **Lustenhower et al.**, 1980; **Barnes**, 1983). The concentrations of TCDD, PeCDD and HxCDD in fly ash from Canadian municipal Incinerators have been studied extensively by **Eiceman et al.** (1980, 1981). **Eiceman et al.** (1979) also determined the TCDD levels in fly ash from Incinerators in Japan and the Netherlands. The average concentrations of the PCDDs in the Canadian studies (**Eiceman et al.**, 1979, 1980, 1981) were estimated with the assumption that the SIM response factors for all the PCDDs were the same as the response factor from **1,2,3,4-TCDD** used as a standard. However, the analytical method used by these authors has been criticized by **Nestrick et al.** (1982). Recently, **Karasek et al.** (1982) also determined the total TCDD, PeCDD and HxCDD levels in a French municipal Incinerator to be none detected, 7.8 and 21.8 ng/g, respectively. It was also concluded by these authors that the PCDDs tend to concentrate in particles of lower mean size (30  $\mu\text{m}$  vs. >850  $\mu\text{m}$ ).

In another study, **Bumb et al.** (1980) studied the PCDD level **in** fly ash from a municipal Incinerator **in** Nashville, TN, several European municipal Incinerators, and the Industrial Incinerators of the Dow Chemical Co. facility **in** Midland, MI. The TCDD concentrations were determined to be 7.7 ng/g (0.4 ng/g of **2,3,7,8-TCDD**), 2-20 ng/g and 0-38 ng/g (**2,3,7,8-TCDD** not detected), **respectively**. The corresponding values of HxCDD were reported to be 14, 30-200 and 1-20 ng/g. However, the analytical method used by these Investigators has been criticized by other Investigators (Hay, 1979). Buser and Rappe (1983) and Buser and Bosshardt (1978) also analyzed the fly ash from Incinerators **in** Switzerland and Canada. In one such study (Buser and Bosshardt, 1978), the total amount of PCDDs **in** the fly ash from a Swiss municipal and Industrial Incinerator were found to be 0.2 and 0.6 ppm, respectively. The **dioxin isomers** known to be most toxic, namely 2,3,7,8-TCDD, **1,2,3,7,8-PeCDD**, **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD**, were only minor constituents of the total **dioxins** found. In another study (Buser and Rappe, 1983), the presence of TCDDs (3 ppb), PeCDDs (20 ppb) and HxCDDs (50 ppb) was indicated **in** the fly ash from a municipal Incinerator **in** Zurich, Switzerland. The TCDD, PeCDD and HxCDD Isomers **with** substitution at 2,3,7,8- positions, such as 2,3,7,8-TCDD, **1,2,3,7,8-PeCDD** and **1,2,3,6,7,8-, 1,2,3,7,8,9-** and **1,2,3,4,7,8-HxCDD** were present only as 2, 14 and **24%** of the total TCDDs, PeCDDs and HxCDDs. A **fly** ash sample from Ontario, Canada, was also found to contain TCDDs (150 ppb), PeCDDs (550 ppb) and HxCDDs (900 ppb). Although the sample was reported to contain significantly higher levels of PCDDs **in** comparison **with** the Swiss fly ash sample, it showed similar proportions of **2,3,7,8-substituted** PCDDs (4, **12** and 27% of the total TCDDs, PeCDDs and HxCDDs, respectively). It is not yet known whether the

higher **levels** of PCDDs result from different Incinerator operating conditions, different feed stock or different fly ash collection conditions (**Buser** and **Rappe**, 1983). **Similarly**, the fly ash from a municipal Incinerator in the United States showed the presence of at least 11 TCDD **isomers**, but **2,3,7,8-TCDD** was found to be a minor product (U.S. EPA, 1980a).

The U.S. EPA evaluated the magnitude and significance of TCDD emissions from combustion processes. In 1981, the U.S. EPA sampled **five** municipal waste **combustors** and concluded that emissions from these waste **combustors** do not present a public health hazard for residents living **in** the Immediate vicinity (CEQ, 1981). In **view** of the recent data of **Pocchiarri et al.** (1983) reporting the presence of 1,3,6,8- and **1,3,7,9-TCDD** (0.4-2 ppt) in **epigeal** parts of a **large** number of plants grown in the proximity of municipal Incinerators, and the **toxicological** evaluation of TCDD in ashes from urban Incinerators (**Bronzetti et al.**, 1983; **Rizzardini et al.**, 1983), the question of health hazard for residents living in the Immediate vicinity of municipal Incinerators needs further evaluation. Another reason for the presence of 1,3,6,8- and **1,3,7,9-TCDD** in **epigeal** parts of plants may also be due to contamination by TCDD-containing herbicide or pesticide application, as observed by **Yamagishi et al.** (1981).

4.5.3. **Soil.** The levels of PCDDs **in soil**, sediment and dust samples are presented in **this** subsection. In general, the PCDDs have been detected in the samples that originated from the areas around certain Industrial sites, waste disposal sites, and sites involved in accidental or unintentional spillage of chemicals containing PCDD contaminants. Very few Investigators determined the levels of other PCDDs besides TCDD. Even in the case of TCDD, the specific **isomer** Identification was not performed in many cases. The levels of TCDD in different **soil**, sediment and dust samples are shown in Table 4-3.

TABLE 4-3

## Levels of TCDD in Soils and Sediments from Different Locations

| Sample Type | Sampling Site            | Sample History  | Concentration in Sample                    |  | Reference                |
|-------------|--------------------------|---|--|--|--------------------------|
|             |                          |   | Total TCDD                                 | 2,3,7,8-TCDD                             |                          |
| Soils       | Love Canal, NY           | waste disposal site   | <0.0025-6.7 ppb                            | NR                                       | Smith et al., 1983b      |
| Sediments   | Love Canal, NY           | sediments from storm sewers and creeks near water disposal site | NR   | 0.9-312 ppb                              | Smith et al., 1983b      |
| Soils       | Love Canal, NY           | soils collected away from source of contamination               | NR   | ND (1-20 ppt) <sup>a</sup>               | U.S. EPA, 1982b          |
| Sediments   | Love Canal, NY           | sediments from storm sewers                                     | NR   | ND (1-20 ppt) <sup>a</sup> -<br>672 ppb  | U.S. EPA, 1982b          |
| Sediments   | Love Canal, NY           | sediments from sump   | NR   | ND (1-20 ppt) <sup>a</sup> -<br>9570 ppb | U.S. EPA, 1982b          |
| Soils       | NR                       | sample originated from an Industrial site                       | ND (20-2300 ppt) <sup>a</sup> -<br>559 ppb | NR                                       | Van Ness et al., 1980    |
| Soils       | Eastern Missouri, U.S.A. | sample originated from contaminated horse arena                 | NR   | detected <sup>b</sup>                    | Buser and Rappe, 1980    |
| Soils       | Seveso, Italy            | sample originated from ICMSA plant accident site                | NR   | detected <sup>b</sup>                    | Buser and Rappe, 1980    |
| Sediments   | canal north of Amsterdam | sample originated from a dump site                              | NR   | 55-5062 ppt                              | Heida, 1983              |
| Soils       | Seveso, Italy            | sample originated from ICMSA plant accident site                | NR   | <5-20,000 µg/m <sup>2</sup>              | DiDomenico et al., 1980c |
| Soils       | Jacksonville, AR         | waste disposal site   | NR   | ND-2.9 ppb                               | Thibodeaux, 1983         |

TABLE 4-3 (cont.)

| Sample Type | Sampling Site                                      | Sample History   | Concentration in Sample  |  | Reference                  |
|-------------|--|--|--|--|----------------------------|
|             |  |  | Total TCDD   | 2,3,7,8-TCDD                                       |                            |
| Sediments   | Jacksonville, AR                                   | sediments from pond and creek near waste disposal site | NR   | ND-22.1 ppb  | Thibodeaux, 1983           |
| Soil/sludge | Love Canal, NY                                     | waste disposal site                                    | 0.3-199 ppb  | NR   | Tiernan, 1982              |
| Soils       | unspecified<br>Midwestern<br>community in<br>U.S.A | sample near a<br>wire reclamation<br>Incinerator       | NO (<3 ppt) <sup>a</sup> -<br>0.021 ppb  | NR   | Hryhorczuk<br>et al., 1981 |
| Soil/dust   | Midland, MI  | sample inside<br>Industrial site                       | 1-120 <sup>c</sup> ppb<br>1-4 <sup>d</sup> ppb   | 0.3-100 <sup>c</sup> ppb<br>0.7-3 <sup>d</sup> ppb | Bumb et al.,<br>1980       |
| Soil/dust   | Urban U.S. areas                                   | no obvious source<br>of contamination                  | ND (1-10 ppt) <sup>a</sup> -<br>0.03 ppb <sup>c</sup><br>ND (1-10 ppt) <sup>a</sup> -<br>0.04 ppb <sup>d</sup> | NR <sup>e</sup>                                    | Bumb et al.,<br>1980       |
| Soils       | Northwest Florida                                  | Eglin Air Force<br>test site                           | 0.010-0.70 ppb <sup>f</sup><br>12.3 ppb <sup>g</sup>   | NR   | Cockerham<br>et al., 1980  |
| Soils       | Eastern Missouri                                   | horse breeding<br>arena sprayed<br>with waste oil      | 31.8-33.0 ppm  | NR   | Carter et al.,<br>1975     |

<sup>a</sup>Not detected and the detection limit indicated within parentheses

<sup>b</sup>Value not quantified

<sup>c</sup>Value for soil

<sup>d</sup>Value for dust

<sup>e</sup>Dust sample from St. Louis, MO, area showed 0.12 ppb 2,3,7,8-TCDD.

<sup>f</sup>This is the soil residue after 10 years of periodic aerial spraying of 2,4-D and 2,4,5-T.

<sup>g</sup>This is the soil residue immediately after spraying.

NR = Not reported; ND = Not detected

It is obvious from Table 4-3 that the waste **disposal site** is responsible for the origin of **2,3,7,8-TCDD** in the Love Canal, NY, area. This is reflected by the **high level** of 2,3,7,8-TCDD found in sediments from sump and in sediments from storm sewers and creeks near waste disposal sites. The reported **levels** of 2,3,7,8-TCDD in **soil** and sediment samples near the Jacksonville, AR, waste disposal **site** are such that **this site** requires careful **reexamination**. It can also be concluded from Table 4-3 that the environment inside a manufacturing (**2,4,5-trichlorophenols** and derivatives) **site** are likely to be contaminated **with** 2,3,7,8-TCDD by levels that may be higher than the background level (sites **with** no obvious sources of **contamination**).

4.5.4. Foods and Biological Samples. The occurrence of PCDDs in foods **could** result from the following: 1) spraying of certain grain crops **with PCDD-contaminated** herbicides, such as **Silvex** and **2,4,5-T**; 2) consumption by livestock of **PCDD-contaminated** forage; 3) **magnification** of residues through the food chain; or 4) consumption of fruits and vegetables in the proximity of municipal Incinerators. Besides determining the PCDD levels in food chains, **this** subsection **will** discuss the levels of these compounds in wildlife and in human tissues (**i.e.**, urine and **milk**). The detection of these compounds in wildlife and human tissue collected near Industrial or waste disposal sites can be taken as an Indication of anthropogenic exposure. Sometimes the tissue levels can be used to estimate the extent of exposure and subsequent excretion and/or accumulation of these compounds.

The detection of 2,3,7,8-TCDD has been reported in locally grown garden fruit and vegetables following the **ICMESA** accident in Seveso, Italy, in **1976** (**Faneli et al.**, 1982; **Cocucci et al.**, 1979; **Pocchiarl et al.**, 1983; **Wipf et al.**, 1982). Studies **with** either the seeds or the mature plants of soybeans or oats showed that **2,3,7,8-TCDD** was neither absorbed by the seeds after



spraying nor taken up from the **soil into** the mature plants (Isensee and Jones, 1971; **Matsumura** and Benezet, 1973). **However**, young plants accumulated up to 40 ppb of **2,3,7,8-TCDD** (Isensee and Jones, **1971**). From the analysis of several parts of fruit trees and kitchen-garden plants such as carrots, onions, potatoes and narcissuses collected from the contaminated (400-1000  $\mu\text{g}/\text{m}^2$  of **2,3,7,8-TCDD** in **soil**) Seveso area in Italy, **Cocucci et al.** (1979) concluded that **2,3,7,8-TCDD** is **translocated** from **soil** to the aerial parts of the plants, probably through the conductive vessels. **This** study further suggested that the **plants** may eliminate 2,3,7,8-TCDD by an unknown mechanism within 4-10 months after transplantation in unpolluted soils. However, the study of Cocucci et al. (**1979**) contradicts the investigations of **Wipf et al.** (1982) in which vegetation samples analyzed from the Seveso area from 1976 through 1979 suggested that the contamination in vegetation was from local dust and not from plant uptake. Unlike the Seveso Incident where release of 2,3,7,8-TCDD in the environment took place, normal use of herbicides containing 2,3,7,8-TCDD impurities may not cause detectable 2,3,7,8-TCDD contamination of the crop. Jensen et al. (1983) analyzed **rice** grain from fields in Arkansas, Louisiana and Texas after application of **2,4,5-T** (containing 0.4 ppm TCDD) at a maximum rate of 2.25 pounds/acre. No 2,3,7,8-TCDD residues (detection limit 2-10 ppt) were found in these **rice** grains nor were any **TCDDs** found in 30 samples of **rice** purchased in retail stores throughout the United States. Contamination of fruits, vegetables or grains in the United States with TCDD has never been reported.

The contamination of a large number of vegetables grown in the proximity of municipal incinerators has been reported by **Pocchiari et al.** (1983). These investigators detected **1,3,6,8-** and **1,3,7,9-TCDD** in the concentration range of 0.4-2 ppt in vegetables whose origin of TCDD was not attributable

to the **ICMESA plant accident**. This finding suggests the possibility of human exposure of TCDD from edible vegetables grown in areas close to municipal Incinerators.

Different Investigators have reported the presence of PCDDs in the fat of cattle that had grazed on pasture **experimentally** treated with **2,4,5-T** (Meselson et al., 1978; Kocher et al., 1978). The **levels** of TCDDs in these studies ranged from 3-70 ppt. Kocher et al. (1978) reported that only **13%** of the fat samples collected (3 of 23 samples) gave a positive response for **2,3,7,8-TCDD** at low levels (3-4 ppt).

Results of a collaborative program to analyze a selected beef sample by the U.S. **EPA**, Dow Chemical Company, Wright State University and Harvard University showed that TCDD could be detected **in** the adipose tissue of cattle **with** access to **2,4,5-T-treated** rangeland (U.S. EPA, **1984**). Of the 85 beef fat samples analyzed, one sample contained 60 ppt of 2,3,7,8-TCDD and two samples appeared to have 2,3,7,8-TCDD levels **in** the range of 5-10 ppt. No 2,3,7,8-TCDD was determined in the rest of the samples. **While** several laboratories detected levels in **this** lower range, the values reported were very near the **limits** of detection.

Bovine **milk** collected after the accident **in** Seveso area was analyzed by **Fanel11** et al. (1980b). The concentration of 2,3,7,8-TCDD was found to vary from none detected (detection limit <40 ppt) to as **high** as 7.9 ppb. Other Investigators have **failed** to detect either 2,3,7,8-TCDD (detection limit 1 ppt) or **HxCDD** (detection **limit** 25 ppt) in **surveillance** (after normal application of 2,4,5-T on pasture) samples of **milk** from the states of Oklahoma, Arkansas and Missouri, or quarantined **milk** in the state of **Michigan** (Lamparski et al., 1978; Mahle et al., 1977).

TCDDs including **2,3,7,8-TCDD**, PeCDDs including **1,2,3,7,8-PeCDD** and HxCODs including **1,2,3,6,7,8-HxCDD** have been detected in fish from a few **PCDD-contaminated** areas. This is discussed in detail in Section 6.2.

PCODs have been detected in gelatin samples obtained from supermarkets and in bulk gelatin (Firestone et al., 1979). Eleven of 15 commercial gelatins examined contained a combined amount of **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD** ranging from 30-700 ppt. Three bulk gelatins of Mexican manufacture showed higher levels of PCDDs. **2,3,7,8-TCDD** was not detected in any sample. The origin of PCDDs in gelatin was speculated to be PCP and **trichlorophenol** that are routinely used in the leather-tanning industry. The use of by-product fat materials from PCP-treated hides as animal feed constituents led to widespread outbreaks of chick edema disease in the late 1950s (Firestone, 1973).

Bumb et al. (1980) analyzed charcoal-broiled steak under conditions representing rare, **well-done** and overdone samples and failed to detect either TCDD (detection limit 1-10 ppt) or **HxCDD** (detection limit 10-50 ppt) in the cooked meat of selected meat samples.

The analysis of human **milk** and urine for **2,3,7,8-TCDD** has been performed. A study of 103 samples of breast **milk** from mothers living in areas within the United States that were sprayed with **2,4,5-T/silvex** revealed no TCDD at a detection limit of 1-4 ppt and **0.1-10** ppt (U.S. EPA, 1980a; Heath et al., 1985). The control samples that were also negative for **2,3,7,8-TCDD** were derived from mothers living in areas where no records for **2,4,5-T** or **silvex** exposure exist (Heath et al., 1985).

In an **interlaboratory** collaborative analytical study on adipose tissue it was revealed that tissues from three Vietnam veterans heavily exposed to

Agent Orange contained **2,3,7,8-TCDD** residues **with** levels ranging from 20-173 ppt (Gross et al., 1984). A survey of 72 autopsy tissue materials from across Canada found **2,3,7,8-TCDD** averaging between 5 and 10 ppt, OCDD averaging between 600 and 800 ppt, and Intermediate levels for **penta-**, **hexa-** and **hepta-dioxins** (Ryan et al., 1985). Results on the distribution of tetra- and octa-chlorinated **dioxins** in autopsy tissues from the general population, supported by the above observations, indicate that there is substantial contamination of the general population in the United States and Canada **with** 2,3,7,8-chlorine substituted tetra- through **octa-dioxins** (Schechter et al., 1985). Rappe et al. (1984, 1985) also reports the presence of PCDDs in human adipose tissue. In the same study Rappe et al. (1985) reported their analytical results on a survey of **mothers' milk** from Sweden, Germany, Denmark and Vietnam. All the samples contained different levels of PeCDD, HxCDD, HpCDD and OCDD residues. The most toxic **isomer**, 2,3,7,8-TCDD, was found only **in** the **milk** samples of mothers from Sweden and Germany but not Vietnam. **This** isomer was not **analyzed** in **milk** samples of mothers from Denmark (Rappe et al., 1985).

The monitoring of urine samples from two people involved **with** spray application (**2,4,5-T**) showed no detectable level of TCDD at a detection limit of ~2 ppt (Lavy et al., 1980).

#### 4.6. EXPOSURE

The exposure of the general United States population to the four PCDDs cannot be estimated because the levels of these compounds in **air**, drinking water and foods have not been established. In fact, no PCDD contamination of any United States drinking water has ever been reported. Although the local atmosphere near a few chemical disposal sites and municipal incinerators has been reported to be contaminated **with** TCDD and **HxCDD**, no comprehen-

**sive** study **is** available to demonstrate the atmospheric levels of these compounds in areas farther away from the point sources. **Similarly**, some of these compounds have been detected in edible aquatic species. **Again**, these **fish** contaminations have been reported in areas near a limited source where effluents contaminated **with** these compounds may have been discharged **into** surface waters. One of the consumer products that has been found to be contaminated **with** HxCDD is gelatin. However, it **is** difficult to estimate the contribution of food to human exposure of PCDDs from such limited data. It seems more prudent to try to estimate the exposure of these compounds to populations in certain localized areas (e.g., dump sites and known sources of Industrial pollution) and certain special population groups (**i.e.**, **occupational**) when adequate data are available.

The concentrations of **2,3,7,8-TCDD** in bottom sediments of a drainage canal passing through a dump area (wastes from **2,4,5-T** production) in northern Amsterdam, Holland, were reported by **Heida** (1983). The concentrations of 2,3,7,8-TCDD in sediments within the dump area varied from 844-5062 ppt and outside the dump area from 55-611 ppt. Analysis of the eel revealed that only two samples originating from shallow ponds adjacent to the **main** drainage canal contained between 1.0 and 1.1 ppt of **2,3,7,8-TCDD**. 2,3,7,8-TCDD was not detected in other eel samples collected farther away from the dump **site**. **This** study demonstrates the possibility of TCDD contamination near dump **sites**.

The **results** of **analysis** for 2,3,7,8-TCDD and HxCDD in human **milk** samples were reported by **Langhorst** and Shadoff (1980). About 6 of the 9 samples showed 2,3,7,8-TCDD at levels slightly higher than the detection limits (0.2-0.7 ppt). All **nine samples** showed HxCDD at levels **slightly** higher than

the detection limit (0.2-0.5 ppt). **However**, these results remain unconfirmed because of the lack of validation of the precision and accuracy of data. Investigations of 103 breast **milk** samples from mothers living in areas **in** the United States sprayed **with 2,4,5-T** revealed no TCOD at a detection limit of 1-4 ppt (U.S. EPA, **1980a**).

The monitoring of urine samples from two people involved **with** spray application (2,4,5-T) showed no detectable level of TCDD at a detection limit of ~2 ppt (Lavy et al., 1980).

In one Polish study (**Gorski**, 1981), **1,2,3,6,7,8-HxCDD** was detected in latex nipples at a concentration of 20-400 ppt. However, no TCOD or PeCDD was detected. The origin of PCDDs **in** the latex was speculated to be the result of **γ-irradiation** of latex (for **crosslinking**) containing PCP during US manufacturing process.

A BCF relates the concentration of a chemical in aquatic species to the concentration **in** water. The steady-state BCFs for a **lipid-soluble** compound in the tissues of various aquatic species seem to be proportional to the percent **lipid** in the tissue. Thus, the per capita **ingestion** of a **lipid-soluble** chemical can be estimated from the per capita consumption of **fish** and shellfish, and a steady-state BCF for the chemical.

Data from a recent survey on **fish** and shellfish consumption in the United States were analyzed by SRI International (U.S. EPA, 1980b). These data were used to estimate that the per capita consumption of freshwater and **estuarine fish** and shellfish in the United States is 6.5 g/day (Stephan, 1980). In addition, **this** information was used **with** data on the fat content of the edible portion of the same species to estimate that the weighted average percent **lipids** for consumed freshwater and estuarine **fish** and shellfish is 3.0%.

Several equations have been developed for predicting the steady-state BCF for an organic compound from its octanol-water partition coefficient (Kenaga and Goring, 1980; Veith et al., 1980; Veith and Kosian, 1983). All of these depend on the availability of a useful value for the partition coefficient. Several estimated values (Leo, 1979; Mabey et al., 1981; Neely, 1983) and one measured value (Neely, 1979; Kenaga, 1980; Neely, 1983) have been reported for the octanol-water partition coefficient for 2,3,7,8-TCDD. Use of six equations with four values for the partition coefficient,  $K_{ow}$ , results in the following predicted BCFs (Table 4-4). The predicted BCFs range from 7000-900,000 using the calculated values of the partition coefficient and from 3000-68,000 using the one measured value.

Several measured BCFs have been reported for 2,3,7,8-TCDD (Table 4-5), but none can be considered definitive values. Many were determined in model ecosystems in which the concentrations in water were not necessarily constant. The measured BCFs, however, range from 2000-9000. A few other BCF values are given in Table 5-1. Until further information is available, the U.S. EPA's best current estimate for the BCF of 2,3,7,8-TCDD in aquatic organisms is 5000. An adjustment factor of  $3.0/7.6=0.39$  can be used to adjust the estimated BCF from the 7.6% lipids on which the equation is based to the 3.0% lipids that is the weighted average percent lipids consumed per capita from fish and shellfish (U.S. EPA, 1980b). The weighted average BCF for 2,3,7,8-TCDD in the edible portion of all freshwater and estuarine aquatic organisms consumed by Americans is calculated to be  $5000 \times 0.395 = 1975$ . Uptake by fish from lower trophic levels may add to uptake from water, so this BCF may underestimate concentrations in wild aquatic organisms.

TABLE 4-4  
 Predicted BCFs from Calculated and Measured Values of  $K_{ow}$  <sup>a</sup>

| Equation                                | $\log K_{ow}$ |                |                |                       |
|---|---------------|----------------|----------------|-----------------------|
|   | Calculated    |                |                | Measured <sup>b</sup> |
|   | 6.84          | 7.14           | 7.28           | 6.15                  |
| $\log BCF = 0.542 \log K_{ow} + 0.124$  | 6,780         | 9,860          | 11,700         | 2,870                 |
| $\log BCF = 0.76 \log K_{ow} - 0.23$    | 93,000        | 157,000        | 201,000        | 27,800                |
| $\log BCF = 0.79 \log K_{ow} - 0.40$    | 101,000       | <b>174,000</b> | 224,000        | 28,740                |
| $\log BCF = 0.635 \log K_{ow} + 0.7285$ | 118,000       | 183,000        | 225,000        | 43,000                |
| $\log BCF = 0.85 \log K_{ow} - 0.70$    | 130,000       | 234,000        | 308,000        | 33,700                |
| $BCF = 0.048 K_{ow}$                    | 332,000       | 663,000        | <b>915,000</b> | 67,800                |

<sup>a</sup>Sources: Kenaga and Goring, 1980; Veith et al., 1980; Veith and Kosian, 1983

<sup>b</sup>This measured value has been reported by Neely, 1979



TABLE 4-5

## Measured Bioaccumulation Factor for 2,3,7,8-TCDD in Freshwater Aquatic Organisms

| Species   | Tissue     | Percent Lipid | Duration (days) | Bioconcentration Factor         | Reference                            |
|---|------------|---------------|-----------------|---------------------------------|--------------------------------------|
| Alga,<br><u>Oedogonium cardiacum</u>            | NR         | NR            | 33              | <b>3094<sup>a</sup></b>         | Isensee, 1978                        |
| Alga,<br><u>Oedogonium cardiacum</u>            | NR         | NR            | 32              | <b>2075<sup>b</sup></b><br>2083 | Isensee, 1978<br>Yocklm et al., 1978 |
| <b>Snail,</b><br><u>Physa</u> sp.               | whole body | NR            | 33              | <b>5471<sup>a</sup></b>         | Isensee, 1978                        |
| <b>Snail,</b><br><u>Physa</u> sp.               | whole body | NR            | 32              | <b>2095<sup>b</sup></b><br>3731 | Isensee, 1978<br>Yocklm et al., 1978 |
| Cladoceran,<br><u>Daphnia magna</u>             | whole body | NR            | 30              | <b>3895<sup>a</sup></b>         | <b>Isensee,</b> 1978                 |
| Cladoceran,<br><u>Daphnia magna</u>             | whole body | NR            | 32              | <b>7070<sup>b</sup></b><br>7125 | Isensee, 1978<br>Yocklm et al., 1978 |
| Catfish,<br><u>Ictalurus punctatus</u>          | whole body | NR            | 28              | 2000                            | U.S. EPA, 1983a;<br>Thomas, 1983     |
| <b>Mosquitofish,</b><br><u>Gambusia affinis</u> | whole body | NR            | <b>14</b>       | <b>4850<sup>b</sup></b><br>4875 | Isensee, 1978<br>Yocklm et al., 1978 |
| —   | —          | NR            | —               | <b>9080<sup>c</sup></b>         | <b>Neely,</b> 1979                   |
| —   | —          | NR            | —               | 5400                            | <b>Kenaga,</b> 1980                  |

<sup>a</sup>These are arithmetic mean of several values given

<sup>b</sup>These are values at equilibrium tissue concentrations

<sup>c</sup>Calculated as ratio of uptake and clearance rate constants

NR = Not reported

The BCF for **2,3,7,8-TCDD** in the earthworm, **Allobophora caliginosa** or **rosea**, from **soil with initial 2,3,7,8-TCDD** concentration in the range of 0.06-9.2 ppb has been determined to be ~ 10 (**Fanellet al.**, 1982).

The BCFs for other PCDDs cannot be estimated because of the lack of solubility data.

Finally, the levels of TCDD in wildlife have been determined by various authors and are discussed in detail in Section 6.2.

#### 4.7. **SUMMARY**

None of the PCDDs are commercially manufactured in the United States or anywhere else in the world. They are produced as unwanted contaminants during the manufacture of primarily **chlorophenols** and their derivatives, such as the herbicides 2,4,5-T and **Silvex**. At the present **time**, there is no known manufacturer of **trichlorophenol** in the United States. Its derivatives distributed in the market before banning, however, continue to be used as pesticides **in** the United States. The level of 2,3,7,8-TCDD contaminants **in** **commercially** available 2,4,5-T and similar **formulations** had been reduced to <0.1 ppm before these products were banned.

The primary sources of PCDDs in the environment probably are **industrial** manufacturers of chlorophenols or their derivatives, and chemical disposal sites containing the wastes from these industries. Municipal waste **inciner-**ation also may produce some environmental emission of PCDDs. The significance of **this** source of emission compared **with** industrial emission and probable contamination from chemical disposal sites cannot be assessed **with** the available data. The **1,2,3,7,8-PeCDD** now found in environmental samples has only been reported in emissions from incinerators.

PCDDs, particularly TCDD and its specific **isomer** 2,3,7,8-TCDD, have been monitored in a number of environmental media, including **air**, water, **soil**,

food and biological media. The monitoring data to date indicate that the maximum level of PCDDs is **likely** to be found in **soil** and drainage sediment samples near **chlorophenol** manufacturing industries and chemical waste disposal sites. PCDDs have rarely been monitored in United States **air** samples. Small amounts of PCDD contamination have been found **in fish** and wildlife in the United States **in** areas around chlorophenol manufacturing industries and chemical waste disposal sites.

## 5. ENVIRONMENTAL FATE AND TRANSPORT PROCESSES

### 5.1. FATE

#### 5.1.1. Water.

5.1.1.1. BIODEGRADATION - 2,3,7,8-TCDD exhibits relatively strong resistance to **biodegradation**. Only 5 of **~100 microbial** strains that have the ability to degrade persistent pesticides show slight ability to degrade 2,3,7,8-TCDD (**Matsumura** and Benezet, 1973). Ward and **Matsumura (1977)** studied the biodegradation of **<sup>14</sup>C-labeled** 2,3,7,8-TCDD by using lake waters and sediments from Wisconsin. The observed half-life of 2,3,7,8-TCDD in sediment-containing lake waters was found to be 550-590 days. In lake water alone, **~70%** of the 2,3,7,8-TCDD remained after 589 days. Using an outdoor pond as a model aquatic ecosystem and dosing **it with <sup>14</sup>C-labeled** 2,3,7,8-TCDD, **Tsushimoto et al. (1982)** and **Matsumura et al. (1983)** estimated the apparent half-life of 2,3,7,8-TCDD to be **~1 year**. **Although** biodegradation may have been responsible for part of the degradation, **it is almost impossible** to estimate the biodegradation half-life of 2,3,7,8-TCDD in aquatic systems from **this** experiment. It is **likely** that the apparent biodegradation loss was due to volatilization through air/water Interface. Other Investigators (**Huetter and Philipp, 1982; Camoni et al., 1983**) have demonstrated the virtually complete lack of degradation of 2,3,7,8-TCDD by microorganisms. It could be inferred from these studies that PeCDD and HxCDD, having more chlorine substitution on benzene rings, **would** be even more resistant to biodegradation than 2,3,7,8-TCDD.

The biodegradation half-life of 2,3,7,8-TCDD can also be estimated from the theoretical rate constant values based on **relative** rates of transformation reported **in** the literature or on structure-activity **analogy values** given by Mabey et al. (1981). Assuming the estimated **biotransformation** rate

constant of  $1 \times 10^{10} \text{ mg cell}^{-1} \text{ hour}^{-1}$  (Mabey et al., 1981) and the concentration of microorganisms capable of degrading TCDD as  $5 \times 10^5 \text{ cell mg}^{-1}$  (Burns et al., 1981), the half-life of biodegradation can be estimated to be >1 year. It should be emphasized that the role that biodegradation plays in the removal of PCDDs from water is not clear.

5.1.1.2. PHOTOTRANSFORMATION -- **2,3,7,8-TCDD** has a UV absorption maximum at **310 nm** with an extinction coefficient of  $5590 \text{ M}^{-1} \text{ cm}^{-1}$  (NRCC, 1981a). **2,3,7,8-TCDD** in a pure state is **photochemically** stable but **it will** photolyze in sunlight in the presence of a hydrogen atom donating substrate (Crosby and Wong, 1977). For example, Plimmer et al. (1973) reported that a **2,3,7,8-TCDD** suspension in distilled water remained unchanged when irradiated **with a sunlamp**. Similarly, a **thin dry film** of **2,3,7,8-TCDD** on a **glass** plate or **2,3,7,8-TCDD** on dry and wet soils showed negligible photodegradation after irradiation **with sunlamps** (Crosby et al., 1971). In contrast, **2,3,7,8-TCDD** in methanol solution or benzene solution of **2,3,7,8-TCDD** in water stabilized by surfactant underwent substantial photodegradation under sunlamp or sunlight irradiation (Plimmer et al., 1973; Crosby et al., 1971). Botre et al. (1978) demonstrated that **cationic** surfactants, namely **1-hexadecylpyridinium** chloride, act as an energy transfer agent in facilitating the **photodecomposition** of TCDD in aqueous solutions. These laboratory studies may not be applicable to the ambient environments. To explain the longer half-life of **2,3,7,8-TCDD** in a model laboratory ecosystem than in an outdoor pond, **Matsumura** et al. (1983) and **Tsushimoto** et al. (1982) speculated that photolysis was the most **likely** cause. In the outdoor environment where the intensity of sunlight was higher compared **with** the laboratory experiments, algae-mediated photosensitization of **2,3,7,8-TCDD** may cause some photodecomposition of **this** compound. **Nestrick** et al. (1980) estimated the photo-

**lytic** half-life of 2,3,7,8-TCDD in **n-hexadecane** under **sunlamp** Irradiation to be ~57 minutes. From the **available** Information, it **is difficult** to predict the fate of 2,3,7,8-TCDD in aquatic media under environmental **photolytic** conditions. In the presence of hydrogen atom donating substrate(s) in surface waters, photolysis may be a significant fate process.

An Increase in chlorine substitution is expected to decrease the rate of **photodegradation** (Nestrick et al., 1980; Helling et al., 1973). For example, Crosby et al. (1971) showed that although complete decomposition of 2,3,7,8-TCDD in **methanol** occurred in 24 hours under **UV** Irradiation, **>80%** OCDD in methanol remained unreacted during the same period under similar Irradiation conditions.

Although the degree of **photolysis** may be related to the extent of **chlorination**, **positional** isomerization also plays a **critical** and perhaps dominant part in the photolysis of higher PCDDs. In higher PCDDs, there appears to be preferential loss of chlorine from the 2, 3, 7 and 8 positions (Nestrick et al., 1980; Buser and Rappe, 1978; Choudhry and Hutzinger, 1984). However, Buser (1979) observed the formation of **2,3,7,8-TCDD** in trace quantities, and PeCDD form **photolysis** of **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD**. PCDD compounds with chlorine substitutions in positions 2, 3, 7 and 8 are likely to photodegrade faster than compounds not having these **positional** substitutions. According to such a predicted **rule**, it is not likely that photodegradation of OCDD and other higher PCDDs will yield a **high** quantity of 2,3,7,8-TCDD as the **stable** end product. For example, the photolysis half-life of **1,2,3,7,8-PeCDD** has been estimated to be 7.6 hours in **n-hexadecane** solution under sunlamp Irradiation (Nestrick et al., 1980). Similarly, the **photolytic half-lives** of **1,2,3,7,8-PeCDD**, **1,2,3,6,7,9-HxCDD** and **1,2,4,6,7,9-HxCDD** in hexane solutions under **sunlight** Irradiation have been determined to be 5.4, **17** and 47 hours, **respectively** (Dobbs and Grant,

1979). **Nestrick et al.** (1980) reported a **half-life** value of 6.8 hours for **1,2,3,6,7,8-HxCDD** in **n-hexadecane** under sunlamp Irradiation. The Intermediates of the **photodegradation** of higher PCDDs are probably lower chlorinated **dioxins**, but the pathways of degradation are not known **with** certainty (NRCC, 1981a).

From the preceding discussions of the photolysis of PCODs **in** the presence of organic hydrogen donating **substrates**, it is difficult to predict the **photolytic** fate of these compounds in natural aquatic media where sufficient organic hydrogen donating substrate(s) may or may not be available. The situation **is** complicated further by the fact that, unlike **in** solution, a predominant amount of PCDDs in surface water may remain sorbed on suspended particles and settled sediments. Moreover, since the penetration of UV light **into** natural water may be very limited, photolytic degradation of PCDDs is not likely to be of environmental importance.

5.1.1.3. **RADICAL OXIDATION AND HYDROLYSIS** -- Although these processes occur, hydrolysis of **2,3,7,8-TCDD** or oxidation **with** free radicals ( $RO_2\cdot$ ,  $RO\cdot$ , etc.) in aquatic media are not likely to be of environmental significance (Callahan et al., 1979; Mabey et al., 1981). Likewise, hydrolysis and oxidation are even less likely to be environmentally significant processes for PeCDD and HxCDD.

5.1.1.4. **VOLATILIZATION** -- Although several Investigators Implicated volatilization as one of the **major** reasons for the observed disappearance of **2,3,7,8-TCDD** from aqueous solution during **microbial** studies, no quantitative information regarding the volatilization of **2,3,7,8-TCDD** from aquatic media **is** available (Ward and **Matsumura**, 1977; **Matsumura** et al., 1983; Huetter and Philipp, 1982). **2,3,7,8-TCDD** may undergo some water-mediated evaporation **in** aquatic media (Matsumura et al., 1983). Using the formulas of **Liss** and Slater (1974), a vapor pressure value of  $1.7 \times 10^{-6}$  torr (0.2 m Pa) and a

solubility value of  $6.2 \times 10^{-10}$  mole/l, the **volatilization half-life** for **2,3,7,8-TCDD** was 6 minutes from water of 1 cm depth and 10 hours from water of 1 m depth (NRCC, **1981a**). The limitations of **this** theory to predict the rate of volatilization have been discussed **in** the NRCC (1981a) document. The Liss-Slater model does not consider terrestrial matrices (suspended solids, sediments, biota, etc.) **normally** encountered in **natural** surface water and thus ignores the effects of these parameters on the volatilization rate. Employing a computerized EXAMS model for two standardized aquatic ecosystems (lake and pond; see NRCC, 1981a, for definitions) and the input parameters for 2,3,7,8-TCDD given in NRCC (1981a), volatilization has been estimated to account for 100% of the fraction lost; **biodegradation** has been **calculated** to be 0%. The volatilization half-life for TCDD has been estimated to be 5.5 and 12 years from pond and lake water, respectively. A transport model has also been used to estimate the volatilization rate of 2,3,7,8-TCDD from a cooling pond on an industrial **site** (Thibodeaux, 1983). The model accounted for movement of **2,3,7,8-TCDD** from the bottom sediment to the water column and then to the **air**. Based on the measured concentrations in the pond bottom sediment (22,100 ng/kg) and the pond surface area (15,050 **m<sup>2</sup>**), the calculated volatilization rate was **15-16** mg/year.

Pertinent data regarding the volatilization of PeCDDs and HxCDDs from aquatic media could not be found in the **available literature**. However, these compounds **with** higher molecular weight and more chlorine substitution are expected to volatilize more slowly than 2,3,7,8-TCDD from aquatic media.

5.1.1.5. SORPTION -- Data from microcosm experiments indicate that 2,3,7,8-TCDD is highly sorbed to sediments and biota (Isensee and Jones, 1975; Ward and **Matsumura**, 1978). **More** than **90%** of 2,3,7,8-TCDD in an aquatic medium may be present in the adsorbed state (Ward and Matsumura,



1978; **Matsumura et al.**, 1983). Considering the low water solubility and the **high octanol/water** partition coefficient, **this** is not surprising. In fact, the equation of **Karickhoff et al.** (1979) predicts a **sorption** partition coefficient **value** of  $10^4$  for **2,3,7,8-TCDD** in sediments containing 2% organic carbon. Similarly, the higher PCDDs are **likely** to be present predominantly **in** the **sediment-sorbed** state in aquatic media.

5.1.2. Air. A number of PCDDs, including TCDDs, PeCDDs and HxCDDs, have been detected in the dust and fly ash from municipal incinerators (Cavallaro et al., 1980b; Clement and Karasek, 1982; Eiceman et al., 1981). **Size fractionations** of fly ash from municipal incinerators have shown that **larger** concentrations of 2,3,7,8-TCDD and PeCDDs occurred on the larger (550  $\mu\text{m}$ ) particles, while the 30  $\mu\text{m}$  particles had greater relative concentrations of OCDD (Clement and Karasek, 1982). **Tiernan et al.** (1982b) also reported higher concentrations of TCDDs on larger particles (3-10  $\mu\text{m}$ ) from a refuse-fueled municipal incinerator effluent than on smaller particles (<1  $\mu\text{m}$ ). PCDDs emitted to the atmosphere from combustion processes appear to be associated **with air** particulate matter (**Nestrick et al.**, 1980). Atmospheric PCDDs originating from other **noncombustion** sources, such as herbicide-treated soils and vaporized PCDDs from aquatic media (**Thibodeaux**, 1983), are also likely to be associated **with air** particulate matter. **Cupitt** (1980) presented mathematical descriptions of **physical** removal mechanisms for the fate of toxic and hazardous materials **in** the **air** environment. For the adsorption of chemicals on aerosol particles he developed a general model based on **aerosol** surface area and chemical saturation vapor pressure. **His** results suggest that adsorption **will** be a reasonable vapor-phase removal mechanism from **air** only for materials **with** saturation vapor pressures of  $10^{-7}$  torr (mm) or **less**. 2,3,7,8-TCDD has an estimated vapor pressure of  $1.7 \times 10^{-6}$  torr.

Photodegradation and wet and dry **deposition** of particulate-bound PCDDs are probably the most important fate-determining processes for the atmospheric PCDDs. The **available** data relating the photodegradation of these compounds in the sorbed phase or as films are conflicting. For example, experiments of earlier investigators involving **photoreactivity** of 2,3,7,8-TCDD as films or sorbed on solid surfaces and exposed to the atmosphere yielded negligible photodegradation with sunlight (Crosby et al., 1971). However, the more recent work of Buser (1979) and the investigations of the other researchers (Plimmer, 1978; Crosby and Wong, 1977) have shown that some photolysis of TCDD in the condensed phase (i.e., coated on glass plate or on silica) may take place. In the condensed phase, **photodecomposition** of TCDD in the bottom layers that are shielded from incident light by the surface layer is prevented.

Gebefuegi et al. (1977) studied **2,3,7,8-TCDD** photochemical degradation under simulated **environmental** conditions by exposing silica **gel-sorbed** 2,3,7,8-TCDD to **light** of wavelength >290 nm and observed 92% decomposition in 7 days. The half-life for photodegradation of 2,3,7,8-TCDD **film** on glass surfaces has been estimated to be 5.8 days under irradiation with sunlamps (Nestrick et al., 1980). It is not known whether a similar photodegradation of particle-bound 2,3,7,8-TCDD will occur in the atmosphere since the state of **sorption** may be different from those obtained under laboratory conditions. The **potential** for oxidation of PCDDs by free radicals (OH•, O•, etc.) and other molecules (O<sub>3</sub>, NO<sub>x</sub>, etc.) that may be present in the atmosphere is unknown.

### 5.1.3. Soil.

**5.1.3.1. SORPTION** - From the **empirical** correlation of Karickhoff et al. (1979), it is possible to predict a soil/water partition coefficient of **4.8x10<sup>4</sup>** for a soil containing **10%** organic matter.

Because of their **high** affinity toward soils, particularly those **with** significant organic content, and because of their extremely low water solubilities, **2,3,7,8-TCDD** (and presumably other PCDDs) tend to remain on or near the surface of **soils** (U.S. EPA, 1984). **With time**, 2,3,7,8-TCDD bound to **soil** becomes more difficult to desorb (Philippi et al., 1981; Huetter and Philippi, 1982).

Several authors have shown that vertical movement of 2,3,7,8-TCDD **in soil** is negligible, **although** movement of 2,3,7,8-TCDD may occur by horizontal transfer (eroded **soil** transported by water) and through contaminated airborne dust particles (U.S. EPA, 1984; Helling et al., 1973). Therefore, underground water supplies are unlikely to be contaminated **with** 2,3,7,8-TCDD. However, as the organic content of **soil** decreases, the likelihood of vertical movement of PCDDs **in soil** increases. In areas of heavy rainfall and sandy **soil**, vertical migration of 2,3,7,8-TCDD and **its** lateral **displacement** by **soil** erosion and runoff would be enhanced (U.S. EPA, 1984). The downward vertical migration of 2,3,7,8-TCDD up to 30 cm **into soil** has been suggested to have occurred in Seveso, Italy (DiDomenico et al., 1980d,e). The monitoring of Seveso **soil** 1 year after the accident showed that the highest 2,3,7,8-TCDD levels were not present in the topmost **soil** layer (0.5 cm), but very often in the second (**0.5-1.0** cm) or third (1.0-1.5 cm) layers. In **view** of the low water **solubility** of 2,3,7,8-TCDD, probable explanations of **this** vertical distribution could be due to volatilization through the air/soil interface or **solvation** of 2,3,7,8-TCDD by organic solvents (NRCC, 1981a), or **biotic** mixing by earthworms or other **soil** invertebrates. It is, therefore, possible that **2,3,7,8-TCDD** may appear in the **air** above and in normal water leachate of soils, particularly after multiple PCDD application or accidental release of 2,3,7,8-TCDD on **soil**.

5.1.3.2. **PHOTOTRANSFORMATION** -- The **photodecomposition** of 2,3,7,8-TCDD on wet or dry **soil** under artificial and **natural** sunlight was studied by Crosby et al. (1971). The photodecomposition was found to be negligible in soils. Similarly, **Plimmer** et al. (1973) determined that photodecomposition of TCDD on soils was too slow to be detected. In a later experiment, **Plimmer** (1978) found that although TCDD decomposed significantly from precoated **silica** plate (**~22%**) in 8 hours of **sunlight** irradiation, practically no decomposition of TCDD was observed from TCDD sorbed on **soil** under **similar** conditions.

The **photodegradation** of TCDD in combination with other pesticide mixtures was studied by Crosby and Wong (1977). When Agent Orange containing 15 ppm of TCDD was **applied** on the surface of glass plates (5 **mg/cm<sup>2</sup>**), rubber plant, Hevea **brasiliensis** (6.7 **mg/cm<sup>2</sup>**), and on the surface of sieved Sacramento loam **soil** (10 **mg/cm<sup>2</sup>**) and exposed to sunlight, TCDD was found to **photodecompose**. The loss of TCDD in 6 hours was **>50%** from **glass** plate, **~100%** from the surface of leaves and **~10%** from the surface of **soil**. The rapid photolysis of TCDD from these surfaces indicates that the herbicide formulation provided a hydrogen donor that probably **allowed** the photolysis to occur. The authors attributed the slower photolysis of **2,3,7,8-TCDD** in **soil** to a shading effect by lower layers of **soil** particles.

5.1.3.3. **BIODEGRADATION** -- **Poiger** and **Schlatter** (1980) noted that 2,3,7,8-TCDD absorbs **strongly** onto **soil particles**, thereby reducing **its bioavailability**. Young (1983) **also** noted that 2,3,7,8-TCDD **is** not likely to metabolize readily by **soil** microorganisms. It can be concluded from the following discussions that the **biodegradation half-life** in **soil** is likely to be >1 year.

The overall half-life of **2,3,7,8-TCDD** in **soil** has been reported to be 1-3 years by Kearney et al. (1972). Studies performed by the U.S. Air Force (Young et al., 1976; IARC, 1977) suggested that **soil** bacteria may **biodegrade** TCDD. The half-life of **this chemical** in soils under relatively dry conditions (Utah test area) was found to be **~330** days and in more moist soils and under warm conditions (Florida test area) was found to be **~190** days. **This is** consistent **with** the **biodegradation** half-life of **~0.5** year for TCDD determined by Commoner and Scott from the **soil** in rural Missouri after the accidental spraying of **TCDD-contaminated oil** (IARC, 1977). However, these half-life estimates may **greatly** underestimate the true **value**, since it has recently been shown that **radiolabeled** TCDD adsorbed to **soil** becomes progressively more resistant to extraction (Phillippi et al., 1981; Huetter and Phillipi, 1982).

The rate of disappearance of 2,3,7,8-TCDD following an accidental 2,3,7,8-TCDD release from a **trichlorophenol** manufacturing plant at Seveso, Italy, was studied by DiDomenico et al. (1980d, 1982). The disappearance of 2,3,7,8-TCDD from the topmost **soil** layer after 1 year was speculated to be due to **photodegradation**, volatilization or vertical movement through the **soil**. These Investigators estimated the **initial** half-life of 2,3,7,8-TCDD in **soil** at the **time** of its release to be 5 months. One month after release, the rate of disappearance of **2,3,7,8-TCDD** slowed down to the equivalent of 1 year in apparent half-life. By the 17th month, the rate declined to an extremely slow level; the apparent half-life figure for **this** phase was calculated to be >10 years. **More** recent data (Young, 1983; Wipf and Schmid, 1983) indicate that the half-life of 2,3,7,8-TCDD in **soil** is about 10-12 years. Since most of the other PCDDs are no more susceptible to transformation/degradation than TCDDs, their half-lives in **soil** are presumed to be similar to that postulated for TCDDs.

5.1.4. Food. Isensee and Jones (1971) conducted experiments to study the possibility of absorption and translocation of 2,3,7,8-TCDD by plants from polluted **soil**. Oats and soybean plants grown to maturity in **soil** contaminated **with** 0.06 ppm 2,3,7,8-TCDD showed **<1** ppb of 2,3,7,8-TCDD in the seeds. **Cocucci et al.** (1979) measured the level of contamination in kitchen garden plants (carrot, potato, onion and narcissus) grown **in soil** from the contaminated Seveso area containing 1000-4000  $\mu\text{g}/\text{m}^2$  of 2,3,7,8-TCDD. 2,3,7,8-TCDD was found to be 3-5 times higher in foliage than in fruits. The fact that the highest 2,3,7,8-TCDD content was found adjacent to the conductive tissue was interpreted as evidence of translocation of 2,3,7,8-TCDD from roots to the outer parts of the **plants**. The investigation of these authors also suggested that 2,3,7,8-TCDD may be eliminated from the mature plants. **Wipf et al.** (1982), however, failed to detect any measurable 2,3,7,8-TCDD **in** the flesh of fruits and vegetables collected from the contaminated area in Seveso during 1977-1979, although the **soil** 2,3,7,8-TCDD concentration was **~10** ppb. These authors concluded that 2,3,7,8-TCDD may not be translocated from **soil** to the plants. A similar conclusion was reached by **Pocchiarri et al.** (1983) from their uptake experiments **with plants**. It can be **concluded** from these studies that 2,3,7,8-TCDD is not likely to concentrate **in** plants grown in contaminated soils.

**With** respect to potential 2,3,7,8-TCDD exposure through aerial parts of plants, when an aqueous suspension of pure 2,3,7,8-TCDD was exposed to either artificial light or sunlight, **photodecomposition** was negligible. However, in conjunction **with** other pesticides, 2,3,7,8-TCDD rapidly degraded when exposed to light (Crosby and Wong, 1977). **This** is consistent **with** the observations that TCDD was found not to persist on foliage (**Sundstrom et al.**, 1979; Crosby and Wong, 1977) after application **with** other pesticides

(2,4,5-T, Agent Orange). The half-life of **2,3,7,8-TCDD** disappearance from grass **in** Texas treated at a **high** rate (12 pounds/acre) of 2,4,5-T containing 0.4 **ppm** 2,3,7,8-TCDD was determined to be 5.6 days (Jensen et al., 1983). Cattle fed rations fortified **with** a maximum of 90 ppt TCDD were monitored for TCDD content **in** the body fat. TCDD from the body fat presumably disappeared **with** a half-life of **~16.5** weeks (Jensen et al., 1981). Similarly, cattle fed rations fortified **with** 500 ppt 2,3,7,8-TCDD showed a maximum level of 90 ppt of 2,3,7,8-TCDD **in cows' milk**. On withdrawal of 2,3,7,8-TCDD containing feed, 2,3,7,8-TCDD disappeared from the **milk with** a half-life of 41 days (Jensen and Hummel, 1982).

## 5.2. TRANSPORT

5.2.1. Water. The two **likely** transport processes for PCDDs **in** aquatic media are volatilization and **sorption** onto suspended **particulates** and subsequent sedimentation. No quantitative data regarding volatilization of any of these compounds from aquatic media are available, although several Investigators Implicated volatilization as one of the major reasons for the observed **loss** of 2,3,7,8-TCDD from aqueous solutions during **microbial** studies (Ward and **Matsumura**, 1977; Huetter and Phlllpp1, 1982). There is a very **wide** difference **in** the calculated values of half-life of **volatilization** for 2,3,7,8-TCDD. For example, calculation based on the Liss and Slater (1974) equation gives a half-life for evaporation of 10 hours from water of 1 m depth (see Section 5.1.1.4.). Calculation based on a **reaeration** rate ratio of 0.373 (Mabey et al., 1981) and an oxygen reaeration rate constant of 0.19 **day<sup>-1</sup>**, 0.96 **day<sup>-1</sup>** and 0.24 **day<sup>-1</sup>** (Mabey et al., 1981) for pond, river and lake water, respectively, gives half-life **values** of 10, 2 and 8 days for 2,3,7,8-TCDD **in** pond, river and lake water, respectively. These **wide** variations are conceivable when examined **with** the volatilization

models for **half-life** (Thibodeaux, 1979). Evaporation **half-life** is shown to be proportional to water depth and Inversely proportional to the mass-transfer coefficient. A more realistic calculation based on EXAMS predicts half-life values for TCDD of 5.5 and **12** years from pond and lake water, respectively (see Section **5.1.1.4.**). The EXAMS calculation routine contains an added element that accounts for the **sorption** of TCDD both on the suspended and on-bottom sediment. For substances **with high** sorption coefficients such as TCDD, the evaporation rate is reduced significantly. A comparison of calculated transport rates from an Industrial **site** indicates that evaporation of TCDD from a contaminated cooling water pond sediment is negligible in comparison **with** other contaminated areas on the **site** (Thibodeaux, 1983). It **will** also become apparent from the following discussion that volatilization may be insignificant compared **with** sorption processes for the transport of TCDD and presumably other PCDDs from aquatic media.

It has already been shown (**see** Section 5.1.1.5.) that **2,3,7,8-TCDD** is **highly** sorbed to sediments and biota (Isensee and Jones, 1975) and **>90%** of 2,3,7,8-TCDD in aquatic media may be present in the sorbed state (**Ward** and Matsumura, 1978). **This** is consistent **with** the sorption partition coefficient value of **this** compound. Although the sorption effects of the higher PCDDs have not been studied, based on their expected higher **octanol/water** partition coefficient values, these compounds are likely to be present predominantly **in** the sediment-sorbed state in aquatic media.

5.2.2. Air. **All** the PCDDs are **believed** to be transported in the vapor-phase and in **particulate** bound form in the atmosphere (see Section **5.1.2.**). The transport of these compounds from stationary point sources (**i.e.** stack emission) and area sources (waste disposal sites) can be theoretically predicted from dispersion modeling (**Josephson**, 1983). Although such



dispersion modeling has been performed for 2,3,7,8-TCDD (SAI, 1980), the correlation between the **theoretical value** and **experimental** monitoring data has never been performed. In the case of accidental release of toxic clouds containing TCDD at Seveso, **Italy, Cavallaro et al.** (1982) determined the transport pattern and the ground deposition of the TCDD from the cloud. They determined that the TCDD deposition from **air** to **soil** should follow an exponential decay pattern along the downwind direction and follow a Gaussian-distribution along the cross-section of the downwind direction. From regression equations, these Investigators determined that the aerial deposition  $Y$  ( $\mu\text{g}/\text{m}^2$ ) should be  $\gamma = 2900 e^{-2.3x}$  for  $x < 2$  km and  $\gamma = 45 e^{-0.5x}$  for  $2 \text{ km} < x < 6$  km. It is doubtful whether this equation can be used in the general case of accidental release of TCDD because of the varying meteorological conditions.

5.2.3. **Soil.** The probable media and modes of transport of PCDDs from soils are the following: 1) to **air** through contaminated airborne dust particles; 2) to surface water by eroded **soil** transported by water; 3) to groundwater by leaching; and 4) to **air** by **volatilization**. Movement of **particulate** matter containing sorbed PCDDs is considered to be a much more important transport mechanism than leaching because of the low water solubility of these compounds (Josephson, 1983). However, one year following the Seveso accident the highest **2,3,7,8-TCDD** levels in **soil** were very often detected in the second (0.5-1.0 cm) or third (1.0-1.5 cm) layers but not in the top most **soil** layer (0.5 cm). This disappearance of at least a part of the 2,3,7,8-TCDD from the topmost **soil** layer was speculated to be due to volatilization or vertical movement down through the **soil** (DiDomenico et al., 1980d). Results of **off-site** transport calculations from contaminated **soil** surfaces are available (Thibodeaux, 1983). The calculations show that

between 120 and 1200 g/year of TCDD were volatilized from a **highly** contaminated **soil** surface between 1978 and 1979 before the Implementation of remedial measures. Over the same period **it** was estimated that 28-37 g/year left the **site** by wind-blown particle **entrainment**, 0.1-1.0 g/year evaporated from a **burial site** and 0.98-2.3 g/year in water runoff. All these sources are areas **in** which the **2,3,7,8-TCDD** was found to remain sorbed on the **soil**. It appears that **volatilization** from **soil** and downward migration caused by **soil** movement, or through **biotic** mixing by earthworms or other **soil** Invertebrates are more **probable** mechanisms by which 2,3,7,8-TCDD may be transported from **soils**.

### **5.3. BIOACCUMULATION/BIOCONCENTRATION**

The bioconcentration of TCDD **in** various aquatic species has been studied under controlled laboratory conditions using static test chambers. The results of these Investigations have been discussed **in** Section 4.6. and are given **in** Table 5-1. In all these experiments, the total amounts accumulated were found to be related to the Initial TCDD concentrations in aquatic phase. The Investigation of Phlllpp1 et **al.** (1981) made it clear that bioaccumulation would be significantly affected by the physical form (sorbed or in solution) in which TCDD occurs **in** the environment. Isensee (1978) reported that the concentration in the tissues of the tested species reached equilibrium **in** 7-15 days. In the absence of any experimental BCFs derived under dynamic test conditions, the values of Isensee (1978) reported in Table 5-1 probably represent the best experimental values available (**in** species other than **fish**) since these values were derived from equilibrium concentrations of TCDD in the tested tissues. The BCF for 2,3,7,8-TCDD in the earthworm, **Allobophora caliginosa** or **rosea.** from **soil with** Initial 2,3,7,8-TCDD concentration in the range of 0.06-9.2 ppb has been determined to be **~10** (**Faneli et al., 1982**).

TABLE 5-1

Bioconcentration Factor of TCDD for Several Aquatic **Organisms**<sup>a</sup>

| Species                               | Initial Aquatic Concentration (ppt) | Bioconcentration Factor   | Reference                          |
|---------------------------------------|-------------------------------------|---------------------------|------------------------------------|
| Algae, <u>Oedogonium cardiacum</u>    | 0.05-1300                           | 2,075                     | Isensee, 1978                      |
| Algae, <u>Oedogonium cardiacum</u>    | 0.05-1300                           | <b>9,000<sup>b</sup></b>  | <b>Isensee</b> and Jones, 1975     |
| Algae, <u>Oedogonium cardiacum</u>    | <b>0.1<sup>c</sup></b>              | 2,080                     | <b>Yockim et al.</b> , 1978        |
| Ostracod                              | 2.6                                 | 110                       | <b>Matsumura</b> and Benezet, 1973 |
| <b>Duckweed, <u>Lemna minor</u></b>   | 0.05-1300                           | <b>3,625<sup>b</sup></b>  | Isensee and <b>Jones</b> , 1975    |
| <b>Snail, <u>Physa</u> sp.</b>        | 0.05-1300                           | 2,095                     | Isensee, 1978                      |
| Snail, <u>Physa</u> sp.               | 0.05-1300                           | <b>20,000<sup>b</sup></b> | Isensee and <b>Jones</b> , 1975    |
| <b>Snail, <u>Helosoma</u> sp.</b>     | <b>0.1<sup>c</sup></b>              | 2,080                     | Yockim et <b>al.</b> , 1978        |
| <b>Daphnids, <u>Daphnia magna</u></b> | 0.05-1300                           | 7,070                     | Isensee, 1978                      |
| <b>Daphnids, <u>Daphnia magna</u></b> | 0.05-1300                           | <b>26,000<sup>b</sup></b> | Isensee and Jones, 1975            |
| Daphnids, <u>Daphnia magna</u>        | 0.4                                 | 2,200                     | Matsumura and Benezet, 1973        |

TABLE 5-1 (cont.)

| Species  | Initial Aquatic Concentration (ppt) | Bioconcentration Factor | Reference                   |
|--|-------------------------------------|-------------------------|-----------------------------|
| Mosquito fish, <u>Gambusia affinis</u>                             | 0.05-1300                           | 4,850                   | Isensee, 1978               |
| Mosquito fish, <u>Gambusia affinis</u>                             | 0.05-1300                           | 26,000 <sup>b</sup>     | Isensee and Jones, 1975     |
| Mosquito fish, <u>Gambusia affinis</u>                             | 0.1 <sup>c</sup>                    | 4,875                   | Yockim et al., 1978         |
| Mosquito larvae, <u>Aedes aegypti</u>                              | 0.45                                | 9,200                   | Matsumura and Benezet, 1973 |
| Brine shrimp, <u>Artemia salina</u>                                | 0.1 <sup>c</sup>                    | 1,570                   | Matsumura and Benezet, 1973 |
| Catfish, <u>Ictalurus punctatus</u>                                | 0.05-1300                           | 9,000 <sup>b</sup>      | Isensee and Jones, 1975     |
| Catfish, <u>Ictalurus punctatus</u>                                | 0.05-1300                           | 4,875                   | Yockim et al., 1978         |
| Brook Silverside, <u>Laludesthes sicculus</u>                      | 1.3                                 | 545 <sup>d</sup>        | Matsumura and Benezet, 1973 |
| Pond Weed, <u>Elodea nuttali</u> and <u>Ceratophyllum demersum</u> | 53.7                                | 30.300                  | Tsushimoto et al., 1962     |

<sup>a</sup>BCF values derived by Isensee and Jones (1975) were based on dry weight for all biological and sediment materials.

<sup>b</sup>Average of several values

<sup>c</sup>These are Initial concentrations of TCDD in soil added to water.

<sup>d</sup>Error in the original publication corrected in the value reported here.

#### 5.4. SUMMARY

The four transformation processes (**photoreaction, biotransformation, hydrolysis and radical oxidation**) that control the fate of a chemical in aquatic media do not appreciably transform TCDD and **possibly** other PCDDs in aquatic media. However, the two former processes may be more important for the transformation of **2,3,7,8-TCDD** in aquatic media. The transport of these compounds to the atmosphere by volatilization from surface water may take place through a **water-mediated** process, particularly **in** the case of 2,3,7,8-TCDD, but significant transport of these compounds to the atmosphere through water may not be likely. Therefore, the PCDDs are expected to be very persistent in aquatic media.

The potential for oxidation of PCDDs by **tropospheric** free radicals is not known. Although appreciable photolysis of TCDD coated on glass plate or sorbed onto **silica** has been observed, **it is** not known whether a **similar photodegradation** of particle-bound TCDD and other PCDDs **will** occur in the atmosphere. The transport of vapor phase and particle-bound PCDDs may be theoretically predicted from dispersion modeling equations. In the case of accidental release of toxic clouds containing TCDD at Seveso, **Italy**, it has been demonstrated that the TCDD deposition from **air** to **soil** followed an exponential decay pattern along the downwind direction and a Gaussian distribution pattern along the cross-section of the downwind direction.

PCDDs are resistant toward photochemical and **biodegradation** reactions in **soil**. The half-life of **2,3,7,8-TCDD** in soils may be >10 years. These compounds are likely to be transported from **soil** through movement of **particulate** matter containing sorbed PCDDs. The most probable transport mechanisms are transport of these compounds to the atmosphere by contaminated airborne dust particles, evaporation, and transport to surface water

**via** eroded **soil** transported by water. Leaching is a less likely transport process for these chemicals except for very sandy soils.

Both the calculated and experimental results show that these compounds **will bioaccumulate in** aquatic organisms. The experimental BCF varies **with** the species and ranges from **~2000-30,000**. However, studies **with** flow-through systems should be performed to establish the realistic **bioaccumulation** factors for these compounds in different aquatic species.

## 6. ECOLOGICAL EFFECTS

### 6.1. EFFECTS ON ORGANISMS

6.1.1. Aquatic **Life** Toxicology. Almost all of the available Information concerning the **toxicity** of PCDDs to wildlife pertains to aquatic species, and most of the aquatic Information **is** based on acute exposure to **calculated**, rather than measured concentrations of **2,3,7,8-TCDD**.

**6.1.1.1. ACUTE TOXICITY** -- The effects of acute exposure to 2,3,7,8-TCDD have been reported for four species of freshwater **fish** and one species of amphibians (Table 6-1). In almost all of these studies, toxic effects were observed only after the acute exposure period ended. **Miller et al.** (1973, 1979) exposed **juvenile coho** salmon, **Oncorhynchus kisutch**, to a range of 2,3,7,8-TCDD concentrations for up to 96 hours. Concentrations were expressed as ng/g wet bw and as **ng/l** of water, based on the amount of 2,3,7,8-TCDD added to the water **in** the test containers and the Initial body weight of **fish**. Test concentrations were measured during the exposure period. After exposure, the **fish** were transferred to clean flowing water and observed for up to 114 days during which they were fed to satiation 3 times/week. Experiments were conducted **with** two groups of **fish** that differed in Initial mean wet weight (3.51 and 6.63 g). Food consumption, growth and survival of smaller **fish** were measured until 60 days after exposure and were found to be significantly reduced at 5.4 yg/kg bw (0.0056 **µg/l**), but not at 0.54 yg/kg bw (0.00056 **µg/l**) or lower. Growth and survival of larger **fish** were measured until 114 days after exposure and were **significantly** reduced at 5.4 yg/kg bw (0.0105 yg/a) but not at 0.54 yg/kg bw (0.00105 **µg/l**) or lower. The actual concentrations in **fish** and water were undoubtedly lower than the calculated values, because much of the added 2,3,7,8-TCDD would be adsorbed to all containers.

TABLE 6-1

## Effect of Acute Exposure to 2,3,7,8-TCDD on Aquatic Animals

| Species                                  | Life Stage, Weight or Length | Duration of Exposure (hours) | Duration of Test (days) | LC <sub>50</sub> (µg/L)   | LT <sub>50</sub> <sup>a</sup> (days) | Lowest Effect Concentration (µg/L) | Mo Effect Concentration (µg/L) | Effect  | Reference                                  |
|--|------------------------------|------------------------------|-------------------------|---------------------------|--------------------------------------|------------------------------------|--------------------------------|---|--|
| Coho Salmon, <u>Oncorhynchus klsutch</u> | 3.5 g                        | 96                           | 64                      | 0.0056                    | 60                                   | 0.0056                             | 0.00056                        | reduced growth, food consumption, survival                                      | Miller et al., 1973, 1979                  |
| Coho Salmon, <u>Oncorhynchus klsutch</u> | 6.6 g                        | 96                           | 114                     | <b>0.0105<sup>b</sup></b> | 114                                  | 0.0105                             | 0.00105                        | reduced growth, food consumption, survival                                      | Miller et al., 1973, 1979                  |
| Rainbow Trout, <u>Salmo gairdneri</u>    | eggs and larvae              | 96                           | 72                      | NR                        | NR                                   | 0.0001                             | ND                             | temporary growth inhibition   | Helder. 1981                               |
| Rainbow Trout, <u>Salmo gairdneri</u>    | eggs and larvae              | 96                           | 164                     | NR                        | NR                                   | 0.001                              | 0.0001                         | teratologic effects, decreased survival and growth                              | Helder. 1981                               |
| Rainbow Trout, <u>Salmo gairdneri</u>    | <b>0.85 g</b>                | 96                           | 72                      | NR                        | NR                                   | 0.010                              | NR                             | decreased survival and growth, histological effects                             | Helder. 1981                               |
| <b>Guppy, <u>Poecilia reticulata</u></b> | <b>9-40 mm</b>               | 120                          | 37                      | NR                        | 21.7                                 | 0.1                                | NO                             | <b>100%</b> mortality by 3.7 days after beginning exposure                      | Miller et al 1973; Norris and Miller, 1974 |
| <b>Guppy, <u>Poecilia reticulata</u></b> | <b>8-12 m</b>                | 24                           | 69                      | NR                        | NR                                   | 0.0001                             | 0.00001                        | higher incidence of fin necrosis  | Miller et al., 1979                        |
| Northern Pike, <u>Esox lucius</u>        | eggs and larvae              | 96                           | <b>23</b>               | NR                        | NR                                   | 0.0001                             | ND                             | temporary inhibition of egg development   | Helder. 1980                               |
| Northern Pike, <u>Esox lucius</u>        | eggs and larvae              | 96                           | 23                      | 0.001                     | 23                                   | 0.001                              | 0.0001                         | decreased survival and growth   | Helder. 1980                               |
| frog, <u>Rana catesblana</u>             | larvae                       | <b>i.p. injection</b>        | 50                      | NR                        | NR                                   | NO                                 | 1000 wg/kg bw                  | no effect on survival <b>metamorphosis</b> , histology                          | Beatty et al., 1976                        |
| Frog, <u>Rana catesblana</u>             | adults (150-250 g)           | <b>i.p. Injection</b>        | 35                      | NR                        | NR                                   | 500 wg/kg bw                       | 250 wg/kg bw                   | temporary decrease in food consumption, but no effects on survival or histology | Beatty et al., 1976                        |

<sup>a</sup>LT<sub>50</sub> = Median lethal time In days after beginning exposure<sup>b</sup>47% Mortality

NR = Not reported; ND = Not determined



Acute exposure experiments were also conducted by these researchers (Miller et al., 1973, 1979; Norris and Miller, 1974) with guppies, Poecilia reticulata. Miller et al. (1973) and Norris and Miller (1974) reported the effects of exposing guppies to nominal concentrations of 0.1, 1.0 and 10.0  $\mu\text{g}/\text{l}$  for 120 hours followed by transfer to clean water. Some fish (8-1854) died in each test concentration during the exposure period. All treated fish died by 37 days after beginning exposure; smaller fish generally died first. Fin necrosis was observed in all fish surviving more than 10 days. In a later study, Miller et al. (1979) measured the incidence of fin necrosis in guppies exposed for 24 hours to much lower nominal concentrations of 2,3,7,8-TCDD and then maintained for 69 days. The incidence of fin necrosis was significantly greater in fish exposed to  $>0.8$   $\text{yg}/\text{kg}$  bw (0.0001  $\mu\text{g}/\text{l}$ ) than in controls or in fish exposed to 0.08  $\text{yg}/\text{kg}$  bw (0.00001  $\mu\text{g}/\text{l}$ ).

The effects of static acute exposure to 2,3,7,8-TCDD on eggs and larvae of northern pike, Esox lucius, and rainbow trout, Salmo gairdneri, were reported by Helder (1980) and Helder (1981), respectively. In both studies, newly fertilized eggs were exposed for 96 hours to a range of nominal 2,3,7,8-TCDD concentrations (0.0001, 0.0010, 0.010  $\mu\text{g}/\text{l}$ ) followed by transfer to clean water. There was no significant increase in egg mortality up to the highest nominal test concentration of 0.010  $\mu\text{g}/\text{l}$  for either species. Significantly greater mortality occurred after hatching and during yolk sac absorption in both species at concentrations as low as 0.0010  $\mu\text{g}/\text{l}$ . Total mortality of pike fry reached 99% at 0.010  $\mu\text{g}/\text{l}$  and 50% at 0.0010  $\mu\text{g}/\text{l}$  by 23 days after fertilization. Total mortality of trout fry was 26% at 0.010  $\mu\text{g}/\text{l}$  and 12% at 0.0010  $\mu\text{g}/\text{l}$ . Although cumulative mortality was not significantly increased at the lowest test concentra-

tion (0.0001  $\mu\text{g}/\text{l}$ ), sublethal effects occurred in both species. At this concentration, growth was significantly, but temporarily, retarded in both species.

Helder (1981) also exposed juvenile trout to nominal concentrations of 0.100 and 0.010  $\mu\text{g}/\text{l}$  for 96 hours and followed growth and survival for 72 days. Growth was significantly reduced in both groups. Mortality reached 100% by 27 days at the highest concentration, but was only 7% at the lowest concentration.

The only other study regarding the effects of acute exposure on aquatic animals is that of Beatty et al. (1976), who investigated the effects of single intraperitoneal injections of 2,3,7,8-TCDD in larval and adult frogs, *Rana catesbeiana*. Groups of 15 tadpoles and 5 adults were injected with 2,3,7,8-TCDD in olive oil at maximum nominal dosages of 1000 and 500  $\mu\text{g}/\text{kg}$  bw, respectively. There were no effects on survival and metamorphosis of larvae through 50 days after injection, or on survival of adults for 35 days after injection. There was a slight, temporary decrease in food consumption by adults at the highest dose. Histopathological examination revealed no significant lesions in metamorphosed or adult frogs. The lack of toxicity in this amphibian species is in sharp contrast to the results previously described with fish. Although the difference may be due, in part, to the different routes of exposure, it is probable that some fish are actually more sensitive, because toxic effects occurred in coho salmon at an internal dose of 5.4  $\mu\text{g}/\text{kg}$  bw (Miller et al., 1973, 1979).

6.1.1.2. CHRONIC TOXICITY - The effects of chronic or subchronic exposure to 2,3,7,8-TCDD have been reported for three species of freshwater invertebrates and three species of freshwater fish (Table 6-2). Miller et al. (1973) exposed adult snails, *Physa* sp., adult oligochaete worms, *Paranais* sp., and mosquito larvae *Aedes aegypti* to a nominal initial concentra-

TABLE 6-2

## Effects of Chronic or Subchronic Exposure to 2,3,7,8-TCDD on Aquatic Animals

| Species   | Life Stage,<br>Weight or<br>Length | Duration<br>of Exposure<br>(days) | Duration<br>of Test<br>(days) | Lowest Effect<br>Concentration<br>( $\mu\text{g}/\text{L}$ ) | No Effect<br>Concentration<br>( $\mu\text{g}/\text{L}$ ) | Effect  | Reference                  |
|---|------------------------------------|-----------------------------------|-------------------------------|--|--|---|----------------------------|
| Mosquito,<br><u>Aedes aegypti</u>               | larvae                             | 17                                | 30                            | ND   | 0.2  | no effect on pupation   | Miller et al.,<br>1973     |
| <b>Oligochaete Worm,</b><br><u>Paranais</u> sp. | adult                              | 55                                | 55                            | 0.2  | ND   | reduced reproduction  | Miller et al.,<br>1973     |
| Snail,<br><u>Physa</u> sp.                      | adult                              | 36                                | 48                            | 0.2  | ND   | reduced reproduction  | Miller et al.,<br>1973     |
| Snail.<br><u>Helosoma</u> sp.                   | adult                              | 32                                | 46                            | ND   | 0.003  | no apparent effects   | YocklM et al.,<br>1978     |
| <b>Water flea,</b><br><u>Daphnia magna</u>      | adult                              | 32                                | 32                            | ND   | 0.003  | no apparent effects   | YocklM et al.,<br>1978     |
| Mosquitoflsh,<br><u>Gambusia affinis</u>        | NR                                 | 15                                | 15                            | 0.003  | ND   | 100% Mortality  | YocklM et al.,<br>1978     |
| Channel Catfish,<br><u>Ictalurus punctatus</u>  | fingerlings                        | 20                                | 20                            | 0.003  | ND   | 100X Mortality  | YocklM et al.,<br>1978     |
| Rainbow Trout.<br><u>Salmo gairdneri</u>        | 7.8 CM                             | 105                               | 105                           | 2300 $\mu\text{g}/\text{kg}$<br>in diet                      | 2.30 $\mu\text{g}/\text{kg}$<br>in diet                  | reduced survival,<br>food consumption and<br>growth. Increased<br>fin erosion | Hawkes and Norris,<br>1977 |

NO = Not determined

tion of 0.20  $\mu\text{g}/\text{l}$  for 36, 55 and 17 days, respectively. There was no significant difference in total pupation or pupation rate between exposed and control mosquito larvae during the 17-day exposure period or for the 30-day total test period. Exposure of adult snails to 0.20  $\mu\text{g}/\text{l}$  for 36 days had no significant effect on adult survival and egg production. The number of **live** juvenile snails and empty **juvenile** shells was counted 48 days after beginning exposure. The total snail hatch was **~30% lower (p=0.056)** in the treated **groups**, but there was no significant difference in the percentage of survival of young snails. Exposure of worms to **2,3,7,8-TCDD** resulted in a significant decrease **in** the total number of worms at 55 days. **Total** and mean dry weight were also reduced, but the variation among replicates reduced the statistical significance of **this** effect to **p=0.057**, indicating that 0.20  $\mu\text{g}/\text{l}$  exerted its principal effect on reproduction rather than individual worm growth.

Miller et al. (1973) also conducted chronic feeding studies **with** rainbow trout. The **results** of **this** study were also reported by Hawkes and Norris (1977). Groups of rainbow trout were fed diets containing 0.0023, 2.30 or 2300  $\text{yg}/\text{kg}$ , 6 days/week for 105 days. The calculated doses were, respectively, 0.000032, 0.036 or **21.0**  $\text{yg}$  2,3,7,8-TCDD/kg freeze-dry bw/day. Consumption of food containing 0.0023 and 2.3  $\mu\text{g}/\text{kg}$  had no effect on survival, food consumption, growth and **fin morphology**. In contrast, **fish** fed the highest dose showed reduced food consumption after 10 days, reduced growth by 7 days, **fin** erosion by 14 days, and mortality that began on day 33 and reached **50%** by day 61 and **88%** by day **71**.

The only other information concerning **subchronic toxicity** to aquatic animals was provided by Yockim et al. (1978), who exposed channel catfish, Ictalurus punctatus, mosquitofish, Gambusia affinis, waterfleas, Daphnia

magna, snails, *Helosoma* sp., and algae, *Oedogonium cardiacum*, to <sup>14</sup>C-labeled 2,3,7,8-TCDD in a recirculating aquatic model ecosystem. Soil was treated with 100 yg/kg and flooded with water, and organisms were added 1 day after flooding. Organisms were removed periodically for measurement of tissue residues. The mean concentration ( $\mu\text{g}/\text{l}$ ) in the water, measured by liquid scintillation counting, was 0.0034 at day 1, 0.0029 at day 3, 0.0024 at day 7, 0.0026 at day 15 and 0.0042 at day 32. The mean concentration through the 32-day period was 0.0031  $\mu\text{g}/\text{l}$ . No effects over the 32-day exposure period were observed in algae, waterfleas or snails as measured by reproductive activity, feeding and growth. All unharvested mosquitofish died by day 14, with a mean tissue concentration of 7.2 yg/kg bw. A second group of mosquitofish added at day 15 were all dead after 15-20 days. Channel catfish added at day 32 all died after 15-20 days of exposure, with a mean tissue concentration of 4.4 yg/kg bw. These results indicate that 15-20 days of exposure to  $\sim 0.003 \mu\text{g}/\text{l}$  was lethal to fish, but had no effects on snails, waterfleas and algae.

**6.1.1.3. AQUATIC PLANT EFFECTS** -- As mentioned earlier, Yockim et al. (1978) did not observe any obvious effects of 0.003  $\mu\text{g}/\text{l}$  on the growth of the freshwater algae, *O. cardiacum*. over a 32-day period. The only other information concerning toxicity to aquatic plants was provided by Zullel and Benecke (1978), who conducted contact inhibition studies with filamentous algae, *Phormidium* sp. Filter paper was spotted in three places with 1 yg of 2,3,7,8-TCDD. Disks (5mm diameter) of filtered algae were placed on the spots, and the filter paper was placed in a petri dish containing nutrient media. The motility of the algae filaments outward from the disks was measured over a 3-hour period with a photoelectric cell. Relative to controls, 1 yg of 2,3,7,8-TCDD caused a significant inhibition of

**motility.** Although the exposure concentration is unknown, these results indicate that this algal species may be affected by contact with contaminated substrates (i.e., sediment).

Jackson (1972) studied the progression of mitosis in the African blood lily, *Haemanthus katherinae*, endosperm cells. In this study, cells were exposed during prophase, prometaphase, metaphase and anaphase to 2,3,7,8-TCDD at nominal levels of either 0, 0.1 or 0.5  $\mu\text{g}/\text{L}$ , and the ability of the cells to progress to the next stage of cell division within a 2-hour period was evaluated. Regardless of the stage of cell division during which exposure occurred, the treatment resulted in an inhibition of progression to the next stage. The authors noted that 2,3,7,8-TCDD strongly adsorbs to glass and speculated that the concentrations in the test chamber were actually lower than reported. It was estimated that the higher concentration may possibly be approaching 0.2  $\mu\text{g}/\text{L}$ , the solubility of 2,3,7,8-TCDD in water.

## 6.2. TISSUE RESIDUES

Levels of 2,3,7,8-TCDD in several species of commercial fish taken from eastern Lake Ontario, Lake Erie and the Welland Canal ranged from 0.002-0.039  $\text{yg}/\text{kg}$  in those fish with positive test results (Josephson, 1983). Rock bass showed no detectable levels. Highest concentrations generally occurred in eels (0.006-0.039  $\text{yg}/\text{kg}$ ), followed by smelt and catfish. The high fat content in these species (37, 13 and 3.5%, respectively) may explain, in part, the higher 2,3,7,8-TCDD concentrations.

Analysis by the NYS Department of Health showed levels of 2,3,7,8-TCDD in 46 muscle (fillet) samples of Lake Ontario fish that ranged from 0.002-0.162  $\text{yg}/\text{kg}$  in 45 samples and were undetectable in one sample (NRCC, 1981a). The fish that were sampled included smallmouth bass, lake trout,

white sucker, brown bullhead, rainbow trout, coho and Chinook salmon, and brown trout. The Ontario Ministry of the Environment (NRCC, 1981a) reported concentrations of **2,3,7,8-TCDD** ranging between 0.010 and 0.019 yg/kg in fillet **samples** of lake trout, brown trout, white bass, white perch and **smelt** in Lake Ontario, but no detectable (**<0.010** yg/kg) levels **in fish** from the Niagara River, Lake **Erie**, Lake Huron or Lake Superior. Other **fish** residue data summarized by NRCC (1981a) included 2,3,7,8-TCDD concentrations in positive samples ranging from 0.020-0.230 yg/kg in **Tittabawassee** River, **Saginaw** Bay and other locations near Midland, MI; 0.015-0.480 yg/kg in the Arkansas River; and 0.019-0.102 yg/kg **in** Lake Ontario and Niagara River. OCDD concentrations in **fish** ranged from 0.040-0.150 yg/kg near Midland, MI, and from 0.004-0.078 yg/kg in the **Honesatonic** River. The levels of 2,3,7,8-TCDD in **fish** and **shellfish** as determined by various authors are given in Table 6-3.

Levels ranging from 0.004-0.695 yg/kg were cited by the U.S. EPA (1984) for the edible portion of channel catfish, carp, **yellow** perch, small-mouth bass, sucker and lake trout from Tittabawassee, Grand and Saginaw Rivers, Lake Michigan and Saginaw Bay. The highest concentrations were detected **in** bottom-feeding catfish and carp, and the lowest concentrations were detected in bass, perch and suckers (Harless and Lewis, 1980b).

Young et al. (1976) measured 2,3,7,8-TCDD residue **levels in** terrestrial and aquatic animals from contaminated areas of **Eglin Air Force Base, FL**, which had received massive amounts of herbicides, one of which (**2,4,5-T**) was contaminated **with** 2,3,7,8-TCDD. Beach **mice** from contaminated areas contained **0.540-1.30** yg/kg in the liver and 0.130-0.140 yg/kg in pelts. Residues in racerunner lizards trapped from the most highly contaminated

TABLE 6-3

Levels of **2,3,7,8-TCDDs** in **Fish** and **Shellfish**

| Type/Section<br>of Fish                 | Sampling Site   | Concentration<br>(ppt)      | Reference  |
|---|---|-----------------------------|--|
| Edible flesh                            | Bayou Neto/Arkansas River   | 480                         | <b>Mitchum et al.</b> , 1980                                 |
| Catfish                                 | Bayou Neto/Arkansas River   | ND (7 ppt) <sup>a</sup> -50 | <b>Mitchum et al.</b> , 1980                                 |
| Buffalo                                 | Bayou Neto/Arkansas River   | ND (7-13 ppt) <sup>a</sup>  | MHchum et al., 1980  |
| Bottom feeder                           | Bayou Neto/Arkansas River   | 77                          | Nltchum et al., 1980   |
| <b>Whole</b> body                       | Tone River, Japan   | 200                         | <b>Yamagishi et al.</b> , 1981                               |
| Rock bass                               | Lake Ontario/Lake <b>Erie/Welland</b> Canal   | ND (<2 ppt) <sup>a</sup>    | Josephson. 1983  |
| Eel, smelt and catfish                  | Lake Ontario/Lake <b>Erie/Welland</b> Canal   | 2-39                        | Josephson. 1983  |
| Crayfish                                | <b>Bergholtz</b> Creek, Love Canal  | 3.7                         | Smith et al., 1983b  |
| Catfish, bass and wall-eyed <b>pike</b> | <b>2,4,5-T</b> contaminated watershed in Arkansas and Texas; <b>Tittabawassee</b> and <b>Saginaw</b> Rivers | ND (5-10 ppt) <sup>a</sup>  | Shadoff et al., 1977; U.S. EPA. 1980a; Buser and Rappe, 1980 |
| Lake trout                              | Lake Ontario  | 51-107                      | <b>O'Keefe et al.</b> , 1983                                 |
| Chinook salmon                          | Lake Ontario  | 26-39                       | <b>O'Keefe et al.</b> , 1983                                 |
| Coho salmon                             | Lake Ontario  | 20-26                       | <b>O'Keefe et al.</b> , 1983                                 |
| Rainbow trout                           | Lake Ontario  | 17-32                       | <b>O'Keefe et al.</b> , 1983                                 |
| Brown trout                             | Lake Ontario  | 8-162                       | O'Keefe et al., 1983   |
| <b>White</b> perch                      | Lake Ontario  | 17-26                       | O'Keefe et al., 1983   |
| White sucker                            | Lake Ontario  | ND (3.2)-10                 | <b>O'Keefe et al.</b> , 1983                                 |

6-10



TABLE 6-3 (cont.)

| Type/Section<br>of Fish | Sampling Site      | Concentration<br>(ppt) | Reference                   |
|-------------------------|--------------------|------------------------|-----------------------------|
| <b>Smallmouth</b> bass  | Lake Ontario       | 5.9                    | <b>O'Keefe</b> et al., 1983 |
| Brown bullhead          | Lake Ontario       | 3.6                    | <b>O'Keefe</b> et al., 1983 |
| Carp/Goldfish           | Cayuga Creek       | 87                     | <b>O'Keefe</b> et al., 1983 |
| Northern <b>pike</b>    | Cayuga Creek       | 32                     | <b>O'Keefe</b> et al., 1983 |
| Pumpkin seed            | Cayuga Creek       | 31                     | O'Keefe et al., 1983        |
| Rock bass               | Cayuga Creek       | 12                     | O'Keefe et al., 1983        |
| Coho <b>salmon</b>      | Lake <b>Erie</b>   | <b>1.4-&lt;3.5</b>     | O'Keefe et al., 1983        |
| <b>Walleye pike</b>     | Lake <b>Erie</b>   | 2.6                    | O'Keefe et al., 1983        |
| Smallmouth bass         | Lake <b>Erie</b>   | <b>1.6-&lt;2.4</b>     | O'Keefe et al., 1983        |
| Carp/Goldfish           | Lake <b>Erie</b>   | ND (2.6)               | O'Keefe et al., 1983        |
| Lake trout              | Lake Huron         | 21                     | <b>O'Keefe</b> et al., 1983 |
| Carp                    | Lake Huron         | 26                     | O'Keefe et al., 1983        |
| Channel catfish         | Lake Huron         | 20                     | <b>O'Keefe</b> et al., 1983 |
| Sucker                  | Lake Huron         | 25                     | O'Keefe et al., 1983        |
| Yellow perch            | Lake Huron         | NO <b>(8.7)</b>        | O'Keefe et al., 1983        |
| Coho salmon             | Lake Michigan      | NO (3.8)               | O'Keefe et al., 1983        |
| Rainbow trout           | Lake Superior      | <b>1.0</b>             | <b>O'Keefe</b> et al., 1983 |
| Perch/sucker            | <b>Saginaw</b> Bay | ND <b>(3.8)-25</b>     | <b>Niemann</b> et al., 1983 |
| Catfish                 | <b>Saginaw</b> Bay | 14-37                  | <b>Niemann</b> et al., 1983 |
| Carp                    | Saglnaw Bay        | 23-47                  | Nlemann et al., 1983        |

TABLE 6-3 (cont.)

| Type/Section<br>of Fish | Sampling Site  | Concentration<br>(ppt)      | Reference                      |
|-------------------------|--|-----------------------------|--------------------------------|
| Catfish                 | Bayon <b>Neto/Arkansas</b> River                               | ND (3.8)                    | <b>Niemann et al.</b> , 1983   |
| Bottom feeders          | Bayon Neto/Arkansas River                                      | NO <b>(6.7)-12</b>          | <b>Niemann et al.</b> , 1983   |
| Lake trout              | Lake Ontario   | 34-54                       | Nlemann et <b>al.</b> , 1983   |
| Rainbow trout           | Lake Ontario   | 43                          | Nlemann et <b>al.</b> , 1983   |
| Ocean haddock           | Atlantic Ocean   | ND (4.6)                    | Nlemann et <b>al.</b> , 1983   |
| Carp                    | Lake Huron   | 3-28                        | Stalling et <b>al.</b> , 1983  |
| Carp                    | <b>Saginaw</b> Bay   | 94                          | Stalling et <b>al.</b> , 1983  |
| Carp                    | Bay Port   | 27                          | Stalling et <b>al.</b> , 1983  |
| Carp                    | Tutabawassee River   | 81                          | Stalling et <b>al.</b> , 1983  |
| Lake trout              | Lake Michigan  | 5                           | Stalling et <b>al.</b> , 1983  |
| Brown trout             | Lake Ontario   | 33                          | <b>Stalling et al.</b> , 1983  |
| <b>Yellow</b> perch     | <b>Woods Pond, HA</b>  | 26                          | Buser and Rappe, 1983          |
| Channel catfish         | Tutabawassee <b>River,</b><br>Saglnaw River and<br>Grand River | <b>157 (13)<sup>c</sup></b> | <b>Harless</b> and Lewis, 1982 |
| Carp                    | Tutabawassee River,<br>Saglnaw River and<br>Grand River        | 55 <b>(7)<sup>c</sup></b>   | Harless and Lewis, 1982        |
| Yellow perch            | Tutabawassee River<br>and Saglnaw River                        | 13 <b>(5)<sup>c</sup></b>   | Harless and Lewis, 1982        |
| Small mouth bass        | Grand River  | 8 <b>(6)<sup>c</sup></b>    | Harless and Lewis, 1982        |

TABLE 6-3 (cont.)

| Type/Section<br>of Fish | Sampling Site                             | Concentration<br>(ppt) | Reference               |
|-------------------------|---|------------------------|-------------------------|
| Sucker                  | Tittabawassee River<br>and Saginaw Bay    | 10 (4) <sup>c</sup>    | Harless and Lewis, 1982 |
| Trout                   | Lake Michigan                             | ND (5) <sup>c</sup>    | Harless and Lewis, 1982 |
| Trout                   | Lake Ontario at<br>Burlington, Canada     | 61.2 (3.6)             | Ryan et al., 1983       |
| Trout                   | Lake Ontario at Toronto<br>Harbor, Canada | 32.3 (3.6)             | Ryan et al., 1983       |
| Trout                   | Lake Huron at<br>Burnt Island, Canada     | 30.4 (3.6)             | Ryan et al., 1983       |

<sup>a</sup>Not detected and the detection limit is indicated within the parentheses.

<sup>b</sup>Only the GC/MS results of these authors are included in tabulation

<sup>c</sup>These are the mean concentrations in samples showing detectable levels of 2,3,7,8-TCDD.

ND = Not detected

areas contained 0.36-0.37  $\mu\text{g}/\text{kg}$  in the visceral mass and **trunk**, respectively. Residues were **also** found in three **fish** species taken from a stream and pond in the contaminated area. Residue **levels** of 0.012  $\mu\text{g}/\text{kg}$  were found in the viscera of **sailfin** shiners and in the bodies (heads and tails removed) of **mosquitofish**. Samples of **skin, muscle, gonad** and gut of spotted **sunfish** contained 0.004, 0.004, **0.018** and 0.085  $\mu\text{g}/\text{kg}$  **2,3,7,8-TCDD**, respectively. 2,3,7,8-TCDD was not detected in Insect **larvae**, snails, diving beetles, crayfish, tadpoles and other **fish** species taken from water-bodies that contained 0.010-0.035  $\mu\text{g}/\text{kg}$  in the sediments.

Finally, the levels of 2,3,7,8-TCDD in wildlife have been determined by various authors. These values are shown in Table 6-4. From the somewhat higher levels of 2,3,7,8-TCDD found **in Saginaw** Bay and in Lake Ontario gull eggs (**Table 6-4**), Norstrom et al. (1982) indicated the possibility of Industrial contamination since the former is near a major **2,4,5-T** manufacturing plant on the Saginaw/Tittabawassee River, and the latter is downstream from a **2,4,5-TCP** plant at Niagara Falls, NY.

### 6.3. ECOSYSTEM EFFECTS

Investigations concerning the ecosystem effects of 2,3,7,8-TCDD are restricted to the field studies of Young et al. (1975) at the **Eglin Air** Force Base. A **1-square mile** area was sprayed **with** massive amounts of herbicides over an 8-year period (1962-1970). In particular, a 92-acre test area was sprayed from **1962-1964 with** 87,186 pounds of 2,4,5-T that was contaminated **with** 2,3,7,8-TCDD. Analysis in 1974 of surface soils in **this** area showed 2,3,7,8-TCDD levels of 0.010-0.710  $\mu\text{g}/\text{kg}$ . Large numbers of beach **mice** were trapped from contaminated and control sites and evaluated for differences **in** organ weights and **histopathology**. The only significant differences **in** organ weight were increased liver weight in females and

TABLE 6-4  
TCDD Levels in Wildlife

6-15

| Type of Animal | Tissue         | Sampling Site                    | 2,3,7,8-TCDD Concentration (ppb) |             | Reference             |
|----------------|----------------|----------------------------------|----------------------------------|-------------|-----------------------|
|                |                |                                  | Average <sup>a</sup>             | Range       |                       |
| Rabbit         | liver          | Seveso, Italy                    | 31                               | 1-<1024     | Fanelll et al., 1980a |
| Field mouse    | whole body     | Seveso, Italy                    | 4.5                              | 0.07-49     | Fanelll et al., 1980c |
| Hare           | liver          | Seveso, Italy                    | 7.7                              | 2.7-13      | Fanelll et al., 1980c |
| Toad           | whole body     | Seveso, Italy                    | 0.2                              | LS          | Fanelll et al., 1980c |
| Snake          | liver          | Seveso, Italy                    | 2.7                              | LS          | Fanelll et al., 1980c |
| Snake          | adipose tissue | Seveso, Italy                    | 16                               | LS          | Fanelll et al., 1980c |
| Earthworm      | whole body     | Seveso, Italy                    | 12                               | LS          | Fanelll et al., 1980c |
| Eagle          | carcass        | throughout U.S.                  | <50 ppb                          | NR          | Helling et al., 1973  |
| Herring gull   | egg            | <b>Saginaw Bay, Lake Ontario</b> | NR                               | 0.043-0.093 | <b>Ogilvie, 1981</b>  |

TABLE 6-4 (cont.)

| Type of Animal | Tissue           | Sampling Site                  | 2,3,7,8-TCDD Concentration (ppb) |       | Reference             |
|----------------|------------------|--------------------------------|----------------------------------|-------|-----------------------|
|                |                  |                                | Average <sup>a</sup>             | Range |                       |
| Herring gull   | egg              | Lake Superior                  | 0.011                            | NR    | Norstrom et al., 1982 |
| Herring gull   | egg              | Lake Michigan                  | 0.009                            | NR    | Norstrom et al., 1982 |
| Herring gull   | egg              | Lake Huron<br>(main body)      | 0.009                            | NR    | Norstrom et al., 1982 |
| Herring gull   | egg              | Lake Huron,<br>Saglnaw Bay, N. | 0.043                            | NR    | Norstrom et al., 1982 |
| Herring gull   | egg              | Lake Huron,<br>Saglnaw Bay, S. | 0.086                            | NR    | Norstrom et al., 1982 |
| Herring gull   | egg              | Lake Erie                      | 0.011                            | NR    | Norstrom et al., 1982 |
| Herring gull   | egg              | Lake Ontario                   | 0.059                            | NR    | Norstrom et al., 1982 |
| Turtle         | egg and liver    | Bayou Meto/<br>Arkansas River  | 0.15                             | LS    | Mitchum et al., 1980  |
| Snake          | liver and muscle | Bayou Meto/<br>Arkansas River  | 0.060                            | LS    | Mitchum et al., 1980  |
| Muskrat        | liver            | Bayou Meto/<br>Arkansas River  | ND (40 ppt) <sup>b</sup>         | LS    | Mitchum et al., 1980  |

TABLE 6-4 (cont.)

| Type of Animal | Tissue              | Sampling Site                                     | 2,3,7,8-TCDD Concentration (ppb) |       | Reference                              |
|----------------|---------------------|---|----------------------------------|-------|--|
|                |                     |   | Average <sup>a</sup>             | Range |  |
| Raccoon        | <b>liver</b>        | Bayou <b>Meto/</b><br>Arkansas River              | ND (10 ppt) <sup>b</sup>         | LS    | <b>Mitchum</b><br>et <b>al.</b> , 1980 |
| Frog           | liver and<br>muscle | Bayou <b>Meto/</b><br>Arkansas River              | >10                              | LS    | MUchum<br>et <b>al.</b> , 1980         |
| Horse          | fat                 | Midwest <b>wire</b><br>reclamation<br>Incinerator | 0.045                            | LS    | Hryhorczuk<br>et <b>al.</b> , 1981     |
| Horse          | liver               | Midwest <b>wire</b><br>reclamation<br>Incinerator | ND (<6 ppt) <sup>b</sup>         | LS    | Hryhorczuk<br>et <b>al.</b> , 1981     |

<sup>a</sup>These are averages of samples that had above detectable levels of TCDD.

<sup>b</sup>Not reported and the limit of detection Indicated in parentheses

NR = Not reported; LS = Limited samples

6-17

Increased spleen weight in **males** and **females** taken from the contaminated sites; however, no **histopathological** effects could be attributed to the collection sites. Similar studies on racerunner lizards showed no significant difference in relative or total body weight of animals collected from contaminated and control sites. Sweep net surveys of the contaminated sites for terrestrial Insects in 1971 and **1973** indicated that there was a significant increase in the number of families and total number of Insects in the contaminated test **site**, which was correlated with the increase in vegetation after herbicide spraying. Aquatic species diversity studies were conducted in **1969**, 1970, 1973 and 1974 on a stream in the contaminated area and a control stream. As mentioned before, **2,3,7,8-TCDD** was detected in sediments and **fish** from the **contaminated** stream; however, there was no significant difference in **ichthyofauna** diversity in the two streams, and no significant change in diversity through **time** in either stream. As a result, the only effects that can be attributed to 2,3,7,8-TCDD contamination were increased **liver** and spleen weight in beach **mice**. The ecological significance of **this** effect is unknown, especially since no obvious detrimental effects were observed in **this** or other species from contaminated sites.

**Korfmacher et al.** (1984) analyzed fat tissue and eggs from snakes for **2,3,7,8-TCDD**. Water snakes were selected as a possible marker for **2,3,7,8-TCDD** contamination. Three snakes were collected from Lake Dupree, Arkansas in 1983. **This** lake is a **site** of 2,3,7,8-TCDD contaminated sediment and **fish** (Arkansas Dept. of Pollution Control and **Ecology**, 1983). Two snakes were collected from a lake evidently not contaminated with 2,3,7,8-TCDD from any industrial source. Eggs were derived from one of the snakes obtained from Lake Dupree. 2,3,7,8-TCDD concentration in the fat material of three snakes from contaminated lake varied from 500-730 ppt, in



the snake eggs varied from 151-294 ppt, and in the fat material from two snakes from noncontaminated lake varied from 38-378 ppt.

The **only** other information pertinent to ecosystem level effects was provided by **Bollen** and **Norris** (1979), who investigated the effects of 2,3,7,8-TCDD on respiration ( $\text{CO}_2$  production) in forest litter and soil samples. **Litter** and **soil samples** were **air dried**, placed in **biometer** flasks, moistened and treated **with** 2,3,7,8-TCDD. Concentrations as **high** as 0.031  $\mu\text{g}/\text{kg}$  dry weight in litter had no effect on respiration. Concentrations as **high** as 0.052  $\mu\text{g}/\text{kg}$  dry weight in **soil** caused a slight but significant stimulation of  $\text{CO}_2$  production. Because higher concentrations were not tested, **it is** unknown whether 2,3,7,8-TCDD would have inhibitory effects on **soil microbial** populations, carbon **metabolism** or nutrient cycling at the higher levels of **soil** contamination found in such contaminated areas as the **Eglin Air Force Base test site**.

#### 6.4. SUMMARY

Almost all of the available information concerning the **toxicity** of PCDDs to wildlife deals **with** aquatic species. Acute exposure to initial nominal 2,3,7,8-TCDD concentrations as low as 0.0001  $\mu\text{g}/\text{l}$  has been shown to cause delayed **sublethal** effects in early **life** stages of northern **pike** and rainbow trout (Helder 1980, 1981) and in adult **guppies** (Miller et al., 1979). Decreased growth, food consumption and survival have been reported in these and other **fish** species after acute exposure to  $\geq 0.001 \mu\text{g}/\text{l}$ . During these tests, the **nominal initial** concentrations **probably** decreased rapidly because of uptake by test organisms, adsorption to the exposure containers and perhaps **volatilization**. As a result, it is possible that constant acute or chronic exposure to dissolved concentrations  $< 0.0001 \mu\text{g}/\text{l}$  would produce toxic effects in sensitive aquatic organisms.

**Several** studies provide evidence that 2,3,7,8-TCDD **is** less toxic to aquatic Invertebrates and amphibians than to the tested **fish** species. **Subchronic** exposure to an **initial** nominal concentration of 0.20  $\mu\text{g}/\text{L}$  had no effect on mosquito population and caused a 30-50% decrease in reproduction of snails and **oligochoete** worms (Miller et al., 1973). In contrast, acute exposure to 0.1  $\mu\text{g}/\text{L}$  caused **100% delayed** mortality in **guppies** (Norris and Miller, 1974) and juvenile rainbow trout (Helder 1981). Similarly, exposure to **relatively** constant, measured, dissolved concentrations of **~0.002-0.004** $\mu\text{g}/\text{L}$  in aquatic **model** ecosystems killed **all** exposed mosquitofish and channel catfish in 15-20 days, but had no discernible effects on snails and waterfleas over a **total** test period of 32-46 days (Yockim et al., 1978). The dying **mosquitofish** and catfish had mean whole-body 2,3,7,8-TCDD concentrations of 7.2 and 4.4  $\text{yg}/\text{kg}$ , respectively. In contrast, single **intraperitoneal** injections of 2,3,7,8-TCDD at maximum doses of 500 or 1000  $\text{yg}/\text{kg}$  bw, respectively, had no effects on adult frogs over a 35-day period or on frog **larvae** over a 50-day period (Beatty et al., 1976).

Chronic feeding studies **with** groups of rainbow trout showed that daily feeding of 2300  $\text{yg}/\text{kg}$  in the **diet** was lethal to all but two **fish** (88%) in 71 days, but no significant effects were seen in **fish** fed daily a **diet** containing 2.3  $\text{yg}/\text{kg}$  for 105 days (Hawkes and Norris, 1977). Residue analysis of single **fish** sampled at the end of the tests showed 2,3,7,8-TCDD levels of 1380  $\text{yg}/\text{kg}$  bw in one **high** dose **fish** and 1.573  $\text{yg}/\text{kg}$  in one low dose **fish**.

Although only limited information was found concerning the effects of 2,3,7,8-TCDD on aquatic **plants**, it is probable that they are less sensitive than **fish**. Using model ecosystems, Yockim et al. (1978) observed no obvious effects on algae at concentrations (0.002-0.004  $\text{g}$ ) that killed **fish**. **Zullet**

and Benecke (1978) observed contact Inhibition of filamentous algae placed in contact with 1  $\mu\text{g}$  quantities of 2,3,7,8-TCDD spotted on filter paper.

The only available Information concerning the effects of low level environmental exposure to 2,3,7,8-TCDD on terrestrial wildlife was reported by Young et al. (1975), who Investigated tissue residues and several biological parameters in mice and lizards from contaminated and control sites at Eglin Air Force Base, FL. The concentrations of 2,3,7,8-TCDD in contaminated soils were 0.010-0.710  $\mu\text{g}/\text{kg}$ . Mice trapped from the contaminated site contained 0.540-1.30  $\mu\text{g}/\text{kg}$  in the liver and had significantly higher spleen and liver weights than mice from control sites. No other differences (histopathology, weights of other organs, Incidence of abnormal fetuses, etc.) were observed. Racerunner lizards from the contaminated site contained 0.36-0.37  $\mu\text{g}/\text{kg}$  in the viscera and trunk and showed no differences in body weight or histopathology compared with lizards from control sites. Residues of 2,3,7,8-TCDD in three fish species taken from a pond and stream adjacent to the contaminated site ranged from 0.004-0.085  $\text{ng}/\text{kg}$ . Sediments derived from the erosion taken from the contaminated site contained localized concentrations of 0.010-0.035  $\text{ng}/\text{kg}$ . PCDD residues have been reported for numerous other fish species and other snakes from contaminated water bodies. The PCDD concentrations (primarily 2,3,7,8-TCDD) in positive fish tests ranged from 0.002-0.695  $\text{ng}/\text{kg}$ .

## 7. COMPOUND DISPOSITION AND RELEVANT PHARHACOKINETICS

### 7.1. ABSORPTION

Data are available regarding the absorption of **2,3,7,8-TCDD** through the gastrointestinal (**GI**) tract and **skin** of experimental animals. Absorption through the respiratory **tract**, however, has not been studied. **Also**, there are no data on the absorption of 2,3,7,8-TCDD when mixed **with** other chlorinated **compounds**, which is presumably the case for human exposures.

7.1.1. Absorption from the Gastrointestinal Tract. Data on the GI absorption of 2,3,7,8-TCDD are summarized in Table 7-1. The GI absorption of 2,3,7,8-TCDD has been investigated more extensively in the rat than in other species. When 2,3,7,8-TCDD was administered in the **diet** at 7 or 20 ppb for 42 days, 50-60% of the consumed dose was absorbed (Fries and Marrow, 1975). Administration of 2,3,7,8-TCDD by gavage in acetone:corn **oil** (1:25 or 1:9) as a single dose or as repeated doses (5 days/week x 7 weeks) resulted in absorption of a larger percentage (70-86%) of the dose (Rose et al., 1976; Piper et al., 1973). It **would** appear, therefore, that the GI absorption of 2,3,7,8-TCDD may vary, depending upon the vehicle used. The influence of vehicle or adsorbent on GI absorption has been investigated by **Potger** and Schlatter (1980), using hepatic concentrations 24 hours after dosing as an indicator of the amount absorbed. They found a linear relationship between ng 2,3,7,8-TCDD administered by gavage in 50% ethanol (for doses of 12-280 ng, **equivalent** to 0.06-1.4  $\mu\text{g}/\text{kg}$ ) and the percentage of the dose in hepatic tissues (36.7-51.5%). At the next higher dose of 1070 ng the percentage was 42%. Administration of 2,3,7,8-TCDD in an aqueous suspension of **soil** resulted in a decrease in the hepatic levels of 2,3,7,8-TCDD as compared **with** hepatic levels resulting from administration of

TABLE 7-1

## Gastrointestinal Absorption of 2,3,7,8-TCDD

| Species       | Vehicle            | Dose Schedule<br>(yg/kg)                             | % Absorption<br>Mean $\pm$ SD | Reference              |
|---------------|--------------------|--|-------------------------------|------------------------|
| Guinea<br>pig | NR                 | NR<br>single dose                                    | 50                            | Nolan et al., 1979     |
| Rat           | 7 ppb,<br>in diet  | 0.5 yg/kg/day x<br>42 days                           | 50 - 60                       | Fries and Marrow, 1975 |
| Rat           | 20 ppb,<br>in diet | 1.4 yg/kg/day x<br>42 days                           | 50 - 60                       | Fries and Marrow, 1975 |
| Rat           | A:C,<br>1:25       | 1.0 yg/kg,<br>single dose                            | 84 $\pm$ 11*                  | Rose et al., 1976      |
| Rat           | A:C,<br>1:25       | 0.1 or 1.0<br>yg/kg/day,<br>5 days/week x<br>7 weeks | 86 $\pm$ 12*                  | Rose et al., 1976      |
| Rat           | A:C,<br>1:9        | 50.0 yg/kg,<br>single dose                           | 70                            | Piper et al., 1973     |
| Hamster       | olive<br>oil       | 650 yg/kg,<br>single dose                            | 74 $\pm$ 23*                  | Olson et al., 1980a    |

\*Mean  $\pm$  standard deviation

NR = Not reported; A:C = Acetone:corn oil, v:v

**2,3,7,8-TCDD** in **50%** ethanol. The extent of the decrease was directly proportional to the length of **time** the 2,3,7,8-TCDD had been **in** contact **with** the **soil**. **McConnell** et al. (1984) observed a dose-response relation of liver accumulation of 2,3,7,8-TCDD as a result of intragastric exposure of young male Hartley guinea **pigs** to 2,3,7,8-TCDD **in** corn **oil** or **in** **soil** (Table 7-2). In Sprague-Dawley female rats, they found as **high** as 40.8 ppb and 20.3 ppb liver accumulation of 2,3,7,8-TCDD by intragastric exposure to 2,3,7,8-TCDD **in** corn **oil** and **in** **soil**, respectively. **Phillippi** et al. (1981) and **Huetter** and **Philippi** (1982) have shown that **radiolabeled** 2,3,7,8-TCDD becomes **progressively** more resistant **with time** to extraction from **soil**. **Poiger** and **Schlatter** (1980) also demonstrated that **2,3,7,8-TCDD** mixed in an aqueous suspension of activated carbon was very poorly absorbed (**<0.07%** of the dose in hepatic tissues). In addition, **Silkworth** et al. (1982) observed an increase in the **LD<sub>50</sub>** value for female guinea **pigs** from 2.5 to 19 **µg/kg** when the 2,3,7,8-TCDD was administered by gavage **in** corn **oil** or aqueous methyl cellulose, respectively.

A comparative study on **the** biological uptake in the rabbit of 2,3,7,8-TCDD in different formulations, including accident-contaminated Seveso **soil**, was conducted by **Bonaccorsi** et al. (1983). On the whole, the results indicated that soil-borne 2,3,7,8-TCDD had a bioavailability lower than that of free (solvent-borne) 2,3,7,8-TCDD.

The feeding of fly ash containing PCDDs to rats **in** the **diet** for 19 days resulted in considerably lower hepatic levels of PCDDs than **did** the feeding of an extract of the fly ash at comparable PCDD dietary concentrations (**Van der Berg** et al., 1983). The PCDDs were tentatively identified as 2,3,7,8-TCDD, **1,2,3,7,8-PeCDD**, **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD**. The

TABLE 7-2

**Liver Accumulation of 2,3,7,8-TCDD in Guinea Pigs  
30 Days after a Single Intra gastric Exposure to 2,3,7,8-TCDD<sup>a</sup>**

| Group | No. of Animals | Composition of the Material Gavaged | Total Quantity Gavaged | Dosage of TCDD ( $\mu\text{g}/\text{kg bw}$ ) | Average Liver Concentration of TCDD <sup>b</sup> ppt $\pm$ SEM |
|-------|----------------|-------------------------------------|------------------------|---|--|
| 1     | 6              | Corn oil                            | 0.1 ml/100 g           | 0   | ND   |
| 2     | 6              | TCDD in corn oil                    | 0.1 ml/100 g           | 1   | $1.6 \pm 0.2$<br>$4.1^c$                                       |
| 3     | 6              | TCDD in corn oil                    | 0.1 ml/100 g           | 3   | $13.3 \pm 2.3$   |
| 4     | 6              | Time Beach soil                     | 0.35 g                 | 1.3   | <1.0   |
| 5     | 5 <sup>d</sup> | Time Beach soil                     | 1.07 g                 | 3.8   | $1.0 \pm 0.1$<br>$3.2^c$                                       |
| 6     | 5 <sup>e</sup> | Time Beach soil                     | 3.60 g                 | 12.8  | $34.3 \pm 6.0$   |
| 7     | 6              | Mlnker Stout soil                   | 0.26 g                 | 1.1   | <1.0   |
| 8     | 6              | Mlnker Stout soil                   | 0.80 g                 | 3.3   | $1.4 \pm 0.3$<br>$2.0 \pm 0.1^c$                               |
| 9     | 6              | Mlnker Stout soil                   | 2.67 g                 | 11.0  | $25.7 \pm 5.2$   |
| 10    | 5 <sup>e</sup> | Time Beach soil (uncontaminated)    | 3.60 g                 | 0   | ND   |

7-4

TABLE 7-2 (cont.)

| Group | No. of Animals | Composition of the Material Gavaged             | Total Quantity Gavaged | Dosage of TCDD ( $\mu\text{g}/\text{kg bw}$ ) | Average Liver Concentration of TCDD <sup>b</sup> ppt $\pm$ SEN |
|-------|----------------|---|------------------------|---|--|
| 11    | 6              | Time Beach soil (uncontaminated but TCOD added) | 2.71 g                 | 10  | 45.4+8.4   |

<sup>a</sup>Source: McConnell et al. (1984)

<sup>b</sup>Detection limit 100 ppt

<sup>c</sup>Animal/animals which died before 30 days

<sup>d</sup>One animal died 2 days after dosing (not included)

<sup>e</sup>One animal died at the time of dosing

SEN = Standard error of the mean

NO = Not detected



difference in hepatic levels noted between fly ash-treated and extract-treated rats was greater for the more highly chlorinated isomers than it was for **2,3,7,8-TCDD**.

The **GI** absorption of **2,3,7,8-TCDD** was also examined in the hamster, the species most resistant to the acute **toxicity** of **this** toxin. Olson et al. (1980a) administered a single, **sublethal**, oral dose of **[1,6-<sup>3</sup>H]-2,3,7,8-TCDD** in olive **oil** (650 **µg/kg**) to hamsters and reported that 74% of the dose was absorbed, while Nolan et al. (1979) reported that absorption in the guinea **pig**, the most sensitive species, was **~50%** following administration of an unspecified amount of 2,3,7,8-TCDD. The vehicle and method for calculating the absorbed dose were not given **in this** report.

7.1.2. Absorption Through the **Skin**. Information on the absorption of 2,3,7,8-TCDD through the **skin** is **extremely limited**. **Polger** and **Schlatter** (1980) administered 26 ng 2,3,7,8-TCDD in 50 **µl** **methanol** to the **skin** of **six** rats. After 24 hours, the **liver** contained 14.8±2.6% of the dose. By comparing **with** hepatic levels obtained (in the same study) after oral administration in 50% ethanol (see Section 7.1.1.), assuming that hepatic levels are valid estimates of the amount absorbed from both oral and dermal routes and that absorption from methanol is equivalent to absorption from 50% ethanol, the amount absorbed from a dermal application can be estimated at ~40% of the amount absorbed from an equivalent oral dose. As compared **with** dermal application in methanol, dermal application of **2,3,7,8-TCDD** to rats in vaseline or **polyethylene** glycol resulted in hepatic tissue concentration of 1.4 and 9.3% of the dose, respectively, but had no observable effect on the concentration of 2,3,7,8-TCDD required to induce **skin** lesions (~1 yg) in the rabbit ear **assay** (Polger and Schlatter, 1980). Application of 2,3,7,8-TCDD in a soil/water paste decreased hepatic 2,3,7,8-TCDD to **~2%** of the administered dose and increased the amount required to produce **skin**

lesions to 2-3 yg in rats and rabbits, **respectively**. Application in an activated carbon/water paste essentially completely eliminated absorption, as measured by percent of dose in the liver, and increased the amount of **2,3,7,8-TCDD** required to produce **skin** lesions to **~160** yg.

## 7.2. DISTRIBUTION

The tissue distribution of 2,3,7,8-TCDD in a number of species is summarized in Table 7-3. As **would** be predicted from the **lipophilic** nature of **this** compound, accumulation tends to occur in tissues **with a high lipid** content. In rats and **mice**, 2,3,7,8-TCDD residues are localized in the liver and adipose tissue. In the rat, hepatic levels of 2,3,7,8-TCDD accounted for **~38-52%** of the administered dose during the first week **following** oral administration of a single dose ranging from 0.07-50 yg/kg (Piper et al., **1973**; **Poiger** and Schlatter, 1979). The latter dose is within the **LD<sub>50</sub>** range for rats. Similar **results** were obtained 7 days following administration of a **single intraperitoneal** dose of 400 yg/kg of [**\*H**]2,3,7,8-TCDD to rats; **43%** of the total dose was localized **in the liver** (Van Miller et al., 1976). In two strains of **mice**, the liver contained **~35%** of an administered dose of **2,3,7,8-TCDD** 1 day after oral or intraperitoneal administration (Manara et al., 1982). In both species, 1-22 days after single-dose oral or **intraperitoneal** administration, levels of 2,3,7,8-TCDD in adipose tissue were similar to or slightly lower than levels **in the liver**, and were considerably higher than concentrations in other tissues (Piper et al., 1973; Rose et al., 1976; Van Miller et al., 1976; Manara et al., 1982), including the thymus (Rose et al., 1976; Van Miller et al., **1976**).

In a 7-week gavage study and a 2-year dietary study of 2,3,7,8-TCDD in rats, 2,3,7,8-TCDD was present in the liver at 3-5 times the concentration in adipose tissue when the daily dose or intake of the compound was **>0.01** yg/kg/day (Rose et al., 1976; **Kociba** et al., 1976) and was present at

TABLE 7-3

## Distribution of 2,3,7,8-TCDD

| Species               | Route of Administration | Principal Organ Depots                               | Reference                       |
|-----------------------|-------------------------|--|---------------------------------|
| Rat                   | oral                    | <b>liver</b>   | Fries and Narrow. 1975          |
| Rat                   | oral                    | liver > fat  | Rose et al., 1976               |
| Rat                   | oral                    | liver > fat  | Piper et al., 1973              |
| Rat                   | oral                    | liver > fat  | <b>Kociba et al., 1978a</b>     |
| Rat                   | oral                    | liver > fat  | Allen et al., 1975              |
| Rat                   | i.p.                    | liver > fat  | Van <b>Miller et al., 1976</b>  |
| <b>Mouse</b>          | oral                    | liver > fat > kidney > lung                          | <b>Manara et al., 1982</b>      |
| Mouse                 | i.p.                    | liver > fat > kidney > lung > spleen                 | <b>Manara et al., 1982</b>      |
| Rhesus monkey         | i.p.                    | fat > <b>skin</b> > liver > adrenals = <b>thymus</b> | Van <b>Miller et al., 1976</b>  |
| Golden Syrian hamster | i.p. or oral            | liver > fat  | Olson et al., 1980a             |
| Guinea pig            | oral                    | fat > liver > adrenals > thymus > <b>skin</b>        | Nolan et al., 1979              |
| Guinea pig            | i.p.                    | fat > liver > <b>skin</b>                            | <b>Gastewicz and Neal, 1979</b> |

i.p. = intraperitoneal

about the same concentration as in adipose tissue when the daily intake was 0.001 yg/kg/day (Kociba et al., 1976). As in the single-dose studies, **2,3,7,8-TCDD** levels were considerably lower in other tissues, including the thymus, than in liver or adipose tissue (Rose et al., 1976).

There is some evidence of sex differences in tissue distribution in rats. During 42 days of administration of 2,3,7,8-TCDD at 7 or 20 ppb in the diet, **~85%** of the total body residue of male rats was located in the liver, as compared **with 70%** in females (Fries and Marrow, 1975). **This** small difference in distribution patterns may have **resulted** from sex differences in relative adipose tissue content.

The ability of mouse liver to sequester 2,3,7,8-TCDD increases with prolonged exposure (Teitelbaum and Poland, 1978). The hepatic uptake of [<sup>3</sup>H]2,3,7,8-TCDD in Swiss-Webster mice was maximal 12 hours after intraperitoneal injection. Hepatic uptake, expressed as percent of total dose, increased from 11.7% in control mice to 60.9% in mice that had been pre-treated with a single dose of unlabeled 2,3,7,8-TCDD 36 hours previously. **This** observation is consistent with other data that indicate that 2,3,7,8-TCDD is a potent inducer of hepatic microsomal mixed-function oxidase (Section 8.1.1.5.) and that >90% of the hepatic 2,3,7,8-TCDD is localized in the microsomes (Allen et al., 1975). The toxicity of 2,3,7,8-TCDD in mice has been demonstrated to correlate with the affinity of the receptor that controls this induction in mice (Poland and Glover, 1980).

In nonhuman primates, the liver seems to have much less of a role in 2,3,7,8-TCDD accumulation. Van Miller et al. (1976) have compared the tissue distribution of [<sup>3</sup>H]2,3,7,8-TCDD in adult rhesus monkeys, infant rhesus monkeys, and Sprague-Dawley rats 7 days after a single intraperitoneal injection of 400 µg 2,3,7,8-TCDD/kg bw. They found that while **43%** of the administered dose was localized in the livers of the rats, only 10.4%

was found **in** the **livers** of adult monkeys and **4.5%** **in** the livers of Infant monkeys. **This** difference cannot be **explained** by differences in absorption or **excretion**, since these parameters were observed to be similar in both species. In **monkeys**, larger percentages of the dose were found in adipose **tissue**, **skin** and muscle than was the case for rats.

**McNulty et al. (1982)** reported that 2 years after administration of a single oral dose of 1  $\mu\text{g}/\text{kg}$  of **2,3,7,8-TCDD** to an adult rhesus macaque monkey, tissue levels of the compound were 1000 ppt **in** adipose tissue and 15 ppt in the liver. These results indicate that prolonged retention of 2,3,7,8-TCDD may occur in **this** species. The tissue distribution of 2,3,7,8-TCDD in the guinea **pig** appears to be similar to the monkey, **with** the highest concentration of the toxin being found in adipose tissue (**Gastewicz and Neal, 1979; Nolan et al., 1979**). The **interspecies** difference in the tissue distribution of 2,3,7,8-TCDD may be related to the relative adipose tissue content of a given species and the affinity of 2,3,7,8-TCDD for the hepatic **microsomal** fraction; however, the significance of these differences remains in doubt. For example, the **hepatotoxicity** of 2,3,7,8-TCDD **in** a given species does not appear to be related to the hepatic concentration of the toxin (**Neal et al., 1982**).

Very **limited** data are available on the tissue distribution of 2,3,7,8-TCDD in humans. **Facchetti et al. (1980)** reported tissue concentrations of 2,3,7,8-TCDD at levels of 1-2 ng/g **in** adipose tissue and pancreas, 0.1-0.2 ng/g in **liver** and **<0.1** ng/g in thyroid, brain, **lung**, kidney and blood in a woman who **died** 7 months after potential exposure to 2,3,7,8-TCDD from the Seveso accident. **This** pattern of 2,3,7,8-TCDD distribution, however, may not be representative for humans since the woman at the **time** of death had an **adenocarcinoma** (which was not considered related to the accident) that involved the pancreas, **liver** and lungs.

In addition, Young et al. (1983) reported **preliminary** results of the analyses of adipose tissue from soldiers exposed to Agent Orange. Two analyses were performed, one using the exact mass of 321.8936 and the other the signal profile at masses of 321.8936 and 319.8965. Three groups were studied consisting of 20 veterans claiming health problems related to Agent Orange exposure; 3 Air Force officers **with** known heavy exposure to Agent Orange during disposal operations and 10 control veterans **with** no known herbicide exposure. In the first group, 10 of the 20 had measurable levels of **2,3,7,8-TCDD** (5 **with** 5-7 ppt, 3 **with** 9-13 ppt, 1 **with** 23 and 35 ppt and another **with** .63 and 99 ppt). In the second **group**, only two officers had measurable **2,3,7,8-TCDD** levels that **did** not exceed 3 ppt. In the 10 control veterans, 4 had 2,3,7,8-TCDD levels between 6 and **14** ppt. Levels of 2,3,7,8-TCDD in adipose tissue **did** not appear to be associated in **this** study **with** 111 health or any particular symptom; however, **it** was considered that information on background **levels** of 2,3,7,8-TCDD in adipose tissue was too limited to draw any **firm** conclusions.

2,3,7,8-TCDD has been demonstrated to be **fetotoxic in** the rat (Section **9.1.**). The ability of 2,3,7,8-TCDD to **gain** access to the developing fetus of Fischer 344 rats **following** a single oral dose of [**<sup>14</sup>C2,3,7,8-TCDD** was investigated by Moore et al. (1976). They found low concentrations of 2,3,7,8-TCDD in the fetus at gestation days 14, 18 or **21**. The radioactivity appeared to be evenly distributed throughout the fetus on days 14 and 18; however, increased **levels** of radioactivity were detected in fetal liver on day **21**.

Nau and Bass (1981) (more recently reported by Nau et al., **1982**) investigated the fetal uptake of 2,3,7,8-TCDD in **NMRI mice** following oral, intraperitoneal or subcutaneous administration of 5, 12.5 or 25 **µg/kg** in

**DMSO:corn oil** or acetone:corn oil. The chemical was usually administered as a single dose 2 days before sacrifice. Embryonic **2,3,7,8-TCDD** concentrations were maximal on **gestational** days 9 and 10; **however**, low levels were found in the embryo and fetus between gestational days 11 and 18. **This** sharp decrease in 2,3,7,8-TCDD concentration coincides **with placentation**. 2,3,7,8-TCDD concentrations in the placenta were an order of magnitude greater than in the fetus itself. The affinity of fetal liver for 2,3,7,8-TCDD was relatively low, as compared **with maternal liver**; however, 2,3,7,8-TCDD levels in fetal livers were 2-4 times higher than the levels in other fetal organs. An attempt was made to correlate 2,3,7,8-TCDD levels in the fetuses **with** the observed incidence of cleft **palate**, but no clear relationship was observed (**i.e.**, 5 minutes to 61 days after injection).

Autoradiographic studies of tissue localization following intravenous administration of [<sup>14</sup>C]2,3,7,8-TCDD in **DMSO** to three strains of **mice** indicated that the liver had the highest concentration and longest retention of radioactivity in the body, followed by the nasal **mucosa** (Appelgren et al., 1983). In pregnant **mice**, the concentration of radioactivity in the fetuses was lower than **in** the dams, but a similar, selective labelling of the liver and the nasal mucosa was seen **in** the fetuses at day 17 of gestation. In the adult animals, labelling of the adrenal cortex was about equal to that of the **liver** at 1 hour after dosing, but thereafter was much lower than in the liver. Labelling of the **thymus**, lymph nodes, bone marrow and prostate were low at all observation times.

### 7.3. METABOLISM

**Vinopal** and **Casida** (1973) found no evidence of water **soluble** metabolites of 2,3,7,8-TCDD following incubation **with** mammalian liver **microsomes** or

**intraperitoneal Injection into mice.** In the same **experiment**, only **unmetabolized 2,3,7,8-TCDD** was **extractable** from mouse liver **11-20** days after treatment. Piper et al. (1973), however, detected **<sup>14</sup>C** activity in the expired **air** and urine within the first 10 days following administration to rats, indicating that some metabolic alteration of **2,3,7,8-TCDD** occurs. Nelson et al. (1977) found that Incubation of **[<sup>14</sup>C]2,3,7,8-TCDD** with rat hepatic **microsomes** resulted in the formation of bound radioactivity which, in contrast to free **2,3,7,8-TCDD**, was not ethyl acetate **extractable**. This binding was found to result from **oxidative** metabolism, as indicated by a requirement for NADPH, and could be induced by **phenobarbital pretreatment**. Binding was not covalent, because the bound radioactivity could be extracted **with chloroform:methanol (9:1)**; this extracted radioactivity **cochromatographed with** the 2,3,7,8-TCDD standard.

Ramsey et al. (1982) detected **five** distinct radioactive compounds in the **bile** of rats given daily oral doses of 15  $\mu$ g **[<sup>14</sup>C]2,3,7,8-TCDD**. Incubation of the **bile with  $\phi$ -glucuronidase** resulted in an increase in the amount of **[<sup>14</sup>C]** extracted, implying the existence of conjugated **[<sup>14</sup>C]-2,3,7,8-TCDD** metabolites. All of the **2,3,7,8-TCDD-derived** radioactivity in the **bile** corresponded to metabolized 2,3,7,8-TCDD. **In vivo metabolism** has also been detected in the Golden Syrian hamster (Olson et al., 1980a) and in dogs (Poiger et al., 1982a). In urine and **bile** from **<sup>14</sup>C-TCDD** treated rats, hamsters and guinea **pigs**, all of the radioactivity corresponded to metabolites of TCDD, as assessed by HPLC (Neal et al., 1982). Enzymatic **hydrolysis** of the TCDD **metabolites** present in urine and **bile** produced alterations in their HPLC profiles that indicated the presence of glucuronide conjugates in **bile** and sulfate conjugates in urine (Olson and Bittner, 1983).



The ability of **1,6-<sup>3</sup>H-2,3,7,8-TCDD** derived radioactivity to **bind** to rat hepatic **macromolecules** **in vivo** was Investigated by **Poland** and Glover (1979). They found maximum levels of 60 **pmol 2,3,7,8-TCDD/mole** of **amino acids** in protein, 12 **pmol 2,3,7,8-TCDD/mole** of **nucleotide** in rRNA, and 6 **pmol of 2,3,7,8-TCDD/mole** of nucleotide in DNA. According to the authors **this** corresponds to one **2,3,7,8-TCDD-DNA** adduct/35 cells (Poland and **Glover**, 1979). Similar results were obtained using a mouse liver **microsomal** system (**Guenther et al.**, 1979a). [**<sup>3</sup>H]**2,3,7,8-TCDD** was found to **bind** to microsomal protein 120-2640 times more readily than to **deproteinized** salmon sperm DNA. They estimated the rate of **2,3,7,8-TCDD** metabolism to be between 9000 and 36,000 times lower than the rate of **P-450-mediated** benzo[a]pyrene metabolism.**

**Tulp** and **Hutzinger** (1978) studied the metabolism of a variety of PCDDs, including **1,2,3,4-TCDD**, in the rat. In di- and higher substituted **dioxins**, only mono- and **dihydroxy** derivatives were detected. Primary **hydroxylation** occurred exclusively at the **2-, 3-, 7- or 8-position**, so the significance of **this** study for the metabolism of 2,3,7,8-TCDD is not clear. **Sawahata et al. (1982)** Investigated the metabolism of 2,3,7,8-TCDD in Isolated rat **hepatocytes**. The **major** product was **deconjugated with  $\phi$ -glucuronidase, derivatized with diazomethane**, and separated **into** two compounds by HPLC. These metabolites were subsequently Identified as **1-hydroxy-2,3,7,8-TCDD** and **2-hydroxy-3,7,8-trichlorodibenzo-p-dioxin**.

**Potger et al. (1982a)** Identified **six** metabolites in the **bile** of dogs that were given [**<sup>3</sup>H]**2,3,7,8-TCDD**. The **major metabolite** was **1,3,7,8-tetrachloro-2-hydroxydibenzo-p-dioxin**. **2-Hydroxy-3,7,8-trichlorodibenzo-p-dioxin****

and **1,2-dichloro-4,5-dihydroxybenzene** were also Identified as minor metabolites. The structures of the three remaining metabolites were not determined; however, two appeared to be **trichloro-dihydroxydibenzo-p-dioxins** and the third was apparently a chlorinated 2-hydroxydiphenyl ether. The presence of these metabolites is consistent with a **1,2-arene** oxide Intermediate.

Isolated rat **hepatocytes** in suspension have been used as an in vitro system for assessing **2,3,7,8-TCDD** metabolism under various conditions. Data indicate that the rate of **2,3,7,8-TCDD** metabolism in rat hepatocytes correlates directly with drug induced changes in hepatic cytochrome P-450 monooxygenase activity, suggesting that 2,3,7,8-TCDD is metabolized by this enzyme (Olson et al., 1981).

Beatty et al. (1978) found a correlation between hepatic mixed-function **oxidase (MFO)** activity and the **toxicity** of **2,3,7,8-TCDD** in rats. Both in **naturally** occurring age- and sex-related differences in MFO activity and **following** the administration of **inducers** and inhibitors of MFO enzyme systems, hepatic MFO activity was inversely related to toxicity that corresponds to direct relationship between the 20-day **LD<sub>50</sub>** and MFO activity.

The fate of 2,3,7,8-TCDD metabolites from dogs has been examined in rats by Weber et al. (1982). 2,3,7,8-TCDD metabolites were extracted from the **bile** of 2,3,7,8-TCDD-treated dogs and administered by gavage to female Sprague-Dawley rats. The 2,3,7,8-TCDD metabolites were rapidly cleared from the bodies of **bile-duct-cannulated** rats, with **>85%** of the dose recovered in the feces, **bile** and urine within 24 hours. In intact rats, only 13% of the dose was excreted in the feces and urine during the first 24 hours, indicating **enterohepatic** circulation; however, the administered radioactivity was completely **eliminated** within 72 hours after dosing.

**Poiger et al. (1982a)** Investigated the **toxicity** of **2,3,7,8-TCDD** metabolites by administering **bile** extract from 2,3,7,8-TCDD-treated dogs to male guinea **pigs** in single oral doses equivalent to 0.6, 6.0 and 60  $\mu\text{g}$  of parent compound/kg **bw**. Other groups of guinea **pigs** received **bile** extract from untreated dogs or 2,3,7,8-TCDD itself. A comparison of the **mortality** data at 5 weeks after dosing indicated that the acute toxicity of 2,3,7,8-TCDD to guinea **pigs** was at least 100 times higher than was the acute toxicity of its metabolites.

Olson and **Bittner** (1983) reported that the rate of metabolite formation in vitro was considerably higher in hepatocytes from the hamster than in hepatocytes from the rat. **Qualitative evaluation** of in vivo and in vitro metabolites by HPLC also suggested major **interspecies** variability. The authors suggested that such differences in metabolism may partially explain the differences in toxicity among species.

#### 7.4. ELIMINATION

The following discussion assumes that elimination is a first order process. **With** the exception of the guinea **pig**, which may follow zero order kinetics (Gasiewicz and **Neal**, 1979), elimination data yield a straight **line** on a **semilogarithmic** plot, indicating a first order process. Hiles and Bruce (1976) pointed out that the studies of Allen et al. (1975) and Piper et al. (1973) can be interpreted **equally** well by either zero or first order kinetics. The majority of the data, however, seem to support the assumption of a first order elimination process.

2,3,7,8-TCDD **is** slowly excreted from the bodies of all species tested (**Table 7-4**), **with** a half-life in the body of **10-43** days. In the Golden Syrian hamster, the least sensitive mammalian species to the acute toxicity of 2,3,7,8-TCDD, excretion occurs readily through both the urine (**41%**) and

TABLE 7-4

## Elimination of 2,3,7,8-TCDD

| Species                | Single Treatment<br>µg/kg (route) | Half-Life for<br>Elimination<br>(days) | Relative % of TCDD-Derived<br>Radioactivity |       | Reference                 |
|------------------------|-----------------------------------|--|---|-------|---------------------------|
|                        |                                   |  | Feces                                       | Urine |                           |
| Guinea pig             | 2 (i.p.)                          | 30.2 ± 5.8                             | 94.0  | 6.0   | Gasiewicz and Neal, 1979  |
| Guinea pig             | 1.45 (oral)                       | 22 - 43                                | NT  | NT    | Nolan et al., 1979        |
| Rat                    | 1.0 (oral)                        | 31 ± 6                                 | >99   | <1    | Rose et al., 1976         |
| Rat                    | 50 (oral)                         | 17.4 ± 5.6                             | 80.0  | 20.0  | Piper et al., 1973        |
| Rat                    | 50 (oral)                         | 21.3 ± 2.9                             | 95.5  | 4.5   | Allen et al., 1975        |
| Rat                    | 400 (i.p.)                        | NT                                     | 91.0  | 9.0   | Van Miller et al., 1976   |
| Monkey<br>(adult)      | 400 (i.p.)                        | NT                                     | 78.0  | 22.0  | Van Miller et al., 1976   |
| Monkey<br>(Infant)     | 400 (i.p.)                        | NT                                     | 39.0  | 61.0  | Van Miller et al., 1976   |
| Monkey                 | 1 (oral)                          | 365                                    | NR  | NR    | McNulty et al., 1982      |
| Mouse                  |                                   |  |   |       |                           |
| C57BL/65               | 10 (i.p.)                         | 11.0 ± 1.2                             | 72.0  | 28.0  | Gasiewicz et al., 1983a,b |
| DBA/2J                 | 10 (i.p.)                         | 24.4 ± 1.0                             | 54.0  | 46.0  | Gasiewicz et al., 1983a,b |
| B6D2F <sub>1</sub> /J* | 10 (i.p.)                         | 12.6 ± 0.8                             | 72.0  | 28.0  | Gasiewicz et al., 1983a,b |
| Hamster                | 650 (i.p.)                        | 10.8 ± 2.4                             | 59.0  | 41.0  | Olson et al., 1980a       |
| Hamster                | 650 (oral)                        | 15.0 ± 2.5                             | NT  | NT    | Olson et al., 1980a       |

\*Offspring of C57BL/6J and DBA/2J that are heterozygous at the Ah locus

NT = Not tested; NR = not reported

feces (59%) (Olson et al., 1980a). The high levels found in the urine of Infant monkeys were probably due to the Incomplete separation of urine and feces (Van Miller et al., 1976). In all the other species so far tested, excretion occurs mainly through the feces (80-100%) with only minor amounts of 2,3,7,8-TCDD metabolites found in the urine (Piper et al., 1973; Allen et al., 1975; Rose et al., 1976; Gasiewicz and Neal, 1979).

Rose et al. (1976) Investigated the elimination of [<sup>14</sup>C]2,3,7,8-TCDD in rats given repeated oral doses of 0.01, 0.1 or 1.0 µg/kg/day Monday through Friday for 7 weeks, or a single dose of 1.0 µg/kg. In these studies, no <sup>14</sup>C was excreted in the urine following a single dose; however, the urine contained 3-18% of the cumulative dose by 7 weeks. This study indicated that steady-state concentrations will be reached in the bodies of rats in ~13 weeks. The rate constant defining the approach to steady-state concentrations was independent of the dosage of 2,3,7,8-TCDD over the range studied. This is consistent with the observations of Fries and Marrow (1975), who found that the total retention in the bodies of rats was proportional to total Intake. When rats were maintained on a diet containing either 7 or 20 ppb TCDD, the amount of TCDD retained in the body was 5.5 times the daily Intake of TCDD at 14 days, 7.5 times the daily Intake at 28 days, and 10.0 times the daily Intake at 42 days.

The data in Table 7-4 suggest some interspecies differences in the half-life for elimination ( $t_{1/2}$ ) of 2,3,7,8-TCDD. In the hamster, the least sensitive species to the acute toxicity of 2,3,7,8-TCDD, a mean  $t_{1/2}$  of 10.8 days was observed (Olson et al., 1980a,b), and in the guinea pig, the most sensitive species to the acute toxicity of 2,3,7,8-TCDD, the mean  $t_{1/2}$  was 30.2 days (Gasiewicz and Neal, 1979). The observed interspecies differences in the  $t_{1/2}$  of 2,3,7,8-TCDD may in part be related to the

relative sensitivity of a given species to the acute **toxicity** of **2,3,7,8-TCDD**.

The intrastrain differences in the  $t_{1/2}$  of **2,3,7,8-TCDD** in three mouse strains may be due to the finding that the DBA/2J strain possesses ~2-fold greater adipose tissue stores than the C57B1/6J and **B6D2F<sub>1</sub>/J** strains (Gasiewicz et al., 1983b). The sequestering of the **lipophilic** toxin in adipose tissue stores of the DBA/2J mouse may contribute to the greater persistence of **2,3,7,8-TCDD** in **this** strain.

In all of the rat studies shown in **Table 7-4**, urinary and fecal elimination were monitored for a period of only 20-22 **days**, and from these data **it** was assumed that elimination followed a single component, first order kinetic model. Recently, Olson and **Bittner** (1983) examined the elimination of **2,3,7,8-TCDD-derived** radioactivity in rats over a 35-day period following a single intraperitoneal exposure at 1  $\mu\text{g } ^3\text{H-2,3,7,8-TCDD/kg}$ . They observed first order kinetics for elimination, **with** a fast component having a  $t_{1/2}$  of 7 days (represents **13%** of **total** elimination) and a slow component having a  $t_{1/2}$  of 75 days (**87%** of **total**). The second, slow component for elimination was evident only when urinary and fecal elimination were monitored for >30 days. **This** study suggests that 2,3,7,8-TCDD may be more persistent than earlier studies suggested. A preliminary study in the rhesus monkey suggests that 2,3,7,8-TCDD may be exceptionally persistent in adipose tissue. McNulty et al. (1982) estimated the apparent half-life of 2,3,7,8-TCDD in the fat of a monkey to be **~1** year.

Studies in the rat, guinea **pig**, hamster and mouse have found that all of the **2,3,7,8-TCDD-derived** radioactivity excreted in the urine and **bile** corresponds to metabolites of 2,3,7,8-TCDD (**Neal et al., 1982, 1984**). The apparent absence of 2,3,7,8-TCDD metabolites in liver and fat suggests that

once **formed**, the metabolites of **2,3,7,8-TCDD** are readily excreted. **Thus**, urinary and biliary elimination of **2,3,7,8-TCDD** is apparently dependent upon metabolism of the toxin. Although urine and **bile** appear to be free of **unmetabolized** 2,3,7,8-TCDD, data from the hamster and rat indicate that a significant amount (10-40X) of unchanged **2,3,7,8-TCDD** may be excreted **into** the feces. Unmetabolized 2,3,7,8-TCDD thus appears to enter the intestinal lumen by some route other than **bile** for a number of days following treatment. These data suggest that the **in vivo** half-life for **elimination** of 2,3,7,8-TCDD may not directly reflect the rate of 2,3,7,8-TCDD metabolism in a given animal (**Neal et al.**, 1982, 1984). These data are consistent with the observation of **Manara et al.** (1982) that the lethal effects of 2,3,7,8-TCDD were decreased in C57Bl/6J **mice** regardless of whether the compound was administered by gavage or **intraperitoneal** injection if the animals were given diets containing activated carbon.

#### 7.5. **SUMMARY**

Exposure to 2,3,7,8-TCDD occurs by **inhalation**, dermal or **GI** absorption. Inhalation exposure to detectable levels of 2,3,7,8-TCDD **is** less likely because of low vapor pressure of **this** compound; however, inhalation exposure could result from inhalation of **mist**, dust or other contaminated **particulate** matter. Monitoring of atmospheric dust in the Seveso area detected 2,3,7,8-TCDD levels ranging from 0.06-2.1 ng **2,3,7,8-TCDD/g** airborne dust (**DiDomenico et al.**, 1980b). **This** corresponds to an estimated 24-hour inhalation exposure of 1.4 pg assuming an average intake of 10 **m<sup>3</sup> air** containing 0.14 mg **dust/m<sup>3</sup>**. No studies on the systemic absorption of 2,3,7,8-TCDD have been performed, so the significance of **this** route of exposure in contaminated areas cannot be assessed.

2,3,7,8-TCDD is readily absorbed under experimental conditions (vide ante) and following environmental contamination (Cockerham et al., 1980; Fanelli et al., 1980c; Walsh, 1977). After being absorbed, 2,3,7,8-TCDD is rapidly distributed to tissues with a high lipid content (fat, skin, adrenals). In most species studied, the major storage site for 2,3,7,8-TCDD is the liver (see Table 7-3). 2,3,7,8-TCDD exposure results in induction of MFO activity and a proliferation of smooth endoplasmic reticulum, the major subcellular storage site for 2,3,7,8-TCDD (Section 8.1.1.5.). The ability of 2,3,7,8-TCDD to produce this effect has been correlated with the sensitivity of various strains of mice to 2,3,7,8-TCDD toxicity (Van Miller et al., 1976; Poland and Glover, 1980).

2,3,7,8-TCDD appears to be distributed throughout the body and stored largely as the parent compound (Olson et al., 1980a); however, metabolism to more polar compounds appears to be necessary for excretion in the urine or bile (Weber et al., 1982; Olson et al., 1980a; Neal et al., 1984). Studies have also indicated that 2,3,7,8-TCDD was metabolized by the hepatic cytochrome P-450 monooxygenase system. The structures of six metabolites in the dog (Poiger et al., 1982b) and two in the rat (Sawahata et al., 1982) have been elucidated; however, the structure of the metabolites of 2,3,7,8-TCDD have not been determined for the other species studied. Although some [1,6-<sup>3</sup>H]-2,3,7,8-TCDD-derived radioactivity was capable of binding covalently to cellular macromolecules (Guenther et al., 1979b; Nelson et al., 1977; Poland and Glover, 1979), metabolism of 2,3,7,8-TCDD seems to be predominantly a detoxification process (Beatty et al., 1978; Polger et al., 1982a).



**2,3,7,8-TCDD** and its metabolites are excreted from the body by a variety of mechanisms. **Lactating** rats excrete **2,3,7,8-TCDD** in the **milk** (Moore et al., 1976). **2,3,7,8-TCDD**, **1,2,3,7,8-PeCDD** and **1,2,3,4,6,7,8-HpCDD** and OCDD have been detected in human **milk** samples from Swedish and German mothers (Rappe et al., 1985). These investigators could detect **1,2,3,4,7,8-**, **1,2,3,6,7,8-** and **1,2,3,7,8,9-HxCDDs** only in the **mothers' milk** from Sweden. Piper et al. (1973) reported the excretion of [**<sup>14</sup>C**]2,3,7,8-TCDD-derived radioactivity in the feces, urine and expired **air** of rats given a single oral dose of 50 **µg/kg**. Over a **21-day** period, 53, 13 and **3%** of the administered radioactivity was **eliminated** through the feces, urine and expired **air**, respectively. This pattern of excretion seems **typical** of most species studied, **with** the exception of the hamster, which was observed to excrete **41%** of the **2,3,7,8-TCDD-derived** radioactivity **in** the urine (Olson et al., 1980a). In all species so far studied, metabolism and excretion are relatively slow processes, **with** the observed initial half-lives **in** experimental animals on the order of a few weeks (see Table 7-4).

## 8. TOXICOLOGY: **ACUTE, SUBCHRONIC** AND CHRONIC

### 8.1. EXPERIMENTAL ANIMALS

#### 8.1.1. Acute.

**8.1.1.1. LETHAL EFFECTS** - There have been studies in a variety of species defining the doses necessary to cause death after acute exposure to **2,3,7,8-TCDD**. A summary of the single dose **LD<sub>50</sub>** data for **2,3,7,8-TCDD** is presented in Table **8-1**. The dose that results in death varies extensively **with species, with** the male guinea pig being the most sensitive species tested (**LD<sub>50</sub>** of 0.6 vg/kg) (Schwetz et al., 1973), and the male hamster the least sensitive species tested (**LD<sub>50</sub>** of 5051 vg/kg) (Henck et al., 1981). The rat and monkey appear to be the second most sensitive species, **with LD<sub>50</sub>s** between 22 and 70 vg/kg (**Schwetz et al., 1973; McConnell et al., 1978a**), while other species tested (rabbit and mouse) had **LD<sub>50</sub>s** between 114 and 283 **µg/kg** (Schwetz et al., 1973; McConnell et al., 1978b; Vos et al., 1974). Schwetz et al. (1973) found male rats more sensitive to 2,3,7,8-TCDD, while Beatty et al. (1978) found **adult** female and weanling male rats more sensitive than adult male rats (**Table 8-1**). In C57B1/10 **mice**, Smith et al. (1981) reported adult males to be far more sensitive to the acute **toxicity** of 2,3,7,8-TCDD than adult females. Thus, data on sex differences **in** sensitivity to the acute toxicity of 2,3,7,8-TCDD are conflicting and may depend on the species or strain examined.

Harris et al. (1973) studied the toxic effects of 2,3,7,8-TCDD **in** rats, **mice** and guinea pigs **with** regard to single or multiple exposures. Similar effects were observed after a single exposure to 2,3,7,8-TCDD as were observed when **multiple** exposures totaled the same dose as received in the single exposure. As illustrated most clearly in rats, a single dose of 25 vg/kg, 6 weekly doses of 5 vg/kg, or 30 daily doses of 1 vg/kg were

TABLE 8-1  
Lethal Doses of 2,3,7,8-TCDD Following Acute Exposure

| Species/Strain                 | Sex/No. /Group | Route/<br>Vehicle                   | Dose Tested<br>( $\mu\text{g}/\text{kg}$ ) | Duration of<br>Observation | LD <sub>50</sub><br>( $\mu\text{g}/\text{kg}$ ) | Comments   | Reference                  |
|--------------------------------|----------------|-------------------------------------|--|----------------------------|---|--|----------------------------|
| Guinea pigs/<br>Hartley        | M/NR           | gavage/corn<br>oil-acetone<br>(9:1) | NR   | 2-8 weeks                  | 0.6<br>(0.4-0.9)*                               | Time to death was 5-34 days, the<br>2,3,7,8-TCDD was 91X pure  | Schwetz et al.,<br>1973    |
| Guinea pigs/<br>Hartley        | M/NR           | gavage/corn<br>oil-acetone<br>(9:1) | NR   | 2-8 weeks                  | 2.1<br>(1.5-3)*                                 | Time to death was 9-42 days, the<br>2,3,7,8-TCDD was 99X pure  | Schwetz et al.,<br>1973    |
| Guinea pigs/<br>Hartley        | M/9            | gavage/<br>corn oil                 | NR   | 30 days                    | 2   | Median time to death was 17-20 days,<br>marked weight loss, thymus atrophy.<br>Intestinal hemorrhage, no porphyria<br>and only mild liver injury | McConnell et al.,<br>1978b |
| 8-2<br>Guinea pigs/<br>Hartley | F/6            | gavage/<br>corn oil                 | 0.1<br>0.5<br>2.5<br>12.5<br>20.0          | 42 days                    | 2.5<br>(1.2-5.4. 95X<br>confidence)             | Time to first death was 32 days in<br>the 2.5 $\mu\text{g}/\text{kg}$ group, with 50X<br>mortality by day 42                                     | Silkworth et al.,<br>1982  |
| Guinea pigs/<br>Hartley        | F/6            | gavage/<br>methyl<br>cellulose      | 0.1<br>0.5<br>2.5<br>12.5<br>20.0          | 12 days                    | 19<br>(15-23. 95X<br>confidence)                | Time to first death was 12 days in<br>the 20.0 $\mu\text{g}/\text{kg}$ group, with 67X<br>mortality by day 42                                    | Silkworth et al.,<br>1982  |
| Rats/<br>Sherman               | M/5-10         | gavage/corn<br>oil-acetone<br>(9:1) | 8<br>16<br>32<br>63                        | 2-8 weeks                  | 22  | Time to death was 9-27 days, the<br>2,3,7,8-TCDD was 91X pure  | Schwetz et al.,<br>1973    |
| Rats/<br>Sherman               | F/NR           | gavage/corn<br>oil-acetone<br>(9:1) | NR   | 2-8 weeks                  | 45<br>(30-66)*                                  | Time to death was 13-43 days, the<br>2,3,7,8-TCDD was 91X pure   | Schwetz et al.,<br>1973    |
| Rats/Sprague-<br>Dawley        | M/6            | i.p./olive<br>oil                   | NR   | 20 days                    | 60  | LD <sub>50</sub> ( $\mu\text{g}/\text{kg}$ , mean + SE) adult<br>male, 60.2 $\pm$ 7.8; weanling male,<br>25.2 $\pm$ 1.4                          | Beatty et al., 1978        |
| Rats/Sprague-<br>Dawley        | F/6            | i.p./olive<br>oil                   | NR   | 20 days                    | 25  | Adult female had a mean $\pm$ SE of<br>24.6 $\pm$ 2.0 $\mu\text{g}/\text{kg}$  | Beatty et al., 1978        |

TABLE 8-1 (cont.)

| Species/Strain             | Sex/No./Group | Route/<br>Vehicle                   | Dose Tested<br>( $\mu\text{g}/\text{kg}$ )                 | Duration of<br>Observation | LD <sub>50</sub><br>( $\mu\text{g}/\text{kg}$ ) | Comments   | Reference                 |
|----------------------------|---------------|-------------------------------------|--|----------------------------|---|--|---------------------------|
| Monkey/rhesus              | F/3           | gavage/<br>corn oil                 | 0<br>70<br>350   | >35 days                   | <70   | Weight loss, edema, severe thymus atrophy, loss of hair, mild liver damage   | McConnell et al., 1978a   |
| Mice/C57B1                 | M/14          | gavage/corn<br>oil-acetone<br>(9:1) | 0<br>100<br>150<br>200                                     | 60 days                    | 114   | Time to death in the high dose group was 15-20 days, bw loss, edema in 25% of treated animals, severe thymic and spleen atrophy, hemorrhage in the region of the eye and small intestine, liver necrosis in the centrilobular region | Vos et al., 1974          |
| Mice/C57B1                 | N/9           | gavage/<br>corn oil                 | NR   | 30 days                    | 283.7   | Median time to death was 22-25 days, dose-related bw loss, thymic atrophy, increased liver weight and porphyria, gross and historic liver alterations, subcutaneous edema. Intestinal hemorrhage                                     | McConnell et al., 1978b   |
| Mice/C57B1/10              | N/5           | gavage/<br>arachis oil              | 85<br>107<br>135<br>170<br>213                             | 45 days                    | 146   | 95% confidence limits of 111-211 $\mu\text{g}/\text{kg}$ . Most deaths occurred from 22-26 days after dosing. Signs of porphyria, edema, hemorrhage.   | Smith et al., 1981        |
| Mice/C57B1/10              | F/5           | gavage/<br>arachis oil              | 85<br>107<br>135<br>170<br>213<br>269<br>338<br>426<br>536 | 45 days                    | >450  | 1 of 4 animals died at dose of 426 $\mu\text{g}/\text{kg}$   | Smith et al., 1981        |
| Mice/C57B1/6J              | N/NR          | i.p./olive<br>oil                   | NR   | 30 days                    | 132   | B6D2F <sub>1</sub> /J mice are the offspring of C57B1/6J and DBA/2J.   | Gasiewicz et al., 1983a,b |
| Mice/DBA/2J                | N/NR          | i.p./olive<br>oil                   | NR   | 30 days                    | 620   | The B6D2F <sub>1</sub> /J mice are heterozygous at the Ah locus.   | Gasiewicz et al., 1983a,b |
| Mice/B6D2F <sub>1</sub> /J | N/NR          | i.p./olive<br>oil                   | NR   | 30 days                    | 300   | No comment   | Gasiewicz et al., 1983a,b |

TABLE 8-1 (cont.)

| Species/Strain                       | Sex/No. /Group | Route/<br>Vehicle                                 | Dose Tested<br>( $\mu\text{g}/\text{kg}$ ) | Duration of<br>Observation | LD <sub>50</sub><br>( $\mu\text{g}/\text{kg}$ )        | Comments  | Reference               |
|--------------------------------------|----------------|---|--|----------------------------|--|---|-------------------------|
| Rabbits/<br>New Zealand              | M&F/NR         | gavage/corn<br>oil-acetone<br>(9:1)               | NR   | 2-8 weeks                  | <b>115</b><br><b>(38-345)*</b>                         | <b>Time to death was 6-39 days, the 2,3,7,8-TCDD was 91X pure</b>   | Schwetz et al.,<br>1973 |
| Rabbits/<br>New Zealand              | M&F/5          | <b>i.p./</b><br>corn oil                          | 32<br>63<br>126<br>252<br>500              | 4 weeks                    | NR   | <b>Time to death was 6-23 days. 2-3 animals/group died in all but the low exposure group</b>  | Schwetz et al.,<br>1973 |
| Rabbits/<br>New Zealand              | M&F/NR         | <b>dermal/</b><br>acetone                         | 31.6<br>63<br>126<br>252<br>500            | 3 weeks                    | 275<br><b>(142-531)*</b>                               | <b>Time to death was 12-22 days</b>   | Schwetz et al.,<br>19"  |
| <b>8-4</b> Hamster/<br>golden Syrian | M/6            | gavage/corn<br><b>oil-acetone</b><br><b>(9:1)</b> | 0<br>300<br>600<br>1000<br>3000<br>6000    | 55 days                    | <b>5051</b><br>(3876-18.487.<br><b>95% confidence)</b> | <b>Time to death was 26-43 days, the liver and thymus appeared to be the primary target organs, only 1 death occurred in the 300 and 3000 wg/kg group</b> | Henck et al., 1981      |
| Hamster/<br>golden Syrian            | M&F/5-6        | <b>i.p./</b><br>olive oil                         | 0<br>500<br>1000<br>2000<br>3000           | 50 days                    | >3000  | <b>Significant, dose-related decrease in thymus weight starting at 500 wg/kg, only 2 deaths occurred out of 11 hamsters in the 3000 wg/kg group.</b>      | Olson et al., 1980b     |
| Hamster/<br>golden Syrian            | M/5            | gavage/<br>olive oil                              | 500<br>1000<br>2000<br>3000                | 50 days                    | 1157   | Death generally occurred between 24 and 45 days, decrease in bw above 2000 wg/kg. <b>proliferative ileitis with mild to severe Inflammation</b>           | Olson et al., 1980b     |
| Dogs/Beagle                          | H/2            | gavage/corn<br><b>oil-acetone</b><br>(9:1)        | 3000                                       | <b>2-8 weeks</b>           | NA   | All animals <b>died</b>   | Schwetz et al.,<br>1973 |
| Dogs/Beagle                          | F/2            | gavage/corn<br><b>oil-acetone</b><br>(9:1)        | 30<br>100                                  | 2-8 weeks                  | NA   | All animals survived  | Schwetz et al.,<br>1973 |

\*The number in parentheses appears to indicate the range of lethal doses; however, the article did not specify what these numbers represented.

i.p. = Intraperitoneal; NR - Not reported; NA = Not applicable

all the threshold dose for observing a decrease in body weight. In general, other endpoints, including lethality, decrease in thymus weight, and a no effect level for body weight change in rats, mice and guinea pigs required a specific threshold level regardless of whether this level was achieved through a single exposure or a small number of multiple exposures.

Although 2,3,7,8-TCDD has over a 10<sup>3</sup>-fold difference in toxicity depending upon the species tested, some of the signs of lethal toxicity were the same regardless of species. One of the most characteristic observations after acute lethal exposure to 2,3,7,8-TCDD was the protracted time between exposure and death (see Table 8-1). In determining the LD<sub>50</sub> in the least sensitive animal, the hamster, the test animals died between 24 and 45 days after a single acute exposure (Olson et al., 1980b), and similar observations were made in all other species tested including the most sensitive species, the guinea pig, in which animals died up to 42 days after treatment (Schwetz et al., 1973).

During this extended period between treatment and death the animals had poor weight gain or loss of weight resulting in a "wasting syndrome" that resembled starvation. Though weight loss is the primary general feature observed in adult rats, in the young animals depletion of body fat results in lean tissue formation (Peterson et al., 1984). In female Wistar rats intubated with 2,3,7,8-TCDD at a dose of 100 µg/kg, the weight loss was biphasic (Courtney et al., 1978). The initial weight loss occurred rapidly during the first 7-10 days after treatment and was associated with decreased food and water consumption. This initial phase of weight loss was reversed with the resumption of normal food intake for 4 or 5 days, only to be followed by a second, more gradual, decline in food and water intake and weight until death. Providing animals with an adequately nutritious liquid diet

by Intubation **did** not appreciably alter the pattern of weight **loss** nor affect **survival**. In contrast, Gaslewicz et al. (1980) observed that providing rats **with** total parenteral nutrition would prevent some of the weight **loss** induced by **2,3,7,8-TCDD**; however, there was no protection from the lethal effects of 2,3,7,8-TCDD. Seefeld and Peterson (1983) and Seefeld et al. (1984) found that a reduction in food intake caused by 2,3,7,8-TCDD **is** primarily responsible for the loss of body weight or depressed growth rate of rats. Pair-fed control rats **lost** weight at the same rate and to the same extent as their **weight-matched** 2,3,7,8-TCDD-treated partners (25 or 50 **µg/kg**) until day 10 after treatment. At 20-35 days after treatment, the body weight of the two groups began to diverge, **with** the pair-fed control group having body weights that were 20-30 g higher than the corresponding 2,3,7,8-TCDD groups. The mortality in the 25 and 50 **µg/kg** groups was 33 and **75%**, respectively, while in the corresponding pair-fed groups the mortality was 0 and **15%**. The authors proposed a hypothesis that 2,3,7,8-TCDD lowers a regulated level or "set-point" for body weight **control** in the rat. The ensuing change in food intake was thought to occur secondarily to the change in set-point (Seefeld and Peterson, 1983; Seefeld et al., 1984; Peterson et al., 1984). Vitamin A or E **did** not protect or inhibit the decrease in body weight, respectively. **Further**, these vitamins provided **little** protection against **2,3,7,8-TCDD-induced** lethality in rats (Hassan et al., 1985).

Also, severe **thymic** atrophy is universally observed in all species given lethal doses of 2,3,7,8-TCDD, and since weight loss and thymic atrophy are both associated **with** malnutrition, van Logten et al. (1981) investigated the effects of dietary protein on the **toxicity** of 2,3,7,8-TCDD. Groups of female Fischer 344 rats administered 2,3,7,8-TCDD (20 **µg/kg**) and maintained on low (3.5%), normal (**26%**) or **high** (55%) protein diets maintained

approximately the same amount of weight ( $-0.2 \pm 3$ ,  $7 \pm 6$  and  $7 \pm 3$  g for each dietary group, respectively) during the subsequent 10-day period. The weight **gain** in treated animals was 10-18 g less than that in the respective **control** rats. Dietary protein also had no effect on preventing or enhancing the **2,3,7,8-TCDD** induced **thymic** atrophy. Although weight loss and **thymic** atrophy were present in most species tested, there were other symptoms that were characteristic of **toxicity** in only some species.

In the guinea **pig**, besides **thymic** atrophy, no gross changes were observed in internal organs after a lethal oral or **i.p.** dose of 2,3,7,8-TCDD (**Greig et al.**, 1973, **Gupta et al.**, 1973). Hemorrhages were observed in a number of organs including the adrenal gland, urinary bladder, **GI** tract and **mesenteric** lymph nodes; however, these were considered unremarkable changes by **Gupta et al.** (1973). Histologic examination confirmed the gross observations **with** atrophy and **lymphoid** cell depletion in the **thymus**, spleen and lymph nodes, and hemorrhages observed in many organs. In addition, marked **hyperplasia** of the urinary bladder was observed. Of particular interest was the absence of severe toxic effects on the liver. Gross observation under UV light indicated no excess of **porphyrin**, while **histologic** examinations revealed diffuse single cell necrosis. Identical observations were made by **McConnell et al.** (1978b) in guinea **pigs** administered lethal doses of 2,3,7,8-TCDD, **with** the additional observation that the sternal bone marrow was **hypocellular** in all types of blood-forming cells.

Turner and Collins (1983) described some histologic changes in the **liver** of guinea **pigs** treated **with** 2,3,7,8-TCDD. Groups consisting of 4-6 **female Hartley** guinea **pigs** were treated **with** 2,3,7,8-TCDD at doses of 0.0, 0.1, 0.5, 2.5, 12.5 or 20  $\mu\text{g}/\text{kg}$ , and 1 male guinea **pig** each was treated **with** a dose of 0.1 or 0.5  $\mu\text{g}/\text{kg}$ . The 2,3,7,8-TCDD was administered by gavage as



an aqueous suspension in 0.75% methyl **cellulose** and surviving animals were killed 42 days after treatment. A second group of guinea **pigs** (6 males and 6 females/dose) were administered soot generated from a **fire in** a transformer cooled by **polychlorinated biphenyls** and chlorinated benzenes (1, 10, 100 and 500 **mg/kg**). The **histologic** observations as described were applied in general to both treatment groups and there was no apparent relationship between dose and response. At the light microscope level, hepatocellular hypertrophy, **steatosis**, focal necrosis, **cytoplasmic** degeneration and **acidophilic hyalin-like** cytoplasmic **inclusion** bodies were observed. Even though there was no dose-response relationship for these **liver** lesions, the doses spanned a range that **resulted in** the **lowest** dose being nonlethal (none of the 4 female guinea **pigs** died during the study), while in the **high** dose group 4 of 6 animals **died** before 42 days post-treatment. The **LD<sub>50</sub>** for female guinea **pigs** was determined in **this** study to be 2.5 or 19  $\mu\text{g/kg}$  bw depending on whether the compound was administered by gavage **in** corn **oil** or in aqueous methyl **cellulose** (Silkworth et al., 1982).

The greatest difference at necropsy **in** the gross and histologic effects in rats and **mice** of exposure to **lethal** doses of **2,3,7,8-TCDD** was pathologic **alterations** in the **liver**, as compared **with** guinea **pigs**. An early report by Buu-Hol et al. (1972) described alterations **in** the architecture of the liver of rats within 5 days of receiving a low dose of 2,3,7,8-TCDD (10  $\mu\text{g/kg}$  by **i.p.** Injection). At higher oral doses of 100 or 50  $\mu\text{g/kg}$ , which killed 43 and 7% of the animals, respectively, Gupta et al. (1973) also observed marked distortion of **liver** architecture **in** rats; however, only **mild** regenerative changes of the liver were observed at the sublethal dose of 5  $\mu\text{g/kg}$  administered weekly for 6 weeks. Liver toxicity appeared to develop slowly in the rat **with** no change **in** **liver** function, as indicated by plasma protein

and **bilirubin** levels, or alkaline **phosphatase**, glutamic-oxalacetic trans-**aminase** (GOT) and **glutamic-pyruvic transaminase** (GPT) activity being detected 3 days after Intubation **with 2,3,7,8-TCDD** at a dose of 200  $\mu\text{g}/\text{kg}$  (**Greig et al.**, 1973). **Bilirubin** levels were, however, **markedly** elevated from 0.33  $\mu\text{g}/100$  ml **in** control animals to 10.97  $\mu\text{g}/100$  ml **in** treated animals 21 days after exposure (the other parameters were not measured at **this time**, although plasma protein was slightly but significantly decreased when determined 9 days **post-treatment**). As in rats, the livers of **mice** exposed to **lethal** levels of 2,3,7,8-TCDD had signs of **necrotic** changes (**Vos et al.**, 1974); however, Jones and Grieg (1975) reported that the **centrilobular** necrosis, **bile** duct proliferation and **lipid accumulation** were more extreme in **mice** than in rats. Examination of mouse **livers** using **long** wave UV light showed fluorescence suggestive of excess **porphyrin** accumulation (**McConnell et al.**, 1978b). Although excess **porphyrins** may be present in the livers from 2,3,7,8-TCDD-exposed rats, fluorescence is not usually observed.

Besides effects on the **liver**, 2,3,7,8-TCDD exposure produced other toxic effects in rats and **mice** that were not observed or were observed to a lesser extent in guinea **pigs**. In rats that **died** from 2,3,7,8-TCDD exposure, there were extensive hemorrhages of the heart, liver, brain, adrenal **gland** and **GI** tract along **with** ulcers and necrosis of the glandular stomach, and **in** females, atrophy of the uterus (**Gupta et al.**, 1973). In **mice**, facial edema was severe and the testicles of males appeared degenerated **with** necrotic **spermatocytes** and spermatozoa present (**McConnell et al.**, 1978b; **Vos et al.**, 1974). Death in **mice** was frequently attributed to terminal hemorrhages (**Vos et al.**, 1974).

In monkeys exposed to lethal levels of 2,3,7,8-TCDD, **McConnell et al.** (1978a) reported **clinical** and **histologic** signs of **toxicity**, some of which

were similar to those already described for other species. Severe **thymic** atrophy and edema occurred **in** treated animals, as well as extensive weight loss that could account for up to 38% of the body mass. As **in** guinea **pigs**, **liver** injury appeared to be **mild**; however, increased serum GOT and aldolase activity and decreased albumin levels indicative of **liver** pathology occurred near the **time** of death. As observed **in** **mice**, the bone marrow of monkeys was hypocellular. In addition to the above signs of **toxicity**, which were observed **in** other species as **well**, monkeys had progressive loss of **hair**, **toenails** and fingernails, **with** associated dermatitis consisting of the development of a crusty texture to the **skin**, squamous metaplasia of sebaceous glands and gastric **mucosal dysplasia**. As **with** most other species, a specific cause of death could not be determined for monkeys. Poland and Knutson (1982) summarized the toxic response of various species to 2,3,7,8-TCDD **in** Table 8-2.

There was very **little** information on the lethal effects of PCDD congeners other than **2,3,7,8-TCDD**. **McConnell** et al. (1978b) determined the **LD<sub>50</sub>** for **nine congeners** of PCDD following a single treatment by gavage **in** **mice** and guinea **pigs**. A comparison of the **LD<sub>50</sub>** expressed as  $\mu\text{mol/kg}$  body weight **is** presented **in** Table 8-3. The limited data suggest that congeners containing chlorine **in** the 2,3,7,8 positions were more biologically active than congeners deficient **in** a chlorine from any one of these positions. It also appears that addition of one or more chlorines to 2,3,7,8-TCDD results **in** a decrease **in** lethality. Although the congeners vary **in** effective dose between **mice** and guinea **pigs**, the relative order of toxicity of these congeners **did** not change. Also, similar effects of toxicity were observed for all congeners as described above for 2,3,7,8-TCDD when the **com-**parison was made within a single species.

TABLE 8-2

Toxic Responses Following Exposure to 2,3,7,8-TCDD: Species Differences<sup>a</sup>

|  | Monkey          | Guinea Pig | Cow <sup>b</sup> | Rat | House | Rabbit <sup>b</sup> | Chicken <sup>b</sup> | Hamster |
|--|-----------------|------------|------------------|-----|-------|---------------------|----------------------|---------|
| <b>Hyperplasia and/or metaplasia</b>   |                 |            |                  |     |       |                     |                      |         |
| Gastric mucus                          | ++ <sup>c</sup> | 0          | +                | 0   | 0     |                     |                      | 0       |
| Intestinal mucosa                      | +               |            |                  |     |       |                     |                      | ++      |
| Urinary tract                          | ++              | ++         | ++               | 0   | 0     |                     |                      |         |
| Bile duct and/or gall bladder          | ++              | 0          | <sup>4</sup>     |     | ++    |                     |                      | 0       |
| Lung: focal alveolar                   |                 |            |                  | ++  |       |                     |                      |         |
| <b>Skin</b>                            | ++              | 0          | *d               | 0   | 0     | ++                  |                      | 0       |
| <b>Hypoplasia, Atrophy or Necrosis</b> |                 |            |                  |     |       |                     |                      |         |
| Thymus                                 | +               | +          | +                | +   | +     |                     | +                    | +       |
| Bone marrow                            | +               | +          |                  |     | ±     |                     | +                    |         |
| Testicle                               | +               | +          |                  | +   | +     |                     | +                    |         |
| Other                                  |                 |            |                  |     |       |                     |                      |         |
| Liver lesions                          | +               | ±          |                  | ++  | +     | ++                  | +                    | ±       |
| Porphyria                              | 0               | 0          |                  | +   | ++    |                     | +                    | 0       |
| Edema                                  | +               | 0          |                  | 0   | +     |                     | ++                   | +       |

<sup>a</sup>References: monkey (McConnell et al., 1978b; Norback and Allen, 1973; Allen et al., 1977); guinea pig (McConnell et al., 1978b; McConnell, 1980; Moore et al., 1979; Turner and Collins, 1983); cow (McConnell, 1980); rat (McConnell, 1980; Kociba et al., 1978a; Kociba et al., 1979); mouse (Schwetz et al., 1973; McConnell et al., 1978b; Vos et al., 1973); rabbit (Kimmig and Schultz, 1957; Schwetz et al., 1973; Vos and Beems, 1971); chicken (Schwetz et al., 1973; Norback and Allen, 1973; Allen and Lalich, 1962; Vos and Koeman, 1970); hamster (Olson et al., 1980b; Henck et al., 1981).

<sup>b</sup>Responses followed exposure to 2,3,7,8-TCDD or structurally related chlorinated aromatic hydrocarbons.

<sup>c</sup>Symbols: 0, lesion not observed; +, lesion observed (number of "+" denote severity); ±, lesion observed to a very limited extent; blank, no evidence reported in literature.

<sup>d</sup>Skin lesions in cattle are observed, but they differ from the skin lesions observed in other species.

Adapted from Poland and Knutson, 1982.

TABLE 8-3

Estimated Single Oral LD<sub>50</sub> - 30 Values for PCDDs<sup>a</sup>

| Chlorination of PCDDs | Guinea Pigs<br>( $\mu\text{mol/kg}$ ) <sup>b</sup> | Mice<br>( $\mu\text{mol/kg}$ ) <sup>b</sup> |
|-----------------------|--|---|
| 2,8                   | >1180  | NR  |
| 2,3,7                 | 120.41   | >10   |
| 2,3,7,8               | 0.006  | 0.88  |
| 1,2,3,7,8             | 0.009  | 0.94  |
| 1,2,4,7,8             | 3.15   | >14   |
| 1,2,3,4,7,8           | 0.185  | 2.11  |
| 1,2,3,6,7,8           | 0.178-0.255 <sup>c</sup>                           | 3.19  |
| 1,2,3,7,8,9           | 0.153-0.255 <sup>c</sup>                           | >3.67                                       |
| 1,2,3,4,6,7,8         | >1.400   | NR  |

<sup>a</sup>Source: McConnell et al., 1978b<sup>b</sup>Spearman-Kärber method<sup>c</sup>Estimated range due to variability in replicates

NR = Not reported

**8.1.1.2. EFFECTS ON THE LIVER** -- The **histological** and ultrastructural changes in the liver induced by **oral** exposure to **2,3,7,8-TCDD** have been reported by Fowler et al. (1973), Jones and Butler (1974) and Jones (1975). Fowler et al. (1973) treated groups of 30 male rats with a **single** dose of **2,3,7,8-TCDD** at 0.0, 5 and 25  $\mu\text{g}/\text{kg}$  by gavage. The animals were killed in groups of 5 on days 1, 3, 6, 9, 16 and 28 after treatment and the livers were prepared for **histologic** examination. The major ultrastructural change observed was a dose-related increase in the smooth and rough **endoplasmic reticulum** (ER) in **cells** near the **bile** canaliculi. The initial increases appeared at day 3, with the maximal response occurring on days 6 and 9. By day 16 the smooth ER was nearly absent from the **parenchymal** cells, although large amounts of rough ER were still present. By day 28 the cells had returned to normal appearance. These changes in liver cells following 2,3,7,8-TCDD treatment would be consistent with the induction of protein and RNA synthesis.

Transmission electron microscopic observations revealed that single **i.p.** administration of 20  $\mu\text{g}/\text{kg}$  of 2,3,7,8-TCDD in Sprague-Dawley male rats produces **necrotizing** hepatic **lesions** that become progressively worse up to the 16th week postexposure followed by gradual improvement of the condition and disappearance of the lesions (Weber et al., 1983).

At higher doses of 200  $\mu\text{g}/\text{kg}$ , Jones and Butler (1974) observed necrosis and **proliferative** changes in the liver of rats to be the predominant lesions. After treatment by gavage, groups of 4 male and 4 female rats were killed and examined on a weekly basis for 10 weeks. By the first week, degenerating cells were observed near the central **vein** and these lesions progressed to areas of focal necrosis by the sixth week. Superimposed on

the **necrotic** changes were **hyperplasia** of the viable **cells with multinucleated** cells common by the ninth week. At week 10 central **vein fibrosis** and scattered necrosis remained. **Fine** structure observed after **this** large dose of 2,3,7,8-TCDD also revealed Increases in smooth ER; however, the most striking effect was degeneration of the plasma membrane **with** the resulting fusion of **parenchymal** cells. In a study of similar **design**, Jones (1975) followed the distribution **with time** after treatment of membrane associated ATPase activity by **histochemical** techniques. At 3 days after treatment, the first changes in ATPase patterns were observed, **with** loss of activity along the **canalicular** borders and some increased activity in the sinusoids. The **midzonal** and **periportal** zones had normal activity at **this time**. The loss of ATPase activity persisted for 34-42 days and paralleled the **histologic** lesions described previously (Jones and Butler, 1974). In rats that survived treatment, the ATPase activity was back to normal by 9 months.

Peterson et al. (1979a) further studied the effect of 2,3,7,8-TCDD at lower doses on hepatocyte plasma membrane ATPase activity. Liver surface membranes (**LSM**) isolated from male **Holtzman** rats 2, 10, 20 or 40 days after intubation **with** 2,3,7,8-TCDD at 0.0, 10 or 25  $\mu\text{g}/\text{kg}$  were used for determination of  $\text{Na}^+$ ,  $\text{K}^+$ -ATPase and  $\text{Mg}^{++}$ -ATPase activity. The activity of  $\text{Na}^+$ ,  $\text{K}^+$ -ATPase was depressed to the same extent for both doses of 2,3,7,8-TCDD from day 2-40 after treatment, while a **similar** depression of the  $\text{Mg}^{++}$ -ATPase activity was observed **only** in the **high** dose group. In the low dose group, there was a decrease in  $\text{Mg}^{++}$ -ATPase at 20 days, but recovery to normal levels occurred by 40 days post-treatment. It was demonstrated that the effect of 2,3,7,8-TCDD on ATPase activity was not the result of 2,3,7,8-TCDD induced food deprivation and in vitro studies indicated that the loss of activity was not due to the direct interference of

**2,3,7,8-TCDD** with the enzyme. Quantitative changes (both Increases and decreases) have been reported for the protein composition of plasma membranes Isolated and analyzed by **electrophoresis** from **Sprague-Dawley** rats 10 days after an **i.p.** Injection of **2,3,7,8-TCDD**, Indicating that exposure was actually affecting membrane components (Brewster et **al.**, 1982).

Peterson et al. (1979a) observed a positive correlation between the levels of **LSM** ATPase activity and both in **vivo** cumulative biliary excretion of **ouabain** and **bile** flow ( **$\mu\text{l}/\text{min}/\text{g}$  liver**). Using perfused liver, however, Peterson et al. (1979b) reported a segregation between LSM ATPase activity and biliary excretion of ouabain when 2,3,7,8-TCDD rats were exposed to the protective agents **pregnenolone-16 $\alpha$ -carbonitrile** or **spireno lactone**. It was concluded that LSM ATPase **did** not directly participate **in** ouabain transport.

Additional studies have described the effect of 2,3,7,8-TCDD on the biliary excretion of a variety of **xenobiotics**. Early studies by Hwang (1973) Investigated 2,3,7,8-TCDD Inhibition of biliary excretion **in** male CD rats given a single dose of 2,3,7,8-TCDD at 25 or 5 yg/kg by gavage. Animals were examined for Indocyanine green (ICG) excretion 1, 7 and 16 days after treatment. **Unlike** Peterson et al. (1979a), Hwang (1973) observed an Inverse relationship between 2,3,7,8-TCDD exposure and **bile** flow, **with** maximum **bile** flow observed **in** the 25 yg/kg dose group at 16 days. Even **with this** Increased **bile** flow, however, the cumulative biliary excretion of ICG was decreased **in** a dose-dependent manner **with** the greatest depression observed 7 and 16 days after the exposure to 2,3,7,8-TCDD. The levels of ICG **in** the plasma and liver was higher **in** treated animals than **in** control animals, while the concentration **in** the **bile** was lower, reflecting the decrease **in** total excretion of ICG.



Yang and Peterson (1977) compared the effect of **2,3,7,8-TCDD** on the biliary excretion of the organic **neutral compound, ouabain**, with that of the organic **anions phenol-3,6-dibromophthalein (DBSP)** and **sulfobromophthalein (BSP)** in male **Holtzman** rats. Animals were **intubated with 2,3,7,8-TCDD** at doses of 10 or 25 **µg/kg** and excretion was evaluated periodically between 2 and 4 days postexposure. The biliary excretion of ouabain was depressed in a dose-related manner starting on the second day post-treatment, **with** maximum depression developing between 10 and 20 days, and some recovery observed by day 40. Decreases in **bile flow** followed a pattern similar to that observed for ouabain. The pattern of biliary excretion was different for DBSP and BSP in which only a transient small decrease was observed 10 days after exposure in the high-dose group. In the low-dose animals there was actually an increase at days 10 and 25 in the excretion of the anions. The results obtained for DBSP and BSP differ sharply from those for the organic neutral ouabain or those reported by Hwang (1973) for the organic **anion ICG**, in which a dose-related decrease in biliary excretion was observed. The authors concluded that the effects of 2,3,7,8-TCDD on the **multiple** pathways involved in biliary excretion depend on the specific compound being studied.

In the guinea **pig** and rhesus monkey, which develop little liver pathology after exposure to 2,3,7,8-TCDD, there was also **little** change in ICG blood clearance rates; in the rabbit, which develops **2,3,7,8-TCDD-induced** liver damage similar to the rat, there was reduced blood clearance of ICG (Seefeld et al., 1979, 1980). In the rabbit, there were increases in serum **sorbitol** dehydrogenase and **glutamic pyruvic transaminase** activity as further indications of **2,3,7,8-TCDD-produced** liver damage. In the monkey, which received 2,3,7,8-TCDD by gavage at doses of 5, 25 or 75 **µg/kg**, there was an initial slight increase in the **blood** clearance of ICG at 2 days post-

treatment, followed in the two higher-dose groups by a dramatic decrease a few days before death. Although some serum enzymes (**sorbitol dehydrogenase** and **glutamic pyruvic transaminase**) Indicative of liver damage were elevated, the **histopathology** of the **liver** was within **normal** limits. It appears that **major** effects on biliary excretion occur only in species that are sensitive to the **hepatotoxic** effects of **2,3,7,8-TCDD**.

Other gross signs of the hepatotoxic effects of 2,3,7,8-TCDD observed in some species included fatty degeneration and **porphyria**. **Early** observations by Cunningham and Williams (1972) described a decrease in **in vivo** (1 hour pulse) Incorporation of **<sup>3</sup>H** sodium acetate **into** liver **lipids** after exposure of male **Wistar** rats to 2,3,7,8-TCDD. The rats (**12-16** animals) were treated **with** 2,3,7,8-TCDD at a dose of 10 **µg/kg** followed in either 3 or 7 days by the assessment of **lipid** synthesis. At 3 days Incorporation decreased from 258 to 98 dpm/mg **lipid** in the control and treated animals, respectively. There was an approximately similar decrease observed 7 days postexposure. When individual classes of lipids were examined, there was a decrease in the synthesis of **triglycerides**, **diglycerides** and **phospholipids**. Although Cunningham and Williams (1972) observed that 2,3,7,8-TCDD decreased **lipid** synthesis, **Albro et al.** (1978) reported an increase in total lipids in the livers of rats 13 days after treatment **with** 2,3,7,8-TCDD at a **lethal** dose of 50 **µg/kg**. For individual classes of lipids there was an increase in free fatty acids and cholesterol esters; no change occurred in the content of phospholipids, free cholesterol or triglycerides. The fatty changes in the **liver** were confirmed by **ultrastructural** examination of liver specimens. At a sublethal dose of 10 **µg/kg** there was a different pattern of **lipid** accumulation; triglycerides and fatty acids increased and **cholesterol** esters decreased. The changes in the **lipid** profile of the **liver** was attributed to

**2,3,7,8-TCDD** Induced mobilization of body fat, a decrease **in lysosomal** **lipase** (**74%** decline in **this** enzyme 10 days after a 50 yg/kg dose of 2,3,7,8-TCDD) and an Increase **in lipid peroxidation** as Indicated by a sharp Increase in the production of **lipofuscin** pigments.

**Porphyria** was **initially** characterized quantitatively in **mice** by Goldstein et al. (1978). **Groups** of 12 male C57B1 **mice** received 4 weekly Intubations of 2,3,7,8-TCDD at doses of 0.0, 1, 5 or 25 **µg/kg**, or a single dose of 150 yg/kg followed 21-25 days after treatment by analysis of the **liver** for **porphyrins**. **Porphyrin** levels were unchanged except in the 25 and 150 yg/kg groups where the levels were Increased 2000- and 4000-fold, **respectively**. The difference in responsiveness to the development of **porphyria** was studied by Smith et al. (1981) in C57B1 **mice** that were sensitive to, and DBA/2 **mice** that were Insensitive to, the **toxicity** of 2,3,7,8-TCDD. **Male** and female C57B1 **mice** had a dose-related Increase in hepatic porphyrins **in** the two **high** dose groups 3 weeks after a single exposure to 2,3,7,8-TCDD at 0.0, 5, 15, 50 or 75 **µg/kg**; however, only minimal nondose-related changes in hepatic **porphyrin** were observed in DBA/2 **mice** exposed to up to 1200 yg/kg. In the sensitive C57B1 **mice** there was only a small difference **in** hepatic **porphyrin** between the sexes even though males were >3 times as sensitive to the toxic effects of 2,3,7,8-TCDD than females (see Table 8-1). Results similar to those above were reported for urinary porphyrin levels in male C57B1 and DBA/2 **mice** given 6 weekly doses of 2,3,7,8-TCDD at 25 yg/kg (Jones and Sweeney, 1980). In the sensitive strain, the Initial elevation of porphyrin occurred in the second week.

In rats Increased urinary porphyrin was observed only after **subchronic** exposure to **2,3,7,8-TCDD** (Cantoni et al., 1981). Female CD rats were

administered weekly oral doses of **2,3,7,8-TCDD** at levels of 0.01, 0.1 and 1.0  $\mu\text{g}/\text{kg}$  for 45 weeks. The Initial Increase was observed in the high-dose group at 3 **months**, and in the other two groups at 4 months, after the start of exposure. Not only **did** the **absolute** amount of **porphyrin** Increase, but the relative distribution also changed to compounds containing more carboxyl groups. Only in the **high** dose group **did** the livers, at the terminal necropsy, show signs of excess porphyrin under examination by UV light.

In attempts to understand the mechanism of **2,3,7,8-TCDD** Induced **porphyria**, the effects of 2,3,7,8-TCDD on the enzymes involved in the synthesis and **catabolism** of porphyrin have been studied. Goldstein et al. (1978) showed that  **$\delta$ -aminolevulinic** acid synthetase, a rate-limiting enzyme in porphyrin synthesis, was **slightly** increased (2-fold) in male C57B1 mice given 4 weekly doses of 2,3,7,8-TCDD at 25  $\mu\text{g}/\text{kg}$ . **This** dose of 2,3,7,8-TCDD increased liver porphyrin **levels** 2000-fold. Catabolism of porphyrin by uroporphyrinogen decarboxylase (**UD**) **also** appeared to be decreased in 2,3,7,8-TCDD treated **mice**. Smith et al. (1981) reported a decrease in UD activity from ~25 to 7 n **moles/hr/g** liver in male and female C57B1 **mice** 3 weeks after a single oral exposure to 2,3,7,8-TCDD at a dose of 75  $\mu\text{g}/\text{kg}$ . No effect of 2,3,7,8-TCDD on UD activity was observed in DBA/2 **mice** that were insensitive to the induction of **porphyria**. A **time** course of changes in UD activity **with** length of **time** after exposure to 2,3,7,8-TCDD indicated a steady decline in activity starting 3 days after exposure to 2,3,7,8-TCDD, which continued until day 21 when the study was terminated. Sweeney and Jones (1978) reported similar results after 5 weekly doses of 2,3,7,8-TCDD at 25  $\mu\text{g}/\text{kg}$ . In **this** study the UD activity declined **~48%** in C57B1 **mice**

and **only** 4% in DBA/2 mice. Other factors besides the Increase in  **$\delta$ -amino-levulinic acid synthetase** and the decrease in **UD** activity may also participate in the dramatic Increase in **liver porphyrin** in mice associated with exposure to near lethal doses of **2,3,7,8-TCDD**.

As a result of the protracted **time** observed between exposure to **2,3,7,8-TCDD** and the development of toxic effects, as well as the reported **teratogenic** and carcinogenic potential of **2,3,7,8-TCDD**, Investigations have been conducted to determine the **influence** of 2,3,7,8-TCDD on DNA synthesis in the liver. **Greig et al. (1974)** measured the **in vivo** Incorporation of  **$^3\text{H}$ -thymidine** (1 hour pulse) **into liver** DNA of male and female Porten strain rats after a single exposure to 2,3,7,8-TCDD at doses of 10 and 200  **$\mu\text{g}/\text{kg}$** . When the 2,3,7,8-TCDD was given either 0, 24 or 72 hours before a **3/4 partial hepatectomy** there was **only** a **slight**, but not significant, decrease in **thymidine** Incorporation observed when DNA synthesis was measured 24 hours after the operation.

Although 2,3,7,8-TCDD had no effect on **in vivo** DNA synthesis, similar studies by Conway and Matsumura (1975) and Dickens et al. (1981) demonstrated an Increase in thymidine Incorporation when determined in vitro. Conway and Matsumura (1975) administered male Sprague-Dawley rats 2,3,7,8-TCDD at a dose of 5  **$\mu\text{g}/\text{kg}$**  followed in 10 days by removal of the liver and the **in vitro** determination of DNA synthesis in liver slices. Incorporation of thymidine **into** the nuclei Increased from 29 **cpm/mg** in control animals to 45 cpm/mg in treated animals. A similar near doubling of DNA synthesis was observed by Dickens et al. (1981); however, when DNA synthesis was stimulated by a 1/3 partial hepatectomy, thymidine Incorporation **into** liver slices was Increased 10-fold in rats treated 5 days earlier **with** 2,3,7,8-TCDD as compared **with hepatectomized** controls. The onset of DNA synthesis

after partial **hepatectomy** (~20 hours) was the same **in** both **2,3,7,8-TCDD** treated and control animals; however, the treated animals had a more rapid and extensive Increase in DNA synthesis between 20 and 32 hours after the partial hepatectomy. The rates of DNA synthesis were again the same **in** both groups 35 hours after the operation. It was shown by hydroxyurea Inhibition that the DNA synthesis in both the treated and control animals was predominantly **semiconservative**. Further studies are needed to determine the reason for the difference observed between **in vitro** and **in vivo** measurements of DNA synthesis in the liver after exposure to 2,3,7,8-TCDD.

Extensive hepatic necrosis **in** the rabbit may be **responsible** for death **in this** species (Poland and Knutson, 1982).

**Besides** the effects on the liver of 2,3,7,8-TCDD exposure described above, it **is** known that 2,3,7,8-TCDD is a potent **inducer** of **microsomal** enzymes. These studies **will** be discussed in Section **8.1.1.5.**, which describes the ability of **this xenobiotic** to Induce microsomal enzymes in a number of tissues and organs.

8.1.1.3. **EFFECTS ON OTHER ORGAN SYSTEMS** -- The most noticeable feature of 2,3,7,8-TCDD **toxicity** is the loss of body weight and the apparent "wasting away" until death. Since decreased food consumption may not totally account for these findings, the effect of 2,3,7,8-TCDD on Intestinal absorption has been studied. **Madge** (1977) assessed the ability of the Intestine to absorb **D-glucose, D-galactose, L-arginine** and **L-histidine** using the everted Intestinal sac technique **in CD-1 mice** exposed to **2,3,7,8-TCDD**. In measurements made 7 days after treatment **with** doses of 0.0, 10, 25, 75, 150, 200 or 300 **µg/kg, D-glucose** was absorbed to a lesser degree at all doses than in control animals. The two low doses produced a dose-related decrease in absorption; however, at doses of **≥75 µg/kg** the decrease was

uniform. At a dose of 150 yg/kg, decreased absorption of **D-glucose** was slight 3 days after **treatment**, became maximally decreased by 7 days, and **this** depressed level was maintained for 28 days, at which **time** the study was terminated. Providing **D-mannose** to the Incubation mixture as an energy supply increased the absorption of D-glucose to control levels; however, the amount of D-glucose on the serosal **side** was still lower than control levels. **This** suggested that Intestinal utilization of D-glucose was taking place and might account for some of the observed **malabsorption**. Treatment **with 2,3,7,8-TCDD** had no effect on the absorption of the other compounds Investigated. In a similar experiment in Sprague-Dawley rats, Ball and Chhabra (1981) also observed malabsorption of D-glucose. In **this** study, however, absorption of **leucine** was also decreased. The decrease in **leucine** absorption took longer to manifest itself; a significant decrease was observed only after 2 weeks treatment **with 2,3,7,8-TCDD**.

In contrast to the results observed for D-glucose, Intestinal **iron** transport was shown to be elevated by exposure to 2,3,7,8-TCDD. **Manis** and Klm (1979a) examined the effect of prior treatment of male Sprague-Dawley rats on the 30-minute transport of **<sup>59</sup>Fe** out of a duodenal loop created by **ligating** a section of the Intestine **in situ**. At single 2,3,7,8-TCDD doses of between 22 and 84 yg/kg there was increased **serosal** transfer of **<sup>59</sup>Fe** measured 48 hours after treatment. At doses >42 yg/kg the increase was **~100%**. The **time** after treatment at which serosal transfer was greatest was 1 day, **with** rapid decline in stimulation to near the levels of controls observed on days 2-7. There was also an apparent effect of route of administration, **with** gavage treatment being more effective in inducing **iron** transport than **i.p.** Injection. In similar experiments calcium transport was decreased, and galactose and **proline** transport were unaffected by prior

exposure to 2,3,7,8-TCDD. **Manis** and **Kim** (1979b) had Identical results when the everted Intestinal sac was used to assess **iron** transport. It was Interesting to note that only duodenal sacs were stimulated, **with** no effect of 2,3,7,8-TCDD exposure observed in the adjacent distal segment of the Intestine. Increased **iron** transport was also observed by **Manis** and **Kim** (1979a) in an unidentified strain of **mice**. Increased **iron** transport may be one of the **earliest** effects of 2,3,7,8-TCDD; however, at present the **toxicologic** relevance of **this** transient disturbance **in iron** transport is unknown.

One of the common gross observations of 2,3,7,8-TCDD **toxicity** is severe edema, suggestive of a breakdown in salt and water **homeostasis**. These observations prompted Investigations to determine the effect of 2,3,7,8-TCDD on the function of the kidney. Pegg et al. (1976) measured renal function in vitro using renal cortical slices obtained from male Sprague-Dawley rats 3 and 7 days after Intubation **with** 2,3,7,8-TCDD at doses of 10 or 25  $\mu\text{g}/\text{kg}$ . (These results were also described by Hook et al., 1977). **Anion** and cation transport were measured by the respective accumulation of **p-aminohippuric** acid and N-methylnicotinamide **into** the cortical slices. Anion accumulation was lower in the **high** dose group; cation transport was lower at both dose levels tested. The decrease in **anion** transport was confirmed in an **in vivo** study. **Ammonio**genesis and **gluconeogenesis** were not affected in 2,3,7,8-TCDD treated rats, even when the animals were made **acidotic**, which suggests no effect on the **kidneys'** ability to maintain acid base balance. Also, sodium **reabsorption** was shown **in vivo** to be within normal range. Since decreases in cation and anion transport were the only effects observed, and since these compounds are transported by a different mechanism, the authors concluded that the effect of 2,3,7,8-TCDD was merely



a general decrease in kidney function reflecting the poor condition of the treated animals (animals in all treated groups had decreased weight **gain**), and not a cause of debilitation.

Although kidney function was only minimally affected by exposure to 2,3,7,8-TCDD, **Greig et al.** (1974) demonstrated that pre-exposure to 2,3,7,8-TCDD could reduce the ability of the rat kidney to respond to stimuli of DNA **synthesis**. Folate-stimulated DNA synthesis measured **in vivo** in Porten strain rats was decreased between 67 and **25%** in animals receiving 2,3,7,8-TCDD at a dose of 10 **µg/kg** on day 0-9 before administration of **follic** acid. No significant difference **in** folate-stimulated DNA synthesis was observed if 2,3,7,8-TCDD was given 23 hours after follic acid. The lack of effectiveness of administering 2,3,7,8-TCDD shortly after treatment **with** follic acid suggested that 2,3,7,8-TCDD **did** not directly interact **with cellular** DNA, nor inhibit the protein synthesis necessary to support folate-stimulated DNA synthesis. Similar inhibitory effects of 2,3,7,8-TCDD were observed when lead acetate was used to stimulate kidney DNA synthesis. The mechanism by which 2,3,7,8-TCDD prevents the kidney from responding to **proliferative** stimuli is not known, although it was demonstrated that another agent capable of inducing **microsomal** enzymes, 3-methylcholanthrene (**3-MC**), had **similar** effects on the kidney.

Additionally a number of **hematologic** and clinical chemistry changes have been observed **in** the blood of laboratory animals after exposure to 2,3,7,8-TCDD. Many of these changes, as described by Zinkl et **al.** (1973), **reflect** damage to previously described organ systems. In female CD rats given 30 daily doses of 2,3,7,8-TCDD at **levels** of 0.1, 1.0 or 10 **µg/kg**, the clinical chemistry of the serum reflected **liver** damage. In the high-dose group, serum GOT and serum GPT were **elevated** starting 13-17 days after initial

treatment. There was a marginal change in GPT in the mid-dose group and lactic dehydrogenase (LDH) in the high-dose group, but the increases were only transitory. Serum cholesterol was increased in the high-dose animals starting at day 10, with a transitory increase again observed in the mid-dose group. Conversely, there was a decrease in serum protein from day 24 on in the high-dose animals. Along with these clinical chemistry changes indicative of liver damage, the only other major effect observed in the blood was **thrombocytopenia**. The decrease in **platelet** count was detected early, by day 3, in the 10 and 1  $\mu\text{g}/\text{kg}$  groups; in the 0.1  $\mu\text{g}/\text{kg}$  group a significant decrease was not observed until day 17. Thrombocytopenia was also observed in female guinea pigs after 8 weekly oral doses of 2,3,7,8-TCDD at 0.2  $\mu\text{g}/\text{kg}$ , and in mice (administered a single dose of 1.0, 10 or 50  $\mu\text{g}/\text{kg}$ ). In guinea pigs **lymphopenia** was also observed. Other hematologic changes were attributed to **hemoconcentration**.

In a more extensive investigation of 2,3,7,8-TCDD-induced **hyperlipidemia** in male Sprague-Dawley rats, Poli et al. (1980) treated animals with a single **i.p. injection** of 2,3,7,8-TCDD at 2 doses of 2.5, 5, 10 and 20  $\mu\text{g}/\text{kg}$ . At day 21 after treatment there was a dose-related increase in total plasma cholesterol and **high density lipoprotein** cholesterol, while no change was observed in **triglycerides** or very low and **low density lipoproteins** (VLDL and LDL, **respectively**). At a dose of 20  $\mu\text{g}/\text{kg}$  the maximum increase in HDL cholesterol and total cholesterol occurred 30 days after treatment, and a significant elevation was still present at 60 days after treatment when the study was terminated. Slight changes in the **apoprotein** of HDL from 2,3,7,8-TCDD rats and control rats were indicative of new apoprotein synthesis. Although the increases in HDL cholesterol may be in response to eliminating excess **lipids**, the exact function has not been

clearly shown. There is some evidence from studies of workers exposed to **2,3,7,8-TCDD** that there were reduced **levels** of blood HDL **cholesterol** and raised total cholesterol as compared **with** a matched control group (Walker and Martin, 1979).

In contrast to rats, male Hartley strain guinea **pigs** given a single **i.p.** Injection of **2,3,7,8-TCDD** at a dose of 2  $\mu\text{g}/\text{kg}$  had increased **hyperlipidemia** characterized by increases in VLDL and LDL (Swift et al., 1981). In **animals** sacrificed 7 days after exposure to 2,3,7,8-TCDD, there was an increase in **total** serum **lipid, cholesterol** esters, **triglycerides** and **phospholipids**, when comparison was made **with** pair-fed, weight-paired or **ad libitum** fed control groups. Serum-free fatty acids were not changed quantitatively; however, some **qualitative** changes occurred, reflecting an increase in the types of fatty acids that were abundant in the adipose tissue of guinea **pigs**. **Analysis** of **lipoproteins** revealed a 19-fold increase in VLDL, a 4-fold increase in LDL, and no change observed **in** the **levels** of HDL. The VLDL was also qualitatively different in the 2,3,7,8-TCDD treated animals, containing **less cholesterol** ester and an **altered C apoprotein**. The importance of these qualitative changes is unclear. The hyperlipidemia may result from the 2,3,7,8-TCDD mobilization of free fatty acids, which are then used **in** the synthesis of VLDL and are subsequently formed **into** LDL. The relationship of the changes **in** serum **lipid** levels to the mechanism of 2,3,7,8-TCDD **toxicity** needs further study.

Elovaara et al. (1977) observed some changes in **biochemicals** of the brain of male **Wistar** and heterozygous Gunn rats given a single intubation of 2,3,7,8-TCDD at a dose of 20  $\mu\text{g}/\text{kg}$ . At 7 days post-treatment, there was a small but significant decrease as compared **with** vehicle treated control animals in both the protein and RNA content of the Wistar rats, while levels

of add **proteinase** and **DT-diaphorase** (an enzyme Induced by **2,3,7,8-TCDD** in the **liver**) had a **small** but significant Increase in the heterozygous Gunn rats. There were no significant changes observed in **homozygous** rats given **2,3,7,8-TCDD** at 20  $\mu\text{g}/\text{kg}$ . The authors noted that add protelnase may participate in chemically Induced degeneration of the brain.

8.1.1.4. **IMMUNOLOGICAL EFFECTS** -- During acute **toxicity** studies with **2,3,7,8-TCDD**, **thymic** atrophy was noted as a consistent effect in all species that have been Investigated. This finding suggested that 2,3,7,8-TCDD may alter the Immune response, and Initiated **immunotoxicity** studies in exposed animals. In guinea **pigs** treated with 8 weekly oral doses of 2,3,7,8-TCDD (0, 0.008, 0.04, 0.2 or 1.0  $\mu\text{g}/\text{kg}$  bw), body weight, spleen weight and thymus weight were depressed, adrenal weight was Increased and leukocyte and lymphocyte counts were elevated (Vos et al., 1973). Upon **histological** examination, **2,3,7,8-TCDD-exposed** rats had a severe depletion of lymphocytes from the thymic cortex (Vos and Moore, 1974). **Hematological** changes were noted in rats exposed to 10 and 14 daily doses of 10  $\mu\text{g}/\text{kg}$  2,3,7,8-TCDD (Weissberg and Zinkl, 1973). Increased red blood cell count, decreased platelet count, Increased **neutrophil** count and Increased packed cell volumes were reported in 2,3,7,8-TCDD-exposed rats. A summary of the data available on the **immunotoxic** effects of 2,3,7,8-TCDD in animals is presented in Table 8-4. A review of **immunotoxicity** and Immunosuppression was reported by Vos (1977).

Vos et al. (1973) Investigated the humoral and cell-mediated Immune response in Hartley guinea **pigs**, CD rats and B6D2F1 **mice**. The humoral Immune response was tested in 2,3,7,8-TCDD-treated hamsters by **injecting** tetanus **toxoid (subcutaneously)** into the footpad and later testing for the concentration of tetanus antitoxin from the serum by an **immunodiffusion**

TABLE 8-4

## Immunological Effects of 2,3,7,8-TCDD In Animals

| Species/<br>Strain     | Sex | Exposure Route                         | Dose(s)  | Duration of Exposure  | Minimum<br>Effective Dose   | Parameter  | Effect   | Reference                                   |
|------------------------|-----|--|--|---|---|--|--|---|
| Mice/B6D2F1            | N   | gavage                                 | 0. 0.2. 1.0. 5.0.<br>25.0 $\mu\text{g}/\text{kg}$ bw/week  | 4 weeks   | NA<br>S.0 $\mu\text{g}/\text{kg}$ bw/week<br>S.0 $\text{tig}/\text{kg}$ bw/week                                   | <b>bw</b><br><b>thymus</b> weight<br>graft-versus-<br>host response  | no change<br>decreased<br>decreased                                      | Vos et al.,<br>1973                         |
| Mice/C57Bl/6           | f.N | Maternally<br>administered<br>(gavage) | 0. 1.0. 2.0. S.0.<br>25.0 $\text{tig}/\text{kg}$           | 4 or 6 weeks (3 or 5<br>administrations)                    | 1.0 $\mu\text{g}/\text{kg}$ bw/week<br>25.0 $\text{tig}/\text{kg}$ bw/week<br>2.0 $\mu\text{g}/\text{kg}$ bw/week | thymus weight<br>PHA response<br><b>skin</b> graft<br>rejection  | decreased<br>decreased<br>prolonged                                      | Vos and<br>Moore, 1974                      |
| Mice/<br>C57Bl/6Jfh    | N   | gavage                                 | 0. 0.5. 1. 5. 10.<br>20 $\mu\text{g}/\text{kg}$ bw/week    | 4 weeks   | 1.0 $\text{tig}/\text{kg}$ bw/week  | <b>Salmonella</b><br><b>Infection</b>  | Increased<br>mortality<br>and<br>decreased<br><b>time</b> to<br>death    | <b>Thigpen</b><br>et al., 1975              |
| Mice/Swiss             | N   | gavage                                 | 0. 1.5. 5. 15.<br>50 $\text{pg}/\text{kg}$ bw/week         | 4 weeks   | 1.5 $\mu\text{g}/\text{kg}$ bw/week   | <b>endotoxin (E. coli)</b><br>susceptibility   | Increased<br>mortality   | Vos et al.,<br>197Ba                        |
| Mice/B6C3F1            | F   | <b>in vitro</b><br>(spleen cells)      | 0.S. S.0. 50 $\text{ng}/\text{ml}$                         | 5-60 seconds  | 50 $\text{ng}/\text{ml}$  | protein. <b>DNA</b> , and<br><b>RNA</b> synthesis  | decreased  | Luster et al.,<br>1979a.b                   |
| Mice/Swiss-<br>Webster | f.N | Maternally<br>administered<br>(diet)   | 0. 1. 2.5. 5. 10.<br>20 $\text{ppb}$ (dietary)             | 10 weeks (pregestation<br>and 3 weeks post-<br>parturition) | 2.5 $\text{ppb}$<br>2.5 $\text{ppb}$<br>5 $\text{ppb}$<br>1 $\text{ppb}$<br>NA                                    | <b>antigenic</b> RBC<br>reaction<br>thyMlc cortex<br>contact sensitivity<br>to <b>DWFB</b><br><b>endotoxin</b><br>( <b>Salmonella</b> )<br>susceptibility<br><b>Listeria</b> Infection | decreased<br>atrophy<br>decreased<br>Increased<br>mortality<br>no change | <b>Thomas</b> and<br><b>Hinsdill</b> , 1979 |
| Mice/CD                | N   | gavage                                 | 0. 0.01. 0.1. 1.0.<br>10.0 $\mu\text{g}/\text{kg}$ bw/week | up to B weeks   | 0.01 $\mu\text{g}/\text{kg}$ bw/week<br>1.0 $\mu\text{g}/\text{kg}$ bw/week                                       | serum <b>immunoglobulin</b><br>level<br>serum <b>immunoglobulin</b><br>level   | Increased<br><b>decreased</b>  | <b>Sharma</b> and<br><b>Gehring</b> , 1979  |
| Mice/CD                | M   | <b>in vitro</b>                        | $10^{-4}$ - $10^{-9}$ M                                    | single  | $10^{-6}$ M   | <b>lymphocyte</b> blasto-<br>genic transforma-<br>tion   | Increased  | <b>Sharma</b> and<br><b>Gehring</b> , 1979  |

TABLE 8-4 (cont.)

| Species/<br>Strain     | Sex | Exposure Route          | Dose(s)                                   | Duration of Exposure                  | Minimum<br>Effective Dose                                  | Parameter   | Effect                              | Reference                    |
|------------------------|-----|-------------------------|---|---------------------------------------|--|---|-------------------------------------|------------------------------|
| Mice/Swiss-<br>Webster | F   | oral (diet)             | 0. 10. 100 ppb                            | 5 weeks (or more)                     | 10 ppb   | tetanus response  | decreased                           | Hinsdill,<br>et al., 1980    |
|                        |     |                         |   |                                       | 10 ppb   | antigenic RBC response                                  | decreased                           |                              |
|                        |     |                         |   |                                       | 10 ppb   | sensitization to DNFb                                   | decreased                           |                              |
|                        |     |                         |   |                                       | 10 ppb   | resistance to <u>Salmonella</u>                         | Increased mortality                 |                              |
|                        |     |                         |   |                                       | 10 ppb   | resistance to <u>Listeria</u>                           | Increased mortality                 |                              |
| Mice/<br>C57B1/6J      | M   | i.p.                    | 0, 1. 2. 6.<br>30 vg/kg bw                | single Injection                      | 1 $\mu$ g/kg   | macrophage and natural killer cell activity             | no change                           | Mantovani<br>et al., 1980    |
|                        |     |                         |   |                                       | 1 vg/kg  | macrophage and natural killer cell number               | decreased                           |                              |
|                        |     |                         |   |                                       |  | antibody production                                     | decreased                           |                              |
| Mice/B6C3F1            | M.F | maternally administered | 0. 1.0. 5.0,<br>15.0 vg/kg bw/day         | 4 days during gestation and lactation | 1.0 vg/kg bw/day   | <u>L. monocytogenes</u> susceptibility                  | Increased                           | Luster et al.,<br>1980       |
|                        |     |                         |   |                                       | 1.0 vg/kg bw/day   | PYB6-tumor susceptibility                               | Increased                           |                              |
|                        |     |                         |   |                                       | 5.0 vg/kg bw/day   | bone marrow <u>hypo-cellularity</u>                     | Increased                           |                              |
| Mice/C57B1/6           | M   | i.p.                    | 0, 0.4. 4.0.<br>40 vg/kg bw/week          | 4 weeks                               | 4.0 $\mu$ g/kg bw/week<br>0.4 vg/kg bw/week                | thymus atrophy<br>cytotoxic T-cell response             | Increased<br>decreased              | Clark et al.,<br>1981        |
| Mice/C57B1/6           | M   | i.p.                    | 0. 0.004. 0.04.<br>0.4 $\mu$ g/kg bw/week | 4 weeks                               | 0.004 $\mu$ g/kg bw/week                                   | <u>in vitro</u> generation of cytotoxic T-cells         | decreased                           | Clark et al.,<br>1981        |
| Rat/CD                 | F   | oral                    | 0. 0.2, 1.0.<br>5.0 vg/kg bw/week         | 6 weeks                               | 5.0 vg/kg bw/week<br>5.0 vg/kg bw/week<br>NA               | bw<br>thymusweight<br>tuberculin hyper-sensitivity      | decreased<br>decreased<br>no change | Vos et al.,<br>1973          |
| Rat/CD                 | F   | oral                    | 0. 10 vg/kg bw/day                        | 10. 14 days                           | 10 $\mu$ g/kg bw/day<br>10 vg/kg bw/day<br>10 vg/kg bw/day | erythrocyte count<br>platelet count<br>neutrophil count | Increased<br>decreased<br>Increased | Weissberg and<br>Zinkl, 1973 |

TABLE 8-4 (cont.)

| Species/<br>Strain                | Sex | Exposure Route                     | Dose(s)  | Duration of Exposure                                      | Minimum<br>Effective Dose            | Parameter  | Effect                         | Reference                 |
|-----------------------------------|-----|------------------------------------|--|---|--------------------------------------|--|--------------------------------|---------------------------|
| Rat/F-344                         | F,M | Maternally<br>administered         | 0. 1.0. S.0 $\mu\text{g}/\text{kg}$<br>bw/dose         | 4 or 6 weeks (3 or 5<br>administrations)                  | 1.0 $\mu\text{g}/\text{kg}$ bw/dose  | bw and thymus<br>weight                            | decreased                      | Vos and<br>Moore, 1974    |
|                                   |     |                                    |  |   | 5.0 $\mu\text{g}/\text{kg}$ bw/dose  | spleen weight                                      | decreased                      |                           |
|                                   |     |                                    |  |   | S.0 $\mu\text{g}/\text{kg}$ bw/dose  | PHA response                                       | decreased                      |                           |
|                                   |     |                                    |  |   | 5.0 $\mu\text{g}/\text{kg}$ bw/dose  | graft-versus-host<br>response                      | decreased                      |                           |
|                                   |     |                                    |  |   | 5.0 $\mu\text{g}/\text{kg}$ bw/dose  | skin graft<br>rejection                            | prolonged                      |                           |
|                                   |     |                                    | NA   | pseudorabies<br>virus infection                           | no change                            |  |                                |                           |
| Rat/Fischer                       | F,M | maternally<br>administered<br>(NR) | NR   | 4-6 weeks (during ges-<br>tation and neonatally)          | NR                                   | Con A and PHA<br>response                          | decreased                      | Moore and<br>Faith, 1976  |
|                                   |     |                                    |  |   | NR                                   | oxazolone skin<br>hypersensitivity                 | decreased                      |                           |
| *<br>30<br>Rat/Fischer-<br>Wistar | F,M | maternally<br>administered<br>(NR) | 0. S $\mu\text{g}/\text{kg}$ bw/dose                   | 3 or 4 applications<br>during gestation and<br>neonatally | 5 $\mu\text{g}/\text{kg}$ bw/dose    | antibody production<br>to bovine gamma<br>globulin | no effect                      | Faith and<br>Luster, 1979 |
|                                   |     |                                    |  |   | 5 $\mu\text{g}/\text{kg}$ bw/dose    | PHA and Con A<br>response                          | decreased                      |                           |
|                                   |     |                                    |  |   | 5 $\mu\text{g}/\text{kg}$ bw/dose    | thymus and bw                                      | decreased<br>until 128<br>days |                           |
| Rat/Sprague-<br>Dawley            | N   | i.v.                               | 0. 1 $\mu\text{g}/\text{kg}$ bw                        | single Injection  | 1 $\mu\text{g}/\text{kg}$ bw         | thymic RNA<br>synthesis                            | decreased                      | Kurl et al.,<br>1982      |
|                                   |     |                                    |  |   |                                      | thymic RNA<br>polymerase<br>activity               | decreased                      |                           |
| Guinea pig/<br>Hartley            | F   | gavage                             | 0. 0.008. 0.04,<br>0.2, 1.0 $\mu\text{g}/\text{kg}$ bw | B weeks   | 0.04 $\mu\text{g}/\text{kg}$ bw/week | bw   | decreased                      | Vos et al.,<br>1973       |
|                                   |     |                                    |  |   | 0.04 $\mu\text{g}/\text{kg}$ bw/week | thymus weight                                      | decreased                      |                           |
|                                   |     |                                    |  |   | 0.04 $\mu\text{g}/\text{kg}$ bw/week | tuberculin hyper-<br>sensitivity                   | decreased                      |                           |
|                                   |     |                                    |  |   | 0.2 $\mu\text{g}/\text{kg}$ bw/week  | tetanus antitoxin                                  | decreased                      |                           |

N = male; F = female; i.p. \* Intrapерitoneal i.v. = Intravenous; PHA = Phytohemagglutinin; Con A = Concanavalin A; RBC = red blood cell; ONFB \* 2,4-dinitro, 1-fluorobenzene; NA = Not applicable; NR = Not reported

technique. Cell-mediated Immunity was tested by **injecting Mycobacterium tuberculosis** (subcutaneously) **into** guinea **pigs** on day 35 of **2,3,7,8-TCDD** treatment (during a schedule of 8 weekly doses). **Intradermal** tuberculin hypersensitivity was determined by measurements of **skin** thickening on days 47 and 54. Decreased **skin** hypersensitivity was noted in hamsters treated **with** 0.04 g **2,3,7,8-TCDD/kg** and higher doses. Decreased tetanus antitoxin levels were evident in guinea **pigs** treated **with** 0.2  $\mu$ g 2,3,7,8-TCDD/kg, but not at lower dose levels. Vos et al. (1973) also tested the cell-mediated Immunity in rats exposed to 2,3,7,8-TCDD (0, 0.2, 1.0 or 5.0  $\mu$ g/kg, once weekly for 6 weeks). **M. tuberculosis** was injected **into** rats by day 28 of the treatment period, followed by Intradermal hypersensitivity testing on day 42. No changes in the thickness of **skin** were noted in 2,3,7,8-TCDD treated rats when compared **with** controls.

**Mice** were used to test the effect of 2,3,7,8-TCDD on cell-mediated Immunity by use of the "graft-versus-host" experiment (Vos et al., 1973). In **this** test, **spleen** cells from **2,3,7,8-TCDD-exposed mice** (0, 0.2, 1.0 or 5.0  $\mu$ g/kg once weekly for 4 weeks) of the C57B1/6 strain were injected **into** the right footpad of a hybrid recipient mouse (C57B1/6 x DBA-2). Donor cells possessing sufficient activity **will** respond to the DBA-2 antigen on the host cells, resulting in the enlargement of the popliteal lymph node. Host cells are tolerant of the donor cells since both have C57B1/6 antigens. In **this** test Vos et al. (1973) noted a significant (**p<0.01**) dose-related decrease in the activity of 2,3,7,8-TCDD-treated spleen cells (as measured by the degree of popliteal lymph node enlargement on the **site** of the spleen cell injection). Lymph node enlargement was significantly less (**p<0.01**) in hybrid recipient **mice** receiving spleen **cells** from **mice** treated **with** 5  $\mu$ g 2,3,7,8-TCDD/kg/week than from donor **cells** of untreated **mice**.



Studies continued in an attempt to identify the mechanism of 2,3,7,8-TCDD-induced immunodeficiency. Rats (**F-344**) exposed pre- and postnatally by maternal dosing (1 or 5 yg **2,3,7,8-TCDD/kg** administered to dams on days 11 and 18 of gestation and 0, 7 and 14 **postnatally**) had prolonged times until graft **rejection**, decreased spleen **cell** graft-versus-host activity and decreased binding response to **phytohemagglutinin** (PHA) (Vos and Moore, 1974; Moore and Vos, 1974). Response to **concanavalin A** (Con A), a humoral immune response, was actually increased.

Since **thymus-derived** lymphocytes (**T-cells**) play a central role in **cell-mediated** immunity and host defense mechanisms, interest turned to these areas of immunology. The effect of **2,3,7,8-TCDD** on host resistance to infection, a vital measure of immune response, was tested by **Thigpen et al.** (1975) in **male** pathogen-free **mice (C57B1/6Jfh)**. 2,3,7,8-TCDD was administered to **mice** at 0.5, 1, 5, 10 or 20 yg/kg once weekly for 4 weeks followed by inoculation with Salmonella bern 2 days after the **final** 2,3,7,8-TCDD administration. Mortality rates and "**time until infection**" were used to determine the **immunological** effect of 2,3,7,8-TCDD. A significant (**p<0.05**) increase in mortality and decrease in **time** of infection were noted in groups treated **with** 1 yg/kg or higher doses of 2,3,7,8-TCDD when compared **with controls**. 2,3,7,8-TCDD at 0.5 yg/kg **did** not alter these parameters and was regarded as a no effect level. The immune-resistance of **mice** to S. bern is therefore reduced by treatment **with** 1 yg **2,3,7,8-TCDD/kg/week** (for 4 weeks).

Pretreatment **with** 2,3,7,8-TCDD greatly enhances the susceptibility of **mice** to E. coli **endotoxin** (Vos et al., 1978a). Injection of 250 yg of **endotoxin** to **mice** pretreated **with** 0, 1.5, 5 and 15 yg 2,3,7,8-TCDD/kg

resulted in 0/5, 1/5, 6/6 and 6/6 deaths, respectively. Mice pretreated with 15 and 50 yg 2,3,7,8-TCDD/kg and injected with 10 yg of endotoxin had 1/4 and 2/4 deaths, respectively. Mice treated with lower doses of 2,3,7,8-TCDD were not susceptible to this quantity of endotoxin. Increased mortality (2/6) in a control group was noted only when 500 yg of endotoxin was administered; however, 10 yg of endotoxin was sufficient to cause similar mortality (2/5) in mice treated with 50 yg 2,3,7,8-TCDD/kg.

The immunocompetence of 5-week-old offspring of Swiss-Webster mice fed diets containing 1, 2.5, 5, 10 or 20 ppb 2,3,7,8-TCDD was tested by several means (Thomas and Hindsall, 1979). The number of cells reactive to antigenic RBC, differential white blood cell counts, organ weights, histopathologies, hypersensitivity to 2,4-dinitro-1-fluorobenzene (DNFB) and the resistance to E. coli lipopolysaccharide (LPS), Listeria monocytogenes and Salmonella typhimurium LPS were all measured for mice exposed to different levels of 2,3,7,8-TCDD. Adult female mice were exposed to 2,3,7,8-TCDD for 4 weeks before mating, throughout gestation and for 3 weeks postparturition. Young mice being tested for immunotoxicity were therefore exposed to 2,3,7,8-TCDD only in utero and through lactation. The typical decrease in thymus weight was noted in mice exposed to 2.5 and 5.0 ppb but was not evident in the 1.0 ppb group. A decrease in the number of plaque-forming cells (PFC) reactive to sheep RBCs was significantly reduced in the 2.5 and 5.0 ppb 2,3,7,8-TCDD-exposed groups. (Because of the poor survival of young in the 10 and 20 ppb 2,3,7,8-TCDD-exposed groups, results and comparisons were usually reported for the three lower dose groups). The humoral content of anti-RBC antibodies, however, was not lower in 2,3,7,8-TCDD-exposed groups when compared with controls. A decrease in the skin hypersensitivity

to DNFB following **sensitization** was noted in **all 2,3,7,8-TCDD-treated** groups (only the 5-ppb group was statistically reduced from controls). 2,3,7,8-TCDD caused an Increased susceptibility (Increased mortality **level**) to **S. typhimurium** in a dose-related fashion. The response to **E. coli** LPS and **L. monocytogenes** was not different from controls. **2,3,7,8-TCDD** exposure **did** not **alter** the response of **lymphocytes** (Band T-cells) in vitro to Con **A**, nor was **mitogen-induced** lymphocyte proliferation affected (Thomas and Hindslll. **1979**).

Similar findings were reported in **Fischer/Wistar** rats exposed to 2,3,7,8-TCDD during gestation (18th day) and neonatally, or neonatally **alone** (on days 0, 7 and 14) (Faith and Luster, 1979). Dams were treated **with** 5 g/kg 2,3,7,8-TCDD on each dose day. Typically, body weight and **thymic** weights were decreased in progeny, which lasted until 135 days of age. The thymic- and splenic-cell response to PHA and Con A was decreased in all 2,3,7,8-TCDD-treated **animals** and **did** not return to normal until day 270. Delayed hypersensitive reaction was also suppressed until 270 days of age. The production of antibodies to bovine gamma globulin, which requires **T-helper** cell function, was not affected by 2,3,7,8-TCDD exposure during rat development (Faith and Luster, **1979**).

Neonatal B6C3F1 **mice**, exposed to prenatal (maternal dosing on day 14 of gestation) and postnatal (days 1, 7 and 14 after birth) doses of 0, 1.0, 5.0 or 15.0 **µg/kg** 2,3,7,8-TCDD, were studied for **immunotoxic** effects and host susceptibility (Luster et al., 1980). At the 15.0 **µg 2,3,7,8-TCDD/kg** dose level, **70%** of the neonates **died with** overt toxic effects (decreased body weight, liver weight, spleen weight and **thymus** weight). Bone marrow hypo-**cellularity** and depressed macrophages-granulocyte progenitor cells and

**pleuripotent stem cells** were associated with **2,3,7,8-TCDD** exposure at the 5.0 and 15.0  $\mu\text{g}/\text{kg}$  dose levels. **Hematological** changes, such as decreased **RBC count, hematocrit** and hemoglobin, and lymphocyte count showed a dose-related response. Host susceptibility to L. monocytogenes and **PYB6-tumor** cells was tested in the 2,3,7,8-TCDD-exposed neonates. Death occurred in 73 and 40% of the L. monocytogenes Inoculated ( $1.2 \times 10^6$  viable organisms) mice in the 5.0 and 1.0  $\mu\text{g}/\text{kg}$  dose groups, respectively, compared with 28% of controls. Tumor development occurred in 44, 60 and 22% of the neonates Inoculated with  $5 \times 10^4$  tumor cells from the 5.0  $\mu\text{g}$  **2,3,7,8-TCDD/kg**, 1.0  $\mu\text{g}$  2,3,7,8-TCDD/kg and control groups, respectively.

Hinsdill et al. (1980) reported that 2,3,7,8-TCDD administered in the **diet** of Swiss-Webster mice at 100 ppb for 5 weeks caused a marked suppression of total serum protein, gamma globulin and albumin, but an increase in  $\gamma$ -globulins. At 10 ppb in the **diet**, 2,3,7,8-TCDD caused decreased immune response to tetanus **toxoid**, sheep RBC, S. typhimurium and L. monocytogenes. and lowered contact sensitivity to DNFB. **This** study also suggested that although young animals are more susceptible to 2,3,7,8-TCDD, older **animals** are still immunosuppressed and exposure in utero and neonatally is not more crucial than in other periods. Vos and Moore (1974) had **previously** reported that **1-month-old mice** were more sensitive to 2,3,7,8-TCDD than were **4-month-old mice** (C57Bl/6). Decreased body weight and **thymus** weight and **spleen cell** response to PHA were evident at **lower** doses in **1-month-old mice** than in **4-month-old mice**.

The effect of single **i.p.** doses of 2,3,7,8-TCDD (**1, 2, 6 and 30  $\mu\text{g}/\text{kg}$** ) on **peritoneal macrophage** and splenic natural killer cell function in mice (C57Bl/6J) was studied by **Mantovani** et al. (1980) and **Vecchi** et al. (1980).

**2,3,7,8-TCDD** treatment at **all** dose **levels** **did** not decrease the **cytostatic** and **cytotoxic** activity of **macrophages** or natural killer cells on a per cell basis. The total number of macrophages and splenic natural killer cells recovered from 2,3,7,8-TCDD-treated animals, however, was reduced when compared **with** untreated controls. Marked **hypocellularity** noted in the bone marrow of 2,3,7,8-TCDD-treated **mice** may account for the decrease in peripheral cell counts (**McConnell et al.**, 1978b). The **lack** of macrophages and natural **killer cells** was suggested as being instrumental in the decreased resistance to infection common to 2,3,7,8-TCDD-exposed animals (**Mantovani et al.**, 1980). Although 2,3,7,8-TCDD was a strong **immunosuppressant**, animals given a lethal dose of 2,3,7,8-TCDD **did** not appear to **die** from infections, nor **did** a germ-free environment protect them from death (**Greig et al.**, 1973).

The actual mechanism of 2,3,7,8-TCDD **immunotoxicity** is unknown but several investigators have tested various hypotheses. Vos et al. (1973, 1978a,b) attempted to address the indirect causes for decreased **thymic** growth and altered **T-lymphocyte** activity following 2,3,7,8-TCDD treatment. Vos et al. (1973) measured serum **cortisol** and **corticosteron** levels in guinea **pigs** exposed to 2,3,7,8-TCDD to evaluate the possible indirect **immunosuppression** by these hormones. There was, however, no significant difference in the level of these hormones between treated and control animals. Indirect **immunosuppression** of **this** type was unlikely. Later studies (Vos et al., 1978a,b) investigated the role of thymic hormones (**thymosin**) on the atrophy of the thymus during 2,3,7,8-TCDD treatment. Thymosin administered in **conjunction with** 2,3,7,8-TCDD **did** not protect **mice** from the typical **2,3,7,8-TCDD-induced immunotoxic** alterations. Thymus weight was maintained but not increased by thymosin, and **thymus-derived cells** continued to show

decreased responsiveness to **mitogens** (PHA, Con A). **Thus, it** is unlikely that **2,3,7,8-TCDD** affects the supply or synthesis of **thymic** hormones which could lead to the observed **immunosuppression**.

van Logten et al. (1980) Investigated the possible Influence of the adrenal **gland**, hypophysis and pituitary, and growth hormone on thymic atrophy and **immunosuppression** following 2,3,7,8-TCDD exposure in female **F-344** rats. **Adrenalectomy** and exogenous growth hormone had no **preventative** action on thymic Involution. **Hypophysectomized** rats showed advanced thymic atrophy.

**Sharma and Gehring (1979)** noted that 2,3,7,8-TCDD caused stimulation of lymphocyte transformation to blast form cells (**mitotically** active precursors) when no mitogens were present in the culture system. **This** represents a phenomenon similar to actual **antigenic** challenge. At low doses (0.01 and 0.1  $\mu\text{g}$  **2,3,7,8-TCDD/kg/week** for up to 8 weeks), serum **immunoglobulin** levels were elevated in **male CD-1 mice**. Larger doses of 2,3,7,8-TCDD (1.0 and 10  $\mu\text{g/kg/week}$ ) **resulted in** a decrease in the serum Immunoglobulin level. It was suggested that 2,3,7,8-TCDD may elicit an antigenic response either by combining **with** a body protein or by causing **cellular** or biochemical damage that releases antigenic proteins. Sharma and **Gehring (1979)** also noted that thymic atrophy was observed after 2 and 4 weeks of treatment but not after 8 weeks. There may be a recovery of thymic tissue, either by Immune tolerance or Immune **unresponsiveness** as a sort of adaptation to **2,3,7,8-TCDD-exposure** and its possible antigenic complex.

Luster et al. (1979a,b) reported that 2,3,7,8-TCDD affects the Immune system directly by altering lymphocyte function. The function of **T-helper** cells was not altered, since no change in response to bovine gamma globulin

(requires **T-helper** cell cooperation) was noted in **Wistar/Fischer** and Fischer rats exposed to 2,3,7,8-TCDD. In vitro. **2,3,7,8-TCDD** (100 **ng/ml**) suppressed **DNA**, RNA and protein synthesis in splenic **lymphoid** cells from B6C3F1 (Luster et al., 1979a). 2,3,7,8-TCDD, however, **did** not decrease the binding of **<sup>3</sup>H-Con A** to lymphocytes, indicating that these receptors are not blocked by 2,3,7,8-TCDD. **T-lymphocytes** were more susceptible to 2,3,7,8-TCDD, measured by specific **mitogen** binding assays, than **B-lymphocytes**. These authors (Luster et al., 1979a) suggested that 2,3,7,8-TCDD may **bind** directly to the **lymphocyte** cell membrane and alter **its** function. Faith and Luster (1979) reported that lymphocytes from the spleen, thymus, bone marrow and lymph nodes of Fischer rats exposed to **2,3,7,8-TCDD** showed abnormal homing patterns within the body. 2,3,7,8-TCDD exposure apparently altered the cell surface markers so that spleen lymphocytes were taken up by the thymus of recipient rats. These authors (Faith and Luster, 1979) suggested that 2,3,7,8-TCDD may change cellular metabolism, which alters the cell membrane constituents or may insert directly **into** the membrane. **Kurl** et al. (1982) reported that 2,3,7,8-TCDD causes changes in **thymic** transcription and RNA synthesis that may lead to cell surface changes. Cell surface changes could presumably result in altered antigen recognition and cell-to-cell recognition, causing immunosuppression and thymic atrophy.

Clark et al. (1981) reported that 2,3,7,8-TCDD treatment (0.4, 4.0, 40 **µg/kg** weekly for 4 weeks by **i.p.** injection) caused functional impairment of **cytotoxic T-cells** in C57B1/6 male **mice**. The authors felt that **this** response was particularly sensitive to 2,3,7,8-TCDD treatment and hypothesized that 2,3,7,8-TCDD directly inhibits the function of these **cells**. Contrary to the hypothesis tested by these authors and that held by Luster

et al. (1979a,b), **2,3,7,8-TCDD** treatment Impaired the generation of **cyto-toxic T-cells** by the spleen (at doses as low as 0.004  $\mu\text{g}/\text{kg}$  when detected **in vitro**) but **did** not appear directly toxic to the **cytotoxic** T-cells. At present, the mechanism of **immunosuppression** caused by 2,3,7,8-TCDD is unknown and the theories available are speculative. In a later study, however, Clark et al. (1983) reported that a 10- to 100-fold greater dose of 2,3,7,8-TCDD was required to suppress cytotoxic T-cells in DBA/2 **mice** as compared **with** C56B1/6 **mice**. **This** Indicates that susceptibility to 2,3,7,8-TCDD **immunotoxicity** segregates **with** the Ah locus, which **is** consistent **with** a receptor mediated mechanism. The receptor mediated mechanism was further supported by the susceptibility of the C57B1/6 x DBA/2J hybrid mouse to 2,3,7,8-TCDD suppression of the cytotoxic T-cells, which is again consistent **with** the dominant Inheritance of Ah (**Nagarkatti et al., 1984**).

Few reports are available in which the **immunological** effects of 2,3,7,8-TCDD exposure were studied in humans. Reggiani (1980) reported that the **immunocapability** of 17 people, ranging in age from 3-60 years, who had been exposed to 2,3,7,8-TCDD, was normal in all cases. In a survey of 41 workers exposed to 2,3,7,8-TCDD, Ward (1982) measured **immunoglobulin G, A, M, D** and E, as well as lymphocytes, T-cells, **B-cells**, PHA response and blood cell counts. These determinations were made 10 years after workers had developed **2,3,7,8-TCDD-induced** chloracne. In **this** group of workers, there was a significant Increase in the proportion of cases **with** reduced **IgD** and **IgM**. It was suggested that the **2,3,7,8-TCDD-exposed** group had a reduced Immune capability and a deficiency **in T-cell** and **B-cell** cooperation. The **immuno-toxicity** of 2,3,7,8-TCDD in humans cannot be properly assessed because of the paucity of data recorded soon after exposure. The most prominent effects in **animals (i.e., humoral responses)** were not measured in humans.



#### 8.1.1.5. ENZYME INDUCTION BY TCDD -

8.1.1.5.1. In Cell Cultures - Although **2,3,7,8-TCDD** has a very low **toxicity** to cells in **culture** (Beatty et al., 1975; Bradlaw et al., 1976; Knutson and Poland, 1980; Yang et al., 1983), it is an extremely potent enzyme **inducer** in these systems (Kouri et al., 1974; Niwa et al., 1975; Bradlaw et al., 1976; Malik and Owens, 1977; Malik et al., 1979; Bradlaw et al., 1980). This enzyme induction is so sensitive that it has been proposed as a **bioassay** for detecting planar **polychlorinated** organic compounds (Bradlaw et al., 1975, Bradlaw and Casterline, 1979; Niwa et al., 1975).

Kouri et al. (1974) found that **2,3,7,8-TCDD** induced aromatic hydrocarbon hydroxylase (AHH) activity in cultured human lymphocytes to the same extent as 3-MC; however, the concentration of 2,3,7,8-TCDD necessary for **maximal** enzyme induction was 40-60 times less than that of 3-MC. Niwa et al. (1975) compared AHH induction by 2,3,7,8-TCDD among cell **cultures** (H-4-II-E, VERO, HTC, LB82, MA, **Hepa-1**, TRL2, ERL-2, **NRKE** and Chang). **ED<sub>50</sub>** values ranged from 0.12 nM in the Hepa-1 cell **line** to **>100** nM in the VERO and HTC **cell** lines. 2,3,7,8-TCDD **did** not induce AHH activity in **LB82** cells. The responsiveness of AHH induction to 2,3,7,8-TCDD was 250-900 times greater than to 3-MC. In addition, cell cultures derived from C57Bl/6N **mice** were **16** times as sensitive to 2,3,7,8-TCDD as cell cultures derived from DBA/2N **mice**. The responsiveness of cell cultures to enzyme induction by 2,3,7,8-TCDD is thus **similar** to the effects seen **in vivo**. The inductive effect of 2,3,7,8-TCDD was **blocked** by **actinomycin D** and **cycloheximide**, implying that induction **involved** the **synthesis** of new mRNA and protein. Enzyme induction by 2,3,7,8-TCDD, therefore, involves an initial RNA synthesis and continuous protein synthesis (Malik and Owens, 1977; Malik et al., 1979).

In **all** of these **studies**, there was no correlation between **cytotoxicity** and enzyme Induction. **This** Implies that, despite the correlation **in vivo** (Section **8.3.5.**), there may be no direct connection between enzyme Induction and the toxicity of **2,3,7,8-TCDD**.

8.1.1.5.2. In **Mice** and Rats – The effects of **2,3,7,8-TCDD** on enzyme activity **in** rats and **mice** have been Investigated **extensively**. **2,3,7,8-TCDD** has been found to alter many enzyme activities in a **wide** variety of organ systems (**vide infra**). **This** alteration primarily results in Increased enzyme activity, although **2,3,7,8-TCDD** has been observed to Inhibit some enzymes.

Hook et al. (1975a) reported that **2,3,7,8-TCDD** suppressed hepatic **microsomal N-demethylation** in male, but not female, rats; however, **cytochrome P-450** and benzpyrene **hydroxylase** activity were Increased. The suppression of **N-demethylase** activity was undetectable for 73 days following a single **oral** dose of 25  $\mu\text{g}$  **2,3,7,8-TCDD/kg** bw. The suppression of N-demethylase activity was seen only **in** adult animals. In **10-day-old** rats, **2,3,7,8-TCDD** had an Inductive effect on **this** activity.

The Inductive effects of **2,3,7,8-TCDD** have been demonstrated to be organ specific. **Aitio** and **Parkki** (1978) Investigated the effects of **2,3,7,8-TCDD** on the activities of **AHH**, **ethoxycoumarin** deethylase, **cytochrome C** reductase, **epoxide** hydratase, **UDP glucuronosyltransferase**, and **glutathione** S-transferase in the liver, kidney, lung, small Intestine and testes of **male Wistar** rats. Monooxygenase activity was **stimulated in** the liver, lung and kidney, but not in any other tissue Investigated. **UDP glucuronosyltransferase** activity Increased by a factor of 7 in the liver, by a factor of <2 in the kidney, and not at all in any other tissue. **Epoxide** hydratase and **glutathione** S-transferase activities were not affected in any of the tissues studied, although stimulation of hepatic **glutathione** S-transferase has been

reported by other Investigators (**Manis** and Apap, 1979). Enzyme Induction has also been reported in rat mammary gland (**Rikans et al.**, 1979), mouse testes (**Mattison and Thorgeirsson**, 1978), and rat prostate gland (Lee and Suzuki, 1980), but the rat **adrenal gland** is apparently insensitive to inductive effects of **2,3,7,8-TCDD** (Guenther et al., 1979b).

In the liver of rats and **mice**, 2,3,7,8-TCDD affects a **wide** range of enzymatic activities, including DT-diphosphorase (Beatty and **Neal**, 1976a,b), **bilirubin catabolism** (**Kapitulnik and Ostrow**, 1978), **ornithine** decarboxylase (Potter et al., 1982), **7-ethoxycoumarin O-demethylase** (Greenlee and Poland, 1978), glutathione S-transferase (Baars et al., 1978; Manis and Apap, 1979), aldehyde dehydrogenase (**Lindahl et al.**, 1978; **Deitrich et al.**, 1977), **uroporphyrinogen** decarboxylase (Jones and Sweeney, 1977),  **$\delta$ -aminolevulinic acid** synthetase (Goldstein et al., 1982a; Woods, 1973), **UDP-glucuronosyl** transferase (**Marselos et al.**, 1978) and a number of **microsomal oxidative** enzyme systems (**vide Infra**).

2,3,7,8-TCDD is four orders of magnitude more potent than **3-MC** as an **inducer** of hepatic AHH activity; **however**, the dose-response curve for the two compounds are parallel and both produce the same maximal response (Poland and Glover, 1974). Simultaneous administrations of maximally inducing doses of both compounds produced no greater response than either alone and both produced a cytochrome **with** a shift in the absorption maximum of the carbon monoxide difference spectrum from 450 to 448 nm. In a number of studies, increased AHH activity and cytochrome P-448 synthesis have been separated (**Chhabra et al.**, 1976); however, other researchers report an apparent connection between cytochrome P-448 and AHH induction (**Kitchin and Woods**, 1977, 1978a,b). Thus, 2,3,7,8-TCDD not only stimulates AHH activity by inducing cytochrome P-450 formation, but may enhance AHH activity by other mechanisms as **well**.

8.1.1.5.3. In Rabbit - The response of the rabbit is quite different from that observed in rats and mice (Hook et al., 1975a). The only changes in hepatic enzyme activities observed were suppression of benzpyrene **hydroxylase** and **benzphetamine N-demethylase**. In the same study, **biophenyl 4-hydroxylase** was induced in the lung and benzpyrene hydroxylase was induced in the kidney. In a similar study, a **hepatotoxic** dose of **2,3,7,8-TCDD** (30 vg/kg) failed to **alter prostaglandin** synthetase activity in hepatic or renal tissue (Kohl and Goldstein, 1981).

In a series of studies, Johnson and **Muller-Eberhard** (1977a,b,c,d), Johnson et al. (1979), Norman et al. (1978a,b), Llem et al. (1980) and Dees et al. (1982) isolated a series of cytochromes P-450 from rabbit liver **microsomes**. These cytochromes were **immunologically** distinct, functioned in different catalytic pathways, and responded differently to induction by **polycyclic** aromatic hydrocarbons. 2,3,7,8-TCDD was found to induce two cytochromes, designated as form 4 and form 6. Form 4 is the **major** cytochrome induced in adult rabbit liver by 2,3,7,8-TCDD; however, form 6 is the **major cytochrome** induced in newborn rabbit liver (Norman et al., 1978b), adult rabbit lung, and adult rabbit kidney (Llem et al., 1980; Dees et al., 1982).

8.1.1.5.4. Other Species - The guinea pig, the species most sensitive to the toxic effects of 2,3,7,8-TCDD, is similar to the rabbit in its response to 2,3,7,8-TCDD. Biophenyl **4-hydroxylase** was induced in the liver, lung and kidney, biophenyl **2-hydroxylase** was suppressed in the **liver**, and benzpyrene hydroxylase was induced in the kidney (Hook et al., 1975b). **Testicular microsomal** cytochrome P-450 content was depressed following a single oral dose of 1 vg/kg, reaching **52%** of controls by 1 day and remaining at **this** level for 9 days (Tofilon et al., 1980). Testicular microsomal

**heme** levels and  **$\delta$ -aminolevulinic** acid synthetase activity were unaffected by **this** treatment. In contrast to the **rat**, **2,3,7,8-TCDD** did not induce DT-diphosphorase in brain, spleen, kidney, lung, heart or liver of **male** guinea pigs (Beatty and Neal, 1978).

**Aryl** hydrocarbon hydroxylase and  **$\delta$ -aminolevulinic** acid synthetase in the chick embryo have been reported to be extremely sensitive to the inductive effects of 2,3,7,8-TCDD (Poland and Glover, 1973a,b), **with** maximal induction occurring **with** 155 **pmoles/egg**. **This** induction is relatively long lasting, **with 70%** of the maximum induced activity present 5 days following a single dose of 2,3,7,8-TCDD. Structure-activity studies demonstrated a perfect correspondence between the **toxicity** and induction potency of a series of **dibenzo-p-dioxin** congeners (Poland and Glover, 1973a).

8.1.2. **Subchronic**. Four laboratory studies described the systemic toxic effects of **subchronic** exposure to 2,3,7,8-TCDD in rodents. Also, one semi-controlled study evaluated the toxic effects to rabbits after confinement to an area containing **soil** contaminated **with** 2,3,7,8-TCDD. No information was found in the literature searched on the effects of subchronic exposure to **1,2,3,7,8-PeCDD**, and only one preliminary study was available describing the effects of subchronic exposure to a mixture of two HxCDDs in rats and **mice**.

**Kociba et al.** (1976) exposed Sprague-Dawley rats to 2,3,7,8-TCDD for **13** weeks. The animals in groups of 12 males and 12 females received the compound suspended in acetone-corn **oil** (1:9) by gavage 5 days/week at doses of 0.0, 0.001, 0.01, 0.1 or 1.0  **$\mu$ g/kg** bw. At the end of the treatment period 5 rats of each sex were killed for **histopathologic** examination, and the remaining animals were continued for postexposure observation. **This** report on gross, **hematologic**, clinical chemistry and histopathologic (on animals terminated at the interim **kill** or killed when moribund) observations was

prepared on data available 13 weeks after termination of treatment. Signs of **toxicity** were observed only at the two higher dose levels, and female rats appeared more sensitive to the toxic effects of **2,3,7,8-TCDD**. During the study there were **five** treatment-related deaths **in** the high-dose group females, **with** three occurring during treatment and two in the post-treatment period. In male animals only two deaths occurred in the post-treatment period in the high-dose group. Both the male and female rats of the 0.1 and **1.0 µg/kg** groups had depressed body weight; however, greater relative depression of body weight was observed in the high-dose females. Other changes such as Increases in **billirubin** concentrations, urinary coproporphyrin excretion, and changes in relative **thymus** or **liver** weight to body weight ratio occurred in the two high-dose female groups, but only in the **1.0 µg/kg** male group. Although male rats had significantly decreased **hematologic** values (packed cell volume, RBC count and hemoglobin) in the two high-dose groups, and these values were normal **in** all female rats, the authors pointed out that these results may have been an artifact resulting from dehydration-Induced **hemoconcentration in** the **female** rats. No specific data were provided, however, to support **this** last conclusion.

After necropsy, gross examination revealed subcutaneous edema, a decrease in the **size** of testes and uteri, and a decrease in the number of corpora **lutea**. Histologic examination revealed Involution of the thymus, decreased number of thymocytes, and focal necrosis and pigment accumulation in the liver. These observations were made only in the animals of the high-dose group, **with** the exception of a slight decrease in the number of thymocytes and **mild** microscopic distortion of the architecture of the liver **in** the group fed 0.1 µg/kg. Although **histologic** evidence from animals killed during the Interim sacrifice was consistent **with** the **liver** and thymus being

the primary target organs, In an animal that **died** during the study there were signs of aortic thrombosis and adrenal hemorrhage, and **in** a second animal there was severe anemia, suggesting possible Involvement of the **hematopoietic** system near the **time** of death.

Liver **toxicity** was the only effect of treatment observed during **histologic** examination of rats (**Osborne-Mendel**) and **mice** (B6C3F1) administered **2,3,7,8-TCDD** for 13 weeks **in** a preliminary **subchronic** toxicity study designed to define an acceptable dose for a chronic toxicity study (NTP **1980a**). The animals **in** groups of 10 males and 10 females were administered the compound in corn oil-acetone (9:1) twice a week at doses for rats of 0.0, **0.5**, **1**, 2, 4 and 8 yg/kg/week, and for **mice** at doses of 0.0, 1, 2, 5, 10 and 20 yg/kg/week. Deaths occurred at the two high-dose levels in rats, **with** 4 females in the 8 yg/kg/week and 1 in the 4 yg/kg/week group dying, while only 2 male rats in the 4 yg/kg/week group **died**. Deaths were accompanied by severe toxic hepatitis. Hepatic lesions were observed in all other rats examined in groups administered 1-8 yg/kg/week; however, not all **animals** in each group were submitted to necropsy. Normal liver histology was observed in the 2 male rats examined from the low-dose groups and only **threshold** toxic effects occurred in the low-dose female rats.

**Similar** effects of treatment were observed **in mice**, **with** a single death occurring in each sex at the high-exposure level, along **with** reports of hepatic lesions on **histologic** examination. In contrast to rats, female **mice** were less sensitive to the **hepatotoxic** effect of **2,3,7,8-TCDD** than were the male **mice**. Hepatic lesions were observed in all dose groups of **male mice**, while the 1 and 2 yg/kg/week dose groups of female **mice** had normal livers. Although the group sizes were small, making conclusions tenuous, it

appeared that sex differences in the sensitivity to the toxic effects of **2,3,7,8-TCDD occurred**, and that the more sensitive sex may vary **with** species tested.

In a more extensive **subchronic** study in rats. **King and Roesler** (1974) followed the **development** of **toxicity** by a series of Interim sacrifices during 28 weeks of exposure to **2,3,7,8-TCDD** and a 12-week post-treatment recovery period. Groups of 35 male and 35 female Sprague-Dawley rats were **intubated** twice weekly **with** 2,3,7,8-TCDD in corn oil-acetone (9:1) at cumulative doses of 0.0, **0.1** and 1  $\mu\text{g}/\text{kg}/\text{week}$ . No treatment-related deaths occurred; however, 3 animals from each group of each sex were killed after 2, 4, 8 and 16 weeks, and 10 animals of each sex were killed after 28 weeks of treatment. In addition, 3 rats of each sex were killed 4 and 12 weeks after termination of exposure. Animals were monitored for gross changes during the study and were examined for gross and **histologic** changes at necropsy.

Besides a dose-related decrease in body weight **gain** in male rats and a decrease in body weight **gain** in the high-dose female rats, the only effect of exposure to 2,3,7,8-TCDD was histologic changes in the liver. Liver pathology was normal in all treated groups up through the Interim **kill** at 16 weeks. Fatty changes in the **liver** were considered the most important observation. The fatty changes ranged from single large **lipid** droplets in a few **centrilobular** hepatocytes to **lipid** droplets in all **centrilobular** hepatocytes **with** extension **into** the **midzonal** hepatocytes. No clear dose-response pattern was observed in **this** study; however, it **did** appear that the severity of fatty changes was greater in male rats. During the recovery period, fatty changes progressively decreased **in** severity but were still present **in** some treated animals 12 weeks after cessation of exposure. Other histologic



changes observed in the liver predominantly in the animals killed at 28 weeks **included** necrosis, increased **nuclear size**, subtle distortion of liver architecture, and **hyperchromatic** nuclei. All of these lesions were considered to be slight or **mild**, and less **toxicologically** relevant than the fatty changes. The data suggested that the **liver** was the most sensitive organ to the toxic effect of **2,3,7,8-TCDD**, and although recovery occurred after termination of treatment, the recovery process was slow.

The recovery **time** was also demonstrated to be long in a **subchronic** study by Goldstein et al. (1982b) of 2,3,7,8-TCDD Induced **porphyria**. Groups of 8 female Sprague-Dawley rats were given 2,3,7,8-TCDD in corn oil-acetone (7:1) weekly by gavage for 16 weeks at doses of 0.0, 0.01, 0.1 or 10.0 yg/kg/week and killed 1 week after the last treatment. Additional groups of rats received doses of 0.0 or 1.0 yg/kg/week for 16 weeks and were allowed to recover for 6 months. The high-dose level was **lethal** to all animals within 12 weeks, while the only other gross **sign** of **toxicity** was a decrease in body weight **gain** in the group receiving 1.0 yg/kg/week. After 16 weeks of exposure to 2,3,7,8-TCDD, liver **porphyrins** were elevated ~1000-fold in 7 of 8 animals receiving 1.0 yg/kg/week, but only 1 of 8 animals in the 0.1 yg/kg/week group had elevated **porphyrin** levels. No effect was observed in the low-dose animals. After a 6-month recovery period the porphyrin level in animals exposed to 1 yg/kg/week was still 100-fold higher than values in the control group. A similar pattern was observed for urinary excretion of **uroporphyrin**. The rate-limiting enzyme in heme synthesis,  **$\delta$ -aminolevulinic** acid synthetase, was also elevated at both the **time** of termination of treatment and at the end of the recovery period; however, other enzymes that were increased after 10 weeks of treatment, cytochrome P-450, AHH and glucuronyl transferase, returned to near normal levels by 6 months. It was

clear that a 6-month recovery period from **subchronic** exposure to 2,3,7,8-TCDD at a dose of **1.0** yg/kg/week was not sufficient for complete reversal of **2,3,7,8-TCDD** Induced **porphyria**.

In addition to the above laboratory studies, **Strik** and de **Wit** (1980) attempted to Investigate the **toxicologic** effect on rabbits of exposure to a natural environment that was contaminated **with** 2,3,7,8-TCDD. Groups of 20 female rabbits and 1 male rabbit were housed for 5 months **in** pens, located **in** **five** separate areas, on **soil** that had been contaminated **with** 2,3,7,8-TCDD. The **soil** had been cleaned by replacement or cultivation before Initiation of the study. The **levels** of 2,3,7,8-TCDD before **cleaning** were from 0.8-23.2  $\mu\text{g}/\text{m}^3$ ; however, the levels of contamination after cleaning were not determined. At the end of 5 months liver histology, Including the localization of **porphyrin**, was examined, and the levels of cytochrome P-450 and P-420 were determined along **with** urinary **levels** of total **porphyrin**, **creatinine** and **D-glucuric-acid**. All of the parameters examined were considered to be within the normal range. Since exposure data were not available, the negative results of **this** study cannot be compared **with** the controlled subchronic laboratory studies already described.

Information on the subchronic toxicity of HxCDD was provided in a preliminary range-finding study for a chronic **bioassay** conducted by NTP (1980b) on a 1-2 mixture of **1,2,3,6,7,8-** and **1,2,3,7,8,9-HxCDD**. Osborne-Mendel rats and B6C3F1 **mice** in groups of 10 males and 10 females were administered the **HxCDD** mixture in corn oil-acetone (9:1) by gavage twice a week for 13 weeks. The total weekly doses given rats were 0.0, 2.5, 5, 10, 50 and 100 yg/kg; **mice** received weekly doses of 0.0, 1.25, 2.5, 5, 10 and 50 yg/kg. At week 10 of the study, the body weight in rats was decreased in a dose-related manner to a maximum of **~20%** in the high-dose group. In **mice**, body weight

was also decreased 10-20% in the treated animals; **however**, there appeared to be no correlation **with** dose. At the end of the study the animals were killed and necropsies were performed on selected animals. In both species liver pathology was **observed, with** threshold to moderate **hepatotoxicity** occurring at doses of 5 and 10 yg/kg/week for male and female **rats**, respectively, and at 10 yg/kg/week for both sexes of **mice**. At higher exposures, splenic **hyperplasia** and cortical atrophy of the thymus were also detected in rats. In rats it was unclear whether the low-dose animals were free of any pathologic findings or none were subjected to necropsy. In **mice** it was stated that no changes were observed in males exposed to **2,3,7,8-TCDD** at 1.25 yg/kg/week or in females exposed to 1.25 or 2.5 yg/kg/week. Although the data are limited, it appears that the same target organs are sensitive to the toxic effects of both 2,3,7,8-TCDD and **this** mixture of HxCDD.

In addition, a second **subchronic** range finding study conducted by NTP **(1980c)** evaluated the dermal **toxicity** of the above mixture of HxCDD. Groups of 10 male and 10 female Swiss-Webster **mice** were treated by dermal application 3 times/week for 13 weeks. The doses used were from 0.01-50 yg/application **with** the test compound dissolved in acetone. There was 100% mortality in the 25 and 50 **µg/application** groups and 80% mortality in the 10 **µg/application** group. On **histologic** examination, there were signs of **liver** damage at the lowest dose tested **in** both sexes; however, the incidence and degree of damage were not well correlated to the dose applied.

8.1.3. Chronic. The toxic effects, other than **neoplasia**, of long-term exposure to 2,3,7,8-TCDD have been studied in rats and **mice**. The primary purpose of many of the studies in rodents was to assess the **carcinogenicity** of 2,3,7,8-TCDD. The observation of non-neoplastic systemic toxic effects

in these studies was often **limited**, and observations were made near the end of the **natural lifespan** when conditions associated **with** aging may have obscured some effects produced by **2,3,7,8-TCDD**. Long-duration **toxicity** assays were **also** conducted in monkeys. Many of the same organs **in** monkeys as **in** rodents were adversely affected by long-term exposure to 2,3,7,8-TCDD; **however**, the monkeys also developed severe **skin** and stomach lesions. Table 8-5 summarizes the toxic effects of chronic exposure to 2,3,7,8-TCDD and provides information on the exposure **levels** that result in the observed effects. There also are data on the chronic **toxicity** of a mixture of 1,2,3,6,7,8- and **1,2,3,7,8,9-HxCDD**. No information was found in the literature search on the effects of chronic exposure to **1,2,3,7,8-PeCDD**.

**8.1.3.1. STUDIES ON LABORATORY RODENTS** -- In an **early study**, Van Miller et al. (1977a,b) defined the dietary level of 2,3,7,8-TCDD that **adversely** affected the longevity of rats following chronic exposure. **Groups** of **10** male **Sprague-Dawley** rats were maintained for 78 weeks on diets containing 1, 5, 50, 500, 1000, 5000, 50,000, 500,000 or 1,000,000 ppt of 2,3,7,8-TCDD. Survival was monitored during the study or at termination 95 weeks after initiation of treatment. No animals survived until the end of the study at the **five** highest exposure levels. The respective week after the start of treatment in which the first death occurred **in** these high-dose groups was 31, **31**, 3, 2 and 2 weeks, **with** all animals in groups >50 ppb dead by week 4. The mortality rate in the 0.0, 1, 5, 50 and 500 ppt groups at 95 weeks was 60, 20, 40, 40 and **50%**. Although the small number of animals in each group makes it impossible to precisely define a dose-response relationship, it was apparent that exposure to >1 ppb curtailed survival.

TABLE 8-5

## Effects of Chronic Exposure to 2,3,7,8-TCDD in Laboratory Rodents

| Species/Strain          | Sex/No.   | Dose                              | Treatment Schedule              | Duration of Study | Parameters Monitored   | Effects of Treatment   | Reference                  |
|-------------------------|-----------|-----------------------------------|---------------------------------|-------------------|--|--|----------------------------|
| Rat/<br>Sprague-Dawley  | M/10      | 0.0 ppt                           | NA                              | 95 weeks          | survival   | 40X survived until 95 weeks, the first death occurred at week 68   | Van Miller et al., 1977a,b |
|                         | M/10      | 1 ppt                             | continuous in diet for 78 weeks | 95 weeks          | survival   | 80X survived until 95 weeks, the first death occurred at week 86   |                            |
|                         | N/10      | 5 ppt                             | continuous in diet for 78 weeks | 95 weeks          | survival   | 60X survived until 95 weeks, the first death occurred at week 33   |                            |
|                         | H/10      | 50 ppt                            | continuous in diet for 78 weeks | 95 weeks          | survival   | 60X survived until 95 weeks, the first death occurred at week 69   |                            |
|                         | H/10      | 500 ppt                           | continuous in diet for 78 weeks | 95 weeks          | survival   | 50X survived until 95 weeks, the first death occurred at week 17   |                            |
|                         | N/10      | 1000 and 5000 ppt                 | continuous in diet for 78 weeks | 95 weeks          | survival   | No animals survived until 95 weeks, the first death occurred at week 31  |                            |
|                         | N/10      | 50,000, 500,000 and 1,000,000 ppt | continuous in diet for 78 weeks | 95 weeks          | survival   | No animals survived until 95 weeks, the first deaths occurred at weeks 2 and 3   |                            |
| Rats/<br>Sprague-Dawley | M&F/50&50 | ~2193 ppt<br>(0.1 µg/kg/day)      | continuous in diet for 2 years  | 2 years           | extensive histopathology, hematology, urine analyses, and clinical chemistry | Cumulative mortality, Increased (F);<br>bw gain, decreased (M,F);<br>Red blood cell count, decreased (N,F);<br>Packed cell volume, decreased (M,F);<br>Hemoglobin, decreased (N,F);<br>Reticulocytes, Increased (M,F);<br>White blood cell count, decreased (F);<br>Serum glutamic pyruvic transaminase, Increased (F)<br>G-Glutamyl transferase, Increased (F);<br>Alkaline phosphatase, Increased (F); | Kociba et al., 1978a, 1979 |

TABLE 8-5 (cont.)

| Species/Strain                              | Sex/No.                   | Dose   | Treatment Schedule   | Duration of Study | Parameters Monitored   | Effects of Treatment   | Reference                             |
|---|---------------------------|--|--|-------------------|--|--|---------------------------------------|
| <b>Rats/<br/>Sprague-Dawley<br/>(cont.)</b> |                           |  |  |                   |  | Urinary <b>coproporphyrin</b> ,<br>Increased (F);<br>Urinary uroporphyrtn.<br>Increased (F);<br><b>Urinary delta-amino-<br/>levulinic acid</b> ,<br>Increased <b>hepatic<br/>degeneration</b> .<br>Increased (M,F) | <b>Kociba et al.</b> ,<br>1978a. 1979 |
| <b>Rat/<br/>Sprague-Dawley</b>              | <b>M&amp;F /50&amp;50</b> | -208 ppt<br>(0.01 <b>µg/kg/day</b> )                   | continuous In<br><b>diet</b> for 2 years                   | 2 years           | extensive <b>histo-<br/>pathology. hema-<br/>tology. urine<br/>analyses and<br/>clinical chemistry</b> | <b>Urinary coproporphyrln</b> ,<br>Increased (F);<br>Urinary <b>uroporphyr in</b> ,<br>Increased (F);<br>Hepatic degeneration,<br>Increased (N,F)  | <b>Kociba et al.</b> ,<br>1978a. 1979 |
|   | <b>M&amp;F /50&amp;50</b> | -22 ppt<br>(0.001 <b>µg/kg/day</b> )                   | continuous <b>in<br/>diet</b> for 2 years                  | 2 years           | extensive <b>histo-<br/>pathology, urine<br/>analyses and<br/>clinical chemistry</b>                   | No differences in values<br>obtained from control<br>animals   |                                       |
| <b>Rat/<br/>Osborne-Mendel</b>              | <b>M&amp;F /75&amp;75</b> | 0.0 <b>µg/kg/week</b>                                  | NA   | 106 weeks         | <b>extensive htsto-<br/>pathology</b>  | Toxic <b>hepatitis</b> ;<br>0/74 (N). 0/75 (F)   | NTP. 1980a                            |
|   | <b>M&amp;F /50&amp;50</b> | 0.5 <b>µg/kg/week</b>                                  | <b>administered</b> by<br>gavage biweekly<br>for 104 weeks | 107 weeks         | extensive <b>histo-<br/>pathology</b>  | Toxic hepatitis;<br>14/50 (N). 32/50 (F)   |                                       |
|   | <b>M&amp;F /50&amp;50</b> | 0.05 <b>µg/kg/week</b>                                 | administered by<br>gavage <b>biweekly</b><br>for 104 weeks | 107 weeks         | extensive htsto-<br>pathology  | <b>Toxic</b> hepatitis;<br>0/50 (N). 1/50 (F)  |                                       |
|   | <b>M&amp;F /50&amp;50</b> | 0.01 <b>µg/kg/week</b>                                 | administered by<br>gavage biweekly<br>for 104 weeks        | 107 weeks         | extensive <b>histo-<br/>pathology</b>  | Toxic hepatitis;<br>1/50 (N). 0/50 (F)   |                                       |
| <b>Mice/B6C3F1</b>                          | <b>M&amp;F /75&amp;75</b> | 0.0 <b>µg/kg/week</b>                                  | NA   | 105-106 weeks     | <b>extensive histo-<br/>pathology</b>  | Toxic hepatitis;<br>1/73 (N). 0/73 (F)   | NTP. 1980a                            |
|   | <b>M&amp;F /50&amp;50</b> | 0.5 <b>µg/kg/week</b> (N)<br>2.0 <b>µg/kg/week</b> (F) | administered by<br>gavage biweekly<br>for 104 weeks        | 107 weeks         | extensive <b>histo-<br/>pathology</b>  | Toxic hepatitis;<br>44/50 (M), 34/47 (F)   |                                       |

TABLE 8-5 (cont.)

| Species/Strain         | Sex/No.   | Dose                                       | Treatment Schedule                            | Duration of Study | Parameters Monitored     | Effects of Treatment                               | Reference               |
|------------------------|-----------|--|---|-------------------|--------------------------|--|-------------------------|
| Mice/B6C3F1<br>(cont.) | M&F/50&50 | 0.05 vg/kg/week (M)<br>0.2 µg/kg/week (F)  | administered by gavage biweekly for 104 weeks | 107 weeks         | extensive histopathology | Toxic hepatitis; 3/49 (M), 2/48 (F)                | NTP, 1980a              |
|                        | M&F/50&50 | 0.01 µg/kg/week (M)<br>0.04 µg/kg/week (F) | administered by gavage biweekly for 104 weeks | 107 weeks         | extensive histopathology | Toxic hepatitis; 5/44 (N), 1/50 (F)                |                         |
| 8-54<br>Mice/Swiss     | M/38      | 0.0 µg/kg/week                             | NA  | 588 days          | histology on all organs  | Dermatitis and amyloidosis; 0/38                   | Toth et al., 1978, 1979 |
|                        | N/44      | 0.007 µg/kg/week                           | administered by gavage weekly for 1 year      | 649 days          | histology on all organs  | Dermatitis and amyloidosis; 5/44                   |                         |
|                        | M/44      | 0.7 vg/kg/week                             | administered by gavage weekly for 1 year      | 633 days          | histology on all organs  | Dermatitis and amyloidosis; 10/44                  |                         |
|                        | N/43      | 7.0 µg/kg/week                             | administered by gavage weekly for 1 year      | 424 days          | histology on all organs  | Early mortality, dermatitis and amyloidosis; 17/43 |                         |

NA . Not applicable

Increased **mortality** was also observed in female **Sprague-Dawley** rats maintained for 2 years on a **diet** that provided a **2,3,7,8-TCDD** dose of 0.1 yg/kg/day, while no increased mortality was observed in male rats at **this** dose or in animals receiving doses of 0.01 or 0.001 yg/kg/day (**Kociba et al.**, 1978a, 1979). The average dietary levels of 2,3,7,8-TCDD associated **with** these doses were 2193, 208 and 22 ppt. Interim **hematologic**, clinical chemistry and urine analyses revealed treatment-related changes in a number of parameters in the high-dose group, along **with** some of the same changes occurring in the mid-dose group, albeit to a lesser degree (see Table 8-6). At termination of the study, gross and **histologic** examination indicated that the **liver** was the most severely affected organ, **with** degenerative, **necrotic** and inflammatory changes observed. Increases in urinary excretion rates of **coproporphyrin** and **uroporphyrin** in the **high** and middle dose females were consistent **with** the observed liver damage. Again, primary liver injury was dose-related **with** the lowest dose representing a NOEL. Although the group sizes (50 males and 50 females **in** the treated groups, and 85 males and 86 females in the control groups) were reported, the description of the experimental results **did** not enumerate the number of animals affected.

When 2,3,7,8-TCDD was administered by gavage in corn oil-acetone (9:1) at dose levels of 0.0, 0.5, 0.05 or 0.01 yg/kg/week, "toxic **hepatitis**" was observed **respectively** in male **Osborne-Mendel** rats at incidences of 0/74, 14/50, 0/50 and **1/50**, and in female rats at incidences of 0/75, 32/49, 1/50 and 0/50 (NTP, 1980a). Toxic hepatitis was defined as "**lipidosis (lipoidosis)** and hydropic degeneration of the cytoplasm of the **hepatocytes**" in the **central, midzonal** and, at times, peripheral portions of the **liver**. No other



non-neoplastic lesions were observed even though extensive **histologic examinations** were performed. The two preceding studies support a NOEL for rats of **~0.001** yg/kg/day. **with** a LOAEL of 0.05 yg/kg/day, and a FEL for liver Injury and possibly decreased survival of 0.5 yg/kg/day.

Non-neoplastic effects of chronic exposure to 2,3,7,8-TCDD **in mice** have been briefly **described** in studies investigating the carcinogenic potential of **2,3,7,8-TCDD**. In an NTP (1980a) **bioassay**, extensive histologic examinations were performed on B6C3F1 **mice** treated biweekly **with 2,3,7,8-TCDD** by gavage in corn oil-acetone (9:1) for 104 weeks followed by an additional 3-week observation period. The doses for male animals were **0.0, 0.01, 0.05** and 0.5 yg/kg/week, and for female **animals**, the doses were 0.0, 0.04, 0.2 and 2.0 yg/kg/week. The only non-neoplastic lesion was toxic hepatitis, which occurred **in** males at Incidence of 1/73, 5/49, 3/49 and 44/50, and in females at Incidences of 0/73, 1/50, 2/48 and 34/47, respectively, in the control, **low-**, medium- and high-dose groups. In a second study, weekly Intubation of 2,3,7,8-TCDD at doses of 0.0, 0.007, 0.7 or 7.0 yg/kg/week for 1 year resulted in **amyloidosis** of the kidney, spleen and liver, and dermatitis at the **time** of death in male Swiss **mice** (Toth et al., 1978, 1979). The Incidence of these lesions in the control, **low-**, medium- and high-dose groups, **respectively**, was 0/38, **5/44**, 10/44 and **17/43**. In the high-dose group, the amyloidosis was extensive and considered to be the cause of early mortality. The amyloidosis may have resulted from the chronic dermal Inflammation produced by the treatment. From the limited data presented in these studies, **it** appears that **mice** and rats were approximately equally sensitive to the toxic effects of 2,3,7,8-TCDD following chronic exposure. Severe toxic effects were observed at doses of 1 yg/kg/day (early mortality) and

0.28-0.07 yg/kg/day (toxic hepatitis), while a LOAEL for dermatitis and amyloidosis of 0.001 yg/kg/day was reported. A NOAEL for mice was not clearly defined by these studies.

The only information available on the effects of chronic exposure to HxCDD was provided by an NTP (1980c) bioassay of a 1:2 mixture of 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDD. Male and female Sprague-Dawley rats and B6C3F1 mice were exposed biweekly to this mixture for 104 weeks and followed for an additional 3-4 weeks before the terminal kill. Both male and female rats and male mice received doses of 0.0, 1.25, 2.5 and 5.0 yg/kg/week; female mice received doses of 2.5, 5.0 and 10 µg/kg/week. The treated male and female rats had a dose-related decrease in body weight gain during the latter portion of the study, and the high dose females had reduced survival. No gross signs of toxicity were observed in mice of either sex. Although extensive histologic examinations were performed, the only treatment-related effect was toxic hepatitis, which was defined as "degenerative hepatocytic changes and/or necrosis associated with mild fibrosis and infiltration." The incidence of this lesion in control-, low-, medium- and high-dose groups, respectively, was as follows: male rats - 0/75, 28/48, 35/50 and 34/48; female rats - 0/73, 33/50, 37/50 and 44/50; male mice - 0/75, 28/50, 35/50 and 34/49; and female mice - 0/75, 33/50, 37/50 and 44/50. The severity of the toxic hepatitis was dose-related; however, it is unclear how severely the liver was damaged at any of the doses. In rats and mice, all doses of this mixture of 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDD represented FELs for liver toxicity.

8.1.3.2. STUDIES IN NONHUMAN PRIMATES - Initial studies indicating the effect of chronic exposure to PCODs including 2,3,7,8-TCDD in nonhuman

primates was conducted using "toxic fat," a contaminated poultry feed additive, which resulted in the death of a large number of chickens (Allen and Carstens, 1967). Groups of 4-5 monkeys, Macaca mulatta, were fed diets containing 0.0, 0.125, 0.25, 0.5, 1.0, 5.0 and 10% toxic fat until death. There was a dose-associated shortening of survival **time**: monkeys in the high-dose group survived only for an average of 91 days and animals in the low-dose group survived an average of 445 days (data for control animals were not provided). During the course of treatment the animals were monitored for **hematologic** and gross clinical changes as well as **histologic** changes in the liver evaluated through needle biopsy samples. At death, major organs were preserved for histologic evaluation. Since both clinical and histologic changes, especially near the **time** of death, appeared similar regardless of dose, the data and observations were combined for all dose **groups**.

During the course of the study, the monkeys consumed less food as compared **with** controls, and progressively lost weight. Gross clinical signs of Intoxication during the last 60 to 30 days of **life** included generalized edema and alopecia. At necropsy, the heart was observed to be **hypertrophic** and 8 of the 27 animals treated **with** the "toxic fat" had small gastric ulcers. At the light microscopic level, the liver had developed moderately distorted architecture **with** vacuolated cells containing neutral fat. The sternal bone marrow was nearly devoid of blood-forming elements, which was consistent **with** the observed decrease in packed blood cell volume and RBC counts. Also, electron micrographs revealed derangement of the rough endoplasmic reticulum and a loss of **ribosomes**, which the authors suggested may have resulted in the observed decrease in serum proteins. Skeletal muscle, lungs, **GI** tract, **skin** and heart had signs of edema as observed under the

light microscope; the electron micrographs of the heart revealed vascular degeneration which, if present in the other tissues, would have accounted for the generalized edema. It was apparent that the active component of "toxic **fat**" affected many essential biologic processes in the monkey. Chemical analysis of the "toxic fat" has since shown that the fat contained PCDDs of which TCDDs represented 64% by mass (Norback and Allen, 1973).

Allen et al. (1977) also assessed the **toxicity** of **2,3,7,8-TCDD** itself incorporated **into** the diets of female rhesus monkeys. The animals were maintained for 9 months on diets containing 500 ppt of 2,3,7,8-TCDD, and the animals that survived treatment were observed for an additional 4 months. During the course of the study, the monkeys were observed for clinical signs of toxicity, monitored for **hematologic** changes and, following death or the termination of the study, were subjected to complete autopsies. Since no control animals were included in **this** study, the data were compared **with pre-exposure** values where possible.

As observed in monkeys fed "toxic fat," the monkeys fed 2,3,7,8-TCDD lost **hair** and developed swollen eyelids and **periorbital** edema after 3 months of treatment. Blood parameters including hemoglobin levels and **hematocrit** decreased; however, blood proteins (total serum protein and albumin/globulin ratio) were not altered except in terminal animals. In the three animals that survived the 9-month exposure period, the toxic symptoms continued to develop during the 4 months of observation. The hematologic changes observed during the treatment period were consistent **with** the microscopic findings at autopsy of bone marrow degeneration. It was suggested that decreased platelet levels resulted in poor clotting and the widespread hemorrhage observed in many organs, which was **particularly** severe in the

stomach. **Also**, the decreased RBC count and resultant **loss** of oxygen-carrying capacity **resulted** in an increase **in** cardiac workload and hypertrophy of the heart. Cellular **hypertrophy, hyperplasia** and metaplasia of the epithelium of the salivary **gland, bile** duct, lung and stomach were also observed microscopically. Although many effects of treatment were observed, it was concluded that the ultimate cause of death was related to the severe **pancytopenia**.

The total dose of **2,3,7,8-TCDD** used over 9 months in **this** study by Allen et al. (1977) was estimated to be between 2 and 3  $\mu\text{g/kg/day}$ , which is approximately the same dose that resulted **in** severe toxic effects following chronic exposure in rats and **mice**. Schantz et al. (1979) reported **in** an abstract that similar, though less severe, effects were observed in female monkeys **following** chronic ingestion of diets containing 50 ppt of 2,3,7,8-TCDD. It was also noted that **this** exposure resulted **in** a decreased ability to **successfully** bear young (see Allen et al., 1977, **in** Section 9). It is apparent that the data available for nonhuman primates do not permit the determination of a NOAEL.

## 8.2. HUMAN

8.2.1. Acute Exposure. Symptoms of acute exposure to materials that contained **2,3,7,8-TCDD** are nausea and vomiting, headache and signs of irritation to the eyes, **skin** and respiratory tract. Acute exposure to chemicals contaminated **with** 2,3,7,8-TCDD may also result in drenching and sweating **with** extensive **dehydration** and weight loss, increase **in** body temperature, severe respiratory distress, fatty degeneration of **liver**, cyanosis, elevated blood urea nitrogen level, followed by fast deterioration of general condition and death from acute congestive heart **failure** (Reggiani, 1982; Hay 1962). Initially a chemical burn-type cutaneous reaction **will** occur (possibly because of other chemicals), usually followed by chloracne after

**several** days to weeks (Taylor, 1979). Chloracne **is** the most characteristic and frequently observed dermal lesion produced by **2,3,7,8-TCDD** and other chlorinated aromatic hydrocarbons in humans (Crow, 1981; **Taylor, 1979**). **This lesion** consists of **hyperplasia** and **hyperkeratosis** of the **interfollicular** epidermis, hyperkeratosis of the **hair follicle**, especially at the infundibulum, and **squamous** metaplasia of the sebaceous glands that form **keratinaceous** comedones and cysts (**Kimbrough, 1974**). These cutaneous eruptions of comedones, cysts and possibly pustules in severe cases, usually occur on the face and **shoulders** (Crow, 1978a; **Passi et al., 1981**). The persistence of **chloracne** varies greatly, **with** severe cases **lasting** for up to 15 years, while **mild** cases may resolve in a matter of months. Similar epidermal changes have been produced by 2,3,7,8-TCDD **in** rhesus monkeys (**McConnell et al., 1978a**; Allen et al., 1977), the ear of the rabbit (**Poiger and Schlatter, 1980**), and hairless **mice** (Knutson and Poland, 1982). These changes have not generally been observed in other laboratory animals, such as guinea **pigs**, hamsters, rats and **mice**.

Chronic exposure to 2,3,7,8-TCDD has probably occurred most in chemical industry workers exposed to low levels of **this** contaminant during the manufacture of **2,4,5-T** on a daily basis. Chloracne **is generally** the first symptom noted in chronic exposure. Systemic symptoms, including altered function of the **neuromuscular** system, **liver**, kidneys, and pancreas, altered blood chemistry (serum **bilirubin**, **GOT**, **GPT**, **lipid** and **cholesterol** levels), **porphyria** cutanea tarda, hyperpigmentation and **hyperkeratosis**, have also been reported in individuals that have had chronic 2,3,7,8-TCDD exposure (Crow, 1978b, 1981). A combination of acute, high-level exposure to 2,3,7,8-TCDD followed by chronic exposure for many years (or a lifetime) has been noted for residents of areas where PCDDs have been **accidentally**

**released into** the environment (Taylor, 1979). Residents of Seveso, Italy, for example, where an explosion of a reactor vessel used to manufacture **2,4,5-T** released PCDDs and other **chemicals into** the atmosphere, were exposed **acutely** for a few days and are now exposed dally to diminishing levels of PCDDs in the **soil**.

The first cases of chloracne associated **with** exposure to PCDDs occurred after a 1949 explosion in a chemical factory producing 2,4,5-T in **Nitro, WV** (Holmstedt, 1980). A total of 228 workers were exposed. Symptoms included nausea, headaches, fatigue, muscular aches and pains, and chloracne (Zack and **Suskind**, 1980). Chemical tests revealed elevated **lipid** levels and prolonged **prothrombin time**. Chronic symptoms, lasting up to 2 years, were severe aches and pains, fatigue, peripheral neuropathy and some residual **chloracne**. Four additional Industrial explosions were reviewed by Holmstedt (1980). In 1953, 75 workers were exposed during an accident at a factory (BASF) in **Ludwigshafen**, Germany. Most of the workers developed chloracne, while **21** workers developed nervous system and Internal organ damage **in** addition to severe chloracne. In 1963, an explosion at a 2,4,5-T producing factory in Amsterdam resulted in the exposure of 106 men to chlorinated **dioxin** by-products. Chloracne was the most common symptom, occurring 4-6 weeks after exposure. As a result of a similar exothermic explosion at the Coalite and Chemicals plant (England) in 1968, which manufactured **2,4,5-tri-chlorophenol**, at least 90 workers were exposed to **dioxins**. Clinical **examinations**, including liver function tests, full blood counts and **urinalysis**, were conducted on 14 employees who were in the building at the **time** of the explosion (May, 1973; Hay, 1982). Eleven of these 14 men showed abnormal **liver** function (**zinc** turbidity, thymol turbidity and serum **transaminase**) and altered **hematological** parameters or **glucosuria**. Later, after normal plant

operations were resumed, additional workers apparently were exposed to **2,3,7,8-TCDD** by contact and developed **chloracne**. Seventy-nine cases of chloracne developed by the end of 1968. The condition appeared on the face in all cases; however, other parts of the body were affected in more severe cases (May, 1973).

The most recent and extensively studied chemical plant explosion occurred on July 10, 1976, at the **ICMESA** (Industria **Chimico-Media-Societa** Azlonaria) plant at Seveso, Italy. This accident, caused by the release of the reactor contents into the atmosphere, exposed workers and residents (>8655 people) of the area to 2,3,7,8-TCDD **2,4,5-trichlorophenol** (Garattini, 1982; Pocchiarri et al., 1983). A total of 447 patients developed chloracne and some complained of nausea, vomiting, headache, diarrhea, **hyperhidrosis** and Irritation of the eyes (Taylor, 1979). Serious cases of **chloracne** and dermal blistering occurred in children and appeared within several weeks of their exposure (Glanotti, 1977; Crow, 1981; Taylor, 1979). Pocchiarri et al. (1979) cited unpublished data reported to the Lombardy Regional Authority (Boeri, 1978; Chiappino et al., 1978; Sirchia, 1978) on the health effects of 2,3,7,8-TCDD to children and adults at Seveso. Reduced peripheral nerve conduction velocities were noted in adults and children, **with abnormalities** being more frequent in people residing nearer the chemical plant. The Immunology of a group (n=45) of exposed children was compared with a similar unexposed group. No significant differences were noted; however, total serum complement activity, lymphocyte **blastogenic** response and peripheral blood lymphocytes were elevated to some degree in the exposed children (Tognoni and Bonaccorsi, 1982). Exposure to 2,3,7,8-TCDD has been associated with increased serum glutamate-oxalacetate **transaminase** (GOT), serum GPT and **gamma-glutamyl transferase** (g-GT) levels in exposed children



(Pocchiari et al., 1979). Compared with normal values for "healthy" individuals, lymphocyte aberrations appeared more frequently; however, the findings were not statistically significant.

A comparison between children (under age 15) who developed chloracne and children of the same area who did not develop skin lesions was reported by Caramaschi et al. (1981). A significant increase in the frequency of headaches and eye irritation ( $p=0.01$ ), GI tract symptoms (nausea, vomiting, loss of appetite, abdominal pain or gastritis) ( $p=1.6 \times 10^{-4}$ ), and abnormal g-GT, serum GPT and aminolevulinic acid levels ( $p=2.3 \times 10^{-4}$ , 0.035 and  $1.2 \times 10^{-5}$ , respectively) was noted in those children who had chloracne (Caramaschi et al., 1981). Ideo et al. (1982) measured urinary D-glucuronic acid levels to assess liver microsomal enzyme activity in 67 children exposed to 2,3,7,8-TCDD at Seveso. A significant ( $p < 0.05$ ) increase in the glucuronic acid levels, used to indicate increased microsomal enzyme activity, was noted in exposed children 3 years after the accident when compared with unexposed children ( $n=86$ ).

The decontamination and cleanup of the ICMESA plant at Seveso began in May, 1980, and the possible contamination of clean-up workers was closely monitored and safety measures were implemented (Ghezzi et al., 1982). Laboratory tests on the blood (GOT, GPT, g-GT, alkaline phosphatase, bilirubin, hemoglobin, cell counts, thromboplastin partial time, albumin, gamma globulin, cholesterol and triglycerides) and urine (porphyrin) of the workers were performed and compared with pre-employment values (of the same group of workers) and with a nonexposed group. No significant changes were noted, but exposure to 2,3,7,8-TCDD was believed to be minimal. A recent review of the Seveso Incident, including its history and human health effects, is reported by Tognoni and Bonaccorsi (1982).

Three cases of **accidental** exposure to PCDDs (**isomer** not specified) while scientists were attempting to prepare a pure standard in the **laboratory** were reported by Oliver (1975). **All** three laboratory scientists reported the same general symptoms: **chloracne** (within several weeks after exposure), **GI** pains, headaches, fatigability and **hypercholesterolemia** (occurring 2-3 years after exposure). One case reported loss of mental and muscular coordination and blurred vision. Most symptoms of the patients subsided **with time**.

Since PCBs and PBBs can cause **neurotoxic** and behavioral effects (Safe, 1984; **Agarwal et al.**, 1981; Anderson et al., 1978) and their toxic effects may be mediated by the same **cytosolic** receptor protein as **2,3,7,8-TCDD**, it may be important to determine whether 2,3,7,8-TCDD has any neurotoxic activities (**Silbergeld, 1984**; Safe, 1985).

Additional reports of toxic effects as a result of acute 2,3,7,8-TCDD exposure in humans were noted by **Kimbrough et al. (1977)**. Children were exposed to **soil in horse arenas (in Eastern Missouri)** sprayed **with oil** contaminated **with 2,4,5-trichlorophenol** (5000 ppm in the **soil**) and 2,3,7,8-TCDD (30 ppm in the **soil**). A 6-year-old **girl** developed headaches, diarrhea, **epistaxis** and **hemorrhagic** cystitis, and became lethargic. Two 3-year-old boys developed chloracne ~1.5 months after playing in a contaminated horse arena. Three **additional** individuals who had exposure to the arenas developed less severe symptoms of headache, **skin** lesions and **polyarthralgia**. The **girl** was re-examined 5.3 years following exposure to the **soil** of the horse arena and showed no **residual** signs of toxicity (**Beale et al.**, 1977). Additional data on these or other cases from Eastern Missouri were not available.

8.2.2. Chronic Studies. Poland et al. (1971) reported a **health** survey study of 73 men employed in the manufacture of **2,4,5-T**. These workers, however, were also exposed to di- and trichlorophenols, PCDD contaminants and

**2,4-D.** Thirteen employees developed moderate to severe **chloracne**; another 35 had **minimal** "active **acne**" (**cysts**, comedones or pustules). Other complaints noted by the workers were eye **irritation**, **hyperpigmentation** and **hirsutism**. Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal **pain** or **blood** in the feces) were reported by 22 of the 73 workers. Findings as to cardiovascular, hepatic, pulmonary and neurological function were regarded as unremarkable and unrelated to occupational exposures. The authors noted that exposure was to several compounds and to assign a causative agent(s) would be conjecture (Poland et al., 1971).

In a brief report, Walker and Martin (1979) reported on some of the clinical findings of eight men who had contracted chloracne as a result of occupational exposure to **2,3,7,8-TCDD**. **Five** men had elevated g-GT and **triglyceride** levels. All eight men had decreased levels of high-density **lipoprotein** (HDL) cholesterol and elevated total/HDL cholesterol ratios consistent **with** higher than average **risk** of **ischaemic** vascular disease. Abnormal **lipid** levels, reported in 6 men, were attributed to enzyme induction. May (1982), however, observed no differences in **triglyceride**, cholesterol, alkaline phosphatase and **glucuronic acid** or g-GT levels in 41 workers exposed to 2,3,7,8-TCDD. These determinations were made 10 years after the workers had developed 2,3,7,8-TCDD chloracne.

**Bleiberg** et al. (1964) found 29 workers in a chemical plant manufacturing **2,4-chlorophenol** and **2,4,5-trichlorophenol** exhibiting features of chloracne. These patients were tested for the presence of **porphyria cutanea tarda** (PCT). **This** investigation revealed evidence of varying degrees of severity of PCT in 11/29 workers, but the authors could not determine any quantitative relationship between the chloracne and PCT. Urinary **uroporphyrins** were elevated in all 11 cases. A number of workers were noted to

have **hyperpigmentation**, **hirsutism**, **fragility** of the **skin** and **vesiculobulbous** eruptions on exposed areas of the **skin**. In **this** paper the authors suggested PCT is perhaps an acquired disease occurring after various insults to the liver (**Bleiberg et al.**, 1964).

In a survey of 204 employees engaged in the manufacture of **2,4,5-T** for 1 month to 10 years, Ott et al. (1980) reported no cases of chloracne, **porphyria** cutanea tarda or other effects indicative of **dioxin** exposure. Maximum allowable **2,3,7,8-TCDD** levels in the final product were <1 mg/kg in 1966 and <0.1 mg/kg in 1972. Estimates of TWA exposure to 2,4,5-T ranged from 0.2-0.8 **mg/m<sup>3</sup>**, so that 2,3,7,8-TCDD levels would be exceedingly low. Cook et al. (1980) reported chloracne, from slight to severe cases, in 49 of 61 employees exposed to 2,3,7,8-TCDD during the manufacture of **trichlorophenol**. Changes in industrial and personal hygiene techniques decreased **potential** exposure to 2,3,7,8-TCDD and subsequent chloracne. Additional toxic effects were not reported. The National Institute for Occupational Safety and Health (**NIOSH**) in a survey of workers at a St. Louis, MO, trucking terminal contaminated **with** 2,3,7,8-TCDD (subsoil concentration of 2,3,7,8-TCDD was as **high** as 17 ppb) found one of the **long-term** former workers had developed **porphyria** cutanea tarda and **angiosarcoma** of the right **ilium** (Hope et al., 1984). **Pazderova-Vejlupkova** et al. (1981) reported that 80 workers developed chloracne, nausea, fatigue and weakness in the lower extremities while engaged in the production of **2,4,5-sodium trichlorophenoxyacetate** and **trichlorophenoxyacetate** butylester. Prominent clinical symptoms among 55 of the 80 workers included **hypercholesterolemia**, **hyperlipemia** and **hyperphospholipemia**, increased plasma alpha and gamma globulins, and decreased plasma albumin. **Porphyria** cutanea tarda was observed in 11 of the 55 workers tested. In some cases illness subsided, while other cases became more

severe **during** a 3-4 year follow-up period. Long-term **pathological** symptoms (**remaining** evident 5 years after exposure) Include deviations in **lipid metabolism**, abnormal glucose tolerance and **high** urinary excretion of uroporphyrins (**Pazderova-Vejlupkova et al.**, 1981). **Polyneuropathy**, usually of the lower extremities, occurred during the period of illness and remained evident after 4 years. Singer et al. (1982) also indicated a decrease in nerve conduction velocities of **sural** nerves in workers exposed to phenoxy acid herbicides (average exposure, 7 years) when compared **with** a similar group of nonexposed workers (40.3 **m/sec** in exposed vs. 42.8 m/sec in nonexposed, **p=0.02**). Although the causative agent is not known, PCDD contaminants are suggested.

The toxic effects attributed to 2,3,7,8-TCDD exposure were studied over a 10-month period in a group of 78 Vietnam veterans who claimed to have been exposed to Agent Orange (Bogen, 1979). Symptoms reported by the veterans included gastrointestinal complaints (anorexia, nausea, diarrhea, constipation, abdominal **pain**), joint **pain** and stiffness, and neurological complaints (numbness, dizziness, headaches, depression and bouts of violent rage). These patients had previously been **chronically** ill and had frequent infections and **allergies** (Bogen, 1979). **This** study was apparently based on personal evaluations of health **in** a survey-type format. No control group was used for comparison and no clinical or medical evaluations of health were made. Most of these complaints are nonspecific, **judgmental** and occur **commonly in** the general public.

In an effort to evaluate the toxic effects attributed to 2,3,7,8-TCDD as a contaminant of Agent Orange, Stevens (**1981**) estimated a minimum toxic dose of 2,3,7,8-TCDD and determined the amount of **this** contaminant to which veterans may have been exposed during Agent Orange spraying. Based on

studies in which rhesus monkeys were fed small amounts of dietary 2,3,7,8-TCDD and analogy **with** human data on the minimum toxic dose of **2,3,7,8-tetrachlorodibenzo-p-furan (TCDF)**, the cumulative minimum toxic dose of 2,3,7,8-TCDD in man was estimated to be 0.1  $\mu\text{g}/\text{kg}$  (Stevens, 1981). Based on application rates (4.1 g Agent **Orange**/ $\text{m}^2$ ) and **2,3,7,8-TCDD** concentration in the herbicide (2 ppm), the average concentration of 2,3,7,8-TCDD on sprayed surfaces of Vietnam was estimated to be  $\sim 8 \mu\text{g}/\text{m}^2$ . Based on accidental exposures to **2,3,7,8-TCDD** in humans (Industrial accidents, Eastern Missouri cases), Stevens (1981) estimated an average Intake transfer factor (ratio of absorbed compound to environmentally available compound) of 1:2050 for **2,3,7,8-TCDD**. Assuming **this** absorption-to-exposure ratio and even assuming that a soldier was directly sprayed (exposed to 8  $\text{yg}/\text{m}^2$ ) for each day of **his** 1-year service in Vietnam, **his** cumulative Intake would be only 1.4  $\mu\text{g}$  or 0.02  $\mu\text{g}/\text{kg}$  of 2,3,7,8-TCDD (Stevens, 1981). Based on these **calculations** and assumptions, Stevens (1981) reported that 5 years of direct daily contact **with** Agent Orange would be necessary to reach a toxic **level** of 2,3,7,8-TCDD and **felt** that claims of illness caused by 2,3,7,8-TCDD in Agent Orange were without merit. Exception is made, however, for certain workers (forest Industries) who may have been exposed to **2,4,5-T** and 2,3,7,8-TCDD for many years.

### 8.3. MECHANISM OF TOXICITY

A number of studies have attempted to determine the mechanism of **toxicity** of 2,3,7,8-TCDD. The ultimate purpose is to provide a better estimate of **man's** relative sensitivity to 2,3,7,8-TCDD and other compounds having a similar mode of action. Specifically, these studies may be able to explain the reason for the marked **interspecies** differences in 2,3,7,8-TCDD **toxicity** and, thus, help determine if humans possess factors that are associated **with** sensitivity to 2,3,7,8-TCDD toxicity.

8.3.1. **Receptor-Mediated Toxicity.** Pharmacogenetic studies have played an important role in understanding the biologic and toxic effects of drugs and **xenobiotics**. Nebert and **coworkers** have shown that carcinogenic polycyclic aromatic hydrocarbons (PAHs) induce the **cytochrome** P-450-dependent monooxygenase AHH in certain responsive strains of **mice** (e.g., **C57B1/6J**, BALBc, C3HF/He), whereas **this** PAH induction activity is minimal or nonexistent in **nonresponsive** strains (DBA/2J) (Nebert, 1979, 1982; Nebert and **Gielen**, 1972; Nebert and Jensen, **1979**; Nebert et al., 1972, 1981, 1983). The gene complex responsible for the induction of AHH and several other enzymes has been designated the Ah locus that comprises **regulatory**, structural and possible temporal genes. Extensive studies on genetically inbred responsive and nonresponsive **mice** (and their backcrosses) indicate that these differences are related to the Aromatic Hydrocarbons (Ah) regulatory gene (termed "Ah complex" or "AH cluster") and **its** gene product, the Ah **cytosolic** receptor protein. **This** receptor protein interacts **with** PAH **ligands** and the resultant PAH:Ah receptor complex translocates **into** the nucleus and presumably initiates the induction of AHH by a process comparable to that proposed for the steroid hormones.

Since the carcinogenic and toxic effects of PAHs are dependent on their **oxidative** metabolism to reactive **electrophilic** forms, **it** is not surprising that the Ah receptor plays an important role in mediating their **toxicity** and **carcinogenicity** (Kouri, 1976; Kouri et al., 1974; Benedict et al., 1973; Shum et al., 1979; Thomas et al., 1973; Legraverend et al., 1980; Duran-Reynolds et al., 1978; Robinson et al., 1975; **Mattison** and **Thorgeirsson**, 1979). Responsive **mice** are more susceptible to the toxic (**inflammation**, **fetotoxicity**, primordial oocyte **depletion**) and carcinogenic effects of PAH at organs/tissues in direct contact **with** the applied chemical; **in contrast**,

**nonresponsive mice** are more susceptible to the **tumorigenic** effects of PAHs at tissue/organ sites remote from the **initial site** of exposure to the PAHs. These differences in **susceptibility** are due to several factors **including AHH-mediated toxication and detoxication.**

**2,3,7,8-TCDD** can produce dermal lesions including epidermal **hyperplasia, hyperkeratosis** and squamous metaplasia of the sebaceous glands in hairless mice (**HRS/J**), homozygous for hr/hr locus, but not in heterozygous (hrA) or normal haired wild type (**+/+**) mice. These effects on the **skin** seem to be mediated through the Ah receptor (**Poland, 1984**).

8.3.1.1. **2,3,7,8-TCDD: SEGREGATION OF ACTIVITY WITH THE Ah LOCUS --** Genetic studies also support the role of the Ah receptor in mediating the toxic and biologic effects of **2,3,7,8-TCDD**. Initial studies by **Poland and coworkers** (Poland et al., 1974, 1983; Poland and Glover, 1975; Nebert et al., 1975) demonstrated that the **microsomal** AHH-inducing activity of 2,3,7,8-TCDD and **3-MC** in several genetically inbred mice strains were similar. **Like MC** and related PAHs, 2,3,7,8-TCDD induced AHH in several responsive mouse strains (**i.e., C57B1/6J**). In contrast to 3-MC, 2,3,7,8-TCDD induced microsomal AHH in the DBA/2J nonresponsive mice; however, the **ED<sub>50</sub>** for this biologic response was significantly higher than values reported for the responsive mice. In genetic crosses between responsive C57B1/6 and nonresponsive DBA/2 mice it was also shown for both 3-MC and 2,3,7,8-TCDD that the trait of responsiveness is inherited in a simple **autosomal** dominant mode (Poland and **Knutson, 1982**). It has been suggested that the observed differences in the activities of 3-MC and 2,3,7,8-TCDD are related to their relative Ah receptor affinities (Poland and Knutson, 1982) and the **pharmacokinetic** and metabolic factors that would more rapidly diminish the "available" concentrations of 3-MC caused by metabolism and excretion.



Several studies with 2,3,7,8-TCDD in genetically Inbred mice support the receptor mediated hypothesis. The Induction of UDP-glucuronosyl transferase, OT diaphorase,  $\delta$ -aminolevulinic acid, glutathione-S-transferase B, T-aldehyde dehydrogenase and choline kinase by 2,3,7,8-TCDD or 3-MC in genetically Inbred mice have also been shown to segregate with the Ah locus (Beatty and Neal, 1976b; Owens, 1977; Kirsch et al., 1975; Dietrich et al., 1977; Ishidate et al., 1980; Poland and Glover, 1973a). Toxicology studies with genetically-Inbred mice confirm the role of the Ah locus in mediating several toxic effects including porphyria, immunotoxicity a wasting syndrome, thymic atrophy and cleft palate formation (Jones and Sweeney, 1980; Poland and Glover, 1980; Courtney and Moore, 1971; Vecchi et al., 1980, 1983). Poland et al. (1982) also linked the tumor-promoting activity of 2,3,7,8-TCDD in hairless mice to the cytosolic receptor. In vitro studies with XB cells in culture also support the role of receptor in mediating a dose-related cell keratinization by 2,3,7,8-TCDD that resembles some of the characteristics of chloracne (Knutson and Poland, 1980). This cell line is also responsive to AHH Induction and contains a cytosolic receptor binding protein. Although the murine Ah receptor has not been characterized, several studies confirm that a protein with high affinity for 3-MC and 2,3,7,8-TCDD is present in low concentrations in the hepatic (~30-50 fmolar) and extrahepatic tissues of responsive C57B1/6J mice (Greenlee and Poland, 1979; Okey et al., 1979, 1980; Poland et al., 1976; Mason and Okey, 1982; Gasiewicz and Neal, 1982; Okey and Vella, 1982; Okey, 1983; Nebert et al., 1983). In responsive C57B1/6J mice and Sprague-Dawley rats, but not in nonresponsive DBA/2J mice, the Ah receptor can be Induced by pretreatment with phenobarbital, which is the only known agent at present that has been demonstrated to affect tissue concentrations of the receptor (Okey and

Vella, 1984). Although the Ah receptor has not been detected in the **cytosol** of OBA/2J **mice**, after the administration of **radiolabeled** 2,3,7,8-TCDD to these **mice**, some of the **radiolabel** is detected in the nuclei of the non-responsive **mice**. Moreover, the sedimentation characteristics of the [<sup>3</sup>H]-2,3,7,8-TCDD:nuclear protein complex in DBA/2J **mice** are similar to those observed with the bound Ah **cytosolic** receptor protein in C57Bl/6J **mice** using a sucrose density gradient **centrifugation** separation technique (Okey, 1983). The cytosolic Ah receptor protein migrates **into** the nucleus of the **cell** only after binding with 2,3,7,8-TCDD (Nebert and Jensen, 1979; Nebert, 1980; Greenlee and Poland, 1979; Okey et al., 1979, 1980; Tukey et al., 1982; Gonzalez et al., 1984), and **this parallels** the observations noted for the interactions between steroids and their receptor proteins. The 2,3,7,8-TCDD inducer-Ah receptor **complex** undergoes a temperature-dependent step before gaining **high** affinity for DNA (Okey et al., 1980; Kimura et al., 1984). The 2,3,7,8-TCDD **Ah-receptor** complex thus binds to the **nucleus** and **regulates** the transcription of **cytochrome P<sub>1</sub>-450**, which represents the gene product of **Ah-structural loci**, in mouse hepatoma cells in culture (Whitlock et al., 1984; Eisen, 1984) and in **mice** with various Ah genotypes (Elsen, 1984). **This** results in induction of AHH activity which may remain elevated for a prolonged period. Such prolongation of activity may be because cytochrome **P<sub>1</sub>-450** mRNA remains elevated even after 1 week following single exposure to 2,3,7,8-TCDD (Elsen, 1984).

In elucidating the mechanisms of 2,3,7,8-TCDD induced **teratogenic** effect in the formation of cleft palate in C57 mouse fetus, the presence of Ah-receptor **in** the palatal shelves of the embryo seems to be necessary for alteration/inhibition of terminal differentiation of the medial epithelial cells **in** the palate (Denker and Pratt, 1981; Pratt, 1983; Pratt et al.,

1984a,b). Pratt and Willis (1985) have even suggested utilizing growth inhibition of an established **line** of human embryonic palatal mesenchymal **cells** for *in vitro* short-term screening for assessment of the **teratogenic** potential of environmental agents.

The presence of Ah-receptor have been detected **in** normal lung, **liver**, kidney, spleen and Intestine from human fetus. In **addition**, normal lung tissue from 10 of the 50 Individuals examined were found to have Ah-receptor (Roberts et al., 1985). Ah-receptor has also been observed in cell lines of human **squamous** cell carcinoma at a concentration of 5-10 **fmol/mg** (Hudson et al., 1983; Roberts et al., 1985). Whether variation **in** Ah-receptor content in human is genetically determined and is a critical determinant of individual susceptibility to PCDDs is not known and warrants further investigation.

8.3.1.2. **2,3,7,8-TCDD AND RELATED TOXIC HALOGENATED ARYL HYDROCARBONS: STRUCTURE-ACTIVITY CORRELATIONS** - The evidence for a receptor mediated mechanism of action for 2,3,7,8-TCDD is supported by data reported for the effects of other halogenated **aryl** hydrocarbons in genetically inbred **mice** and other diverse animal species. A number of reviews and comparative studies (Allen et al., 1979; Kimbrough, 1974; Kimbrough et al., 1978; McConnell and Moore, 1979; Taylor, 1979) clearly indicate that the toxic halogenated mixtures and individual compounds (including the PCDDs, PCDFs, PCBs and PBBs) elicit similar toxic and biologic responses that include 1) a wasting syndrome which is manifested by a progressive weight loss and decreased food consumption by the treated animals; 2) **skin** disorders including acneform eruptions or **chloracne**, alopecia, edema, **hyperkeratosis**, and hypertrophy of the **Melbomian** glands; 3) **lymphoid** involution and atrophy; 4) **porphyria** (resembling **porphyria** cutanea tarda); 5) endocrine and reproductive disorders; 6) modulation of chemical **carcinogenesis**; and 7) the

Induction of numerous enzymes including the cytochrome **P-448** (or P-450c) dependent **monooxygenases**. It is apparent that the effects of these compounds are not manifested in **all** the animal species tested. **McConnell** and Moore (1979) summarized the pathologic findings observed in several animal species after pretreatment with PCDDs, PCDFs, PCBs and PBBs; these data illustrate the different species and organ/tissue susceptibilities to these compounds. It is also evident that for most of these effects, all the toxic halogenated **aromatics** elicit similar effects in these species that also contain the **cytosolic** receptor protein (**Carlstedt-Duke**, 1979; **Carlstedt-Duke et al.**, 1979, 1981; Okey, 1983; Okey and **Vella**, 1982; Mason and Okey, 1982). These observations support a common mechanism of action for all the toxic halogenated **aryl** hydrocarbons (Poland and Knutson, 1982; Safe et al., 1982; McConnell and Moore, 1979).

Several reports have demonstrated the effects of structure on the activity of PCODs. The most active member of **this** group is substituted in the **lateral** 2, 3, 7 and 8 positions; activity is decreased with 1) decreasing **lateral substituents**, and 2) increasing **Cl** substitution. Moreover, for several PCODs, there is an excellent correlation between the **toxicity** of individual PCDD congeners in guinea **pigs** and **mice** (McConnell et al., 1978b) and their AHH induction potencies in chick embryos and rat hepatoma H-4-II-E cells in **culture** and their binding affinities for the C57Bl/6J mouse hepatic cytosolic receptor protein (Poland et al., 1976, 1979; Bradlaw et al., 1980; Bradlaw and **Casterline**, 1979). Comparable structure-activity correlations have been reported for the PCDFs in which the most active compound, 2,3,7,8-TCDF, is an approximate **isostereomer** of **2,3,7,8-TCDD** (Poland et al., 1979; Poland and Knutson, 1982). Moreover, **like** the PCDDs, there was an excellent correlation among the toxicity of several individual PCDFs (**Yoshihara et**

a1., 1981), their AHH Induction potencies in rat H-4-II-E **hepatoma cells** and binding affinities to male **Wistar** rat hepatic **cytosolic** receptor protein (**Bandiera et al.**, 1983).

Correlations between structure-activities of PCDDs and Ah-receptor **site** binding, AHH Induction potencies and systemic **toxicity** have also been suggested (Safe et al., 1984). **2,3,7,8-TCDD**, the **isomer** substituted **with Cl** in all four lateral positions **is** most active for all of the above three parameters. Increased or decreased substitution of **2,3,7,8-substituted** PCDDs tend to decrease receptor binding affinity and toxic action.

The most active PCB congeners, **3,4,4',5-tetra-**, **3,3',4,4'-tetra-**, **3,3',4,4',5-penta-** and **3,3',4,4',5,5'-hexachlorobiphenyl**, are substituted at both para and at two or more meta positions. The four coplanar PCBs induce rat hepatic **microsomal** AHH and cytochromes P-450a, P-450c and P-450d and resemble **3-MC** and 2,3,7,8-TCDD in their mode of induction of the cytochrome P-450 **isozymes** (34) (Parkinson et al., 1980a,b, 1983; Safe et al., 1982; Sawyer and Safe, 1982; Poland and Glover, 1980; Goldstein et al., 1977). **Like Aroclor 1254**, all the **monoortho** and at least eight **dioortho-chloro** analogs of the coplanar PCBs exhibited a "mixed-type" induction pattern and induced **microsomal** AHH, **DMA P N-demethylase** and cytochromes P-450a to P-450e (Parkinson et al., 1983, 1980a,c). Quantitative structure-activity relationships (QSARs) within **this** series of PCBs were determined by comparing their AHH induction potencies ( $EC_{50}$ ) in rat hepatoma H-4-II-E cells and their binding affinities ( $ED_{50}$ ) for the 2,3,7,8-TCDD rat **cytosolic** receptor protein (Sawyer and Safe, 1982; Bandiera et al., 1983). The results showed that there was an excellent correlation between AHH induction potencies and receptor binding avidities of these compounds and the order of activity was coplanar PCBs (**3,3',4,4'-tetra-**, **3,3',4,4',5-penta-** and

**3,3',4,4',5,5'-hexachlorobiphenyls**) > **3,4,4',5-tetrachlorobiphenyl** > **mono-ortho coplanar** PCBs > **diortho** coplanar PCBs. It was **also** apparent that the **relative toxicities** of **this** group of PCBs paralleled their biological potencies (**Biocca et al.**, 1981; **Yoshihara et al.**, 1979; **Marks et al.**, 1981; **McKinney et al.**, 1976; **Yamamoto et al.**, 1976; **Ax and Hansen**, 1975; **Kuroki and Masuda**, 1977).

The coplanar and **monoortho** coplanar PCBs also exhibit differential effects in the Inbred C57Bl/6J and DBA/2J **mice**. These compounds induce AHH and cause **thymic** atrophy in the former "responsive" **mice** whereas at comparable or higher doses none of these effects are observed in the **nonresponsive** DBA/2J **mice** (Parkinson et al., 1982). The results obtained for **structurally** diverse PCDDs, PCBs and PCDFs clearly support the role of the receptor protein in initiating the broad spectrum of biologic and toxic effects elicited by these chemicals. **Bandiera et al.** (1983) demonstrated that the 2,3,7,8-TCDD receptor protein **is** not only susceptible to halogen substitution patterns but also the structure of the **substituent**. The cytosol receptor binding avidities and AHH induction potencies in rat hepatoma H-4-II-E cells for several **4'-X-2,3,4,5-tetrachlorobiphenyls** were remarkably dependent on the structure of the X substituent. The binding data for **13** different **substituents** was subjected to **multiparameter** regression analysis to correlate binding avidities **with** the physical and chemical characteristics of the critical lateral X **substituents**. The equation

$$\log \left( \frac{1}{EC_{50}} \right) = 1.53\sigma + 1.47 I + 1.09 HB + 4.08$$

showed that **ligand** binding was dependent on **substituent electronegativity** ( $\sigma$ ), **lipophilicity** (I) and hydrogen binding (HB) **with** a correlation coefficient (r) equal to 0.978 for **13** different substituents.

Dependency of **ligand-receptor complex** and the biological activity of PCDOs on their electronic and geometric structure Investigated by an **in vitro molecular** fragment analysis has also been suggested (Cheney, 1982).

The receptor mediated hypothesis for the mechanism of action of 2,3,7,8-TCDD still requires further confirmation and numerous problems must be clarified. For **example**:

1. Several cell culture lines that appear to have the Ah receptor are highly resistant to the **toxicity** of TCDD; the nonresponsive HTC and responsive H-4-II-E cell lines (**i.e.**, for AHH inducibility by TCDD) do not possess **cytosolic** receptor; however, the **nonresponsive** HTC cells possess more nuclear receptor binding protein than the responsive H-4-II-E cells (Okey, 1983; Okey et al., 1980).
2. Hepatic cytosolic receptor levels in rats (**Wistar** and Sprague-Dawley), C57B1/6J mice, hamsters and guinea pigs are comparable (**Gasiewicz et al.**, 1983b); however, their susceptibility to the **biologic** and toxic effects of TCDD are highly variable: guinea pigs are highly susceptible to the lethal effects of TCDD (**LD<sub>50</sub>** = 1-2  $\mu\text{g}/\text{kg}$ ) whereas the susceptibility of the other species follows the order rat > C57B1/6J mice > DBA/2J mice > hamster (**Neal et al.**, 1982).
3. "Responsiveness" of the mouse to **2,3,7,8-TCDD** induced toxicity seems to be highly dependent on the genetic conditions, as regards the **Ah<sup>b</sup> allele** gene, of the animal. However, cell lines "nonresponsive" to **P<sub>1</sub>-450** induction by 2,3,7,8-TCDD have also been found to possess Ah-receptor protein (**Guenther and Nebert**, 1977).

Ah receptor protein is also present in human tissue (Roberts et al., 1985). Whether variation in **Ah-locus** is critical for individual susceptibility to toxicity by PCDDs remains to be demonstrated in human population.

8.3.2. Metabolism. The metabolism of 2,3,7,8-TCDD has been examined in the guinea pig, rat, mouse and hamster. Urine and bile from **<sup>14</sup>C-TCDD**-treated animals were found to be free of **unmetabolized** 2,3,7,8-TCDD, demonstrating that metabolism was required for elimination through these routes (Olson et al., 1983). The direct intestinal elimination of unchanged 2,3,7,8-TCDD in feces suggests, however, that some routes of excretion may not be dependent on prior metabolism of the toxin (Olson et al., 1983).

Thus, it is not possible to directly correlate the half-life for elimination of **2,3,7,8-TCDD** with its *in vivo* rate of **metabolism** in a given species. The relative persistence of 2,3,7,8-TCDD in a given species may be related to the *in vivo* rate of 2,3,7,8-TCDD metabolism, excretion of the toxin not dependent upon metabolism (direct Intestinal elimination, lactation, **sebum**), and the relative tissue distribution of 2,3,7,8-TCDD, particularly to adipose stores. Qualitative and quantitative differences in the metabolism and disposition of 2,3,7,8-TCDD have been observed between various species, and these may in part be related to the remarkable **interspecies** differences in sensitivity to 2,3,7,8-TCDD **toxicity** (Olson et al., 1983).

**Poiger et al. (1982a)** suggested that 2,3,7,8-TCDD **metabolism** represents detoxification, since they observed relatively **little** toxicity in guinea pigs given extracts of dog **bile** containing 2,3,7,8-TCDD **metabolites**. However, a recent study proposes that **metabolites** of 2,3,7,8-TCDD may inhibit **uroporphyrinogen** decarboxylase activity and lead to **2,3,7,8-TCDD-induced porphyria** (De Verneuil et al., 1983). Current data on the structural identification of 2,3,7,8-TCDD metabolites suggest that reactive **epoxide** intermediates may be formed during metabolism (Polger et al., 1982b; **Sawahata et al., 1982**). Poland and Glover (1979) reported that the maximum possible in *vivo* covalent binding of **1,6-<sup>3</sup>H-2,3,7,8-TCDD** derived radioactivity to hepatic DNA was 4 orders of magnitude less than the levels of binding observed **with** other chemical carcinogens. The study found much higher levels of 2,3,7,8-TCDD derived radioactivity bound to hepatic protein of the rat. No data is available, however, on the degree 2,3,7,8-TCDD derived radioactivity **is** bound to tissues of various species of laboratory animals, which have demonstrated remarkable variability in sensitivity to 2,3,7,8-TCDD. **While** biliary excretion products may represent detoxified,



polar metabolites of 2,3,7,8-TCDD, **it** remains to be shown whether **unexcreted** reactive metabolites initiate some of the toxic responses associated **with** exposure to **this** toxin.

8.3.3. • Vitamin A Depletion. Many of the toxic effects of 2,3,7,8-TCDD resemble the effects of vitamin A deficiency, such as epithelial **lesions**, **keratosis** and Immunosuppression. The administration of a single oral dose of 0.1, 1.0 or 10 **µg 2,3,7,8-TCDD/kg** bw produces a dose-related decrease in the hepatic storage of **retinol** in Sprague-Dawley rats {Thunberg, **1984**; Thunberg et **al.**, 1979, 1980). The authors suggested, but **did** not demonstrate, that the low storage of **retinol** in the 2,3,7,8-TCDD-treated animals is the result of an increased turnover of retinol.

Hakansson and Ahlborg (1985) pretreated male Sprague-Dawley rats **with** 2,3,7,8-TCDD at 10 **µg/kg** bw 4 days before the oral administration of 1200 **IU/kg of retinyl** acetate. One hundred ninety-two hours **postadministration** of retinyl acetate the 2,3,7,8-TCDD-pretreated rats excreted **41%** of the retinyl acetate compared to the control excreting only 30%. After **2,3,7,7-**TCDD treatment the decrease in vitamin A content was 39-53, 19-67 and **18-44%** in the liver, Intestine and epididymis, **respectively**. 2,3,7,8-TCDD treatment also influenced vitamin A content in the thymus, initially increasing by 42X in 6 hours and then decreasing by **40%** in 192 hours as compared to the controls. 2,3,7,8-TCDD pretreatment increased the vitamin A content in the kidney 3-30 times that of the control. It is important to note that the kidney becomes the primary vitamin A storage organ in vitamin A deficient animals (Johnson and Baumann, 1947; Moore and **Sharman**, 1950). In a similar study Thunberg and Hakansson (1983) has also found an increase of vitamin A storage in the kidney after a single oral dose of 2,3,7,8-TCDD in male Sprague-Dawley **rats.**, Results from these observations suggest strongly that

**pretreatment with** a single oral dose of **2,3,7,8-TCDD** can affect both storage and excretion of **retinyl** acetate as well as the vitamin A storage in several tissues.

These results suggest that an induced vitamin A deficiency may be responsible for some, but not all, of the toxic effects produced by 2,3,7,8-TCDD. At the highest dose of 2,3,7,8-TCDD, dietary **retinol supplements** could not fully compensate for the 2,3,7,8-TCDD-produced decrease in hepatic retinol content.

8.3.4. Lipid Peroxidation. Increased **lipid peroxidation** has been suggested as a possible mechanism of **2,3,7,8-TCDD-induced toxicity** (Sweeney and Jones, 1983). This hypothesis is based on the following limited pieces of evidence. First, **iron** deficiency inhibits in vitro **lipid peroxidation** (Bus and Gibson, 1979; Sweeney et al., 1979) and reduces the **hepatotoxic** effects of 2,3,7,8-TCDD (Sweeney et al., 1979). Secondly, **lipofuscin** pigments, by-products of **lipid peroxidation**, are increased in the heart muscle of rats treated with 2,3,7,8-TCDD (Albro et al., 1978). Thirdly, Sweeney and Jones (1983) reported that administration of the **antioxidant** butylated **hydroxyanisole** (BHA) at a level of 0.75% in the **diet** provided some protection from **2,3,7,8-TCDD-induced prophyria** and neutral **lipid** accumulation. At this dose level of BHA, 4 of the 6 **mice** (sex not specified) tested were protected; however, at a lower dose (0.25%), all animals were protected from these toxic effects. No beneficial effects were observed when the antioxidant vitamin E (0.01%) was included in the **diet**.

Recently, Stohs et al. (1983) obtained direct evidence that 2,3,7,8-TCDD accelerates **lipid peroxidation** in Sprague-Dawley rats. Groups of 4-8 female rats were treated for 3 days with 2,3,7,8-TCDD at doses of 0, 10, 20 or 40 **µg/kg** by gavage (in a corn oil vehicle). At days 1, 6 and 11 after the

**Last** treatment the animals were sacrificed and **lipid peroxidation** was determined in Isolated **liver microsomes** by the reaction of formed **malondialdehyde with thiobarbituric acid**. At **all** sacrifice periods, Increased **lipid** peroxidation was observed and the Increase was dose-related. The maximal Increase detected on day 6 after the last treatment was 5- to 6-fold greater than in the **controls**. In addition, these workers measured **lipid** peroxidation **in vivo** by the determination of conjugated **dienes** in rats receiving 2,3,7,8-TCDD at 40  $\mu\text{g}/\text{kg}$ . Using **this** latter method, similar Increases in **lipid** peroxidation were detected, although the maximal Increase of 2.35-fold was observed at day 1 postexposure rather than day 6. The authors suggested that the **in vivo** formation of reactive free radicals during lipid peroxidation could account for the nonspecific nature of **2,3,7,8-TCDD toxicity**.

Since  $\beta$ -carotene can quench singlet oxygen ( $^1\text{O}_2$ ) and vitamin E is an **antioxidant**, Hassan et al. (1985) studied the effects of vitamins A and E on **2,3,7,8-TCDD** induced **lipid** peroxidation. Vitamin A was found to inhibit **lipid** peroxidation, elevated the activity of **glutathione peroxidase** and prevented a **2,3,7,8-TCDD-induced** decrease in GSH content in the liver. Vitamin E markedly inhibited **microsomal lipid** peroxidation, but **did** not have any effect on glutathione **peroxidase** activity or glutathione content.

8.3.5. Endocrine Imbalance. Some of the toxic response to 2,3,7,8-TCDD, including **hirsutism** and diminishing libido, indicate that 2,3,7,8-TCDD may produce some of its **toxicity** through endocrine disturbances (Oliver, 1975). **Nienstedt** et al. (1979) reported that a single oral dose of 20  $\mu\text{g}$  2,3,7,8-TCDD/kg bw significantly reduced testosterone **catabolism**. Catabolism of exogenous estrogen in **ovariectomized** rats is also decreased by 2,3,7,8-TCDD **pretreatment** (Silverlock and Muther, 1982). In **this** study, there was a 57% increase in serum estrone concentrations following administration of 10 mg

**estrone/100 g bw/day** for 4 days to either control or **2,3,7,8-TCDD** pretreated **ovariectomized** rats. No differences were observed in the increase in uterine wet weight **following** estrone administration in control and 2,3,7,8-TCDD pretreated rats. Thus, the **uterotrophic** response was not altered by any **2,3,7,8-TCDD-mediated** change in estrone disposition.

**Shiverick** and **Muther** (1983) also measured **estradiol** metabolism in female **Holtzman** rats given 2,3,7,8-TCDD at a dose of 1  $\mu\text{g/kg}$  bw on days 4-19 of gestation. At **this** fetal toxic dose, the catechol estrogen formation ability of isolated **liver microsomes** from the dams was decreased 50% when measured on day 20 of gestation. These **microsome** preparations had a **4-fold** increase in the **7 $\alpha$ -hydroxylation** of testosterone, while there was no change in the **16 $\alpha$ -** or **6 $\beta$ -hydroxylase** activity. Although steroid metabolism was altered in microsomes isolated from 2,3,7,8-TCDD-treated pregnant rats, similar exposure of pregnant rats on days 4-15 of gestation resulted in no change in circulating levels of serum **17 $\beta$ -estradiol**. The authors suggested that other mechanisms besides **liver** metabolism of steroids may be **involved** in the **fetotoxic** effect of 2,3,7,8-TCDD.

**Gustafsson** and **Ingelman-Sundberg** (1979) observed that 2,3,7,8-TCDD produced greater change in steroid metabolism in female Sprague-Dawley rats than **in** male rats of the same strain, resulting in a **liver** enzyme pattern displaying less sex differentiation than in **uninduced** rats. Based on **this** result, they propose that some of the effects of 2,3,7,8-TCDD resulted from an interaction **with** the **hypothalamo-pituitary axis**, rather than from a direct effect on steroid metabolism.

Since **glucocorticoid** hormones are known to have a **catabolic** effect on **lymphoid** tissues, such as the thymus and spleen, and these tissues degenerate after exposure of rats to 2,3,7,8-TCDD, **Neal et al.** (1979) investigated

the ability of **2,3,7,8-TCDD** to either stimulate the production or mimic the effects of these hormones. In male Sprague-Dawley rats treated by gavage with **2,3,7,8-TCDD** at a dose of 50 yg/kg (the  $\sim$ **LD<sub>50</sub>**), there was a slight depression in blood glucocorticoids during post-treatment days 1-4, followed by an  $\sim$ **2.5-fold** increase on post-treatment days 7 and 14. While in competitive binding assays between **2,3,7,8-TCDD** and a synthetic hormone, dexamethasone, 2,3,7,8-TCDD had no affinity for the hormone receptor. Thus, 2,3,7,8-TCDD may have stimulated **glucocorticoid** production but was not able to mimic the action of these hormones by binding to the glucocorticoid receptor. It was determined, however, that the increase in glucocorticoids was likely not to participate in the **toxicity** of 2,3,7,8-TCDD through adrenal **hyperfunction**, since prior adrenalectomy **did** not provide any protection from the lethal effects of 2,3,7,8-TCDD in rats.

#### 8.4. SUMMARY

8.4.1. Experimental Animal Data. A **wide** range of lethal doses has been reported for 2,3,7,8-TCDD depending on the species tested. The male guinea pig was the most sensitive, with an **LD<sub>50</sub>** value of 0.6 yg/kg; the male hamster was the least sensitive, with an **LD<sub>50</sub>** value of 5051 yg/kg (Schwetz et al., 1973; Henck et al., 1981). At least for acute exposure, the toxicity of 2,3,7,8-TCDD appears to depend on the total dose administered over a given **time** and not on whether exposure occurs through a single treatment or a limited number of multiple treatments. Unlike most lethal exposures to toxicants, death resulting from a lethal exposure to a single dose of 2,3,7,8-TCDD occurs long after treatment (5-45 days, see Table 8-1). The most common symptoms after lethal exposure were weight loss, often characterized as "wasting away," and **thymic** atrophy. Although **liver** damage was not observed in the guinea pig, the most sensitive species

to 2,3,7,8-TCDD, extensive **liver** damage was reported in rats and **mice** (Gupta et al., 1973). In general, no specific cause of death **could** be identified. In a limited comparison of the **LD<sub>50</sub>** for 9 congeners of PCDOs, it appeared that biologic activity required chlorine in the **2,3,7,8-positions** (McConnell et al., 1978b), **with** 2,3,7,8-TCDD being the most potent congener.

The liver has been studied **extensively with** regard to 2,3,7,8-TCDD acute **toxicity** in rats and **mice**. Single **high** doses, 200 yg/kg, of 2,3,7,8-TCDD produced **liver** necrosis in rats (Jones and Butler, 1974); however, lower doses of 5 and 25 yg/kg produced fatty changes and proliferation of the ER (Fowler et al., 1973). Along **with** increases in ER, there was an associated marked increase in **MFO** activity (see Section 8.1.1.5.). **Additional** membrane changes included degeneration of the plasma membrane **with** loss of ATPase activity. In species sensitive to the **hepatotoxic** effects of 2,3,7,8-TCDD, there was **also** a decreased ability to excrete some **xenobiotics** into the **bile** (Yang and Peterson, 1977; Hwang, 1973). **Porphyria** was also observed, **with** the mouse being more sensitive than the rat. In addition to effects on the **liver**, 2,3,7,8-TCDD also affects intestinal absorption by increasing and decreasing the absorption of specific nutrients. In some species, the **cellularity** of the blood was decreased.

Effects of 2,3,7,8-TCDD exposure on the immune system have been studied extensively. 2,3,7,8-TCDD is **undisputably** an acute **immunotoxic** substance in animal models, causing decreases in **thymic** and splenic weight and hindering, **predominantly**, cell-mediated immunity. **T-lymphocyte** function is primarily affected, although a reduction in the immune response to a **thymus-independent** antigen (type III pneumococcal **polysaccharide**) has been reported following 2,3,7,8-TCDD exposure (Vecchi et al., 1980). 2,3,7,8-TCDD presumably affects **lymphocytes** or thymic **cells** directly, since several studies have

negated Indirect routes of Immunosuppression (**hormonal** controls). 2,3,7,8-TCDD at **immunotoxic levels** that alter **all** function, however, **is not directly cytotoxic** to lymphocytes (**Kociba** and Schwetz, 1982). Its effects may be **reversible** after long recovery periods (Faith and Luster, 1979).

**2,3,7,8-TCDD** has been shown to alter serum **immunoglobulin** levels in **mice** at oral doses as low as 0.01 and 0.1 yg/kg/week when administered for up to 8 weeks (**Sharma** and **Gehring**, 1979). Thomas and Hinds (1979) reported reduced hypersensitivity to DNFB, decreased Immune response to **E. coli** LPS and decreased **thymic** weight in young **mice** exposed to 2.5 and 5 ppb 2,3,7,8-TCDD (0.33 and 0.65 yg/kg) through maternal dosing. **Thigpen et al.** (1975) postulated a NOEL of 0.5 yg **2,3,7,8-TCDD/kg/week** for 4 weeks, but more precise tests of **immunotoxicity** suggest a lower NOEL would be appropriate, especially for neonatal and young animals.

The mechanism of **2,3,7,8-TCDD-induced immunotoxicity** is not yet known. 2,3,7,8-TCDD is not **likely** to decrease Immune responsiveness through an endocrine control. 2,3,7,8-TCDD may act as an **antigenic** agent causing Immunosuppression and thymic atrophy (Sharma and **Gehring**, 1979). It has also been suggested that 2,3,7,8-TCDD attaches to the cell membrane of **T-lymphocytes**, **altering** the **cell** surface, which could Interfere **with** antigen and cell-to-cell recognition (Luster et **al.**, 1979a,b; Faith and Luster, 1979).

In **subchronic toxicity** studies in rats and **mice**, the **liver** appeared to be a target organ. The Induction of **liver** damage after repeated exposure to small doses of 2,3,7,8-TCDD was shown in rats. Histologic changes in the **liver** of rats killed 2, 4, 8, 16 and 28 weeks after exposure to weekly doses of 1 yg/kg bw revealed no fatty changes until week 28; however, 12 weeks after termination of the 28-week exposure, there was still evidence of fatty

changes in the liver (**King and Roesler, 1974**). A similar **long** Induction period was observed by Goldstein et al. (1982b) for **porphyrin** accumulation in the liver of rats. Following 16 weeks of exposure to **2,3,7,8-TCDD** and a 6-month postexposure **period**, porphyrin levels were still elevated. The only study in **mice** (NTP, 1980a) described toxic hepatitis as the only effect of **subchronic** exposure to low levels of 2,3,7,8-TCDD. In these and other subchronic studies, NOELs of 0.01 yg/kg/day (**Kociba et al., 1976**), 0.5 yg/kg/week (NTP, 1980a) and 0.01 yg/kg/week (Goldstein et al., 1982b) have been reported for rats. In **mice**, a NOEL of 2 yg/kg/week was obtained in females, while males exposed to 1 yg/kg/week (the lowest dose tested) developed toxic hepatitis. Similar hepatic lesions were observed after exposure to a mixture of HxCDDs **with** NOELs of 2.5 and 1.25 yg/kg/week reported for rats and **mice**, respectively (NTP, 1980b).

In chronic **toxicity** studies in rats and **mice**, it was again the liver that appeared to be the most sensitive organ. Changes in the liver of rats included **initially** fatty infiltration, and at higher doses, necrosis. The studies in rats indicated that 0.001 yg/kg/day was a NOEL, while 0.05 and 0.1 yg/kg/day were the NOAEL and **FEL** for liver damage (Kociba et al., **1978b**, 1979; NTP, 1980a). In **mice**, a NOEL was not determined, **with** the lowest doses tested, 0.0015 and 0.006 yg/kg/day, producing liver damage in male and female B6C3F1 **mice** (NTP, **1980a**), while the lowest dose tested in Swiss **mice**, 0.001 yg/kg/day, produced **amyloidosis** of the kidney, spleen and **liver** (Toth et al., 1978, 1979). In nonhuman primates, chronic exposure to **2,3,7,8-TCDD** in the **diet** at 50 or 500 ppt resulted in **hair** loss, edema and **pancytopenia** (Allen et al., 1977; Schantz et al., 1979). Data were not available to determine a NOEL for monkeys. Also, in the only study **avail-**



able for 1,2,3,6,7,8- or **1,2,3,7,8,9-HxCDD**, the lowest doses tested, 1.25 and 2.5  $\mu\text{g}/\text{kg}/\text{week}$  for males and females, **respectively**, produced toxic hepatitis and represented a **FEL** (NTP, 1980b).

8.4.2. Human Data. There seems to be general agreement that exposure to **2,3,7,8-TCDD**, whether acutely or chronically, **leads** to chloracne, altered **liver** function, **hematological** abnormalities, **porphyria** cutanea tarda, hyperpigmentation and **hirsutism**. Recently, **Suskind** and Hertzberg (1984) have demonstrated an association between exposure to **2,4,5-T** contaminated **with 2,3,7,8-TCDD** and the history of **GI** ulcer. No evidence of Increased **risk** for cardiovascular disease, hepatic disease, renal damage or central or peripheral nervous system problems could be found in a group of workers exposed to 2,4,5-T following a run way reaction (Suskind and **Hertzberg**, 1984). However, occupational or accidental exposure to 2,3,7,8-TCDD has been shown to produce neurological ailments in addition to the above ailments. The **neurological** problems include peripheral **polyneuropathies**, Impairment of sensory functions including sight disorders, **loss** of hearing, taste and sense of smell, central lassitude, weakness, Impotence and loss of **libido** (**Reggiani**, 1982; **Kimbrough** et al., 1984). Only one estimate was available, which speculates a cumulative minimum toxic dose of 0.1  $\mu\text{g}/\text{kg}$  for man (Stevens, 1981). The available follow-up reports and epidemiological studies, primarily on **populations** exposed **occupationally, accidentally** or in Vietnam, indicate that toxic effects noted soon after exposure to 2,3,7,8-TCDD may subside or may persist for many years.

8.4.3. **Mechanisms of Toxicity**. In the preceding sections, **five** possible mechanisms by which 2,3,7,8-TCDD may produce its toxic effects were reviewed. The data suggest that metabolism of 2,3,7,8-TCDD is a detoxification process, resulting in the production of metabolites that are less toxic

than the parent **compound**, **although** Intermediate or minor metabolites of **2,3,7,8-TCDD** may be Involved in **toxicity**. Vitamin A **depletion**, Increased **lipid peroxidation** and effects on the **hypothalamo-pituitary axis** have all been Implicated as possible mechanisms for **2,3,7,8-TCDD-induced** toxic response. It seems **probable** that these mechanisms are **responsible** for some, but not all, of the toxic effects of 2,3,7,8-TCDD.

The major mechanism of 2,3,7,8-TCDD toxldty that has received Intense Investigation Involves effects mediated by specific **cytosolic** receptors produced by the Ah locus. The toxldty of various **dioxins** has been correlated **with** binding to the cytosollic receptor and enzyme Induction **in** a **wide** range of animal spesdes and under a variety of experimental conditions (**vide** ante). While these studies have been done **in** several spesdes, species differences in the toxic response to 2,3,7,8-TCDD do not correlate **with** spesdes differences in receptor concentration or affinity, or **with** the degree of enzyme Induction. It thus appears that the toxldty of 2,3,7,8-TCDD may be mediated by binding to the cytosollic receptor responsible for enzyme Induction; however, **this** theory does not apply in various species, and cell culture studies Indicate that enzyme Induction is not necessarily a **cytotoxic** process.

## 9. TERATOGENICITY AND OTHER REPRODUCTIVE EFFECTS

### 9.1. STUDIES ON EXPERIMENTAL MAMMALS

9.1.1. **2,3,7,8-TCDD** Administered as a Contaminant of Other Chemicals. Courtney et al. (1970a,b) were the first to report that **2,4,5-T** was capable of causing **teratogenic** effects in rats and **mice**. In these studies, rats and two strains of **mice** were exposed subcutaneously or orally to 2,4,5-T containing 30 ppm 2,3,7,8-TCDD. The mixture was teratogenic and **fetotoxic** to **mice** at **>46.4** mg/kg. Rats were more sensitive, exhibiting fetotoxic responses at 10 mg/kg for **this 2,4,5-T/2,3,7,8-TCDD** mixture. Since **this** Initial report, research has focused on determining the role of 2,3,7,8-TCDD contamination in eliciting the teratogenic response. These studies are summarized in Table 9-1.

Neubert and **Dillmann** (1972) conducted a detailed study to determine the significance of 2,3,7,8-TCDD contamination. These Investigators assayed three 2,4,5-T samples: a highly purified sample containing **<0.02** ppm 2,3,7,8-TCDD (referred to as Sample A), a purified sample identical to that used by **Roll (1971)** that contained **0.05±0.02** ppm 2,3,7,8-TCDD (Sample B), and a commercial sample containing an undetermined quantity of 2,3,7,8-TCDD (Sample C). All three samples induced cleft palates at sufficiently **high** doses (30-90 mg/kg). In terms of the number of fetuses **with cleft palate/** the total number of fetuses, the dose/response pattern observed by Neubert and **Dillmann** (1972) was similar to that observed by **Roll (1971)** using a similar grade of 2,4,5-T. In addition to the three 2,4,5-T samples, Neubert and **Dillmann** (1972) also assayed a sample of 2,3,7,8-TCDD alone and in various combinations **with** the highly purified sample of 2,4,5-T. **This** approach allows at least partial quantification of the significance of 2,3,7,8-TCDD contamination **in 2,4,5-T-induced** cleft palates. When the

TABLE 9-1

## Studies on the Potential Teratogenic Effects of 2,3,7,8-TCDD Contaminated 2,4,5-T

| Species/Strain | Vehicle                | Form of 2,4,5-T | TCOD Level               | Dally Dose                          | Treat-ment Days | Observation Day | Maternal Response   | Fetal Response   | Reference                  |
|----------------|------------------------|-----------------|--------------------------|-------------------------------------|-----------------|-----------------|---|--|----------------------------|
| Mice/NMRI      | Rape-seed oil          | acid            | <0.02 ppm (Sample A)     | B. 15, 30, 45, 60, 90 and 120 mg/kg | 6-15            | 18              | No toxic effects; decreased Mternal weight at doses of 90 Mg/kg and greater | Significant increases in the incidence of cleft palates at doses above 30 Mg/kg (see text for additional details). Significantly decreased (p<0.005) fetal weight at all dose levels.        | Neubert and Dillmann, 1972 |
| Mice/NMRI      | Rape-seed oil          | acid            | 0.05+0.02 ppm (Sample B) | 30, 60 and 90 Mg/kg                 | 6-15            | 18              | No toxic effects; decreased Mternal weight at 90 Mg/kg                      | Increases in the incidence of cleft palate at 60 and 90 Mg/kg; significant (p<0.005) at all dose levels  | Neubert and Dillmann, 1972 |
| Mice/NMRI      | Rape-seed oil          | acid            | NR (Sample C)            | 90 Mg/kg                            | 6-15            | 18              | No toxic effects but decreased Mternal weight                               | Increase in the incidence of cleft palate; significant (p<0.005) decrease in fetal weight  | Neubert and Dillmann, 1972 |
| Mice/NMRI      | Rape-seed oil          | butyl ester     | NR                       | 1? and 17 Mg/kg                     | 6-15            | 18              | No toxic effects  | Significant decrease in fetal weight but no effect on Mortality; Increase in the frequency of cleft palate similar to that seen with acid (see text)   | Neubert and Dillmann, 1972 |
| Mice/NMRI      | NR                     | acid            | 0.05+0.02 ppm            | 20, 35, 60, 90 and 130 Mg/kg        | 6-15            | NR              | Toxic effects observed at 90 and 130 Mg/kg                                  | Increases in the percentage of resorptions and/or dead fetuses at 90 and 130 Mg/kg; Increases in the incidence of cleft palate and retardation of skeletal development at 35 Mg/kg and above | Roll, 1971                 |
| Nice/CD-I      | Corn oil:acetone (9:1) | acid            | <0.05 ppn                | 115 Mg/kg                           | 10-15           | 18              | No significant effect on weight gain or liver-to-bw ratios                  | No effect on fetal Mortality or fetal weight but an increase in the incidence of cleft palate  | Courtney, 1977             |

TABLE 9-1 (cont.)

| Species/Strain   | Vehicle  | Form of<br>2,4,5-T | TCDD Level | Daily Dose                      | Treat-<br>ment<br>Days | Obser-<br>vation<br>Day | Maternal Response   | Fetal Response   | Reference   |
|--|--|--------------------|------------|---------------------------------|------------------------|-------------------------|---|--|---|
| Mice/C57BL/6   | Honey:water<br>(1:1)                           | acid               | 30 PPM     | 46.4 and 113<br>Mg/kg           | 6-14                   | 18                      | NR  | Significant ( $p < 0.01$ )<br>Increases in the Incidence<br>of cleft palate in the high<br>dose group and cystic<br>kidney in both dose groups;<br>Increased fetal mortality<br>also observed in the high<br>dose group  | Courtney<br>et al., 1970a,b                           |
| Mice/AKR   | Honey:water<br>(1:1)                           | add                | 30 ppm     | 113 Mg/kg                       | 6-15                   | 19                      | Increase in liver-<br>to-bw ratio   | Significant ( $p < 0.05$ )<br>Increases in the Incidence<br>of cleft palate and fetal<br>mortality   | Courtney<br>et al., 1970a,b                           |
| <sup>6</sup><br>1<br>CO<br>Rats/Sprague-<br>Dawley<br>(groups of<br>25 rats) | Gavage/hydroxy-<br>propyl-methyl-<br>cellulose | acid               | 0.5 ppm    | 1. 3. 6. 12 or<br>24 mg/kg/day  | 6-15                   | ?                       | No effect on bw<br>and no observable<br>signs of toxicity   | A slight but statistically<br>significant ( $p < 0.05$ )<br>decrease in Implantations<br>and Utter size in lowest<br>dose group only; no frank<br>teratogenic effects based<br>on a detailed examination<br>of the control and 24 mg/kg<br>dose group; the only effect<br>noted was an Increase in<br>the incidence of 5th par-<br>tially ossified sternbrae | Emerson et al.,<br>1970. 1971                         |
| Rats/Wistar  | Gavage/aqueous<br>gelatin or<br>corn oil       | acid               | <0.5 Mg/kg | 25. 50. 100 or<br>150 mg/kg/day | 6-15                   | 22                      | Some maternal<br>Mortality and<br>decreased bw<br>gain at 150 mg/kg;<br>no signs of<br>toxicity at<br>100 mg/kg or<br>below | At 100 or 150 mg/kg.<br>decreased fetal weight,<br>Increased fetal mortality<br>and an Increase in the<br>Incidence of skeletal<br>anomalies; no significant<br>effect at the two lower<br>dose levels   | Khera and<br>McKinley, 1972;<br>Khera et al.,<br>1971 |
| Rats/Wistar  | Gavage/aqueous<br>gelatin or<br>corn oil       | butyl<br>ester     | <0.5 Mg/kg | 50 or 150<br>Mg/kg/day          | 6-15                   | 2?                      | MR  | No significant effect on<br>fetal mortality, fetal<br>weight or the Incidence<br>of anomalies  | Khera and<br>McKinley, 1972;<br>Khera et al.,<br>1971 |

TABLE 9-1 (cont.)

| Species/Strain   | Vehicle  | Form of<br>2,4,5-T | TCDD Level  | Daily Dose                                | Treat-<br>ment<br>Days | Observation<br>Day | Maternal Response   | Fetal Response  | Reference                   |
|--|--|--------------------|-------------|---|------------------------|--------------------|---|---|-----------------------------|
| Rats/Holtzman  | Gavage/1:1<br>solution of<br>honey and water   | acid               | 30 PPM      | 4.6, 10.0 and<br>46.4 Mg/kg/day           | 10-15                  | 20                 | NR  | Significant ( $p < 0.01$ )<br>Increases in fetal Mor-<br>tality at the 2 higher<br>dose levels; dose-related<br>Increases in the percent<br>of abnormal fetuses per<br>litter; a high incidence<br>of cystic kidneys in<br>treated groups | Courtney<br>et al., 1970a,b |
| Rats/CD  | Gavage/15%<br>sucrose solution   | acid               | 0.5 ppm     | 10.0, 21.5,<br>46.4 and 80.0<br>mg/kg/day | 6-15                   | 20                 | Reduced Maternal<br>weight gain at the<br>2 higher dose<br>levels ( $p < 0.05$ )<br>and Increased<br>liver-to-bw ratio<br>at the highest dose<br>level ( $p < 0.05$ ) | Increase in the Incidence<br>of kidney anomalies, but<br>no Increase in cleft<br>palate   | Courtney and<br>Moore, 1971 |
| Rats/strain<br>not specified                                 | Gavage/Methocel  | add                | 0.5 ppm     | 50 mg/kg                                  | 6-15                   | NS                 | No effect on Mor-<br>tality or bw gain  | No significant effect on<br>fetal Mortality or fetal<br>weight; a significant<br>( $p < 0.05$ ) Increase in the<br>Incidence of delayed<br>ossification   | Sparschu<br>et al., 1971a   |
| Rats/strain<br>not specified                                 | Gavage/methocel  | acid               | 0.5 ppm     | 100 mg/kg                                 | 6-10                   | NS                 | Increased Mor-<br>tality and<br>decreased bw gain   | Increase in the Incidence<br>of delayed ossification<br>and poorly ossified or<br>malaligned sternbrae<br>( $p < 0.05$ )  | Sparschu<br>et al., 1971a   |
| Syrian<br>hamsters/<br><i>Mesocricetus</i><br><i>auratus</i> | Gavage/acetone,<br>corn oil, and<br>carboxymethyl<br>cellulose in<br>ratio of 1:5.8:10 | acid               | <0.1-4.5ppm | 20, 40, 80<br>and 100 Mg/kg               | 6-10                   | 14                 | NS  | Dose-related Increases in<br>fetal mortality, gastro-<br>intestinal hemorrhages,<br>and fetal abnormalities;<br>see text for discussion<br>of effect TCDD level on<br>development   | Collins et al.,<br>1971     |

NS = Not specified; NR = Not reported

litter ls used as the basic **experimental unit**, the Incidences of cleft palate (number of Utters **with** cleft palate/total numbers of Utters) versus the dose can be plotted on log **dose/probit** response paper, correcting for background response using **Abbott's** equation. According to **this** method, the **ED<sub>50</sub>** (by eye-fit) for cleft palate Induction are as follows:

**2,3,7,8-TCDD:** 4.6  $\mu\text{g/kg}$  bw

**2,4,5-T (Sample A):** 115  $\text{mg/kg}$  bw

**2,4,5-T (Sample B):** 46  $\text{mg/kg}$  bw

If the assumption were made that all **teratogenic** activity ln the 2,4,5-T samples were attributable to 2,3,7,8-TCDD contamination, the expected **ED<sub>50</sub>** for samples A and B would be 230,000  $\text{mg/kg}$  ( $0.0046 \text{ mg/kg} \times 0.02 \text{ ppm}^{-1}$ ) and 92,000  $\text{mg/kg}$  ( $0.0046 \text{ mg/kg} \times 0.05 \text{ ppm}^{-1}$ ), respectively. Since the observed **ED<sub>50</sub>** was lower by a factor of over 1000, **this** suggests that 2,3,7,8-TCDD ls not the sole factor ln **2,4,5-T-induced** cleft palate.

The nature of possible Interaction between 2,4,5-T and 2,3,7,8-TCDD ls more difficult to define. Based on assays of **five** mixtures of 2,3,7,8-TCDD and the highly purified 2,4,5-T, Neubert and **Dillmann** (1972) noted a greater than additive effect on the Induction of cleft palates. A similar conclusion can be reached lf one assumes that Sample A was a **"totally pure"** sample of 2,4,5-T. Using the assumptions of **simple** similar action (**Finney**, 1971) and treating Sample B as a mixture of 2,3,7,8-TCDD and 2,4,5-T, the expected **ED<sub>50</sub>** for Sample B would be 119.8  $\text{mg/kg}$ . The observed value of 46  $\text{mg/kg}$  again suggests a greater than additive effect. A more detailed statistical analysis of these data, however, would be required to support the assumptions of simple similar action or Independent joint action that are Implicit ln these analyses. Furthermore, the Inability to define precisely the

levels of **2,3,7,8-TCDD** in the **2,4,5-T** samples and the possible significance of other contaminants would preclude **an** unequivocal Interpretation of the results of the analysis.

Nevertheless, three of the studies summarized in Table 9-1 (Neubert and **Dillmann**, 1972; **Roll**, 1971; Courtney, 1977) have demonstrated the Induction of cleft palate in **mice** by using 2,4,5-T samples containing 2,3,7,8-TCDD levels of  $0.05 \pm 0.02$  ppm or less. Although 2,3,7,8-TCDD contamination **is** undoubtedly a factor in the **teratogenic** activity of 2,3,7,8-TCDD contaminated 2,4,5-T, the above analysis suggests that 2,3,7,8-TCDD contamination is not the sole factor, and that some teratogenic activity must be attributed to 2,4,5-T itself or other contaminants in 2,4,5-T.

9.1.2. 2,3,7,8-TCDD Studies in **Mice**. Courtney and Moore (**1971**) tested a purified sample of 2,3,7,8-TCDD for teratogenic potential. A summary of **this** study and others assessing the teratogenic potential of purified 2,3,7,8-TCDD are presented in Table 9-2. **CD-1**, DBA/2J and C57B1/6J **mice** were given subcutaneous Injections of 2,3,7,8-TCDD at 1 or 3  $\mu\text{g}/\text{kg}/\text{day}$  on days 6-15 of gestation **in** the study by Courtney and Moore (1971). **This** dose regime **did** not result in **maternal** toxicity, although an Increase in the maternal **liver/bw** ratio was observed in DBA/2J and C57B1/6J **mice**. 2,3,7,8-TCDD had no measurable effect on fetal mortality; however, anatomical abnormalities were observed in all strains and at all dose levels, **with C57B1/6J** being the most sensitive strain. The abnormalities observed were cleft palate and unspecified kidney anomalies.

Moore et al. (**1973**) treated pregnant C57B1/6 **mice with** an oral dose of 2,3,7,8-TCDD at 1 or 3  $\mu\text{g}/\text{kg}/\text{day}$  on days 10-13 of gestation, or 1  $\mu\text{g}/\text{kg}$  on day 10 of gestation. At the **high** dose level, the average Incidence of cleft palate was **55.4%**. Kidney anomalies (hydronephrosis) were observed on



TABLE 9-2

## Studies on the Potential Teratogenic Effect of 2,3,7,8-TCDD

| Species/Strain                               | Vehicle                         | Daily Dose                                   | Treatment Days                     | Observation Day | Maternal Response                                    | Fetal Response  | Reference                     |
|--|---------------------------------|--|------------------------------------|-----------------|--|---|-------------------------------|
| <b>9-7</b><br>Mouse/C57B1/6<br>Mouse/AKR     | DNSO or<br>honey:water<br>(1:1) | 21.5. 46.4.<br>113.0 mg/kg                   | 6-14 or 9-17                       | 19 <sup>a</sup> | Increased liver/<br>bw ratio                         | fetocidal, cleft palate,<br>cystic kidney   | Courtney<br>et al., 1970b     |
| Mouse/CD-1<br>Mouse/OBA/2J<br>Mouse/C57B1/6J | DNSO                            | 0.5. 1. 3 pg/kg                              | 6-15                               | 17* or 18       | Increased liver/<br>bw ratio                         | cleft palate,<br>kidney anomalies   | Courtney and<br>Noore. 1971   |
| Mouse/C57B1/6                                | acetone:<br>corn oil<br>(1:9)   | 1. 3 vg/kg                                   | 10-13 or 10                        | 18*             | none reported  | cleft palate, kidney<br>anomalies   | Noore et al.,<br>1973         |
| Mouse/CD-1                                   | DNSO or<br>corn oil             | 25, 50. 100.<br>200. 400 µg/kg               | 7-16                               | 18 <sup>b</sup> | Increased liver/<br>bw ratio                         | cleft palate, hydronephrotic<br>kidneys, hydrocephalus, open<br>eyes, edema, petechiae  | Courtney, 1976                |
| Mouse/CF-1                                   | corn oil/<br>acetone<br>(98:2)  | 0.001. 0.01.<br>0.1. 1.0.<br>3.0 pg/kg       | 6-15                               | 18 <sup>a</sup> | none reported  | cleft palate, dilated renal<br>pelvis   | Smith et al.,<br>1976         |
| Mouse/NMRI                                   | rape-seed<br>oil                | 0.3. 3.0. 4.5.<br>9.0 pg/kg                  | 6-15                               | 18              | no effect observed                                   | fetocidal at the high dose,<br>cleft palate at doses at or<br>above 5 pg/kg   | Neubert and<br>Dillmann, 1972 |
| Rat/CD                                       | DNSO                            | 0. 0.5.<br>2.0 pg/kg                         | 6-15. 9 and<br>10. or 13<br>and 14 | 20 <sup>a</sup> | none reported  | kidney malformations at<br>both dose levels   | Courtney and<br>Noore. 1971   |
| Rat/Sprague-<br>Dawley                       | corn oil/<br>acetone            | 0. 0.03. 0.125.<br>0.5. 2.0 and<br>8.0 pg/kg | 6-15                               | 20*             | vaginal hemorrhage<br>at 2.0 and<br>8.0 pg/kg        | Intestinal hemorrhage at<br>0.125 and 0.5 pg/kg.<br>fetal death at higher doses,<br>subcutaneous edema                        | Sparschu<br>et al., 1971b     |
| Rat/Wistar                                   | corn oil/<br>anisole            | 0.0. 0.125,<br>0.25. 1. 2. 4.<br>8. 16 pg/kg | 6-15                               | 22              | maternal toxicity<br>observed at or<br>above 1 pg/kg | Increased fetal death<br>observed at or above<br>1 pg/kg. subcutaneous<br>edema and hemorrhages in<br>the 0.25-2 pg/kg groups | Khera and<br>Ruddick, 1973    |

TABLE 9-2 (cont.)

| Species/Strain     | Vehicle                | Daily Dose   | Treatment Days       | Observation Day  | Maternal Response   | Fetal Response   | Reference             |
|--------------------|------------------------|--|----------------------|------------------|---|--|-----------------------|
| Rat/Sprague-Dawley | corn oil/acetone (9:1) | 0.1, 0.5, 2.0 $\mu\text{g}/\text{kg}$                    | 1-3                  | • 21             | decrease in bw gain in the high dose group  | decreased fetal weight in the 0.5 and 2 $\mu\text{g}/\text{kg}$ group  | Glavinl et al., 1982a |
| Rat/Sprague-Dawley | diet                   | 0.001, 0.01 and 0.1 $\mu\text{g}/\text{kg}$ <sup>c</sup> | throughout gestation | post-parturition | low fertility at 0.01 and 0.1 $\mu\text{g}/\text{kg}$ decreased bw at 0.01 and 0.1 $\mu\text{g}/\text{kg}$ dilated renal pelvis | low survival at 0.01 and 0.1 $\mu\text{g}/\text{kg}$ , decreased bw at 0.01 $\mu\text{g}/\text{kg}$ , slight dilated renal pelvis at 0.001 $\mu\text{g}/\text{kg}$ in the F <sub>1</sub> but not succeeding generations <sup>d</sup> | Hurray et al., 1979   |
| Rabbit/New Zealand | corn oil/acetone (9:1) | 0.0, 0.1, 0.25, 0.5 and 1 $\mu\text{g}/\text{kg}$        | 6-15                 | 28               | Maternal toxicity at doses of 0.25 $\mu\text{g}/\text{kg}$ and above  | Increases in extra ribs and total soft tissue anomalies  | Glavinl et al., 1982b |

<sup>a</sup>First day of gestation designated day zero

<sup>b</sup>First day of gestation designated day one

<sup>c</sup>The high dose level (0.1  $\mu\text{g}/\text{kg}/\text{day}$ ) was discontinued due to very low fertility in adults

<sup>d</sup>Nisbet and Paxton (1982) re-evaluated the study by Murray et al. (1979) using different statistical methods and considered the effects in the 0.001  $\mu\text{g}/\text{kg}$  group to be statistically significant.

an average of 95.1% of the fetuses/Utter, **with 83.1%** having bilateral kidney anomalies. When the dose was decreased to 1 yg/kg/day, the average Incidence of cleft palate dropped to **1.9%**; however, the Incidence of kidney anomalies remained relatively **high, with** an average Incidence of 58.9%. On the average, bilateral kidney **anomalies** occurred in 36.3% of the **fetuses/Utter**. A single dose of 1 yg/kg on day 10 of gestation produced kidney anomalies in 34.3% of the fetuses; however, no cleft palates were observed. When C57B1/6 **mice** were treated **with** 1 yg/kg on day 10 of gestation and were then **allowed** to Utter, the detection of kidney lesions on postnatal day 14 was found to depend largely on whether the pups nursed on a 2,3,7,8-TCDD-treated mother. When pups from a **2,3,7,8-TCDD-treated** mother nursed on control **mice**, kidney anomalies were found in **only** 1/14 Utters. In contrast, when pups from control mothers nursed on 2,3,7,8-TCDD-treated **mice**, kidney anomalies were observed in 4/14 litters. In the pups exposed to **2,3,7,8-TCDD** both in utero and during the postnatal period, kidney anomalies were observed in 5/7 Utters. Kidney anomalies observed following in utero exposure or exposure through the **milk** were similar, and these kidney anomalies may not be considered a purely **teratogenic** response.

Neubert et al. (1973) reviewed what was known of the **embryotoxic** effects of 2,3,7,8-TCDD **in** mammalian species. Also reported were their own studies and previous work (Neubert and Dillmann, 1972) using **NMRI mice**, in which cleft palate was observed to be a common abnormality; however, no kidney anomalies were reported. Neubert and Dillmann (1972) administered 2,3,7,8-TCDD by gavage to 20 female **mice** on days 6 through 15 of gestation at doses of 0.3, 3.0, 4.5 and 9.0 yg/kg. At day 18 of gestation, extensive **reabsorption** was observed in the high-dose group **with** 6/9 Utters totally resorbed. In the few surviving fetuses, there was an 81% Incidence of cleft

palate. At lower doses, there were 9 and 354 Incidences at doses of 4.5 and 3.0 yg/kg, respectively, and no cleft palates were observed in 138 fetuses examined in the 0.3 yg/kg group. Fetal mortality was increased at the 9.0 yg/kg dose if animals were treated only on days 9 through 13; however, the incidence of cleft palate remained high at a frequency of 60%. In a series of experiments to determine the time of gestation at which 2,3,7,8-TCDD was effective in inducing cleft palate, mice were treated for a single day between days 7 and 13 of gestation with 2,3,7,8-TCDD at a dose of 45 yg/kg. A maximum number of induced cleft palates occurred when animals were treated on either day 8 or 11 of gestation; exposure to 2,3,7,8-TCDD after day 13 of gestation produced no cleft palates in the fetuses.

Courtney (1976) compared the teratogenic potential of 2,3,7,8-TCDD administered orally with 2,3,7,8-TCDD administered subcutaneously. CD-1 mice were dosed with 2,3,7,8-TCDD on days 7 through 16 of gestation at levels of 25, 50, 100, 200 or 400 yg/kg/day; the 400 yg/kg dose was not used in animals treated by subcutaneous injection. Doses of 200 or 400 yg/kg/day produced vaginal bleeding and high rates of abortion. A dose of 100 yg/kg/day was fetotoxic, resulting in decreased fetal weight and survival. Anatomic abnormalities were observed at all dose levels, with cleft palate and hydronephrotic kidneys being most common. Other abnormalities observed included hydrocephalus, open eye, edema and petechiae. Subcutaneous administration of 2,3,7,8-TCDD produced a greater teratogenic response at a lower dose than oral administration, with abnormalities observed in 87% of the fetuses following subcutaneous administration and 42% after oral administration of a dose of 25 yg/kg/day.

The effects of 2,3,7,8-TCDD on the incidence of fetal anomalies were also studied by Smith et al. (1976) in CF-1 mice. The mice were given

0.001-3.0 yg 2,3,7,8-TCDD/kg/day by gavage from day 6 through 15 of gestation. The Incidence of cleft palate was found to be significantly Increased in 1.0 and 3.0 yg/kg/day dose **groups**, and the Incidence of kidney **anomalies** was significantly Increased at 3.0 yg/kg/day. There were no observable **teratogenic** effects in the study at 0.1 yg/kg/day; however, some were noted at lower dose levels, although not statistically significantly elevated.

Poland and Glover (1980) compared cleft **palate** formation by **2,3,7,8-TCDD** in the responsive **C57B1/6J**, the **nonresponsive** DBA/2J and the hybrid **B6D2F1/J** strains of **mice**. Female **mice** were mated **with** male **mice** of the same genetic strain, and on day 10 of pregnancy the pregnant **mice** were given a single subcutaneous dose of 3.0, 10.0 or 30.0 yg/kg of 2,3,7,8-TCDD dissolved in **p-dioxane** or the solvent (control) alone (0.4 **ml/kg**). On day **18**, the animals were killed and the number of cleft palates and resorbed fetuses was determined. At doses of 3.0 and 10.0 yg/kg of 2,3,7,8-TCDD, cleft palates (**3%** Incidence among **live** fetuses) were observed only in the C57B1/6J **mice** at the higher dose level. At a dose of 30 **µg/kg**, the Incidence of cleft palates among **live** fetuses for the C57B1/6J, B6D2F1/J and DBA/2J **mice** was 54, **13** and 2%, respectively. **This** study also reported that cleft palate formation was significantly higher in several other responsive mouse strains compared **with** nonresponsive **mice**. At a dose level of 30 yg/kg of 2,3,7,8-TCDD, the Incidence of cleft palates among **live** fetuses for the responsive C57B1/6J, **A/J**, BALB/cByJ and SEC/1REJ **mice** was 54, 73, 65 and 95%, respectively. The only responsive mouse (CBA/J) strain that was resistant to **2,3,7,8-TCDD-mediated** cleft palate was also resistant to the teratogenic effects of cortisone. In contrast, the Incidence of cleft palates in the nonresponsive DBA/2J, **RF/J**, **AKR/J**, **SWR/J** and **129/J** **mice** was

between 0 and 354 at the 30 yg/kg dose level. In a reciprocal blastocyst transfer study between **2,3,7,8-TCDD** "responsive" (NMRI) and "nonresponsive" (DBA) strains of mice it has been demonstrated that **2,3,7,8-TCDD** exposure (30 yg/kg bw) on day 12 of gestation developed cleft palate in 75-100% of NMRI fetuses, Irrespective whether these embryo were kept in their own (NMRI) dams or transferred to DBA dams. However, none of the 2,3,7,8-TCDD exposed DBA fetuses transferred to NMRI dams or kept in their own (DBA) dams had cleft palate (D'Argy et al., 1984). These results suggest that the responsive mice, containing high levels of the Ah receptor, are highly susceptible to the effects of 2,3,7,8-TCDD in producing cleft palate, whereas the nonresponsive mice, which contain low (or 0) levels of the Ah receptor protein, are resistant to this teratogenic effect of 2,3,7,8-TCDD. These data and other results (Hassoun and Dencker, 1982) suggest that cleft palate formation elicited by 2,3,7,8-TCDD segregates with the Ah locus.

Dencker et al. (1981), Pratt (1983) and Pratt et al. (1984a,b) found an association between **2,3,7,8-TCDD-induced** cleft palate and Ah activity in mice. Significant concentrations of TCDD have been detected in the placenta of pregnant TCDD-dosed mice, resulting in cleft palate induction in the fetus without any apparent effect in the dams. Sensitivities to TCDD vary among strains. The AKR strain lack Ah receptors and remain insensitive to cleft palate whereas the C57 strain possess Ah responsiveness and are sensitive to TCDD-induced cleft palate. These observations further prove that the Ah locus is the cause of strain differences in cleft palate production. It is thought that TCDD forms a complex with the Ah receptor and becomes incorporated into the chromatin. This alters the terminal differentiation of the medial epithelial cells in the palate.

9.1.3. **2,3,7,8-TCDD** Studies In Rats. In an early study, Courtney and Moore (1971) tested the **teratogenic** potential of 2,3,7,8-TCDD in pregnant rats (CD) injected subcutaneously on a daily basis **with** 2,3,7,8-TCDD (0.5 or 2 yg/kg) **in DMSO** on days 6 through 15, days 9 and 10, or days 13 and 14 of gestation and examined on day 20 of gestation. Kidney malformations were observed in fetuses exposed to 2,3,7,8-TCDD. In the group exposed **transplacentally** at a dose of 0.5 yg/kg, 4/6 litters had fetuses **with** kidney malformations (average number of kidney defects/litter was 1.8). An 11 and **34%** incidence of kidney anomalies occurred in groups exposed to 2,3,7,8-TCDD on days 9 and 10, and 13 and 14, respectively. In addition, **six hemorrhagic GI** tracts were observed in the treated group (these data were not enumerated **with** respect to dose); however, **this** was considered a primary **fetotoxic** effect of 2,3,7,8-TCDD and not a malformation.

2,3,7,8-TCDD was administered by gavage to groups (10-14 animals/group) of pregnant Sprague-Dawley rats at dose levels of 0, 0.03, 0.125, 0.5, 2.0 or 8.0 yg/kg/day on days 6 through 15 of gestation (Sparschu et al., 1971b). No adverse teratogenic effects were reported in fetuses exposed **transplacentally** at the 0.03 yg/kg level. At the 0.125 yg/kg **level**, three dead fetuses were reported, fetal weights were slightly depressed, and intestinal hemorrhage was noted in 18 of 127 examined fetuses. In the group given doses of 0.5 yg/kg, the number of viable fetuses was reduced, **resorptions** were increased, 6 dead fetuses were reported, and 36 of 99 fetuses suffered an intestinal hemorrhage. In the 2.0 yg/kg group, only 7 **live** fetuses were reported (occurring **in** only 4/11 litters), 4 having intestinal hemorrhage. Early and late resorptions were prevalent. No **live** fetuses, but many early resorptions, were reported in the group exposed to 8.0 yg **2,3,7,8-TCDD/kg/day**. Subcutaneous edema appeared dose-related,

occurring in a considerable number of fetuses from the higher dose groups. Male fetuses appeared to be more susceptible to **2,3,7,8-TCDD** exposure; however, there was no significant difference in the sex ratio of **live** fetuses.

**Khera** and **Ruddick** (1973) tested a **wide** range of 2,3,7,8-TCDD doses for **teratogenic** and **fetotoxic** potential. Groups of 7-15 **Wistar** rats were **intubated with** 2,3,7,8-TCDD at doses of 0.125, 0.25, 1, 2, 4, 8 or 16 yg/kg on days 6 through 15 of gestation. At day 22 of gestation, there were no **live** fetuses in groups exposed to **>4** yg/kg, and reduced **Utter size** was observed in the 1 and 2 yg/kg group. Unspecified **maternal toxicity** was reported in all groups where there was fetal mortality. In groups exposed to 0.25-2 yg/kg, there were fetal anomalies observed as either gross or microscopic lesions consisting of subcutaneous edema of the head and neck, and hemorrhages in the Intestine, brain and subcutaneous tissue. The Incidences of grossly observed lesions were 0/18, 2/11, 7/12 and 11/14 in the control, 1, 1 and 2 yg/kg dose groups, respectively (the study was conducted in two parts, and the 1 yg/kg dose was repeated). **With** regard to the other dose **levels** tested, the table enumerating the results had an entry of "not done." The Incidence of microscopically observed lesions for the control, 0.25, 0.5, **1**, 1 and 2 yg/kg groups was 0/10, 1/33, 3/31, 3/10, 3/6 and 3/7, respectively. There were no effects of treatment observed in the 0.125 yg/kg group.

**Khera** and **Ruddick** (1973) also exposed dams to 2,3,7,8-TCDD at doses of 0.125, 0.25, 0.5 and 1 yg/kg on days 6 through 15 of gestation and allowed the dams to **Utter** and wean the pups. In **this** experiment, **maternal toxicity** was reported in the 0.5 and 1 yg/kg group. At birth, there were fewer viable pups, and the pups had lower body weight in all but the 0.125 yg/kg



group. At weaning on day 21 after birth, there were no surviving pups in the 1 yg/kg group, and 40% of the pups in the 0.5 yg/kg group **did** not survive. Fostering pups from dams exposed to **2,3,7,8-TCDD** at 1 yg/kg onto control dams **did** not appreciably increase survival, while fostering control pups onto dams exposed to 2,3,7,8-TCDD **did** not increase pup mortality. These data suggest that poor pup survival was a result of delayed **toxicity** from in utero exposure to 2,3,7,8-TCDD.

Glavln1 et al. (1982a) assessed the effect of small doses of 2,3,7,8-TCDD administered during the **preimplantation** period in Sprague-Dawley rats. The animals, in groups of 20, were treated by gavage **with** 2,3,7,8-TCDD at doses of 0.0, 0.1, 0.5 and 2 yg/kg on days 1-3 of gestation. (The legends to the tables in **this** paper indicated that the low dose was 0.125 yg/kg.) At day 21 of gestation, no toxic effects were observed in the dams except for a decrease from **19.3-12.9 g** in average maternal weight **gain** in the **high** dose animals as compared **with** controls. In the fetuses, weight was significantly reduced (**p<0.05**) in the 0.5 and 2 yg/kg groups. **Malformed** utters and malformation/fetuses examined were 2, 5, 5 and 6, and 2/270, 8/260, 5/255 and 8/253, respectively, in the control 0, 0.1, 0.5 and 2 yg/kg groups; however, these increases in the treated animals were not statistically significant. The anomalies observed were restricted to cystic kidney. **This** exposure to 2,3,7,8-TCDD early in pregnancy **did** not affect implantation frequency, and the decrease in fetal weight was considered a result of 2,3,7,8-TCDD delayed implantation.

In a second study, Glavln1 et al. (1983) administered the same doses of 2,3,7,8-TCDD (0.0, 0.125, 0.5 or 2 yg/kg) daily to 15 female CRCD rats per group by gavage in corn **oil:acetone** (9:1) for 2 consecutive weeks before mating. Females that **did** not become pregnant during three estrous cycles

were **necropsied** to determine signs of **toxicity**, while pregnant animals were allowed to proceed to day 21 of **gestation**, at which **time** necropsies were performed **with** particular emphasis on reproductive organs and reproductive success. At the lowest dose tested (0.125  $\mu\text{g}/\text{kg}$ ), there were no overt **clinical** signs of toxicity in the dams or adverse effects in any of the fetal parameters examined. At the 0.5 and 2  $\mu\text{g}/\text{kg}$  levels, average maternal weight was decreased. Also, one animal in each of these groups **did** not become pregnant, although necropsy **did** not reveal any obvious dysfunctions. The **only** other overt **sign** of toxicity was **listlessness** during the treatment period in the animals of the high-dose group. The only significant ( $p < 0.01$ ) fetal effect observed in the 0.5  $\mu\text{g}/\text{kg}$  group was an increase in **postimplantation** losses from **2.9%** in the control group to **10.2%**. In the high-dose group, there were decreases in corpora **lutea** and implantations (averages of **17.6%** in control and **14.9%** in treated animals, and **15.5%** in control and **12.0%** in treated animals, respectively), and increases in both pre- and postimplantation losses of **11.7%** for controls and **19.5%** ( $p < 0.05$ ) in treated animals, and **2.9%** in control and **30.3%** ( $p < 0.001$ ) in treated animals, respectively. In addition to these signs of fetal **toxicity**, 9/10 litters in the high-dose group contained at least one malformed fetus as compared with 1/13, 2/13 and 2/13 in the control, 0.125 and 0.5  $\mu\text{g}/\text{kg}$  groups. The predominant fetal malformations were cystic kidney and dilated renal pelvis, which have been observed in other studies in which **2,3,7,8-TCDD** was administered during gestation.

The reproductive effects of 2,3,7,8-TCDD were also studied in a 3-generation study using Sprague-Dawley rats (Murray et al., 1979). Throughout the study, animals were continuously maintained on diets providing doses of 0, 0.001, 0.01 or 0.1  $\mu\text{g}$  **2,3,7,8-TCDD/kg/day**. The parental group ( $f_0$ ) was

maintained for 90 days on the test diets before mating. The  $f_0$  rats were mated twice, producing the **filial** generations ( $f_{1A}$  and  $f_{1B}$ ). Selected  $f_{1B}$  and  $f_2$  rats were mated at ~130 days of age to produce the  $f_2$  and  $f_3$  Utters, respectively. In later generations, the high-dose group (0.1 yg **2,3,7,8-TCDD/kg/day**) was discontinued because few offspring were produced in **this** group. At the Intermediate dose (0.01 yg/kg/day), 2,3,7,8-TCDD caused lower body weight in exposed rats of both sexes ( $f_1$  and  $f_2$ ). At the low dose, no toxic effects were discerned.

Fertility was greatly reduced in the  $f_0$  generation exposed to 0.1 yg 2,3,7,8-TCDD/kg/day. At 0.01 yg 2,3,7,8-TCDD/kg/day, fertility was significantly ( $p < 0.05$ ) reduced in the  $f_1$  and  $f_2$  rats. Fertility in rats (of any generation) exposed to **0.001** yg 2,3,7,8-TCDD/kg/day was not different from that of control rats. Decreases in Utter **size** were noted in the  $f_{1A}$  group exposed to 0.1 yg/kg/day and the  $f_2$  and  $f_3$  Utters exposed at 0.01 yg/kg/day. Statistically significant decreases in fetal survival throughout gestation were noted in  $f_2$  and  $f_3$  Utters of the **0.01** yg 2,3,7,8-TCDD/kg/day exposed dams. At 0.001 yg **2,3,7,8-TCDD/kg/day**, a decreased **gestational** survival was reported for the  $f_2$  Utters, but not for other generations. Decreased neonatal survival was noted among  $f_{1A}$  and  $f_2$  pups exposed to 0.01 yg 2,3,7,8-TCDD/kg/day, but not among  $f_{1B}$  or  $f_3$  pups. Postnatal body weights of the  $f_2$  and  $f_3$  Utters at 0.01 yg 2,3,7,8-TCDD/kg/day were significantly depressed. At the **low** dose (0.001 yg **2,3,7,8-TCDD/kg/day**), necropsy of **21-day-old** pups revealed a statistically significant ( $p < 0.05$ ) Increase in dilated renal pelvis in the  $f_1$  generation. Subsequent generations at **this** dose level or any at the Intermediate dose (0.01 yg 2,3,7,8-TCDD/kg/day) **did** not have a significant Increase in **this** abnormality. Significantly decreased thymus weight and

Increased liver weight were reported in the **f<sub>3</sub>** generation, but not in the **f<sub>2</sub>** generation (**f<sub>2</sub>** generation data not obtained) of the Intermediate dose group. Murray et al. (1979) concluded that **2,3,7,8-TCDD** Ingested at 0.01 or 0.1 yg/kg/day Impaired reproduction among rats, and NOAELs were associated with 0.001 yg **2,3,7,8-TCDD/kg/day**.

Nisbet and Paxton (1982) reevaluated the primary data of Murray et al. (1979) using different **statistical** methods. From **this reevaluation it** was concluded that **2,3,7,8-TCDD** significantly reduced the **gestational** Index, decreased fetal weight, and Increased **liver-to-body** weight ratios and the Incidence of dilated renal pelvis in both lower-dose groups. Nisbet and Paxton (1982) concluded that the dose of 0.001 yg/kg/day was not a NOAEL in **this** study. The **FIFRA** Scientific Advisory **Panel** has also reviewed the data from **this** 3-generation study and concluded that the effects observed at the 0.001 yg/kg dose were not consistent enough between the different generations to consider them treatment-related (U.S. EPA, 1979b). Although the panel considered the data suggestive of an **embryotoxic** effect, they concluded that 0.001 yg/kg represented a NOEL.

Crampton and Rogers (1983) **2,4,5-trichlorophenoxyacetic acid (2,4,5-T)** contaminated with 30 ppb of TCDD appears to have **behaviorally teratogenic** effect in Long-Evans rats at doses as low as 6 **mg 2,4,5-T/kg** bw administered to mother rats on day 8 of gestation.

9.1.4. **2,3,7,8-TCDD** Studies in Rabbits and Ferrets. A report by Glavinl et al. (1982b) describes the effects of exposure to 2,3,7,8-TCDD on fetal development in rabbits. Groups of 10-15 New Zealand rabbits were administered 2,3,7,8-TCDD by gavage at doses of 0.0, **0.1**, 0.25, 0.5 and 1 yg/kg on days 6 through 15 of gestation. The dams were examined for Implantation sites, **resorptions** and **live** fetuses, and the fetuses were examined for

**malformations** on day 28 of gestation. Decreased maternal weight **gain** and unspecified signs of **maternal toxicity** occurred **in** dams exposed to 2,3,7,8-TCDD at doses of **>0.25** yg/kg. At doses of 0.5 and 1 yg/kg, there were 2 and 4 deaths, **respectively**, among the dams. There were Increases in abortions and **resorptions** at a dose of **>0.25** yg/kg, and no **live** fetuses were detected in the **high** dose group. **In** the fetuses, the most common observation was a significant Increase in extra **ribs** from **33.3%** in the controls to 82, 66.6 and **82%** in the 0.1, 0.25 and 0.5 yg/kg dose groups. Although there was no significant Increase in specific soft-tissue anomalies, there was an Increase from 0/87 to 3/78, 2/33 (**p<0.05**) and 2/28 (**p<0.05**) in total soft-tissue anomalies in the control, 0.1, 0.25 and 0.5 yg/kg groups. The most prevalent soft-tissue anomaly was **hydronephrosis**, which the authors pointed out was a common finding in rat fetuses exposed to **2,3,7,8-TCDD** **in utero**. These effects were considered to be signs of **embryotoxicity** rather than a **teratogenic** effect.

In addition to the **fetotoxic** effects of prenatal exposure to 2,3,7,8-TCDD, Norman et al. (1978b) demonstrated that 2,3,7,8-TCDD could induce liver **microsomal** enzymes following **in utero** exposure. Pregnant New Zealand rabbits were given subcutaneous injections of 2,3,7,8-TCDD at a dose of 30 **nmol/kg** (9.6 yg/kg) on day 24 of gestation, and the livers of newborns were examined for enzyme activity within 12 hours after birth. While **this** treatment increased the liver cytochrome P-450 levels **in** the adults ~2-fold, from **1.8-3.7 nmol/mg** protein, the Increase in the newborns was **~5-fold**, from 0.3-1.6 nmol/mg protein. **SDS-polyacrylamide** gel **electrophoresis** revealed that 2,3,7,8-TCDD induced a single form (form 6) of cytochrome P-450, and that **this** form was one of the two that were **also** induced by 2,3,7,8-TCDD in the adult liver. The identity of form 6 was confirmed by **immunologic**

reaction and its **peptide** fingerprint. It was shown that Induction of cytochrome P-450 in newborns resulted in **levels** of benzo(a)pyrene **hydroxylase** and **7-ethoxy-resorufin-O-deethylase** activity similar to adult levels. The consequence to the newborn of these changes in the development of liver **microsomal** enzymes has not been established.

Muscarella et al. (1982) reported in an abstract the **fetotoxic** and **teratogenic** effects of subcutaneously administered **2,3,7,8-TCDD** on ferrets. An unspecified number of **animals** received 1, 6, **13.5**, 20, 30 or 60  $\mu\text{g}$  of **2,3,7,8-TCDD/kg** on day 18 of gestation or two doses given on days 18 and 20 of gestation at one-half the level of the single dose. The animals were examined on day 28, 29 or 30 of gestation and the results were reported without reference to specific experimental groups. In all test groups there were increases in fetal deaths and resorbed fetuses, along with growth retardation. Terata observed included unilateral and bilateral palatoschisis, open eyelids, anasarca and **brachygnathia**. The author concluded that **2,3,7,8-TCDD** was a teratogen in ferrets.

9.1.5. 2,3,7,8-TCDD Studies in **Nonhuman** Primates. Dougherty et al. (1975) found no evidence of **teratogenicity** or **embryotoxicity** in rhesus monkeys that were given on days 22-38 of gestation daily oral doses (in gelatin capsules) of up to 10 mg/kg/day of **2,4,5-T** containing 0.05 ppm 2,3,7,8-TCDD. The 2,3,7,8-TCDD dose at the highest dose level of 2,4,5-T administered (10 mg/kg/day) would correspond to 0.5  $\mu\text{g}$  **2,3,7,8-TCDD/kg/day**. Palate closure in the monkey, however, occurs on **gestational** days 42-44 and the kidney is also a late developing organ.

Adverse effects of exposure to 2,3,7,8-TCDD on reproductive success in monkeys have also been described. Schantz et al. (1979) fed a **diet** containing 50 ppt 2,3,7,8-TCDD to rhesus monkeys for 20 months. Seven months **into**

the study the female monkeys were bred to control **males**. There were four abortions and one stillbirth; two monkeys **did** not conceive even though they were mated repeatedly; and two monkeys carried their young to term. The total **2,3,7,8-TCDD** Intake over the 7 months was estimated by the authors to be 0.35 yg/kg, corresponding to a calculated dally dose of 0.0015 vg **2,3,7,8-TCDD/kg/day**.

Allen et **al.** (1979) and **Barsotti** et **al.** (1979) fed adult female rhesus monkeys for 6-7 months on diets containing 50 or 500 ppt of 2,3,7,8-TCDD. These exposure levels correspond to total doses per animal at the end of 7 months of 1.8 and 11.7 yg 2,3,7,8-TCDD. Although menstrual cycles were not affected in either treatment group, 5/8 animals **in** the high-dose group had either decreased serum **estradiol** or decreased progesterone levels. Hormone levels were normal in the low dose animals. At 7 months, the females were bred **with** nonexposed males, and 6/8 and 3/8 females in the **low-** and high-dose groups, respectively, were Impregnated. The animals were continued on treatment during pregnancy. Of the Impregnated animals, 4/6 and 2/3 had spontaneous abortions, while the remaining Impregnated animals had normal births. All of the control females (one group of 8 and another group of unspecified **size**) conceived and gave birth to **"normal"** offspring. The **high** dose resulted in the death of **five** animals between the 7th and 12th month of treatment.

**McNulty** (1978) treated pregnant rhesus monkeys by gastric gavage to 2,3,7,8-TCDD in a vehicle of corn oil:acetone solution. Group I animals were administered total dosage of 5 yg/kg bw (two animals), 1 yg/kg bw (four animals) and 0.2 yg/kg bw (four animals) in **nine** divided doses, 3 times/week during weeks 4, 5 and 6 (days 20 through 40) after conception. Group II, consisting of 12 animals, received single doses of 1 yg/kg bw of

**2,3,7,8-TCDD** on days 25, 39, 35 and 40 after conception. Three animals were exposed in each of these 4 days. The vehicle control group, consisting of 11 animals, was treated **with** corn oil:acetone only, on the same schedule as Group I animals. Both of the females that received the highest dose (5 yg/kg) had fetal losses. In the next lower-dosed animals (1 yg/kg in both groups), 12 of 16 females had fetal losses; and in the lowest-dosed animals (0.2 yg/kg in Group I), one abortion occurred in four pregnancies. Maternal **toxicity** was observed in many of these treated females. The difference in frequency of fetal loss between all pregnant animals given 1 yg/kg and the rate of **historical** abortion in the **author's** breeding colony was found to be significant. The author concluded that short exposure to 1 yg/kg bw of 2,3,7,8-TCDD during early pregnancy results in **fetal** loss in rhesus monkeys. In a recent report, **McNulty (1984)** reveals that he failed to detect any malformations in the fetus but observed widespread maternal toxicity and **fetocidal** effects in monkeys as a result of intragastric exposure to 2,3,7,8-TCDD.

9.1.6. Studies in Chickens. The effects of 2,3,7,8-TCDD on the development of the heart in chicken embryos was studied by Cheung et al. (1981) as a consequence of the known induction of hydropericardium by 2,3,7,8-TCDD in **adult** chickens and the relation between changes in **hemodynamics** and cardiovascular malformation. Groups of at least 20 White-Leghorn eggs were **injected with** 2,3,7,8-TCDD in acetone:corn oil (0.5:9.5 v/v) on day zero of embryo development. Administered doses ranged from 0.009-77.5 **pmol/egg** (**0.00029-2.5x10<sup>-2</sup>** yg/egg) in 5 **μl**. The embryos were examined on day **14** of development. A dose-related increase in cardiovascular malformations was observed **with** 1 pmol/egg resulting in malformations in **50%** of the embryos. Increases in **all** types of malformations (ventricular septal



defect, aortic arch anomaly, aortic arch anomaly and **ventricular** septal defect, and **conotruncal malformations**) occurred. Hydropericardium was observed in some embryos (not enumerated), but it could not be concluded that **this** was the cause of the cardiovascular **malformations**. Malformed legs and crossed beaks associated **with microphthalmia** was observed in treated embryos, however, the incidence, 7/284 and 2/284, respectively, was low.

9.1.7. Studies of the **Teratogenic** and Reproductive Effects of HxCDD. In addition to **2,3,7,8-TCDD**, the **teratogenic** potential of a related chlorinated **dibenzo-p-dioxin** compound, HxCDD (congeners not specified), has been investigated in rats. Pregnant Sprague-Dawley rats were treated by gavage **with** 0.1, 1.0, 10 or 100 yg HxCDD/kg/day on days 6-15 of gestation (**Schwetz et al.**, 1973). Treatment **with high** levels of HxCDD (10 and 100 yg/kg) was highly lethal to fetuses during late gestation. There was a significant dose-related increase in late **resorptions** from **0%** (at 0.1 yg/kg/day) to 79% (at 100 yg/kg/day). Decreases in the weight and length of surviving fetuses were due to HxCDD. The incidences of cleft palate, subcutaneous edema, malformed vertebrae and **split** sternbrae were **significantly** increased in fetuses of rats treated **with** 100 yg HxCDD/kg/day. No increase in fetal anomalies was noted in fetuses exposed to 0.1 yg HxCDD/kg, and only subcutaneous edema was more prevalent in groups exposed at 1 or 10 yg HxCDD/kg/day when compared **with controls**.

Pertinent information regarding the **teratogenicity** or reproductive effects of PeCDDs was not located in the available literature.

## 9.2. STUDIES ON HUMAN POPULATIONS

A positive association between **2,4,5-T** exposures and increases in birth defects or abortions has been reported in human populations in Oregon (U.S. EPA, 1979c), New Zealand (**Haniffy et al.**, 1981), and Australia (Field and

Kerr, 1979). A lack of any such association has been reported in human populations in Arkansas (Nelson et al., 1979), Hungary (Thomas, 1980b), New Zealand (Dept. of Health, New Zealand, 1980; McQueen et al., 1977), and Australia (Aldred, 1978). Almost all of the reports are geographic correlation studies, and because of the uncertainties inherent in this type of epidemiologic investigation, as well as the difficulties in distinguishing the effects of 2,4,5-T from those of 2,3,7,8-TCDD contamination, none of the reportedly positive associations unequivocally identify either 2,4,5-T or 2,3,7,8-TCDD as the causative agent. Similarly, the reportedly negative associations do not rule out 2,4,5-T or 2,3,7,8-TCDD as potential teratogens or abortifacients in humans.

Based on a report of a high incidence of abortions in a small group of women living around Aulsebrook, Oregon, who may have been exposed to the herbicide 2,4,5-T from aerial spraying (Smith, 1979), the U.S. EPA (1979c) initiated a study, often referred to as the "Aulsebrook II study," to determine if spontaneous abortion rates differed between the exposed and unexposed populations, if spontaneous abortion rates evidenced seasonal variation in these two groups, and if such seasonal variations were associated with 2,4,5-T spray application.

The Spontaneous Abortion Rate Index, as defined by the U.S. EPA, is "basically the ratio of the number of hospitalized spontaneous abortions to the number of births corresponding to the spontaneous abortions, based on the residence zip code of the women contributing to each event." Upon completion of the study, the U.S. EPA concluded that (1) the 1972-1977 Spontaneous Abortion Rate Index for the study area was significantly higher than in the Rural Control Area or the Urban area; (2) there was a statistically significant seasonal cycle in the abortion index in each of the areas with a period of ~4 months. In particular there was an outstanding peak in

the study area in June; and (3) there was a statistically significant correlation between the Spontaneous Abortion Rate Index and spray patterns in the study area when a lag-time of 2 or 3 months was included. The U.S. EPA concluded, however, that "**This** analysis is a correlational **analysis**, and correlation does not necessarily mean causation."

**Milby et al.** (1980), citing three critiques of the **Alsea II** study (not published in the open literature), state that the statistical method and basic design of the **Alsea II** study were sufficiently flawed to make **this** study of no use in human **risk** assessment. The **Alsea II** study has also been reviewed by a panel of scientists who, in a **published** report of their meeting, also concluded that the basic design of the study was inadequate to demonstrate either an effect or absence of an effect of exposure to **2,4,5-T** (Coulston and **Olajos**, 1980). The **major** inadequacies of the study were that the data collection methods were likely to result in the underestimation of abortions, particularly in the urban area (the incidence of abortions in all three groups was within the expected background rate of **8-15%**); only a **small** part of the area from which the exposed **subjects** were selected was actually sprayed **with** 2,4,5-T, and the study was not controlled for other factors such as age, smoking habits and alcohol consumption, which may affect the spontaneous abortion rate. Based on a new report by Smith (1979), the U.S. EPA is attempting or has attempted to correlate **2,3,7,8-TCDD** levels in the affected areas **with** the observed rate of abortion. No published reports have been **located** on the outcome of **this** effort.

Nelson et al. (1979) noted a general increase in the reported incidence of **facial** cleft in both **high** and low exposure groups in Arkansas from 1948-1974. In **this** study, exposure estimates were based on average

**rice** production in different areas of Arkansas, and the Incidence of cleft palate was determined by screening birth certificates and checking records of the Crippled Children's Services. No consistent exposure/effect correlations were noted, and the general Increase **with time** in the Incidence of facial clefts was attributed to better reporting procedures; however, there does not have to be a direct correspondence of malformations in human beings and experimental animals.

Of the four reports available from New Zealand (Dept. of Health, New Zealand, 1980; **McQueen et al.**, 1977; **Hanify et al.**, 1981; Smith et **al.**, 1982a), the report by the Department of Health is essentially anecdotal, involving two women who gave birth to malformed **children** (one **with** an **atrial** septal defect and a malformation of the **tricuspid** valve of the heart, and the other **with** biliary **atresia**). In both cases, exposure to **2,4,5-T** could not be ruled out. Based on an analysis of spraying records, the **time** course of the pregnancies and plant damage near the **women's** homes, however, the Department of Health, New Zealand (1980) concluded that there was insufficient evidence to implicate 2,4,5-T spraying as a causative factor. Even if the spraying had been implicated, a lack of information on **2,3,7,8-TCDD** levels in the spray and the absence of any monitoring data on 2,4,5-T or 2,3,7,8-TCDD would limit the usefulness of **this** report.

The study by McQueen et al. (1977) is not published in the open literature but is summarized by Milby et al. (1980). According to the summary, McQueen et **al.** (1977) "...examined the epidemiology of neural-tube defects in three areas in New Zealand and concluded '**there** is no evidence to implicate 2,4,5-T as a causal factor in human birth **defects.**'" No additional details are provided.

Hanify et al. (1981) performed an **epidemiologic** study in Northland, New Zealand, in areas where spraying of **2,4,5-T** was done by various companies for a number of years. The rate of birth defects was obtained from an examination of hospital records in seven **nonoverlapping** areas on a monthly basis over a period extending from 1959-1977. The rate of birth defects from 1959-1965 represented the rate for a nonexposed population since **this** was prior to the use of 2,4,5-T, while the incidence of birth defects from 1972-1976 represented the rate for the exposed population. During the **time** of the survey there were 37,751 births, 436 stillbirths, 264 deaths shortly after birth, and **510 congenital anomalies**. Three categories of birth defects, heart abnormalities, **hypospadias** and **epispadias**, and talipes, had elevated rate ratios of  $>1$  ( **$p=0.05$** ) in comparisons between the exposed (**1972-1976**) and **control** (1959-1965) populations. Exposure estimates were made for the seven areas and for different years using company records of aerial spraying and a model that factored in assumed fractional removal rates/month (**this** factor was assumed to be either 1.0 or 0.25). Comparisons of the rate of specific malformations **with** exposure demonstrated a statistically significant association between the occurrence of talipes and exposure when the fractional removal rate was assumed to be 0.25. There was, however, no statistically significant association where 1.0 was used as the **fractional** removal rate.

Smith et al. (1982a) investigated the outcome of pregnancy in **families** of professional 2,4,5-T applicators and **agricultural** contractors in New Zealand. Agricultural contractors were chosen as the control population since both sprayers and contractors were of the same economic group **with** similar outdoor occupations. **The** survey was conducted by **mail with** 89% of the chemical applicators responding and 83% of the agricultural contractors

responding to questions asking whether they used **2,4,5-T** and **its** temporal relationship to reproductive histories regarding birth, miscarriages, stillbirths and congenital defects. The relative risks of congenital defects and miscarriages were 1.19 (**0.58-2.45%** confidence limits) and 0.89 (**0.61-1.30%** confidence limits) for the wives of chemical sprayers as compared **with** the wives of **agricultural** contractors. These data indicate that exposure of fathers and mothers (**i.e.**, while cleaning clothes) had no effect on the outcome of pregnancy. Biases that may have affected the results, such as the age of the mother at childbirth, smoking habits and birth to Maori parents were investigated and eliminated as possible confounders.

The two reports from Australia (Aldred, 1978; Field and **Kerr**, 1979) also present apparently conflicting results. The report by Aldred (1978) is not published in the open literature, but the following summary is taken from **Milby et al.** (1980): "The report concluded that birth defects in a group of babies born in the [Yarram] district in 1974 and 1976 could not be attributed to exposure to 2,4,5-T or **2,4-D.**" Additional details that might be useful in assessing the rationale for **this** statement are not provided in the summary. The report by Field and Kerr (1979) plotted the incidence of neural-tube defects (anencephaly and meningocele) in New South Wales, **Australia**, over the years **1965-1975**, and the usage of 2,4,5-T in **all** of Australia during the previous years. The authors noted a decrease in the incidence of neural-tube defects expected on the basis of the **plotted line** in 1975 and 1976, when Australia instituted monitoring of 2,4,5-T to ensure a **2,3,7,8-TCDD** level  $<0.1$  **ppm**. The data were not tested for significance; although Field and Kerr (1979) indicate that they consider the epidemiological data on neural-tube defects to be "relatively **complete**," they do not comment on the increasing incidence of neural-tube defects during the **time**

period of **this** study and whether or not an Increase in the thoroughness of reporting neural-tube defects could have contributed to the apparent correlation of **2,4,5-T** exposure **with** these defects. A **replotting** of the data suggests that the Incidence of cleft palate correlates better **with** 2,4,5-T usage than **with time**. Nonetheless, the appropriateness of correlating 2,4,5-T usage in all of Australia **with** the Incidence of defects **in** one area of Australia **is** questionable.

Thomas (1980b) used an approach similar to that of Field and Kerr (1979) on data from Hungary. One **major** difference, however, is that Thomas (1980b) compared the Incidence of stillbirths, cleft lip, cleft palate, **spina bifida**, anencephalus and cystic kidney disease in all of Hungary between 1976 and 1980 **with** 2,4,5-T use in **1975** in all of Hungary. Because Hungary requires compulsory notification of malformations diagnosed from birth to age 1 year, because a relatively large percentage (55%) of the Hungarian population lives in rural areas where 2,4,5-T exposure may be expected to be greatest, and because annual use of 2,4,5-T in Hungary had risen from 46,000 kg in 1969 to 1,200,000 kg in 1975, Thomas (1980b) considered Hungary to be "...probably the best country in which to examine possible health effects of **this** herbicide." All Indices of birth defect rates decreased or remained **stable** over the period of study.

In addition to contamination of 2,4,5-T being a potential source of **2,3,7,8-TCDD** exposure, **2,3,7,8-TCDD** is also an Inadvertent contaminant of **2,4,5-trichlorophenol** (TCP). Chronic exposure to 2,3,7,8-TCDD may occur during the manufacture of TCP and **high** level acute exposure to 2,3,7,8-TCDD has occurred after an accident in July, 1976 at the **ICMESA** TCP chemical factory in Seveso, Italy (**Bonaccorsi et al.**, 1978). In **this** accident, the reaction used to produce TCP became uncontrolled, producing conditions

favorable for **2,3,7,8-TCDD** formation before venting the contents of the **chemical** reactor **into** the atmosphere. The resulting cloud of chemicals settled over a heavily populated area. Although the amount of **2,3,7,8-TCDD** released was not known, the reported cases of chloracne, a symptom of acute exposure to 2,3,7,8-TCDD, indicated that exposure to 2,3,7,8-TCDD had occurred. Some preliminary results are available from epidemiologic studies of reproductive events in the inhabitants of Seveso, and **recently** a study has become **available** on the reproductive history of men employed in the chemical manufacturing industry **with** possible chronic exposure to 2,3,7,8-TCDD (Townsend et al., 1982).

Epidemiologic studies to determine the reproductive effects in individuals exposed to 2,3,7,8-TCDD and TCP following the accidental contamination of a populated area around Seveso, Italy, are not completed. The incidence of spontaneous abortions occurring between March 1976 and January 1978 have been reported for inhabitants in the area around Seveso by **Bonaccorsi** et al. (1978), **Reggiani** (1980) and **Bisanti** et al. (1980). The spontaneous abortion rate in the contaminated area for the three trimesters following the accident was 13.1, 11.0 and 13.05%, which was similar to the worldwide 15-20% frequency of spontaneous abortion. Subdividing the contaminated area **into** highly, **moderately**, and least contaminated, and examining the rates for each area individually, also **failed** to demonstrate any change in the spontaneous abortion rate. The incidence rates of malformations also were examined; however, the numbers were too few for meaningful assessment. There are several inadequacies in these studies that might make them insensitive in detecting reproductive effects. The authors noted that there are many difficulties in interpreting these data. Adequate data on the incidence



rates of spontaneous abortions and birth defects were not **adequately** available for the region before the accident as a result of suspected under-reporting. There was Inadequate reporting even after the accident because of **political** turmoil **with** regard to the management of health services. **Also**, an unknown number of pregnancies were surgically aborted for fear of **2,3,7,8-TCDD-induced** birth defects. In a recent review of the progress of **epidemiologic** Investigations of the Seveso accident, **Tognoni** and **Bonaccorsi** (1982) Indicated that the data on spontaneous abortions and malformation rates still needed **verification**, and that these data were too preliminary to allow for conclusions.

Townsend et al. (1982) Investigated the reproductive history of wives of employees potentially exposed to **2,3,7,8-TCDD** during chlorophenol production in **Midland**, MI. A total of 930 potentially exposed males were Identified who had worked for  $\geq 1$  month between January 1939, and **December** 1975, in a job **with** potential 2,3,7,8-TCDD exposure. Exposure estimates of low, moderate and **high** were made by an Industrial **hygienist** primarily from job description and surface contamination data; however, the **high** potential exposure group was reserved for process workers during **1963-1964** when changes **in** operations resulted in a number of cases of chloracne. The control population was an equal number of male employees not Involved in any process that might **involve** exposure to **2,3,7,8-TCDD** and matched for date of **hire**. In these groups, 586 wives were Identified and 370 agreed to participate as the exposed group, while 345 wives of a potential control group of 559 agreed to participate. After Identification of the participants, a personal Interview was conducted **with** the wives to determine pregnancy outcome. Of the total of 737 conceptions in the exposed category and 1785 conceptions in the control category (conceptions that occurred in the

exposed group before work records Indicating potential exposure to 2,3,7,8-TCDD were placed in the control group), there was no statistically significant Increase in spontaneous abortions, stillbirths, Infant deaths or selected congenital **malformations**. Sample sizes were too small to provide meaningful data if the populations were subdivided by extent of exposure. The authors suggested that many confounding factors could account for these negative results, such as the Inappropriate selection of the populations, the use of "exposed" persons in both exposed and **control** groups, unidentified **covariables** and low power; however, it was asserted that these results were consistent **with** animal data, which report that paternal exposure to **2,3,7,8-TCDD** does not affect the conceptus.

**Poole** (1983), in testimony before the House Committee on Science and **Technology**, described a **reanalysis** of the primary data used by Townsend et al. (1982). In **this reanalysis**, the relative **risk** of cleft palate and cleft lip were reported to be 1.9 (**90%** confidence **intervals** of 1.0-3.6) in the years **1971-1974** for both the control and exposed groups (**the** comparison population was not described). At the same House Committee hearing, Houk (**1983**) presented data from the Birth Defect Monitoring Program of the Centers for Disease Control on the yearly rate of cleft palate alone or cleft lip **with** or without **cleft** palate for births in Midland County, Michigan (**the site** of **Dow's** chlorophenol production facility) during the years 1970-1981. The data indicated an increased rate for these defects of between 50 and **100%** in the years 1971-1975, **with** the rate returning to normal from 1976-1981. The observed increase was statistically significant if the rates for cleft palate alone and cleft lip **with** or without cleft palate were combined; however, it was the opinion of Houk (1983) that these defects should not be combined since the causal mechanism may be

different. The Michigan Department of Public Health (1983a) **also** reported these results and, **in addition**, demonstrated that the same results occurred if the comparison was made **with** other counties in Michigan as well as **with** the general population of the United States. It was noted in **this** report that "runs" of increases in **oral** cleft for successive years have occurred in **six** other counties **with** no obvious chemical exposure. The Michigan Department of Public Health (1983a) interpreted the data to indicate that a more detailed case control study was necessary to determine if any common factors may exist, such as exposure to chemicals contaminated **with 2,3,7,8-TCDD**.

A similar but limited study of the reproductive history of the wives of employees of the Long Island Railroad was performed by Honchar for **NIOSH (1982)**. The employees were concerned about the use of 2,4,5-T for maintenance along the right-of-way. There were 170 **live** births as indicated by union files during the study period from 1975-1979. For each birth, insurance claims were reviewed to determine any health problems during the first year of **life**. The incidence of major birth defects was underrepresented in the study population when **compared with** data from the Metropolitan Atlanta Congenital Defects Program (**3** observed and 3.81 expected). Some minor health problems (**i.e.**, tear duct obstruction) were elevated; however, the authors considered **this** to have resulted from diagnostic **bias**. It was concluded that no association between birth defects and exposure to 2,4,5-T was demonstrated in **this** study.

To test any possible association between birth defects and exposure to Agent Orange in Vietnam veterans, **Erickson et al.** (1984) conducted a case-control study on newborns **with** various types of congenital defects in the metropolitan Atlanta area during the years 1968 through 1980. Though most of the Vietnam veterans received from the Army Agent Orange Task Force an

estimated opportunity Index score regarding their exposure to Agent Orange, **25%** of the Vietnam veterans interviewed in **this** study felt that they were exposed and approximately an equal proportion **did** not know if they were exposed to Agent Orange. Increased estimated risks for fathering babies **with** 1) **spina bifida**, 2) cleft **lip with** or without cleft palate and 3) certain tumors were found in **this** study. However, the authors concluded that "Vietnam veterans who had greater estimated opportunity for Agent Orange exposure **did** not seem to be at a greater **risk** for fathering babies **with all** types of defects combined" (Erickson et al., 1984).

### 9.3. OTHER **REPRODUCTIVE** EFFECTS

The effects of a mixture of **2,4,5-T**, **2,4-D** and **2,3,7,8-TCDD** (simulated Agent Orange; however, the free acids were used rather than butyl esters to **eliminate** problems of **volatility**) on the fertility and reproductive capacities of male C57Bl/6 **mice** were studied by Lamb et al. (1980, 1981a). Groups of 25 **mice** were treated **with** dietary **levels** of the three compounds so that the daily doses/kg bw were 40 **mg** each of **2,4,5-T** and 2,4-D, and 2.4 **µg** of 2,3,7,8-TCDD (Group II); 40 **mg** each of 2,4,5-T and 2,4-D and 0.16 **µg** of 2,3,7,8-TCDD (Group III); or 20 **mg** each of 2,4,5-T and 2,4-D and 1.2 **µg** of 2,3,7,8-TCDD (Group IV). A vehicle control group (Group I) was given a **diet** containing 2% corn **oil**. An 8-week exposure period was followed by an 8-week observation period during which fertility and reproductive assessments **were** conducted. Sperm **concentrations**, sperm **motility** and sperm abnormalities were evaluated. In addition, the males were mated **with** virgin females (3 females/week for 8 post-treatment weeks) to assess mating frequency, average fertility, percent implantations and **resorptions**, and percent fetal malformations. There was no significant decrease in any of the parameters used as a measure of fertility and reproductive capacity in any groups of treated

**mice** when compared **with** controls. Lamb et al. (1981b), **in** a further report of **this** work, Indicated that germ cell **toxicity** was not apparent and survival of offspring of exposed **mice** was unaffected. No **external**, visceral or skeletal terata were noted **in** offspring whose sires were exposed to the phenoxy **acids/2,3,7,8-TCDD** mixture **in this** study. The only effects noted were dose-related decreases **in** body weight **in** the treated males, and these effects were reversed when treatment was terminated.

#### 9.4. SUMMARY

**2,3,7,8-TCDD** has been demonstrated to be **teratogenic in all** strains of **mice** tested. The most common malformations observed are cleft palate and kidney anomalies; however, other malformations have been observed occasionally. **With** an **MED of** 1  $\mu\text{g/kg/day}$  for **mice**, 2,3,7,8-TCDD is the most potent teratogen known. At higher doses, 2,3,7,8-TCDD has a marked **feto-toxic** effect, as measured by decreased fetal weight and Increased fetal toxldty. **Hemorrhagic GI** tract has been associated **with** 2,3,7,8-TCDD fetal toxldty.

**In** rats, **it** has also been observed that 2,3,7,8-TCDD produced teratogenic and **fetotoxic** responses **in** all strains tested. **In this** species, the most common fetal anomalies observed were edema, hemorrhage and malformation of the kidney **with** effects observed at doses of  $\geq 0.1 \mu\text{g/kg/day}$ . **In** addition, there is some evidence that 2,3,7,8-TCDD can Induce **microsomal** enzymes **in** the fetus exposed **in** utero. and **this** Induction is accompanied by damage to the **fine** structure of the liver cell; however, other reports Indicate that **enzyme** Induction occurs **only** after birth following exposure to 2,3,7,8-TCDD through the **mother's milk**. As **in mice**, **hemorrhagic** GI tracts have been observed **in** rat fetuses exposed **in** utero to 2,3,7,8-TCDD.

Rabbits and monkeys are **also susceptible** to the **fetotoxic** effects of **2,3,7,8-TCDD**; **however**, the studies of these species have been too limited to clearly evaluate a **teratogenic** response or define a threshold dose for **fetotoxicity**.

A number of **studies**, mostly correlation studies, have been conducted on groups of persons exposed to 2,3,7,8-TCDD as a contaminant of the herbicides **2,4,5-T** or the chemical of TCP. Although some studies have shown a positive association between exposure to 2,4,5-T and birth defects or abortions, other studies have not. In Investigations concerning **potential** exposure to 2,3,7,8-TCDD through the manufacture of TCP, there has been no positive substantiated association between exposure and reproductive difficulties. In these studies, exposure was always mixed, **with** 2,3,7,8-TCDD being only a minor component. Hence, **it** is not possible to attribute **with** certainty any positive finding to 2,3,7,8-TCDD. It is also **possible**, since **levels** of 2,3,7,8-TCDD contamination of 2,4,5-T and TCP were only estimated, that the negative results reflect the exposure was too low or the study designs too insensitive to elicit a detectable response. From an extensive review of dioxin-induced animal and human reproductive **toxicity** data by **Mattison et al.** (1984) and another review of 15 reports dealing **with** human exposure to **dioxins** and reproductive effects by Hatch (1984), **it** can be concluded that **epidemiologic** observations from well designed studies are warranted before deriving any conclusion on **dioxin-induced** reproductive toxicity **in** humans. **Although** the evidence from human studies **is** insufficient to prove 2,3,7,8-TCDD **is** teratogenic, the **animal** data clearly indicate teratogenic or fetotoxic effects in all animal species tested.

## 10. **MUTAGENICITY AND OTHER INDICATIONS OF GENOTOXICITY**

### 10.1. RELEVANT STUDIES

10.1.1. Assays in **Microorganisms**. Short-term in vitro test systems have been developed to assess the **biologic**, toxic and **genotoxic** effects of chemicals. These assays have proven to be useful Indicators of potential activity of diverse **industrial** chemicals, a broad range of drugs and **xenobiotics**, carcinogens and crude environmental extracts. The most widely used short-term test **system**, the Ames test for bacterial **mutagenesis**, employs several strains of **Salmonella typhimurium** that are highly susceptible to the effects of **mutagenic** chemicals. Despite the obvious utility of the Ames test and related short-term assays, their predictive **capabilities (i.e., the correlation between bacterial mutagenicity and carcinogenicity)** have not been fully assessed (Bartsch et al., 1982).

**Mutagenicity** assays in microorganisms have been used to assess the genotoxic effects of **2,3,7,8-TCDD**; however, the results of most of these assays have indicated little potential for mutagenic effects (Table 10-1).

Hussain et al. (1972) exposed **S. typhimurium histidine-dependent** strains TA1530 and TA1532 in liquid suspension to 2,3,7,8-TCDD followed by plating **into** selective medium to observe reversion to prototypes. No increase in the reversion rate was observed **with** strain TA1530 at exposure levels of 1 and 10 **µg/ml**. These exposures resulted in cell survivals of 90 and **<1%, respectively**. In strain TA1532, increased reversion frequency was not observed at 2,3,7,8-TCDD concentrations of **<2-3 µg/ml**, which **resulted** in a **0-50%** decrease in survival; however, at 2,3,7,8-TCDD levels that resulted in a 99.54 decrease in survival, there was an increased number of revertant colonies/surviving cells. **This** positive response is questionable because of the extremely **high toxicity** observed. The dose levels were not specified.

TABLE 10-1

The Results of Mutagenicity Assays for 2,3,7,8-TCDD in *Salmonella typhimurium*

| Type of Assay        | Strains of <i>Salmonella typhimurium</i> |      |        |        |        |        |        |        |        |        |     |       |        |        | Reference               |
|----------------------|--|------|--------|--------|--------|--------|--------|--------|--------|--------|-----|-------|--------|--------|-------------------------|
|                      | S-9                                      | TA98 | TA1530 | TA1535 | TA1537 | TA1538 | TA1532 | TA1950 | TA1975 | TA1978 | G46 | TA100 | TA1531 | TA1534 |                         |
| Spot test            | +/-                                      | NT   | NT     | 0      | 0      | 0      | 0      | NT     | NT     | NT     | NT  | NT    | NT     | NT     | McCann, 1978            |
| Plate Incorporation  | +/-                                      | MT   | NT     | 0      | 0      | 0      | 0      | NT     | NT     | NT     | NT  | NT    | NT     | NT     | McCann, 1978            |
| Plate Incorporation* | +/-                                      | 0    | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0   | 0     | NT     | NT     | Gilbert et al., 1980    |
| Fluctuation test     | +/-                                      | 0    | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0   | 0     | NT     | NT     | Gilbert et al., 1980    |
| Spot test            | -  | NT   | 0      | NT     | NT     | NT     | +      | NT     | NT     | NT     | 0   | NT    | QR     | QR     | Seller, 1973            |
| Plate Incorporation  | +  | 0    | NT     | 0      | 0      | 0      | NT     | NT     | NT     | NT     | NT  | 0     | NT     | NT     | Gelger and Neal, 1981   |
| Plate Incorporation  | -  | NT   | NT     | NT     | 0      | NT     | NT     | NT     | NT     | NT     | NT  | NT    | NT     | NT     | Gelger and Neal, 1981   |
| Suspension assay     | -  | NT   | 0      | NT     | NT     | NT     | QR     | NT     | NT     | NT     | NT  | NT    | NT     | NT     | Hussain et al., 1972    |
| Suspension assay     | +/-                                      | 0    | NT     | 0      | 0      | NT     | NT     | NT     | NT     | NT     | NT  | 0     | NT     | NT     | Mortelmans et al., 1984 |

\*The assay was performed under both aerobic and anaerobic conditions.

NT = Not tested; QR = Questionable response; 0 = Negative response; + = Positive response



The source of the **2,3,7,8-TCDD** sample studied in **this** paper was the Food and Drug Administration, and **its** reported purity was 99%. Also, Seller (1973) observed a positive **mutagenic** response in a spot test of 2,3,7,8-TCDD performed in the absence of a metabolic activation system. **However**, the purity of the sample studied was not provided. In tester strains G46 and TA1530, the ratio of **revertants/10<sup>8</sup>** cells in the treated plates divided by spontaneous **revertants/10<sup>8</sup>** cells was **<1**. In strains TA1531 and **TA1534**, the ratio was between 1 and 2, which was considered a "doubtful" mutagenic response, while in strain TA1532, the ratio was **>10**. There was no mention of the **2,3,7,8-TCDD** levels tested in **this** assay. The positive controls, **diethylsulfate**, **2-aminopurine** and 2-aminofluorene, produced ratios of 2 to 5, **<1** and 5 to 10, respectively, in strain TA1532. In both the study by **Hussain et al. (1972)** and the study by Seller (1973), 2,3,7,8-TCDD produced a positive mutagenic response **only** in the **S. typhimurium** strain TA1532, which is sensitive to **frameshift mutagens**.

Hussain et al. (1972) also performed a **mutagenicity** test of 2,3,7,8-TCDD in two other **microbial** test systems. A positive response was observed in Escherichia coli Sd-4 as indicated by a reversion to streptomycin independence. In **this** assay, cells were treated in suspension for 1 hour **with** 2,3,7,8-TCDD at 0.5-4 **µg/ml**. The greatest mutation frequency (256 mutants x **10<sup>-8</sup>**, as compared **with** the control frequency of 2.2 mutants x **10<sup>-8</sup>**) occurred at a dose level of 2 **µg/ml**. The **absolute** number of colonies/plate was 7 for the **control** and 46 for the treated plate. The dose of 2 **µg/ml** caused an **89%** decrease in cell survival. A duplicate **sample** resulted in an **82%** decrease in survival and a mutation frequency of **34x10<sup>-8</sup>**. These results indicate that the **reproducibility** of the assay may not have been perfect, but both **results** are well above the control value of

$2.2 \times 10^{-6}$ . A dose-response relationship was not observed, indicating that the results at 2  $\mu\text{g}/\text{mL}$  are only suggestive of a positive response. In addition, the positive results were obtained at a concentration of 2,3,7,8-TCDD (2  $\mu\text{g}/\text{mL}$ ) that was well above solubility in water (0.2  $\mu\text{g}/\text{L}$ ), which also casts doubt on the significance of the positive result. In the second test system, the ability of 2,3,7,8-TCDD to increase prophage induction in E. coli K-39 cells was examined. The vehicle control, DMSO, inhibited prophage induction as compared with the untreated controls, while the most effective dose level of 2,3,7,8-TCDD (0.5  $\mu\text{g}/\text{mL}$ ) resulted in an increased prophage induction as compared with the vehicle control but not as compared with the untreated controls. Hussain et al. (1972) concluded that 2,3,7,8-TCDD was capable of causing increases in the reverse mutation rate in E. coli Sd-4 and that 2,3,7,8-TCDD had a weak ability to induce prophage in E. coli K-39 cells.

The studies that followed these two early reports of Hussain et al. (1972) and Seller (1973) failed to detect mutagenic activity of 2,3,7,8-TCDD in S. typhimurium. Wassom et al. (1978) cited a personal communication from McCann (1978), which reported that 2,3,7,8-TCDD was inactive in both the spot test and plate incorporation assay with S. typhimurium strains TA1532, TA1535, TA1537 and TA1538. Doses and other experimental protocols were not mentioned except that the tests were performed both with and without metabolic activation. Gilbert et al. (1980) reported that 2,3,7,8-TCDD gave "substantially negative results" with S. typhimurium strains TA98, TA100, TA1530, TA1535, TA1537, TA1538, G46, TA1532, TA1950, TA1975 and TA1978. Both the standard plate incorporation assay and the bacterial fluctuation test were used, and both were performed with and without S-9 prepared from the livers of Aroclor 1254 pretreated rats. In the plate incorporation assay, the test compound was tested at 1-2000  $\mu\text{g}/\text{plate}$  under both aerobic

and anaerobic conditions. Details were not provided for the fluctuation assay. It is difficult to assess possible reasons for the conflicting **results** between the earlier studies and these later **mutagenicity** assays, since information on experimental conditions was limited in the negative studies.

In an attempt to resolve the conflicting results and observe a **mutagenic** response, **Geiger** and **Neal** (1981) tested **2,3,7,8-TCDD** in the standard plate incorporation assay using S-9 prepared from different sources. In order to maximize the amount of compound tested, **dioxane**, a better solvent for 2,3,7,8-TCDD than the commonly employed **DMSO**, was used. Even **with** the use of dioxane, the limited solubility of 2,3,7,8-TCDD allowed only 20 **µg/plate** to be tested, a dose that was shown to be **nontoxic** to the **cells**. The S-9 used in these assays was prepared from the livers of Aroclor 1254 pretreated male Sprague-Dawley rats and male Golden Syrian hamsters, and from 2,3,7,8-TCDD induced male hamsters. In all assays at 2,3,7,8-TCDD concentrations of 0.2, 2, 5 or 20 **µg/plate**, and **regardless** of the source of the S-9, there was no observed mutagenic response. In further attempts to duplicate the previous positive results, Geiger and Neal (1981) tested the same concentrations of 2,3,7,8-TCDD in strain TA1537, a more sensitive direct descendent of strain TA1532, for mutagenic activity **in** the absence of S-9. Again, no increase in the number of revertants was observed. In assays either **with** or without S-9, positive controls had predictable increases in the number of revertant colonies. The authors concluded that 2,3,7,8-TCDD was not active under the conditions of **this** assay; however, testing at higher concentrations may elicit a positive response. It was also noted that many other **polychlorinated** aromatic compounds are not mutagenic **in** the Ames test, even though there is positive evidence of **carcinogenicity**.

The National Toxicology Program (NTP) provided data on 2,3,7,8-TCDD from four assay systems: the *S. typhimurium* (strains TA98, TA100, TA1535 and TA1537) histidine reversion assay, the sex-linked recessive lethal test in *Drosophila*, and cytogenetic studies (sister chromatid exchange and chromosome aberrations) in Chinese hamster ovary cells. Negative results were obtained in all of these assays (Mortelmans et al., 1984; Zimmering et al., 1985; NTP, 1985).

Mutagenic effects of 2,3,7,8-TCDD in yeast were observed by Bronzetti et al. (1983). Positive results for reversion and gene conversion were obtained in vitro and in the host-mediated assay. The in vitro experiments yielded small dose-related increases in *trp*<sup>+</sup> revertants and *ilv* revertants. An S10 metabolic activation system was required. Exposure of the yeast to 2,3,7,8-TCDD at the highest level tested (10 µg/ml) resulted in 16% survival and yielded 4-fold increases in reversion and gene conversion.

In the host-mediated assay, male mice were exposed to 25 µg of 2,3,7,8-TCDD/kg (Bronzetti et al., 1983). After 5, 10, 20 or 30 days, 0.2 ml of a yeast culture (4 x 10<sup>8</sup> cells) was instilled retroorbitally. Four hours later, the liver and kidneys were removed and the yeast cells in these organs were assayed for mutagenic responses. Increases (4- to 6-fold) in reversion and gene conversion were observed in yeast cells obtained from the livers and kidneys. The toxic response of the animals to an exposure of 25 µg/kg was not described in this report. The positive results described in this paper suggest that 2,3,7,8-TCDD is mutagenic in yeast, but more definitive studies are needed before a firm conclusion can be drawn.

Hay (1982) has found that 2,3,7,8-TCDD dissolved in DMSO transformed baby hamster kidney cells (BHK) in vitro. The dioxin isomers 2,8-dichlorodioxin and 1,3,7-trichlorodibenzo-p-dioxin also transformed BHK cells,

but the response was weak. The **unchlorinated dibenzo-p-dioxin** and the fully **chlorinated octachlorodibenzo-p-dioxin** were both negative in the BHK assay (**i.e.**, there was no cell **transformation**).

Abernethy et al. (1985) **failed** to transform C3H/10T<sub>1/2</sub> cells in culture by single treatments with 0.06 mM to 5  $\mu$  dosage of **2,3,7,8-TCDD** or Initiate transformation in these treated cells by subsequent exposure with tumor promoter **12-O-tetradecanoylphorbol-13-acetate** (TPA). However, these authors could transform C3H/10 T<sub>1/2</sub> cells in vitro by **N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)** and **this** transformation could be enhanced by subsequent treatment with low concentration ( $\geq 4$  pM) of **2,3,7,8-TCDD**. Maximum enhancement was observed at a concentration of 40 pM of 2,3,7,8-TCDD. **This** study indicates that 2,3,7,8-TCDD induced promotional activities can be **observed** in C3H/10 T<sub>1/2</sub> cells in cultured.

Rogers et al. (1982) reported that 2,3,7,8-TCDD induced mutations in the excess **thymidine**, **thioguanine** and **methotrexate** selective systems in L5178Y mouse lymphoma cells in culture. However, no significant mutation was noted in **ouabain** or cytosine **arabioside selective** systems.

10.1.2. Interactions with Nucleic Acids. In vitro reactions of 2,3,7,8-TCDD with **bacteriophage QB RNA** were **evaluated** by **Kondorosi et al.** (1973). Active RNA was purified from QB phage followed by incubation for 1 hour at 37°C with 0.0, 0.2, 2.0 or 4.0  $\mu$ g/ml of 2,3,7,8-TCDD. At all concentrations tested, 2,3,7,8-TCDD had no effect on the **transfectivity** of QB RNA. Other compounds tested included the **alkylating agents methyl**, ethyl and **isopropyl methane-sulfonate**, and **diethyl pyrocarbonate**, all of which inactivated QB RNA under the same experimental conditions. The authors suggested that 2,3,7,8-TCDD inactivity in this assay indicated that **2,3,7,8-TCDD** was

an Intercalating agent, and hence would require **double** stranded ONA in order to Interact. The data presented in **this** study, however, were Insufficient to support **this** conjecture.

**In vivo** binding of **radiolabeled 2,3,7,8-TCDD** to liver **macromolecules** was studied in Sprague-Dawley rats by Poland and Glover (1979). Both male and female animals were administered [**<sup>3</sup>H]**2,3,7,8-TCDD** i.p. at a dose of 7.5 **µg/kg**. **This** dose corresponded to a tritium level of 0.87 **mCi/kg**. The **animals** were **killed** 12, 48 and 168 hours after treatment, or 24 hours after treatment when the animals were pretreated **with** the enzyme **inducers** **pheno-barbital** or **unlabeled 2,3,7,8-TCDD**. Following sacrifice, Isolation of macromolecules, and removal of free labeled 2,3,7,8-TCDD, the amount of label bound to protein, RNA and DNA was determined. The greatest nonextractable binding of labeled 2,3,7,8-TCDD occurred to protein; however, the amount of label bound was small and only amounted to **0.03-0.1%** of the total radioactivity administered. The total amount of label associated **with** RNA and DNA was, respectively, only 50 and 4 cpm above background. **Time** after exposure, sex or prior enzyme Induction had no significant effect on 2,3,7,8-TCDD binding. As a result of the **extremely** low levels of radioactivity associated **with** RNA and DNA, **it** is uncertain whether 2,3,7,8-TCDD truly binds covalently to these macromolecules and, if so, whether there is any biological significance to **this** low level of apparent binding.**

10.1.3. **Cytogenetic** Effects of 2,3,7,8-TCDD. The effects of 2,3,7,8-TCDD exposure on the extent of chromosomal aberrations in the bone marrow of male rats were reported in an abstract by Green and **Moreland** (1975). In the Initial experiment, no Increase in chromosomal aberration was observed after **five** daily gavage treatments at a 2,3,7,8-TCDD dose of 10 **µg/kg**. In the second portion of **this** study, rats were exposed by a single intraperitoneal

Injection of **2,3,7,8-TCDD** at 5, 10 or **15 µg/kg** or a single gavage treatment at **20 µg/kg**. The animals at the two highest exposure levels were killed 24 hours post-treatment, while the remaining animals were killed 29 days post-treatment. Again, no Increase in chromosomal aberrations was **observed**, except in the positive control group exposed to **triethylenemelamine**.

In a later report, a small but significant Increase in chromosomal aberrations was observed in the bone marrow cells of male and female Osborne-Mendel rats (Green et al., 1977). Bone marrow cells for **cytogenetic** analysis were obtained from **Osborne-Mendel** rats used in a range-finding study preliminary to a chronic **bioassay** (Green et al., 1977). The animals in groups of 8 males and 8 females received twice weekly intubations of **2,3,7,8-TCDD** at respective doses of 0.25, **1.0**, 2.0 and 4.0, or 0.25, 0.5, 2.0 and 4.0 µg/kg for 13 weeks. Because **it** was not required for the range-finding study, a control group was not included. Bone marrow cells were analyzed for abnormalities and cells in mitosis in the animals that survived to the end of the study (4-8 **animals/group**). The only significant increases in chromosomal aberrations in comparison **with** the low dose group were in males at 2 and 4 µg/kg and females at 4 µg/kg. The greatest incidence observed was 4.65% of the **cells with** chromosomal breaks in the high-dose males; **this** was considered only weakly positive. The weak response, as well as the lack of data from control animals and the reported difficulty of obtaining cells from the high-dose animals as a result of **2,3,7,8-TCDD toxicity**, makes the conclusion from **this** study that 2,3,7,8-TCDD produced chromosomal breaks tenuous.

A similar weak response was observed by **Loprieno et al. (1982)** in male and female **CD-1 mice** that received an intraperitoneal injection of 2,3,7,8-TCDD at a dose of 10  $\mu\text{g}/\text{kg}$ . At 96 hours post-treatment, there was a significant ( $p < 0.01$ ) increase in bone marrow cells with gaps and chromatid aberrations. When chromosomal aberrations were analyzed at 24 hours post-treatment, there was no significant change in the incidence of cells with aberrant chromosomes. The study was continued with a more extensive experiment using CD-COBS female rats. The rats were treated weekly by gavage (vehicle acetone-corn oil 1:6) at doses of 0, 0.01, 0.10 or 1.00  $\mu\text{g}/\text{kg}$  for 45 weeks. Analysis of bone marrow cells for chromosomal aberrations 24 hours after the last treatment failed to detect significant increases.

**Czeizel and Kiraly (1976)** reported an increased incidence ( $p < 0.001$ ) of chromatid-type and unstable chromosome aberrations in the peripheral lymphocytes of workers exposed to the herbicides **2,4,5-trichlorophenoxyethanol (2,4,5-TCPE)** and **Buminal**. The **2,3,7,8-TCDD** levels in the final product were  $< 0.1 \text{ mg}/\text{kg}$ ; however, the exposure levels for individual workers were not available.

**Mulcahy (1980)** reported no increased incidences of chromosomal aberrations in the lymphocytes of 15 soldiers exposed to Agent Orange. The exposure was for 6-15 months and all subjects complained of symptoms, including skin eruptions, which they associated with Agent Orange. The analyses were performed with lymphocytes obtained ~10 years after the last exposure, and comparisons were made with eight subjects who had no history of exposure to 2,3,7,8-TCDD. Neither sister chromatid exchange nor structural aberrations including both gaps and breaks were increased. The authors noted that the long time between exposure and analysis may have accounted for the negative results.



In addition, Regglanl (1980) and **Mottura et al.** (1981) studied the **2,3,7,8-TCDD** exposed Inhabitants In Seveso. Regglanl (1980) examined 4 adults and **13** children (3-13 years) for chromosomal aberrations within 2 weeks of the accident. These 17 Individuals were examined to support claims of and determine extent of **injury**. Although burn-like **skin** lesions In these 17 **individuals** Indicated **chemical** exposure, no Increase In chromosomal aberrations was detected. The methods of performing the analyses and the actual number of aberrations detected were not described. Similar negative **results** were reported In an abstract by Mottura et al. (1981). In **this** study, subjects were chosen from the area of heavy contamination following the accident (acute **high** level exposure), from the working population of the plant (chronic **low** level exposure) and a nonexposed control population. The number of subjects In each group was not provided. The specimens were examined by three Independent laboratories and no laboratory reported an Increase **in** chromosomal aberrations, although there was a significant difference In the reported scores between **laboratories**. There was no Information In **this** abstract on the extent of Individual exposure or the length of **time** that elapsed between the accident and obtaining samples for analyses of chromosomal aberrations.

Tenchlnl et al. (1979) also conducted a **cytogenetic** study of the exposed **individuals** at Seveso, Italy and of the aborted fetal tissue from exposed mothers. No significant chromosomal aberrations could be observed **in** the **peripheral** lymphocytes of the exposed Idlvlduals. But aborted fetuses showed a nonsignificant Increase In chromosomal abnormalities compared to the spontaneously aborted fetuses as observed **in** the general population. In a subsequent study, **Tenchini** et al. (1983) observed a significant Increase

in the frequencies of aberrant **cells** and in the average number of aberrations per damaged cell in fetal tissues from exposed pregnancies. **This** is a potentially interesting observation, but the study has the following pitfalls. First, the **controls** were nonconcurrent. **This** is a **major problem in** the interpretation of the results from pregnancies before and after exposure. Second, cells carrying the chromosomal aberrations described are not expected to survive more than one cell cycle, but **in this** study cells were examined that had undergone several cell divisions. **This** casts doubt on the validity of a positive result.

**DiLernia et al.** (1982) conducted additional studies on lymphocytes prepared in 1976 and 1979 from eight persons considered acutely exposed to **2,3,7,8-TCDD** in the Seveso accident, eight **ICMESA** factory workers (considered chronically exposed), and 14 control subjects (eight had chromosome preparations made in 1976 and **six** in 1979). Cells were examined for average number of SAs (Satellite Associations; evidence for functional **ribosomal** genes), both on a cell basis and for the large **acrocentric** chromosomes (D group **chromosomes**). There was no change **in** the frequency of SAs on a per cell basis in any of the groups as compared to control values, nor in D group chromosomes from acutely exposed subjects examined immediately after the accident. There was, however, a decrease **in** the average frequency of SAs in group D chromosomes of acutely exposed subjects examined in 1977 and in ICMESA workers at both the 1976 and 1979 examinations. Although the biologic relevance of these observations has not yet been confirmed, **DiLernia et al.** (1982) observed a similar decrease in SAs after exposure of lymphocytes to x-irradiation. It was concluded that the decrease in SAs may have resulted from **mutagenic** damage to functional nucleolar organizing regions.

## 10.2. SUMMARY

A limited number of Initial studies on the **mutagenicity** of **2,3,7,8-TCDD** in bacteria reported positive **results** in S. typhimurium strain TA1532 in the absence of a mammalian metabolic activation system (**Hussain et al.**, 1972; Seller, 1973). More recent attempts to repeat these results **with** strain TA1532 or related strains have failed (**Geiger and Neal**, 1981; Nebert et al., 1976; **Gilbert et al.**, 1980; **McCann**, 1978). These authors have **also** reported no increase in mutation rate when 2,3,7,8-TCDD was tested in the presence of a mammalian metabolic activation system. In other **in vitro** assays, 2,3,7,8-TCDD has produced a positive response in reversion to streptomycin independence in **E. coli** Sd-4 cells and questionable positive response **with** prophage induction in **E. coli** K-39 cells (Hussain et al., 1972). Also, 2,3,7,8-TCDD has been reported to be **mutagenic** in the yeast **S. cerevisiae** in both the **in vitro** assay **with S-10** and the host-mediated assay (**Bronzetti et al.**, 1983). Rogers et al. (1982) also reported positive mutagenicity results in the mouse lymphoma assay system. In the **E. coli** studies, the poor survival of the cells or the interference of the vehicle solvent, **DMSO**, **with** the assay makes the evaluation of the studies difficult. **With** the data available, it is not possible to resolve the conflicting reports on the mutagenic potential of 2,3,7,8-TCDD.

Overall, the data indicate **little** potential for the interaction of 2,3,7,8-TCDD **with** nucleic acids or the ability of 2,3,7,8-TCDD to produce chromosomal aberrations. **Kondoros** et al. (1973) demonstrated that 2,3,7,8-TCDD **did** not react **with** RNA in vitro in the absence of a **metabolic** activation system. **In vivo** studies using **radiolabeled** 2,3,7,8-TCDD indicated some association of nonextractable label **with** RNA and DNA (Poland and Glover, 1979); however, the level of bound label was very low. Similar marginal

data were available on the **clastogenic** effect of **2,3,7,8-TCDD**. Although two **in vivo** studies in rats (Green and **Moreland**, 1975; Loprleno et **al.**, 1982) failed to demonstrate treatment-related chromosomal aberration, a second study by the same authors (**Green et al.**, 1977) using a longer exposure period reported a small increase in the number of aberrations. A similar small increase was observed by Loprleno et al. (1982) following a single **intraperitoneal** injection of 2,3,7,8-TCDD in **mice**. In humans exposed to 2,3,7,8-TCDD during the manufacture of **2,4,5-TCPE** and **Bumino1**, **Czeizel** and **Kiraly** (1976) reported an increase in the number of chromosomal aberrations; however, no increase was detected in individuals exposed to 2,3,7,8-TCDD following an **industrial** accident in Seveso, Italy (Regglan1, 1980; Mottura et **al.**, 1981; Tenchln1 et **al.**, 1979). In contrast, **Tenchini** et **al.** (1983) reported positive results in a Seveso study, but **this** study has problems. The studies of the **clastogenic** effect of 2,3,7,8-TCDD were presented **with little** or no experimental detail to assist in evaluating the merits of the reports. The data available are too limited to indicate whether 2,3,7,8-TCDD can interact **with** nucleic acids or produce chromosomal aberrations.

The differences among the results reported **could** be due to **several** factors, such as treatment protocols, solubility problems, purity of the **samples** tested and the **high toxicity** of 2,3,7,8-TCDD. **This** chemical may be a weak mutagen, but because it is very toxic, the dose range for detecting a positive genetic effect may be very narrow. Therefore, additional experimentation is necessary before any conclusive determination can be made. Suggested further testing includes the ability of 2,3,7,8-TCDD to induce forward mutations **in** mammalian cells in culture, additional yeast and bacterial studies and the sex-linked recessive lethal test in **Drosophila**.

Pertinent information regarding the **mutagenicity** of PcCDDs and HxCDDs were not located in the available literature.

## 11. CARCINOGENICITY

The purpose of **this** section is to provide an evaluation of the likelihood that **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD), and a mixture of **1,2,3,7,8,9-** and **1,2,3,6,7,8-hexachlorodibenzo-p-dioxin** (HxCDD), are human carcinogens and, on the assumption that they are human carcinogens, to provide a basis for estimating their public health impact, **including** a potency evaluation, in relation to other carcinogens. The evaluation of **carcinogenicity** depends heavily on animal **bioassays** and epidemiologic evidence. However, information on **mutagenicity** and metabolism, **particularly** in **relation** to interaction **with** DNA, as well as to **pharmacokinetic** behavior, has an important bearing on both the qualitative and quantitative assessment of **carcinogenicity**. The **available** information on these subjects is reviewed in other sections of **this** document. **This** chapter presents an evaluation of the animal bioassays, the human epidemiologic evidence, the quantitative aspects of assessment, and finally, a summary and conclusions section dealing **with** all of the relevant aspects of carcinogenicity.

### 11.1. ANIMAL STUDIES

11.1.1. Studies Using **2,3,7,8-TCDD**. The **polychlorinated dibenzo-p-dioxins** (PCDDS), 2,3,7,8-TCDD and a mixture of 1,2,3,7,8,9- and **1,2,3,6,7,8-HxCDD**, have been tested for carcinogenicity in rats and **mice** by administering the compound in the **diet** and by gavage. Also, the tumor incidence in native **mice** inhabiting an area **with** heavy exposure to the herbicide Agent Orange has been assessed and compared **with mice** from an **uncontaminated** habitat. The results of these bioassays are discussed in **this** section. Along **with** studies using the oral route, both 2,3,7,8-TCDD and a mixture of 1,2,3,7,8,9- and **1,2,3,6,7,8-HxCDD** have been tested for **tumorigenicity** by

dermal application. Using the **skin** two-stage **tumorigenicity model**, 2,3,7,8-TCDD has been tested for promoting and Initiating activity as well as anti-carcinogenic activity. Other model systems have been used to a more limited extent in studies of the effect of **2,3,7,8-TCDD** on the carcinogenic potential of chemical carcinogens.

11.1.1.1. VAN MILLER ET AL. (ORAL) RAT STUDY (1977a,b) -- In a limited **study**, Van Miller et al. (1977a,b) maintained small groups of **male** Sprague-Dawley rats on diets containing 2,3,7,8-TCDD. The animals, in groups of 10, were fed diets containing 0.0, **0.001**, 0.005, 0.05, 0.5, 1.0, 5.0, 50, 500 or 1000 ppb of 2,3,7,8-TCDD for 78 weeks. As determined from the food consumption of two animals from each group, these exposure levels corresponded to doses of 0.0, 0.0003, 0.001, 0.01, 0.1, 0.4, 2.0, 2.4, 240 and 500 **µg/kg/week**, respectively. At week 65 of treatment, all surviving animals were examined by **laparotomy**, and biopsy samples were obtained from any gross tumors. Following termination of treatment, the animals were observed for an additional 17 weeks before sacrificing all surviving animals. Necropsy was performed on animals killed when moribund, found dead or killed at termination of the study, and the animals were examined for both gross and microscopic lesions. Intake and mortality are shown in Table 11-1.

All animals in groups maintained on diets containing 1-1000 ppb of 2,3,7,8-TCDD were dead by week 90 of treatment; the first deaths in groups at the 1000 and 1 ppb levels were observed at 2 weeks and 31 weeks of treatment, respectively. Animals exposed to 0.001-0.5 ppb of 2,3,7,8-TCDD had similar food consumption and survival as control animals; however, all treated animals had **histopathologic** degenerative changes in the kidneys.

TABLE 11-1  
2,3,7,8-TCOO Intake and Mortality in Male Sprague-Dawley **Rats**<sup>a</sup>

| <b>Dose<sup>b</sup></b><br>(ppb) | <b>Weekly Dose/Rat</b><br><b>(<math>\mu</math>g/kg bw)</b> | <b>Week of</b><br><b>First Death</b> | <b>Number of Rats</b><br><b>Dead at 95th Week</b> |
|----------------------------------|--|--------------------------------------|---|
| 0.0                              | --   | 68                                   | 6/10 (60X)  |
| 0.001                            | 0.0003   | 86                                   | 2/10 <b>(20%)</b>                                 |
| 0.005                            | 0.001  | 33                                   | 4/10 <b>(40%)</b>                                 |
| 0.05                             | 0.01   | 69                                   | 4/10 (40X)  |
| 0.5                              | <b>0.1</b>   | 17                                   | 5/10 <b>(50%)</b>                                 |
| <b>1</b>                         | 0.4  | 31                                   | 10/10 <b>(100%)</b>                               |
| 5                                | 2.0  | 31                                   | <b>10/10</b> (100X)                               |

<sup>a</sup>Source: Van Miller et al., 1977a,b

<sup>b</sup>Rats at 50, 500 and 1000 ppb dose levels were all dead within 4 weeks.

**Complete** necropsies were done and **samples** of tissues were taken for microscopic examination from the control groups and each treatment group (Laboratory audit\* and personal communication **with** author).

Special staining methods were used as an **aid** in the diagnosis of neoplasms. Various benign and malignant tumors were found in each treatment group. No tumors were observed in the controls (Table 11-2).

Statistically significant increases of **squamous** cell tumors of the lungs and **neoplastic** nodules of the liver were observed in rats ingesting **5** ppb TCDD (Table 11-3). In addition, two animals in the 5 ppb dose group and one animal **in** the 1 ppb dose group had liver **cholangiocarcinomas**, which are rare in Sprague-Dawley rats. These results provide evidence of a carcinogenic effect.

The observation of no tumors of any **kind in** the controls is unusual for Sprague-Dawley rats. In addition, the reporting of the study was not extensive. These factors may tend to **lessen** the reliance that can be placed on the positive results of **this** study. However, **this** study is suggestive of a carcinogenic response upon exposure to TCDD in rats.

**11.1.1.2. KOCIBA ET AL. (ORAL) RAT STUDY (1978a)** -- Although **this** study was published as **Kociba et al., 1978a**, a fuller version was submitted in an unpublished report (Kociba et al., 1977).

In **this** study, groups of 50 Sprague-Dawley rats (Spartan **substrain**) of each sex were maintained for up to 2 years on diets providing 0.1, 0.01 or 0.001 **µg/kg/day 2,3,7,8-TCDD**. **Vehicle** control groups consisted of 86 animals of each sex. The test was appropriately conducted **with** the

---

\*The audit of **this** study brought out the fact that it was intended to be **only** a range-finding study. Therefore, only small numbers of animals were used. **This** may have made the study relatively insensitive for detecting carcinogenic effects at doses **<1** ppb.



TABLE 11-2

Benign and Malignant Tumors In Rats Ingesting 2,3,7,8-TCDD<sup>a</sup>

| Dose <sup>b</sup> | Benign | Malignant | Number of Tumors | Number of Rats With Tumors |
|-------------------|--------|-----------|------------------|----------------------------|
| 0                 | 0      | 0         | 0                | 0/10 (0%) <sup>c</sup>     |
| 1 ppt             | 0      | 0         | 0                | 0/10 (0X)                  |
| 5 ppt             | 1      | 5         | 6 <sup>d</sup>   | 5/10 (50%) <sup>e</sup>    |
| 50 ppt            | 2      | 1         | 3 <sup>f</sup>   | 3/10 (30%)                 |
| 500 ppt           | 2      | 2         | 49               | 4/10 (40%) <sup>h</sup>    |
| 1 ppb             | 0      | 4         | 51               | 4/10 (40X)                 |
| 5 ppb             | 8      | 2         | 10 <sup>j</sup>  | 7/10 (70%)                 |

<sup>a</sup>Source: Van Miller et al., 1977a,b

<sup>b</sup>Rats at dose levels of 50, 500 and 1000 ppb were all dead within 4 weeks.

<sup>c</sup>40 male rats used as controls for another study, received at the same time and kept under identical conditions, did not have neoplasms when killed at 18 months.

<sup>d</sup>1 rat had ear duct carcinoma and lymphocytic leukemia

1 adenocarcinoma (kidney)

1 malignant histiocytoma (retroperitoneal)

1 angiosarcoma (skin)

1 Leydig cell adenoma (testis)

<sup>e</sup>3 rats died with aplastic anemia

<sup>f</sup>1 fibrosarcoma (muscle)

1 squamous cell tumor (skin)

1 astrocytoma (brain)

<sup>g</sup>1 fibroma (striated muscle)

1 carcinoma (skin)

1 adenocarcinoma (kidney)

1 sclerosing seminoma (testis)

<sup>h</sup>1 rat had a severe liver infarction

<sup>i</sup>1 rat cholangiocarcinoma and malignant histiocytomas (retroperitoneal)

1 angiosarcoma (skin)

1 glioblastoma (brain)

1 malignant histiocytoma (retroperitoneal)

<sup>j</sup>1 rat had squamous cell tumor (lung) and neoplastic nodule (liver)

2 cholangiocarcinomas and neoplastic nodules (liver)

3 squamous cell tumors (lung)

1 neoplastic nodule (liver)

TABLE 11-3

Liver Tumors in Rats Ingesting 2,3,7,8-TCDD<sup>a</sup>

| Dose (ppb) | Neoplastic<br>Nodules              | Cholangiocarcinomas     | Squamous Cell<br>Tumors of the Lungs |
|------------|------------------------------------|-------------------------|--------------------------------------|
| 0          | 0/10 (0%)                          | 0/10 (0%)               | 0/10                                 |
| 1          | 0/10 (0%)                          | 1/10 (10%)              | 0/10                                 |
| 5          | 4/10 (40%)<br>p=0.043 <sup>c</sup> | 2/10 (20%) <sup>b</sup> | 4/10 (40%)<br>p=0.043 <sup>c</sup>   |

<sup>a</sup>Source: Van Miller et al., 1977a,b

<sup>b</sup>The two animals had both neoplastic nodules of the liver and cholangiocarcinomas.

<sup>c</sup>p-values calculated using the Fisher Exact Test.

high-dose group given a dose which induced signs of tissue **toxicity**, reduced weight increments in both **sexes**, and shortened **lifespans** in female rats. Clinical tests performed at intervals during the study monitored organ specific toxicity, **particularly** of the liver. Pathologic examinations included **histopathologic** evaluation of all **major** tissues in both the high-dose and control animals, but only of selected tissues identified as possible target organs and suspect tumors in lower-dose groups. **This** approach is **suitable** for the identification of a carcinogenic effect, but does not determine actual tumor incidences in all groups except in those organs identified as target organs. It, therefore, is adequate to define dose-response relationships only in these target organs. Tissues examined from most animals in all dose groups included liver, lungs, kidneys, urinary bladder, tongue, brain, **testes/ovaries** and prostate/uterus. For these tissues, a quantitative analysis can be performed using the actual number of tissues examined **histopathologically** for animals at **risk**. For other tissues (excluding **skin**, mammary glands and nasal turbinates/hard palate), actual tumor incidence cannot be **evaluated** for the two lower doses. For **skin**, mammary glands and nasal turbinates/hard palate, the number of animals **necropsied** is the appropriate denominator to determine incidence, because detection of these tumors is based on observation of the tumor at necropsy.

A laboratory audit of **this** study by H. Spencer and **W.S. Woodrow**, Hazard Evaluation Division, Office of Pesticide Programs, U.S. EPA, **did** not reveal significant new information. Reviewers concluded that the study was properly conducted, adhering to the accepted procedures (Spencer and Woodrow, 1979).

Based on data reported for food consumption, body weight and dietary level of TC00, the daily doses were reasonably constant for most of the

**study, although** somewhat below the value expected **in** most groups during the third month.

**High** early mortality was observed in all groups in **this** study but was only statistically significant in the high-dose group. The **survival** curves show progressive mortality beginning as early as the 12th month and leading to 50% mortality by 21 **months.\*** The effects of **this** early mortality are a reduction in expected tumor incidence because of a truncated latency period, and a reduction in sensitivity of the study because of a reduction in number of animals at **risk** during the **time** of expected tumor manifestation. Cumulative mortality and Interval **mortality** rates are given in Tables **A-1** to **A-4** of Appendix A (Clement Associates, 1979).

The results of **this** study provide substantial evidence that **2,3,7,8-TCDD** is carcinogenic in rats. 2,3,7,8-TCDD induced a highly statistically significant increase of both **hepatocellular** carcinomas and **hepatocellular neoplastic** nodules in female rats at doses of 0.1 and 0.01 pg/kg/day (2200 and 210 ppt in the **diet**, respectively). The increase of hepatocellular carcinomas alone, in the high-dose females, was also highly significant. In addition, at the highest dose level, 2,3,7,8-TCDD induced a statistically significant increase in stratified squamous cell carcinomas of the hard palate and/or nasal **turbinates** in both males and females, squamous cell carcinomas of the tongue in males, and highly significant keratinizing squamous cell carcinomas of the lungs in females (Tables 11-4, 11-5 and 11-6).

---

\*In the 0.001 group of males, **44%** of the animals had **died** by 18 months. The mortality patterns were analyzed by the **Whitney-Wilcoxon** test and the **Kolmogorov-Simonov** test. These tests showed that mortality was significantly higher in the high-dose females than in controls, and while indications of increased mortality were found in other groups, they were not part of a consistent pattern.

**TABLE 11-4**

Hepatocellular Carcinomas and Hepatocellular Hyperplastic Nodules  
 in Female **Sprague-Dawley** Rats Maintained on Diets Containing **2,3,7,8-TCDD<sup>a</sup>**

| Dose Level<br>( $\mu\text{g}/\text{kg}/\text{day}$ ) | Hepatocellular<br><b>Hyperplastic</b><br>Nodules | Hepatocellular<br><b>Carcinomas<sup>b</sup></b> | Total Number<br><b>With Both</b><br>Types of Tumors <sup>b</sup> |
|--|--|---|--|
| 0  | 8/86 (9%)  | 1/86 (1%)                                       | 9/86 (10%)   |
| 0.001<br>(22 ppt)                                    | 3/50 (6%)  | 0/50 (0%)                                       | 3/50 (6%)  |
| 0.01<br>(210 ppt)                                    | 18/50 (36%)                                      | 2/50 (4%)                                       | 18/50 (36%) <sup>c</sup><br>( $p=4.36 \times 10^{-4}$ )          |
| 0.1<br>(2200 ppt)                                    | 23/49 (48%)                                      | 11/49 (22X)<br>( $p=5.6 \times 10^{-5}$ )       | 34/50 (71%)<br>( $p=4.56 \times 10^{-13}$ )                      |

<sup>a</sup>Source: Kociba et al., 1977

<sup>b</sup>p-values calculated using the Fisher Exact Test (one-tailed).

<sup>c</sup>Two rats had both hepatocellular carcinomas and hyperplastic nodules.

TABLE 11-5

Tumor Incidence in **Female** Rats Fed Diets Containing **2,3,7,8-TCDD<sup>a</sup>**

| Dose Level<br>( $\mu\text{g/kg/day}$ ) | Stratified Squamous Cell<br>Carcinomas of Hard Palate<br>or Nasal <b>Turbinates</b> | Keratizing Squamous<br>Cell Carcinomas of<br>Lungs |
|--|---|--|
| 0                                      | 1/54 (2%)   | 0/86 (OX)  |
| 0.001<br>(22 ppt)                      | 0/30 (OX)   | 0/50 (OX)  |
| 0.01<br>(210 ppt)                      | 1/27 (4X)   | 0/50 (OX)  |
| 0.1<br>(2200 ppt)                      | 5/24 (21%)<br>( $p=0.01$ ) <sup>b</sup>   | 7/49 (14%)<br>( $p=0.0006$ ) <sup>b</sup>          |

<sup>a</sup>Source: Kociba et al., 1977<sup>b</sup>p-values calculated using the Fisher Exact Test (one-tailed).

TABLE 11-6

Tumor Incidence in Male Rats Fed Diets Containing **2,3,7,8-TCDD**<sup>a</sup>

| Dose Level<br>( $\mu\text{g/kg/day}$ ) | Stratified Squamous Cell<br>Carcinomas of the Tongue                | Hard Palate/Nasal Turbinates<br>Stratified Squamous Cell Carcinoma <sup>b</sup> |
|--|---|---|
| 0                                      | 0/76 (OX)   | 0/51 (OX)   |
| 0.001<br>(22ppt)                       | 1/49 ( <b>2%</b> ) NS   | 1/34 (3X) NS  |
| 0.01<br>(210 ppt)                      | 1/50 (2X) NS  | 0/27 (OX) NS  |
| <b>0.1</b><br>(2200 ppt)               | 3/42 (7X) ( <b><math>p=4.3 \times 10^{-2}</math></b> ) <sup>c</sup> | 4/30 (13X) ( <b><math>p=0.016</math></b> ) <sup>c</sup>                         |

<sup>a</sup>Source: Kociba et al., 1977<sup>b</sup>Includes examinations from both original and updated report (5/20/79).<sup>c</sup>p-values calculated using the Fisher Exact Test.NS = Not significant at **p=0.05**.

Dr. Robert Squire, pathologist at the Johns Hopkins University **Medical School** and **consultant** to the CAG, evaluated the **histopathologic** slides from Dow **Chemical Company's** 2-year rat feeding studies on **2,3,7,8-TCDD** by **Kociba et al.** (1978a). Dr. Squire and **his** associates examined all liver, **lungs**, tongues, hard palates and nasal **turbinates** available from the 2,3,7,8-TCDD study. Their **histopathological** findings, as **well** as Dr. **Kociba's histopathological** evaluations, are summarized in Tables 11-7 and 11-8 and Appendix B. Although there are some differences between the diagnoses of Drs. Kodba and Squire, the conclusions about the target organ for cancer Induction and the dose levels at which Induction occurred are the same.

11.1.1.3. NATIONAL **TOXICOLOGY** BIOASSAY PROGRAM (ORAL) RAT STUDY (1980a,b) - A cancer **bioassay** for the possible **carcinogenicity** of 2,3,7,8-TCDD was tested by the **Illinois** Institute of Technology in rats and **mice** under a contract sponsored by the National Cancer Institute (NCI).

In the rat study, 50 Osborne-Mendel rats of each sex were administered 2,3,7,8-TCDD\* suspended in a vehicle of 9:1 corn **oil-acetone** by gavage 2 days/week for 104 weeks at doses of 0.01, 0.05 or 0.5 **µg/kg/week**. Seventy-five rats of each sex served as vehicle controls. One untreated **control** group containing 25 rats of each sex was present in the 2,3,7,8-TCDD treatment room and one untreated control group containing 25 rats of each sex was present **in** the vehicle control room. All surviving rats were **killed** at 105-107 weeks.

---

\*Purity of 2,3,7,8-TCDD was found to be **99.4%**; two Impurities tentatively Identified as a **trichlorodibenzo-p-dioxin** and a **pentachlorodibenzo-p-dioxin**. The presence of 0.1-0.2% **hexachlorodibenzo-p-dioxin** was also detected by gas chromatography and mass **spectrometry**.



TABLE 11-7

Dow 2,3,7,8-TCDD Oral Rat Study by Dr. Kociba, With Dr. Squire's Review (8/15/80)  
Sprague-Dawley Female Rats - Spartan Substratn (2 years)<sup>a,b</sup>

| Tissues and Diagnoses   | Dose Levels ( $\mu\text{g}/\text{kg}/\text{day}$ ) |             |             |   |   |   |   |  |
|---|--|-------------|-------------|---|---|---|---|--|
|   | 0 (control)  |             | 0.001       |   | 0.01  |   | 0.1   |  |
|   | S  | K           | S           | K   | S   | K   | S   | K  |
| Lung<br>Squamous cell carcinomas                                | 0/86   | 0/86        | 0/50        | 0/50                                      | 0/49  | 0/49  | 8/47 (17%)<br>( $p=1.61 \times 10^{-6}$ )   | 7/49 (14%)<br>( $p=6.21 \times 10^{-6}$ )    |
| Nasal turbinate/hard palate<br>squamous cell carcinomas         | 0/54   | 1/54        | 0/30        | 0/30                                      | 1/27  | 1/27  | 5/22 (23%)<br>( $p=1.43 \times 10^{-8}$ )   | 5/24 (21%)<br>( $p=9.46 \times 10^{-8}$ )    |
| Liver<br>Neoplastic nodules/<br>hepatocellular carcinomas       | 16/86  | 9/86        | 8/50        | 3/50<br>( $p=4.37 \times 10^{-4}$ )       | 27/50<br>( $p=2.42 \times 10^{-5}$ )        | 18/50<br>( $p=4.37 \times 10^{-4}$ )        | 33/47 (70%)<br>( $p=4.92 \times 10^{-9}$ )  | 34/48 (71%)<br>( $p=9.53 \times 10^{-10}$ )  |
| Total combined<br>(each animal had at least<br>one tumor above) | 16/86<br>19%                                       | 9/86<br>10% | 8/50<br>16% | 3/50<br>6%<br>( $p=4.37 \times 10^{-4}$ ) | 27/50<br>54%<br>( $p=2.42 \times 10^{-5}$ ) | 18/50<br>34%<br>( $p=4.37 \times 10^{-4}$ ) | 34/47<br>72%<br>( $p=1.20 \times 10^{-9}$ ) | 34/49<br>69%<br>( $p=2.13 \times 10^{-12}$ ) |

<sup>a</sup>Source: Kociba et al., 1977; Squire, 1980

<sup>b</sup>p-values calculated using the Fisher Exact Test.

S = Dr. Squire's histopathologic analysis; K = Dr. Kociba's histopathologic analysis

TABLE 11-8

Dow 2,3,7,8-TCDD Oral Rat Study by Dr. Kociba, With Dr. Squire's Review (8/15/80)  
Sprague-Dawley Male Rats - Spartan Substrain (2 years)\*

| Tissues and Diagnoses   | Dose Levels ( $\mu\text{g}/\text{kg}/\text{day}$ ) |      |            |      |            |      |  |  |
|---|--|------|------------|------|------------|------|--|--|
|   | 0 (control)  |      | 0.001      |      | 0.01       |      | 0.1  |  |
|   | S  | K    | S          | K    | S          | K    | S  | K  |
| Nasal <b>turbinate/hard</b> palate<br>squamous <b>cell</b> carcinomas | 0/55   | 0/51 | 1/34       | 1/34 | 0/26       | 0/27 | 6/30 (20%)<br><b>(<math>p=1.36 \times 10^{-3}</math>)</b>  | 4/30 (13%)<br><b>(<math>p=1.6 \times 10^{-2}</math>)</b> |
| Tongue<br>squamous <b>cell</b> carcinomas                             | 0/77   | 0/76 | 2/44       | 1/49 | 1/49       | 1/49 | 3/44 (7%)<br><b>(<math>p=4.60 \times 10^{-2}</math>)</b>   | 3/42 (7%)<br><b>(<math>p=4.34 \times 10^{-2}</math>)</b> |
| Total - 1 or 2 above<br>(each rat had at least<br>one tumor above)    | 0/77   |      | 2/44<br>5% |      | 1/49<br>2% |      | 9/44<br>20%<br><b>(<math>p=6.28 \times 10^{-3}</math>)</b> |  |

\*p-values calculated using the Fisher Exact Test.

S = Dr. Squire's histopathologic analysis

K = Dr. Kociba's histopathologic analysis

In rats, a dose-related depression in mean body weight gain became evident in the males after week 55 of the bioassay and in the females after week 45.

The results of histopathologic diagnosis of primary tumors caused by the oral administration of 2,3,7,8-TCDD are presented in Table 11-9. In male rats an increased incidence of follicular-cell adenomas or carcinomas of the thyroid was dose-related and was statistically significantly higher in the low-, mid- and high-dose groups than in the vehicle controls. In addition, a statistically significant increase in subcutaneous tissue fibromas was found in males of the high-dose group.

In female rats, a statistically significant increase of each of the following tumors was found in the high-dose group: hepatocellular carcinomas and neoplastic nodules ( $p=0.001$ ), subcutaneous tissue fibrosarcomas ( $p=0.023$ ) and adrenal cortical adenomas ( $p=0.039$ ), as shown in Table 11-10.

These results confirm the carcinogenic effect observed in the Kociba et al. (1978a) study using Sprague-Dawley (Spartan substrain) rats.

11.1.1.4. TOTH ET AL. (ORAL) HOUSE STUDY (1979) - This study investigated the carcinogenicity of 2,3,7,8-TCDD in Swiss mice. Ten-week-old outbred Swiss/H/RIOP mice were used. 2,3,7,8-TCDD was administered in a sunflower oil vehicle by gavage to groups of 45 male mice once a week at doses of 7.0, 0.7 and 0.007  $\mu\text{g}/\text{kg}$  bw for a year (groups 9, 10, 11, respectively, in Table 11-11). Matched male vehicle controls were administered sunflower oil once a week. Matched controls to a companion study investigating the carcinogenicity of (2,3,5-trichlorophenoxy)ethanol (TCPE) contaminated with low levels of 2,3,7,8-TCDD, were administered carboxymethyl cellulose (the vehicle used in that study) once a week. Two untreated controls were also maintained.

TABLE 11-9

Incidence of Primary Tumors in Male Rats Administered 2,3,7,8-TCDD by Gavage<sup>a</sup>

| Type of Tumor   | Vehicle Control | $\mu\text{g/kg/week}$         |                               |                                  |
|---|-----------------|-------------------------------|-------------------------------|----------------------------------|
|   |                 | Low Dose <sup>b</sup><br>0.01 | Mid Dose <sup>b</sup><br>0.05 | High Dose <sup>b</sup><br>0.5    |
| Subcutaneous tissue<br>Fibroma                                      | 3/75 (4X)       | 1/50 (2%)                     | 3/50 (6X)                     | 7/50 (14X)<br><b>p=0.048</b>     |
| <b>Liver</b><br>Neoplastic nodule<br>or hepatocellular<br>carcinoma | 0/74 (0X)       | 0/50 (0X)                     | 0/50 (0X)                     | 3/50 (6X)                        |
| Adrenal<br>Cortical adenoma   | 6/72 (8X)       | 9/50 (18X)                    | 12/49 (24X)                   | 9/49 (18X)                       |
| Thyroid<br>Follicular cell<br>adenoma                               | 1/69 (1%)       | 5/48 (10%)<br><b>p=0.042</b>  | 6/50 (16X)<br><b>p=0.021</b>  | 10/50 (20X)<br><b>p=0.001</b>    |
| Thyroid<br>Follicular cell<br>adenoma or<br>carcinoma               | 1/69 (1%)       | 5/48 (10%)<br><b>p=0.042</b>  | 8/50 (16X)<br><b>p=0.004</b>  | 11/50 (22X)<br><b>p&lt;0.001</b> |

<sup>a</sup>Source: NTP, 1980a<sup>b</sup>p-values calculated using the Fisher Exact Test.

TABLE 11-10

Incidence of Primary Tumors in Female Rats Administered  
2,3,7,8-TCDD by Gavage<sup>a</sup>

| Type of Tumor   | $\mu\text{g/kg/week}$ |              |                               |       |                  |             |                               |       |                |
|---|-----------------------|--------------|-------------------------------|-------|------------------|-------------|-------------------------------|-------|----------------|
|   | Vehicle Control       |              | Low Dose <sup>b</sup><br>0.01 |       | Mid Dose<br>0.05 |             | High Dose <sup>b</sup><br>0.5 |       |                |
| Subcutaneous tissue<br><b>Fibrosarcoma</b>                          | 0/75                  | (0%)         | 2/50                          | (4%)  | 3/50             | (6%)        | 4/49                          | (8%)  | <b>p=0.023</b> |
| Liver<br><b>Neoplastic</b> nodule                                   | 5/74                  | (7%)         | <b>1/49</b>                   | (2%)  | 3/50             | (6%)        | 12/49                         | (24%) | <b>p=0.006</b> |
| <b>Liver</b><br>Neoplastic nodule<br>or hepatocellular<br>carcinoma | 5/75                  | (1%)         | 1/49                          | (2%)  | 3/50             | <b>(6%)</b> | <b>14/49</b>                  | (29%) | <b>p=0.001</b> |
| Pituitary<br>Adenoma  | 1/66                  | (2%)         | 5/47                          | (11%) | 2/44             | (5%)        | 3/43                          | (7%)  | <b>p=0.044</b> |
| Adrenal<br>Cortical adenoma   | 11/73                 | <b>(15%)</b> | 8/49                          | (16%) | 4/49             | (8%)        | 14/46                         | (30%) | <b>p=0.039</b> |

<sup>a</sup>Source: NTP, 1980a

<sup>b</sup>p-values calculated using the Fisher Exact Test.

TABLE 11-11

Cumulative Data on Tumor Incidence<sup>a</sup>

| Group | TCPE <sup>b</sup><br>(mg/kg) | Treatment            |                                 | Sex | Effective<br>Number of<br>Mice | Number<br>of Tumor<br>Bearing<br>Mice | Number of Animals with Tumors of: |      |           |                 |                     |
|-------|------------------------------|----------------------|---------------------------------|-----|--------------------------------|---------------------------------------|-----------------------------------|------|-----------|-----------------|---------------------|
|       |                              | TCDD<br>(µg/kg)      | Vehicle <sup>c</sup><br>(mg/kg) |     |                                |                                       | Liver<br>(X)                      | Lung | Lymphomas | Other<br>Organs | Average<br>Lifespan |
| 1     | 67.0                         | 0.112<br>(1.6 ppm)   | 50                              | N   | 88                             | 69                                    | <b>42<sup>d</sup></b> (18)        | 50   | 7         | 16              | 595                 |
|       |                              |                      |                                 | F   | 83                             | 61                                    | 7 (8)                             | 52   | 15        | 25              | 652                 |
| 2     | 70.0                         | 0.007<br>(0.1 ppm)   | 50                              | N   | 98                             | 78                                    | <b>57<sup>e</sup></b> (58)        | 18   | 11        | 16              | 571                 |
|       |                              |                      |                                 | F   | 96                             | <b>59</b>                             | 9 (9)                             | 39   | <b>15</b> | 23              | 582                 |
| 3     |                              | control              |                                 | N   | 93                             | 63                                    | 24 (26)                           | 44   | 8         | 17              | 577                 |
|       |                              |                      |                                 | F   | 84                             | 57                                    | 4 ( <b>5</b> )                    | 41   | 23        | 13              | 639                 |
| 4     | 7.0                          | 0.07<br>(10 ppm)     | 50                              | N   | 93                             | 79                                    | 25 (27)                           | 38   | 18        | 22              | 641                 |
|       |                              |                      |                                 | F   | 96                             | 60                                    | 10 (10)                           | 38   | 19        | 19              | 589                 |
| 5     | 7.0                          | 0.0007<br>(0.1 ppm)  | 50                              | N   | 94                             | 77                                    | 23 (24)                           | 50   | 23        | 17              | 660                 |
|       |                              |                      |                                 | F   | 93                             | 71                                    | 8 ( <b>9</b> )                    | 42   | 36        | 21              | 590                 |
| 6     | 0.7                          | 0.00007<br>(0.1 ppm) | 50                              | N   | 97                             | 78                                    | 24 (25)                           | 51   | 20        | 17              | 643                 |
|       |                              |                      |                                 | F   | 94                             | 64                                    | 5 (5)                             | 38   | 22        | 21              | 566                 |
| 7     | --                           |                      | 50                              | N   | 96                             | 74                                    | 32 (33)                           | 44   | 14        | 22              | <b>615</b>          |
|       |                              |                      |                                 | F   | 84                             | 55                                    | 4 ( <b>5</b> )                    | 38   | 18        | 17              | 565                 |
| e     |                              | control              |                                 | N   | 96                             | 78                                    | 32 (33)                           | 38   | 22        | <b>15</b>       | 651                 |
|       |                              |                      |                                 | F   | 91                             | 57                                    | 4 (4)                             | 31   | 24        | 19              | 549                 |
| 9     |                              | 7.0                  | 10                              | N   | 43                             | 27                                    | 13 (30)                           | 11   | 6         | 7               | 424                 |
| 10    |                              | 0.7                  | 10                              | N   | 44                             | 36                                    | 21 ( <b>48</b> )                  | 18   | 12        | 4               | 633                 |
| 11    |                              | 0.007                | 10                              | N   | 44                             | 39                                    | 13 (29)                           | 27   | 10        | 6               | 649                 |
| 12    | --                           | --                   | 10                              | N   | 38                             | 27                                    | 7 (18)                            | 15   | 6         | 7               | 588                 |

<sup>a</sup>Source: Toth et al., 1979<sup>b</sup>TCPE = Trichlorophenoxy ethanol<sup>c</sup>Carboxymethyl cellulose in groups 1-8. sunflower oil in groups 9-12.<sup>d</sup>p<1%<sup>e</sup>p<0.1%

**This** study appears to have been generally well conducted. However, the administration of **2,3,7,8-TCDD** over a period of only 1 year, which is far short of the **life** expectancy of the **mice** used, made the study relatively insensitive. Animals were followed for their entire lifetimes. Autopsies were performed after spontaneous death or when the **mice** were **moribund**, and all organs were examined **histologically**. Sections were stained **with hematoxylin** and **eosin** for light microscopy. Pathological findings were evaluated and analyzed statistically. The findings of the 2,3,7,8-TCDD study and the comparison study on TCPE are given in Table 11-11.

Analysis of the results of **this** study focused on the Incidence of **liver** tumors in the groups treated **with** 2,3,7,8-TCDD and the Incidence of these tumors in the matched controls (group 12) and **in** the males in the three other control groups. Males in groups 3 and 8, the two untreated control groups, had 2654 and 3354 liver tumors, respectively (**p<0.20**). The carboxy-**methyl** cellulose male controls (group 7) had 3354 (32/96) liver tumors. No significant differences in liver tumors were observed when males in **all** four control groups were compared **with** each other (**p<0.05**). Nevertheless, there was evidence that the Incidence of **liver** tumors in the control groups was associated **with** the average **lifespan** in the respective groups. The two groups that had <600 days average survival (groups 3 and 12) had the fewest liver tumors (26 and 18%, **respectively**). On the other hand, the two groups that had an average survival of **>600** days (groups 7 and 8), had **33%** liver tumors each. The test for linear trend (tumors vs. days of average survival) was not quite significant (**p=0.065**).

Among the three treatment groups (groups 9, 10 and 11), the middle dose (0.7 **µg/kg**) showed the highest Incidence of liver tumors (21/44 = 48%).

**This** Incidence was significantly higher than the Incidence of liver tumors in either the sunflower oil controls ( $p < 0.01$ ) or the pooled controls (all four control groups combined) ( $p < 0.025$ ).

The highest-dose group (7.0  $\mu\text{g}/\text{kg}$ ) had an Increased Incidence of liver tumors compared **with** the matched sunflower oil controls (13/43 = **30%**), but **this** Increase was not statistically significant ( $p = 0.11$ ). The Incidence of liver tumors **in** the high-dose group was comparable **with** that of the pooled controls. The highest-dose group, however, had a much reduced average survival in comparison **with** any of the control groups (only 424 days compared **with** 577, 588, **615** and 651 days in the four control groups). **This** poor survival may have accounted for the lack of a **statistically** significant Increase in liver tumors in the high-dose group. Furthermore, if time-to-tumor data had been available, **it** is likely that the high-dose group would have shown a significant decrease in time-to-tumor compared **with** the controls. Therefore, the Increase **in** liver tumors that was observed **in** the high-dose group in comparison **with** the matched control group, although not statistically significant, is considered to be consistent **with** an **oncogenic** effect.

In **conclusion**, the results of **this** study provide suggestive evidence of an oncogenic effect.

**11.1.1.5. NATIONAL TOXICOLOGY BIOASSAY PROGRAM (ORAL) MOUSE STUDY (1980a,b)** -- A cancer **bioassay** for the possible **carcinogenicity** of 2,3,7,8-TCDD was tested by the Illinois Institute of Technology in **mice** under a contract sponsored by the NCI.

In the mouse study, groups of 50 B6C3F1 **mice** of each sex were **adminis-**tered **2,3,7,8-TCDD** suspended in a vehicle of **9:1** corn **oil-acetone** **2 days/** week for 104 weeks at doses of 0.01, 0.05 and 0.5  $\mu\text{g}/\text{kg}/\text{week}$  for male **mice**



and 0.04, 0.2 and 2.0  $\mu\text{g}/\text{kg}/\text{week}$  for female mice. Seventy-five mice of each sex were used as vehicle controls. One untreated control group of 25 mice of each sex was present in the 2,3,7,8-TCDD treatment room. One untreated control group of 25 mice of each sex was present in the vehicle control room. In mice, the mean body weight gain in the treated groups was comparable with that of the vehicle control groups. However, the mean body weight of the treated mice was lower when it was compared with untreated controls.

The results of the histopathologic diagnosis of primary tumors are presented in Table 11-12. The results indicate that, in male mice, 2,3,7,8-TCDD induced a statistically significant incidence of hepatocellular carcinomas ( $p=0.002$ ) and both hepatocellular carcinomas and neoplastic nodules combined ( $p<0.001$ ) in male mice of the high-dose group.

In female mice, 2,3,7,8-TCDD induced statistically significant increases of hepatocellular carcinomas ( $p=0.014$ ) and both hepatocellular adenomas and carcinomas ( $p=0.002$ ) in the high-dose group. In addition, a statistically significant increase in tumor incidences of fibrosarcoma, histiocytic lymphoma, thyroid follicular-cell adenoma and cortical adenoma or carcinoma were also observed in the high-dose group (Table 11-13).

The incidence of liver tumors observed in this study confirms the earlier observations of an increase in liver tumors in the male mouse study performed by Toth et al. (1979).

#### 11.1.1.6. OTHER RELATED STUDIES --

11.1.1.6.1. Pitot et al. Promotion Study in Rats (1980) -- Pitot et al. (1980) investigated a two-stage model of hepatocarcinogenesis. Twenty-four hours after a partial hepatectomy (to enhance cell proliferation), female Sprague-Dawley rats were divided into seven groups (Table 11-14).

TABLE 11-12

Incidence of Primary Tumors in Male Mice Administered  
2,3,7,8-TCDD by Gavage<sup>a</sup>

| Type of Tumor                                       | Vehicle Control | $\mu\text{g/kg/week}$ |                  |                               |
|---|-----------------|-----------------------|------------------|-------------------------------|
|   |                 | Low Dose<br>0.01      | Mld Dose<br>0.05 | High Dose <sup>b</sup><br>0.5 |
| <b>Liver</b><br>Hepatocellular<br>adenoma           | 7/73 (10%)      | 3/49 (6X)             | 5/49 (10%)       | 10/50 (20%)                   |
| Liver<br><b>Hepatocellular</b><br>carcinoma         | 8/73 (11%)      | 9/49 (18%)            | 8/49 (16%)       | 17/50 (34%)<br>$p=0.002$      |
| Liver<br>Hepatocellular<br>adenoma and<br>carcinoma | 15/73 (21%)     | 12/49 (24%)           | 13/49 (27%)      | 27/50 (54X)<br>$p<0.001$      |

<sup>a</sup>Source: NTP, 1980a

<sup>b</sup>p-values calculated using the Fisher Exact Test.

TABLE 11-13

Incidence of Primary Tumors in Female Mice Administered  
2,3,7,8-TCDD by Gavage<sup>a</sup>

| Type of Tumor  | Vehicle Control | $\mu\text{g}/\text{kg}/\text{week}$ |                  |  |
|--|-----------------|-------------------------------------|------------------|--|
|  |                 | Low Dose<br>0.04                    | Mid Dose<br>0.2  | High Dose <sup>b</sup><br>2.0          |
| Subcutaneous tissue<br><b>Fibrosarcoma</b>                       | 1/74 (1%)       | 1/50 ( <b>2%</b> )                  | <b>1/48</b> (2%) | 5/47 (11%)<br><b>p=0.032</b>           |
| <b>Hematopoietic</b><br>system<br>Histiocytic<br><b>lymphoma</b> | 9/74 (12%)      | 4/50 (8%)                           | 4/48 (17%)       | 14/47 (30%)<br><b>p=0.016</b>          |
| <b>Hematopoietic</b><br>system<br>All lymphoma                   | 18/74 (24%)     | 11/50 ( <b>22%</b> )                | 13/48 (27%)      | 20/47 ( <b>43%</b> )<br><b>p=0.029</b> |
| Hematopoietic<br>system<br>Lymphoma or<br>leukemia               | 18/74 (24%)     | 12/50 ( <b>24%</b> )                | 13/48 (27%)      | 20/47 (43%)<br><b>p=0.029</b>          |
| Liver<br>Hepatocellular<br>carcinoma                             | 1/73 (1%)       | 2/50 (4%)                           | 2/48 (4%)        | 6/47 (13%)                             |
| Liver<br>Hepatocellular<br>adenoma or<br>carcinoma               | 3/73 (4%)       | 6/50 (12%)                          | 6/48 (13%)       | 11/47 (23%)<br><b>p=0.002</b>          |
| Thyroid<br>Follicular-cell<br>adenoma                            | 0/69 (0%)       | 3/50 (6%)                           | 1/47 (2%)        | 5/46 (11%)<br><b>p=0.009</b>           |

<sup>a</sup>Source: NTP, 1980a

<sup>b</sup>p-values calculated using the Fisher Exact Test.

TABLE 11-14

Promoting Effect of 2,3,7,8-TCDD on Hepatocarcinogenesis by a Single Dose of Diethylnitrosamine (DEN) and Partial Hepatectomy (PH)<sup>a,b</sup>

| Group No. | Treatment                           | N <sup>c</sup> | No. of Enzyme-Altered foci per cm <sup>2</sup> of Liver | Percent Liver Volume which is Enzyme-Altered foci | Number of Rats with Carcinoma            |
|-----------|-------------------------------------|----------------|---|---|--|
| 1         | PH + DEN                            | 4              | 346 ± 65  | 5.0   | 0  |
| 2         | PH + TCDD (low dose)                | 5              | 46 ± 15   | 0.1   | 0  |
| 3         | PH + TCDD ( <b>high</b> dose)       | 5              | 76 ± 20   | 0.1   | 0  |
| 4         | PH + PhenobarbHal                   | 6              | <b>138</b> ± 40   | 0.1   | 0  |
| 5         | PH + DEN + TCDD (low dose)          | 5              | 1582 ± 300  | 7.8   | 0 <sup>d</sup>                           |
| 6         | PH + DEN + TCDD ( <b>high</b> dose) | 7              | 1280 ± <b>40</b>  | 35.0  | 5/7 <sup>e</sup> (p=0.0075) <sup>f</sup> |
| 7         | PH + DEN + PhenobarbHal             | 4              | 1510 ± 185  | 5.0   | 2  |

<sup>a</sup>Source: Pitot et al., 1980

<sup>b</sup>Female rats (200 g) were intubated where shown with DEN. Seven days later TCDD (injected subcutaneously) or phenobarbital (0.05% in the diet) administration was begun and continued for 28 weeks at which time the animals were sacrificed and the livers examined. The low and high doses of TCDD were 0.14 and 1.4 µg/kg/2 weeks, respectively, administered subcutaneously. DEN was given at a dose of 10 mg/kg. See text for further details.

<sup>c</sup>Denotes the number of animals used in each group.

<sup>d</sup>Three rats showed "neoplastic nodules."

<sup>e</sup>One rat showed a "neoplastic nodule."

<sup>f</sup>p-value calculated using the Fisher Exact Test.

The **animals** in groups 1, 5, 6 and 7 received diethylnitrosamine (DEN). The rats in group 1 were then maintained on a standard laboratory **diet** for 32 weeks. The rats in groups 2 and 3 received no DEN, but starting 1 week after **hepatectomy** received biweekly subcutaneous injections of 0.14 or 1.4  $\mu\text{g}/\text{kg}$  of 2,3,7,8-TCDD in corn **oil** for a period of 28 weeks (2,3,7,8-TCDD was 98.6% pure and provided by Dow Chemical Co.). Groups 5 and 6 received **DEN**, and 1 week later were initiated on a regimen of 14 biweekly injections of 0.14 and 1.4  $\mu\text{g}/\text{kg}$  of 2,3,7,8-TCDD. The animals in group 4 received 0.05% sodium **phenobarbital** in the **diet** starting 1 week after partial hepatectomy for 28 weeks, and the animals in group 5 received DEN and 1 week later were also administered 0.05% sodium **phenobarbital** in the **diet** for the duration of the experiment. At the end of the experiment, rats were **killed** and sections of the **liver** were removed and frozen on **solid CO<sub>2</sub>**. Serial sections of the frozen blocks of liver were cut and stained consecutively for glucose-6-phosphatase (G6Pase), **canalicular** ATPase, **glutamyl transpeptidase** (GGTase) **with hematoxylin** and **eosin**. The number of enzyme-altered **foci** were determined from photographs of **histochemically** stained sections. **Hepatocarcinomas** were diagnosed by standard histopathological criteria.

The results presented in Table 11-14 showed that the number of **foci with** single enzyme changes, the number of **foci with** multiple enzyme changes, and the total liver volume, substantially increased **with** the administration of 2,3,7,8-TCDD. No carcinomas were detected in four rats treated **with** DEN **only**, but **five** of seven rats treated biweekly **with** 2,3,7,8-TCDD at 1.4  $\mu\text{g}/\text{kg}$  in addition to DEN had **hepatocellular** carcinomas, and **six** of seven rats had hepatocellular carcinomas or hepatocellular **neoplastic** nodules **with** a statistical significance ( $p=0.0075$ ). Three of **five** rats treated biweekly **with** 2,3,7,8-TCDD at 0.14  $\mu\text{g}/\text{kg}$  in addition to DEN had hepatocellular

**neoplastic** nodules (**p=0.083**). Rats receiving only **2,3,7,8-TCDD** after partial **hepatectomy** showed no significant increase in enzyme-altered **foci** and no **neoplasia**.

The results of **this** study provide evidence that 2,3,7,8-TCDD acts as a potent promoter in **this** two-stage model of **hepatocarcinogenesis**, causing increased neoplasia and increases in enzyme-altered foci at exceedingly low **levels**.

11.1.1.6.2. National Toxicology **Bioassay** Program **Skin** Painting Study in **Mice** (1980b) -- **This** cancer **bioassay** of 2,3,7,8-TCDD for possible **carcinogenicity** in Swiss-Webster **mice** was tested by the Illinois Institute of Technology under a contract sponsored by NCI. In **this** study, groups of 30 male and **female** Swiss-Webster **mice** were used. 2,3,7,8-TCDD in acetone suspension was applied to the **skin** of **mice** 3 days/week for 104 weeks. Male **mice** received 0.001  $\mu\text{g}$  2,3,7,8-TCDD per application, and the **female mice** received 0.005  $\mu\text{g}$  2,3,7,8-TCDD per **application**.

In another experiment, the same number of animals were pretreated **with** one application of 50  $\mu\text{g}$  **7,12-dimethylbenz(1)anthracene** (DMBA\*) in 0.1 ml acetone 1 week before 2,3,7,8-TCDD application was initiated. Forty-five **mice** of each sex received 0.1 ml acetone 3 times/week and 30 animals of each sex were used as untreated controls; no **DMBA** control was used.

In the male and female groups of **mice** treated **with** 2,3,7,8-TCDD or 2,3,7,8-TCDD following a single application of DMBA, mean body weights were not affected as compared **with** the vehicle controls. Mean body weights of

---

\*DMBA obtained from K and K Laboratories (Cleveland, **Ohio**). Its purity was not evaluated by NCI, but was stated by the manufacturer to be at least 95%.

treated and vehicle **control** groups of females were lower than those of untreated controls. **Mean** body weights of males were less than that of untreated controls.

The results of **histopathologic** diagnosis are shown in Table 11-15. The **results** show that **2,3,7,8-TCDD** induced **statistically significant (p<0.05)** increases of **fibrosarcoma** in the Integumentary systems of female **mice** treated **with** 2,3,7,8-TCDD alone and **2,3,7,8-TCDD** following a single Initial application of **DMBA**.

11.1.1.6.3. Berry et al. **Skin** Painting Study in **Mice (1978, 1979)** – Berry et al. (1978) applied 2,3,7,8-TCDD in acetone **solution** at 0,1 **µg/mouse** twice **weekly** for 30 weeks to the **skin** of 30 female Charles River **CD-1 mice** after Initiation **with** a single dermal **application** of the known **skin** carcinogen **DMBA** in acetone. After 30 weeks of promotion **with** 2,3,7,8-TCDD, no **papillomas** were observed on the **DMBA-initiated mice**. In the positive controls, **DMBA-initiated mice** were treated **with 12-O-tetradecanoyl-phorbol-13-acetate (TPA)** for 30 weeks; **92%** of these **mice** developed tumors.

Berry et al. (1979) also studied the effects of **treatment with** 2,3,7,8-TCDD and **7,12-dimethylbenz(a)anthracene (DMBA)** in a two-stage **tumorigenesis bioassay** in mouse **skin**. In **this** study, tumors on the shaved **skin** of female **CD-1 mice** were Initiated by topical application of **DMBA** and were promoted **with** **TPA**. **Pretreatment with** 2,3,7,8-TCDD markedly Inhibited the Initiation of tumors by **DMBA**. The effects were greatest when 2,3,7,8-TCDD was applied 3-5 days before Initiation and were **negligible** when **it** was **applied only** 5 minutes before Initiation. The Inhibition was **almost** complete (94-96%) when a single dose of 1 **µg** of 2,3,7,8-TCDD/mouse was applied, but was only slightly less effective (89%) when the dose was Increased to 10 **µg/mouse**.

TABLE 11-15

Incidence of Primary Tumors in **Mice** Administered **2,3,7,8-TCDD**  
or **2,3,7,8-TCDD** Following **DMBA** by Dermal **Application<sup>a</sup>**

| Type of Tumors       | Vehicle Control | Dose Levels <sup>b</sup>                                |   |
|----------------------|-----------------|---|---|
|                      |                 | TCDD  | DMBA (50 $\mu$ g)<br>plus TCDD                          |
| MALE                 |                 |   |   |
| Integumentary system |                 | 0.001 $\mu$ g x 3/weeks                                 | 0.001 $\mu$ g x 3/weeks                                 |
| <b>Fibrosarcoma</b>  | 3/42 (7%)       | 6/28 (21%)<br><b>p=0.08</b>                             | 6/30 (20%)<br><b>p=0.10</b>                             |
| FEMALE               |                 |   |   |
| Fibrosarcoma         | 2/41 (5%)       | 0.005 $\mu$ g x 3/weeks<br>8/27 (30%)<br><b>p=0.007</b> | 0.005 $\mu$ g x 3/weeks<br>8/29 (28%)<br><b>p=0.010</b> |

<sup>a</sup>Source: NTP, 1980b

<sup>b</sup>p-value calculated using the Fisher Exact Test.



The **time** course of the Inhibitory effects was **closely** parallel to the **time** course of Induction of arylhydrocarbon hydroxylase in the **skin** of the **mice**. It was also associated **with** substantial reduction **in** the covalent binding of the **DMBA** metabolite to DNA and **RNA**, but **with** no change in their binding to protein.

The same authors also reported Inhibitory effects of 2,3,7,8-TCDD on the Initiation of mouse **skin** tumors by **benzo(a)pyrene** (BaP), although the effect was not as great (maximum 65%) **with** BaP as **with** DMBA.

**11.1.1.6.4. Cohen et al. Skin Painting Study in Mice (1979) --** Cohen et al. (1979) showed that pretreatment of **mice with** **dermally** applied **2,3,7,8-TCDD** resulted in the Inhibition of **skin** tumor Induction by subsequent treatment **with** DMBA and BaP. The Inhibition of **skin carcinogenesis** by BaP in **mice** after pretreatment **with** 2,3,7,8-TCDD was associated **with** an Increase in covalent binding of BaP metabolites to **DNA**, RNA and protein (in contrast to the results **with** DMBA, which showed a reduction **in** binding to DNA and RNA). However, the BaP metabolites that were bound to DNA and RNA in **mice** pretreated **with** 2,3,7,8-TCDD differed from those in untreated **mice**. In particular, pretreatment **with** 2,3,7,8-TCDD **markedly** reduced the formation of the presumptive ultimate carcinogenic metabolite of BaP, **7,8-diol-9,10-epoxy-BaP** and its covalent binding **with** **guanosine** in DNA.

**11.1.1.6.5. Kouri et al. Mouse Study (1978) --** This study was designed as an Investigation of the **cocarcinogenic** activity of 2,3,7,8-TCDD administered to **mice in conjunction with** subcutaneous administration of **3-methylcholanthrene** (3-MC). Two Inbred strains in **mice**, C57BL/6Cum (abbreviated B6) and DBA/2Cum (abbreviated D2), were used. These strains are responsive and **nonresponsive**, respectively, to the Induction of **aryl** hydrocarbon **hydroxylase** (AHH) by 3-MC.

Groups of **mice** of both sexes were **injected subcutaneously** at 4-6 weeks of age **with** either **150 µg** of **3-MC** dissolved in **trioctanoin** or **with trioctanoin** alone. Some groups were also **injected with 2,3,7,8-TCDD** dissolved in **p-dioxane**, either simultaneously **with** the administration of 3-MC or 2 days earlier. Two doses of 2,3,7,8-TCDD (1 **µg/kg** and 100 **yg/kg**) were used, and the effects of both intraperitoneal and subcutaneous **injections** were investigated. Two sets of experiments involving 29 groups of **mice** were conducted ~1 year apart (Tables 11-16 and 11-17).

After treatment, the **mice** were observed for 36 weeks, during which **time** they were palpated weekly for the presence of tumors; latency was calculated when the subcutaneous tumors became 1 cm in diameter. Only tumors characterized **histologically** as **fibrosarcomas** at the **site** of inoculation were considered. It is unclear whether or not these were the only tumor types observed. The term "carcinogenic **index**" used by the authors was defined as the percentage of tumor incidence 8 months after treatment divided by the average latency in days multiplied by **100**. No details were given of the number of animals in each group at the start of each experiment, but the numbers dying in the first 28 days and the numbers at **risk** (surviving 36 weeks) were tabulated. The results of **this** study are shown in Tables 11-16 and **11-17**.

No subcutaneous tumors were observed in controls or in **mice** treated **with** 2,3,7,8-TCDD alone. In B6 (responsive) **mice**, the administration of 2,3,7,8-TCDD **did** not significantly enhance the induction of tumors by 3-MC. However, in both experiments involving D2 (**nonresponsive**) **mice**, the administration of 2,3,7,8-TCDD simultaneously **with** 3-MC appeared to enhance the carcinogenic response. The "carcinogenic **index**" increased from 1-6 in groups treated **with** 3-MC alone to 14 **in** the group treated subcutaneously

TABLE 11 16

Effects of Intraperitoneal Administration of 2,3,7,8-TCDD on 3-MC-Initiated Subcutaneous Tumors<sup>a</sup>

| Inbred Strain | Treatment                    |  | No. of Mice Dying Because of Treatment <sup>b</sup> | No. of Mice at Risk for Tumors <sup>c</sup> | No. of Mice with Tumors <sup>d</sup> | X of Mice with Tumors | Average Latency (days) | Carcinogenic Index <sup>e</sup> |
|---------------|------------------------------|--|---|---|--------------------------------------|-----------------------|------------------------|---------------------------------|
|               | -2 Days                      | 0 Days   |   |   |                                      |                       |                        |                                 |
| <b>B6</b>     | <b>i.p.</b> p-dioxin         | <b>s.c.</b> trloctanoln                            | 1   | 39  | 0                                    | 0                     |                        |                                 |
|               | <b>i.p.</b> TCDD (100 wg/kg) | <b>s.c.</b> trloctanoln                            | 20  | 27  | 0                                    | 0                     |                        |                                 |
|               | None                         | <b>s.c.</b> 3-HC                                   | 1   | 36  | 29                                   | <b>81</b>             | 125                    | 65                              |
|               | None                         | <b>i.p.</b> TCDD (100 wg/kg)                       | 20  | 30  | 0                                    | 0                     |                        |                                 |
|               | None                         | <b>i.p.</b> TCDD (100 wg/kg) +<br><b>s.c.</b> 3-HC | 30  | 43  | 33                                   | 71                    | 123                    | 63                              |
|               | None                         | <b>i.p.</b> TCDD (1 wg/kg)                         | 4   | 46  | 0                                    | 0                     |                        |                                 |
|               | None                         | <b>i.p.</b> TCDD (1 wg/kg) *<br><b>s.c.</b> 3-MC   | 6   | 27  | 27                                   | 100                   | 132                    | 76                              |
|               | <b>i.p.</b> TCDD (100 wg/kg) | <b>s.c.</b> 3-HC                                   | 20  | 25  | 21                                   | 84                    | <b>129</b>             | 65                              |
|               | <b>i.p.</b> TCDD (1 wg/kg)   | <b>s.c.</b> 3-HC                                   | 6   | 23  | 16                                   | 70                    | 140                    | 50                              |
| <b>B2</b>     | <b>i.p.</b> p-dioxane        | <b>s.c.</b> trloctanoln                            | 6   | 22  | 0                                    | 0                     |                        |                                 |
|               | <b>i.p.</b> TCDD (100 wg/kg) | <b>s.c.</b> trloctanoln                            | 24  | 25  | 0                                    | 0                     |                        |                                 |
|               | None                         | <b>s.c.</b> 3-HC                                   | 3   | 34  | 1                                    | 3                     | 217                    | 1                               |
|               | None                         | <b>i.p.</b> TCDD (100 wg/kg)                       | 30  | 38  | 0                                    | 0                     |                        |                                 |
|               | None                         | <b>i.p.</b> TCDD (100 wg/kg) *<br><b>s.c.</b> 3-HC | 43  | <b>43</b>                                   | 10                                   | 23                    | 178                    | <b>13<sup>f</sup></b>           |
|               | None                         | <b>i.p.</b> TCDD (1 wg/kg)                         | 5   | 48  | 0                                    | 0                     |                        |                                 |
|               | None                         | <b>i.p.</b> TCDD (1 wg/kg) +<br><b>s.c.</b> 3-HC   | 5   | 34  | 5                                    | <b>15</b>             | 199                    | 7                               |
|               | <b>i.p.</b> TCDD (100 wg/kg) | <b>s.c.</b> 3-HC                                   | 20  | 28  | 0                                    | 0                     |                        |                                 |
|               | <b>i.p.</b> TCDD (1 wg/kg)   | <b>s.c.</b> 3-HC                                   | 6   | 31  | 0                                    | 0                     |                        |                                 |

<sup>a</sup>Source: Kouri et al., 1978<sup>b</sup>During the first 28 days following treatment.<sup>c</sup>Defined as the number of mice surviving the 36-week observation period.<sup>d</sup>At the end of the 36-week experiment.<sup>e</sup>Percentage of Incidence of tumors, divided by the average latency in days, multiplied by 100 (8).<sup>f</sup>This carcinogenic Index value lies outside (greater than) the 99% confidence Interval (i.e., p<0.01) constructed from seven different studies over the past 5 years during which 150 wg of 3-HC was given s.c. to 0? mice. These studies included 295 D? lce, the mean = 5 0 for all seven studies was a carcinogenic Index of 5.43 - 2.70.

TABLE 11-17

Effect of Intraperitoneal or Subcutaneous Administration of 2,3,7,8-TCDD Given 2 Days Before or Simultaneous With Subcutaneous Administration of 3-HC on Tumorigenesis in D<sup>0</sup> Mice<sup>a</sup>

| Treatment             |                                      | No. of Mice Dying Because of Treatment | No. of Mice at Risk for Tumors | No. of Mice with Tumors | X of Mice with Tumors | Average latency (days) | Carcinogenic Index    |
|-----------------------|--------------------------------------|--|--------------------------------|-------------------------|-----------------------|------------------------|-----------------------|
| -2 Days               | 0 Days                               |  |                                |                         |                       |                        |                       |
| None                  | s.c. 3-HC                            | 0                                      | 30                             | 3                       | 10                    | 177                    | 6                     |
| l.p. p-dioxane        | s.c. 3-HC                            | 10                                     | 40                             | 3                       | 10                    | 194                    | 5                     |
| l.p. TCDD (100 wg/kg) | s.c. 3-HC                            | 35                                     | 65                             | 9                       | 14                    | 145                    | 10                    |
| None                  | l.p. p-dioxane + s.c. 3-HC           | 5                                      | 45                             | 5                       | 11                    | <b>176</b>             | 6                     |
| None                  | l.p. TCDD (100 pg/kg) »<br>s.c. 3-HC | 38                                     | 62                             | 17                      | 27                    | 183                    | <b>15<sup>b</sup></b> |
| None                  | l.p. TCDD (1 wg/kg) *<br>s.c. 3-HC   | 22                                     | 78                             | 8                       | 10                    | 162                    | 6                     |
| None                  | s.c. p-dioxane + s.c. 3-HC           | ?                                      | 68                             | 8                       | 12                    | 180                    | 6                     |
| None                  | s.c. TCDD (100 pg/kg)                | 8                                      | 42                             | 0                       | 0                     |                        |                       |
| None                  | s.c. TCOO (100 pg/kg) +<br>s.c. 3-HC | <b>10</b>                              | <b>82</b>                      | 46                      | 55                    | 145                    | <b>38<sup>b</sup></b> |
| None                  | s.c. TCOO (1 pg/kg)                  | 2                                      | 48                             | 0                       | 0                     |                        |                       |
| None                  | s.c. TCDD (1 pg/kg) »<br>s.c. 3-HC   | 2                                      | 98                             | 21                      | 21                    | 154                    | 14b                   |

<sup>a</sup>Source: Kouri et al., 1978

<sup>b</sup>These carcinogenic Index values lie outside the 99% confidence interval.

with **2,3,7,8-TCDD** at 1 yg/kg, and 13-15 in the groups treated **intraperitoneally** with **2,3,7,8-TCDD** at 100 yg/kg. The authors concluded that **2,3,7,8-TCDD** acts as a **cocarcinogen**, possibly as an **inducer** of AHH at the **site of inoculation**.

A more appropriate statistical analysis would be a comparison of tumor incidence in 2,3,7,8-TCDD-treated groups with tumor incidence in corresponding **3-MC-treated** groups within the same experiment. The results of **this analysis** are given in Table 11-18.

From these results, the CA6 concluded that the experiment adequately demonstrated the enhancement by 2,3,7,8-TCDD of tumor induction when 2,3,7,8-TCDD was administered simultaneously with **3-MC** at the higher dose (100 yg/kg). The reported results at the lower dose (1 yg/kg) are not **statistically** significant unless the reduction in **latency** is taken into account, which is difficult to do rigorously. Despite defects in reporting (failure to specify the initial number of animals in each group and to report tumor incidence by sex), the **results** provide evidence that 2,3,7,8-TCDD acts as a cocarcinogen. The failure of 2,3,7,8-TCDD to induce tumors when administered alone was not unexpected since only a single dose was administered and the duration of the study was very short (36 weeks).

**11.1.1.6.6.** Poland et al. Study (1982) -- Poland et al. (1982) described studies which indicate that genetic differences in **mice** affect the **tumor-promoting** capacity of 2,3,7,8-TCDD in the mouse **skin** two-stage **tumorigenesis** model. Both 2,3,7,8-TCDD and TPA were compared for **tumor-promoting** activity in **DMBA-initiated HRS/J mice** that were either heterozygous (**hour/+**) or **homozygous** (**hour/hour**) for the recessive "hairless" trait. Promotion with **biweekly applications** of 2 yg of TPA for 25 weeks resulted in **papilloma** incidences of 100 and **70%** in (**hourA**) and (**hour/hour**) **mice**,

TABLE 11-18

Incidence of Tumors in Mice Treated With 3-MC  
and WHh 3-MC and 2,3,7,8-TCDD<sup>a</sup>

| Experiment | Dose of<br>TCDD<br>( $\mu\text{g}/\text{kg}$ ) | Route of<br>Administration | Tumor Incidence |      | p-Value <sup>b</sup>     |
|------------|--|----------------------------|-----------------|------|--------------------------|
|            |  |                            | TCOD and 3-MC   | 3-MC |                          |
| 1          | 100  | <b>Intraperitoneal</b>     | 10/43           | 1/34 | <b>p=0.01</b>            |
| 2          | 100  | Intraperitoneal            | <b>17/62</b>    | 5/45 | <b>p=0.03</b>            |
| 2          | 100  | subcutaneous               | 46/82           | 5/42 | p=3.0 x 10 <sup>-7</sup> |
| 2          | 1  | subcutaneous               | 21/98           | 5/45 | <b>p=0.1</b>             |

<sup>a</sup>Source: Kouri et al., 1978

<sup>b</sup>p-value calculated using the Fisher Exact Test (one-tailed).

respectively. Promotion of **DMBA-initiated (hour/+)** mice with 2,3,7,8-TCDD (50 ng/application for 8 weeks followed by 20 ng/application) did not result in the formation of tumors, while promotion of **(hour/hour) mice** resulted in both the same Incidence and multiplicity of tumors as observed in TPA-promoted mice. With either **DMBA** or methyl-N-nitrosoguanidine (**MNNG**)-initiated (hour/hour) mice, the effective dose of 2,3,7,8-TCDD was **~100-fold** less than TPA on a molar basis. Histologic examination of the **skin** showed that TPA produced both acute Inflammation and **hyperplasia in (hour/+)** and (hour/hour) mice, while 2,3,7,8-TCDD produced **hyperplasia** and **hyperkeratosis only** in (hour/hour) mice with no Inflammatory response. The lack of a **2,3,7,8-TCDD-induced** Inflammatory response suggested to the authors that 2,3,7,8-TCDD promoted **skin papillomas** in (hour/hour) mice by a mechanism different from TPA.

11.1.1.6.7. DiGiovanni et al. Study (1977, 1980) - Investigations have also been conducted on the effects of prior or simultaneous treatment with 2,3,7,8-TCDD on the subsequent development of **skin** tumors by chemical carcinogens. When 2,3,7,8-TCDD (0.1 µg) was administered **simultaneously** with DMBA (200 nmol) to the backs of **CD-1 mice** in a single Initiation dose, the **skin papilloma** Incidence following promotion with TPA was nearly the same as when DMBA alone was used as the Initiator (DiGiovanni et al., 1977). Although simultaneous exposure to 2,3,7,8-TCDD and DMBA **did** not appreciably affect tumor **yield**, Berry et al. (1979) demonstrated a marked **93%** decrease in the Incidence of DMBA-initiated tumors when **CD-1 mice** were pretreated 3 days before DMBA Initiation with 1 µg/mouse of 2,3,7,8-TCDD. The **time** of treatment with 2,3,7,8-TCDD in relation to Initiation was shown to be critical in the **antitumorogenic** effects of 2,3,7,8-TCDD (Berry et al., 1979;

DlGiovanni et al., 1979a, 1980), as shown in Figure 11-1. **Maximum** tumor inhibition of between 86 and 94% occurred when pretreatment was between 1 and 5 days before Initiation. If pretreatment was **10** days before **DMBA** Initiation, the tumor **yield** was decreased by 78%, **while 2,3,7,8-TCDD** treatment 5 minutes before or 1 day after DMBA Initiation had no effect on tumor yield. There was some Indication of an Inverse relationship between the pretreatment dose of 2,3,7,8-TCDD (3 days before DMBA Initiation) and the Incidence of tumors. 2,3,7,8-TCDD doses of 0.0, 0.01, 0.1 and 2 **µg/mouse** **resulted** in decreased tumor yields, respectively, of 0, 83, 92 and **96%** (DlGiovanni et al., 1979a). Also under similar experimental conditions Cohen et al. (1979) observed a 75% decrease in the Incidence of **skin** tumors in Sencar **mice** pretreated **with** 1 **µg** of 2,3,7,8-TCDD 3 days before Initiation by DMBA.

DlGiovanni et al. (1980) Investigated the **antitumorigenic** effect of 2,3,7,8-TCDD in **CD-1 mice** with chemical carcinogens other than DMBA (see Figure 11-1). As observed **with** DMBA, exposure to 2,3,7,8-TCDD 3 days before Initiation **with** either benzo(a)pyrene (BaP) or 3-MC resulted in a decrease in tumor yield as compared **with** acetone-pretreated animals; however, pretreatment **with** 2,3,7,8-TCDD 5 minutes before or 1 day after Initiations was Ineffective **in** changing the tumor yield. The maximum decrease in tumor production was 86 and 57%, respectively, for BaP and 3-MC Initiated **mice**. A different **temporal** relationship was observed in the ability of 2,3,7,8-TCDD to Inhibit tumor formation by BaP-diol-epoxide as compared **with** the **previously** studied **polyaromatic** hydrocarbons (PAH). When 2,3,7,8-TCDD was applied 3 days or 5 minutes before, or 1 day after Initiation **with** BaP-diol **epoxide**, there was an 81.5 and 49% decrease **in** tumor yield. Examination of PAH metabolism in the **skin** of **mice** treated **with** 2,3,7,8-TCDD showed a






FIGURE 11-1

Time-Dependent Inhibition by **2,3,7,8-TCDD** of Tumor Initiation

Summary of the time-dependent Inhibitory effect of 2,3,7,8-TCDD on tumor Initiation by DMBA ( $\Delta$ ), BaP (o), **3-MC** (A) and BaP-diol-epoxide (o). Animals were Initiated with 10 nmol DMBA, 100 nmol BaP, 100 nmol 3-MC and 200 nmol BaP-diol-epoxide and promoted 1 week later with twice weekly application of TPA.

**21-fold** Increase in **aryl** hydrocarbon hydroxylase (AHH) activity 72 hours after treatment (DiGiovanni et al., 1980). The in vitro metabolism of **DMBA** by dermal homogenates from **2,3,7,8-TCDD-treated mice** indicated both qualitative and quantitative changes in metabolism (Cohen et al., 1979; DiGiovanni et al., 1979a; Berry et al., 1979). The similarity in the **time** frame of AHH induction and the antitumorigenic effect of pretreatment **with 2,3,7,8-TCDD** suggested that the **antitumorigenic** properties of 2,3,7,8-TCDD resulted from 2,3,7,8-TCDD induced alteration in the **metabolism** of the initiating chemical. Although metabolic change was a possible mechanism for the inhibition of DHBA, **3-MC** and BaP initiation, the ability of 2,3,7,8-TCDD to inhibit tumor yield when administered 1 day after initiation **with** BaP-diol-epoxide indicated by DiGiovanni et al. (1980) that more than one mechanism may participate in the anticarcinogenic effect of **2,3,7,8-TCDD**.

11.1.1.6.8. Cockerham et al. 1980 Field Study on Beach **Mice** - Cockerham et al. (1980) performed a **field** study on beach **mice**, Peromyscus polionotus, that inhabited an area which was heavily treated **with** the herbicide **2,4,5-T**, of which 2,3,7,8-TCDD was a contaminant. Analysis of the **soil** in the contaminated area revealed average 2,3,7,8-TCDD levels of 150 ppt at the surface. Measured levels of 2,3,7,8-TCDD in the liver of beach **mice** from the contaminated area were determined to be 1300 ppt **in** males and 960 ppt **in** females. Detection of 2,3,7,8-TCDD in the **liver** indicates that the compound was absorbed; however, since seeds in the area **did** not contain 2,3,7,8-TCDD, it was believed that the animals ingested the compound from contaminated dust while grooming. In the 10 male and 5 female animals captured in the contaminated area, there were no **histopathologic** differences, including **neoplastic** lesions, observed in the liver as compared **with** 9 male and 6 female **mice** captured in a noncontaminated area. The only observed difference **in**

the two groups of **mice** was a statistically significant (**95%** confidence) Increase in **liver-to-body** weight ratios. The authors back-calculated from the **2,3,7,8-TCDD** levels of the **liver** and estimated a dally **2,3,7,8-TCDD** dose of 0.0012  $\mu\text{g}/\text{kg}$  bw. It was noted that **this** exposure was much lower than the exposures used in laboratory studies to produce tumors.

#### 11.1.2. Studies Using HxCDD.

**11.1.2.1. NATIONAL TOXICOLOGY BIOASSAY PROGRAM (ORAL) STUDY IN RATS AND MICE** (NTP, 1980d) -- Although **1,2,3,6,7,8-HxCDD** and **1,2,3,7,8,9-HxCDD** have not been tested Individually for **carcinogenicity**, the NTP has performed a chronic **bioassay** in both **Osborne-Mendel** rats and B6C3F1 **mice** to determine the **carcinogenicity** of a mixture of 1,2,3,6,7,8- and **1,2,3,7,8,9-HxCDD** (NTP, 1980d). The mixture consisted of **31%** of the **1,2,3,6,7,8-HxCDD** congener and **67%** of the **1,2,3,7,8,9-HxCDD** congener, **with a total** HxCDD purity of **98%**. The following Impurities were detected in HxCDD used for **this** bioassay: PeCDD, 0.0454; TCDD, **0.09%±0.03%**; TriCDD, 0.004%; DCDD, 0.004X and **Bromo** PeCDD, **<0.004%**. The specific **isomers** of these Impurities were not Identified. The compound was protected from light during storage, and every 3 months a stock acetone suspension was prepared. The working solution was administered to the test animals in corn **oil-acetone** (9:1) by gavage 2 times/week. **All** treated groups consisted of 50 animals of each sex, while the control groups, both vehicle and untreated controls, consisted of 75 animals of each sex. The male and female rats, and the male **mice** received HxCDD doses of 0.0, **1.25**, 2.5 and 5  $\mu\text{g}/\text{kg}/\text{week}$ , and the female **mice** received doses of 0.0, 2.5, 5.0 and 10  $\mu\text{g}/\text{kg}/\text{week}$ . Treatment was continued for 104 weeks followed by a 3- to 4-week observation period. Complete necropsies, Including extensive **histologic** examinations, were performed on animals at the **time** of natural death, when moribund or at the termination of the study.

A decrease in body weight **gain** was seen at the two higher exposure levels. A dose-related **"toxic hepatitis"** that was noninflammatory and consisted of degenerative changes in the **liver, eosinophilic foci of cellular alteration, mild fibrosis** and **bile duct hyperplasia** was also observed. **Cytomegaly** and **lipidosis** were included in these degenerative changes. The only **neoplastic** lesions that appeared to be treatment-related were neoplastic nodules of the liver and hepatocellular carcinomas (Table 11-19). The combined incidences of these tumors in male rats were 0/74, 0/49, 1/50 and 4/48, while in female rats the incidences were 5/75, 10/50, 12/50 and 30/50 for the control, **low-**, medium- and high-dose groups, **respectively**. The incidence of **liver** tumors in male rats showed a positive dose-related trend by the **Cochran-Armitage** test; the incidence in the high-dose **male** rat group was statistically different from the control group by the Fisher exact test (**p=0.022**) but the requirements by NTP for overall significance were not met based on the **Bonferroni inequality**. The NTP thus concluded that the evidence for the carcinogenicity of HxCDD in male rats was inconclusive. In female rats, the **Cochran-Armitage** test was significant at **p<0.001**, and the **liver** tumor incidence of the high-dose animals was significantly (**p<0.001**) different from that of the control group, as well as **with** the mid-dose group (**p=0.006**).

Subsequent to the release of the NTP gavage study of HxCDD in rats and **mice** (NTP, 1980d), several **pathologists** reevaluated the microscopic slide material of the **female** rats. These reviews resulted from a report by Squire (1983) which stated that many of the entities diagnosed as tumors by NTP were actually **nonneoplastic** regenerative nodules; but **his** report concluded that the HxCDD **bioassay** still provided evidence of a weak **hepatocarcinogenic**

TABLE 11-19

Liver Tumor Incidences in Male and Female **Osborne-Mendel** Rats  
Administered HxCDD for 104 **Weeks**<sup>a</sup>

| Diagnoses                               | Treatment Group         |                 |                         |                         |   |
|---|-------------------------|-----------------|-------------------------|-------------------------|---|
|   | Untreated Control       | Vehicle Control | Low Dose                | Mld Dose                | High Dose                               |
| MALE                                    |                         |                 |                         |                         |   |
| <b>Neoplastic</b><br>nodule (NN)        | <b>2/75<sup>b</sup></b> | 0/74            | 0/49                    | 1/50                    | 3/48                                    |
| Hepatocellular<br>carcinoma (HC)        | 0/75                    | 0/74            | 0/49                    | 0/50                    | 1/48                                    |
| Combined NN + HC                        | 2/75                    | 0/74            | 0/49                    | 1/50                    | 4/48<br><b>p=0.002<sup>c</sup></b>      |
| FEMALE                                  |                         |                 |                         |                         |   |
| <b>Neoplastic</b><br>nodule (NN)        | 1/73                    | 5/75            | 10/50<br><b>p=0.026</b> | 12/50<br><b>p=0.006</b> | 30/50<br><b>p=6.94x10<sup>-11</sup></b> |
| <b>Hepatocellular</b><br>carcinoma (HC) | 0/74                    | 0/75            | 0/50                    | 0/50                    | 4/50<br><b>p=0.024</b>                  |
| Combined NN + HC                        | 1/73                    | 5/75            | 10/50<br><b>p=0.026</b> | 12/50<br><b>p=0.006</b> | 30/50<br><b>p=6.94x10<sup>-11</sup></b> |

<sup>a</sup>Source: Adapted from NTP, 1980c

<sup>b</sup>Incidence =  $\frac{\text{No. of rats with lesion}}{\text{No. of rats examined microscopically}}$

<sup>c</sup>p-values calculated using the Fisher Exact Test.

effect in rats and **mice**. Drs. R. **Schueler** and B. Haberman also reported discrepancies in the diagnoses of liver tumors from the NTP gavage study. Their findings were reported in an Internal U.S. EPA memorandum from CAG to J. **Bellin** (U.S. EPA, 1983b) **with** an attached report prepared by Dr. R. Schueler, Research Pathology Associates, Inc. (Schueler, 1983). Finally, Dr. E. McConnel of NTP requested that Dr. P. **Hildebrandt** of **Tracor-Jitco**, Inc., review the microscopic slides of the HxCDD **bioassay** (gavage) **in** the **female** rat; **his** findings (Hildebrandt, 1983) agreed closely **with** those of Drs. Schueler and Haberman. Dr. **Hildebrandt's** findings (Table 11-20), although not as statistically significant as the original NTP findings, still confirmed that the HxCDD mixture administered by gavage produced an increased incidence of liver tumors in treated female rats as compared **with** control animals, as well as an increase in "toxic hepatitis."

In **mice** there were no gross signs of HxCDD **toxicity**; however, as observed in rats, there was a dose-related incidence of "toxic hepatitis" consisting of degenerative liver changes and/or necrosis associated **with** cellular **infiltration** and **mild fibrosis**. The only **neoplastic** changes that were treatment-related were increases in **hepatocellular** adenomas and carcinomas (**Table 11-21**). The adenomas were characterized as groups of cells **with** a uniform **cell** type that **did** not conform to the lobular architecture and which caused compression of the surrounding normal **liver**, while the carcinomas contained **cells with** greater **histologic** deviations, disorganized growth and more cells in mitosis. A few **liver** tumors in control and dosed groups **metastasized** to the lungs. The incidence of hepatocellular adenomas or carcinomas were 15/73, 14/50, 14/49 and 24/48 in male **mice**, and 3/73, 4/48, 6/47 and **10/47** in female **mice** of the control, **low-**, medium- and high-dose groups, respectively. In both male and female **mice**, the **liver** tumor

TABLE 11-20

Liver Tumor Incidences in Female **Osborne-Mendel** Rats Administered  
HxCDD by Gavage for 104 **Weeks**<sup>a</sup>

| Diagnoses                         | Untreated<br>Control    | Vehicle<br>Control | $\mu\text{g}/\text{kg}/\text{week}$ |                                   |  |
|-----------------------------------|-------------------------|--------------------|-------------------------------------|-----------------------------------|--|
|                                   |                         |                    | Low Dose<br>1.25                    | Mid Dose<br>2.5                   | High Dose<br>5                               |
| <b>Neoplastic<br/>nodule (NN)</b> | <b>1/73<sup>b</sup></b> | 2/75               | 5/50                                | 7/50<br><b>p=0.02<sup>c</sup></b> | 16/50<br><b>p=6.0x10<sup>-6</sup></b>        |
| Hepatocellular<br>carcinoma (HC)  | 0/73                    | 0/75               | 0/50                                | 0/50                              | 2/50   |
| Combined NN + HC                  | <b>1/73</b>             | 2/75               | 5/50                                | 7/50<br><b>p=0.02</b>             | <b>18/50</b><br><b>p=7.3x10<sup>-7</sup></b> |

<sup>a</sup>**Source:** Adapted from **Hildebrandt**, 1983

<sup>b</sup> Incidence =  $\frac{\text{No. of rats with lesion}}{\text{No. of rats examined microscopically}}$

<sup>c</sup>**p-values** calculated using the Fisher Exact Test.

TABLE 11-21

Liver Tumor Incidences in Male and Female B6C3F1 Mice Administered  
HxCDD by Gavage for 104 Weeks<sup>a</sup>

| Diagnoses                            | Treatment Group    |                 |          |          |  |
|--------------------------------------|--------------------|-----------------|----------|----------|--|
|                                      | Untreated Control  | Vehicle Control | Low Dose | Mld Dose | High Dose                              |
| MALE                                 |                    |                 |          |          |  |
| Hepatocellular adenoma (HA)          | 15/75 <sup>b</sup> | 7/73            | 5/50     | 9/49     | 15/48<br><b>p=0.003<sup>c</sup></b>    |
| <b>Hepatocellular</b> carcinoma (HC) | 12/75              | 8/73            | 9/50     | 5/49     | 9/48                                   |
| Combined HA + HC                     | 27/75              | 15/73           | 14/50    | 14/49    | 24/48<br><b>p=7.33x10<sup>-4</sup></b> |
| FEMALE                               |                    |                 |          |          |  |
| Hepatocellular adenoma (HA)          | 2/74               | 2/73            | 4/48     | 4/47     | 9/47<br><b>p=0.003</b>                 |
| Hepatocellular carcinoma (HC)        | 0/74               | 1/73            | 0/48     | 2/47     | 2/47                                   |
| Combined HA + HC                     | 2/74               | 3/73            | 4/48     | 6/47     | 10/47<br><b>p=0.004</b>                |

<sup>a</sup>Source: Adapted from NTP, 1980c

<sup>b</sup>**Incidence** =  $\frac{\text{No. of rats with lesion}}{\text{No. of rats examined microscopically}}$

<sup>c</sup>p-values calculated using the Fisher Exact Test.



Incidence showed a significant dose-related trend by the **Cochran-Armitage test**, and the Incidence of tumors in the high-dose group was significantly higher than the Incidence in the control group by the Fisher exact test.

The obvious question was raised concerning the presence of tetrachloro-dibenzo-p-dioxin as an Impurity (**0.09%**) in the test material, which may have contributed to the observed liver tumor Incidence. The analysis presented in Table 11-22 shows that the calculated 95% upper-limit liver cancer response due to **0.09%** TCDD Impurity is so low as compared with the observed liver cancer response due to HxCDD in this cancer bioassay study, it is reasonable to conclude that the Impurity in the test material **did** not contribute significantly to the observed carcinogenic response for HxCOD.

McGaughy and Rispln (1985) made the following comments regarding the three documents listed below, which evaluated Issues that have been raised with respect to the **NCI/NTP** HxCDD carcinogenicity bioassay on rats and mice:

1. The responses outlined by the Office of Health and Environmental Assessment (OHEA) were prepared for presentation to **EPA's** Science Advisory Board on November 28, 1984.
2. The document entitled "**Response** to Comments" was prepared by Agency staff and a consultant pathologist.
3. A memorandum from Dr. John **Doull**, member of **EPA's** Science Advisory Board, concerning the HxCDD audit by Dr. G. **Schoenig**.

The above documents respond to questions that were raised concerning many aspects of the bioassay study. These questions relate, for example, to allegations of problems in:

- test procedures, such as problems in preparation of the test material; flaws in methods of administration; flaws in **recordkeeping** procedures and practices.
- pathology practices, such as non-uniform and substandard tissue harvesting practices; non-uniform **histologic** procedures; **bias** in **histology** review; and deficiencies in correlation between gross and microscopic observations.

TABLE 11-22

Liver Tumor Response for HxCDD (Observed)  
and TCDD Contaminant (Calculated)

| Animal                | HxCDD Dose<br>(yg/kg/week) | Liver Cancer<br>Response<br>Observed | <b>0.09% TCDD<br/>Contaminant<br/>Dose<sup>a</sup><br/>(ug/kg/week)</b> | Liver Cancer<br>Response<br>Calculated 95%<br>Upper Limit |
|-----------------------|----------------------------|--------------------------------------|---|---|
| <u>Rat (OH)</u>       |                            |                                      |   |   |
| Male                  | 5                          | <b>4/48<sup>b</sup></b>              | 0.0045  | TCDD has shown<br>no effect in<br>NCI study               |
| Female                | <b>5</b>                   | <b>18/50<sup>c</sup></b>             | 0.0045  | <b>0.02/50<sup>d</sup></b>                                |
| <u>House (B6C3F1)</u> |                            |                                      |   |   |
| Male                  | 5                          | <b>24/48<sup>e</sup></b>             | 0.0045  | <b>0.20/48<sup>d</sup></b>                                |
| Female                | 10                         | <b>10/47<sup>f</sup></b>             | 0.009   | <b>0.22/47<sup>e</sup></b>                                |

<sup>a</sup>It is assumed that all of the contaminant is **2,3,7,8-TCDD**.

<sup>b</sup>NTP reviewed

<sup>c</sup>Re-evaluation by Hildebrandt (see Table 11-35)

<sup>d</sup>Based on response in NCI **2,3,7,8-TCDD** study; see Table **B-10**.

<sup>e</sup>Based on response in NCI **2,3,7,8-TCDD** study; see Table **B-11**.

<sup>f</sup>Based on response in NCI **2,3,7,8-TCDD** study; see Table **B-12**.

- **alleged bias in** the above practices **with** respect to treated and control animals.
- pathology Interpretation: disagreement in conclusions reached by different **pathologists**.

From our review of these documents we conclude that there were indeed some procedural flaws during the **in-life** portion of the study, and there were minor **recordkeeping** problems. The management of a two-year rodent study is a very **complex** undertaking. It is therefore not surprising that the procedural and recordkeeping deficiencies highlighted by the two audits occurred. They do not invalidate the study.

The detailed review by Agency staff and Dynamac Corporation of Dr. **Schoenig's** findings concerning room **bias** did not substantiate **his** allegations. Similarly, review of Dr. **Schoenig's** criticism of the **histologic** practices did not **reveal** meaningful deficiencies in tissue harvesting, preparation of microscopic slides, and histologic diagnoses.

Differences in Interpretation among pathologists have previously been addressed by the Agency (see the OHEA document attached hereto). The slight differences in Interpretation among the different pathologists do not alter the conclusion as to the carcinogenic potential of HxCDD.

We conclude that the HxCDD **bioassay** is valid, and that **it** can appropriately be used for the assessment of the carcinogenic potential of HxCDD.

Under the test conditions of **this** bioassay, the 1:2 mixture of 1,2,3,7,8- and **1,2,3,7,8,9-HxCDD** was carcinogenic, as indicated by a statistically significant increased incidence in tumors of the liver in female rats and in both male and female **mice**, and by a borderline liver tumor response in **male** rats.

11.1.2.2. NATIONAL TOXICOLOGY BIOASSAY **PROGRAM** SKIN-PAINTING STUDY IN MICE (NTP, **1980b,c**) -- Both **2,3,7,8-TCDD** (NTP, **1980b**) and a 2:1 mixture of 1,2,3,6,7,8- and **1,2,3,7,8,9-HxCDD** (NTP, 1980c) have been tested in **mice** for **tumorigenic** potential by dermal **application**. These studies were conducted under the NTP and the description of the chemicals used was the same as previously presented in the discussion of NTP (1980a,d). There was no

Information found in the literature searched on the **tumorigenic** effect of **1,2,3,7,8-PeCDD** following dermal exposure. The tumorigenic response after chronic dermal exposure to HxCDD was presented in Table 11-23.

In both NTP **bioassays** (1980b,c), groups of 30 male and 30 female **Swiss-Webster mice** were treated **with** 100  $\mu\text{l}$  of a solution of the test compound in acetone 3 times/week for 104 weeks. Groups of 45 animals were employed as vehicle controls, and 2 groups of 15 animals were used as untreated controls. The concentration of **2,3,7,8-TCDD** used resulted in a dose of 0.01  $\mu\text{g}/\text{application}$  in male **mice** and 0.005  $\mu\text{g}/\text{application}$  in female **mice**; the concentration of HxCDD used resulted in a dose of 0.005  $\mu\text{g}/\text{application}$  for the initial 16 weeks of the study, followed by a subsequent increase to 0.01  $\mu\text{g}/\text{application}$  for the remainder of the study. **Subchronic toxicity** studies used to define the dose levels for the chronic **bioassay** indicated that all the doses used resulted in some liver damage but no increase in mortality. In the chronic study, animals were killed when moribund at the termination of the study and examined for gross tumors. **Microscopic** examinations were also made of all major organs.

In **mice** exposed to **2,3,7,8-TCDD** (NTP, 1980b), there was no treatment-related difference in body weight of either sex between exposed animals and control groups; however, male **mice** treated **with** **2,3,7,8-TCDD** had a significant shortening of **lifespan**. Nontumorigenic hepatic lesions were observed in treated female **mice**; no mention was made of these lesions occurring in male **mice**. The only tumors that were treatment-related were integumentary system **fibrosarcomas**, **with** tumors developing on or near the **site** of application. The incidence of these tumors in male **mice** was 3/42 and 6/28, and in female **mice** the incidences were 2/41 and 8/27, respectively, for the vehicle control groups and the treated animals. Only the tumor incidence in female

TABLE 11-23

**Carcinogenicity** Bloassays of **2,3,7,8-TCDD** and HxCDD by Dermal Application to **Mice<sup>a</sup>**

| Compound     | Sex      | Dose <sup>b</sup>   | Duration of Exposure | Target Organ                | Tumor Type                               | Tumor Incidence |
|--------------|----------|---|----------------------|-----------------------------|--|-----------------|
| 2,3,7,8-TCDD | <b>M</b> | 0.01 $\mu\text{g}/\text{application}$                       | <b>104</b> weeks     | <b>integumentary</b> system | fibrosarcoma                             | 6/28            |
|              | H        | 0.0 $\mu\text{g}/\text{application}$<br>(vehicle control)   | <b>104</b> weeks     | Integumentary system        | fibrosarcoma                             | 3/42            |
|              | H        | 0.0 $\mu\text{g}/\text{application}$<br>(untreated control) | NA                   | Integumentary system        | fibrosarcoma                             | 0/28            |
|              | F        | 0.005 $\mu\text{g}/\text{application}$                      | <b>104</b> weeks     | Integumentary system        | fibrosarcoma                             | 7/28            |
|              | F        | 0.0 $\mu\text{g}/\text{application}$<br>(vehicle control)   | <b>104</b> weeks     | Integumentary system        | fibrosarcoma                             | 2/41            |
|              | F        | 0.0 $\mu\text{g}/\text{application}$<br>(untreated control) | NA                   | Integumentary system        | <b>fibrosarcoma</b>                      | 1/27            |
| HxCDD        | H        | 0.01 $\mu\text{g}/\text{application}^{\text{c}}$            | 104 weeks            | lung                        | <b>alveolar/</b><br>broncholar carcinoma | 5/30            |
|              | H        | 0.0 $\mu\text{g}/\text{application}$<br>(vehicle control)   | 104 weeks            | lung                        | <b>alveolar/</b><br>broncholar carcinoma | 1/41            |

TABLE 11-23 (cont.)

| Compound      | Sex      | Dose <sup>b</sup>   | Duration of Exposure | Target Organ | Tumor Type                                     | Tumor Incidence |
|---------------|----------|---|----------------------|--------------|--|-----------------|
| HxCDD (cont.) | <b>M</b> | 0.0 $\mu\text{g}/\text{application}$<br>(untreated control) | NA                   | lung         | <b>alveolar/<br/>bronchiolar<br/>carcinoma</b> | 4/28            |
| HxCDD         | F        | 0.01 $\mu\text{g}/\text{application}^{\text{c}}$            | 104 weeks            | <b>skin</b>  | fibrosarcoma                                   | 4/27            |
|               | <i>f</i> | 0.0 $\mu\text{g}/\text{application}$<br>(vehicle control)   | 104 weeks            | <b>skin</b>  | fibrosarcoma                                   | 2/41            |
|               | F        | 0.0 $\mu\text{g}/\text{application}$<br>(untreated control) | NA                   | <b>skin</b>  | fibrosarcoma                                   | 0/30            |

<sup>a</sup>Source: NTP, 1980b,c

<sup>b</sup>The compound was applied 3 times/week in 100  $\mu\text{l}$  of acetone.

<sup>c</sup>For the initial 16 weeks of the study, the dose was 0.005  $\mu\text{g}/\text{application}$ .

NA = Not applicable

**mice** was statistically ( $p=0.007$ ) greater than control values; however, **life** table analyses indicated that the **time** to tumor was shorter in both male and female treated **mice**. The incidence of tumors in untreated and vehicle control groups was similar.

In the **bioassay** of **HxCDD (NTP, 1980c)**, no gross or **nonneoplastic histologic** effects associated **with** treatment were observed. Although there was a **slight** increase in the incidence of **skin fibrosarcomas** in female **mice**, this increase was significant in comparison **with** the vehicle control group, but not significantly different from the untreated control group. The opposite occurred **with** the incidence of **alveolar/bronchiolar** carcinomas of the lung **in** male **mice**, which was significantly elevated in comparison **with** untreated but not vehicle-treated controls. It was concluded that although dermal exposure to **2,3,7,8-TCDD** resulted in a carcinogenic response in both male and female Swiss-Webster **mice**, dermal exposure to a mixture of **1,2,3,7,8-TCDD** and **1,2,3,7,8,9-HxCDD** did not result in a carcinogenic response under the conditions of **this** bioassay. A summary of the **carcinogenicity bioassays** is given **in** Table 11-24.

11.1.3. Summary of Animal Carcinogenicity. In a preliminary study by Van Miller (**1977a,b**), 2,3,7,8-TCDD was tested for carcinogenicity following oral administration to rats. At the **five** highest dietary levels, 0.005, 0.05, 0.5, 1.0 and 5.0 ppb, which allowed long-term survival of the animals, an increased incidence of total tumors was observed. In animals at an exposure level of **0.001** ppb and in the control **animals** there were no tumors. **This** study, however, provides only suggestive evidence of a carcinogenic response since no increase in site-specific tumors was detected and the group sizes, **~10** animals/group, were too small for an assessment of a treatment-related response. In a second, more extensive study by **Kociba et al.** (1978a) a positive carcinogenic response was detected. In **this** study the estimated

TABLE 11-24

## Carcinogenicity Bioassays of PCDD Administration by the Oral and Dermal Route

| Exposure Route/<br>Compound | Species/Strain          | Sex | Dose or Exposure                         | Duration of Treatment | Duration of Study | Vehicle                       | Tumor Type   | Tumor Incidence | Reference  |
|-----------------------------|-------------------------|-----|--|-----------------------|-------------------|-------------------------------|--|-----------------|------------|
| Gavage/<br>2,3,7,8-TCDD     | rats/<br>Osborne-Mendel | M   | 0.0 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 105 weeks         | corn oil-<br>acetone<br>(9:1) | follicular-cell adenomas<br>or carcinoma of the<br>thyroid       | 1/69            | NTP. 1980a |
|                             |                         |     | 0.1 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | follicular-cell adenomas<br>or carcinoma of the<br>thyroid       | 5/48            |            |
|                             |                         |     | 0.05 $\mu\text{g}/\text{kg}/\text{week}$ | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | follicular-cell adenomas<br>or carcinoma of the<br>thyroid       | 8/50            |            |
|                             |                         |     | 0.5 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 105 weeks         | corn oil-<br>acetone<br>(9:1) | follicular-cell adenomas<br>or carcinoma of the<br>thyroid       | 11/50           |            |
| Gavage/<br>2,3,7,8-TCDD     | rats/<br>Osborne-Mendel | F   | 0.0 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 105 weeks         | corn oil-<br>acetone<br>(9:1) | neoplastic nodule or<br>hepatocellular carcinoma<br>of the liver | 5/75            |            |
|                             |                         |     | 0.1 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | neoplastic nodule or<br>hepatocellular carcinoma<br>of the liver | 1/49            |            |
|                             |                         |     | 0.05 $\mu\text{g}/\text{kg}/\text{week}$ | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | neoplastic nodule or<br>hepatocellular carcinoma<br>of the liver | 3/50            |            |
|                             |                         |     | 0.5 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | neoplastic nodule or<br>hepatocellular carcinoma<br>of the liver | 14/49           |            |
| Gavage/<br>2,3,7,8-TCDD     | mice/B6C3F1             | N   | 0.0 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 105 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma   | 8/73            | NTP. 1980a |
|                             |                         |     | 0.1 $\mu\text{g}/\text{kg}/\text{week}$  | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma   | 9/49            |            |



TABLE 11-24 (cont.)

| Exposure Route/Compound            | Species/Strain         | Sex | Dose or Exposure | Duration of Treatment | Duration of Study | Vehicle                       | Tumor Type  | Tumor Incidence | Reference                   |
|------------------------------------|------------------------|-----|------------------|-----------------------|-------------------|-------------------------------|---|-----------------|-----------------------------|
| Gavage/<br>2,3,7,8-TCDD<br>(cont.) | mice/B6C3F1            |     | 0.05 µg/kg/week  | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma  | 8/49            | NTP. 1980a                  |
|                                    |                        |     | 0.5 µg/kg/week   | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma  | 17/50           |                             |
| Gavage/<br>2,3,7,8-TCDD            | mice/B6C3F1            | F   | 0.0 µg/kg/week   | 104 weeks             | 105 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma,<br>follicular-cell adenomas<br>of the thyroid | 1/73<br>0/69    | NTP. 1980a                  |
|                                    |                        |     | 0.04 µg/kg/week  | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma,<br>follicular-cell adenomas<br>of the thyroid | 2/50<br>3/50    |                             |
|                                    |                        |     | 0.2 µg/kg/week   | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma,<br>follicular-cell adenomas<br>of the thyroid | 2/48<br>1/47    |                             |
|                                    |                        |     | 2.0 µg/kg/week   | 104 weeks             | 107 weeks         | corn oil-<br>acetone<br>(9:1) | hepatocellular carcinoma,<br>follicular-cell adenomas<br>of the thyroid | 6/47<br>5/46    |                             |
| Oral/<br>2,3,7,8-TCDD              | rat/<br>Sprague-Dawley | N   | 0.0 ppb          | 78 weeks              | 95 weeks          | in diet                       | all tumors  | 0/10            | Van Miller<br>et al., 1977a |
|                                    |                        |     | 0.001 ppb        | 78 weeks              | 95 weeks          | in diet                       | all tumors  | 0/10            |                             |
|                                    |                        |     | 0.005 ppb        | 78 weeks              | 95 weeks          | in diet                       | all tumors  | 5/10            |                             |
|                                    |                        |     | 0.05 ppb         | 78 weeks              | 95 weeks          | in diet                       | all tumors  | 3/10            |                             |
|                                    |                        |     | 0.5 ppb          | 78 weeks              | 95 weeks          | in diet                       | all tumors  | 4/10            |                             |
|                                    |                        |     | 1.0 ppb          | 78 weeks              | 95 weeks          | in diet                       | all tumors  | 4/10            |                             |
|                                    |                        |     | 5.0 ppb          | 78 weeks              | 95 weeks          | in diet                       | all tumors  | 7/10            |                             |

TABLE 11-24 (cont.)

| Exposure Route/Compound                 | Species/Strain         | Sex                                    | Dose or Exposure                         | Duration of Treatment | Duration of Study   | Vehicle   | Tumor Type  | Tumor Incidence             | Reference            |                      |
|---|------------------------|--|--|-----------------------|---|---|---|-----------------------------|----------------------|----------------------|
| Oral/<br>2,3,7,8-TCDD                   | rat/<br>Sprague-Dawley | M                                      | 0.0 $\mu\text{g}/\text{kg}/\text{day}$   | 105 weeks             | 105 weeks   | in diet   | squaaous cell carcinoma of the hard palate.<br>squaaous cell carcinoma of the tongue.<br><b>adenoma</b> of the adrenal cortex | 0/85<br><b>0/85</b><br>0/85 | Kociba et al., 1978a |                      |
|   |                        |  | 0.001 $\mu\text{g}/\text{kg}/\text{day}$ | 105 weeks             | 105 weeks   | in diet   | squaaous cell carcinoma of the hard palate.<br>squaaous cell carcinoma of the tongue.<br>adenoma of the adrenal cortex        | 0/50<br>1/50<br>0/50        |                      |                      |
|   |                        |  | 0.01 $\mu\text{g}/\text{kg}/\text{day}$  | 105 weeks             | 105 weeks   | in diet   | squaaous cell carcinoma of the hard palate.<br>squaaous cell carcinoma of the tongue.<br><b>adenoma</b> of the adrenal cortex | 0/50<br>1/50<br>2/50        |                      |                      |
|   |                        | 0.1 $\mu\text{g}/\text{kg}/\text{day}$ | 105 weeks                                | 105 weeks             | in diet   | squaaous cell carcinoma of the hard palate.<br>squaaous cell carcinoma of the tongue,<br><b>adenoma</b> of the adrenal cortex | 4/50<br><b>3/50</b><br>5/50   |                             |                      |                      |
|   |                        | F                                      | 0.0 $\text{pg}/\text{kg}/\text{day}$     | 105 weeks             | 105 weeks   | in diet   | hepatocellular carcinoma, squaaous cell carcinoma of the tongue,<br>squaaous cell carcinoma of the lung                       | 0/86<br><b>0/86</b><br>0/86 |                      | Kociba et al., 1978a |
|   |                        |  | 0.001 $\mu\text{g}/\text{kg}/\text{day}$ | 105 weeks             | 105 weeks   | in diet   | hepatocellular carcinoma, squaaous cell carcinoma of the tongue.<br>squaaous cell carcinoma of the lung                       | 0/50<br>0/50<br>0/50        |                      |                      |
| 0.01 $\mu\text{g}/\text{kg}/\text{day}$ | 105 weeks              |  | 105 weeks                                | in diet               | hepatocellular carcinoma.<br><b>squamous</b> cell carcinoma of the tongue.<br>squaaous cell carcinoma of the lung | 2/50<br>1/50<br>0/50  |   |                             |                      |                      |

TABLE 11-24 (cont.)

| Exposure Route/<br>Compound | Species/Strain                                  | Sex | Dose or Exposure                    | Duration of Treatment | Duration of Study | Vehicle                | Tumor Type   | Tumor Incidence | Reference              |
|-----------------------------|---|-----|-------------------------------------|-----------------------|-------------------|------------------------|--|-----------------|------------------------|
| Oral/<br>2,3,7,8-TCDD       | rat/<br>Sprague-Dawley                          | F   | 0.1 vg/kg/day                       | 105 weeks             | 105 weeks         | in diet                | hepatocellular carcinoma,                            | 11/49           | Kociba et al., 1976a   |
|                             |   |     |                                     |                       |                   |                        | squamous cell carcinoma of the tongue,               | 4/49            |                        |
|                             |   |     |                                     |                       |                   |                        | squamous cell carcinoma of the lung                  | 7/49            |                        |
| Gavage/<br>2,3,7,8-TCDD     | mice/Swiss/<br>H/Rlop                           | M   | 0.0 vg/kg/week                      | 365 days              | 588 days          | sunflower oil          | liver tumors   | 7/38            | Toth et al., 1979      |
|                             |   |     | 0.007 vg/kg/week                    | 365 days              | 649 days          | sunflower oil          | liver tumors   | 13/44           |                        |
|                             |   |     | 0.7 vg/kg/week                      | 365 days              | 633 days          | sunflower oil          | liver tumors   | 21/44           |                        |
|                             |   |     | 7.0 vg/kg/week                      | 365 days              | 424 days          | sunflower oil          | liver tumors   | 13/43           |                        |
| Oral/<br>2,3,7,8-TCDD       | mice/<br><u>Peromyscus</u><br><u>pollenotus</u> | M&F | 0.0012 vg/kg/day                    | NA                    | NA                | contaminated soil      | liver  | 0/15            | Cockerham et al., 1980 |
|                             |   |     | 0.0 vg/kg/day                       | NA                    | NA                | contaminated soil      | liver  | 0/15            |                        |
| Gavage/HxCDD                | rats/<br>Osborne-Mendel                         | M   | 0.0 vg/kg/week<br>(vehicle control) | 104 weeks             | 105 weeks         | corn oil-acetone (9:1) | liver neoplastic nodules or hepatocellular carcinoma | 0/74            | NTP. 1980d             |
| Gavage/HxCDD                | rats/<br>Osborne-Mendel                         | N   | 1.25 vg/kg/week                     | 104 weeks             | 106 weeks         | corn oil-acetone (9:1) | liver neoplastic nodules or hepatocellular carcinoma | 0/49            | NTP. 1980d             |
|                             |   |     | 2.5 vg/kg/week                      | 104 weeks             | 107 weeks         | corn oil-acetone       | liver neoplastic nodules or hepatocellular carcinoma | 1/50            |                        |
|                             |   |     | 5.0 vg/kg/week                      | 104 weeks             | 107 weeks         | corn oil-acetone       | liver neoplastic nodules or hepatocellular carcinoma | 4/48            |                        |

11-55

TABLE 11-24 (cont.)

| Exposure Route/Compound | Species/Strain             | Sex      | Dose or Exposure      | Duration of Treatment | Duration of Study | Vehicle                       | Tumor Type  | Tumor Incidence | Reference         |
|-------------------------|----------------------------|----------|-----------------------|-----------------------|-------------------|-------------------------------|---|-----------------|-------------------|
| Gavage/HxCDD            | <b>rats/Osborne-Mendel</b> | F        | 0.0 vg/kg/week        | 104 weeks             | 105 weeks         | corn oil-acetone (9:1)        | liver neoplastic nodules or <b>hepatocellular carcinoma</b> | 5/75            | <b>MTP, 1980d</b> |
|                         |                            |          | 1.25 vg/kg/week       | 104 weeks             | 107 weeks         | corn oil-acetone (9:1)        | liver neoplastic nodules or <b>hepatocellular carcinoma</b> | 10/50           |                   |
|                         |                            |          | <b>2.5</b> vg/kg/week | 104 weeks             | 107 weeks         | corn oil-acetone <b>(9:1)</b> | liver neoplastic nodules or hepatocellular carcinoma        | 12/50           |                   |
|                         |                            |          | 5.0 vg/kg/week        | 104 weeks             | 107 weeks         | corn oil-acetone (9:1)        | liver neoplastic nodules or hepatocellular carcinoma        | 30/50           |                   |
| <b>Gavage/HxCDD</b>     | mice/B6C3F1                | <b>M</b> | 0.0 vg/kg/week        | 104 weeks             | 105 weeks         | corn oil-acetone <b>(9:1)</b> | hepatocellular adenomas or carcinomas                       | 15/73           | MTP, 1980d        |
|                         |                            |          | 1.25 vg/kg/week       | 104 weeks             | <b>108</b> weeks  | corn oil-acetone (9:1)        | hepatocellular adenomas or carcinomas                       | 14/50           |                   |
|                         |                            |          | 2.5 vg/kg/week        | 104 weeks             | 107 weeks         | corn oil-acetone <b>(9:1)</b> | hepatocellular adenomas or <b>carcinomas</b>                | 14/49           |                   |
|                         |                            |          | 5.0 vg/kg/week        | 104 weeks             | 108 weeks         | corn oil-acetone (9:1)        | hepatocellular adenomas or carcinomas                       | <b>24/48</b>    |                   |
| Gavage/HxCDD            | <b>mice/B6C3F1</b>         | F        | 0.0 vg/kg/week        | 104 weeks             | 106 weeks         | corn oil-acetone (9:1)        | hepatocellular adenomas or carcinomas                       | 3/73            | MTP, 1980d        |
|                         |                            |          | 2.5 vg/kg/week        | 104 weeks             | 108 weeks         | corn oil-acetone (9:1)        | hepatocellular adenomas or carcinomas                       | 4/48            |                   |
|                         |                            |          | <b>5.0</b> vg/kg/week | 104 weeks             | 108 weeks         | corn oil-acetone (9:1)        | hepatocellular adenomas or carcinomas                       | 6/47            |                   |
|                         |                            |          | 10.0 vg/kg/week       | 104 weeks             | 107 weeks         | corn oil-acetone (9:1)        | <b>hepatocellular</b> adenomas or carcinomas                | 10/47           |                   |

NA = Not available

Intake of 2,3,7,8-TCDD from the **diet** was 0.0, 0.001, 0.01 and 0.1  $\mu\text{g}/\text{kg}/\text{day}$ . In the high-dose group, both male and female animals had significant increases in site-specific tumors. The target organs and tumor types in male animals were squamous cell carcinomas of the tongue, **squamous** cell carcinomas of the hard palate and nasal **turbinates**, and adenomas of the adrenal cortex; in female animals the target organs and tumor types were hepatocellular carcinomas, squamous cell carcinomas of the tongue and nasal turbinates, and squamous cell carcinomas of the lung. The data demonstrate that dietary exposure to **2,3,7,8-TCDD** at levels that produce a daily dose of 0.1  $\mu\text{g}/\text{kg}$  results in increased tumor incidences in both male and female rats.

Under the National Toxicology Program, 2,3,7,8-TCDD was tested for **carcinogenicity** in rats following administration by gavage (**NTP**, 1980a). Both male and female animals were exposed to weekly doses of 0.0, 0.01, 0.05 and 5  $\mu\text{g}/\text{kg}$  bw. The only tumors that appeared to be treatment-related were **follicular** cell adenomas or carcinomas of the thyroid in male animals, and **neoplastic** nodules or **hepatocellular** carcinomas of the liver in female animals. The incidence of these tumors was **significantly** greater than control in the high-dose groups, and the incidence of both tumors showed a positive dose-related trend. Under the conditions of **this** assay, 2,3,7,8-TCDD was concluded to be carcinogenic in both male and female rats.

Further studies in **mice** exposed by gavage have provided support for the carcinogenicity of 2,3,7,8-TCDD. Toth et al. (1979) exposed male **mice** to 2,3,7,8-TCDD at doses of 0.0, 0.007, 0.7 and 7.0  $\mu\text{g}/\text{kg}/\text{week}$  in a study to determine whether **2,4,5-TCPE**, its contaminant 2,3,7,8-TCDD or both were carcinogens. At the 0.7  $\mu\text{g}/\text{kg}/\text{week}$  level there was a significantly increased incidence of liver tumors. Liver tumors were not significantly increased in the **high-dose** group; however, early mortality in **this** group may

have precluded observing late-developing tumors. Similar Increased Incidences of **liver** tumors were observed in the NTP (1980a) study in the high-dose male **mice** exposed to 0.5  $\mu\text{g}/\text{kg}/\text{week}$  and in the high-dose female **mice** exposed to 2  $\mu\text{g}/\text{kg}/\text{week}$  of **2,3,7,8-TCDD** by gavage. Female **mice** also had an Increased Incidence of **follicular-cell** adenomas of the thyroid. In both **studies**, **2,3,7,8-TCDD** was carcinogenic to **mice**, with effective doses ranging between 0.5 and 2  $\mu\text{g}/\text{kg}/\text{day}$ , depending on sex and the Individual study.

The mouse **skin** two-stage **tumorigenicity** model has **also** been used to test the carcinogenic potential of 2,3,7,8-TCDD. Following **long-term** dermal application 3 times/week of 2,3,7,8-TCDD at levels of 0.01 and 0.005  $\mu\text{g}/\text{application}$  to male and female **mice**, respectively, there was an Increased Incidence of **skin** tumors only in female **mice** (NTP, 1980b). Along **with** the Indication that 2,3,7,8-TCDD was a complete carcinogen in **this** system, DiGiovanni et al. (1977) reported that 2,3,7,8-TCDD was also a tumor Initiator in mouse **skin**. The ability of 2,3,7,8-TCDD to Initiate tumors, however, has yet to be confirmed since appropriate vehicle and promotion-only control groups were not Included. Attempts to demonstrate tumor-promoting activity **with** 2,3,7,8-TCDD on mouse **skin** have produced negative results in some assays (NTP, 1980b; Berry et al., 1978, 1979); however, Poland et al. (1982) reported that 2,3,7,8-TCDD was a tumor promoter when tested on the **skin** of **mice** homozygous for the "hairless" trait, but not in **mice** heterozygous for **this** recessive trait. Pitot et al. (1980) also reported that 2,3,7,8-TCDD was a promoter for DEN-initiated **hepatocarcinogenesis** in rats following parenteral administration of the compounds. On mouse **skin**, 2,3,7,8-TCDD was a complete carcinogen and possibly a tumor Initiator, while no tumor-promoting activity could be attributed to 2,3,7,8-TCDD in the assays. In rat liver Initiated **with** DEN, 2,3,7,8-TCDD was a tumor promoter.

In studies of the Interaction of **2,3,7,8-TCDD** with other **chemical carcinogens**, Kouri et al. (1978) reported that **2,3,7,8-TCDD** was a **cocarcinogen with 3-MC** when administered by subcutaneous Injection. In the mouse **skin bioassay**, Initiation with simultaneous administration of 2,3,7,8-TCDD and **DMBA**, however, **did** not affect tumor yield (DiGiovanni et al., 1977). Similarly, no effect was observed when 2,3,7,8-TCDD was administered either Immediately before (5 minutes) or 1 day after DMBA Initiation (Berry et al., 1979; DiGiovanni et al., 1977, 1979b; Cohen et al., 1979). When treatment with 2,3,7,8-TCDD occurred **1-10** days before DMBA Initiation, 2,3,7,8-TCDD demonstrated a potent **anticarcinogenic** action. Although 1-5 days prior exposure to 2,3,7,8-TCDD Inhibited tumor Initiation by BaP, 3-MC and BaP-**diol-epoxide**, the tumor Initiating ability of the latter compound was also Inhibited when 2,3,7,8-TCDD exposure occurred either 5 minutes before or 1 day after **initiation** (DiGiovanni et al., 1980). The Increased AHH activity resulting from 2,3,7,8-TCDD exposure may account for the antlcardnogenlc activity by altering the metabolism of the Initiating compound; however, DiGiovanni et al. (1980) suggest that the Inhibition of the Initiating activity of BaP-diol-epoxide 1 day after Initiation Indicates that more than one mechanism participates In the antlcardnogenlc activity of 2,3,7,8-TCDD.

HxCDD has also been tested for **carcinogenicity in rats and mice** treated by gavage and by dermal application to **mice** (NTP, 1980c,d). In these studies, a 1:2 mixture of 1,2,3,6,7,8- and **1,2,3,7,8,9-HxCDD** was tested. In the oral study, animals received HxCDD at doses of 0.0, 1.25, 2.5 or 5.0 **µg/kg/week**, except for female **mice**, which received 0.0, 2.5, 5.0 and 10.0 **µg/kg/week**. In both species and either sex only tumors of the **liver** occurred at a significantly greater Incidence than controls. In male rats and male and female **mice**, the **liver** tumor Incidence was significantly

Increased over control values only in the high-dose **groups**, while in female rats the Incidence was significantly greater at both the medium- and high-dose levels. In the study of HxCDD **carcinogenicity** in mouse **skin** conducted by NTP (1980c), there were no treatment-related tumors **in** either the **carcinogenicity bioassay** or the tumor promotion assay using **DMBA** as an Initiator. It was concluded that **this** mixture of HxCDD was carcinogenic to rats and **mice** following administration by gavage; **however, there** was no **tumor1-genic** activity when HxCDD was applied to mouse **skin**.

**No** chronic animal **bioassays** were found **in** the literature searched on the carcinogenicity of **1,2,3,7,8-PeCDD**.

## 11.2. **CASE REPORTS AND EPIDEMIOLOGICAL STUDIES\***

**11.2.1.** Case Reports. Observations of an unusual occurrence of relatively rare **soft-tissue** sarcomas were first made by Harden (1977). Of some 87 patients seen from 1970-1976 at the Department of **Oncology**, University Hospital, Umea, Sweden, seven individuals **with** soft-tissue sarcomas were identified. All seven had had occupational exposure to phenoxy acids 10-20 years earlier. The tumors were 2 **leiomyosarcomas**, 1 **liposarcoma**, 1 **rhabdomyosarcoma**, 1 **myxofibrosarcoma** and 2 additional sarcomas of which the **histopathology** was uncertain, but one was probably a neurofibrosarcoma and the **other** a **rhabdomyosarcoma**. The clustering of **this** rare tumor type among these patients prompted the author to suggest that **epidemiological** studies **be** done to determine **if** exposure to phenoxy acids and the impurities they contain are related to the occurrence of soft-tissue sarcomas.

---

\*Portions of **this** section were taken from U.S. EPA (1980c).



Zack and **Suskind** (1980) reported a soft-tissue sarcoma death in a cohort study of workers exposed to **2,3,7,8-TCDD** in a trichlorophenol process accident in Nitro, West Virginia. **This** tumor, a fibrous **histiocytoma**, was noted by the author as a rare event. **This study**, referred to as the Nitro **study**, is discussed later.

Cook et al. (1980) in a cohort mortality study of 61 male employees of a trichlorophenol manufacturing area, who exhibited **chloracne** following a 1964 exposure incident, noted four deaths by the end of **his** study period, one of which was due to a fibrosarcoma. The authors **did** not seem to attribute any special significance to **this** finding at the **time**.

Ott et al. (1980) in a cohort mortality study of 204 employees exposed to **2,4,5-T** during **its** manufacture from 1950 to **1971**, found no soft-tissue sarcomas among 11 deaths that had occurred by 1976. One of these 11 deaths was due to a malignant neoplasm.

In a review of the studies of Zack and Suskind (1980), Cook (1980), an unpublished study by Zack (in which a **liposarcoma** was found), a study by Ott et al. (1980) and **Honchar** and **Halperin** (1981) noted 3 (**2.9%**) soft-tissue sarcomas in a total of 105 deaths. Among U.S. males aged 20-84, **0.07%** of the deaths were reported as soft tissue sarcomas (**ICD 171**, 8th Revision, **1975**)\* indicating an unusual excess of such tumors. **This** may be an underestimate because of the possibilities that some soft-tissue sarcomas may have been coded to categories other than ICD 171. Individually, none of the reported case studies reported a significant excess of soft-tissue sarcomas.

---

\*Department of Health, Education, and Welfare. U.S. Public Health Service. National Center for Health Statistics of the United States, 1974. **Vol. II**. Mortality, Part A.

Cook (1981a) found an additional malignant fibrous **histiocytoma** after a later review of the medical records from **his** earlier cohort study. Cook, who was familiar **with** the three earlier **cases**, noted that frank **chloracne** occurred previously **in** two cases of the four having a diagnosis of malignant fibrous histiocytoma. A third person diagnosed as having a **fibrosarcoma** worked in a trichlorophenol (TCP) process area contaminated **with 2,3,7,8-TCDD**. **This** individual exhibited facial dermatitis but there was no diagnosis of chloracne. The fourth case (diagnosed as a **liposarcoma**) was an individual who had been employed earlier in a plant producing **2,4,5-T**. Cook (1980) noted that although chloracne was not reported, it could not be discounted. He also noted that all four were cigarette smokers and suggested that smokers **with** chloracne caused by **2,3,7,8-TCDD** exposure may be subject to an increased **risk** of fibrous soft-tissue sarcomas, although no prior reports have shown soft tissue sarcomas associated **with** cigarette **smoking**.

Hardell and Eriksson (1981) discounted **this** hypothesis by citing that only one of **Hardell's** seven cases exhibited chloracne before the appearance of the soft-tissue sarcomas, and that in their subsequent later case control study, they found no difference in smoking habits between **his** cases and controls.

Hoses and **Selikoff** (1981) reported a fifth soft-tissue sarcoma **in** a worker employed at the Nonsanto Chemical Company at a **time** when trichlorophenol and 2,4,5-T were being produced. The worker **died** of a **retroperitoneal neurogenic** sarcoma (malignant **schwannoma**) **in** 1980 at the age of 58. The employee, before **his** death, in a detailed occupational history **said** that he believed he was exposed to these chemicals while he was a truck driver, hauler and maintenance worker, but that he **did** not work in the production of either chemical. He was a nonsmoker and had no history of chloracne.

Johnson et al. (1981) treated a father and son **with** soft-tissue sarcomas (the 33-year-old son was diagnosed as having a **fibrosarcomatous mesothelioma**, while the 53-year-old father had a **liposarcoma**). Both were exposed to halogenated phenol derivatives. The author noted that **2,4-dichlorophenol** can be a precursor of **2,4-D** and **2,4,5-T**. The father had had prolonged exposure before **his** disease. The son supposedly had a shorter **latency**, according to the author. In neither case was the follow-up **time** given.

Sarma and Jacops (1981) reported three cases of thoracic soft-tissue sarcoma in individuals who were presumably exposed to Agent Orange while serving in Vietnam. The diagnoses were fibrous **histiocytoma**, **mediastinal fibrosarcoma**, and a **pleural/diaphragmatic leiomyosarcoma**. All three served in areas where defoliants were used at the **time**. One was drenched **with** the material in one spraying.

Bishop and Jones (1981) found two cases of **non-Hodgkin's** lymphomas of the scalp in a related clinical study of 158 employees of a pentachlorophenol manufacturing plant in Wales. **Homologues** of **2,3,7,8-TCDD** occurred as contaminants at up to 300 **ppm** at intermediate manufacturing stages and 5 ppm in the final products. **Mild**, moderate and severe cases of **chloracne** were seen in many employees, including the two men who subsequently developed lymphomas. Both men worked in processes where exposure to other chemicals **occurred**, including exposure to aromatic hydrocarbons. The authors reported that only 0.28 tumors of **this** type could be expected to occur **in** a group of 158 workers (ICO 200 and 202), although the basis for the computation of expected numbers is not stated.

Olsson and Brandt (1981) noted that of 123 male patients seen at their clinic in Sweden **with** a recent diagnosis of **non-Hodgkin's lymphoma** (NHL), 5 had cutaneous lesions as the only clinically detectable manifestation of

NHL. Four of the **five** were reported to have repeatedly sprayed large areas **with** phenoxy acid herbicides. In the remaining 118 NHL **patients**, only seven had a similar occupational exposure to phenoxy acids. The authors reported **this** to be significant at **p<0.001**. Olsson and Brandt suggested that a relationship exists between cutaneous presentation of NHL and occupational exposure to phenoxy **acids**, and believed their observations were similar to those of Bishop and Jones (1981).

The total number of workers **with** these illnesses who were exposed to phenoxy acids and/or chlorophenols is **small**, but considering the rarity of **this** cancer, it is unusual that so many cases of soft-tissue sarcomas have occurred. A Lancet editorial (Anonymous, 1982) calls **this** phenomenon "disturbing."

#### 11.2.2. **Epidemiologic** Studies.

**11.2.2.1. SOFT-TISSUE SARCOMAS** -- Soft-tissue sarcomas (STS) constitute a collection of heterologous lesions that include both malignant and **nonmalignant** tumors. Not all of them have their origin in primordial **mesenchymal** cells. Some exceptions are tumors of peripheral nerves, and neuroectodermal tumors that are **classified** as STS but are derived from nonmesenchymal cells. Classification, grading and staging of STSs **is** difficult because of the capacity of such cells to differentiate **into** many different tissues. Fairly precise **histogenetic classification** of such tumors is accomplished through consideration of growth patterns and cell morphology and evaluation of **intracellular** and **extracellular** products of tumor **cells**. There are a dozen distinctly different classes of **mesenchymal** cells that develop **into** the following **six** well-defined tissue complexes: fibrous tissue, **tendosynovial** tissue, adipose tissue, muscle, vessels and bone.

STSS can be Induced **in** any of these tissue types (**Hajdu, 1983**). The classification of STSS for cause of death coding **in** the ninth and latest revision of the International Classification of Diseases (**ICD, 1975**) places STSS **into** one of several categories. But chiefly, they fall **into** "malignant neoplasms of connective and other soft-tissue" (ICD 171). **Lymphosarcomas, retroperitoneal sarcomas and extra skeletal STSS of the bone are coded elsewhere.** In some Instances, if **site** is mentioned, it is coded to the **site [i.e., leiomyosarcoma of the stomach (ICD 151.9), neurofibroma of the chest wall (215.4)].**

Questions have been raised concerning the appropriateness of lumping together malignant tumors of different sites and tumor types in order to derive **risk** estimates. It may not be scientifically appropriate to do so because an elevated **risk** cannot readily be ascribed to a particular **site** or type as is usual **with** most carcinogenic chemicals and substances. Unfortunately, **with** respect to STSS, tallies of deaths from STSS of particular sites and types are not maintained separately by the vital statistics offices because of their rarity; therefore, it **is** impossible to derive **risk** estimates for particular types at given sites. Altogether, **~2000 deaths/year** can be attributed to STSS in the United States, most of which are coded to ICD category **171** for purposes of developing incidence and mortality rates for **this** composite cause. Within ICD 171, individual types that may be correlated **with** exposure cannot be identified.

A separate problem that potentially could arise from assigning STSS to multiple ICD codes is that incidence and death rates from STSS may be underestimated. Furthermore, **risk** estimates derived from dividing observed cases (or deaths) by expected cases (or deaths) could be biased upward. **This** could happen when observed STSS classified to ICD codes other than ICD 171

are lumped together in **ICD 171** while expected STSs are based upon STSs **classifiable** to **ICD 171** only. Thus, action of **this** sort, especially **with** respect to cohort studies of Individuals exposed to dioxin-containing herbicides and/or **chlorophenols**, could lead to **risk** estimates that may be biased upward by the Inclusion of STSs **in** the observed category for **risk** estimation that should be coded to categories other than 171.

Prompted by clinical observations over a 7-year period of malignant sarcomas in seven men **with** previous occupational exposure to **phenoxyacetic** acid herbicides (Hardell, 1977), researchers at the Department of Oncology, University Hospital, **Umea**, Sweden, initiated case-control **epidemiologic** studies to test the hypothesis of an **etiologic** association (Hardell and **Sandstrom**, 1979). Cases were defined as male patients **with** sarcomas of soft connective tissue, such as smooth muscle (**leiomyosarcoma**) and fat (**liposarcoma**). The distribution of tumor types **in** the two studies **is** shown in Table 11-25. Sarcomas of tissues, such as bone and cartilage, were excluded as cases. According to the authors, these tumors may have a different **etiology** and there occurred a different age-distribution in patients **with** these tumors as compared **with** that of STS (Hardell, 1983).

Two case-control studies were conducted: the first in northern Sweden (referred to below as Study A) and the second **in** the southern part of the country (Study B). The exposures to the substances of primary interest are shown in Table 11-26. In the north (Study A), occupational exposure to phenoxyacetic acids took place in both forestry and agricultural work. In the south (Study B), these exposures were predominantly **agricultural**. The phenoxyacetic acids to which exposure occurred consisted predominantly of **2,4,5-T** and **2,4-D** in both studies. Exposure to **2,4,5-T** in the absence of **2,4-D** was rarely reported in either study. Exposure to chlorophenols, which

TABLE 11-25

Distribution of Tumor Types in Two **Case-Controls** Studies  
of Soft-Tissue Sarcoma

| Diagnosis                  | Tissue of Origin               | Percent of Cases                      |  |
|----------------------------|--------------------------------|---------------------------------------|--|
|                            |                                | Study <b>A</b> <sup>a</sup><br>(n=52) | Study <b>B</b> <sup>b</sup><br>(n=110) |
| <b>Leiomyosarcoma</b>      | Smooth muscle                  | 30                                    | 23                                     |
| Fibrous <b>histiocyoma</b> | Subcutaneous connective tissue | <b>17</b>                             | 25                                     |
| <b>Liposarcoma</b>         | Fat tissue                     | <b>14</b>                             | 6                                      |
| <b>Neurogenic sarcoma</b>  | Nerve tissue                   | 10                                    | 4                                      |
| <b>Angiosarcoma</b>        | Blood vessels                  | 8                                     | 2                                      |
| <b>Myxosarcoma</b>         | Primitive connective tissue    | 6                                     | 8                                      |
| <b>Fibrosarcoma</b>        | Fibrous tissue                 | 4                                     | 8                                      |
| Other sarcomas             |                                | <u><b>11</b></u>                      | <u><b>24</b></u>                       |
| Total                      |                                | 100                                   | <b>100</b>                             |

<sup>a</sup>**Unpublished** Information supplied by Harden to EPA (Harden and Sandstrom, 1979)

<sup>b</sup>**Eriksson et al.**, 1979, 1981

TABLE 11-26

Exposure Frequencies in Two Case-Control Studies of Soft-Tissue Sarcoma

| Substance(s)            | Percent Exposed |                     |                  |                     |
|-------------------------|-----------------|---------------------|------------------|---------------------|
|                         | Study A         |                     | Study B          |                     |
|                         | Cases<br>(n=52) | Controls<br>(n=206) | Cases<br>(n=110) | Controls<br>(n=219) |
| Phenoxyacetic adds only | <b>23.1</b>     | 6.3                 | 12.7             | 2.3                 |
| Chlorophenols only      | 11.5            | 2.4                 | 10.0             | 3.6                 |
| Both                    | <b>1.9</b>      | <b>0.5</b>          | <b>0</b>         | <b>0</b>            |
| Total                   | 36.5            | 9.2                 | 22.7             | 5.9                 |

\*Sources: Study A, Harden and Sandstrom, 1979; Study B, Eriksson et al., 1979, 1981



contain **chlorinated** dibenzodioxin Impurities (Levin et al., 1976), occurred mostly in sawmill work and paper pulp production. Very few persons reported exposure both to **phenoxyacetic** acid and chlorophenols in these studies. Of the two predominant phenoxyacetic acids, only **2,4,5-T** is known to be contaminated with **2,3,7,8-TCDD**. In Study B, a relative risk of 4.9 (90% confidence Intervals 1.6-11.1) was found in relation to exposure to phenoxyacetic acid herbicide other than **2,4,5-T (2,4-D, MCPA, mecoprop, dichloroprop)**.

Relative risks in relation to the three major categories of exposure are shown in Table 11-27.\* Studies A and B indicate a risk of developing STSs among workers exposed to phenoxyacetic acids only, chlorophenols only, or phenoxyacetic acids and/or chlorophenols several times higher than among persons not exposed to these chemicals. In each comparison, the relative risk is high and was thus unlikely to have resulted by chance alone.

Since little is known of the etiology of STSs, the consideration of confounding in these studies was largely a hypothetical matter. The authors presented the effects of age, sex, and place of residence as possible confounding factors in the selection of controls.† Because of the high correlation between exposure to the substances of interest and employment in agriculture and forestry, a possible alternative hypothesis could be that some other unknown factor present in these occupations was responsible for the elevated relative risks.

---

\*In the analyses considering phenoxyacetic acids only and chlorophenols only, persons exposed to the other categories of substances were excluded. In Study A, the three persons exposed to both chlorophenols and phenoxyacetic acids were included in all comparisons.

†Controls were matched individually to cases on the basis of these factors. Unmatched analyses are presented in Table 11-26 for the sake of simplicity. The matched-method relative risks for exposure to phenoxyacetic acids and/or chlorophenols were 6.2 ( $p < 0.001$ ) in Study A and 5.1 ( $p < 0.001$ ) in Study B.

TABLE 11-27

Relative Risks of Soft-Tissue Sarcoma in Relation to Exposure to  
Phenoxyacetic Acids and Chlorophenols in Two Case-Control Studies<sup>a</sup>

|                                      | Phenoxyacetic Acids<br>Only |                 | Chlorophenols<br>Only |         | Phenoxyacetic Acids<br>and/or<br>Chlorophenols |         |
|--------------------------------------|-----------------------------|-----------------|-----------------------|---------|--|---------|
|                                      | Study A                     | Study B         | Study A               | Study B | Study A  | Study B |
| Relative risk <sup>b</sup>           | 5.3                         | 6.8             | 6.6                   | 3.3     | 5.7  | 4.7     |
| 90% Confidence interval <sup>c</sup> | 2.7-10.2                    | <b>3.1-14.9</b> | 2.8-15.6              | 1.6-7.0 | 3.2-10.2                                       | 2.7-8.3 |
| Significance level <sup>d</sup>      | <0.001                      | <0.001          | <0.001                | <0.005  | <0.001   | <0.001  |

<sup>a</sup>Source: Study A, Hardell and Sandstrom, 1979; Study B, Eriksson et al., 1979, 1981

<sup>b</sup>Unmatched odds ratio

<sup>c</sup>Test-based method of Miettinen, 1976

<sup>d</sup>Chi square statistic, no continuity correction, one-tailed test

To test **this** hypothesis, it is possible to calculate the **relative risk** in relation to the **phenoxyacetic** acid exposure in Study B, restricting the analysis to workers within **agriculture** and forestry. The result is a **relative risk** of 6.1 (**90%** confidence Interval 2.4-15.4). **This** finding suggests that a confounding **risk** factor for STS distributed throughout agriculture and forestry work was not responsible for the overall increase in **risk** found in relation to phenoxyacetic acid exposure.

**Because** exposure histories were obtained by means of questionnaires and interviews, the major **potential** source of **bias** in these studies stems from the need to rely upon the personal recollection of cases and controls for exposure histories. The published papers indicate that the researchers **paid** a great deal of attention to **this** potential problem and specific efforts were made to avoid it during the conduct of the study.

In addition, the relative **risk** calculated by considering the agriculture and forestry workers who **did** not report exposure to phenoxyacetic acids or chlorophenols and comparing them **with** unexposed persons in other occupations was 0.9 (90% confidence Interval 0.3-2.4) in Study B. **This** suggests that **little** recall **bias** was present (Axelson, 1980).

In an update of their earlier study, Eriksson et al. (1981) obtained information on the effects of phenoxy acids in the absence of the impurities -- polychlorinated dibenzodioxins and dibenzofurans. The **risk** ratio given exposure to phenoxy acids free of polychlorinated dibenzodioxins and dibenzofurans equaled 4.2 based upon 7 of 14 respondents who indicated exposure to phenoxy acid herbicides. When consideration was given to persons exposed only to phenoxy acids that contain such impurities, the relative **risk** was 17.0. A description of the basis for the determination of exposure or **nonexposure** to **dioxins** is not well presented in **this** study.

The author concluded that exposure to phenoxy adds and **chlorophenols** "might constitute a **risk** factor **in** the development of soft-tissue sarcomas." **This risk** relates not only to **2,4,5-trichlorophenoxy** adds containing **dioxin** Impurities but to other phenoxy adds as well. Some doubt was raised concerning the **possible** misclassification of Individuals who were exposed to phenoxy adds free of **polychlorinated** dibenzodioxins [**i.e.**, in particular, **"dichloroprop"** in the Eriksson et al. (1981) **study**]. In a recent communication from Harden (1983), Eriksson **recalculated his risk** estimates after **reclassifying his** dichloroprop-exposed cases and controls **into** the category of probable exposure to phenoxy adds contaminated **with** polychlorinated dibenzodioxins and removing them from the nonexposed category. **His** new estimates were 4.0 based upon 5 of 8 respondents who were exposed to phenoxy adds allegedly free of contamination and 10.9 for those exposed to contaminated phenoxy add. The first estimate was of only borderline significance utilizing the **Miettinen** test based statistic, thus, weakening any finding that the **risk** of STS extends to phenoxy adds free of dioxin.

In a cohort mortality investigation Cook et al. (1980) studied 61 males involved in a 1964 exposure incident who had absorbed **2,3,7,8-TCDD** through the **skin** and developed **chloracne**. The **skin** lesions characterizing chloracne ranged from a few comedones on the back of one employee (predating **his** entry **into** the process area where exposure could occur) to severe cysts and comedones over the faces, scalps, ears, necks and backs of the remaining employees of the group. Since the **main** route of exposure was not through the respiratory tract, no measurements of dioxin in the **air** were provided by the author. On the other hand, the author divided the cohort of 61 males **into** potentially **"high"** vs. **"low"** exposure by place of work based upon

**dermal** exposure, although not stated. **Vital** status was traced from the data of the Incident through **1978**. Altogether only 4 deaths were observed by the end of the **follow-up**, vs. 7.8 expected. Of these, 3 were cancer deaths vs. 1.6 expected. The remaining death was hypersensitive heart disease vs. 3.8 expected. The **histopathologic** causes of death of the three cancer victims were 1) **fibrosarcoma**, 2) **glioma with** metastases, and 3) adenocarcinoma. The authors report that all three victims smoked a minimum of one pack of cigarettes a day for "many years." Not enough information is provided by the authors to conclude that any of these four deaths were smoking related. **Site** of tumor is not mentioned in the cancer deaths.

Cancer mortality is slightly elevated in **this** cohort. The study has low sensitivity and lacks a sufficient latent period. **This** increased mortality was not attributable to any particular cause and no deaths were attributable to liver cancer. **Additionally**, the authors state that only one of the cancer deaths possessed "**documented**" evidence of chloracne, **although this** appears to be at variance **with** the definition of the cohort, which was reported by the authors to consist of males who reported to the medical department **with skin** conditions subsequently "diagnosed as chloracne." The authors concluded that the latency period was sufficient to "allow the identification of a potent human carcinogen," since it "exceeded 14 years." Orris (**1981**) noted that in the Hardell and Sandstrom (1979) study the authors stated that the latent period for soft-tissue tumors may be as long as 27 years and for many, over **14** years. In any case, Hueper and Conway (**1964**) noted that the latent period for the chemical induction of solid malignant tumors in man exceeds 15 years and is probably <30 years.

Smith et al. (1982b) conducted an **initial** case-control study of 102 males Identified from the New Zealand Cancer Registry as having STSs (**ICD 171**) between 1976 and **1980**. For each case, three controls each **with** another form of cancer were matched by age and year of registration. The selection of cancer controls from the same registry was done to eliminate recall **bias** and/or Interviewer **bias**. The distribution of **histological** types in the cases is given in Table 11-28. An Interview to elicit **occupational** history Information was accomplished by telephone either **with** the next of **kin** to the patient or the patient himself if he was well enough, **although** the Information was not used in **this** preliminary **analysis**.

Comparisons between cases and controls were accomplished by use of occupational groupings according to the Standard Classification System of New Zealand focusing on those occupational groups **with** a potential for exposure to phenoxy herbicides and **chlorophenols**. Expected cases for each major occupational classification were derived based upon the occupational distribution of the controls. The authors found no **unusual** excess of cases of STS in any **major** occupational category. In agriculture, forestry and fishing, 14 cases were observed vs. 14.0 expected. In laborers, production and transport workers, 35 cases were observed vs. 37.0 expected. A further breakdown of these two broad categories **into** finer **subcategories** within the major occupational categories revealed no significant excesses. The study, however, is not useful in assessing the **risk** of STS from exposure to phenoxy adds and/or chlorophenols for several reasons. First, as was pointed out by the authors but subsequently dismissed by them as having not much of an **influence**, is the possibility that movement from one major occupational category to another over the **time** period involved for **latent** conditions to

TABLE 11-28

**Distribution of Histological Types of Soft-Tissue Sarcomas\***

| Cell Type                     | Number of Cases | Percent   |
|-------------------------------|-----------------|-----------|
| <b>Fibrosarcoma</b>           | 25              | 24        |
| <b>Liposarcoma</b>            | 20              | 20        |
| Rhabdomyosarcoma              | 9               | 9         |
| <b>Leiomyosarcoma</b>         | 7               | 7         |
| <b>Malignant Histiocytoma</b> | 6               | 6         |
| Other                         | 22              | 21        |
| Unspecified                   | <u>13</u>       | <u>13</u> |
| Total                         | 102             | 100       |

\*Source: Smith et al., 1982b

manifest themselves could introduce a negative **bias into** any estimates of relative risks. The latency for STS was suggested to be a minimum of 15 years (Hueper and Conway, 1964).

The finding of no switching from one occupational category to another that was noted in the "first 20 Interviews" in which a change could be noted is not necessarily indicative of fidelity to the same job over long periods in all 408 cases and controls. Information identifying a change may be lacking in those cases and controls if in fact one **did** occur possibly because of several reasons, for example, separation of the earlier work history from the latter and purging of earlier employment records. Besides the "first 20 Interviews" where a change could be noted is not necessarily representative of the entire cohort in any case.

**Furthermore,** the authors do not know absolutely that any of their cases and controls were exposed to phenoxy acids or chlorophenols or to both since apparently no effort was made to confirm "potential" exposures. Only differences in occupational classification were noted where "**potentially**" cases or controls could have had exposure to the **dioxin-containing** herbicides. It was pointed out that the **risk** estimates noted do not "**preclude**" the possibility that an association may be found in **this** study when the cases and controls (or surviving **kin**) are interviewed for chemical spraying at a later **time**. The authors themselves concluded that the **preliminary** study results "should not be taken as substantial evidence against the hypothesis that phenoxy herbicides and chlorophenols may cause human **cancer**."

The distribution of tumor types differed considerably from the Harden and Eriksson study to the Smith study. **Leiomyosarcomas**, malignant **histiocytomas**, **neurogenic** sarcomas and **myxosarcoma** seem to predominate in the Hardell and Eriksson study, whereas **fibrosarcomas** and **liposarcomas** appear



prominently **in** the Smith study. More attention should be devoted to the study of the distributions of STS types in registry data everywhere **in** order to determine if such variations in the reporting of STS types are random occurrences. It is possible that the cancer effect of exposure to **phenoxy** herbicides may be narrowed to just certain types of STSs, the predominant ones in the Swedish studies.

In a later study of STSs, Smith et al. (1983a) conducted a case-control study of STSs **in** males that were reported to the New Zealand Cancer Registry by Public Hospitals between 1976 and 1980. The author matched one cancer control randomly chosen from the registry **with** each **case**, initially starting **with 112** of each. Controls were matched for year of registration and by date of birth  $\pm$  2 years. Inquiries were made by the authors **with** the hospital consultant, **family** doctor, and finally the **next-of-kin** or patient if alive. Telephone interviews were conducted by only one interviewer, who had no knowledge of the **patient's** cancer history, and were completed on 80 cases and 92 controls. Because some 32 potential cases (14 ineligible) and 20 controls were excluded or lost from the study for various reasons, **it** raises a question whether control of confounding by age and year of registration was maintained **in** the **final** group of 172 cases and control **included** in the **analysis**. Presumably the corresponding "matched" case or control to each of the 52 lost members of the total study group were not excluded. However, since the span of registration was only 5 years, not much age confounding could occur.

Patients were classified as having had potential exposure to phenoxy-**acetic** acids if they had definite, probable or possible exposure to phenoxy-**acetic** acid through spraying or hand contact. The actual chemical was identified only in some instances. The authors concluded in all remaining

situations that **if** the member sprayed "**gorse**" and/or "blackberries" **this** was tantamount to potential exposure to phenoxyacetic **acid**. Smith (1983) calculated elevated but nonsignificant relative risks of exposure to phenoxyacetic acid ranging from 1.3 in those individuals who were "probably exposed" for a minimum of 5 days not in the previous 10 years before cancer registration to **1.6** in individuals "probably exposed" for a minimum of 1 day not in the previous 5 years before cancer registration. When **risk** ratios were calculated after stratifying by year of birth and whether or not the patient or a relative was interviewed, the rates increased to 1.7 (**from** 1.6) in the latter and **1.4** (from 1.3) **in** the former calculation, although still nonsignificant. If the numbers would allow, it would be of interest to repeat the above calculations excluding only those **with** potential exposure occurring only within the 15-year period just before cancer registration. The small numbers that remain following the 15-year lapse probably precludes such an analysis. Furthermore, the categories of exposure "probably or definitely" exposed for **>1** day or even 5 days raises a question whether any of the cases or controls could really be **said** to have ever come in contact **with** enough phenoxyacetic **acid** to **justify** such a designation. It could be that, in fact, potentially exposed individuals in New Zealand have had **little** or no contact **with** the herbicide.

The authors **did** conclude that the finding of a relative **risk** of **1.7** in individuals **with** **>1** day exposure not in the last 5 years cannot be entirely discounted. But then the authors stated that if length of exposure was **>5** days prior to 10 years before cancer registration, they would expect an increase, and since they do not see an increase, there is no evidence of a "real causal **link**." One might ask whether **this** is a suitable criterion for providing evidence of a causal association. Perhaps a more valid group for

study would be one where the potential exposure was considerably longer than "5 days" and >15 years before Initial cancer registration. As **kind** of a subtle **justification** for the finding of no significant **risk** in workers exposed in phenoxy **acids**, the author alluded to the fact that there were 500 **full-time** workers registered in New Zealand who **did** full **time** ground spraying and altogether some 2000 workers who were at some **time** professionally involved in **phenoxyacetic** acid herbicide spraying from the **air** or ground **with** exposure "very much greater" than that of patients in **this** study. **This** **kind** of argument has appeal if these workers could be shown to have had their exposure sufficiently far in the past that latency considerations could be adequately addressed. However, the real question again remains; how much real exposure **did** those patients in the study really have 10-15 years earlier, and in what numbers. The author remarked that it was surprising that he found no STS victims who had ever worked full-time in phenoxyacetic acid herbicide spraying. Perhaps they have not yet been observed for a long enough period. The **time** interval of 10 years and/or 5 years from exposure to registration may not have been **long** enough to allow latent effects to become evident. However, as was pointed out by the author, the findings do not support the hypothesis that exposure to phenoxyacetic acid herbicides causes STS. But neither do they support a negative finding without better documentation regarding actual exposure and **time** of actual exposure. Smith (1983), however, noted that **his** documentation of exposure to **2,4,5-T** (and **2,4-D**) was at least as good as that in the Hardell and Sandstrom (**1979**) study, and that although Hardell and **Sandstrom** (1979) noted higher relative risks of <30 days exposure, Smith (1983) **did** not. Hence the paradox. Smith (1983) admitted the possibility that **2,3,7,8-TCDD** contaminations might be lower **in** New Zealand as opposed to 2,3,7,8-TCDD contamination in the Swedish studies, although there is no evidence for **it**.

He still maintains that **his** study showed that exposure to **phenoxyacetic** adds may not be associated **with** STS.

**Pazderova-Vejlupkova et al. (1981)** studied 80 workers involved in the production of **2,4,5-sodium trichlorophenoxyacetate** and butylester of trichlorophenoxyacetic acid who subsequently became 111 from exposure to **2,3,7,8-TCDD** during the period 1965-1968. **Only** 55 members of **this** group were **followed** for 10 years. The remaining 25 either refused participation or moved leaving no forwarding address. Most patients developed chloracne while 11 developed **porphyria cutanea tarda**. Chief chemical signs were metabolic disturbances, pathologically elevated **lipids with abnormalities in the lipoprotein spectrum**, and "pathological" changes in glucose tolerance. Other symptoms noted were biochemical deviations consistent **with** "a **mild liver lesion**," light **steatosis**, **periportal fibrosis** or activation of Kupffer **cells**, or nervous system focal damage (peripheral neuron **lesion** in lower **extremities**). Altogether **six** patients were reported to be deceased during **this** 10-year period, 2 from **bronchogenic carcinoma**, 1 from cirrhosis, 1 atherosclerosis predpue **cerebi** and 2 in auto accidents. No STSs or **lymphomas** were found. Since there was no comparison population **with** which to estimate relative **risk** for cancer, the study must be classified at best as clinical **with** respect to cancer. The 6 deaths (of 55) that occurred during the 10-year observation period cannot be construed to be associated **with** exposure to the **2,4,5-T**. Because of the small number of cases and the short follow-up period, nothing can be **said** concerning the association of exposure **with** cancer, especially specific types of cancer such as STS or non-**Hodgkin's lymphoma**.

**Riihimaki et al. (1982, 1983)** studied a cohort of 1926 herbicide applicators formed in 1972 from personnel records of four Finnish employers

(e.g., the Forestry Authority, Highway Authority, State Railways and a state-owned electric power company). Chlorinated **phenoxyacids** had been used since the 1950s **in Finland** for spraying. They constituted 2:1 mixtures of emulsified esters of **2,4-D** and **2,4,5-T** dissolved in water. Analyses from old herbicide formulations dating back to the 1960s revealed that these mixtures contained 0.1-0.9 mg/kg of **2,3,7,8-TCDD**.

**This** cohort of male workers was exposed a minimum of 2 weeks during at least one growing season from 1955-1971. Follow-up continued 9 years through **1980** for mortality but only until **1978** for morbidity. Fifteen Individuals could not be traced by 1980. Expected deaths were generated based upon cause- and age-specific national Finnish death rates for 1975. Expected cases were similarly calculated based upon national Incidence rates of 1975.

By 1980, 144 deaths had occurred vs. 184.0 expected, a deficit of **22% in** observed mortality. Only 26 cancer deaths had occurred vs. 36.5 expected, a 29% deficit. The authors separated out "natural" deaths from the total. The observed residual deaths equaled 39 while the expected deaths equaled 28.7. **This** excess was of borderline significance. The authors also considered 10-year and **15-year latent** periods. Even after 15 years, the deficit of deaths continued to manifest itself both in categories of all causes and total cancers; 35 observed vs. 53.6 expected and 5 observed vs. 11.3 expected, **respectively**. **Similarly**, the 7-year **follow-up** of cancer morbidity revealed 26 cases of cancer vs. 37.2 expected. After a 10-year latent period, 16 cancer cases were observed vs. 20.1 expected. None of the 26 cancer deaths or 26 cancer cases were of the STS or lymphoma type. (However, only 0.1 STS and 0.5 **lymphomas** were expected.) In no instance was cancer of any **site** significantly elevated.

The authors noted that **this** unusual deficit of **mortality** and morbidity of between 70 and 82% (even after 15 years from Initial exposure) was probably a consequence of the "**healthy worker effect**" in that only **able-bodied** and healthy Individuals were selected **into** the Industry. The fact that the cohort was assembled **in** 1972 from records of persons who were exposed as early as 1955 (**17** years prior) raises the likelihood that in 1972 a "survivor" **population** remained (45 deaths before **1972** were **eliminated** from the cohort) that was relatively healthy. **Furthermore**, the unusually large number of not "natural" expected and observed deaths (probably accidents and external causes) occurring to **this** cohort indicate a **relatively** youthful population was under scrutiny. The leading cause of death to persons under 35 years is from accidents, based on national **vital** statistics.

The authors correctly noted that, because of limitations **in** the study **material**, only powerful carcinogenic effects could be detected. **Risk** ratios higher than 1.5 for **all** cancers, 4.0 for **lymphomas** and **10.0** for STS could be excluded based on **this** data set from the **authors'** own **calculations**. More follow-up is needed in order to provide a stable assessment of the **relationship** between exposure and cancer. The authors concluded that **this** study **will allow** no assessment of STS because "**the** number of persons having a sufficiently long **latency** period is too small." It was suggested that more valid conclusions could be made **only with** the passage of **time** (Riihimaki et al., 1983).

Recently, the Michigan Department of Public Health (1983b), produced an ecological study of soft and connective tissue cancer mortality rates in Midland and other selected Michigan counties. They found that **mortality** rates for **this** cause were 3.8-4.0 times the national average for the periods **1960-1969** and 1970-1978, **respectively**, for white females in **Midland**. These

estimates are based upon 5 deaths and 7 deaths, respectively, and are listed in Table 11-29. No excess **risk** was reported among white males, however. The Michigan Department of Health concluded that because of the occurrence of these two successive elevated rates, it **is** unlikely to be a chance happening. At the same **time** the age-adjusted male and female cancer mortality rates for Midland were below that of the State of Michigan for the period 1970-1979. Midland County is the home of a **major** chemical company that produced **phenoxyacetic** acid herbicides until **recently**. The authors stated that a detailed review of death certificates, hospital records, residency and occupational histories of the 20 male and female cases revealed no **"commonalities"** suggesting a "single causative agent," although a majority or their spouses had worked at **this** chemical facility. They recommend that a case-control study should be employed to evaluate possible influences, such as lifestyle, occupation or location of residence on the **risk** of STS.

In a series of reports prepared under the auspices of the U.S. Air Force, Col. William H. Wolfe and **his** associates just completed the first phase of a study of Air Force **personnel** involved in the aerial dissemination of TCDD-containing herbicides in the **Republic** of Vietnam (RVN). During the period of **time** beginning in 1962 and ending in 1971, **~1278** male Air Force personnel (**Ranch Handers**) were identified as having been involved in the effort to 1) defoliate vegetation in Vietnam in order to decrease the **risk** of ambush and 2) destroy enemy crops (Wolfe et al., 1985). Based on an 1984 report of baseline mortality study results (Wolfe et al., **1984**), the cohort involved in the mortality study was smaller at 1256 because of the

TABLE 11-29

## Midland County Soft and Connective Tissue Cancer Deaths 1960-1981\*

| Identification |          |           | Type, Site and Progression of Malignancy |                                      |   | Month and Year Diagnosed |
|----------------|----------|-----------|--|--------------------------------------|---|--------------------------|
| Year of Death  | Sex      | Age       | Type                                     | Primary Site                         | Metastases  |                          |
| 1961           | F        | 24        | <b>Hemangiosarcoma</b>                   | Face                                 | Skull and upper lobe of lung                        | 5-58                     |
| <b>1963</b>    | F        | 75        | <b>Liposarcoma</b>                       | Right gluteal                        | Unknown   | Unknown                  |
| 1964           | F        | 51        | <b>Leiomyosarcoma</b>                    | Uterus                               | Widespread  | 11-63                    |
| 1968           | F        | 37        | <b>Liposarcoma</b>                       | <b>Spine</b>                         | <b>Lungs, pelvis</b>                                | <b>1-66</b>              |
| 1969           | F        | 45        | <b>Fibrosarcoma</b><br>Leiomyosarcoma    | Right thigh<br>Uterus                | <b>Lung, liver</b><br>Adrenal gland and <b>skin</b> | 10-68                    |
| 1970           | F        | 59        | <b>Kaposi sarcoma</b>                    | Right leg                            | Lymph nodes   | 8-68                     |
| 1970           | F        | 56        | Fibrosarcoma<br>Leiomyosarcoma           | Right thigh<br>Abdominal <b>wall</b> | Spine<br>Lung                                       | 1960<br>1967             |
| 1974           | F        | 1         | <b>Rhabdomyosarcoma</b>                  | Inguinal area                        | Unknown   | 8-73                     |
| 1976           | F        | 77        | Liposarcoma                              | Right thigh                          | Buttock, <b>lung, rib,</b><br><b>lymph nodes</b>    | 12-74                    |
| 1978           | <b>F</b> | <b>64</b> | Leiomyosarcoma                           | <b>Left knee</b>                     | <b>Liver, lymph nodes,</b><br><b>lung, bone</b>     | <b>7-70</b>              |

11-84



TABLE 11-29 (cont.)

| Identification |          |     | Type, Site and Progression of Malignancy |                                 |  | Month and Year Diagnosed |
|----------------|----------|-----|--|---------------------------------|--|--------------------------|
| Year of Death  | Sex      | Age | Type                                     | Primary Site                    | Metastases                               |                          |
| 1978           | F        | 26  | <b>Rhabdomyosarcoma</b>                  | <b>Rectum</b>                   | Lung, <b>neck</b> , Inguinal region      | 6-76                     |
| 1978           | F        | 88  | <b>Fibrosarcoma</b>                      | Right cheek                     | Facial area                              | 6-78                     |
| 1979           | F        | 27  | <b>Leiomyosarcoma</b>                    | Left thigh                      | Lung                                     | 3-78                     |
| 1962           | N        | 63  | Rhabdomyosarcoma                         | Left <b>lower</b> leg           | Lung and right outer chest wall          | 8-61                     |
| 1967           | <b>M</b> | 77  | <b>Mesothelioma</b>                      | Lung                            | Lung, peritoneum and diaphragm           | 6-67                     |
| 1967           | <b>M</b> | 20  | Rhabdomyosarcoma                         | Pharynx                         | <b>Periorbital</b> area and <b>liver</b> | <b>1-67</b>              |
| 1969           | M        | 32  | <b>Liposarcoma</b>                       | Left arm                        | Perineum and buttock                     | 6-64                     |
| 1971           | M        | 76  | <b>Leiomyosarcoma</b>                    | Small Intestine                 | Liver                                    | 10-69                    |
| 1972           | H        | 89  | <b>Leiomyosarcoma</b>                    | Retro- <b>peritoneal</b> region | Hepatic system                           | 7-72                     |
| 1976           | M        | 53  | Fibrosarcoma                             | <b>Peritoneum</b>               | Lung, liver                              | 3-75                     |

11-85

\*Source: Adapted from Michigan Department of Public Health. 1983b

exclusion of 22 **killed** in action and was divided **into** three **main** occupational categories as follows:

|   |            |
|---|------------|
| 1. Officers (pilots, navigators and others) | 466        |
| 2. Enlisted (flight engineers)              | 206        |
| 3. Enlisted (others)                        | <u>584</u> |
| TOTAL                                       | 1256       |

The authors categorized the Ranch Handers as having had **"exposure"** to the TCDO-containing herbicides **if** they were **involved** in the aerial spraying of the herbicides. They were matched to 6171 cargo mission **air** crew members and support personnel generally on a 5 to 1 basis according to similarity of training and military background experiences, occupation and race. The comparison population presumably had no exposure to TCDO. In an earlier 1983 report (Lathrop et **al.**, 1983), 50 deaths were identified in the study group versus 250 in the comparison population. Of these 50 deaths, 23 were due to external causes, 4 were malignant neoplasms, 16 were circulatory causes, 5 were digestive disorders and 1 was an endocrine disorder.

In the later **December** 1984 update, **Wolfe** et **al.** (1984) added 4 more deaths to the study population for a total of 54 deaths occurring to Ranch Hands while adding 15 to the 250 that had already occurred in the comparison group through December **31**, 1983. Altogether **this** update produced a total of 6 cancer deaths **in** the Ranch Hands versus 43 cancer deaths in the comparison population. The greatest cause of death in both Ranch Handers and the comparison population were accidents **with** 19 and 94, respectively. None of the 6 cancer deaths and 1 of the 43 deaths **in** the comparison group were STSs. Comparison of overall mortality **in** the Ranch Handers **with** other **Air** Force military **personnel** was nearly **identical (~4.3%)**. Ranch Hand ground

enlisted personnel suffered somewhat greater (although not significant) mortality than **did** Ranch Hand officers. Comparison of mortality **in** the Ranch Handers **with** other groups such as U.S. white **males**, Department of Defense retired enlisted men, U.S. civil servants, active duty **Air** Force and West Point officers from the **class** of 1956, were similar except for **Air** Force active duty officers who exhibited significantly **less mortality**. The authors attribute **this** to higher health qualification standards.

There were few biological markers that might tend to support the assumption that Ranch Hands were exposed to **2,3,7,8-TCDD**. In the Banbury report, Lathrop et **al.** (1984) reported that the **dermatologic** evaluation revealed no cases of chloracne through clinical diagnosis or **bioassay**. A questionnaire analysis of acne **in** Ranch Handers and comparison groups showed no unusually different incidence, severity, duration or distribution of anatomical locations in either group. Lathrop et **al.** (1984) **said** in fact that the "historical occurrence of **chloracne** was **highly unlikely** in the Ranch **Handers**".

**This** study suffers from several deficiencies that limit **its usefulness** in a determination of human health effects, notably cancer, and especially STS from exposure to **2,3,7,8-TCDD-contaminated phenoxy** herbicides. First, it is mainly a study of basically young men who were involved in the Air Force aerial spraying missions. **This** is evidenced by the exceptionally large number of accidents **attributable** to members of the cohort. It is the largest single cause of death in these men. Because **this is** a young group it is unlikely that **substantial** mortality **will** occur to the cohort until many more years of follow-up have passed. In fact, even after 15 years following initial exposure **<5%** of the cohort have **died**. Since most cancers

have a latency of >15 years following Initial exposure It is not **likely** that a cancer **risk** from **2,3,7,8-TCDD**, if any, **will** manifest Itself for some **time**.

**Furthermore**, the relatively rare STS, which is thought to have an even longer latency period, may not appear as a **risk** in **this** cohort until well after the 20th year. Additionally, **this** cohort exhibits little evidence of actual exposure to the herbicide **in** question, thus raising the possibility of misclassification. In other small cohort studies (Cook et al., 1980; Ott et al., 1980; Zack and **Suskind**, 1980) substantial numbers of the study cohorts exhibited evidence of exposure to 2,3,7,8-TCDD as indicated by the presence of chloracne, a clear biological marker. Few of the Ranch Hands exhibited evidence of **this** condition (Lathrop et al., 1984). In fact, as was suggested by the authors, the historical occurrence of chloracne was considered highly **unlikely in** the Ranch Hands. Neither do they present convincing evidence of other conditions suggestive of an association **with** exposure to the dioxin-containing herbicide that cannot be explained by confounders, according to the authors. In fact Ranch Hands, who were heavily populated **with** officers, pilots, navigators and flight engineers, may not have been as heavily exposed to the phenoxy herbicides as other U.S. military personnel in Southeast **Asia**. Perhaps Army combat foot soldiers or the non-Ranch Hand personnel who **did** the spraying on the ground around the military bases would constitute a more appropriate cohort for study. Lathrop et al. (1984) concluded that the absence of any association of "**clinical endpoints**" **with** herbicide exposure must be viewed as insufficient evidence supporting a cause-and-effect relationship. But **this** absence of any "**clinical endpoints**" might also indicate evidence of a lack of exposure to the

phenoxy herbicides in question by the Ranch **Handers**. **This** study must be viewed as Inadequate **in** assessing the **risk** of cancer from exposure to **2,3,7,8-TCDD-containing** phenoxy herbicides.

In a separate review of the epidemiological evidence for STS from exposure to **2,4,5-T-containing** herbicides, the United Kingdom Ministry of Agriculture, Fisheries and Food (1983) concluded that there was no evidence to recommend altering their earlier conclusion that formulations of phenoxy herbicides and **related** wood preservatives as "presently **cleared**" are safe and may continue to be used. **This** report readily discounts the positive studies of Harden and Eriksson (1979) as being biased, and it makes no reference to the later validity study by **Hardell** (1981) of **his** own work utilizing colon cancer **controls** (see Section **11.2.2.2.**). In **this** report **Hardell** answered these early criticisms that were reiterated by the British in their report. At the same **time**, the British report appears to put undue emphasis on **nonpositive** studies that do not demonstrate a **risk**, although most of them have methodological limitations (e.g., low power, insufficient latency and inappropriate study methods). In short, the **British** review appears to be overly optimistic about the safety of **2,4,5-T** herbicides.

**Fingerhut et al.** (1984) recently completed a review of medical and available exposure records of seven U.S. chemical workers that have been diagnosed as having STS and who were reported to have had possible exposure to **dioxin**. These cases collectively produced a clustering effect of the **relatively** rare STSs among former employees of a portion of the U.S. chemical industry where exposure to compounds contaminated **with 2,3,7,8-TCDD** is most likely to have occurred. **Fingerhut et al.** (1984) reported that a subsequent review of the Armed Forces Institute of Pathology and a review of one of the authors of the **Fingerhut** paper confirmed the diagnosis of 5 of the 7 U.S. **chemical** workers as STSs.

In terms of occupational **exposure**, Fingerhut et al. (1984) proposed a strict definition of exposure as **follows**: a record must exist somewhere that shows an assignment to either a 2,4,5-T department or to a **trichloro-**phenol department at some **time** in the past. If such a record **did** not exist, then the Individual would not have been considered to have had a confirmed exposure. Four of the seven who had a confirmed exposure in **this** manner were also members of cohorts that had been studied previously, while the remaining three could not be confirmed as having been assigned to any 2,4,5-T department or **trichlorophenol** department. The latter three were not identified as having been part of any earlier study but were case reports of Johnson et al. (1981) and Hoses and **Selkoff** (1981). Individuals who were members of study cohorts of "exposed **individuals**" might be expected to have better documentation of exposure, based upon employment records, than would cases turning up **in** a medical practice.

However, Fingerhut et al. (1984) pointed out that of these three cases, one worked 32 years **in** production, clerical, truck driving **and** maintenance jobs in a chemical manufacturing **site** that produced **trichlorophenol** and 2,4,5-T; the second worked 2.5 years as a production worker **in** a plant that made 2,4,5-T; and the third was a production and maintenance worker for 29 years at the same facility as the second worker. It would seem that the opportunity for exposure to **2,3,7,8-TCDD** containing 2,4,5-T or **trichloro-**phenol must be considered a distinct possibility in the first two cases, especially since both were involved **with** maintenance for many years.

Johnson et al. (1981) pointed out that the second case could not have satisfied a minimum latency requirement for exposure to TCDD since **his** 2.5 years as a production worker occurred just before **his** diagnosis and death.

However, **this man's** father was employed **with this** same plant almost as long as **his** son was alive and it seems plausible that because of **this** connection the son may have been exposed.

One must have reservations about the usefulness of a classification scheme that relies on documentation of an assignment to a specific area of a plant as proof of exposure to **dioxin** without real evidence substantiating that exposure (**i.e.**, either biological or physical **measurements**), while at the same **time** assignment to all other areas of the same plant is considered insufficient evidence of exposure although nothing is offered to substantiate the presence or lack of exposure to **2,3,7,8-TCDD** in either case. In most occupational prospective cohort **epidemiologic** studies, employment at a plant where the suspect agent is produced or found has been considered sufficient enough to **call** such a person "exposed" and thus included **in** a cohort for study. On the other hand, if the **Fingerhut et al.** (1984) definition were retrospectively **applied** to the already small occupational cohorts from which the first four STSs came, even two of these relatively rare STSs might probably constitute an excessive **risk** in the much smaller cohorts circumscribed by their definition. **Fingerhut et al.** (1984) agreed that an excess **risk** of STS would remain even **with** just two confirmed **cases**, and hence the possibility of a causal relationship between exposure to 2,3,7,8-TCDD and the **development** of STSs cannot yet be ruled out.

In summary, the associations reported **in** the two Swedish soft-tissue sarcoma studies are strong enough to make it **unlikely** that they have resulted entirely from random variation **bias** or confounding, even though the possibility cannot be **excluded**. These studies provide a strong suggestion that **phenoxyacetic** acid herbicides, chlorophenols or their impurities are carcinogenic in humans.

11.2.2.2. **MALIGNANT LYMPHOMAS** - A separate series of clinical observations at the Department of Oncology in Umea, Sweden (Hardell, 1979), led the researchers to conduct a case-control study of malignant lymphoma in relation to phenoxyacetic acid, chlorophenols, and other organic compounds (Hardell et al., 1980, 1981). Approximately 33% of the cases in this study were patients with Hodgkin's disease; the remainder of the cases were non-Hodgkin's lymphomas.

This study employed essentially the same methods and produced results comparable with those of the STS studies: statistically significant 5-fold to 6-fold relative risks in relation to phenoxyacetic acids and chlorophenols were confirmed. In addition, an elevated relative risk was found in connection with exposure to organic solvents, such as benzene, trichloroethylene, and styrene. In the published report, the methods and results were incompletely documented, especially the possibility of confounding by exposure to the organic solvents.

In the update of the earlier 1980 study, Hardell et al. (1981), utilizing the same basic data source, found that 36.1% of the cases had been exposed to phenoxy herbicides or chlorophenols, while only 9.6% of their controls were so exposed. The estimated relative risk was 6.0 when matching was considered and 5.3 when matching was eliminated. When cases and controls that were exposed to chlorophenols only were excluded, the relative risk of lymphoma from phenoxy acids alone was 4.8 (95% C.I. 2.9-8.1). On the other hand, if exposures to phenoxy acids are excluded and consideration is given to just chlorophenols (which includes combined exposure to phenoxy acids and chlorophenols), then the relative risk equaled 4.3 (95% C.I. 2.7-6.9). The author further subdivided this group into "low-grade" vs. "high-grade" exposures to chlorophenols. A continuous exposure of not more than 1 week or repeated intermittent exposures totaling not more than 1



month was classified as low-grade. The relative **risk** for high-grade exposure was **8.4** (95% C.I. 4.2-16.9), while that for low-grade exposure equaled 9.2 (95% C.I. 1.6-5.2). If exposure to organic solvents is **examined**, given that cases and controls exposed to only phenoxy adds and/or chlorophenols were excluded except for combined exposure to organic solvents, it is found that high-grade and low-grade relative risks were 2.8 (95% C.I. 1.6-4.8) and 1.2 (95% C.I. 0.5-2.6), respectively. However, the author noted that exposure to phenoxy adds and high-grade organic solvents (exposure to chlorophenols excluded) produced a relative **risk** of 11.2 (95% C.I. 3.2-39.7) based upon a few cases and controls **with** exposure to both. The authors concluded that "exposure to organic solvents, chlorophenols and/or phenoxy adds constitutes a **risk** factor for malignant **lymphoma**."

The Harden et al. (1981) study is still subject to the same methodological criticisms to which the earlier study was subjected. Chief among those is the possibility of observational and/or recall **bias** creeping into the responses that are elicited from self-administered questionnaires on **kind** and length of exposure. Secondly, confounding by exposure to potentially carcinogenic organic **solvents** and other agents **could** have had an effect on the **risk** estimate, although Harden (1981) insists that they **did not**.

Other research has tentatively suggested that lumberjacks may be at increased **risk** of **lymphoma** (Edling and Granstam, 1979). The **Nitro** study found three deaths from cancers of the lymphatic and **hematopoietic** system, against only 0.88 expected (**p=0.06**, one-tailed **Poisson** test).

The lymphoma case-control study (Harden et al., 1980, 1981) is consistent **with** the two STS studies discussed above. On the other hand, the consistency could **also reflect** an (as yet) unidentified common flaw in all these studies.

The two Swedish case control studies on STSs and a later case **control** study of malignant **lymphoma** (Hardell et al., 1981) were subjected to a validity analysis **with** respect to the assessment of exposure by Hardell and Eriksson (1981). To answer the question raised regarding the **recall** of occupation in a forestry/agriculture Job, secondary to the recall of exposure to phenoxy adds and/or chlorophenols, the cases and controls were divided **into** three groups: those who **worked** their entire **time** since 1950 in an agriculture/forestry Job; those who worked some **time in an agriculture/forestry** job but not exclusively; and the remainder who never worked in a forestry/agriculture job. The study found that the **risk** ratio was still 8.2 for STS in exclusively agriculture/forestry workers who were exposed to phenoxy adds compared **with** workers found in other occupations having no apparent exposure to phenoxy adds or chlorophenols. Even when comparing phenoxy add- and/or **chlorophenol-exposed** agricultural/forestry workers exclusively **with** nonexposed agricultural/forestry workers, the **risk** ratio was still 7.1. **This** argument seems to answer effectively questions regarding recall of occupation secondary to exposure.

On the other hand, the relative **risk** remains 5.4 when comparing phenoxy add and/or **chlorophenol** exposed workers exclusively **in** occupations other than agriculture/forestry **with** nonexposed workers **in** those same occupations, thus, suggesting the presence of either recall **bias** or still another occupation **with** potential exposure to phenoxy adds and/or **chlorophenols** (Table 11-30).

When woodworkers are separated out (possible exposure to chlorophenols in treatment of wood) the **risk** ratio becomes 9.7 (Table 11-31). These data suggest the presence of some recall **bias**.

TABLE 11-30  
Other Occupations (Minus Forestry/Agriculture)\*

| Group     | Phenoxy <b>Acids/Chlorophenols</b> | Non-exposed                              |
|-----------|------------------------------------|--|
| Cases     | 11                                 | 68                                       |
| Referents | 5                                  | 167                                      |
|           | RR = 5.4                           | <b>X<sup>2</sup> = 11.01 (P&lt;0.01)</b> |

\*Source: Harden and Eriksson, 1981

RR = Relative risk

TABLE 11-31

Other Occupations (Minus **Forestry/Agriculture/Woodworkers**)\*

| Group     | Phenoxy <b>Acids/Chlorophenols</b> | Non-exposed                             |
|-----------|------------------------------------|---|
| Cases     | 4                                  | 66                                      |
| Referents | 1                                  | 160                                     |
|           | RR = 9.7                           | <b>X<sup>2</sup> = 5.98 (P&lt;0.05)</b> |

\*Source: Hardell and **Eriksson, 1981**

RR = Relative **risk**

Another focus of the **Hardell and Eriksson (1981)** study was to determine if observational **bias** on the part of the Investigators **could** explain the **significantly high risk** estimates. To answer the question, the study compared the exposure data derived from the **interviewee's** returned questionnaires only **with** the combined information from both the phone interviews and questionnaires. The study found no substantial differences in the frequency of reporting exposure.

Still a third consideration of possible **bias** involves recall of exposure to phenoxy acids and/or chlorophenols because of subject knowledge of having cancer in the cases versus no knowledge of cancer in the referent population. The study chose as a referent group for the 52 STS cases (**Hardell and Sandstrom, 1979**) and the 169 malignant **lymphomas** (**Hardell et al., 1981**) a group of 154 colon cancer cases from the same population source and compared their exposure to phenoxy acids and/or **chlorophenols** by broad age groupings, and by rural vs. urban residence.

Utilizing a Mantel-Haenszel rate ratio, the study found the **risk** of exposure to phenoxy acids remaining **significantly high** at 5.5 and to chlorophenols 5.4 in the STS cases compared **with** the colon cancer **controls**. Similarly, **with** the malignant **lymphomas**, the identically derived **risk** ratios remain **significantly high** at 4.5 **with** respect to phenoxy acids and/or chlorophenol exposure **in** the cases, hence, the study concludes, no "substantial observational **bias**" exists. If it is assumed **in this** study that recall **bias** was and is the same as observational **bias**, then such a conclusion may not be entirely warranted from the comparison. **Certainly, it** appears that no recall **bias** existed because of subject "knowledge of having cancer" based on the authors' analysis. But it does not rule out the possibility that recall **bias** can still be present in their data for other

reasons. **Hardell et al. (1981)** refers to an Intense "debate about phenoxy adds and their presumptive **risk**" In Sweden at the **time** the colon cancer study was conducted. But, there is no reason to think that colon cancer victims would assume their disease was brought about from exposure to **dioxin** containing chemicals if no connection was suggested.

It seems plausible that STS and **non-Hodgkin's lymphoma** patients would either learn at the **time** of their diagnosis that exposure to **dioxin-containing** chemicals was the **likely** cause of **this** rare type of tumor or quickly learn from other **sources**, such as the news media, that exposure to herbicides containing dioxin could cause **this** rare form of cancer whereas colon cancer victims (a rather common form of **cancer**) would not necessarily be led to believe that exposure to the same dioxin-containing chemicals caused their disease. Hence, it is not difficult to imagine that such unusual victims of cancer could better "remember" exposure to such chemicals than could colon cancer patients.

Therefore, although the Hardell (1981) study may explain any biases introduced from secondary recall of occupation, observational **bias** introduced from the telephone interviewer and recall **bias** based on subject knowledge of cancer, it does not adequately answer questions of recall **bias** introduced through the acquired awareness on the part of the victim of STS or **non-Hodgkin's** lymphoma that **his** condition may have been caused by exposure to dioxin-containing herbicides.

11.2.2.3. STOMACH CANCER -- Studies of two of the oldest cohorts of workers known to have been exposed to **2,3,7,8-tcdd** containing **phenoxyacetic** acid herbicides report stomach cancer mortality rates significantly higher than expected. The results in each study were based on small numbers of deaths. In one study (Axelson et al., 1980), 348 Swedish railroad workers

with at least 46 days of herbicide exposure between 1955 and 1972 were followed through October 1978. The workers were grouped on the basis of their primary herbicide exposures: those primarily exposed to **phenoxyacetic acids (2,4-D and 2,4,5-T) only**, to **amitrole (aminotriazole) only**, and to both types of herbicides. After a 10-year latency was **achieved**, 3 stomach cancer deaths were observed vs. 0.71 expected (**p<0.05**). None were attributable to **amitrol** alone, but two were assigned to phenoxy acids alone while the remaining stomach cancer death occurred in a worker exposed to both amitrol and phenoxy acids. The excess was more pronounced (3 observed vs. 0.57 expected, **p<0.05**) among those **with** early exposure (**1957-1961**) to phenoxy acids and/or amitrol. If persons who were exposed to just amitrol alone are excluded, thus leaving individuals exposed to phenoxy **acid** alone and amitrol in combination, the excess is enhanced further (3 observed vs. 0.41 expected, **p<0.01**).

**Axelsson et al.** (1980) also noted an excess in total "tumors" after 10 years latency as **well** (15 observed vs. 6.87 expected, **p<0.005**). **This** is pronounced in those exposed **early** to phenoxy acids **alone** (6 observed vs. 2.60 **expected, p<0.01**) and phenoxy acids in combination **with** amitrol (5 observed vs. **1.34** expected, **p<0.05**). **Presumably**, "tumors" **in** Sweden are analogous to malignant neoplasms **in** the United States. The author states that no specific type of tumor predominates and no breakdown by tumor type is provided.

The other study showing increased stomach cancer mortality **is** the follow-up of 75 workers exposed to **2,3,7,8-TCDD** during and after a 1953 runaway reaction at a **trichlorophenol** manufacturing facility in **Ludwigshafen**, Federal Republic of Germany (**Thiess and Frentzel-Beyme, 1977**). Two sources

were used to calculate expected deaths: national mortality rates for the period 1971-1974, and 1972-1975 rates for Rhinehessen-Palatinate, the region in which **Ludwigshafen** is located.\*

The **results**, shown in Table 11-32, indicate an increased rate of stomach cancer mortality that also is not likely to have been due to chance alone.

Two aspects of the methodology used could have influenced these results. First, the available report does not include an analysis allowing for a minimum period of cancer induction. All three stomach cancer deaths in the Ludwigshafen cohort occurred more than 10 years after initial exposure. Employing a 10-year restriction to follow-up (as in the Swedish cohort study) would result in a higher relative **risk** estimate by reducing the number of expected deaths.

Secondly, national and regional mortality rates from the 1970s were used to generate expected deaths to compare **with** observed mortality over a much longer period (1953-1977). The substantial decline **in** stomach cancer mortality in West Germany during the late 1950s and 1960s would likely make these expected figures too large.

The researchers also used an internal control group that does not raise the second concern discussed above. **This** group consisted of 75 men, each matched to study group members by age and date of entry **into** employment, and selected at random from a list of over 10,000 persons who had been included in previous cohort studies by the same **investigators**. No stomach cancer deaths occurred **in this** control group during the follow-up period. Thus, use of the internal control groups also indicates an excess of stomach cancers in the exposed workers.

---

\*The report originally included expected deaths using rates for the **city** of Ludwigshafen, which were later shown to be inaccurate.



TABLE 11-32

Analysis of Stomach Cancer **Mortality** In a Group of  
West **German** Factory Workers Exposed to **2,3,7,8-TCDD\***

| Source for<br>Expected Deaths                   | <u>Stomach Cancer Deaths</u> |          | Relative<br><b>Risk</b> | Significance<br>Level |
|---|------------------------------|----------|-------------------------|-----------------------|
|   | Observed                     | Expected |                         |                       |
| Federal Republic<br>of Germany<br>1971-1974     | 3                            | 0.559    | 5.4                     | 0.02                  |
| <b>Rhinehessen-<br/>Palatinate</b><br>1972-1975 | 3                            | 0.495    | <b>6.1</b>              | 0.01                  |

\*Source: Thless and Frentzel-Beyme, 1977

In an update of **this** earlier study, **Thiess et al.** (1982) continued the follow-up of **his** cohort through 1979 by adding 2 additional years of follow-up and apparently reducing the **size** of **his** cohort from 75 to 74. Altogether 21 deaths (4 more than from the earlier study) occurred vs. 18 and 19 deaths in the 2 matched (**1 to 1**) Internal comparison groups. **With** respect to cancer deaths, the numbers were respectively 7, 5 and 5. The first control group was manually matched from the total number of persons (5500 Included in the **cohort** until the end of **1976**) and the second, at random, by computer for some 8000 employees. In addition, 19 expected total deaths were estimated based on **1970-1975** mortality statistics of **Rhinehessin-Palatinate**, 18 expected deaths based on 1970-1975 mortality statistics of **Ludwigshafen**, and 20 expected deaths based upon **1971-1974** mortality statistics of the Federal Republic of Germany. Just as in the earlier study, the three stomach carcinomas noted earlier appear to be significantly **elevated** regardless of which external comparison group is used (Table 11-33).

On the other hand, one stomach cancer appeared in the randomized Internal control group. None appeared in the manually matched Internal control. No other elevated risks for any other cause were evident and no STSs appeared. When latency was considered only, the **risk** of stomach cancer remained significantly **elevated** after a lapse of **10** years (3 observed, 0.52 expected, **p<0.016**) and then after a lapse of 15 years (2 observed, 0.23 expected, **p<0.02**) based upon death rates of Rhinehessin-Palatinate, 1970-1975.

Again, these study conclusions are limited by the small **size** of the study group and the very few cancer deaths noted at any particular **site**. Thus, it **is** insensitive to the detection of a **significantly** elevated **risk** for most causes of cancer, especially STS and lymphomas. Although, stomach cancer is elevated significantly, **it** is based only upon three deaths and

TABLE 11-33

**Reanalysis** of Stomach Cancer Mortality in a Group  
of West German Factory Workers Exposed to 2,3,7,8-TCOO\*

| Source for<br>Expected Deaths                    | <u>Stomach Cancer Deaths</u> |          | Relative<br><b>Risk</b> | Significance<br>Level |
|--|------------------------------|----------|-------------------------|-----------------------|
|  | Observed                     | Expected |                         |                       |
| Federal Republic of<br>Germany <b>1971-1974</b>  | <b>3</b>                     | 0.7      | 4.3                     | 0.034                 |
| <b>Rhinehess in-<br/>Palatinate</b><br>1970-1975 | 3                            | 0.64     | 4.7                     | 0.027                 |
| Ludwigs-Shafen<br>1970-1975                      | 3                            | 0.61     | 4.9                     | 0.024                 |

\*Source: **Thiess et al.**, 1982

since one stomach cancer death has been noted in an Internal control group in the updated **version**, it appears that **this** finding has been weakened somewhat. Furthermore, as was pointed out **earlier**, trends in stomach cancer mortality during the 1950s, 1960s and **1970s could** make the comparison of stomach cancer mortality **with** expected deaths less valid based upon **1970-1975** rates.

In summary, the evidence that **phenoxyacetic** adds and/or **2,3,7,8-TCDD** might increase the **risk** of stomach cancer consists of two studies, each of which reports a statistically significant excess that is based on only three stomach cancer deaths. Further follow-up of these and **similar** cohorts is warranted, but **firm** conclusions cannot yet be made.

Four additional cohort studies have reported results that do not show increased stomach cancer mortality rates in groups of workers exposed to phenoxyacetic adds and/or **2,3,7,8-TCDD**. These are studies of **2,4,5-T** production workers in **Midland**, Michigan (Ott et al., 1980), Finnish phenoxyacetic add herbicide applicators (Riihimaki et al., 1978), the **Nitro** study in which workers were exposed to 2,3,7,8-TCDD (Zack and Suskind, 1980) and **trichlorophenol** manufacturing workers (Cook et al., 1980).

As previously **mentioned**, the NHro study included a single death from STS and a **weakly** suggestive increase in lymphatic and **hematopoietic** system cancer mortality. The **Midland** study of 204 workers included **only** one cancer death, a tumor in the respiratory system. In the Finnish **study**, **histologic** information on tumor types was not provided; however, there were no deaths from **lymphoma**.

The **results** pertinent to stomach cancer mortality in the three studies are shown in Table 11-34. Results of neither the Midland study nor the

TABLE 11-34

Stomach Cancer Mortality in Three Studies of Workers Exposed to Phenoxyacetic Acid Herbicides and/or 2,3,7,8-TCDD

| Stomach Cancer Deaths |                    | Relative Risk | 95% Confidence Interval | Reference              |
|-----------------------|--------------------|---------------|-------------------------|------------------------|
| Observed              | Expected           |               |                         |                        |
| 0                     | 0.14 <sup>a</sup>  | 0             | 0-26.3                  | Ott et al., 1980       |
| 5                     | 6.9 <sup>a,b</sup> | 0.7           | 0.2-1.7                 | Riihimaki et al., 1978 |
| 0                     | 0.5 <sup>b</sup>   | 0             | 0-7.4                   | Zack and Suskind, 1980 |

<sup>a</sup>Estimated from total cancer expected deaths (see footnote in text).

<sup>b</sup>Entire follow-up period without regard for minimum time for cancer Induction (Ott et al., 1980 used a 10-year minimum Induction period).

**Nitro** study contradict the findings of the Swedish and West German Investigations **previously** discussed. **This** can be shown **in** two ways. **First**, the upper **95%** confidence **limits** for the **relative risk** estimates from these two "negative" studies exceed even the highest point estimates of relative **risk** (6.1) from the two "positive" studies (see Table 11-31).

**This** Indicates that the relative **risk** estimates from the Midland and NHro studies, even though equal to zero, are nevertheless not **significantly** different from the estimates of 6.1, given the sample sizes, follow-up periods, age distribution and comparison group rates.

In addition, the smallest detectable relative **risk** in the Midland study ( $\alpha = 0.05$ ,  $\phi = 0.2$  one-tailed **Poisson** test) was 21.4 (3 observed deaths, 0.14 **expected**).\* Similarly, the smallest detectable relative **risk** in the NHro study ( $\alpha = 0.05$ ,  $\phi = 0.2$ , one-tailed **Poisson** test) was 10.0 (5 observed **deaths**, 0.5 expected). **This** calculation is based on results for the entire follow-up period. If, as in the Midland study, a minimum period of cancer induction had been employed, the expected deaths would have been fewer and the smallest reasonably detectable relative **risk** would have been greater. **This** analysis of statistical power indicates that the NHro and Midland studies had very low probabilities of detecting the **~6-fold** increases in **risk** suggested by the Swedish and West German Investigations.

---

\*Ott et al. (1980) did not report expected deaths from stomach cancers. The figure 0.14 was obtained by multiplying the numbers of expected deaths from all cancers (2.6, allowing a **10-year** minimum induction period) by the percentage of stomach cancers among the expected deaths in the NHro study ( $0.5/9.04 = 5.5\%$ ). The two studies used United States white male mortality rates and covered similar calendar years in **follow-up** (1949-1978 in NHro and 1950-1976 in Midland), but a similarity in age distributions cannot be established from the published reports.

Statistically, the study of Finnish herbicide **applicators** is Inconsistent **with** the results of the Swedish and **West** German cohort studies. The smallest reasonably detectable relative **risk** ( $\alpha = 0.05$ ,  $\phi = 0.2$ , one-tailed **Poisson** test) was only 3.1 (11 observed deaths, 3.6 **expected**).\* The study, therefore, appears powerful enough to detect relative risks even smaller than those seen **in** the Swedish and West German studies. A partial explanation for **this** apparent Inconsistency could be **in** the fact that the Finnish study set the minimum period of herbicide exposure for membership **in** the cohort at 10 days (2 working weeks) and noted that the "total strength of exposure has, **in** most cases, been a few weeks only." The Swedish study of herbicide applicators set the minimum exposure at 46 days (>1 spraying **season**).

There are also certain Inconsistencies in the data from the Finnish study that the authors note but **find difficult** to explain. In particular, no cancer deaths occurred during the **latter** part of the study period among Forestry Authority workers (1 of 4 groups included in the cohort), even though 9.0 deaths were expected. **This** finding strongly suggests some deficiency in follow-up or in the source records from which vital status was determined.

In summary, four cohort studies of workers exposed to **phenoxyacetic** acid herbicides and/or **2,3,7,8-TCDD** do not report increased risks of stomach cancer. Only one of these, however, was statistically powerful enough to be Inconsistent **with** the two studies that tentatively suggest an increase **in** stomach cancer **risk**. The **available** report of **this** study of Finnish herbicide applicators contains **methodologic** questions that require clarification.

---

\*The expected stomach cancer deaths were estimated in the same manner as for the Midland study. A proportion of **20%** of all cancer deaths was applied because Finnish male **mortality** rates are known to be very **high**.

11.2.3. Summary of Case Reports and **Epidemiologic** Studies. By adding together the number of workers exposed to phenoxy acids and/or chlorophenols from **all** case **studies**, an **unusually high** number of STSs is **shown**, considering the rarity of the disease. **This** excess is suggestive of an association of cancer **with** exposure to phenoxy acids and/or chlorophenols, and consequently, **with** the Impurities found in these herbicides, including 2,3,7,8-TCDD.

Two Swedish case-control studies report highly significant association of STS **with** exposure to phenoxy acid and/or **chlorophenols**. They do not pinpoint the **risk** to the **dioxin** contaminants, however. In fact, in one study, the **risk** was found to extend to phenoxy acids free of dioxin Impurities. In that study, the **risk** increases to 17 when phenoxy acids known to contain dioxin Impurities (**polychlorinated dibenzodioxins** and **dibenzofurans**) are considered. The extent of possible observer **bias** and recall **bias** introduced **into** these studies by using **self-administered** questionnaires is not of sufficient magnitude to have produced the **highly** significant risks found in the studies.

Later studies **did** not reveal a significant excess **risk** of STS. However, methodology problems make these latter studies limited **with** respect to **evaluating** the **risk** of STSs from exposure to phenoxy acids and/or chlorophenols and, consequently, **2,3,7,8-TCDD**.

The Swedish **case-control** studies provide **limited** evidence for the **carcinogenicity** of phenoxy acids and/or chlorophenols in humans. However, **with** respect to the dioxin Impurities contained therein, the evidence for the human carcinogenicity for **2,3,7,8-TCDD** based on the **epidemiologic** studies is **only** suggestive because of the difficulty of **evaluating** the **risk** of 2,3,7,8-TCDD exposure **in** the presence of the confounding effects of phenoxy acids and/or **chlorophenol**.



There is less evidence incriminating **2,4,5-T** and/or **2,3,7,8-TCDD** as the cause of **malignant** lymphoma and stomach cancer in humans.

### **11.3. QUANTITATIVE ESTIMATION OF RISKS OF EXPOSURE TO 2,3,7,8-TCDD AND HxCDDs**

11.3.1. Introduction. **This** quantitative section deals **with** the incremental **unit risk** from exposure to 2,3,7,8-TCDD and HxCDDs by Inhalation and oral routes, and their potencies **relative** to other carcinogens that the CAG has evaluated. The Incremental **unit risk** estimate for an **air** pollutant present in such small quantities as the **dioxins** is defined as the Increased lifetime cancer **risk** occurring to an Individual exposed continuously from birth throughout lifetime to an **air** concentration of 1  $\mu\text{g}/\text{m}^3$  of the agent. The **unit risk** from oral exposure is **similarly** defined in terms of either  $\mu\text{g}/\text{kg}$  bw/day or in terms of **ng/l** water. These calculations are done to estimate in quantitative terms the Impact of the agent as a carcinogen. **Unit risk** estimates are used for two purposes: 1) to compare the carcinogenic potency of **several** agents **with** each other and 2) to **give** a crude Indication of the population **risk** that might be associated **with** known (or anticipated) **air** or water exposure to these agents.

The Incremental **unit** risks for both the **inhalation** and oral routes **will** be estimated from animal oral **bioassays**, since there are no **animal** Inhalation studies, and none of the **epidemiology** studies provides sufficient exposure Information for **extrapolation** purposes. The **animal-to-man** extrapolations for the oral route **will** assume equivalent absorption in both species. However, the **unit risk** for the ambient **air** concentration of 2,3,7,8-TCDD must be considered in terms of both **its** physical properties and **its** sources. It does not occur naturally but is emitted in small amounts from sources including the production of 2,4,5-T, **trichlorophenol**, **silvex** and hexachlorophene; the application of **2,3,7,8-TCDD-contaminated** herbicides or wood

preservatives; the burning of municipal waste, wood and PCBs; and, **possibly**, dust from **2,3,7,8-TCDD-contaminated soil**.

**Physically, 2,3,7,8-TCDD** has a very low vapor pressure and is not normally airborne. At room temperature it **is** a crystalline solid, melting at 305°C. When 2,3,7,8-TCDD **is** present **in air**, it **is likely** to be attached to **particulates**, to which it strongly binds. It has been measured **in air only** in the vicinity of burning processes and in dust from contaminated **soil**, and has not been found in the general **air** environment.

11.3.2. Procedures for the Determination of Incremental **Unit Risk** from Animal Data and Description of the Low-Dose Animal Extrapolation Model. Following **is** an abbreviated description of the procedures used in animal-to-man extrapolation. A more complete description is given **in** Anderson et al. **(1983)**.

In the development of quantitative estimates of carcinogenic **risk** from lifetime animal studies it **is** assumed, unless evidence exists to the contrary, that **if** a carcinogenic response occurs at the dose levels used in the study, then responses **will** also occur at all lower doses **with** an incidence determined by the dose as indicated by the extrapolation model. While both TCDD and HxCDD cause cancer in animals at lower doses than any other known or suspect carcinogen, environmental levels are also extremely low. Thus, an extrapolation methodology must be employed.

There is no **solid** scientific basis for any **mathematical** extrapolation model that relates carcinogen exposure to cancer risks at the extremely low concentrations that must be dealt **with in** evaluating environmental hazards. Such low levels of **risk** cannot be measured directly either by animal experiments or by **epidemiologic** studies.

In the absence of any strongly suggestive evidence to the contrary for TCDD or HxCOD, the linear **nonthreshold** model has been adopted as the primary basis for **risk** extrapolation in the low-dose region of the dose-response relationship. The **risk** estimates made **with this** model should be regarded as conservative, representing the most **plausible** upper limit for the **risk; i.e., the true risk is** not likely to be higher than the estimate, but **it** could be lower.

The mathematical formulation chosen to describe the linear **nonthreshold** dose-response relationship at low doses is the linearized multistage model. It is called the linearized model because the procedure determines a linear function,  $q_1^*$ , consistent **with** the observed data in a **statistical** sense. Thus, the multistage model procedure employs enough arbitrary constants to be able to **fit** almost any **monotonically** increasing dose-response data, and then it incorporates a procedure for estimating the largest possible linear slope (in the 95% upper confidence limit sense) at low extrapolated doses that is consistent **with** the data at all dose levels of the experiment. The multistage model has the form

$$P(d) = 1 - \exp [-(q_0 + q_1 d + q_2 d^2 + \dots + q_k d^k)]$$

where

$$q_1 > 0, \quad i = 0, 1, 2, \dots, k$$

and  $P(d)$  = the lifetime **risk** (probability) of cancer at dose  $d$ .

**Equivalently,**

$$P_t(d) = 1 - \exp [(q_1 d + q_2 d^2 + \dots + q_k d^k)]$$

where

$$P_t(d) = \frac{P(d) - P(0)}{1 - P(0)}$$

is the extra **risk** over background rate at dose  $d$ . The estimate  $q_1^*$  is the **95%** upper-limit on  $q_1$  at lower doses. A more complete description of the model is given in Appendix B.

**11.3.3.** Selection of Data. For some **chemicals**, **several** studies in different animal **species**, strains and sexes, each run at several doses and different routes of exposure may be available. A choice must be made as to which of the data sets from several studies to use in the model. The procedures used in evaluating these data are consistent with the approach of making a maximum-likely **risk** estimate. They are listed below as follows:

1. The tumor Incidence data are separated according to organ sites or tumor types. The set of data (**i.e.**, dose and tumor Incidence) used in the model **is** the set where the Incidence **is statistically significantly** higher than the control for at least one test dose level and/or where the tumor Incidence rate shows a statistically significant trend **with** respect to dose level. The data set that gives the highest estimate of the lifetime carcinogenic **risk**,  $q_1^*$ , is selected in most cases. However, efforts are made to exclude data sets that appear to have produced spuriously **high risk** estimates because of a small number of animals. That is, if two sets of data show a similar dose-response relationship, and one has a very small sample **size**, the set of data having the larger sample **size** is selected for calculating the carcinogenic potency.
2. If there are two or more data sets of comparable **size** that are identical **with** respect to species, strain, sex and tumor sites, the geometric mean of  $q_1^*$ , estimated from each of these data sets, is used for **risk** assessment.

In some cases one or more of these studies may be negative, but the **95%** upper limit  $q_1^*$  will still be greater than zero.

3. If two or more significantly increased tumor sites are observed in the same study, and if the data are available, the number of animals **with** at least one of the specific tumor sites under consideration is used as Incidence data in the model. Alternatively, the total number of significant tumors may also be used in some cases.

**11.3.4.** Calculation of Human Equivalent Dosages for **Animal-to-Man** Extrapolation. It is appropriate to correct for metabolism differences between species and absorption factors through different routes of administration.

Following the suggestion of **Mantel** and **Schneiderman** (1977), it is assumed that mg/surface area/day provides an equivalent dose between species. To a close approximation, since the surface area is proportional

to the 2/3 power of the weight, as would be the case for a perfect sphere, the exposure in mg/day per 2/3 power of the weight is also considered to be equivalent exposure. In an animal experiment, **this** equivalent dose **is** computed **in** the following manner.

Let

$L_e$  = duration of experiment

$l_e$  = duration of exposure

$m$  = average dose/day in mg during administration of the agent  
(**i.e.**, during  $l_e$ ) and

$w$  = average weight of the experimental animal

Then, the **lifetime** average exposure **is**

$$d = \frac{l_e \times m}{L_e \times w^{2/3}}$$

A more expanded discussion is given in Anderson et al. (1983).

11.3.5. Alternative Methodological Approaches. The methods used by the CAG for quantitative assessment are consistently conservative, **i.e.**, tending toward **high** estimates of **risk**. The most important part of the methodology contributing to **this** conservatism in **this** respect **is** the linear **nonthreshold** extrapolation model. There are a variety of other extrapolation models that could be used, most of which would **give** lower **risk** estimates. These alternative models have not been used by the CAG in the following analysis, but three are included for comparison in the appendix. The models presented there are the one-hit, **probit** and **Weibull** models. The CAG feels that **with** the limited data available from these animal **bioassays**, most of which are conducted at **high** dosage levels, almost nothing is known about the true shape of the dose response curve at low environmental levels. The position **is** taken by the CAG that the **risk** estimates obtained by use of the **linear nonthreshold** model are upper limits, and the true **risk** could be lower.

Another modification of the method described here involves the choice of the specific animal **bioassay** as the basis for extrapolation. The present approach is to use the most sensitive responder. **Alternatively**, the average responses of all of the adequately tested bioassay animals could be **used**, and then some confidence limits placed on **this** estimate.

Extrapolations from animals to humans could also be done on the basis of relative weights rather than surface areas. The latter approach, used here, has more basis in human pharmacological responses; it is not clear which of the two approaches is more appropriate for carcinogens. In the absence of information on **this** point, **it** seems appropriate to use the most **generally** accepted method, which also is more conservative. In the case of 2,3,7,8-TCDD and **HxCDD** gavage studies, the use of extrapolation based on surface area rather than weights increases the incremental **unit risk** estimates by a factor of 5.8 for rats and about 13 for **mice**.

**11.3.6. Interpretation of Quantitative Estimates.** The incremental **unit risk** estimate based on animal **bioassays** is an approximation to the excess **risk** in populations exposed to known carcinogen concentrations. **This is** because there may be important species differences **in** uptake, metabolism and organ distribution of carcinogens, as well as species differences **in** target **site susceptibility, immunological** responses, hormone function, and dietary factors and other diseases. The concept of equivalent doses for humans compared **with** animals on a mg/surface area basis has little experimental verification regarding carcinogenic response. Human populations are more variable than laboratory animals **with** respect to genetic constitution and **diet**, living environment, activity patterns and other cultural factors.

The **unit risk** estimate can **give** an Indication of the **relative** response per **unit** dose ("potency") of a given agent compared **with** other carcinogens. The comparative potency of different agents should be more reliable when the comparison **is** based on studies in the same test **species**, strain and sex, and by the same route of exposure.

The quantitative aspect of the carcinogen **risk** assessment **is** Included here because it may be of use in the regulatory decision-making process, for example, setting **regulatory** priorities and evaluating the adequacy of technology-based controls. However, the estimation of cancer risks to humans at low levels of exposure **is** uncertain. At best, the linear extrapolation model used here provides a rough but plausible estimate of the upper limit of **risk**; **i.e.**, it **is** not **likely** that the true **risk would** be much more than the estimated **risk**, but it could very well be considerably lower. The **risk** estimates presented in subsequent sections should not be regarded as an accurate representation of the true cancer risks even when the exposures are accurately defined. The estimates presented may be factored **into** regulatory decisions to the extent that the concept of upper **risk limits** **is** found to be useful.

11.3.7. Incremental **Unit Risk** Estimates for **2,3,7,8-TCDD via** the Oral and Inhalation Routes. The positive animal cancer data available for calculating an Incremental **unit risk** estimate for **2,3,7,8-TCDD** are presented in Appendix B in Tables **B-1** through B-5. These are as follows:

1. The Dow (1978) **diet** study on Sprague-Dawley rats, Spartan **substrain**. Significantly increased cancers in the males included stratified **squamous** cell carcinomas of the tongue and squamous cell carcinomas of the nasal **turbinates** and hard palate. Both the original pathological analysis (**Kociba**) and that of an Independent reviewer (Squire) are presented (Table B-1). Significant cancers in **the** females included **lung**, **nasal turbinate** and hard palate cancers, and **liver** tumors (Table B-2). As **with** the males, the total number of animals **with** at least one of these significant tumors was recorded.

2. The NCI gavage study in Osborne-Hendel rats and B6C3F1 mice.
  - a. 2,3,7,8-TCDD in male rats caused an increase in follicular cell adenomas and carcinomas combined of the thyroid. However, these tumors were not considered biologically significant for risk assessment purposes. In females, the combined neoplastic nodules and hepatocellular carcinomas were considered significant (Table B-3), and these data were used. The adrenal cortical adenomas or carcinomas were not considered biologically significant.
  - b. 2,3,7,8-TCDD in male mice caused an increase in hepatocellular carcinomas and in combined hepatocellular adenomas and carcinomas (Table B-4). In female mice, 2,3,7,8-TCDD caused an increase in subcutaneous tissue fibrosarcomas, lymphomas or leukemias of the hematopoietic system, liver hepatocellular carcinomas and adenomas, and thyroid follicular cell adenomas (Table B-5).

The above data have been fit by the linearized multistage model described in Section 11.3.2. These results are presented in Appendix B in some detail in Tables B-6 through B-12, and summarized in Table B-13. The results of all estimates are within an order of magnitude, with the upper-limit estimates lowest for the Dow male rats, higher for the NCI study, both rats and mice, and highest for the combined tumor sites of the female rats in the Dow study. The data from which the steepest slope factor ( $q_1^*$ ) (i.e., greatest potency) was calculated were from the Squire review of the slides. A summary of Squire's review is presented in Table B-2 and the results of the linearized multistage model extrapolation procedure are presented in Table B-9. An examination of Table B-9 shows that the high-dose group in the study was eliminated because its inclusion resulted in a poor fit of the model ( $p < 0.01$ ). A second analysis of the female rat data adjusted for early increased mortality in the high-dose group by eliminating all animals that died during the first year, so that the first tumors considered were those detected during the 13th month of the study. The results of the analysis from this adjustment are presented in Tables B-8A and B-9A.



The **results** yield acceptable **fits** of the data without dropping the responses at the highest dose levels, and these results were chosen for the **final** Incremental **unit risk** estimates. The **slope** estimates for the **Kociba** (Table B-8A) and **Squire** (Table B-9A) analyses,  $1.51 \times 10^5$  and  $1.61 \times 10^5$   $(\text{mg/kg/day})^{-1}$ , were averaged by taking the geometric mean, and the final estimate thus becomes

$$q_1^* = [(1.51 \times 10^5) \times (1.61 \times 10^5)]^{1/2} = 1.56 \times 10^5 \text{ (mg/kg/day)}^{-1}.$$

**This** estimate is about one-third that derived from the Squire review in Table B-8.

**This** upper-limit estimate represents a range of uncertainty that is related as much to the fitting procedure as to the model itself. The dropping of the highest dose-response data and the resulting increased 95% upper-limit slope estimate based on the Squire analysis can be defended on the basis that the highest dose data in **this bioassay** is 100 times that of the lowest, and would therefore contain very little information about the shape of the dose-response curve at low dose levels. It could **also** be argued on the basis of a saturation effect of either dose or response; the data can partially support either hypothesis. An adjustment of the multi-stage model needed to incorporate such an effect or effects, however, is felt to be unwarranted by the **sparsity** of the supporting evidence. As an alternative, to incorporate **this uncertainty**, a range of 95% upper-limit estimates of  $q_1^* = 9.0 \times 10^4$  to  $4.25 \times 10^5$   $(\text{mg/kg/day})^{-1}$  has been chosen to accommodate **this** unusual data set.

In order to estimate an **incremental unit risk** for a 1 **ng/l** concentration in drinking water, the following conversion is used:

$$1 \text{ } \mu\text{g/kg/day} \times 70 \text{ kg} \times 10^3 \text{ ng}/\mu\text{g} \times 1 \text{ day}/2 \text{ a} = 3.5 \times 10^4 \text{ ng/l}$$

based on human consumption of 2 l water/day for a lifetime. **Therefore,** the Incremental **unit risk** corresponding to 1 ng 2,3,7,8-TCDD/l water is

$$q_1^* = 1.56 \times 10^{-4} (\mu\text{g}/\text{kg}/\text{day})^{-1} \times \frac{1 \text{ ng}/\text{kg}/\text{day}}{3.5 \times 10^{-4} \text{ ng}/\text{l}} = 4.5 \times 10^{-3} (\text{ng}/\text{l})^{-1}$$

Similarly, the lower and upper limits of the range vary from  $q_1^* = 2.6 \times 10^{-3}$  to  $1.2 \times 10^{-2} (\text{ng}/\text{l})^{-1}$ .

**This** Incremental **unit risk** estimate from an oral study must be transformed before an estimate can be made from exposure to **2,3,7,8-TCDD** in the ambient **air**. Exposure **will** be assumed to occur only through respiration of **2,3,7,8-TCDD-contaminated particulates**. The amount of exposure depends on the **particulate size** distribution. Based on the report of the International Commission on Radiological Protection (**ICRP**, 1959), it can be assumed that **100%** of **particulates** of <0.1 micron in **size** pass the nasopharyngeal (upper respiratory **tract**) barrier and are deposited on the tracheobronchial and alveolar passages. For the larger-sized particles, the percentage deposition of **5-micron** particles in the lower respiratory tract is not more than **30%**. Even those larger **particles** retained by the upper respiratory tract, however, may be swallowed and eventually absorbed by **ingestion**. In the absence of specific data on the **size** distribution and eventual fate of the particles, the information developed by the ICRP, Committee 2, **will** be used. The Committee developed the **following** estimates for retention of particulate matter in the lungs. For compounds not readily soluble, 25% **will** be exhaled, 50% **will** be deposited in the upper respiratory passages and subsequently swallowed, and the final 25% **will** be deposited in the lungs (lower respiratory passages). Of **this** final 25%, half is eliminated from the lungs and swallowed **in** the first 24 hours, making a total of 62.5% swallowed; the remaining 12.5% remains in the lung alveoli for long periods of **time**; eventually some are transferred to pulmonary lymph nodes.

If we take a worst-case estimate and assume that all of the swallowed material is eventually absorbed **into** the body, then **75%** of the **inhaled material** will be absorbed. We further assume a breathing rate of 20 **m<sup>3</sup>/day** for a 70 kg man. Given these assumptions and the fact that one **picogram** is equal to **10<sup>-9</sup> mg**, the lifetime cancer **risk** for an ambient concentration of **1 pg/m<sup>3</sup>** of **2,3,7,8-TCDD** is **3.3 x 10<sup>-5</sup>**, as calculated **below**:

$$q_1^*(\text{resp.}) = 1.56 \times 10^5 \text{ (mg/kg/day)}^{-1} \times 1 \times 10^{-9} \text{ mg/pg} \times .75 \times 20 \text{ m}^3/70 \text{ kg}$$

or

$$q_1^*(\text{resp.}) = 3.3 \times 10^{-5} \text{ (pg/m}^3\text{)}^{-1}.$$

Similarly, the range of estimates is **1.9 x 10<sup>-5</sup>** to **9.1 x 10<sup>-5</sup> (pg/m<sup>3</sup>)<sup>-1</sup>**.

11.3.8. Incremental **Unit Risk** Estimate for HxCDDs (1,2,3,6,7,8 and 1,2,3,7,8,9) **Via** the Oral and Inhalation Routes. The results of the National Toxicology Program (NTP) gavage study on a mixture of 1,2,3,6,7,8- and **1,2,3,7,8,9-HxCDD** showed positive results for male and female rats (combined liver **neoplastic nodules** or hepatocellular carcinomas), the greater response being **in** the females. In the females, carcinomas appeared only **in** the high-dose group. In the male rats, there was also a definite trend in neoplastic nodules and carcinomas combined, but **this** was only marginally significant. These results are presented **in** Table 11-35, which includes the recent NTP **reevaluation** of the **female** rat **liver** slides. The review shows responses in the range of 5054 less than that of the original analysis. The responses for neoplastic nodules and combined nodules and carcinomas are **still** statistically significant. These results have been **detailed** in the **qualitative** section of **this** document.

TABLE 11-35

NTP HxCDD (Gavage) **Bioassay (NTP, 1980d)**  
 Osborne-Nendel Rats (2 years)  
 Incidences of **Neoplastic** Nodules and Hepatocellular Carcinomas

| Tumor   | Vehicle Control | Untreated Control | $\mu\text{g/kg/week}$ |                 |                          | Estimates <sup>a</sup><br>of $q_1^*$<br>( $\mu\text{g/kg/day}$ ) <sup>-1</sup> |
|---|-----------------|-------------------|-----------------------|-----------------|--------------------------|--|
|   |                 |                   | Low-Dose<br>1.25      | Mid-Dose<br>2.5 | High-Dose<br>5           |  |
| <b>MALE (700 g)<sup>b</sup></b>               |                 |                   |                       |                 |                          |  |
| Number of animals examined                    | 74              | 75                | 49                    | 50              | 48                       | —  |
| Hepatocellular carcinoma (HC)                 | 0               | 0                 | 0                     | 0               | 1(2%)                    | —  |
| Neoplastic nodule (NN)                        | 0               | 2(3%)             | 0                     | 1(2%)           | 3(6%)                    | $5.6 \times 10^{-1}$   |
| HC + NN combined                              | 0               | 2(3%)             | 0                     | 1(2%)           | <b>4(8%)<sup>c</sup></b> | $5.9 \times 10^{-1}$   |
| Human equivalent dose<br>$\mu\text{g/kg/day}$ | 0               | 0                 | 0.04                  | 0.08            | 0.15                     | --   |

11-120

TABLE 11-35 (cont.)

| Tumor   | Vehicle Control | Untreated Control | $\mu\text{g}/\text{kg}/\text{week}$ |                     |                      | Estimates <sup>a</sup><br>of $q_1^*$<br>( $\mu\text{g}/\text{kg}/\text{day}$ ) <sup>-1</sup> |
|---|-----------------|-------------------|-------------------------------------|---------------------|----------------------|--|
|   |                 |                   | Low-Dose<br>1.25                    | Mid-Dose<br>2.5     | High-Dose<br>5       |  |
| FEMALE (450 g) <sup>d</sup>                                 |                 |                   |                                     |                     |                      |  |
| Number of animals examined                                  | 75              | 73                | 50                                  | 50                  | 50                   | --   |
| Hepatocellular carcinoma (HC)                               | 0               | 0                 | 0                                   | 0                   | 2(4%)                | $3.2 \times 10^{-1}$   |
| <b>Neoplastic</b> nodule (NN)                               | 2(3X)           | 1(1%)             | 5(10%)                              | 7(14%) <sup>c</sup> | 16(32%) <sup>e</sup> | 3.3  |
| HC + NN combined  | 2(3X)           | 1(1%)             | 5(10%)                              | 7(14%) <sup>c</sup> | 18(36%) <sup>e</sup> | 3.5  |
| Human equivalent dose<br>$\mu\text{g}/\text{kg}/\text{day}$ | 0               | 0                 | 0.03                                | 0.06                | 0.12                 | --   |

<sup>a</sup>95% upper-limit estimate of linear term in the multistage model based on human equivalent dosages using surface area correction.

<sup>b</sup>Analysis by NTP (1980d)

<sup>c</sup> $p < 0.05$  versus vehicle-control

<sup>d</sup>Reevaluation by Hildebrandt (1983)

<sup>e</sup> $p < 0.001$  versus vehicle-control

In **female mice**, there was a **dose-related** trend in **hepatocellular carcinomas**, but only the combined adenomas and carcinomas were significant. In male **mice**, there was a minor trend in **hepatocellular** adenomas, but no increase, statistical or otherwise, in hepatocellular carcinomas (Table 11-36).

**Although** no statistically significant increase in carcinomas occurred in **mice** or rats of either sex, when **neoplastic** nodules in the rats and hepatocellular adenomas in the **mice** were included in the data, the results became significant for **all** groups. These combined results were then fitted to the **multistage** model for **all** four groups. As shown in Tables 11-35 and 11-36, the 95% upper-limit **unit risk** estimates are as follows:

|              |  |
|--------------|--|
| Rat - male   | $q_1^* = 0.59 (\mu\text{g/kg/day})^{-1}$ |
| female       | $q_1^* = 3.5 (\mu\text{g/kg/day})^{-1}$  |
| Mouse - male | $q_1^* = 11.0 (\mu\text{g/kg/day})^{-1}$ |
| female       | $q_1^* = 2.9 (\mu\text{g/kg/day})^{-1}$  |

The usual CAG procedure is to use the most sensitive **sex-species** for estimating the **95%** upper-limit **unit risk**. Under that procedure, which is based on the linearized multistage **model with** surface area correction for animal-to-man extrapolation, the male mouse data base yielding a  $q_1^* = 11.0 (\mu\text{g/kg/day})^{-1}$  would be **selected** to provide the upper limit estimate of potency. However, as examination of Tables 11-35 and 11-36 show, there are **several** reasons to **give** weight to the female rat data base also. These are as follows: 1) low spontaneous (control) rates in the rat vs. the male mouse liver; 2) statistically significant increases in both the **mid** and **high level** dose groups vs. **control** for the female rat; the male mouse response was significant only at the **high** dose; 3) a more distinct dose response trend in the female rat vs. the male mouse; and 4) the only **hepatocellular** carcinomas in the female rat were in the **high** dose group. There were none in 148 control animals. By comparison, the male mouse showed no clear trend in carcinomas.

TABLE 11-36

NTP HxCDD (Gavage) **Bioassay (NTP, 1980d)**  
 B6C3F1 **Mice (104 weeks)**  
 Incidences of Adenomas and Hepatocellular Carcinomas

| Tumor   | Vehicle Control | Untreated Control | <u><math>\mu\text{g}/\text{kg}/\text{week}</math></u> |                 |                            | Estimates of $q_1^{*a}$<br>( $\mu\text{g}/\text{kg}/\text{day}$ ) <sup>-1</sup> |
|---|-----------------|-------------------|---|-----------------|----------------------------|---|
|   |                 |                   | Low-Dose<br>1.25                                      | Mid-Dose<br>2.5 | High-Dose<br>5             |   |
|   |                 |                   | HALES   |                 |                            |   |
| Number of animals examined  | 73              | 75                | 50  | 49              | 48                         | —   |
| Hepatocellular carcinoma<br>(HC)                                      | <b>8(11%)</b>   | <b>12(16%)</b>    | 9(18%)  | 5(10%)          | 9(19%)                     | 3.71  |
| Hepatocellular adenoma<br>(HA)  | <b>7(10%)</b>   | <b>15(20%)</b>    | 5(10%)  | 9(18%)          | <b>15(31%)<sup>b</sup></b> | 6.99  |
| Combined HA and HC  | <b>15(21%)</b>  | <b>27(36%)</b>    | 14(29%)   | 14(29%)         | <b>24(50%)<sup>c</sup></b> | 11.00   |
| Human equivalent dally<br>dose ( $\mu\text{g}/\text{kg}/\text{day}$ ) | 0               | 0                 | 0.014   | 0.027           | 0.054                      | --  |

11-123

TABLE 11-36 (cont.)

| Tumor  | Vehicle Control | Untreated Control | $\mu\text{g}/\text{kg}/\text{week}$ |                 |                            | Estimates of $q_1^{*a}$<br>( $\mu\text{g}/\text{kg}/\text{day}$ ) <sup>-1</sup> |
|--|-----------------|-------------------|-------------------------------------|-----------------|----------------------------|---|
|  |                 |                   | Low-Dose<br>2.5                     | Mid-Dose<br>5.0 | High-Dose<br>10.0          |   |
| FEMALES  |                 |                   |                                     |                 |                            |   |
| Number of animals examined   | 73              | 74                | 48                                  | 47              | 47                         | --  |
| Hepatocellular carcinoma (HC)                                      | <b>1(1%)</b>    | 0                 | 0                                   | <b>2(4%)</b>    | <b>2(4%)</b>               | <b><math>9.5 \times 10^{-1}</math></b>  |
| Hepatocellular adenoma (HA)  | 2(3%)           | <b>2(3%)</b>      | 4(8X)                               | <b>4(9%)</b>    | <b>9(19%)<sup>b</sup></b>  | 2.61  |
| Combined HA and HC   | <b>3(4%)</b>    | <b>2(3%)</b>      | <b>4(8%)</b>                        | <b>6(13%)</b>   | <b>10(23%)<sup>b</sup></b> | 2.94  |
| Human equivalent dally dose ( $\mu\text{g}/\text{kg}/\text{day}$ ) | 0               | 0                 | 0.027                               | 0.054           | 0.107                      | --  |

<sup>a</sup>95% upper-limit estimate of linear term ln the multistage model based on human equivalent dosages using surface area correction.

<sup>b</sup> $p < 0.01$  versus vehicle-control

<sup>c</sup> $p < 0.001$



In addition to the above reasoning, we point to the uncertainty of the surface area correction. Nearly all the quantitative Increase **in** the estimate of the 95% upper **limit risk** of the male mouse vs. the female rat (11.0/3.5 = 3.1) can be attributed to the surface area correction **in** the **extrapolation procedure**, which is greater for **mice** than for rats by a factor of 2.5. The surface area correction is an assumption used in the HxCDD analysis but neither supported nor contradicted by data.

Finally, for 2,3,7,8-TCDD, the female rat (different strain) has been shown to be more sensitive than the mouse even **with** the surface area correction.

Based on the above **qualifications**, the CAG has decided to modify the procedure slightly and to take the geometric mean of the **95% upper-limit** estimates from the male mouse and the female rat. The final estimate is

$$q_1 = (3.5 \times 11.0)^{1/2} = 6.2 \text{ } (\mu\text{g/kg/day})^{-1}$$

In terms of exposure to 1  $\mu\text{g/l}$  of HxCDD contaminant and 2 l/day for a lifetime, we use the same assumptions as **with 2,3,7,8-TCDD**:

$$1 \text{ } \mu\text{g/kg/day} = 3.5 \times 10^4 \text{ ng/l.}$$

Thus, for 1  $\text{ng/l}$  in the drinking water the estimate of Incremental **risk** is

$$P = 1 - e^{-6.2/3.5 \times 10^{-4}} = 1.8 \times 10^{-4}$$

In terms of continuous lifetime exposure to ambient **air** containing 1  $\text{pg/m}^3$  HxCDD, the transformation as was done before **with 2,3,7,8-TCDD**, is

$$q_1^*(\text{HxCDD}) \text{ (resp.)} = 6.2 \times 10^3 \text{ (mg/kg/day)}^{-1} \times 1 \times 10^{-9} \text{ mg/pg} \times 0.75 \times 20 \text{ m}^3/70 \text{ kg}$$

$$q_1^*(\text{HxCDD}) \text{ (resp.)} = 1.3 \times 10^{-6} \text{ (pg/m}^3\text{)}^{-1}.$$

**11.3.9. Relative Potency.** One of the uses of **unit risk** is to compare the relative potencies of carcinogens. Potency is defined for **this** purpose as the linear portion of the dose-response **curve**, which was used to calculate the **unit risk** factors. To estimate the relative potency on a **per-mole**

basis, the **unit risk** slope factor is multiplied by the molecular **weight**, and the resulting number is expressed in terms of  $(\text{mMol/kg/day})^{-1}$ . This is called the "**relative** potency Index."

Figure 11-2 is a histogram representing the frequency distribution of potency Indices of 55 chemicals evaluated by the CAG as suspect carcinogens. The actual data summarized by the histogram are presented in Table 11-37. Where human data are available for a **compound**, they have been used to calculate the Index. When no human data are available, animal oral studies have been used in preference to animal Inhalation studies, since animal oral studies have been conducted on the majority of these chemicals; **this** allows potency comparisons by route.

The potency Index for **2,3,7,8-TCDD** based on **liver**, lung and nasal **turbinate** and hard palate tumors in the female rat in the Dow 2,3,7,8-TCDD feeding study (**Kociba et al. (1978a)**) is  $5 \times 10^7 (\text{mMol/kg/day})^{-1}$ . This number is derived by multiplying as follows: the 95% upper-limit slope estimate from the Dow study using the geometric mean of the Squire and Kodba analyses,  $q_1^* = 1.56 \times 10^5 (\text{mg/kg/day})^{-1}$ , by the **molecular** weight of 322. Rounding off to the nearest order of magnitude gives a **log** 10 value of 8, which is the scale presented on the horizontal **axis** of Figure 11-2. The Index of  $5 \times 10^7$  is the most potent of 55 chemicals that the CAG has evaluated as suspect carcinogens. It is 50 times more potent than the third most potent chemical, **bis(chloromethyl)** ether, and 50,000,000 times as potent as vinyl chloride. The potency Index of HxCDD, based on combined **hepatocellular** adenomas and carcinomas in male **mice** in the NTP gavage study (NTP, 1980d), and combined nodules and hepatocellular carcinomas in female rats by gavage (NTP, 1980d) is  $2.4 \times 10^{+6} (\text{mMol/kg/day})^{-1}$ . This is derived by





FIGURE 11-2

Histogram Representing the Frequency **Distribution** of the Potency Indices of 55 Suspect Carcinogens Evaluated by the Carcinogen Assessment Group

TABLE 11-37

Relative **Carcinogenic** Potencies Among **SS Chemicals** Evaluated by the Carcinogen **Assessment** Group as Suspect **Human** Carcinogens

| Compounds                        | CAS Number       | Level of Evidence <sup>a</sup> |         | Grouping<br>Based on<br>IARC<br>Criteria | Slope <sup>b</sup><br>(mg/kg/day) <sup>-1</sup> | Molecular<br>Weight | Potency<br>Index <sup>c</sup> | Order of<br>Magnitude<br>(log <sub>10</sub> index) |
|----------------------------------|------------------|--------------------------------|---------|--|---|---------------------|-------------------------------|--|
|                                  |                  | Humans                         | Animals |  |   |                     |                               |  |
| <b>Acrylonitrile</b>             | 107-13-1         | L                              | S       | 2A                                       | 0.24 (W)  | 53.1                | 1x10 <sup>+1</sup>            | +1   |
| <b>Aflatoxin B<sub>1</sub></b>   | <b>1162-65-8</b> | L                              | S       | 2A                                       | 2900  | 312.3               | 9x10 <sup>+5</sup>            | +6   |
| <b>Aldrin</b>                    | 309-00-2         | I                              | L       | 3  | 11.4  | 369.4               | 4x10 <sup>+3</sup>            | +4   |
| <b>Allyl chloride</b>            | <b>107-05-1</b>  |                                |         |  | <b>1.19x10<sup>-2</sup></b>                     | 76.5                | 9x10 <sup>-1</sup>            | 0  |
| Arsenic                          | <b>7440-38-2</b> | S                              | I       | 1  | 15 (H)  | 149.8               | 2x10 <sup>+3</sup>            | +3   |
| B[a]P                            | 50-32-8          | I                              | S       | 2B                                       | 11.5  | <b>252.3</b>        | 3x10 <sup>+3</sup>            | +3   |
| Benzene                          | <b>71-43-2</b>   | S                              | S       | 1  | <b>2.9x10<sup>-2</sup></b> (U)                  | 78                  | 2x10 <sup>0</sup>             | 0  |
| <b>Benzidene</b>                 | 92-87-5          | S                              | S       | 1  | 234 (H)   | 184.2               | 4x10 <sup>+4</sup>            | +5   |
| Beryllium                        | 7440-41-7        | L                              | S       | 2A                                       | <b>2.6</b> (U)                                  | 9                   | 2x10 <sup>+1</sup>            | +1   |
| <b>1,3-Butadiene</b>             | 106-99-0         | 1                              | S       | <b>2B</b>                                | <b>1.0x10<sup>-1</sup></b> (I)                  | 54.1                | 5x10 <sup>0</sup>             | +1   |
| Cadmium                          | <b>7440-43-9</b> | L                              | S       | 2A                                       | 6.1 (H)   | 112.4               | 7x10 <sup>+2</sup>            | +3   |
| Carbon tetrachloride             | <b>56-23-5</b>   | 1                              | S       | 2B                                       | <b>1.30x10<sup>-1</sup></b>                     | 153.8               | 2x10 <sup>+1</sup>            | +1   |
| <b>Chlordane</b>                 | 57-74-9          | 1                              | L       | 3  | 1.61  | 409.8               | 7x10 <sup>+2</sup>            | +3   |
| Chlorinated ethanes              |                  |                                |         |  |   |                     |                               |  |
| <b>1,2-Dichloroethane</b>        | 107-06-2         | I                              | S       | 2B                                       | <b>9.2x10<sup>-2</sup></b>                      | 98.9                | 9x10 <sup>0</sup>             | +1   |
| <b>Hexachloroethane</b>          | 67-72-1          | I                              | L       | 3  | <b>1.42x10<sup>-2</sup></b>                     | 236.7               | 3x10 <sup>0</sup>             | 0  |
| <b>1,1,2,2-Tetrachloroethane</b> | 79-34-5          | I                              | L       | 3  | 0.20  | 167.9               | 3x10 <sup>+1</sup>            | +1   |
| <b>1,1,2-Trichloroethane</b>     | 79-00-5          | I                              | L       | 3  | <b>5.73x10<sup>-2</sup></b>                     | 133.4               | 8x10 <sup>0</sup>             | +1   |
| Chloroform                       | 67-66-3          | 1                              | S       | 2B                                       | <b>8.1x10<sup>-2</sup></b>                      | 119.4               | 1x10 <sup>+1</sup>            | +1   |
| Chromium VI                      | 7440-47-3        | S                              | S       | 1  | 41 (W)  | 100                 | 4x10 <sup>+3</sup>            | f4   |
| DDT                              | 50-29-3          | I                              | S       | 2B                                       | 0.34  | 354.5               | 1x10 <sup>+2</sup>            | +2   |
| <b>Dichlorobenzidine</b>         | 91-94-1          | I                              | S       | 2B                                       | 1.69  | <b>253.1</b>        | 4x10 <sup>+2</sup>            | +3   |

11-128

TABLE 11-37 (cont.)

| Compounds  | CAS Number      | Level of Evidence <sup>a</sup> |         | Grouping Based on IARC Criteria | Slope <sup>b</sup> (mg/kg/day) <sup>-1</sup> | Molecular Weight | Potency Index <sup>c</sup> | Order of Magnitude (log <sub>10</sub> index) |
|--|-----------------|--------------------------------|---------|---------------------------------|--|------------------|----------------------------|--|
|  |                 | Humans                         | Animals |                                 |  |                  |                            |  |
| <b>1,1-Dichloroethylene</b><br>(Vinylidene chloride)               | 75-35-4         | I                              | L       | 3                               | <b>1.16</b> (I)                              | 97               | 1x10 <sup>+2</sup>         | <b>+2</b>                                    |
| <b>Dichloromethane</b><br>(Methylene chloride)                     | 75-09-2         | 1                              | S       | <b>2B</b>                       | <b>1.4x10<sup>-2</sup></b> (I)               | 84.9             | 1x10 <sup>0</sup>          | 0  |
| <b>Dieldrin</b>  | 60-57-1         | I                              | S       | 2B                              | 30.4   | 380.9            | <b>1x10<sup>+4</sup></b>   | <b>+4</b>                                    |
| <b>2,4-Dinitrotoluene</b>  | 121-14-2        | I                              | S       | 2B                              | 0.31   | 182              | <b>6x10<sup>+1</sup></b>   | <b>+2</b>                                    |
| <b>Diphenylhydrazine</b>   | <b>122-66-7</b> | I                              | S       | 2B                              | 0.77   | 180              | <b>1x10<sup>+2</sup></b>   | <b>+2</b>                                    |
| <b>Epichlorohydrin</b>   | 106-89-8        | I                              | S       | 2B                              | <b>9.9x10<sup>-2</sup></b>                   | 92.5             | <b>9x10<sup>-1</sup></b>   | 0  |
| <b>Bis(2-chloroethyl)ether</b>                                     | 111-44-4        | I                              | S       | 2B                              | <b>1.14</b>                                  | 143              | <b>2x10<sup>+2</sup></b>   | +2   |
| <b>Bis(chloromethyl) ether</b>                                     | 542-88-1        | S                              | S       | 1                               | 9300 (I)                                     | 115              | <b>1x10<sup>+6</sup></b>   | <b>+6</b>                                    |
| <b>Ethylene dibromide</b> (EDB)                                    | 106-93-4        | I                              | S       | 2B                              | 41   | 187.9            | <b>8x10<sup>+3</sup></b>   | <b>+4</b>                                    |
| <b>Ethylene oxide</b>  | <b>75-21-8</b>  | L                              | S       | 2A                              | <b>3.5x10<sup>-1</sup></b> (I)               | 44.1             | 2x10 <sup>+1</sup>         | <b>+1</b>                                    |
| <b>Heptachlor</b>  | <b>76-44-8</b>  | I                              | S       | 2B                              | 3.37   | 373.3            | 1x10 <sup>+3</sup>         | <b>+3</b>                                    |
| <b>Hexachlorobenzene</b>   | 118-74-1        | I                              | S       | 2B                              | 1.67   | 284.4            | <b>5x10<sup>+2</sup></b>   | <b>+3</b>                                    |
| <b>Hexachlorobutadiene</b>   | 87-68-3         | I                              | L       | 3                               | <b>7.75x10<sup>-2</sup></b>                  | 261              | <b>2x10<sup>+1</sup></b>   | <b>+1</b>                                    |
| <b>Hexachlorocyclohexane</b><br>technical grade                    |                 |                                |         |                                 | 4.75   | 290.9            | <b>1x10<sup>+3</sup></b>   | <b>+3</b>                                    |
| alpha isomer   | 319-84-6        | 1                              | S       | 2B                              | 11.12  | 290.9            | <b>3x10<sup>+3</sup></b>   | <b>+3</b>                                    |
| beta isomer  | 319-85-7        | I                              | L       | 3                               | 1.84   | 290.9            | 5x10 <sup>+2</sup>         | 0  |
| gamma isomer   | 58-89-9         | 1                              | L       | 3                               | 1.33   | 290.9            | 4x10 <sup>+2</sup>         | <b>+3</b>                                    |
| <b>Hexachlorodibenzodioxin</b><br>1,2,3,6,7,8- and<br>1,2,3,7,8,9- | 34465-46-8      | 1                              | S       | 2B                              | <b>6.2x10<sup>+3</sup></b>                   | 391              | <b>2x10<sup>+6</sup></b>   | +6   |
| <b>Nickel refinery dust</b>  |                 | S                              | S       | 1                               | 1.05 (W)                                     | <b>240.2</b>     | 2.5x10 <sup>+2</sup>       | <b>+2</b>                                    |
| <b>Nickel subsulfide</b>   | 0120-35-722     | S                              | S       | 1                               | 2.1 (W)                                      | <b>240.2</b>     | 5.0x10 <sup>+2</sup>       | <b>+3</b>                                    |

TABLE 11-37 (cont.)

| Compounds                                  | CAS Number | Level of Evidence <sup>a</sup> |         | Grouping<br>Based on<br>IARC<br>Criteria | Slope <sup>b</sup><br>(mg/kg/day) <sup>-1</sup> | Molecular<br>Weight | Potency<br>Index <sup>c</sup> | Order of<br>Magnitude<br>(log <sub>10</sub> Index) |
|--|------------|--------------------------------|---------|--|---|---------------------|-------------------------------|--|
|  |            | Humans                         | Animals |  |   |                     |                               |  |
| <b>Nitrosamines</b>                        |            |                                |         |  |   |                     |                               |  |
| Dimethylnitrosamine                        | 62-75-9    | I                              | S       | 2B                                       | 25.9 (not by q1*)                               | 74.1                | 2x10 <sup>+3</sup>            | +3   |
| Diethylnitrosamine                         | 55-18-5    | I                              | S       | 2B                                       | 43.5 (not by q1*)                               | 102.1               | 4x10 <sup>+3</sup>            | +4   |
| Dibutylnitrosamine                         | 924-16-3   | I                              | S       | 2B                                       | 5.43  | 158.2               | 9x10 <sup>+2</sup>            | +3   |
| N-nitrosopyrrolidine                       | 930-55-2   | I                              | S       | 2B                                       | 2.13  | 100.2               | 2x10 <sup>+2</sup>            | +2   |
| N-nitroso-N-ethylurea                      | 759-73-9   | I                              | S       | 2B                                       | 32.9  | 117.1               | 4x10 <sup>+3</sup>            | +4   |
| N-nitroso-N-methylurea                     | 684-93-5   | I                              | S       | 2B                                       | 302.6   | 103.1               | 3x10 <sup>+4</sup>            | +4   |
| N-nitroso-diphenylamine                    | 86-30-6    | I                              | S       | 2B                                       | 4.92x10 <sup>-3</sup>                           | 198                 | 1x10 <sup>0</sup>             | 0  |
| PCBs                                       | 1336-36-3  | I                              | S       | 2B                                       | 4.34  | 324                 | 1x10 <sup>+3</sup>            | +3   |
| <b>Phenols</b>                             |            |                                |         |  |   |                     |                               |  |
| 2,4,6-Trichlorophenol                      | 88-06-2    | I                              | S       | 2B                                       | 1.99x10 <sup>-2</sup>                           | 197.4               | 4x10 <sup>0</sup>             | +1   |
| 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDO) | 1746-01-6  | I                              | S       | 2B                                       | 1.56x10 <sup>+5</sup>                           | 322                 | 5x10 <sup>+7</sup>            | +8   |
| Tetrachloroethylene                        | 127-18-4   | L                              | L       | 3  | 5.1x10 <sup>-2</sup>                            | 165.8               | 8x10 <sup>0</sup>             | +1   |
| Toxaphene                                  | 8001-35-2  | I                              | S       | 2B                                       | 1.13  | 414                 | 5x10 <sup>+2</sup>            | +3   |
| Trichloroethylene                          | 79-01-6    | I                              | L/S     | 3/2B                                     | 1.1x10 <sup>-2</sup>                            | 131.4               | 1x10 <sup>0</sup>             | 0  |
| Vinyl chloride                             | 75-01-4    | S                              | S       | 1  | 1.75x10 <sup>-2</sup> (I)                       | 62.5                | 1x10 <sup>0</sup>             | 0  |

<sup>a</sup>S = Sufficient evidence; L = Limited evidence; I = Inadequate evidence

<sup>b</sup>Animal slopes are 95X upper-bound slopes based on the linearized multistage model. They are calculated based on animal oral studies, except for those indicated by I (animal Inhalation), M (human occupational exposure) and H (human drinking water exposure). Human slopes are point estimates based on the linear nonthreshold model. Not all of the carcinogenic potencies presented in this table represent the same degree of certainty. All are subject to change as new evidence becomes available. The slope value is an upper bound in the sense that the true value (which is unknown) is not likely to exceed the upper bound and may be much lower, with a lower bound approaching zero. Thus, the use of the slope estimate in risk evaluations requires an appreciation for the implication of the upper bound concept as well as the "weight of evidence" for the likelihood that the substance is a human carcinogen.

<sup>c</sup>The potency Index is a rounded-off slope in (mmol/kg/day)<sup>-1</sup> and is calculated by multiplying the slopes in (mg/kg/day)<sup>-1</sup> by the molecular weight of the compound.

multiplying the mean **95%** upper-limit slope factor  $q_1^* = 6.2 \times 10^3$  (mg/kg/day)<sup>-1</sup> by the **molecular weight, 391**. **This** potency is about one-twentieth that of **2,3,7,8-TCDD**, making **it** the second most potent of 55 chemicals that the CAG has evaluated as suspect carcinogens.

The ranking of relative potency Indices is subject to the uncertainties involved in comparing a number of potency estimates for different chemicals based on varying routes of exposure **in** different **species**, using data from studies whose quality varies widely. Furthermore, all the Indices are based on estimates of **low-dose risk** using linear extrapolation from the observational range. These Indices are, therefore, not **valid** for the comparison of potencies in the experimental or observation range **if linearity** does not exist there. Nevertheless, the potency rankings of one and two for these **dioxins** cannot be easily dismissed.

#### 11.4. SUMMARY AND CONCLUSIONS

##### 11.4.1. Summary.

**11.4.1.1. QUALITATIVE ASSESSMENT OF 2,3,7,8-TCDD**—There are several chronic animal cancer **bioassay** studies of 2,3,7,8-TCDD: 1) a Dow Chemical Company (**Kociba et al.**, 1977, 1978a) study in male and **female** Sprague-Dawley (Spartan **substrain**) rats; 2) the Van Miller et al. (1977a,b) study **in** male Sprague-Dawley rats; 3) the Toth et al. (1979) study in Swiss **mice**; 4) the National Toxicology Program (1980a,b) studies in rats and **mice**; 5) the **Pitot** et al. (1980) promotion study in rats; and 6) the **Kouri** et al. (1978) **cocarcinogenicity** study in **mice**.

The 1978 study by the Dow Chemical Company of male and female Sprague-Dawley rats fed 2,3,7,8-TCDD **in** doses of 22, 210 and 2200 ppt showed a highly statistically significant excess of hepatocellular carcinomas in female rats at the highest dose level and hepatocellular carcinomas and

**hepatocellular hyperplastic** nodules **in** female rats at both the middle and **high** dose levels, as compared **with** the controls. In **addition**, at the **high** dose there were significant Increases **in** carcinomas of the hard palate/nasal **turbinates** **in** both males and females, of the tongue **in** males, and of the lungs **in** females. The Van Miller et al. (1977a,b) study **also** showed some evidence of a carcinogenic response **in** the liver and lungs of male Sprague-Dawley rats at dosages of 1000 and 5000 ppt **in** the **diet**, even though the study used a relatively small number of animals. The Toth et al. (1979) study provides suggestive evidence that **2,3,7,8-TCDD** Induced an Increased Incidence of liver tumors **in** male **mice** (females were not tested) receiving 0.7 **µg/kg/week** by gavage.

In the National Cancer Institute rat study (NTP, 1980a), male and female Osborne-Mendel rats were administered **2,3,7,8-TCDD** by gavage at three dose levels: 0.01, 0.05 and 0.5 yg/kg/week. **2,3,7,8-TCDD** Induced statistically significant Increases of hepatocellular carcinomas, subcutaneous fibrosarcomas and adrenal cortical adenomas **in** high-dose female rats. 2,3,7,8-TCDD also Induced significant Increases of thyroid tumors **in** male rats at all dose levels.

In a companion mouse study by the National Cancer Institute (NTP, 1980a), male and female B6C3F1 **mice** were given 2,3,7,8-TCDD by gavage at dose levels of 0.01, 0.05 and 0.5 yg/kg/week for males and 0.04, 0.2 and 2.0 **µg/kg/week** for **females**. 2,3,7,8-TCDD Induced statistically significant Increases of hepatocellular carcinomas **in** the high-dose males and females, and thyroid tumors, subcutaneous fibrosarcomas and **histiocytic lymphomas in** females.

In the study by **Pitot** et al. (1980), 2,3,7,8-TCDD has been shown to be a potent liver cancer promoter after Initiation **with** dlethylnitrosamine.



Several tests of 2,3,7,8-TCDD as a promoter on mouse **skin** were negative, but Poland et al. (1982) showed that 2,3,7,8-TCDD can promote **in** one mouse strain. In the study by Kouri et al. (1978), 2,3,7,8-TCDD has been shown to be a potent cocarcinogen **with** 3-methyl chloranthrene.

2,3,7,8-TCDD is a potent **inducer** of arylhydrocarbon hydroxylase (AHH) in mammals. The AHH contains enzyme **epoxidase** that is known to mediate the formation of **epoxides**, that are **potentially** active carcinogenic metabolites. 2,3,7,8-TCDD may be metabolized **in** mammalian species by the reactive **epoxide** intermediate to **dihydrodiol** and further **conjugated**. 2,3,7,8-TCDD was found in liver and fat at the end of the 2-year rat feeding study. Significant covalent binding of 2,3,7,8-TCDD (<sup>14</sup>C or tritium) derived radioactivity **with** protein has been demonstrated. Covalent binding of 2,3,7,8-TCDD (<sup>14</sup>C or tritium) derived radioactivity **with** DNA is not significant in liver cells.

Currently available studies on the **mutagenicity** of **2,3,7,8-TCDD** are inconclusive. Two bacterial systems, **Escherichia coli** and **S. typhimurium** (without metabolic activation), exhibited positive **mutagenic** activity. However, in another study of **S. typhimurium** (**with** and without **metabolic** activation), the results were negative.

Several **epidemiological** studies have been conducted that are relevant to the **carcinogenicity** assessment of 2,3,7,8-TCDD. Two Swedish epidemiologic case-control studies (Hardell and Sandstrom, 1979; Eriksson et al., 1979, 1981) reported a significant association between STSs and occupational exposure to phenoxyacetic acid herbicides and/or **chlorophenols** that contain 2,3,7,8-TCDD as an impurity. These studies indicated **~5-fold** to 7-fold increases in the **risk** of developing soft-tissue sarcomas among people exposed **only** to phenoxyacetic acids and/or chlorophenols in comparison **with** people not exposed to these chemicals. The associations are **high** enough to

make it unlikely that they have resulted entirely from random variation **bias** or confounding, although the possibility exists that recall **bias** may account for a **small** part of the excess; but not enough to account for the excessively **high** risks. When an attempt was made to separate exposures **into** two categories based on expected presence or absence of **polychlorinated dibenzo-p-dioxin** Impurities, the relative risks were 17 and 4.2, respectively. **This** Indicates that agents themselves, without the **dioxin** Impurities, may be contributing to the **risk** of STSs as well. The nonpositive studies that seemingly do not support the finding of an elevated **risk** of cancer, specifically STS, suffer from a variety of methodological problems that **will** make such a **risk** Impossible to detect **in** some and difficult to detect **in** others. Several of these require many more years of follow-up before a significant elevated **risk** of the relatively rare STS is found. Within **this** group of **nonpositive** studies are several where evidence of exposure to **2,3,7,8-TCDD** is questionable at best and as such no elevated **risk** of STS **will** ever be found. On the other hand, several small-scale cohort studies **with** proven evidence of exposure to chemicals containing **2,3,7,8-TCDD** have produced a small number of the relatively rare STS that certainly would not have been expected at the **time**. However, several epidemiologic studies are now **in** progress, the results of which are not yet available, that **will** provide additional epidemiologic evidence that may influence our conclusions at a later **time**. Another Swedish case-control study (Harden et al., 1980, 1981) provides suggestive evidence of an increased **risk** of developing lymphomas resulting from occupational exposure to phenoxyacetic acids.

Two cohort studies, one by Axelson et al. (1980) and the other by **Thiess** and **Frentzel-Beyme** (1978) provide suggestive evidence that phenoxyacetic acids and/or 2,3,7,8-TCDD increase the **risk** of stomach cancer **in** humans.

Four other cohort studies by Ott et al. (1980), Riihimaki et al. (1978), Cbok et al. (1980) and Zack and Suskind (1980) Indicated no significantly Increased risk of stomach cancer in people exposed to phenoxyacetic acids and/or chlorophenols, but two of these studies were of relatively low statistical power, and another study has certain inconsistencies requiring clarification.

11.4.1.2. QUALITATIVE ASSESSMENT OF HxCDD -- Hexachlorodibenzo-p-dioxin has been tested for carcinogenicity in rats and mice by gavage (NTP, 1980d) and by dermal application to mice (NTP, 1980b,c). In these studies, a 1:2 mixture of 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDD was tested. In the oral study, animals received HxCDD at doses of 0.0, 1.25, 2.5 or 5.0 µg/kg/week, except for female mice, which received 0.0, 2.5, 5.0 and 10.0 µg/kg/week. In both species and both sexes, only tumors of the liver occurred at a significantly greater incidence than in controls. In male rats and male and female mice, the liver tumor incidence was significantly increased over control values only in the high-dose groups, while in female rats the incidence was significantly greater at both the medium- and high-dose levels. At the request of EPA this study was audited during May-August 1985 by several scientists as to the pathologic evaluation and conduct of the study. The scientists have reconfirmed the NTP conclusions that the study provides carcinogenic evidence in both rats and mice. In the study of HxCDD carcinogenicity in mouse skin conducted by NTP (1980c), there were no treatment-related tumors in either the carcinogenicity bioassay or the tumor promotion assay using DMBA as an Initiator. There are no available epidemiologic carcinogenicity studies in the published literature for HxCDD as the sole compound of concern. The mutagenic potential for HxCDD is unknown since no tests are reported in the available literature.

**11.4.1.3. QUANTITATIVE ASSESSMENT OF 2,3,7,8-TCDD AND HxCDD** - Quantitative estimates of the potential carcinogenic impact on humans, due to both oral and Inhalation exposure to both **2,3,7,8-TCDD** and HxCDD, have been calculated. These estimates are **all** based on **animal-to-human** extrapolation procedures. The animal gavage and feeding studies provide the only data base for estimating the carcinogenic potency (**unit risk**) for **2,3,7,8-TCDD** and HxCDD. While the epidemiology studies provide positive, although limited, evidence for **carcinogenicity**, the population exposures are unknown and the findings cannot be attributed to exposure to 2,3,7,8-TCDD alone. Thus the Ingestion **unit** risks as well as the estimates for Inhalation **unit risk** are derived from the gavage and feeding studies.

There is insufficient metabolism and **pharmacokinetic** information to alter the typically used assumptions regarding dose extrapolation. The reported **intra-gastric** absorption for 2,3,7,8-TCDD in rats varies from **52-86%**; there are no absorption data for HxCDD. The assumptions used in both the TCDD and HxCDD **unit risk** estimates assume that human absorption by oral exposure **is** equal to that of the rat. Information regarding absorption by Inhalation is totally lacking and is assumed to be 75% based on an **ICRP** (1959) lung uptake model. The upper limit **unit** risks were calculated using a multistage extrapolation model that **is** linear at low doses as programmed in GLOBAL 79.

For cancer **risk** due to oral exposures, the upper-limit quantitative Incremental **unit risk** estimate is  $q_1^* = 1.56 \times 10^{-1} \text{ (ng/kg/day)}^{-1}$ , derived from the **Kociba et al. (1977, 1978a)** 2,3,7,8-TCDD feeding study in female rats that induced a statistically significant increased incidence of tumors in the **liver**, lungs, hard palate and nasal **turbinates**. Based on continuous lifetime exposure to 1 **ng/d** **2,3,7,8-TCDD** in drinking water, the

95% upper limit estimate of Individual Incremental cancer risk is  $4.5 \times 10^{-3}$  with a range of upper limit values of  $2.6 \times 10^{-3}$  to  $1.2 \times 10^{-2}$ , depending upon pathological Interpretation and mortality correction. Based on continuous lifetime exposure to 1  $\mu\text{g}/\text{m}^3$  2,3,7,8-TCDD in ambient air, the 95% upper-limit estimate of Individual Incremental cancer risk is  $3.3 \times 10^{-3}$ , with a range of upper-limit estimates of  $1.9 \times 10^{-3}$  to  $9.1 \times 10^{-3}$  depending upon pathologic Interpretation and mortality correction. Since the inhalation unit risk values are based upon the observed Incidence in the feeding study, an Implicit assumption is made that 2,3,7,8-TCDD is as potent by Inhalation as by ingestion exposure.

An upper-limit Incremental unit risk estimate for a mixture of HxCDDs has been calculated from the NCI gavage study (NTP, 1980d). Based on combined liver hepatocellular carcinomas and neoplastic nodules in female rats, and hepatocellular adenomas and carcinomas in male mice,  $q_1^* = 6.2 \times 10^{-3} (\text{ng}/\text{kg}/\text{day})^{-1}$ . A continuous lifetime exposure to 1  $\text{ng}/\text{L}$  of HxCDD in drinking water is estimated to result in an upper limit Incremental unit risk of  $1.8 \times 10^{-4}$ . Similarly, for ambient air, a continuous lifetime exposure to 1  $\mu\text{g}/\text{m}^3$  of HxCDD is estimated to yield an upper-limit unit risk of  $1.3 \times 10^{-6}$ .

The cancer potency of 2,3,7,8-TCDD as represented by a potency Index is also estimated relative to 54 other chemicals which the CAG has evaluated as carcinogens. The relative potency Index is  $5 \times 10^7 (\text{mMol}/\text{kg}/\text{day})^{-1}$ , making 2,3,7,8-TCDD the most potent animal carcinogen evaluated by the CAG. It is about 50 times more potent than the third most potent chemical, bis-(chloromethyl)ether and ~50,000,000 times more potent than vinyl chloride. The relative potency Index for HxCDD is  $2 \times 10^6 (\text{mMol}/\text{kg}/\text{day})^{-1}$ , making it the second most potent carcinogen, about one-twentieth the low dose potency of 2,3,7,8-TCDD.

11.4.2. Conclusions. There **is** evidence from chronic animal cancer bioassay studies that **2,3,7,8-TCDD** and HxCDD are probable human carcinogens. There are no chronic animal cancer **bioassay** studies available that evaluate the carcinogenic potential for other **polychlorinated** dibenzo-p-dioxin compounds. The available data for **2,3,7,8-TCDD** and HxCDD come from gavage and feeding studies, there being no studies **available** for Inhalation exposure. The epidemiologic evidence for the **carcinogenicity** of 2,3,7,8-TCDD alone is inadequate, and there have been no epidemiologic studies, as yet, for MxCDD as the sole compound of concern.

2,3,7,8-TCDD has induced hepatocellular carcinomas **in** two strains of **female** rats and both sexes of one mouse strain, along **with** the induction of thyroid tumors, subcutaneous **fibrosarcomas** and tumors of the lung, nasal **turbinates/hard** palate in male rats, and tongue tumors **in** female rats. These effects notably occur at **extremely** low doses. There is evidence that 2,3,7,8-TCDD is also a promoter and a **cocarcinogen**. The evidence of **carcinogenicity** for **2,3,7,8-TCDD** in animals **is** regarded as "sufficient" using the EPA Interim **weight-of-evidence** classification system for carcinogens (U.S. EPA, 1984).

The human evidence for the carcinogenicity of 2,3,7,8-TCDD alone **is** regarded as "Inadequate" using the EPA **classification** criteria, because of the difficulty of attributing the observed effects solely to the presence of 2,3,7,8-TCDD that occurs as an impurity **in** the **phenoxyacetic** acids and **chlorophenols**. However, the human evidence for the carcinogenicity of chlorinated phenoxy acetic herbicides and/or chlorophenols **with** chlorinated **dibenzodioxin** impurities is judged to be "limited" according to the EPA criteria.

The overall evidence for **carcinogenicity**, considering both animal and human studies, would place 2,3,7,8-TCDD alone **in** the **B2** category of EPA's **classification** scheme, and 2,3,7,8-TCDD **in** association **with** the phenoxy herbicides and/or **chlorophenols** **in** the **B1** category. Chemicals **in** category B are regarded as being "probably" carcinogenic in humans.

The EPA has, in the past, used an IARC weight-of-evidence **classification** scheme for evaluating carcinogenicity data. Using IARC **classification** criteria, the positive evidence **in** the rat and mouse studies, together **with** Inadequate evidence in humans for 2,3,7,8-TCDD alone, **is** equivalent to an IARC 2B category, meaning that 2,3,7,8-TCDD is "**probably**" carcinogenic in humans. However, the **overall** weight-of-evidence for 2,3,7,8-TCDD **in** combination **with** chlorinated **phenoxyacetic** acid herbicides and/or chlorophenols would be classified as IARC 2A, meaning that chlorophenoxyacetic acid and/or **chlorophenols** containing 2,3,7,8-TCDD are "**probably**" carcinogenic in humans.

Hepatocellular tumors have been induced in **mice** and rats of both sexes following administration of a 1:2 mixture of **1,2,3,6,7,8-** and 1,2,3,7,8,9-HxCDD. **This** level of carcinogenic evidence in **animals** would be regarded as "sufficient" according to the EPA classification scheme. Based on animal evidence and the lack of epidemiologic data, HxCDD would be placed in **EPA's** B2 category, which characterizes HxCDD as "probably" carcinogenic in humans. Using the IARC classification scheme, based on animal evidence and no epidemiology data, HxCDD **would** be considered to be **in** a 2B category meaning that HxCDD is "probably" carcinogenic in humans.

Assuming that 2,3,7,8-TCDD and HxCDD are carcinogenic in humans, upper bound Incremental **unit** cancer risks have been estimated for both **ingestion** and Inhalation exposure. The development of these **unit risk** estimates is for the purpose of **evaluating** the magnitude of the **possible** health impact

from exposure to these compounds. The upper bound nature of these **risk** estimates is such that the true **risk** is not **likely** to be exceeded and may be **lower**.

Using the data from a feeding study **with** female rats, the cancer potency (**unit risk** per mg/kg/day) for **2,3,7,8-TCDD** is  $1.56 \times 10^{-1} \text{ (ng/kg/day)}^{-1}$ . The upper limit estimate of Incremental cancer **risk** is  $4.5 \times 10^{-9}$  for a continuous lifetime exposure to **1 ng/l** of **2,3,7,8-TCDD** in drinking water. The upper limit estimate of Incremental cancer **risk** is  $3.3 \times 10^{-9}$  for a continuous lifetime exposure to **1 pg/m<sup>3</sup>** of 2,3,7,8-TCDD in ambient **air**.

Using data from a gavage study **with** female rats and male **mice** the cancer potency for HxCDD is  $6.2 \times 10^{-9} \text{ (ng/kg/day)}^{-1}$ . The upper limit estimate of Incremental cancer **risk** is  $1.8 \times 10^{-4}$  for a lifetime exposure to **1 ng/l** of HxCDD in drinking water. For ambient **air** a lifetime exposure to **1 pg/m<sup>3</sup>** of HxCDD is estimated to have an upper limit **risk** of  $1.3 \times 10^{-6}$ .

In terms of low dose response, 2,3,7,8-TCDD and the **1:2** mixture of 1,2,3,6,7,8- and **1,2,3,7,8,9-HxCDD** rank as the most potent and second most potent, respectively, carcinogens evaluated by **EPA's** CAG.



## 12. SYNERGISM AND ANTAGONISM

The Interactions of 2,3,7,8-TCDD **with** other toxic substances are predominately mediated through **its** potent enzyme Induction. **2,3,7,8-TCDD** **pretreatment** significantly **alters** the metabolism of many other compounds, resulting in either **potentiation** or Inhibition of their biological effects.

### 12.1. CHEMICAL CARCINOGENS

Synergistic and antagonistic activities of 2,3,7,8-TCDD **with** chemical carcinogens have been discussed in depth in Chapter 11 of **this** document.

### 12.2. NONCARCINOGENIC CHEMICALS

2,3,7,8-TCDD pretreatment has been observed to modify the effects of anesthetics (**Greig**, 1972). Adult male Porten rats were given a single oral dose of 200 yg **2,3,7,8-TCDD/kg** bw 1-3 days preceding treatment **with** 100 **mg/kg zoxazolamine hydrochloride** or 150 mg/kg **hexabarbitone** sodium. 2,3,7,8-TCDD pretreatment resulted in a 54% decrease in the duration of the paralysis Induced by zoxazolamlne and a 2-fold Increase in the sleeping **time** produced by hexabarbltone. A recent report compares the **immunotoxicity** of 2,3,7,8-TCDD, **2,3,7,8-TCDF** and **2,3,7,8-TCDF** plus 2,3,7,8-TCDD (**coadministered**) (Rizzardi et al., 1983). Seven days after administration of 1.2 yg/kg of 2,3,7,8-TCDD to C57B1/6J **mice**, sheep red blood cells were Injected Intraperitoneally and plaque-forming cells (PFC) in the **spleen** were counted 5 days later. 2,3,7,8-TCDD Inhibited antibody production by 80%. In a parallel study, a dose of 2,3,7,8-TCDF was administered (10 yg/kg) and no significant **immunotoxic** effects were observed. **Coadministration** of 2,3,7,8-TCDD (1.2 yg/kg) plus 2,3,7,8-TCDF (10 yg/kg) **resulted** in 50% reduction in antibody production and demonstrates a significant antagonistic effect by 2,3,7,8-TCDF. Coadministration of these two **isostereomers** resulted **in** antagonistic effects **with** respect to the Induction of hepatic

**microsomal cytochrome P-450** and **7-ethoxycoumarin O-deethylase**. Sweeney et al. (1979) found that **iron** deficiency protected **mice** against the **development** of **hepatocellular** damage (including **porphyria**) normally caused by 2,3,7,8-TCDD exposure.

### 12.3. SUMMARY

Exposure to **2,3,7,8-TCDD** has been observed to alter the **biological** response of many species to some compounds. **This altered** response is presumed to be the **result** of altered **enzyme** activities in tissue in which **2,3,7,8-TCDD** exerts an Inductive effect (vide ante, see Section 8.1.1.5.), although other mechanisms are possible (see Section 8.3.).

**2,3,7,8-TCDD** pretreatment increases the conversion of some chemical carcinogens to mutagens by hepatic S-9 preparations in in vitro test systems; however, exposure to 2,3,7,8-TCDD often has an **anticarcinogenic** effect in vivo (see Section 11.1.1.1.). **This** anticarcinogenic effect may be the result of increased detoxification or an increased **cytotoxicity** following increased production of metabolites. 2,3,7,8-TCDD pretreatment has the **potential** of altering the biological effects of many compounds that are not chemical carcinogens. **This** modification may reduce the effectiveness, as in the case of **zoxazolamine**, or increase the effectiveness, as in the case of **hexobarbitone** (Greig, 1972). The direction and extent of the **alteration** depends both on the effect of 2,3,7,8-TCDD on the particular enzyme system involved and on whether metabolism is an activating or deactivating process.

## 13. REGULATIONS AND STANDARDS

### 13.1. WATER

Previous release of **PCDD-containing** herbicides has been one mechanism by which these agents enter the environment. Their **high** environmental stability and low water solubility (0.2 ppb) make the 2,3,7,8- TCDD tend to settle in the bottom sludge of waterways. The major **risk** to humans comes from eating bottom-feeding **fish** in which **2,3,7,8-TCDD** has **bioaccumulated**. The U.S. EPA has set criteria of  $1.3 \times 10^{-7}$ ,  $1.3 \times 10^{-8}$  or  $1.3 \times 10^{-9}$   $\mu\text{g}$  **2,3,7,8-TCDD/l** based on estimated human lifetime cancer risks of  $10^{-5}$ ,  $10^{-6}$  and  $10^{-7}$ , respectively. These criteria are based on the assumption of a daily consumption of 6.5 g contaminated **fish** and shellfish **with** the **additional** daily consumption of 2 a of contaminated drinking water (U.S. EPA, 1984). No information is available regarding concentration limits of **1,2,3,7,8-PeCDD**, **1,2,3,7,8,9-HxCDD** or 1,2,3,6,7,8- HxCDD in ambient water.

### 13.2. AIR

Many normal combustion processes are suspected of releasing **dioxins** to the atmosphere. However, the effect on human **health** from **this** source is unknown, and no criteria exist regarding concentration limits.

### 13.3. FOOD

According to the FDA (Cordle, 1981, 1983; FDA, 1981, 1983) and the Code of **Federal** Regulations (41 CFR 321), **fish with** a 2,3,7,8-TCDD content averaging <25 ppt pose no serious health concern. Federal legal limits for Great Lakes **fish** distributed in Interstate commerce are deemed unnecessary because most of the samples analyzed by the FDA contained <25 ppt. Canada has established a 20 ppt concentration limit for 2,3,7,8-TCDD in Lake Ontario commercial **fish** Imported **into** the United States to comply **with** the levels believed by the FDA to be safe (NRCC, 1981a).

A tolerance for hexachlorophene **methylenebis (2,3,6-trichlorophenol)** in or on feedstock cottenseeds has been established at 0.05 ppm, with the condition that **it** not contain >0.1 ppm of **2,3,7,8-TCDD (U.S. EPA, 1982c)**.

No Information regarding concentration limits of other **dioxin isomers** is available.

#### 13.4. SUMMARY

The regulation of dioxin by-products in substances such as chlorophenols and **2,4,5-trichlorophenoxyacetic** acid is apparently expected to eliminate dioxin releases to the environment. The Canadian concentration limit for **2,3,7,8-TCDD in fish** is the only known criterion, and it agrees with levels regarded by the FDA as being protective of human health. In the absence of specific guidelines and standards regarding concentration limits of 2,3,7,8-TCDD, the FDA examines individual contamination situations separately, and gives only general guidance regarding relative **risk** to humans (Delgado, 1983). No Information is available regarding concentration limits for other PCDDs.

#### 14. EFFECTS OF MAJOR CONCERN AND HEALTH HAZARD ASSESSMENT

Of the four congeners of PCDDs discussed in **this** report (**2,3,7,8-TCDD**, **1,2,3,7,8-PeCDD**, **1,2,3,7,8,9-** and **1,2,3,6,7,8-HxCDD**), the majority of **toxicologic** data are on **2,3,7,8-TCDD**. The **limited** data on the other congeners indicate that they are qualitatively similar **in** their toxic action to **2,3,7,8-TCDD** when comparisons are made in a single species; however, they are less toxic than the **2,3,7,8-TCDD** congener. **This** is **illustrated in mice**, in which **2,3,7,8-TCDD** has an **LD<sub>50</sub>** value of **0.88 μmol/kg** and **1,2,3,7,8-PeCDD**; **1,2,3,6,7,8-** and **1,2,3,7,8,9-HxCDD** have **LD<sub>50</sub>** values of **0.94**, **3.19** and **3.67 μmol/kg**, respectively (McConnell et al., 1978b). **This** suggests that either the position or the number of chlorine effects the **toxicity** of the PCDDs.

In more recent studies using biochemical **endpoints**, Poland et al. (1979), Bradlaw and **Casterline** (1979) and Bradlaw et al. (1980) supported the contention that the position and number of chlorines on TCDD, PeCDD and HxCDD are critical for the **biologic** activity of the compound. In **this** study, the **ED<sub>50</sub>** for the induction of AHH activity in **hepatoma** cells in culture was used to establish a range of potency for congeners of PCDDs. Although acute toxicity and induction of AHH activity have been used to quantify the difference in the **biologic** activity of the congeners **2,3,7,8-TCDD**, **1,2,3,7,8-PeCDD** and **1,2,3,7,8,9-HxCDD**, the extrapolation of **this** data to estimate quantitative dose-response relationships for the chronic **toxicity** of **individual** congeners is not **sufficiently** supported at the present **time**. From the following data described, **it** is clear that sufficient information for quantitative hazard assessment is available only for **2,3,7,8-TCDD** and a mixture of the two HxCDD congeners.

## 14.1. PRINCIPAL EFFECTS

**14.1.1. Toxicity.** The principal effect observed in all species after acute exposure to **2,3,7,8-TCDD** is weight loss and **thymic** atrophy (see Table 8-1). The decrease in weight proceeds over a protracted length of **time** even after a **single** exposure to a lethal dose. By the **time** of death, an almost **complete** absence of body fat stores was often observed. At death, severe deterioration of the animal was observed; however, there was no specific lesion to associate **with** the cause of death. **This** was **particularly** evident in the guinea **pig**, the most sensitive species to 2,3,7,8-TCDD toxicity. Necropsy revealed no remarkable alteration in any internal organ except for thymic atrophy (Gupta et al., 1973). Although liver damage was observed in rats, rabbits and **mice** (Schwetz et al., 1973), there are insufficient data to indicate that **this** effect is the **underlying** cause of **mortality** after acute exposure to 2,3,7,8-TCDD. Also, **in** the guinea **pig** and monkey, which have the same **general** progression of gross signs of **toxicity** as do rats, rabbits and **mice**, there is **only mild** liver damage (see Section 8.1.). In addition, **2,3,7,8-TCDD** is an immunosuppressant in **mice** (see Section 8.1.1.4.).

As a result of the long **time** necessary for the development of toxic symptoms in animals, **subchronic** and chronic studies are better able to define dose and effect relationships than are acute studies. Subchronic and chronic animal studies that define NOELs and LOELs are summarized in Table 14-1 for orally administered 2,3,7,8-TCDD. The NOEL for subchronic exposure is **~10** times higher than that observed for chronic exposures, suggesting that the cumulative dose might be an important factor in 2,3,7,8-TCDD toxicity. There are only limited data on the NOEL and LOEL for HxCDD

TABLE 14-1

No-Observed-Effect Levels and Low-Observed-Effect Levels Obtained from **Subchronic** and **Chronic Oral Toxicity Studies of 2,3,7,8-TCDD**

| Species/Strain            | <u>µg/kg/day</u> |                 | Duration of Exposure | Duration of Study | Reported Effect  | Reference                     |
|---------------------------|------------------|-----------------|----------------------|-------------------|--|-------------------------------|
|                           | NOEL             | LOEL            |                      |                   |  |                               |
| <b>Rat/Sprague-Dawley</b> | 0.01             | 0.1             | 13 weeks             | 26 weeks          | decreased bw   | <b>Kociba et al.</b> , 1976   |
| <b>Rat/Osborne-Mendel</b> | 0.07             | 0.14            | <b>13</b> weeks      | <b>13</b> weeks   | toxic hepatitis  | NTP, 1980a                    |
| Rat/Sprague-Dawley        | 0.0014           | 0.014           | 16 weeks             | 40 weeks          | elevated <b>porphyrin</b> levels                             | Goldstein et al., 1982b       |
| Rat/Sprague-Dawley        | ND               | <b>0.014</b>    | 28 weeks             | 40 weeks          | fatty changes in the <b>liver</b> , decreased bw             | <b>King</b> and Roesler, 1974 |
| <b>Mice/B6C3F1</b>        | ND               | 0.014           | <b>13</b> weeks      | <b>13</b> weeks   | toxic hepatitis  | NTP, 1980a                    |
| Monkey/Rhesus             | ND               | <b>&lt;0.02</b> | 36 weeks             | 52 weeks          | <b>pancytopenia</b>  | Allen et al., 1977            |
| Rat/Sprague-Dawley        | 0.001            | 0.01            | <b>104</b> weeks     | <b>104</b> weeks  | degenerative and <b>necrotic</b> changes in the <b>liver</b> | Kociba et al., 1978a, 1979    |
| <b>Rat/Osborne-Mendel</b> | 0.0014           | 0.007           | <b>104</b> weeks     | 107 weeks         | toxic hepatitis  | NTP, 1980a                    |
| Mice/Swiss                | ND               | 0.001           | 52 weeks             | <b>life</b>       | dermatitis and <b>amyloidosis</b>                            | Toth et al., 1979             |

ND = Not determined

(Table 14-2) and these were obtained from studies using a 1:2 mixture of 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDD. As observed with 2,3,7,8-TCDD, there is a suggestion that the cumulative dose of this mixture is an important consideration in defining a NOEL. For both 2,3,7,8-TCDD and the mixture of HxCDD, the liver appeared to be a target organ.

2,3,7,8-TCDD has been shown to produce fetal anomalies in rats, mice, rabbits, ferrets and chickens (see Table 9-2). In mice fetuses, 2,3,7,8-TCDD induces cleft palate and kidney malformations, while in rat fetuses, hemorrhage, edema and a number of anomalies were observed. There was only one study available assessing the teratogenicity of 2,3,7,8-TCDD in rabbits reported by Glavini et al. (1982b) in which increases in extra ribs and total soft-tissue anomalies were observed. In mice, 1 µg/kg/day given for 9-10 days during the middle of gestation was the minimum dose necessary to elicit a teratogenic response (Smith et al., 1976; Moore et al., 1973), while dilated renal pelvis and decreased fetal weight were observed in the rat fetuses of dams receiving doses of 2,3,7,8-TCDD as low as 0.001 µg/kg/day throughout gestation. The statistical and biological significance of effects at this later dose, however, is argued (Murray et al., 1979; Nisbet and Paxton, 1982; U.S. EPA, 1979c). The fetuses of rats appear to be very sensitive to the effects of 2,3,7,8-TCDD, with adverse effects occurring at maternal exposures that were similar to the NOEL observed in chronic studies (see Table 14-1). Also, Schwetz et al. (1973) demonstrated that HxCDD (isomers not specified) was both fetotoxic and teratogenic when administered to pregnant rats at 100 µg/kg on days 6-15 of gestation.

Some epidemiology studies have shown a positive association between exposure to 2,4,5-T, of which 2,3,7,8-TCDD is a known contaminant, and birth



TABLE 14-2

No-Observed-Effect Levels and Low-Observed-Effect Levels  
Obtained from **Subchronic** and Chronic Oral **Toxicity** Studies of **HxCDD<sup>a,b</sup>**

| Species/Strain            | <u>µg/kg/day</u> |      | Duration<br>of<br>Exposure | Duration<br>of Study | Reported Effects      |
|---------------------------|------------------|------|----------------------------|----------------------|-----------------------|
|                           | NOEL             | LOEL |                            |                      |                       |
| <b>Rat/Osborne-Mendel</b> | 0.35             | 0.7  | 13 weeks                   | 13 weeks             | hepatotoxicity        |
| <b>Mice/B6C3F1</b>        | 0.7              | 1.4  | 13 weeks                   | 13 weeks             | <b>hepatotoxicity</b> |
| Rat/Osborne-Mendel        | ND               | 0.18 | 104 weeks                  | 107 weeks            | toxic hepatitis       |
| <b>Mice/B6C3F1</b>        | ND               | 0.18 | 104 weeks                  | <b>107 weeks</b>     | toxic hepatitis       |

<sup>a</sup>Source: NTP, 1980b

<sup>b</sup>The HxCDD was a 1:2 mixture of 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDD.

ND = Not determined

defects or abortions. Other studies have **failed** to demonstrate an association (see Section **9.2.**). These studies **in** humans can neither support nor refute the **animal teratogenicity** data, since among many other difficulties in interpreting human data the exposures were always mixed, and there were inadequate data concerning the **levels** of **2,3,7,8-TCDD** to which the populations were exposed.

Animal studies also demonstrate that **2,3,7,8-TCDD** is a carcinogen (see Table 11-1). The limited studies by Van Miller et al. (1977a,b) and Toth et al. (1978, 1979) indicated that 2,3,7,8-TCDD caused a variety of tumors in rats and **mice**, and the more intensive studies by Kociba et al. (1978a) and NTP (1980a) support these early findings. Also, **papillomas** have been reported in **female mice** after dermal application of 2,3,7,8-TCDD (NTP, 1980b), and using the **skin tumorigenesis** model, it has been shown that 2,3,7,8-TCDD may affect the carcinogenic potential of other chemical carcinogens (see Section **11.1.1.2.**). Human exposure to 2,3,7,8-TCDD has resulted from contamination of other **polychlorinated** compounds **with** 2,3,7,8-TCDD (see Section **11.1.3.**).

A **1:2** mixture of 1,2,3,6,7,8- and **1,2,3,7,8,9-HxCDD** also has been tested for **carcinogenicity** in rats and **mice** treated by gavage and by dermal application in **mice** (NTP, 1980c,d). In both species, **this** mixture produced liver tumors when administered by gavage, while in the dermal study there was no increase in the incidence of **skin** tumors.

Epidemiological studies of workers exposed to chemicals contaminated **with** 2,3,7,8-TCDD such as **2,4,5-trichlorophenoxyacetic acid** and **2,4,5-trichlorophenol** are consistent **with** the position that 2,3,7,8-TCDD is probably carcinogenic for humans; the available evidence indicates an excess incidence of soft tissue sarcoma. Because 2,3,7,8-TCDD is almost always found

In association **with** the materials (**chlorophenols**, combustion products, etc.) It may never be possible to evaluate the **carcinogenicity** of 2,3,7,8-TCDD by itself **in** humans.

14.1.2. **Mutagenicity.** There have been many studies of the mutagenic **potential** of 2,3,7,8-TCDD (see Chapter 10). **In vitro** assays using bacteria and yeast have generally indicated that 2,3,7,8-TCDD is not a mutagen. These negative results were obtained both in the presence and **absence of** a mammalian metabolic activation system. A few studies have reported positive results (**Hussain et al.**, 1972; Seller, 1973; **Bronzetti et al.**, 1980); however, these positive studies had deficiencies in either experimental design, or were reported only qualitatively **with** inadequate description of **experimental** detail for **evaluation**. **With** the available data, **it** is impossible to assert whether or not 2,3,7,8-TCDD is devoid of mutagenic **potential**. There are also some conflicting data from humans and animal studies that indicate that 2,3,7,8-TCDD causes chromosomal aberrations. Because the human data are derived from populations in which exposure to other **biologically** active compounds **is** possible, and because the increases observed in animal studies were small, **it** is still not substantiated that 2,3,7,8-TCDD produces **clastogenic** changes.

Pertinent data regarding the mutagenic potential of **1,2,3,7,8-PeCDD**, **1,2,3,7,8,9-HxCDD** or **1,2,3,6,7,8-HxCDD** could not be found in the available literature.

#### 14.2. SENSITIVE POPULATIONS

Although there are no data from human studies to indicate the presence of sensitive populations, the data from animal studies suggest that the fetus and newborn may be at greater **risk**. Studies in chickens, rats, **mice**,

rabbits, ferrets and monkeys have shown that in **utero** exposure to 2,3,7,8-TCDD can result in **malformations**, fetal **toxicity** and abortions (see Table 9-2). The lowest dose reported to adversely affect the fetus in utero was **0.001 µg/kg/day** administered to the dams throughout gestation (from Murray et al., 1979, according to Nisbet and Paxton, 1982); **this** dose is similar to the NOEL reported for chronic exposure of adult rats (see Table 14-1). Moore et al. (1973) observed that the nursing of pups on mothers exposed to **2,3,7,8-TCDD** could also **result** in kidney anomalies detected at the **time** of weaning. These data suggest that both the fetus and the newborn may be more sensitive than the adult to the adverse effects of exposure to **2,3,7,8-TCDD**.

In addition, 2,3,7,8-TCDD is known to be a powerful **inducer** of the MFO system. There is information to indicate that MFO induction by 2,3,7,8-TCDD can affect the biologic activity of other **xenobiotics** that require metabolic activation (see Chapter 12). **Scarpelli** et al. (1980), for example, demonstrated that pretreatment of hamsters **with** 2,3,7,8-TCDD resulted in greater activation of **mutagenic nitrosamines** when assayed in vitro **with** isolated **microsomes**. Individuals exposed to **chemicals** that are activated by the MFO may experience a **synergistic** effect and be at greater **risk**. In a similar manner, if the MFO detoxifies a **xenobiotic**, pretreatment **with** 2,3,7,8-TCDD may antagonize the action of other compounds.

### 14.3. FACTORS INFLUENCING HEALTH HAZARD ASSESSMENT

It is expected that the PCDDs discussed here would be highly persistent compounds in the environment, and that human exposure may occur through ingestion of contaminated food and water, by inhalation of the compound absorbed to **respirable particulates**, or through dermal contact. Although potential exposure may occur by all routes, most of the **toxicologic** information is from studies of oral exposure. The limited observation of toxic

effects in humans and animals after dermal contact with 2,3,7,8-TCDD in organic solvents. Indicates that dermal absorption occurs. Poiger and Schlatter (1980) have shown in rats that both dermal and GI absorption is dependent on the vehicle. Greatest absorption after oral exposure occurred when 2,3,7,8-TCDD was administered in organic solvent followed by aqueous suspension, with little absorption occurring if the 2,3,7,8-TCDD was adsorbed onto activated carbon. In a similar manner, dermal absorption was poor if the 2,3,7,8-TCDD was applied in a soil and water paste. Inhalation exposure is likely to occur through airborne particulate matter containing absorbed 2,3,7,8-TCDD; however, it is not possible with the available data to predict how efficiently absorption will occur through the respiratory tract. The use of standard respiratory absorption assumptions in risk assessment are most likely to provide conservative criteria levels.

#### 14.4. QUALITATIVE HEALTH HAZARD ASSESSMENT

The data available from animal studies are sufficient to provide some assessment of the human health hazards associated with exposure to 2,3,7,8-TCDD and a mixture of 1,2,3,7,8,9- and 1,2,3,6,7,8-HxCDD. The only data available on 1,2,3,7,8-PeCDD are an acute LD<sub>50</sub> value and studies of induction of AHH activity. Although both types of data indicate that 1,2,3,7,8-PeCDD might have slightly less biological activity than 2,3,7,8-TCDD, the data are insufficient to adequately predict the risk associated with a particular dose of 1,2,3,7,8-PeCDD. This would be the case if attempts were made to use these data from acute exposure to extrapolate the effects of chronic exposure whether these effects are toxic or carcinogenic. For the other PCDDs discussed, the hazard assessment can be based on toxicity, teratogenicity or carcinogenicity.

Although there have been human epidemiology studies investigating the toxic, reproductive and carcinogenic effect of exposure to **2,3,7,8-TCDD**, these studies have major deficiencies for use **in health** assessment. **2,3,7,8-TCDD** is a contaminant of the chemicals **2,4,5-T** and TCP, and **all** human data are derived from populations exposed to mixtures. In these studies, **it** is not **possible** to attribute **with** certainty any observed effect to exposure to 2,3,7,8-TCDD. **Also**, exposure data of sufficient quality are not available to define a dose-response relationship in human population. Without adequate exposure data, health assessments cannot be made.

14.4.1. Animal **Toxicity** Data. Animal studies that are useful for hazard assessment are studies **with** adequate experimental design to define the levels of exposure that produce threshold effects. Tables 14-1 and 14-2 summarize these studies, providing data on NOEL (or NOAEL) and LOEL (or LOAEL). Since there is suggestive evidence that the cumulative dose **is** important to the **toxicity** of 2,3,7,8-TCDD and the mixture of **HxCDD** tested, the chronic toxicity studies would be more appropriately used for hazard assessment. The NOEL from the two studies **in** rats (**Kociba et al.**, 1978a, 1979; NTP, **1980a**) are 0.001 and 0.0014 pg/kg/day; however, in the mouse (NTP, 1980a), the dose of 0.07 **µg/kg/day** was a **FEL**, as indicated by fatty changes in the liver, and 0.007 was a NOEL.

In addition, it may be inappropriate to derive a **toxicity-based** hazard assessment for 2,3,7,8-TCDD from these chronic studies, since a 3-generation study by Murray et al. (1979) indicates that exposure of pregnant rats to **this** dose of 2,3,7,8-TCDD (0.001 pg/kg/day) throughout gestation resulted in the observation of dilated renal pelvis in the fetuses. Murray et al. (1979) and U.S. EPA (**1979c**) consider **this** effect not to be treatment-related because **it** occurred in only one generation at **this** dose and not at higher

doses. Hence, 0.001 yg/kg/day represented a NOAEL. **However**, a reevaluation of these data by different statistical methods (**Nisbet and Paxton, 1982**) Indicated a statistically significant Increase of dilated renal pelvis at higher doses, as well as the lowest one, and lower fetal weight in the 0.001 yg/kg group. **With** these data, 0.001 yg/kg could be considered a LOAEL. No other studies are **available** regarding the effects of **2,3,7,8-TCDD** at even **lower** doses.

A toxicity-based hazard assessment is **also** possible for the mixture of HxCDD tested by NTP (1980b). As is shown in Table 14-2, however, the description of the **histologic** observations was not sufficiently **detailed** to determine whether the low dose represented a NOAEL or a LOAEL. These data could be used for hazard assessment in either case **with** an additional uncertainty factor for a LOAEL (Federal Register, 1980b).

14.4.2. Animal **Carcinogenicity**. In addition to the Inadequate data base for a toxicity-based hazard assessment, the strong evidence of **carcinogenicity in animals** for 2,3,7,8-TCDD **would justify** a **carcinogenicity-based** assessment. That two adequate cancer **bioassays** used sufficiently large groups of **animals** exposed for an appreciable portion of their **lifespan** Indicates that 2,3,7,8-TCDD is an animal carcinogen (NTP, 1980a; **Kociba et al.**, 1978a) (**Table 14-3**). In the NTP (1980a) study, male rats developed **follicular-cell** adenomas or carcinomas of the thyroid. Female rats and **mice** of both sexes had Increased Incidences of **follicular-cell** adenomas of the thyroid. In the study by Kociba et al. (1978a), rats maintained on diets that provided doses of 0.0, 0.001, 0.01 and 0.1 yg/kg/day had **elevated** Incidences of carcinomas of the hard palate and tongue, and adenoma of the adrenal cortex in males of the **high** dose group, and carcinomas of the liver, tongue and lungs **in females** of the high-dose group. The evidence is sufficient to Indicate that 2,3,7,8-TCDD is an animal carcinogen.

**TABLE 14-3**  
**Carcinogenicity Bioassays of 2,3,7,8-TCDD**

| Exposure Route | Species/Strain                  | Sex | Dose or Exposure             | Duration of Treatment | Duration of Study | Vehicle                | Tumor Type   | Tumor Incidence | Reference         |
|----------------|---------------------------------|-----|------------------------------|-----------------------|-------------------|------------------------|--|-----------------|-------------------|
| Gavage         | <b>rats/<br/>Osborne-Mendel</b> | N   | 0.0 <b>µg/kg/week</b>        | 104 weeks             | 105 weeks         | corn oil-acetone (9:1) | <b>follicular-cell</b> adenomas or carcinoma of the thyroid              | 1/69            | <b>NTP, 1980a</b> |
|                |                                 |     | 0.01 <b>µg/kg/week</b>       | 104 weeks             | <b>107</b> weeks  | corn oil-acetone (9:1) | folllcular-cell adenomas or carcinoma of the thyroid                     | 5/48            |                   |
|                |                                 |     | 0.05 <b>µg/kg/week</b>       | <b>104</b> weeks      | 107 weeks         | corn oil-acetone (9:1) | folllcular-cell adenomas or carcinoma of the thyroid                     | 8/50            |                   |
|                |                                 |     | <b>0.5</b> pg/kg/week        | 104 weeks             | 107 weeks         | corn oil-acetone (9:1) | folllcular-cell adenomas or carcinoma of the thyroid                     | <b>11/50</b>    |                   |
| <b>Gavage</b>  | <b>rats/<br/>Osborne-Mendel</b> | F   | 0.0 pg/kg/week               | 104 weeks             | 108 weeks         | corn oil-acetone (9:1) | <b>neoplastic</b> nodule or <b>hepatocellular</b> carcinoma of the liver | 5/75            | <b>NTP, 1980a</b> |
|                |                                 |     | <b>0.1</b> <b>µg/kg/week</b> | 104 weeks             | 107 weeks         | corn oil-acetone (9:1) | neoplastic nodule or hepatocellular <b>carcctnoma</b> of the liver       | 1/49            |                   |
|                |                                 |     | 0.05 <b>µg/kg/week</b>       | <b>104</b> weeks      | 107 weeks         | corn oil-acetone (9:1) | neoplastic nodule or hepatocellular carcinoma of the liver               | 3/50            |                   |
|                |                                 |     | 0.5 <b>vg/kg/week</b>        | 104 weeks             | 107 weeks         | corn oil-acetone (9:1) | neoplastic nodule or <b>hepatocellular</b> carcinoma of the liver        | 14/49           |                   |

14-12



TABLE 14-3 (cont.)

| Exposure Route | Species/Strain            | Sex      | Dose or Exposure       | Duration of Treatment | Duration of Study | Vehicle                | Tumor Type   | Tumor Incidence             | Reference                   |
|----------------|---------------------------|----------|------------------------|-----------------------|-------------------|------------------------|--|-----------------------------|-----------------------------|
| <b>Gavage</b>  | <b>mice/B6C3F1</b>        | H        | 0.0 vg/kg/week         | 104 weeks             | <b>105</b> weeks  | corn oil-acetone (9:1) | hepatocellular carcinoma   | 8/73                        | NTP, 1980a                  |
|                |                           |          | 0.01 <b>µg/kg/week</b> | 104 weeks             | 107 weeks         | corn oil-acetone (9:1) | hepatocellular carcinoma   | 9/49                        |                             |
|                |                           |          | 0.05 <b>µg/kg/week</b> | 104 weeks             | 107 weeks         | corn oil-acetone (9:1) | hepatocellular carcinoma   | <b>8/49</b>                 |                             |
|                |                           |          | 0.5 vg/kg/week         | 104 weeks             | 107 weeks         | corn oil-acetone (9:1) | hepatocellular carcinoma   | 17/50                       |                             |
| Gavage         | <b>mice/B6C3F1</b>        | F        | 0.0 vg/kg/week         | 104 weeks             | 105 weeks         | corn oil-acetone (9:1) | hepatocellular carcinoma, follicular-cell adenomas of the thyroid  | 1/73<br>0/69                | NTP, 1980a                  |
|                |                           |          | 0.04 vg/kg/week        | 104 weeks             | 107 weeks         | corn oil-acetone (9:1) | <b>hepatocellular</b> carcinoma, follicular-cell adenomas of the thyroid   | 2/50<br>3/50                |                             |
|                |                           |          | 0.2 vg/kg/week         | 104 weeks             | <b>107</b> weeks  | corn oil-acetone (9:1) | <b>hepatocellular</b> carcinoma, follicular-cell adenomas of the thyroid   | <b>2/48</b><br>1/47         |                             |
|                |                           |          | 2.0 vg/kg/week         | <b>104</b> weeks      | 107 weeks         | corn oil-acetone (9:1) | hepatocellular carcinoma, follicular-cell adenomas of the thyroid  | 6/47<br>5/46                |                             |
| Oral           | <b>rat/Sprague-Dawley</b> | <b>M</b> | 0.0 vg/kg/day          | <b>105</b> weeks      | 105 weeks         | <b>in diet</b>         | squamous cell carcinoma of the hard palate, squamous cell carcinoma of the tongue, adenoma of the adrenal cortex | 0/85<br><b>0/85</b><br>0/85 | <b>Kociba et al., 1978a</b> |

TABLE 14-3 (cont.)

| Exposure Route  | Species/Strain         | Sex       | Dose or Exposure | Duration of Treatment | Duration of Study                           | Vehicle | Tumor Type                                  | Tumor Incidence | Reference            |
|-----------------|------------------------|-----------|------------------|-----------------------|---|---------|---|-----------------|----------------------|
| Oral<br>(cont.) | rat/<br>Sprague-Dawley |           | 0.001 vg/kg/day  | 105 weeks             | 10S weeks                                   | in diet | squamous cell carcinoma of the hard palate. | 0/50            | Kociba et al., 1978a |
|                 |                        |           |                  |                       |   |         | squamous cell carcinoma of the tongue.      | 1/50            |                      |
|                 |                        |           |                  |                       |   |         | adenoma of the adrenal cortex               | 0/50            |                      |
|                 |                        |           | 0.01 µg/kg/day   | 105 weeks             | 105 weeks                                   | in diet | squamous cell carcinoma of the hard palate. | 0/50            |                      |
|                 |                        |           |                  |                       |   |         | squamous cell carcinoma of the tongue.      | 1/50            |                      |
|                 |                        |           |                  |                       |   |         | adenoma of the adrenal cortex               | 2/50            |                      |
|                 |                        |           | 0.1 µg/kg/day    | 105 weeks             | 105 weeks                                   | in diet | squamous cell carcinoma of the hard palate. | 4/50            |                      |
|                 |                        |           |                  |                       |   |         | squamous cell carcinoma of the tongue.      | 3/50            |                      |
|                 |                        |           |                  |                       |   |         | adenoma of the adrenal cortex               | 5/50            |                      |
| Oral            | rat/<br>Sprague-Dawley | F         | 0.0 µg/kg/day    | 105 weeks             | 105 weeks                                   | in diet | hepatocellular carcinoma.                   | 1/86            | Kociba et al., 1978a |
|                 |                        |           |                  |                       |   |         | squamous cell carcinoma of the hard palate, | 0/86            |                      |
|                 |                        |           |                  |                       |   |         | squamous cell carcinoma of the lung         | 0/86            |                      |
|                 |                        |           | 0.001 µg/kg/day  | 105 weeks             | 105 weeks                                   | in diet | hepatocellular carcinoma.                   | 0/50            |                      |
|                 |                        |           |                  |                       |   |         | squamous cell carcinoma of the hard palate, | 0/50            |                      |
|                 |                        |           |                  |                       |   |         | squamous cell carcinoma of the lung         | 0/50            |                      |
|                 | 0.01 wg/kg/day         | 105 weeks | 105 weeks        | in diet               | hepatocellular carcinoma,                   | 2/50    |   |                 |                      |
|                 |                        |           |                  |                       | squamous cell carcinoma of the hard palate, | 1/50    |   |                 |                      |
|                 |                        |           |                  |                       | squamous cell carcinoma of the lung         | 0/50    |   |                 |                      |
|                 | 0.1 wg/kg/day          | 105 weeks | 105 weeks        | in diet               | hepatocellular carcinoma,                   | 11/49   |   |                 |                      |
|                 |                        |           |                  |                       | squamous cell carcinoma of the hard palate, | 4/49    |   |                 |                      |
|                 |                        |           |                  |                       | squamous cell carcinoma of the lung         | 7/49    |   |                 |                      |

A single bioassay tested a mixture of the two congeners of HxCDD for **carcinogenicity** (NTP, 1980b). The results summarized in Table 14-4 show that male and female rats and **mice** exposed to **this** mixture of HxCDD had Increased Incidences of **neoplastic** nodules or carcinomas of the liver. Increased Incidence of tumors in two species **is** sufficient to indicate that **this** mixture was carcinogenic to animals; **however**, caution is required in interpreting these data for hazard evaluation since the NTP (1980a) study used a mixture containing two **isomers**, **1,2,3,6,7,8-** and **1,2,3,7,8,9-**, of HxCDD and the HxCDD mixture used for **this** bioassay was found to be contaminated **with** other PCDDs **including 0.09%** ( $\pm 0.03\%$ ) of TCDD. The specific **isomer** of PCDDs was not identified. There is insufficient evidence to confirm whether both isomers are independently carcinogenic or whether only one isomer or **this** specific mixture is needed to elicit a carcinogenic response. Since the position of the chlorines may be extremely important for the toxic/carcinogenic properties of HxCDD, information obtained from **this** combined exposure may not be applicable to the individual congeners.

TABLE 14-4

## Carcinogenicity Bioassays of a 1:2 Mixture of 1,2,3,6,7,8- and 1,2,3,7,8,9-HxCDD

| Exposure Route | Species/Strain          | Sex | Dose or Exposure | Duration of Treatment | Duration of Study | Vehicle                    | Tumor Type   | Tumor Incidence | Reference  |
|----------------|-------------------------|-----|------------------|-----------------------|-------------------|----------------------------|--|-----------------|------------|
| Gavage         | rats/<br>Osborne-Nendel | N   | 0.0 tig/kg/week  | 104 weeks             | 105 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 0/74            | NTP, 1980b |
| Gavage         | rats/<br>Osborne-Nendel | N   | 1.25 tig/kg/week | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 0/49            | NTP, 1980d |
|                |                         |     | 2.5 µg/kg/week   | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 1/50            |            |
|                |                         |     | 5.0 µg/kg/week   | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 4/48            |            |
| Gavage         | rats/<br>Osborne-Nendel | F   | 0.0 µg/kg/week   | 104 weeks             | 105 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 5/75            | NTP, 1980d |
|                |                         |     | 1.25 µg/kg/week  | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 10/50           |            |
|                |                         |     | 2.5 µg/kg/week   | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 12/50           |            |
|                |                         |     | 5.0 µg/kg/week   | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | liver neoplastic nodules<br>or hepatocellular<br>carcinoma | 30/50           |            |

TABLE 14-4 (cont.)

| Exposure Route | Species/Strain          | Sex | Dose or Exposure    | Duration of Treatment | Duration of Study | Vehicle                    | Tumor Type                               | Tumor Incidence | Reference  |
|----------------|-------------------------|-----|---------------------|-----------------------|-------------------|----------------------------|--|-----------------|------------|
| Gavage         | rats/<br>Osborne-Mendel | F   | 0.0 vg/kg/week      | 104 weeks             | 105 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 15/73           | NTP, 1980d |
|                |                         |     | 1.25 vg/kg/week     | 104 weeks             | 108 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 14/50           |            |
|                |                         |     | 2.5 vg/kg/week      | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 14/49           |            |
|                |                         |     | 5.0 vg/kg/week      | 104 weeks             | 108 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 24/48           |            |
| Gavage         | mice/B6C3F1             | F   | 0.0 vg/kg/week      | 104 weeks             | 106 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 3/75            | NTP, 1980d |
|                |                         |     | 2.5 vg/kg/week      | 104 weeks             | 108 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 4/48            |            |
|                |                         |     | 5.0 $\mu$ g/kg/week | 104 weeks             | 108 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 6/47            |            |
|                |                         |     | 10.0 vg/kg/week     | 104 weeks             | 107 weeks         | corn oil-<br>acetone (9:1) | hepatocellular adenomas<br>or carcinomas | 10/47           |            |

## 15. REFERENCES

Abernethy, D.J., W.F. Greenlee, J.C. Huband and C.J. Boreiko. 1985. **2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)** promotes the transformation of **C3H/10T<sub>1/2</sub>** cells. **Carcinogenesis**. 6: 651-653.

ACP (Advisory Committee on Pesticides). 1980. Further Review of the Safety for Use in the U.K. of the Herbicide **2,4,5-T**, Pesticides Branch, Ministry of **Agriculture, Fisheries and Food**, London, England.

Adamoli, P., E. Angeli, G. Bandi, et al. 1978. Analysis of **2,3,7,8-tetra-chlorodibenzo-p-dioxin** in the Seveso area. In: Chlorinated **Phenoxy** Adds and Their Dioxins, C. Rainel, Ed. **Ecol. Bull.** 27: 31-38.

Agarwal, A.K., H.A. Tilson and S.C. Bondy. 1981. **3,4,3',4'-Tetrachloro-biphenyl** given to mice prenatally produces long-term decreases in striatal **dopamine** and receptor binding sites in the caudate nucleus. **Toxicol. Lett.** 7: 417-424.

Altio, A. and M.G. Parkki. 1978. Organ specific Induction of drug metabolizing enzymes by **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the rat. **Toxicol. Appl. Pharmacol.** 44(1): 107-114.

Albro, P.W. 1979. Problems in analytical methodology: Sample handling, extraction, and clean up. **Ann. NY Acad. Sci.** 320: 19-27.

**Albro, P.W.** and B.J. Corbett. **1977.** Extraction and clean up of animal tissues for subsequent determination of mixtures of chlorinated dibenzo-p-dioxin and dibenzofurans. Chemosphere. 6: **381-385.**

Albro, **P.W.**, J.T. Corbett, **M. Harriss** and L.D. Lawson. 1978. Effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on lipid profiles in tissue of the Fischer rat. **Chem. Biol. Interact.** 23(3): 315-330.

Albro, P.M., M.I. Luster, K. Chae, et **al.** 1979. A **radioimmunoassay** for chlorinated **dibenzo-p-dioxins.** Environ. Biol. Chem. Branch, **Natl. Inst., Environ. Health Sci.,** Research Triangle Park, NC 27709.

Aldred, J.E. 1978. Report of the Consultative Council on Congenital Abnormalities in the Yarrow District. Minister of Health, Melbourne, Victoria, Australia. (Cited in Milby et **al.**, 1980)

Allen, **J.R.** and **L.A.** Carstens. **1967.** Light and electron microscopic observations in Macaca mulatta monkeys fed toxic fat. Am. J. Vet. Res. 28: **1613-1629.**

Allen, J.R. and J.J. **Lalich.** 1962. Response of chickens to prolonged feeding of crude "**toxic fat.**" Proc. Soc. Exp. **Biol.** Med. 109: 48-51.

Allen, J.R., **J.P.** Van Miller and D.H. Norback. 1975. Tissue distribution, excretion, and biological effects of **(14-c)** tetrachlorodibenzo-p-dioxin in rats. Food **Cosmet. Toxicol.** 13(5): 501-505.

Allen, J.R., D.A. Barsotti, J.P. Van Miller, L.J. Abrahamson and J.J. Lalich. 1977. Morphological changes in monkeys consuming a diet containing low levels of TCDO. Food Cosmet. Toxicol. 15: 401.

Allen, J.R., D.A. Barsotti, L.K. Lambrecht and J.P. Van Miller. 1979. Reproductive effects of halogenated aromatic hydrocarbons on nonhuman primates. Ann. NY Acad. Sci. 320: 419-425.

Anderson, E.L. and the Carcinogen Assessment Group of the U.S. Environmental Protection Agency. 1983. Quantitative approaches in use to assess cancer risk. Risk Analysis. 3(4): 277.

Anderson, H.A., R. Lillis and I.J. Selikoff. 1978. Unanticipated prevalence of symptoms among dairy farmers in Michigan and Wisconsin. Environ. Health Perspect. 23: 217-226.

Anonymous. 1979. Dioxin is found in cleanup worker's blood. Chemical Week. 124: 22.

Anonymous. 1982. Phenoxyherbicides, trichlorophenols, and soft-tissue sarcomas. May 8. Lancet. p. 1051-1052.

Appelgren, L.-E., I. Brandt, E.B. Brittebo, M. Gillner and J.-A. Gustafsson. 1983. Autoradiography of 2,3,7,8-tetrachloro[<sup>14</sup>C]-dibenzo-p-dioxin (TCDD): Accumulation in the nasal mucosa. Chemosphere. 12(4/5): 545-548.

Arkansas Department of Pollution Control and Ecology. 1983. Summary of Technical Data. Jacksonville, AR.



**AWPI** (American Wood Preservers Institute). 1977. **Memo** to the Office of Pesticide Program, U.S. EPA, Research Triangle Park, NC.

Ax, R.L. and L.G. Hansen. 1975. Effects of purified PCB analogs on chicken reproduction. *Poult. Sci.* 54: 895-900.

**Axelson, O.** 1980. A note on observational **bias** case-referent studies. *Scand. J. Work Environ. Health.* **6(1)**: 80-82.

Axelson, **O.**, L. Sundell, **K.** Anderson, C. **Edling**, C. **Hogstedt** and H. **Kling**. 1980. Herbicide exposure and tumor mortality: An updated **epidemiologic** investigation on Swedish railroad workers. *Scand. J. Work Environ. Health.* **6**: 73-79.

Baars, **A.J.**, **M. Jansen** and D.D. **Breimer**. 1978. The Influence of phenobarbital, 3-methylcholanthrene, and **2,3,7,8-tetrachlorodibenzo-p-dioxin** on glutathione S-transferase activity of rat liver cytosol. *Biochem. Pharmacol.* 27(21): 2487-2494.

**Ball, L.M.** and R.S. Chhabra. 1981. Intestinal absorption of nutrients in rats treated with **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCOD). *J. Toxicol. Environ. Health.* 8/4: 629-638.

**Ballschmiter, K.**, W. **Krämer**, H. **Magg**, et al. 1984. Distribution of polychlorinated dibenzo-dioxin and -furan emissions between **particulates**, flue gas condensate and impinger absorption in stack gas sampling. *Chemosphere.* **13**: 1139-1142.

**Bandiera, S., T.W. Sawyer, M.A. Campbell, P. Fujita and S. Safe.** 1983. Comparative binding to the **cytosolic 2,3,7,8-tetrachlorodibenzo-p-dioxin** receptor: Effects of structure on the affinities of substituted **halogenated biphenyls** - a QSAR analysis. **Biochem. Pharmacol.** 32: 3803-3813.

Barnes, D.G. 1983. "**Dioxin**" Production from Combustion of **Biomass** and Waste. Presented at the Symposium on Energy from Biomass and Wastes. VII. Lake Buena Vista, **FL.** Jan. 24-28.

**Barsotti, D.A., L.J. Abrahamson and J.R. Allen.** 1979. Hormonal **alterations** in female rhesus monkeys fed a **diet** containing **2,3,7,8-tetrachlorodibenzo-p-dioxin.** **Bull. Environ. Contam. Toxicol.** 21: 463-469.

Bartsch, H., L. **Tomatis** and C. **Malaveille.** 1982. **Qualitative** and quantitative comparisons between **mutagenic** activities of chemicals. **In: Mutagenicity: New Horizons in Genetic Toxicology, J.A. Heddle, Ed.** Academic Press, NY. p. 36-72.

**Baughman, R. and H. Meselson.** 1973. An analytical method for detecting TCDD (**dioxin**): Levels of TCDD in samples from Vietnam. **Environ. Health Perspect.** 5: 27-35.

**Beale, M.G., W.T. Shearer, M.M. Karl and A.M. Robson.** 1977. Long-term effects of dioxin exposure. **Lancet.** April 2. p. 748.

Beatty, **P.W. and R.A. Neal.** 1975. Effect of alteration of hepatic mixed function **oxidase** activity on the **toxicity** of **2,3,7,8-tetrachlorodibenzo-dioxin (TCOD)** in rats. **Toxicol. Appl. Pharmacol.** 33: 151.

Beatty, P. and R.A. Neal. 1976a. Induction of DT-diaphorase by **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD). **Biochem. Biophys. Res. Commun.** 12. 68(1): 197-204.

Beatty, P.W. and R.A. Neal. 1976b. Induction of DT-diaphorase activity of rat liver by **2,3,7,8-tetrachlorodibenzo-p-dioxin**. **Toxicol. Appl. Pharmacol.** 37: 189.

Beatty, P. and R.A. Neal. 1978. Factors affecting the Induction of **DT-diaphorase** by **2,3,7,8-tetrachlorodibenzo-p-dioxin**. **Biochem. Pharmacol.** 27(4): 505-510.

Beatty, P.W., K.J. Lembach, M.A. Holscher and R.A. Neal. 1975. Effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on mammalian cells in tissue cultures. **Toxicol. Appl. Pharmacol.** 31(2): 309-312.

Beatty, P.W., M.A. Holscher and R.A. Neal. 1976. **Toxicity** of 2,3,7,8-**tetrachlorodibenzo-p-dioxin** in larval and adult forms of Rana catesbeiana. **Bull. Environ. Contam. Toxicol.** 16(5): 578-581.

Beatty, P.W., W.K. Vaughn and R.A. Neal. 1978. Effect of alteration of rat hepatic mixed-function **oxidase (MFO)** activity on the **toxicity** of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). **Toxicol. Appl. Pharmacol.** 45(2): 513-519.

Benedict, W.F., N. Conslidine and D.W. Nebert. 1973. Genetic differences in **aryl** hydrocarbon hydroxylase Induction and benzo[a]pyrene-produced **tumor1-genesis** in the mouse. **Mol. Pharmacol.** 9: 266-277.

**Benfenati, E., F. Glzzl, R. Reginate, R. Fanelli, M. Lodi and R. Taghaferri.** 1983. **Polychlorinated dibenzo-p-dioxins (TCDD) and polychlorinated dibenzofurans (PCDF)** in emissions from an urban Incinerator. II. Correlation between concentration of **micropollutants** and combustion conditions. **Chemosphere.** (In **press**)

**Berry, D.L., J. DiGiovanni, M.R. Juchau, W.M. Bracken, G.L. Gleason and T.J. Slaga.** 1978. Lack of tumor-promoting ability of certain environmental chemicals in a two-stage mouse **skin tumorigenesis** assay. 20(1): 101-108.

**Berry, D.L., T.J. Slaga, J. DiGiovanni and M.R. Juchau.** 1979. Studies **with chlorinated dibenzo-p-dioxins, polybrominated biphenyls, and polychlorinated biphenyls** in a two-stage system of mouse **skin tumorigenesis**: Potent anti-carcinogenic effects. Ann. NY Acad. **Sci.** 320: 405-414.

**Biocca, M., B.W. Gupta, K. Chae, J.D. McKinney and J.A. Moore.** 1981. Toxicity of selected symmetrical **hexachlorobiphenyl isomers** in the mouse. **Toxicol. Appl. Pharmacol.** 58: 461-474.

Bisanti, L., F. **Bonetti, F. Caramaschi, et al.** 1980. Experiences from the accident of Seveso. Acta. Morphol. Acad. Sc. Hung. 28(1-2): 139-157.

Bishop, C.M. and **A.H. Jones.** 1981. Non-Hodgkin's **lymphoma** of the scalp in workers exposed to **dioxins.** Lancet. 2(8242): 369.

**Bleiburg, J., M. Wallen, R. Brodtkin and I. Applebaum.** 1964. Industrially acquired **porphyria.** Arch. **Dermatol.** 84: 793-797.

- Boeri, E.** 1978. Report to **Lombardy** Regional Authority (**unpublished**).  
(Cited in **Pocchiarri et al.**, 1979}
- Bogen, G. 1979. Symptoms in Vietnam veterans exposed to Agent Orange. *J. Am. Med. Assoc.* 242(22): 2391.
- Bollen, **W.B.** and **L.A. Norris.** 1979. Influence of **2,3,7,8-tetrachloro**dibenzo-p-dioxin on respiration in a forest floor and **soil**. *Bull. Environ. Contam. Toxicol.* 22(4-5): 648-652.
- Bonaccorsi, A., R. Fanelli** and G. **Tognoni.** 1978. In the wake of Seveso. *Ambio.* 7(5-6): 234-239.
- Bonaccorsi, **A., A. diDomenico, R. Fanelli,** et al. 1983. The Influence of **soil** particle adsorption on **TCDD** biological uptake in the rabbit. *Arch. Toxicol.* (In press)
- Botre, C., A. **Memoli** and F. **Alhaique.** 1978. **TCDD solubilization** and photo-decomposition in aqueous solutions. *Environ. Sci. Technol.* 12(3): 335-336.
- Bradlaw, **J.A.** and J.L. **Casterline,** Jr. 1979. Induction of enzyme activity in cell culture: A rapid screen for detection of planar polychlorinated organic compounds. *J. Assoc. Off. Anal. Chem.* 62: 904-906.
- Bradlaw, J.A.,** L.H. Garthoff, O. Graff and N.E. Hurley. 1975. Detection of chlorinated **dioxins** Induction of **aryl** hydrocarbon hydroxylase activity in rat hepatoma cell culture. *Toxicol. Appl. Pharmacol.* 33(1): 166.

Bradlaw, **J.A.**, L.H. Garthoff, N.E. Hurley and D. Firestone. 1976. **Aryl hydrocarbon hydroxylase activity of twenty-three halogenated dlbenzo-p-dioxins** (Meeting Abstract). **Toxicol. Appl. Pharmacol.** 37(1): 119.

**Bradlaw, J.A.**, L.H. Garthoff, N.E. Hurley and D. Firestone. 1980. Comparative Induction of **aryl** hydrocarbon hydroxylase activity **in vitro** by analogues of dlbenzo-p-dioxin. **Food Cosmet. Toxicol.** 18: 627-635.

Brewster, **D.W.**, B.V. **Madhukar** and F. **Matsumura**. 1982. Influence of **2,3,7,8-TCDD** on the protein composition of the plasma membrane of hepatic cells from the rat. **Biochem. Biophys. Res. Commun.** 107(1): 68-74.

**Bronzetti, G.**, I. Lee, E. **Zeiger**, et al. 1980. Genetic effects of TCDD **in vitro** and **in vivo** using D7 strain of **S. cerevisiae**. **Mutat. Res.** 74/3 (75).

Bronzetti, **G.**, C. Bauer, C. **Corsi**, R. Del Carratore, R. **Neeri** and **M. Paoline**. 1983. **Mutagenicity** study of TCDD and ashes from urban Incinerator "in vitro" and "in **vivo**" using yeast D7 strain. **Chemosphere.** 12: 549-553.

Brumley, **W.C.**, **J.A.G.** Roach, **J.A.** Sphon, et al. 1981. Low-resolution multiple ion detection gas **chromatographic-mass spectrometric** comparison of **six** extraction-cleanup methods for determining **2,3,7,8-tetrachlorodibenzo-p-dioxin** in fish. **J. Agric. Food Chem.** 29(5): 1040-1046.

**Bumb, R.R.**, **W.B. Crummett**, S.S. **Cutie**, et al. 1980. Trace chemistries of fire: A source of chlorinated **dioxins**. **Science.** 210: 385-390.

Burns, L.H., **D.M. Cline** and R.R. **Lassiter**. 1981. Exposure analysis model-  
ing system (EXAMS). Prepared by the Environmental Research Laboratory, ORD,  
U.S. EPA, Athens, GA.

Bus, J.S. and J.E. **Gibson**. 1979. Lipid **peroxidation** and **its** role in  
toxicology. In: **Reviews in Biochemical Toxicology**, E. Hodgson, J.R. Bend  
and R.M. Philpot, Ed. **Elsevier/North Holland**, NY. 1: 125-149.

Buser, H.R. 1975. **Polychlorinated dibenzo-p-dioxin**: Separation and Identifi-  
cation of **isomers** by gas chromatography-mass **spectrometry**. *J. Chromatogr.*  
114: 95-108.

Buser, H.R. 1976. High-resolution gas **chromatography** of **polychlorinated**  
dibenzo-p-dioxins and **dibenzofurans**. *Anal. Chem.* 48: 1553-1557.

Buser, H.R. 1978. Analysis of **TCDD** by gas chromatography-mass spectrometry  
using glass capillary columns. In: **Dioxin: Toxicological and Chemical**  
**Aspects**, F. Cattabeni, A. Cavallaro and G. Galli, Ed. SP Medical and Scien-  
tific Books, NY. p. 27-41.

Buser, H.R. 1979. Formation of **polychlorinated** dibenzofurans (PCDFs) and  
dibenzo-p-dioxins (PCDDs) from **pyrolysis** of **chlorobenzenes**. *Chemosphere.*  
6: 415-424.

Buser, H.R. and H.P. **Bosshardt**. 1976. Determination of polychlorinated  
**dibenzo-p-dioxins** and dibenzofurans in commercial pentachlorophenols by  
combined GC-MS. *J. Assoc. Off. Anal. Chem.* 59: 562-569.

Buser, H.R. and H.P. Bosshardt. 1978. **Polychlorinated** dibenzo-p-dioxins, **dibenzofurans**, and benzenes in the fly ash of municipal and Industrial Incinerators. **Mitt. Geb. Lebens. Hyg.** 69: 191-199.

Buser, H.R. and C. Rappe. 1978. **Identification** of substitution patterns in **polychlorinated** dibenzo-p-dioxins (**PCDDs**) by mass spectrometry. **Chemosphere.** 7: 199-211.

**Buser,** H.R. and C. Rappe. 1980. **High resolution gas chromatography** of the 22 tetrachlorodibenzo-p-dioxin **isomers.** **Anal. Chem.** 52: 2257-2262.

Buser, H.R. and C. Rappe. 1983. **Isomer-specific** separation and analysis of **2,3,7,8-substituted polychlorinated** dibenzo-p-dioxins (PCDDs) using high-resolution gas chromatography and mass spectrometry. **Anal. Chem.** (In review)

Buser, H.R., H.P. Bosshardt and C. Rappe. 1978. **Identification** of polychlorinated dibenzo-p-dioxin Isomers formed in fly ash. **Chemosphere.** 7: 165-172.

Buu-Hoi, **N.P.**, Pham-Huu-Chanh, G. Sesque, **M.C. Azum-Gelade** and G. Saint-Ruf. 1972. Organs as targets of **dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin)** Intoxication. **Naturwissenschaften.** 59(4): 174-175.

Callahan, **M.A.**, **M.W. Slimak**, **N.W. Gabel**, et al. 1979. **Water-Related Environmental Fate of 129 Priority Pollutants.** Vol. I. EPA 440/4-79-029a, Office of Water Planning and Standards, Office of Water and Wastewater Management, U.S. EPA, Washington, DC.



**Camoni, I., A. DiMuccio, D. Pontecorvo, et al.** 1983. Lack of in vitro oxidation of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCOD) in the presence of laccase from **Polyporus versicolor** fungus. **Chemosphere**. (In press)

**Cantoni, L., M. Rizzardi, G. Belvedere, R. Cantoni, R. Fanelli and M. Salmona.** 1981. Induction of mixed-function **oxidase** by chronic treatment with **2,3,7,8-tetrachlorodibenzo-p-dioxin** in female rats. **Toxicology**. 21(2): 159-167.

**Caramaschi, F., G. del Crono, C. Favarett, S.E. Giambelluca, E. Montesarchio and G.M. Fara.** 1981. Chloracne following environmental contamination by TCDD in Seveso, **Italy**. **Int. J. Epidemiol.** 10(2): P135-143.

**Carlstedt-Duke, J.M.** 1979. Tissue distribution of the receptor for **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the rat. **Cancer Res.** 39(8): 3172-3176.

Carlstedt-Duke, **J.M.**, G. Elfstrom, B. Hogberg and **J.A. Gustafsson.** 1979. Ontogeny of the rat hepatic receptor for **2,3,7,8-tetrachlorodibenzo-p-dioxin** and its **endocrine** independence. **Cancer Res.** 39(11): 4653-4656.

Carlstedt-Duke, **J.M.B.**, V.B. **Harnemo**, B. Hogberg and J.A. Gustafsson. 1981. Interaction of the hepatic receptor protein for **2,3,7,8-tetrachlorodibenzo-p-dioxin** with DNA. **J. Biochem. Biophys. Acta.** 672(2): 131-141.

Carter, C.D., R.D. **Kimbrough**, J.A. **Liddle**, et al. 1975. **Tetrachlorodibenzo-p-dioxin**: An accidental poisoning episode in horse arenas. **Science**. 188: 738-740.

Cavallaro, A., G. Bartolozzi, D. Carreri, G. Bandl, L. Luciani and G. Villa. 1980a. Method for the determination of **2,3,7,8-tetrachlorodibenzo-p-dioxin** at ppt levels in vegetables by **high resolution gas chromatography** and **low-resolution** mass spectrometry. **Chemosphere. 9(10): 623-628.**

Cavallaro, A., G. Bandl, G. Invernizzi, L. Luciani, E. Mongini and A. Corni. 1980b. Sampling, occurrence and evaluation of PCODs and PCDFs from Incinerated solid urban waste. **Chemosphere. 9(10): 611-621.**

Cavallaro, A., G. Tebaldi and R. Gauldi. 1982. Analysis of transport and ground deposition of the TCDD emitted on **10** July 1976 from the **ICMESA** factory (Seveso, Italy). **Atmos. Environ. 16: 731-740.**

**CEQ (Council on Environmental Quality).** 1981. 12th Annual Report of the Council on Environmental Quality. **Washington, DC. p. 129.**

Chen, 3-Y.T. 1973. Infrared studies of chlorinated dibenzo-p-dioxins and structurally related compound. **J. Assoc. Off. Anal. Chem. 56: 962-975.**

/

Cheney, B.V. 1982. Structural factors affecting the **aryl** hydrocarbon hydroxylase Induction by **dibenzo-p-dioxins** and **dibenzofurans.** **Int. J. Quantum Chem. XXI: 445-463.**

Chess, E.K. and M.L. Gross. 1980. **Determination** of tetrachlorodibenzo-p-dioxins by mass **spectrometric metastable** decomposition monitoring. **Anal. Chem. 52: 2057-2061.**

**Cheung, M.O., E.F. Gilbert and R.E. Petersen.** 1981. Cardiovascular **teratogenicity** of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the chick embryo. **Toxicol. Appl. Pharmacol.** 61: 197-204.

Chhabra, R.S., **T.J. Michael, R.M. Philopot** and **J.R. Fouts.** 1976. Relation between Induction of **aryl** hydrocarbon hydroxylase and de novo synthesis of **cytochrome P-448 (P1-450)** in mice. **Environ. Health Sci.,** Research Triangle Park, NC.

**Chiappino, G., R. Gilioli and V. Foa.** 1978. Report of Lombardy Regional Authority (unpublished). (Cited in Pocchiarl et al., 1979)

Choudhary, G. 1983. Occupational exposure to **polychlorinated dibenzo-p-dioxins** and **dibenzofurans:** A perspective. **In:** Chlorinated Dioxins and **Dibenzofurans** in the Total Environment, G. Choudhary, L.H. Keith and C. Rappe, Ed. Butterworth **Pubs.,** Boston, MA. p. 335-353.

**Choudhry, G.G. and O. Hutzinger.** 1984. Photochemical formation and degradation of **polychlorinated dibenzofurans** and **dibenzo-p-dioxins.** **In:** Residue Reviews. Residues of Pesticides and Other Contaminants in the Total Environment, **F.A. Gunther and J.D. Gunther,** Ed. **Springer-Verlag,** New York. Vol. 84, p. 113-161.

Clark, **D.A., J. Gaultie, M.R. Szewczuk** and G. Sweeney. 1981. Enhanced suppressor cell activity as a mechanism of **immunosuppression** by 2,3,7,8-tetrachlorodibenzo-p-dioxin (41275). **Proc. Soc. Exp. Biol. Med.** 168(2): 290-299.

**Clark, D.A.**, G. Sweeney, S. Safe, E. Hancock, **D.G. Kilburn** and J. **Gauldie**. 1983. Cellular and genetic basis for suppression of **cytotoxic T cell** generation by **haloaromatic** hydrocarbons. **Immunopharmacology**. 6: 143-153.

Clement Associates. 1979. Exposure, **toxicity** and **risk** assessment of **2,4,5-T/TCDD**. Prepared for U.S. EPA under contract no. **68-01-5095**.

Clement, R.E. and **F.W. Karasek**. 1982. Distribution of organic compounds adsorbed on size-fractionated municipal Incinerator fly ash particles. **J. Chromatogr.** 234: 395-405.

Cochrane, **W.P.**, J. Singh, **W. Miles** and B. **Wakeford**. 1981. Determination of chlorinated dibenzo-p-dioxin contaminants in **2,4-D** products by gas chromatography-mass **spectrometric** techniques. **J. Chromatogr.** 217: 289-299.

**Cockerham**, L.G., **A.L. Young** and C.E. **Thalke**. 1980. **Histopathological** and ultrastructural studies of liver tissue from TCDD-exposed beach **mice** (*Peromyscus polionotus*). **J. AD-A083 323/6 PC A04/MF A01**. 61 p.

**Cocucci, S.**, F. Di Gerolamo, A. **Verderio**, et al. 1979. Absorption and **translocation** of **tetrachlorodibenzo-p-dioxin** by plants from polluted **soil**. **Experientia**. 35(4): 482-484.

Cohen, **G.M.**, **W.M. Bracken**, **R.P. Iyer**, D.L. Berry, **J.K. Selkirk** and T.J. **Slaga**. 1979. **Anticarcinogenic** effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on benzo(a)pyrene and **7,12-dimethylbenz(a)anthracene** tumor Initiation and its relationship to DNA binding. **Cancer Res.** 39(10): 4027-4033.

**Collins, T.F.S., C.H. Williams and G.C. Gray. 1971. Teratogenic studies with 2,4,5-T and 2,4-D in the hamster. Bull. Environ. Contam. Toxicol. 6(6): 559-567.**

Conway, C.C. and F. **Matsumura. 1975. Alteration of cellular utilization of thymidine by TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin). Bull. Environ. Contam. Toxicol. 13(1): 52-56.**

Cook R.R. 1981a. Dioxin, chloracne and soft-tissue sarcoma. *Lancet.* 1: 618-619.

Cook, R.R. **1981b. Mortality experience of employees to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Reply to comments. J. Occup. Med. 23(1): 8.**

Cook, R.R., J.C. **Townsend, M.G. Ott and L.G. Silverstein. 1980. Mortality experience of employees exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Occup. Med. 22(8): 530-532.**

Cordle, F. 1981. The use of epidemiology in the regulation of **dioxins** in the food supply. *Regulatory Toxicol. Pharmacol.* 1: 379-387.

Cordle, F. 1983. Use of **epidemiology** in the regulation of dioxins in the food **supply.** in: *Accidental Exposure to Dioxins: Human Health Aspects*, F. Coulston and F. Pocchiarl, Ed. Academic Press, NY. p. 245-256.

**Coulston, F.** and **E.J. Olajos.** 1980. Panel Report: Panel to Discuss the Epidemiology of **2,4,5-T.** New York **City,** July 10-11, 1979. **Ecotoxicol. Environ. Safety.** 4: **96-102.**

Courtney, **K.D.** 1976. Mouse **teratology** studies **with** chlorodibenzo-p-dioxins. **Bull. Environ. Contam. Toxicol.** 16(6): P674-681.

Courtney, **K.D.** 1977. Prenatal effects of herbicides evaluation by the **prenatal development** Index. **Arch. Environ. Contam. Toxicol.** 6(1): 33.

Courtney, **K.D.** and **J.A. Moore.** 1971. Teratology studies **with 2,4,5-T** and **2,3,7,8-TCDD.** **Toxicol. Appl. Pharmacol.** 20: 396-403.

Courtney, **K.D., D.W. Gaylor, M.D. Hogan** and **H.L. Falk.** 1970a. **Teratogenic** evaluation of pesticides: Large-scale screening study. **Teratology.** 3: 199.

Courtney, **K.D., D.W. Gaylor, M.D. Hogan, M.L. Falk, R.R. Bates** and **I. Mitchell.** 1970b. Teratogenic evaluation of 2,4,5-T. **Science.** 168: 864-866.

Courtney, **K.D., J.P. Putnam** and **J.E. Andrews.** 1978. **Metabolic** studies **with TCDD (dioxin)** treated rats. **Arch. Environ. Contam. Toxicol.** 7(4): 385-396.

**Crampton, M.A.** and **L.J. Rogers.** 1983. Low doses of **2,4,5-trichlorophenoxy-acetic** acid are **behaviorally teratogenic** to rats. **Experientia.** 39: 891-892.

- Crosby, D.G. and A.S. Wong. 1976. **Photochemical** generation of chlorinated **dioxins**. Chemosphere. 5: 327-332.
- Crosby, D.G. and A.S. Wong. 1977. **Environmental** degradation of 2,3,7,8-**tetrachlorodibenzo-p-dioxin** (TCDO). Science. 195: 1337-1338.
- Crosby, **D.G.**, A.S. Wong, J.R. **Plimmer** and **E.A.** Woolson. 1971. **Photodecomposition** of chlorinated dibenzo-p-dioxins. Science. 173(3998): 748-749.
- Crow, K. 1978a. Chloracne: The chemical disease. New **Sci.** **78(1098)**: 78-80.
- Crow, K.D. 1978b. Chloracne -- An up to date assessment. J. Ann **Occup. Hyg.** 21(3): 297-298.
- Crow, K.D. 1981. Chloracne and **its** potential clinical Implications. **Clin. Exp. Dermatol.** 6/3: 243-257.
- Crummett**, W.B. 1980. Dioxin detection. Nature. 283: 330.
- Crummett**, W.B. **1983**. Status of analytical systems for the determination of PCDDs and PCDFs. Chemosphere. 12: 429-446.
- Crummett, W.B. and R.H. **Stehl**. 1973. Determination of chlorinated **dibenzo-p-dioxins** and **dibenzofurans** in various materials. Environ. Health Perspect. 5: 15-25.

**Crummett, W.B., R.R. Bumb, L.L. Lamparski, N.H. Mahle, T.J. Nestrick and L.W. Whiting.** 1981. Environmental chlorinated **dioxins** from combustion: The trace chemistries of **fire** hypothesis. **In:** Impact of Chlorinated Dioxins and **Related Compounds in the Environment**, O. Hutzinger et al., Ed. Pergamon Press, Oxford. p. 253-263.

Crump, **K.S.** and **W.W.** Watson. 1979. GLOBAL 79: A Fortran program to extrapolate **dichotomous** animal **carcinogenicity** data to low dose. **NIEHS**, Contract No. **I-ES-2123**.

Crump, **K.S., H.A. Givess** and **L.L. Deal.** 1977. Confidence Intervals and test of hypothesis concerning dose-response relations Inferred from animal **carcinogenicity** data. Biometrics. 33: 437-451.

Cunningham, **H.M.** and **D.T. Williams.** 1972. Effect of **2,3,7,8-tetrachloro-**dlbenzo-p-dioxin on growth rate and the synthesis of **lipids** and proteins in rats. Bull. Environ. **Contam. Toxicol.** 7(1): 45-51.

**Cupitt, L.T.** 1980. Fate of Toxic and Hazardous Materials **in** the Air Environment. EPA EPA 600/3-80-084, Environmental Sciences Research Laboratory, Research Triangle Park, NC.

**Cutie, S.S.** 1981. Recovery efficiency of **2,3,7,8-tetrachlorodibenzo-p-dioxin** from active carbon and other **particulates**. Anal. Chim. Acta. 123: 25-31.



**Czeizel, E. and J. Kiraly. 1976. Chromosome examinations** in workers producing **Klorinol** and **Buminol**. **In:** The Development of a Pesticide as a Complex Scientific Task, L. **Banki**, Ed. **Medicina: Budapest.** p. 239-256. **(Cited in NRCC, 1981a)**

**Czuczwa, J.M. and R.A. Hites. 1984. Environmental fate of combustion-generated polychlorinated dioxins and furans.** Environ. **Sci. Technol.** 18(6): 444-450.

Czuczwa, **J.M.**, B.D. **McVeety** and R.A. **Hites.** 1984. **Polychlorinated dibenzo-p-dioxins** and **dibenzofurans** in sediments from **Stsklwlt Lake, Isle Royale.** Science. 226: 568-569.

Czuczwa, **J.M.**, B.D. **McVeety** and R.A. **Hites.** 1985. **Polychlorinated dibenzo-dioxins** and **dibenzofurans** in sediments from **Stsklwlt Lake, Isle Royale.** **Chemosphere.** 14(6/7): 623-626.

**D'Argy, R., E. Hassoun and L. Dencker. 1984. Teratogenicity of TCDD and the congener 3,3'-4,4'-tetrachloroazobenzene** in sensitive and non-sensitive mouse strains after reciprocal blastocyst transfer. **Toxicol. Lett.** 21: 197-202.

Dees, J.H., B.S. **Masters**, U. **Muller-Eberhard** and E.F. **Johnson.** 1982. Effect of **2,3,7,8-tetrachlorodibenzo-p-dioxin** and **phenobarbital** on the occurrence and distribution of four cytochrome P-450 **isozymes** in rabbit kidney, lung, and liver. **Cancer Res.** 42(4): 1423-1432.

**Deitrich, R.A., P. Bludeau, T. Stock and M. Roper. 1977.** Induction of different rat liver supernatant aldehyde dehydrogenases by **phenobarbital** and tetrachlorodibenzo-p-dioxin. *J. Biol. Chem.* **252(17)**: 6169-6176.

Delgado, S. 1983. **Division** of Regulatory Guidance, Case and Advisory Branch, U.S. FDA. Personal **communication**.

Dencker, L. and **R.M. Pratt.** 1981. Association between the presence of the Ah-receptor in embryonic **murine** tissues and sensitivity to TCDD-induced **cleft** palate. *Teratol. Carinog. Mutagen.* **1**: 399-406.

Department of Health, New Zealand. **1980.** Report to the Minister of Health of an investigation **into** allegations of an association between human congenital defects and **2,4,5-T** spraying **in** and around Te **Kuiti**. *New Zealand Med. J.* p. 314-315.

De **Verneuil, H., S. Sassa and A. Kappas.** **1983.** Effects of **polychlorinated biphenyl** compounds, **2,3,7,8-tetrachlorodibenzo-p-dioxin**, **phenobarbital** and **iron** on hepatic **uroporphyrinogen** decarboxylase. *Biochem. J.* **214**: 145-151.

Dickens, **M., M.D. Seefeld and R.E. Peterson.** 1981. Enhanced liver DNA synthesis in partially **hepatectomized** rats pretreated **with 2,3,7,8-tetra-**chlorodibenzo-p-dioxin. *Toxicol. Appl. Pharmacol.* **58(3)**: 389-398.

**DiDomenico, A., V. Silano, G. Vivlano and G. Zapponi.** 1980a. Accidental release of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) at Seveso, Italy. I. Sensitivity and specificity of analytical procedures adopted for TCDD assay. *Ecotoxicol. Environ. Safety.* **4(3)**: 283-297.

DiDomenlco, **A.**, V. **Silano**, G. **Vivlano** and G. **Zapponi**. 1980b. **Accidental** release of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** as Seveso, Italy. VI. TCDD levels in atmospheric particles. **Ecotoxicol. Environ. Safety**. 4(3): 346-356.

**DiDomenlco, A.**, V. **Silano**, G. **Viviano** and G. **Zapponi**. 1980c. Accidental release of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** at **Seveso**, Italy. II. TCDD distribution in the **soil** surface layer. **Ecotoxicol. Environ. Safety**. 4(3): 298-320.

DiDomenlco, **A.**, V. **Sllano**, G. **Viviano** and G. **Zapponi**. 1980d. Accidental **release** of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** in Seveso, Italy. V. Environmental persistence of TCDD in **soil**. **Ecotoxlcol. Environ. Safety**. 4(3): 339-345.

DiDomenlco, **A.**, V. **Sllano**, G. **Vivlano** and G. **Zapponi**. 1980e. Accidental **release** of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** at Seveso, Italy. IV. **Vertical** Distribution of TCDD in **soil**. **Ecotoxlcol. Environ. Safety**. 4(3): 327-338.

DiDomenlco, **A.**, G. **Viviano** and G. **Zapponi**. 1982. Environmental persistence of **2,3,7,8-TCDD** at Seveso. **In: Chlorinated Dioxins and Related Compounds: Impact on the Environment**, O. **Hutzinger** et al., Ed. **Pergamon Press**, NY. p. 105-114.

Dietrich, **R.A.**, R. **Bludeau**, **M. Roger** and J. **Schmuck**. 1978. Induction of aldehyde **dehydrogenases**. **Biochem. Pharmacol.** 27: 2343-2347.

DlGiovanni, J., A. **Viaje**, D.L. Berry, T.J. **Slaga** and M.R. **Juchau**. 1977. Tumor-initiating ability of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) and arochlor **1254** in the two-stage system of mouse **skin carcinogenesis**. Bull. Environ. Contam. **Toxicol.** 18(5): 552-557.

DlGiovanni, **J.**, D.L. Berry, M.R. Juchau and T.J. Slaga. 1979a. 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Potent **anticarcinogenic** activity in **CD-1 mice**. **Biochem. Biophys. Res. Commun.** 86(3): 577-584.

DlGiovanni, **J.**, D.L. Berry, T.J. Slaga, **A.H.** Jones and M.R. Juchau. 1979b. Effects of **pretreatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin** on the capacity of hepatic and **extrahepatic** mouse tissues to convert **procarcinogens** to **mutagens** for Salmonella typhimurium auxotrophs. **Toxicol. Appl. Pharmacol.** 50(2): 229-239.

DlGiovanni, **J.**, D.L. Berry, G.L. Gleason, G.S. **Kishore** and T.J. Slaga. 1980. Time-dependent inhibition by **2,3,7,8-tetrachlorodibenzo-p-dioxin** of **skin tumorigenesis with polycyclic hydrocarbons**. **Cancer Res.** 40(5): 1580-1587.

DlLernia, R., C. **Crimaudo** and G. **Pacchetti**. 1982. The study of X-rays and TCDD effects on satellite associations may suggest a simple model for application in environmental **mutagenesis**. **Hum. Genet.** 61(1): 42-47.

Dobbs, **A.J.** and C. Grant. **1979**. Photolysis of highly chlorinated **dibenzo-p-dioxins** by sunlight. **Nature.** 278: 163-165.

Dougherty, **W.J.**, **M. Herbst** and **F. Coulston**. 1975. The **non-teratogenicity** of **2,4,5-trichlorophenoxyacetic** acid in the rhesus monkey, **Macaca mulatta**. Bull. Environ. **Contam. Toxicol.** 13: 477-482.

Dow Chemical Co. 1978. The trace chemistries of **fire** -- A source of and routes for the entry of chlorinated **dioxins into** the environment. The Chlorinated Dioxin Task Force, the **Michigan** Division, Dow Chemical, U.S.A.

**Duran-Reynolds, M.**, **F. Lillie**, **H. Bartsch** and **K.J. Blank**. 1978. The genetic basis of **susceptibility** to leukemia induction in **mice** by **3-methylcholanthrene** applied subcutaneously. J. Exp. **Med.** 147: 459-469.

**Edling, C.** and **S. Granstam**. 1979. XXXVI. National Conference of the Medical Society sponsored by the Swedish Medical Society at Stockholmsmasan, **Alvifi**, Stockholm, December 5-8, 1979. Summaries transaction of the Swedish **Medical** Society. 88(3): 73-74. (translation)

**Eiceman, G.A.**, **R.E. Clement** and **F.W. Karasek**. 1979. Analysis of fly ash from municipal Incinerators for trace organic compounds. Anal. **Chem.** 51(14): 2343-2350.

**Eiceman, G.A.**, **A.C. Vlau** and **F.W. Karasek**. 1980. Ultrasonic extraction of **polychlorinated** dibenzo-p-dioxins and other organic compounds from fly ash from municipal Incinerators. Anal. Chem. 52: 1492-1496.

**Eiceman, G.A.**, R.E. Clement and **F.W. Karasek**. 1981. Variations in concentrations of organic compounds Including **polychlorinated** dibenzo-p-dioxins and polynuclear aromatic hydrocarbons in fly ash from a municipal Incinerator. **Anal. Chem.** 53(7): 955-959.

Elsen, H.J. 1984. The nuclear TCDD:Ah receptor complex and the Induction of **cytochrome P<sub>1</sub>-450** on RNA. **In**: Biological Mechanisms of **Dioxin** Action. Banbury Report 18. A. Poland and R.D. **Kimbrough**, Ed. Cold Spring Harbor **Laboratory**. p. 201-211.

Elovaara, E., H. **Savolainen**, **M.G. Parkki**, A. Altio and H. Valnio. 1977. **Neurochemical** effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in **Wistar** and Gunn rats. **Research Commun. Chem. Pathol. Pharmacol.** 18: 487-494.

**Emerson, J.L.**, D.J. Thompson, C.G. **Gerbig** and V.B. Robinson. 1970. **Teratogenic** study of **2,4,5-trichlorophenoxyacetic** acid in the rat. **Toxicol. Appl. Pharmacol.** 17: 317.

Emerson, **J.L.**, D.J. Thompson. R.J. **Strebing**, C.G. Gerbig and B. Robinson. 1971. **Teratogenic** studies of **2,4,5-T** in the rat and rabbit. **Food Cosmet. Toxicol.** 9: 395.

Environmental Canada. 1984. **Chlorophenols** and their Impurities in the Canadian environment. 1983 Supplement. Economic and **Technical** Review Report. EPS3-EP-84-3. Environmental Protection Programs. Directorate, **Canada**.

**Erickson, J.O., J. Mulinare, P.W. McClain, et al.** 1984. Vietnam veterans' risks for fathering babies with birth defects. J. Am. Med. Assoc. 252(7): 903-912.

Eriksson, M., L. Hardell, N.O. Berg, T. Moller and O. Axelson. 1979. Case-control study on malignant **mesenchymal** tumors of the soft-tissue and exposure to chemical substances. Lakartidningen. 76: 3872-3875. (translation)

Eriksson, M., L. Hardell, N. O'Berg, T. Moller and O. Axelson. 1981. Soft-tissue sarcomas and exposure to chemical substances: A case-referent study. Br. J. Ind. Hed. 38: 27-33.

**Facchetti, S., A. Fornari** and H. Montagna. 1980. Distribution of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the tissues of a person exposed to the toxic cloud at Seveso (Italy). Adv. Mass Spectrom. 8B: 1405-1414.

Faith, R.E. and H.I. Luster. 1979. Investigations of the effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on parameters of various Immune functions. Ann. NY Acad. Sci. 320: 564-571.

**Fanelli, R., C. Chiabrando, H. Salmona, S. Garattini** and P.G. Caldera. 1978. Degradation of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in organic solvents by gamma ray Irradiation. Experientia. 34: 1126-1127.

Fanelli, R., M.P. Bertonl, M. Bonfanti, et al. 1980a. Routine analysis of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in biological samples from the contaminated area of Seveso, Italy. Bull. Environ. Contam. Toxicol. 24(6): 818-823.

Fanelli, R., M.P. Bertonl, M.G. Castelll, et al. 1980b. **2,3,7,8-Tetra-**chlorodibenzo-p-dioxin toxic effects and tissue levels in animals from the contaminated area of Seveso, Italy. Arch. Environ. Contam. Toxicol. 9(5): 569-577.

Fanelli, R., M.G. Castelll, G.P. Martelli, A. Nosedà and S. Garattini. 1980c. Presence of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in wildlife living near Seveso, Italy: A preliminary study. Bull. Environ. Contam. Toxicol. 24(3): 460-462.

Fanelli, R., C. Chiabrando and A. Bonaccorsi. 1982. TCDO contamination in the Seveso Incident. Drug Metab. Rev. 13: 407-422.

FDA (Food and Drug Administration). 1981. FDA advises Great Lakes states to monitor **dioxin-contaminated fish**. FDA talk paper dated August 28. In: Food Drug Cosmetic Law Reports, Paragraph 41, 321. Commerce Clearing House, Inc. September 8.

FDA (Food and Drug Administration). 1983. Statement by S.A. Miller, Director, Bureau of Foods, FDA, before The Subcommittee on Natural Resources, Agriculture Research and Environment, U.S. House of Representatives, June 30.



Federal Register. 1971. EPA Method 5. Determination of **Particulate** Emissions from Stationary Sources. 36: 24876-24895. December 23.

Federal Register. 1980a. Storage and Disposal of **Waste** Material; Prohibition of Disposal of Tetrachlorodibenzo-p-dioxin. 45(98): 32676.

Federal Register. 1980b. Water Quality Criteria Documents; Availability. 45(231): 79318-79379.

Field, B. and C. **Kerr**. 1979. Herbicide use and Incidence of neural-tube defects. Lancet. **1(8130)**: 1341-1342.

**Fingerhut, M.A.**, W.E. **Halperin**, P.A. Honchar, A.B. Smith, D.H. Groth and W.O. Russell. 1984. An **evaluation** of reports of **dioxin** exposure and soft tissue sarcoma pathology in U.S. chemical **workers**. in: Biological Mechanisms of Dioxin Action. Banbury Report 18. A. Poland and R.D. **Kimbrough**, Ed. Cold Spring Harbor **Laboratory**. p. 461-470. ,

**Finney**, D.J. **1971**. **Probit** Analysis. Cambridge University Press, London. 333 p.

Firestone, D. 1973. Etiology of chick edema disease. Environ. Health Perspect. 5: 59-66.

Firestone, D. 1977a. Chemistry and analysis of pentachlorophenol and its contaminants. FDA **By-lines**. 2: 57-89.

Firestone, D. 1977b. Determination of polychlorodibenzo-p-dioxins and **polychlorodibenzofurans** in commercial **gelatins** by gas-liquid **chromatography**. J. Agric. Food Chem. 25: 1274-1280.

Firestone, D., J. Riss, N.L. Brown, R.P. Barron and J.N. Damico. 1972. Determination of polychlorodibenzo-p-dioxins and **related** compounds in commercial chlorophenols. J. Assoc. Off. Anal. Chem. 55(1): 85-92.

Firestone, D., M. Clower, Jr., A.P. Borsetti, R.H. Teske and P.E. Long. 1979. **Polychlorodibenzo-p-dioxin** and pentachlorophenol residues in **milk** and blood of cows fed technical **pentachlorophenol**. J. Agric. Food Chem. 27(6): 1171-1177.

Fowler, B.A., G.W. Lucier, H.W. Brown and O.S. McDaniel. 1973. Ultrastructural changes in rat liver cells following a single oral dose of TCDD. Environ. Health Perspect. 5: 141-148.

Fries, G.F. and G.S. Marrow. 1975. Retention and excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin by rats. J. Agric. Food Chem. 23(2): 265-269.

Garattini, S. 1982. TCDD toxicology with particular reference to Seveso: Introductory remarks. Drug Metab. Rev. 13(3): 345-353.

Gasiewicz, T.A. and R.A. Neal. 1979. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** tissue distribution, excretion, and effects on clinical chemical parameters in guinea pigs. Toxicol. Appl. Pharmacol. 51(2): 329-340.

Gasiewicz, T.A. and R.A. Neal. 1982. The examination and **quantitation** of tissue **cytosolic** receptors for **2,3,7,8-tetrachlorodibenzo-p-dioxin** using **hydroxyapatite**. *Anal. Biochem.* 124: 1-11.

Gasiewicz, T.A., M.A. Holscher and R.A. Neal. 1980. The effect of total parenteral nutrition on the **toxicity** of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the rat. *Toxicol. Appl. Pharmacol.* 54: 469-488.

**Gasiewicz, T.A., J.R. Olson, L.E. Geiger** and R.A. Neal. 1983a. Absorption, distribution and metabolism of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) in experimental animals. **In:** Human and Environmental Risks of Chlorinated Dioxins and Related Compounds, R.E. Tucker, **A.L. Young** and **A.P. Gray**, Ed. Plenum Press, NY. p. 495-525.

Gasiewicz, T.A., L.E. Gelger, G. **Rucci** and R.A. Neal. 1983b. Distribution, excretion, and metabolism of **2,3,7,8-tetrachlorodibenzo-p-dioxins** in C57B1/6J, DBA/2J and **B6D2F<sub>1</sub>/J** mice. *Drug Metab. Dispos.* (In press)

**Gebefuegi, I., R. Baumann** and F. **Korte**. 1977. Photochemical degradation of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) under simulated environmental conditions. *Naturwissenschaften.* 64(9): 486-487.

Gelger, L.E. and R.A. Neal. 1981. **Mutagenicity** testing of **2,3,7,8-tetra-**chlorodibenzo-p-dioxin in histidine auxotrophs of **Salmonella typhimurium**. *Toxicol. Appl. Pharmacol.* 59(1): 125-129.

Ghezzi, I., P. Cannatelli, G. Assennato, et al. 1982. Potential 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure of Seveso decontamination workers: A controlled prospective study. *Scand. J. Work Environ. Health.* 8(Suppl. 1): 176-179.

Glanotti, F. 1977. Chloracne due to tetrachloro-2,3,7,8-dibenzo-p-dioxin in children. *Ann. Dermatol. Venereol.* 104(12): 825-829.

Glavini, E., M. Prati and C. Vismara. 1982a. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin administered to pregnant rats during the preimplantation period. *Environ. Res.* 29(1): 185-189.

Glavini, E., M. Prati and C. Vismara. 1982b. Rabbit teratology study with 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Environ. Res.* 27(1): 74-78.

Glavini, E., M. Prati and C. Vismara. 1983. Embryotoxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin administered to female rats before mating. *Environ. Res.* 31: 105-110.

Gilbert, P., G. Saint-Ruf, F. Poncelet and M. Mercier. 1980. Genetic effects of chlorinated anilines and azobenzenes on Salmonella typhimurium. *Arch. Environ. Contam. Toxicol.* 9(5): 533-541.

Glizzi, F., R. Reginato, E. Benfenati and R. Fanelli. 1982. Polychlorinated dibenzo-p-dioxins (PCDD) and polychlorinated dibenzofurans (PCDF) in emissions from an urban incinerator. I. Average and peak values. *Chemosphere.* 11: 577-583.

Glaser, **J.A.**, D.L. Foerst, G.D. **McKee**, **S.A.** Quave and **W.L.** Budde. 1981. Trace analyses for **wastewaters**. *Environ. Sci. Technol.* **15(12)**: 1426.

**Goldstein, J.A.**, P. **Hickman**, H. Bergman, J.D. **McKinney** and **M.P.** Walker. 1977. Separation of pure **polychlorinated biphenyl isomers** into two types of **inducers** on the basis of Induction of **cytochrome P-450** or P-448. *Chem.-Biol. Interact.* **17**: 69-87.

Goldstein, **J.A.**, **M. Friesen**, **T.M. Scotti**, P. **Hickman**, J.R. Hass and H. Bergman. 1978. Assessment of the contribution of chlorinated dibenzo-p-dioxins and **dibenzofurans** to hexachlorobenzene-induced **toxicity, porphyria**, changes in mixed function oxygenases, and **histopathological** changes. *Toxicol. Appl. Pharmacol.* **46(3)**: 633-649.

**Goldstein, J.A.**, P. **Linko**, J.N. **Huckins** and **D.L. Stalling**. 1982a. Structure-activity relationships of chlorinated benzenes as Inducers of different forms of cytochrome P-450 in rat liver. *Chem. Biol. Interact.* **41(2)**: **131-139**.

Goldstein, **J.A.**, P. **Linko** and H. Bergman. 1982b. Induction of **porphyria** in the rat by chronic versus acute exposure to **2,3,7,8-tetrachlorodibenzo-p-dioxin**. *Biochem. Pharmacol.* **31(8)**: 1607-1613.

Gonzalez, **F.J.**, R.H. Tukey and **D.W. Nebert**. 1984. Structural gene products of the Ah locus. Transcriptional regulation of cytochrome **P<sub>1</sub>-450** and **P<sub>3</sub>-450 mRNA** levels by 3-methylcholanthrene. *Mol. Pharmacol.* **26**: 117-121.

- Gorski, T. 1981. Presence of **polychlorinated** dibenzo-p-dioxins in latex nipples. Bull. Environ. Contam. Toxicol. 27: 68-71.
- Gray, A.P., S.P. Ceba and J.S. Cantrell. 1975. Intervention of the Smiles rearrangement in synthesis of dibenzo-p-dioxins: 1,2,3,6,7,8- and **1,2,3,7,8,9-hexachlorodibenzo-p-dioxin (HCDD)**. Tetrahedron Lett. 33: 2873-2876.
- Gray, A.P., S.P. Ceba, I.J. Solomon and O. Aniline. 1976. Synthesis of specific **polychlorinated** dibenzo-p-dioxins. J. Org. Chem. 41: 2435-2437.
- Green, S. and F.S. Moreland. 1975. **Cytogenetic** evaluation of several **dioxins** in the rat. Toxicol. Appl. Pharmacol. 33: 161.
- Green, S., F. Moreland and C. Sheu. 1977. **Cytogenic** effect of 2,3,7,8-**tetrachlorodibenzo-p-dioxin** on rat bone marrow cells. U.S. FDA, Washington, DC. FDA By-Lines. 6: 292.
- Greenlee, W.F. and A. Poland. 1978. An Improved assay of **7-ethoxycoumarin O-deethylase** activity: Induction of hepatic enzyme activity in C57B1/6J and DBA/2J mice by **phenobarbital**, **3-methylcholanthrene** and **2,3,7,8-tetrachloro-dibenzo-p-dioxin**. J. Pharmacol. Exp. Ther. 205(3): 596-605.
- Greenlee**, W.F. and A. Poland. 1979. Nuclear uptake of **2,3,7,8-tetrachloro-dibenzo-p-dioxin** in C57B1/6J and DBA/2J mice. Role of the hepatic cytosol receptor protein. J. Biol. Chem. 254(19): 9814-9821.

Greig, J.B. 1972. Effect of **2,3,7,8-tetrachlorodibenzo-1,4-dioxin** on drug metabolism in the rat. **Biochem. Pharmacol.** 21(23): 3196-3198.

Greig, J.B., G. Jones, **W.H. Butler** and **J.M. Barnes.** 1973. Toxic effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin.** **Food Cosmet. Toxicol.** 11: 585-595.

Greig, J.B., **D.M. Taylor** and J.D. Jones. 1974. Effects of **2,3,7,8-tetrachloro-dibenzo-p-dioxin** on stimulated DNA synthesis in the liver and kidney of the rat. **Chem. Biol. Interact.** 8(1): 31-39.

Gross, **M.L.,** T. Sun, **P.A. Lyon,** et al. 1981. Method validation for the determination of **tetrachlorodibenzodioxin** at the low parts-per-trillion level. **Anal. Chem.** 53(12): 1902-1906.

Gross, M.L., J.O. Lay, Jr., **P.A. Lyon,** et al. 1984. **2,3,7,8-Tetrachloro-dibenzo-p-dioxin levels** in adipose tissue of Vietnam veterans. **Environ. Res.** 33: 261-268.

Guenther, **T.M.** and **D.W. Nebert.** 1977. **Cytosolic** receptor for **aryl** hydrocarbon **hydroxylase** Induction by **polycyclic** aromatic compounds. **J. Biol. Chem.** 252: 8981-8989.

Guenther, **T.M.,** J.M. **Fysh** and **D.W. Nebert.** 1979a. **2,3,7,8-Tetrachloro-dibenzo-p-dioxin:** Covalent binding of reactive metabolic intermediates principally to protein in vitro. **Pharmacology.** 19: 12-22.

Guenther, T.M., D.W. Nebert and R.H. Menard. 1979b. **Microsomal aryl hydrocarbon hydroxylase** in rat adrenal: Regulation by ACTH but not by **polycyclic** hydrocarbons. **Mol. Pharmacol.** 15(3): 719-728.

Gupta, B.N., J.G. Vos, J.A. Moore, J.G. Zinkl and B.C. Bullock. 1973. Pathologic effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in laboratory animals. **Environ. Health Perspect.** 5: 125-140.

Gustafsson, J.A. and M. Ingelman-Sundberg. 1979. Changes in steroid hormone metabolism in rat **liver microsomes** following administration of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD). **Biochem. Pharmacol.** 28(4): 497-499.

Hailey, C.L., J.S. Stanley, A.M. Magin, R.V. Northcutt and D.P. Redford. 1983. Emissions of Organic Pollutants from Coal-Fired Utility Boiler Plants. Presented at the ACS Annual Meeting, Seattle, WA. March 20-25.

Hajdu, S.I. 1983. Classification of soft tissue tumors and **tumor-like** lesions. Presented at Symposium on Public Health Risks of the Dioxins, **Rockefeller Univ.**, October 19-20.

Häkansson, H. and U.G. Ahlborg. 1985. The effect of **2,3,7,8-tetrachloro-dibenzo-p-dioxin** (TCDD) on the uptake, distribution and excretion of a single oral dose of **[11,12-<sup>3</sup>H]retinyl** acetate and on the vitamin A status in the rat. **J. Nutr.** 115: 759-771.



**Hallett, D.** 1984. Environment Canada, **Toronto**, Ontario. Private communication with Dr. S.H. Safe, Texasd **A&M Univ.**, College Station, TX.

**Hanify, J.A., P. Metcalf, C.L. Nobbs and R.J. Worsley.** 1981. **Aerial** spraying of **2,4,5-T** and human birth **malformations**: An epdemiological Investigation. Science. 212: **349-351**.

Hardell, L. 1977. Malignant **mesenchymal** tumors and exposure to phenoxy-**acids**: A **clinical** observation. Lakartidningen. 74: 2753-2754. (**translation**)

Hardell, L. 1979. **Malignant lymphoma** of histiocytic type and exposure to **phenoxyacetic** adds or chlorophenols. Lancet. 1: 55-56.

Hardell, L. 1981. Relation of soft-tissue sarcoma, malignant lymphoma and colon cancer to phenoxy adds, **chlorophenols** and other agents. Scand. J. Work Environ. Health. 7: 119-130.

Hardell, L. 1983. Letter to D. **Bayliss**, Carcinogen Assessment Group, U.S. EPA, Washington, DC, August 5.

Hardell, L. and M. Eriksson. 1981. Soft-tissue sarcomas, phenoxy herbicides, and chlorinated phenols. Lancet. 2(8240): 8/1/81.

**Hardell, L. and A. Sandstrom.** 1979. Case-control study: Soft-tissue sarcomas and exposure to phenoxyacetic adds or chlorophenols. Br. J. Cancer. 39: 711-717.

Harden, L., M. Eriksson and P. Lenner. 1980. **Malignant lymphoma** and exposure to chemical substances, especially organic solvents, chlorophenols, and phenoxy adds. *Lakartidningen*. 77: **208-210**. (translation)

Hardell, L., M. Eriksson, P. Lenner and E. Lundgren. 1981. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy adds: A case-control study. *Br. J. Cancer*. 43: 169-176.

Harless, R. 1981. Internal memo to M. Dellarco. Office of Toxic Substances, U.S. EPA, Washington, DC.

Harless, R.L. and R.G. Lewis. 1980a. Quantitative capillary column gas chromatography-mass spectrometry methods of analysis for toxic organic compounds. **Sym.:** Practical Solutions to Quantitative Capillary Column Gas Chromatography. **Cong.:** Anal. Chem. Appl. Spectro., Atlantic City, NJ. March, 1980.

Harless, R.L. and R.G. Lewis. 1980b. Quantitative determination of **2,3,7,8-tetrachlorodibenzo-p-dioxin** residues by gas chromatography/mass spectrometry. Presented at **Workshop** on Impact of Chlorinated **Dioxins** and Related Compounds on the Environment. **Instituto Superiore di Sanita**, Rome, Italy. October 22-24.

Harless, R.L. and R.G. Lewis. 1982. Quantitative determination of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDO) isomers. In: Chlorinated Dioxins and Related Compounds. Impact on the Environment, O. **Hutzinger**, R.W. Frel, E. **Merian** and F. **Pocchiari**, Ed. **Pergamon** Press, NY. p. 25-35.

Harless, R.L. and E.O. Oswald. 1978. Gas **chromatography/mass** spectrometry Interface for glass capillary columns. Paper presented at the 26th Annual Conference Mass Spectrometry. May **28-June 2, 1978**.

**Harless, R.L., E.O. Oswald, M.K. Wilkinson, et al.** 1980. Sample preparation and gas chromatography-mass spectrometry determination of **2,3,7,8-tetrachlorodibenzo-p-dioxin**. Anal. Chem. 52(8): 1239-1245.

Harris, **H.W., J.A.** Moore, J.G. Vos and B.N. Gupta. 1973. General biological effects of TCDO in laboratory **animals**. Environ. Health. Perspect. 5: 101-109.

Harvan, D.J., J.R. Hass, J.L. Schroeder and B.J. Corbett. 1981. Detection of **tetrachlorodibenzodioxins** in air filter samples. Anal. Chem. 53(12): 1755-1759.

Hass, J.R. and M.D. **Friesen**. 1979. Qualitative and quantitative methods for **dioxin analysis**. Ann. NY Acad. **Sci.** 320: 28-42.

Hass, J.R., M.D. Friesen, D.J. Harvan and C.E. Parker. 1978. Determination of **polychlorinated** dibenzo-p-dioxins in biological samples by negative chemical ionization mass spectrometry. Anal. Chem. 50(11): 1474-1479.

Hassan, M.Q., S.J. Stohs and **W.J.** Murray. 1985. Effects of vitamins E and A on **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced lipid peroxidation** and other biochemical changes in the rat. Arch. Environ. Contam. **Toxicol.** 14: 437-442.

Hassoun, E.M. and L. Dencker. 1982. TCDD **embryotoxicity** in the mouse may be enhanced by **β-naphthoflavone**, another **ligand** of the Ah-receptor. Toxic. Lett. 12: 191-198.

Hatch, M.C. 1984. Reproductive effects of the **dioxins**. In: Public Health Risks of the Dioxins, W.W. Lawrence, Ed. William Kaufmann, Los Altos, CA. p. 255-271.

Hawkes, C.L. and L.A. Norris. 1977. Chronic oral **toxicity** of 2,3,7,8-**tetrachlorodibenzo-p-dioxin** (TCDD) to rainbow trout. Trans. Am. Fish Soc. 106(6): 641-645.

Hay, A. 1979. Dispute over Dow **Chemical's** theory of **dioxin** traces. Nature. 281: 619-620.

Hay, A. 1982. **Toxicology** of dioxins. In: The Chemical Scythe: Lessons of 2,4,5-T and Dioxin. Plenum Press, NY and London. p. 41-47.

Heida, H. 1983. TCDD in bottom sediments and eel around a refuse dump near Amsterdam, Holland. **Chemosphere**. 12: 503-509.

Heath, R.G.E., R.L. Harless, M.L. Gross, P.A. Lyon, A.E. Dupuy, Jr. and D.D. **McDaniel**. 1985. Determination of **2,3,7,8-TCDD** in human **milk** at the 0.1 to 10 ppt level: **Method** validation and survey results. (Submitted for publication)

Helder, T. 1980. Effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on early **life** stages of the **pike** (*Esox lucius* L.). **Sci. Total Environ.** 14(3): 255-264.

Helder, T. 1981. Effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on early **life** stages of rainbow trout (*Salmo gairdneri*, Richardson). **Toxicol.** 19(2): 101-112.

Helling, C.S., A.R. Isensee, E.A. Woolson, et al. 1973. Chlorodioxins in pesticides, soils and **plants**. **J. Environ. Quality.** 2(2): 171-178.

Henck, J.W., M.A. New, R.J. Kociba and K.S. Rao. 1981. **2,3,7,8-Tetra-**chlorodibenzo-p-dioxin: Acute oral **toxicity** in hamsters. **Toxicol. Appl. Pharmacol.** 59: 405-407.

Hildebrandt, P.K. 1983. Letter to E.E. McConnell, NTP, October 31, 1983, **with** attached tables.

Hiles, R.A. and R.D. Bruce. 1976. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** elimination in the rat: First order or zero order? **Food Cosmet. Toxicol.** 14(6): 599-600.

Hinsdill, R.D., D.L. Couch and R.S. Speirs. 1980. **Immunosuppression** in **mice** induced by **dioxin** (TCDD) in feed. **J. Environ. Pathol. Toxicol.** 4(2-3): 401-425.

- Holmstedt, B. 1980. Prolegomena to Seveso **Ecclesiastes I 18**. Arch. Toxicol. 44(4): 211-230.
- Honchar, P.A. and W.E. Halperin. 1981. **2,4,5-Trichlorophenol** and soft-tissue sarcoma. Lancet. 1(8214): 268-269.
- Hook, G.E.R., J.K. Haseman and G.W. Lucier. 1975a. Induction and suppression of hepatic and **extrahepatic microsomal** foreign-compound-metabolizing systems by **2,3,7,8-tetrachlorodibenzo-p-dioxin**. Chem.-Biol. Interact. 10(3): 199-214.
- Hook, G.E.R., T.C. Orton, J.A. Moore and G.W. Luder. 1975b. Tetrachlorodibenzo-p-dioxin-induced changes in the **hydroxylation** of **biphenyl** by rat liver **microsomes**. Biochem. Pharmacol. 24(3): 335-340.
- Hook, J.B., K.M. McCormack and W.M. Kluwe. 1977. Renal effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin**. In: **Pentachlorophenol**, K.R. Rao, Ed. Plenum Press, NY. p. 381-387.
- Hope, W., D. Lischwe, R. Russell and S. Weiss. 1984. **Porphyria cutanea tarda** and sarcoma in a worker exposed to **2,3,7,8-tetrachlorodibenzodioxin**. Missouri J. Am. Med. Assoc. 251(12): 1534, 1537.
- Houk, V.N. 1983. Testimony by Dr. Vernon W. Houk, **Director**, Center for Environmental Health, Center for Disease Control, Public Health Service, Department of Health and Human Services before the United States House of Representatives Science and Technology Committee, Subcommittee on Natural Resources, Agricultural Research and Environment. March 23.

Hryhorczuk, D.O., **W.A. Withrow**, C.S. Hesse and V.R. Beasley. 1981. **Wire** reclamation Incinerator as a source of **environmental** contamination with **tetrachlorodibenzo-p-dioxins** and **tetrachlorodibenzofurans**. Arch. Environ. Health. 36(5): 228-234.

**Huckins**, J.N., D.L. Stalling and W.A. Smith. 1978. Foam-charcoal **chromatography** for **analysis** of **polychlorinated dibenzodioxins** in Herbicide Orange. Assoc. Off. Anal. Chem. 61(1): 32-38.

Hudson, L.G., R. Shaikh, W.A. Toscano and W.F. Greenlee. 1983. Induction of **7-ethoxycoumarin o-deethylase** activity in cultured human epithelial cells by **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDO): Evidence for TCDD receptor. **Biochem. Biophys. Res. Comm.** 115: 611-617.

Hueper, W.C. and W.D. **Conway**. 1964. Chemical Carcinogenesis and Cancers. Springfield, Thomas.

Huetter, R. and **M. Philippi**. 1982. Studies on **microbial** metabolism of TCDD under laboratory conditions. Pergamon Ser. Environ. Sci. 5: 87-93.

Hummel, **R.A.** 1977. Clean-up techniques for the determination of parts per trillion residue **levels** of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD). **J. Agric. Food Chem.** 25: 1049-1053.

Hummel, R.A. and **L.A. Shadoff**. 1980. Specificity of low resolution gas **chromatography-low** resolution mass **spectrometry** for the detection of tetrachlorodibenzo-p-dioxin in environmental samples. Anal. Chem. 52: 191-192.

Hussain, S., L. Ehrenberg, G. Lofroth and T. Gejvall. 1972. **Mutagenic** effects of TCDD on bacterial systems. **Ambio**. 1: 32-33.

Hutzinger, O., K. Olle, J.W. Lustenhouwer, A.B. Okey, S. Bandiera and S. Safe. 1981. **Polychlorinated** dibenzo-p-dioxins and **dibenzofurans**: A bio-analytical approach. **Chemosphere**. 10(1): 19-25.

Hwang, S.W. 1973. Effect of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on the biliary excretion of **indocyanine** green in rat. **Environ. Health Perspect.** 5: 227-231.

IARC (**International** Agency for Research on Cancer). 1977. IARC Monographs on the Evaluation of the Carcinogenic **Risk** of Chemicals to Man. Some **Fungi-**gants, the Herbicides **2,4-D** and **2,4,5-T**, Chlorinated Dibenzodioxins and Miscellaneous Industrial Chemicals. Vol. 15, IARC, Lyon, **France**. p. 41-102.

ICO (**International Classification** of Diseases). 1975. 9th revision. WHO, **Geneva**.

ICRP (International Commission on Radiological Protection). 1959. **Publica-**tion 2. Report of Committee on **Permissible** Dose for **Internal** Radiation. Pergamon Press, London.

Ideo, G., G. Bellati, A. Bellobuono, P. Mocarelli, A. Marocchi and P. Brambilla. 1982. Increased urinary D-glucuronic acid excretion by children living in an area polluted with **tetrachlorodibenzoparadioxin** (TCDD). **Chim. Acta**. 120(3): 273-283.



Isensee, A.R. 1978. **Bioaccumulation** of **2,3,7,8-tetrachlorodibenzo-para-dioxin**. *Ecol. Bull. C. Rame1*, Ed. 27: 255-262.

Isensee, A.R. and G.E. Jones. 1971. Absorption and **translocation** of root and **foliage applied 2,4-dichlorophenol, 2,7-dichlorodibenzo-p-dioxin, and 2,3,7,8-tetrachlorodibenzo-p-dioxin**. *J. Agric. Food Chem.* 19: 1210-1214.

**Isensee**, A.R. and G.E. Jones. 1975. Distribution of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** in aquatic model ecosystem. *Environ. Sci. Technol.* 9: 668-672.

**Ishidate, K., M.** Tsuruoka and Y. **Nakazawa**. 1980. Induction of **choline kinase** by **polycyclic** aromatic hydrocarbon carcinogens in rat liver. *Biochem. Biophys. Res. Commun.* 96: 946-952.

Jackson, W.T. 1972. **Regulation** of mitosis. III. **Cytological** effects of **2,4,5-trichlorophenoxyacetic acid** and of **dioxin** contaminants in **2,4,5-T** formulations. *J. Cell Sci.* 10: 15-25.

Jensen, D.J. and R.A. Hummel. 1982. Secretion of TCDD in **milk** and cream following the feeding of **TCDD** to **lactating** dairy cows. *Bull. Environ. Contain. Toxicol.* 29: 440-446.

Jensen, D.J., R.A. Hummel, N.H. **Mahle**, C.W. Kocher and H.S. Hgglns. 1981. Residue study on beef cattle consuming **2,3,7,8-tetrachlorodibenzo-p-dioxin**. *J. Agric. Food Chem.* 29(2): 265-268.

Jensen, D.J., M.E. Getzendaner, R.A. Hummel and J. Turley. 1983. Residue studies for **(2,4,5-trichlorophenoxy) acetic acid** and **2,3,7,8-tetrachlorodibenzo-p-dioxin** in grass and rice. J. Agric. Food Chem. 31: 118-122.

Jett, G. 1982. Memorandum to J.S. Bellin (Office of Solid Waste, U.S. EPA, Washington, DC). Re: Hazardous waste estimates for **phenoxyacetic** compounds and priority pollutant **chlorophenols** in the pesticide Industry. June 1.

Johnson, E.F. and U. Muller-Eberhard. 1977a. Resolution of two forms of **cytochrome P-450** from **liver microsomes** of rabbits treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Biol. Chem. 252(9): 2839-2845.

Johnson, E.F. and U. Muller-Eberhard. 1977b. Multiple forms of cytochrome P-450 from liver microsomes of rabbits treated with **2,3,7,8-tetrachlorodibenzo-p-dioxin** (Meeting Abstract). Fed. Proc. 36(3): 833.

Johnson, E.F. and U. Muller-Eberhard. 1977c. Purification of the major cytochrome P-450 of liver microsomes from rabbits treated with **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCOD). Biophys. Res. Commun. 76(3): 652-659.

Johnson, E.F. and U. Muller-Eberhard. 1977d. Multiple forms of cytochrome P-450 resolution and purification of rabbit liver **aryl hydrocarbon hydroxylase**. Biochem. Biophys. Res. Commun. 76(3): 644-651.

Johnson, E.F., G.E. Schwab and U. Muller-Eberhard. 1979. Multiple forms of cytochrome P-450: **Catalytic** differences exhibited by two homogeneous forms of rabbit cytochrome P-450. Mol. Pharmacol. 15(3): 708-718.

- Johnson, F.E., M.A. Kugler and S.M. Brown. 1981. Soft-tissue sarcomas and chlorinated phenols. *Lancet*. 2(8236): 40.
- Johnson, R.M. and C.A. Baumann. 1947. Storage and distribution of vitamin A in rats fed certain isomers of carotene. *Arch. Biochem.* 14(3): 361-367.
- Jones, G. 1975. A histochemical study of the liver lesion induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin) in rats. *J. Pathol.* 116(2): 101-105.
- Jones, G. and W.H. Butler. 1974. A morphological study of the liver lesion induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. *J. Pathol.* 112: 93-97.
- Jones, G. and J.B. Greig. 1975. Pathological changes in the liver of mice given 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Experientia*. 31(11): 1315-1317.
- Jones, K.G. and G.D. Sweeney. 1977. Association between induction of aryl hydrocarbon hydroxylase and depression of uroporphyrinogen decarboxylase activity. *Res. Commun. Chem. Pathol. Pharmacol.* 17(4): 631-638.
- Jones, K.G. and G.D. Sweeney. 1980. Dependence of the porphyrinogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin upon inheritance of aryl hydrocarbon hydroxylase responsiveness. *Toxicol. Appl. Pharmacol.* 53(1): 42-49.
- Josephson, J. 1983. Chlorinated dioxins and furans in the environment. *Environ. Sci. Technol.* 17: 124A-128A.

- Junk, **G.A.** and J.J. Richard. 1981. Dioxins not detected in effluents from coal/refuse combustion. **Chemosphere**. 10: 237-241.
- Kapitulnik, J.** and J.D. **Ostrow**. 1978. Stimulation of **bilirubin catabolism** in jaundiced Gunn rats by an **inducer** of **microsomal** mixed-function monooxygenases. Proc. **Natl. Acad. Sci.** 75(2): 682-685.
- Karasek, F.W.,** R.E. Clement and **A.C. Vlan**. 1982. Distribution of PCDOs and other toxic compounds generated on fly ash **particulates** in municipal Incinerators. J. Chromatogr. 239: **173-180**.
- Karickhoff, S.W.,** D.S. Brown and **T.A. Scott**. 1979. **Sorption** of **hydrophobic** pollutants on natural sediments. Water Res. 13: 241-248.
- Kearney, **P.C., E.A. Woolson** and **C.P. Ellington, Jr.** 1972. Persistence and metabolism of **chlorodioxins** in soils. Environ. Sci. **Technol.** **6(12):** 1017-1019.
- Kenaga, E.E. 1980. Correlation of **bioconcentration** factors of chemicals in aquatic and terrestrial organisms **with** their physical and chemical properties. Environ. Sci. Technol. **14:** 553-556.
- Kenaga, E.E. and C.A.I. Goring. 1980. Relationship between water solubility, **soil sorption, octanol-water** partitioning, and concentration of chemicals in biota. **In:** J.G. Eaton et **al., Ed.,** Aquatic Toxicology **ASTM STP 707,** American Society for Testing and Materials, Philadelphia, PA. p. 78-115.

**Kende, A.S.** and J.J. Wade. 1973. Synthesis of new **stemic** and **electronic** analogs of **2,3,7,8-tetrachlorodibenzo-p-dioxin**. Environ. Health Perspect. 5: 49-57.

Kende, **A.S.**, J.J. Wade, D. Ridge and A. Poland. 1974. Synthesis and Fourier transform **carbon-13** nuclear magnetic resonance spectroscopy of new toxic polyhalodibenzo-p-dioxins. J. Org. Chem. 39: 931-937.

**Khera, K.S.** and **W.P. McKinley**. 1972. Pre- and postnatal studies on **2,4,5-T** and **2,4-D** and their derivatives in rats. **Toxicol. Appl. Pharmacol.** 22: 14.

Khera, K.S. and **J.A. Ruddick**. 1973. **Polychlorodibenzo-p-dioxins**: Perinatal effects and the dominant **lethal** test in **Wistar** rats. In: Chlorodioxins -- Origins and Fate, E.H. Blair, Ed. Adv. Chem. Ser. No. 120. Am. Chem. Soc., Washington, DC. p. 70-84.

Khera, K.S., B.L. Huston and W.P. McKinley. 1971. Pre- and postnatal studies on 2,4,5-T, 2,4-D, and derivatives in **Wistar** rats. **Toxicol. Appl. Pharmacol.** 19: 369-370.

**Kim, P.**, G.C. Yang, **D. Firestone** and **A.E. Pohland**. 1975. Photochemical **Dechlorination** of Chlorinated Dibenzo-p-dioxins. Presented at the 1st Chemical Congress of the North American Continent, Mexico **City**, November.

**Kimble, B.J.** and M.L. Gross. 1980. Tetrachlorodibenzo-p-dioxin **quantitation** in **stack-collected** coal fly ash. **Science.** 207: 59-61.

- Kimbrough, R.D.** 1974. The toxicity of **polychlorinated polycyclic** compounds and related chemicals. *CRC Crit. Rev. Toxicol.* 2: 445-489.
- Kimbrough, R.D., C.O. Carter, **J.A. Liddle** and R.E. **Cline**. 1977. Epidemiology and pathology of a **tetrachlorodibenzodioxin** poisoning episode. *Arch. Environ. Health.* 32(2): 77-86.
- Kimbrough, R.D., J. Buckley, L. **Fishbein**, et al. 1978. Animal toxicology. *Environ. Health Perspect.* 24: 173-184.
- Kimbrough, R.D., H. **Falk**, P. Stehr and G. Fries. 1984. **Health** Implications of **2,3,7,8-tetrachlorodibenzodioxin** (TCOD) contamination of residential soil. *J. Toxicol. Environ. Health.* 14: 47-93.
- Kimmig, J.** and K.H. **Schulz**. 1957. **Berufliche** akne (sog. chlorakne) durch **chlorierte aromatische zyklische ather.** *Dermatologia.* 115: 540-546. (Ger.)
- Kimura, S., F.J. Gonzalez** and **D.W. Nebert**. 1984. The **murine** Ah locus: Comparison of the complete cytochrome **P<sub>1</sub>-450** and **P<sub>3</sub>-450** cDNA **nucleotide** and **amino acid** sequences. *J. Biol. Chem.* 259(17): 10705-10713.
- King, M.E.** and **A.R. Roesler**. 1974. Subacute Intubation study on rats **with** the compound 2,3,7,8-tetrachlorodioxin. U.S. EPA. **NTIS** PB-257 677. p. 27.
- Kirsch, et al.** 1975. Structural and functional studies of **ligandin**, a major renal organic anion-binding protein. *J. Clin. Invest.* 55: 1009.

Kitchin, K.T. and J.S. Woods. 1977. **2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)** Induced synthesis of **cytochrome P-448** and **aryl hydrocarbons hydroxylase (AHH)** activity in female rat **liver** (Meeting Abstract). *Pharmacol.* 19(2): 232.

Kitchin, K.T. and J.S. Woods. 1978a. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** Induction of **aryl hydrocarbon hydroxylase (AHH)** in hepatic **microsomes** from **female rats**. *Toxicol. Appl. Pharmacol.* 45(1): 297.

Kitchin, K.T. and J.S. Woods. 1978b. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** Induction of aryl hydrocarbon hydroxylase in female rat liver, evidence for de novo synthesis of cytochrome P-448. *Mol. Pharmacol.* 14: 890-899.

Knutson, J.C. and A. Poland. 1980. **2,3,7,8-Tetrachlorodibenzo-p-dioxin:** Failure to demonstrate **toxicity** in twenty-three cultured cell types. *Toxicol. Appl. Pharmacol.* 54(3): 377-383.

Knutson, J.C. and A. Poland. 1982. Response of **murine** epidermis to the **2,3,7,8-tetrachlorodibenzo-p-dioxin:** Interaction of the Ah and hr loci. *Cell.* 30(1): 225-234.

Kocher, C.W., N.H. Mahle, R.A. Hummel, L.A. Shadoff and M.E. Getzender. 1978. A search for the presence of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in beef fat. *Bull. Environ. Contam. Toxicol.* 19: 229-236.

Kociba, R.J. and B.A. Schwetz. 1982. Toxicity of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)**. *Drug Metab. Rev.* 13: 387-406.

Kodba, R.J., **P.A. Keeler**, C.N. Park and **P.J. Gehring**. 1976. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** results of a **13-week** oral **toxicity** study in rats. **Toxicol. Appl. Pharmacol.** 35: 553-573.

Kodba, R.J., O.G. **Keyes**, J.E. Beyer, et al. 1977. Results of a two-year chronic toxicity and **oncogenicity** study of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in rats. Unpublished report submitted to U.S. EPA.

Kodba, R.J., D.G. Keyes, J.E. Beyer, et al. 1978a. Results of a two-year chronic toxicity and oncogenicity study of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in rats. **Toxicol. Appl. Pharmacol.** 46(2): 279-303.

Kodba, R.J., D.G. Keyes, J.E. Beyer and **R.M. Carreon**. 1978b. Toxicologic studies of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCOD) in rats. **Toxicol. Occup. Med.** (Dev. Toxicol. Environ. Sci.) 4: 281-287.

Kodba, R.J., D.G. Keyes, J.E. Beyer, R.M. Carreon and **P.J. Gehring**. 1979. Long-term **toxicologic** studies of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) in laboratory animals. **Ann. NY Acad. Sci.** 320: 397-404.

**Kohli**, K.K. and **J.A. Goldstein**. 1981. Effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on hepatic and renal **prostaglandin** synthetase. **Life Sci.** 29(3): 299-305.

**Kondorosi, A.**, I. Fedorcsak, F. **Solymsy**, L. Ehrenberg and S. Osterman-Golkar. 1973. **Inactivation** of QBRNA by **electrophiles**. **Mutat. Res.** 17: 149-161.



Kooke, R., **J.W.A. Lustenhouwer**, K. **Olie** and O. **Hutzinger**. 1981. Extraction efficiencies of **polychlorinated** dibenzo-p-dioxins and **polychlorinated dibenzofurans** from fly ash. *Anal. Chem.* 53: 461-463.

**Korfmacher, W.A.**, K.R. **Rowland**, R.K. **Mitchum**, J.J. **Daly**, R.C. **McDaniel** and **M.V. Plummer**. 1984. Analysis of snake tissue and snake eggs from **2,3,7,8-tetrachlorodibenzo-p-dioxin** via fused silica GC combined with atmospheric pressure ionization **MS**. *Chemosphere*. 13: 1229-1233.

**Kouri, R.** 1976. Relationship between levels of **aryl** hydrocarbon hydroxylase activity and susceptibility to **3-methylcholanthrene** and **benzo(a)pyrene-induced** cancers in Inbred strains of mice. In: **Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism and Carcinogenesis**, Vol. 1, R.J. **Freudenthal** and **P.W. Jones**, Ed. Raven Press, NY. p. 139.

Kouri, R.E., H. **Rattie**, III, **S.A. Atlas**, A. **Nlwa** and **D.W. Nebert**. 1974. Aryl hydrocarbon hydroxylase Induction in human lymphocyte cultures by **2,3,7,8-tetrachlorodibenzo-p-dioxin**. *Life Sci.* 15(9): 1585-1595.

Kouri, R.E., **T.H. Rude**, R. **Joglekar**, et al. 1978. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** as **cocarcinogen** causing **3-methylcholanthrene-initiated** subcutaneous tumors in mice genetically "**nonresponsive**" at Ah locus. *Cancer Res.* 38(9): 2777-2783.

**Kuri, R.N.**, J. **Lund**, L. **Poellinger** and **J.A. Gustafsson**. 1982. Differential effect of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on nuclear RNA polymerase activity in the rat liver and **thymus**. *Biochem. Pharmacol.* 31(15): 2459-2462.

**Kuroki, H. and Y. Masuda.** 1977. Structures and concentrations of the **main** components of **polychlorinated biphenyls** retained in patients **with** Yusho. **Chemosphere.** 6: 465-469.

Lamb, J.C., **J.A. Moore** and **T.A. Markes.** 1980. Evaluation of **2,4-D, 2,4,5-T,** and TCDD **toxicity in** C57BL/6 **mice:** Reproduction and fertility in treated male **mice** and evaluation of congenital malformation in their offspring. National Toxicology Program, Research Triangle Park, NC.

Lamb, J.C., T.A. Markes, B.C. Gladen, **J.W. Allen** and J.A. Moore. 1981a. Male fertility, sister **chromatid** exchange, and germ cell toxicity following exposure to mixtures of **chlorinated phenoxy** adds containing **2,3,7,8-tetra-**chlorodibenzo-p-dioxin. **J. Toxicol. Environ. Health.** 8: 825-834.

Lamb, J.C., J.A. Moore, T.A. Marks and **J.K. Haseman.** 1981b. Development and viability of offspring of male **mice** treated **with** chlorinated phenoxy adds and **2,3,7,8-tetrachlorodibenzo-p-dioxin.** **J. Toxicol. Environ. Health.** 8(5-6): 835-844.

**Lamparski, L.L. and T.J. Nestrick.** 1980. Determination of tetra-, hexa-, hepta-, and **octachlorodibenzo-p-dioxin isomers** in **particulate** samples at parts per trillion **levels.** **Anal. Chem.** 52: 2045-2054.

Lamparski, L.L., N.H. **Mahle** and **L.A. Shadoff.** 1978. Determination of **pentachlorophenol, hexachlorodibenzo-p-dioxin,** and octachlorodibenzo-p-dioxin in bovine **milk.** **J. Agric. Food Chem.** 26(5): 1113-1116.

Lamparski, L.L., T.J. Nestrick and R.H. Stehl. 1979. Determination of **part-per-trillion** concentrations of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in fish. *Anal. Chem.* 51(9): 1453-1458.

Lamparski, L.L., R.L. Stehl and R.L. Johnson. 1980. Photolysis of **penta-chlorophenol-treated** wood; **chlorinated** dibenzo-p-dioxin formation. *J. Environ. Sci. Tech.* 14: 196-200.

Langhorst, M.L. and L.A. Shadoff. 1980. Determination of **part-per-trillion** concentrations of tetra-, hexa-, hepta-, and octa-chlorodibenzo-p-dioxins in human **milk** samples. *Anal. Chem.* 52: 2037-2044.

Lathrop, G.D., P.M. Moynahan, R.A. Albanese and W.D. Wolfe. 1983. An **epidemiologic** investigation of health effects in **Air** Force personnel following exposure to herbicides. Baseline mortality study results. June 30. USAF School of Aerospace **Medicine** (AFSC), Brooks Air Force **Base**, TX.

Lathrop, G.D., W.D. Wolfe, R.A. Albanese and P.M. Moynahan. 1984. An **epidemiologic** investigation of **health** effects in **Air** Force personnel following exposure to herbicides. Executive summary baseline morbidity study. In: Biological Mechanisms of **Dioxin** Action. Banbury Report 18. A. Poland and R.D. **Kimbrough**, Ed. Cold Spring Harbor **Laboratory**. p. 471-474.

Lavy, T.L., J.S. Shepard and J.D. **Mattice**. 1980. Exposure measurements of applicators spraying **(2,4,5-trichlorophenoxy)** acetic acid in the forest. *J. Agric. Food Chem.* 28: 626-630.

Lee, **I.P** and K. Suzuki. 1980. Induction of **aryl** hydrocarbon hydroxylase activity in the rat prostate glands by **2,3,7,8-tetrachlorodibenzo-p-dioxins**. J. Pharmacol. Exp. Ther. **215(3): 601-605**.

Legraverend, C., B. **Mansour**, **D.W.** Nebert and **J.M.** Holland. 1980. Genetic differences in benzo[a]pyrene-initiated **tumorigenesis** in mouse **skin**. Pharmacology. 20: 242-255.

Leo, **A.J.** 1979. Letter to C. Stephan. Pomona College, Claremont, CA. May 11.

Levin, J.O., C.F. Rappe and **C.A. Nilssen**. 1976. Use of chlorophenols or fungicides in sawmills. Scand. J. Work Environ. Health. 2: 71.

Libertl, A. and D. Brocco. 1981. Formation of **polychlorodibenzodioxins** in urban incinerator emissions. In: Impact of Chlorinated Dioxins and Related Compounds on the Environment, O. **Hutzinger** et al., Ed. Pergamon Press, **Oxford**. p. 245-251.

**Liem**, H.H., U. **Muller-Eberhard** and E.F. Johnson. 1980. **Differential** Induction by **2,3,7,8-tetrachlorodibenzo-p-dioxin** of multiple forms of rabbit **microsomal cytochrome P-450**: Evidence for tissue specificity. J. **Mol.** Pharmacol. 18(3): 565-570.

Lindahl, R., M. Roper and R.A. Dietrich. 1978. Rat liver aldehyde dehydrogenase - Immunochemical Identity of **2,3,7,8-tetrachlorodibenzo-p-dioxin** inducible normal liver and **2-acetylaminofluorene** inducible hepatoma isozymes. **Biochem. Pharmacol.** 27(20): 2463-2465.

Liss, Q.S. and P.G. Slater. 1974. Flux of gases across the air-sea Interface. *Nature.* 247: 181.

Loprieno, N., I. Sbrana, O. Rusciano, D. Lasclalfar1 and T. Lari. 1982. **in vivo cytogenetic** studies on mice and rats exposed to **2,3,7,8-tetrachlorodibenzo-p-dioxin**. In: Chlorinated Dioxins and Related Compounds. Impact on the Environment, O. Hutzinger, R.W. Frel, E. Merian and P. Pocchiari, Ed. Pergamon Press, NY. p. 419-428.

Lustenhower, J.W.A., K. Olie and O. Hutzinger. 1980. Chlorinated **dibenzo-p-dioxins** and related compounds in Incinerator effluents: A review of measurements and mechanisms of formation. **Chemosphere.** 9: 501-522.

Luster, M.I., R.E. Faith and G. Clark. 1979a. Laboratory studies on the Immune effects of halogenated **aromatics**. *Ann. NY Acad. Sci.* 320: 473-484.

Luster, M.I., G. Clark, L.D. Lawson and R.E. Faith. 1979b. Effects of a brief in vitro exposure to **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on mouse lymphocytes. *J. Environ. Pathol. Toxicol.* 2(4): 965-977.

Luster, **M.I., G.A. Boorman,** J.H. Dean, et al. 1980. Examination of bone marrow, **immunologic** parameters and host susceptibility following pre- and postnatal exposure to **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD). *Int. J. Immunopharmacol.* 2(4): 301-310.

Mabey, **W.R.,** J.H. Smith, R.T. **Podoll,** et al. 1981. Aquatic Fate Processes **Data** for Organic Priority Pollutants. EPA 440/4-81-014, Monitoring and Data Support **Div.,** Office of Water and Regulations and Standards, Washington, DC. p. 107-108.

**Madge,** D.S. 1977. Effects of trichlorophenoxyacetic acid and **chlorodioxins** on small Intestinal function. *Gen. Pharmacol.* 8: 319-324.

**Mahle,** N.H. and **L.A. Shadoff.** 1982. The mass spectrometry of chlorinated dibenzo-p-dioxins. *Biomed. Mass Spectrom.* 9: 45-60.

**Mahle,** N.H., H.S. Higgins and M.E. Getzendaner. 1977. Search for the presence of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in bovine **milk.** *Bull. Environ. Contam. Toxicol.* 18(2): 123-130.

Malik, N. and **I.S. Owens.** 1977. Studies on the requirements for Induction of UDP glucuronosyl-transferase (**T'ASE**) activity in the Reuber hepatoma H-4-**II-E** established cell **line** (Meeting **Abstract**). *Pharmacology.* 19(2): 150.

Malik, **N.,** G.M. Koteen and I.S. Owens. 1979. Induction of **UDP-glucuronosyl-transferase** activity in the Reuber H-4-II-E hepatoma cell culture. *Mol. Pharmacol.* 16(3): 950-960.

Manara, L., P. **Coccia** and T. **Croci**. 1982. Persistent tissue **levels** of TCDD in the mouse and their reduction as related to prevention of **toxicity**. **Drug Metab. Rev.** 13(3): 423-446.

**Manis**, O. and R. Apap. 1979. Intestinal organic **anion** transport, **glutathione** transferase and **aryl** hydrocarbon **hydroxylase** activity: Effect of **dioxin**. **Life Sci.** 24(15): 1373-1380.

Manis, J. and G. **Kim**. 1979a. Stimulation of **iron** absorption by **polychlorinated** aromatic hydrocarbons. **Am. J. Physiol.** 236(6): E763-E768.

Manis, J. and G. **Kim**. 1979b. Introduction of **iron** transport by a potent **inducer** of aryl hydrocarbon hydroxylase, **2,3,7,8-tetrachlorodibenzo-p-dioxin**. **Arch. Environ. Health.** 34(3): 141-145.

Mantel, N. and **M.A. Schneiderman**. 1977. Estimation of "safe" levels, a hazardous undertaking? **Cancer Res.** 35: 1379-1386.

**Mantovani, A., A. Vecchi, W. Lunni, et al.** 1980. Effect of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on **macrophage** and natural killer cell-mediated **cytotoxicity** in mice. **Biomedicine.** 32(4): 200-204.

Marks, **T.A., G.A. Kimmel** and R.E. Staples. 1981. Influence of symmetrical **polychlorinated biphenyl isomers** on embryo and fetal development in mice. **Toxicol. Appl. Pharmacol.** 61: 269-276.

**Marselos, M.,** R. Torronen and A. **Aitto.** 1978. Responses of the **D-glucuron-**ic acid pathway in rat tissues to treatment with **tetrachlorodibenzo dioxin.** *Xenobiotics.* 8(7): 397-402.

Mason, **M.E.** and **A.B.** Okey. 1982. **Cytosolic** and nuclear binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin to the AH receptor in extra-hepatic tissues of rats and **mice.** *Eur. J. Biochem.* 123(1): 209-215.

**Matsumura, F.** and **H.J.** Benezet. 1973. Studies on the **bioaccumulation** and **microbial** degradation of **2,3,7,8-tetrachlorodibenzo-p-dioxin.** *Environ. Health Perspect.* 5: 253-258.

Matsumura, **F., J.** Quensen and G. **Tsushimoto.** 1983. Microbial degradation of TCDD in a model ecosystem. **In:** Human and Environmental Risks of Chlorinated **Dioxins** and Related Compounds, R.E. Tucker, **A.L.** Young and **A.P.** Gray, Ed. Plenum Press, NY. p. 191-219.

**Mattison, D.R.** and S.S. **Thorgeirsson.** 1978. **Gonadal aryl** hydrocarbon hydroxylase in rats and **mice.** *Cancer Res.* 38(5): 1368-1373.

Mattison, O.R. and S.S. **Thorgeirsson.** 1979. Ovarian **aryl** hydrocarbon **hydroxylase** activity and primordial oocyte **toxicity** of **polycyclic** aromatic hydrocarbons in **mice.** *Cancer Res.* 39: 3471-3475.

Mattison, O.R., M.S. **Nightingale** and E.K. **Silbergeld.** 1984. Reproductive toxicity of **tetrachlorodibenzo-p-dioxin.** **In:** Public Health Risks of the Dioxins, **W.W.** Lawrence, Ed. William **Kaufmann,** Los Altos, CA. p. 217-235.



- May, G. 1973. Chloracne from the accidental production of **tetrachlorodibenzo-p-dioxin**. **Br. J. Ind. Med.** 30(3): 276-283.
- May, G. 1982. Tetrachlorodibenzo-p-dioxin: A survey of subjects ten years after exposure. **Br. J. Ind. Med.** 39(2): 128-135.
- McCann. 1978. Unpublished study. (Cited in **Wassom et al.**, 1978)
- McConnell, E.E. 1980. Acute and chronic toxicity, **carcinogenesis**, reproduction, **teratogenesis** and **mutagenesis in animals**. in: Halogenated Biphenyls, Terphenyls, Naphthalenes, Dibenzodioxins and Related Products, R.D. Kimbrough, Ed. **Elsevier/North-Holland Biomedical Press**, NY. p. 109-150.
- McConnell, E.E. and J.A. Moore. 1979. **Toxicopathology** characteristics of the **halogenated aromatics**. **Ann. NY Acad. Sci.** 320: 138-150.
- McConnell, E.E., J.A. Moore and D.W. Dalgard. 1978a. Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rhesus monkeys (Macaca mulatta) following a **single oral** dose. **Toxicol. Appl. Pharmacol.** 43: 175.
- McConnell, E.E., J.A. Moore, J.K. Haseman and M.W. Harris. 1978b. The comparative **toxicity** of chlorinated dibenzo-p-dioxins in **mice** and guinea **pigs**. **Toxicol. Appl. Pharmacol.** 44(2): 335-356.
- McConnell, E.E., G.W. Lucier, R.C. Rumbaugh, et al. 1984. Dioxin in soil: Bioavailability after **ingestion** by rats and guinea **pigs**. **Science.** 223: 1077-1079.

- McGaughy, R.** and **A. Rispln.** 1985. U.S. EPA, **Washington, DC.** Memorandum to D. Barns, U.S. EPA, Washington, DC, August 8.
- McKinney, J.D., K. Chae, B.N. Gupta, J.A. Moore and J.A. Goldstein.** 1976. **Toxicological** assessment of **hexachlorobiphenyl isomers** and **2,3,7,8-tetrachlorodibenzofuran** in chicks. I. Relationship of chemical parameters. **Toxicol. Appl. Pharmacol.** 36: 65-80.
- McKinney, J., **P. Albro, M. Luster, B. Corbett, J. Schroeder** and L. Lawson. 1981. Development and reliability of a radio **immunoassay** for **2,3,7,8-tetrachlorodibenzo-p-dioxin.** In: Impact of **Chlorinated Dioxins and Related Compounds** on the Environment, **O. Hutzinger et al.,** Ed. **Pergamon Press, Oxford.** p. 67-75.
- McNulty, **W.P.** 1978. Direct testimony before the **administrator,** U.S. Environmental Protection Agency, **FIFRA** Docket No. 415, EPA Exhibit No. 106.
- McNulty, **W.P.** 1984. **Fetocidal** and **teragenic** actions of TCDD. In: Public Health Risks of the Dioxins, **W.W. Lawrence,** Ed. **William Kaufmann,** Los **Altos, CA.** p. 245-253.
- McNulty, **W.P., K.A. Nielsen-Smith, J.O. Lay, Jr., et al.** 1982. Persistence of TCDD in monkey adipose tissue. **Food Cosmet. Toxicol.** 20: 985-987.
- McQueen, **E.G., A.M.O. Veale, W.S. Alexander** and **M.N. Bates.** 1977. **2,4,5-T** and human birth defects. Report of the Division of Public Health, New Zealand Dept. of Health. (Cited **in** **Milby et al.,** 1980)

**Meselson, M., P.W. O'Keefe** and R. **Baughman.** 1978. The evaluation of possible health hazards from TCOD in the environment. Presented at the Symposium on the Use of Herbicides in Forestry, Arlington, VA. February 21-22.

Michigan Department of Public Health. 1983a. Evaluation of Congenital Malformation Rates for Midland and Other Selected Michigan Counties Compared Nationally and **Statewise** 1970-1981. Michigan Dept. of Public Health. May 4.

Michigan Department of Public Health. 1983b. Evaluation of Soft and Connective Tissue Cancer Mortality Rates for Midland and Other Selected Michigan Counties Compared Nationally and Statewide. Michigan Dept. of Public Health. May 4.

Miettinen, O. 1976. **Estimability** and estimation in case referent studies. *Am. J. Epidemiol.* 103: 226.

Millby, T.H., E.L. **Husting,** M.D. **Whorton** and S. Larson. 1980. Potential Health Effects Associated **with** the Use of Phenoxy Herbicides: A Summary of Recent Scientific Literature. A Report for the National Forest Products Association from Environmental Health Associated, Inc., Berkeley, CA.

**Miller, R.A., L.A. Norris** and C.L. Hawkes. 1973. **Toxicity** of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in aquatic organisms. *Environ. Health Perspect.* 5: 177-186.

Miller, **R.A.**, **L.A. Norris** and B.R. Loper. 1979. The response of coho salmon and **guppies** to **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) in water. Am. Fish. Soc. Trans. 108(4): 401-407.

**Mitchum**, R.K., G.F. **Moler** and **W.A. Korfmacher**. 1980. Combined capillary gas **chromatography/atmospheric** pressure negative chemical **ionization/mass spectrometry** for the determination of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in tissue. Anal. Chem. 52(14): 2278-2282.

**Moore, J.A.** and R.E. Faith. 1976. **Immunologic** response and factors affecting **its** assessment. Environ. Health Perspect. 18: 125-131.

Moore, J.A. and J.G. Vos. 1974. Evaluating the rodent Immune system as a focus for **tetratogenic** effects. Teratology. 9(3): A-29.

Moore, **J.A.**, B.N. Gupta, J.G. Zinkl and J.G. Vos. 1973. Postnatal effects of maternal exposure to **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD). Environ. **Health** Perspect. 5: 81-85.

Moore, **J.A.**, **M.W. Harris** and **P.W. Albro**. 1976. Tissue distribution of **(<sup>14</sup>C)tetrachlorodibenzo-p-dioxin** in pregnant and neonatal rats. **Toxicol. Appl. Pharmacol.** 37(1): 146-147.

Moore, **J.A.**, E.E. McConnell, **D.W. Dalgard** and M.W. Harris. 1979. Comparative **toxicity** of three **halogenated dibenzofurans** in guinea **pigs**, **mice** and rhesus monkeys. Ann. NY. Acad. **Sci.** 320: 151-163.

Moore, T. and **I.M. Sharman**. 1950. Vitamin A in the kidney of male and **female** rats. **Biochem. J.** 47: xl111-xl11v.

**Mortelmans, K., S. Haworth, W. Speck** and E. **Zieger**. 1984. **Mutagenicity** testing of Agent Orange components and related compounds. **Toxicol. Appl. Pharmacol.** 75: 137-146.

Moses, M. and **I.J. Selikoff**. 1981. Soft-tissue sarcomas, phenoxy herbicides and chlorinated phenols. *Lancet*. 1(8234): 1370.

Mottura, **A.**, G. Zel, F. Nuzzo, et **al**. 1981. Evaluation of results of chromosome analyses on lymphocytes of TCDD exposed subjects after the Seveso accident. *Mutat. Res.* 85(4): 238-239.

**Mulcahy, M.T.** 1980. Chromosome aberrations and "Agent Orange". *Med. J. Aust.* 2(10): 573-574.

Murray, F.J., **F.A. Smith, K.D. Nitschke, C.G. Humiston, R.J. Kociba** and **B.A. Schwetz**. 1979. Three-generation reproduction study of rats given 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the **diet**. **Toxicol. Appl. Pharmacol.** 50: 241-251.

Muscarella, D., D. Dennett, J.G. **Babish** and D. Noden. 1982. The effects of **2,3,7,8-tetrachlorodibenzo-p-dioxins** on fetal development in the ferret. *Toxicologist*. 2: 73.

**Nagarkatti, P.S., G.D. Sweeney, J. Gauldie and D.A. Clark.** 1984. Sensitivity to suppression of **cytotoxic** T cell generation by **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) is dependent on the AH genotype of the **murine** host. **Toxicol. Appl. Pharmacol.** 72: 169-176.

NAS (National Academy of Sciences). 1977. Drinking Water and Health: Part II. NAS, **Washington, DC.**

Nash, R.G. and M.L. **Beall, Jr.** 1980. Distribution of **Silvex, 2,4-D,** and TCDD applied to turf in chambers and field plots. **J. Agric. Food Chem.** 28: 614-623.

Nau, H. and R. Bass. 1981. Transfer of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) to the mouse embryo and fetus. **Toxicology.** 20(4): 299-308.

Nau, **H.,** R. Bass and D. Neubert. 1982. Transfer of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) to the mouse embryo, fetus and neonate. **In:** Chlorinated Dioxins and Related Compounds. Impact on the Environment, 0. **Hutzinger, R.W. Frel, E. Merian and F. Pocchlarl,** Ed. **Pergamon Press, NY.** p. 325-337.

**Neal, R.A., P.W. Beatty and T.A. Gastewicz.** 1979. Studies of the mechanisms of **toxicity** of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD). **Ann. NY Acad. Sci.** 320: 204-213.

Neal, R.A., J.R. Olson, T.A. Gasiewicz and L.E. Geiger. 1982. The **toxicokinetics** of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in mammalian systems. **Drug Metab. Rev.** 13: 355-385.

Neal, R.A., T. Gasiewicz, L. Gelger, J. Olson and T. Sawahata. 1984. Metabolism of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in mammalian systems. **In: Biological Mechanisms of Dioxin Action. Banbury Report 18.** A. Poland and R.O. Kimbrough, Ed. Cold Spring Harbor **Laboratory.** p. 49-60.

Nebert, D.W. 1979. **Multiple** forms of **inducible drug-metabolizing** enzymes: A reasonable mechanism by which any organism can cope **with** adversity. **Mol. Cell. Biochem.** 27: 27-46.

Nebert, D.W. 1980. The Ah locus. A gene **with** possible Importance **in** cancer predictability. Quantitative aspects of **risk** assessment in chemical **carcinogenesis.** **Arch. Toxicol. (Suppl. 3): 195-207.**

Nebert, D.W. 1982. **Pharmacogenetics** and human cancer. Host factors in human carcinogenesis. IARC Scientific Pub. No. 39. **Lyon, France.**

Nebert, D.W. and J.E. Gielen. 1972. Genetic regulation of **aryl** hydrocarbon hydroxylase Induction **in** the mouse. **Fed. Proc.** 31: 1315-1327.

Nebert, D.W. and N.M. Jensen. 1979. The Ah locus: Genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by **cytochrome P-450 mediated monooxygenases.** **CRC Crit. Rev. Biochem.** 6: 401-437.

Nebert, **D.W.**, **F.W. Goujon** and **J.E. Gielen**. 1972. Aryl hydrocarbon hydroxylase Induction by **polycyclic** hydrocarbons: Simple **autosomal** dominant trait in the mouse. **Natl. New. Biol.** 236: 107-110.

Nebert, **D.W.**, et al. 1975. Genetic expression of **aryl** hydrocarbon hydroxylase activity in the mouse. **J. Cell. Physiol.** 85: 393-414.

Nebert, **D.**, **S. Thorgjersson** and **J. Felton**. 1976. Genetic differences in **mutagenesis, carcinogenesis, and drug toxicity**. **In:** in vitro Metabolic Activation in Mutagenesis Testing, **F. de Serres, J. Folets, J. Bend** and **R. Philpot**, Ed. Elsevier/North Holland **Biomedical Press, Amsterdam**. p. 105-124.

Nebert, **D.W.**, **H.J. Elsen, M. Negishi, M.A. Lang, L.M. Hjelmeland** and **A.B. Okey**. 1981. Genetic mechanisms controlling the Induction of polysubstrate **monooxygenase (P-450)** activities. **Ann. Rev. Pharmacol. Toxicol.** 21: 431-462.

Nebert, **D.W.**, **M. Negishi** and **H.J. Elsen**. 1983. Genetic differences in **enzymes** which **metabolize** drugs, chemical carcinogens and other environmental pollutants. **In:** Human and Environmental Risks of Chlorinated Dioxins and Related Compounds, **R.E. Rucker, A.L. Young** and **A.P. Gray**, Ed. Plenum Press, NY. p. 441-462.

**Neely, W.B.** 1979. Estimating rate constants for the uptake and clearance of chemicals by **fish**. **Environ. Sci. Technol.** 13: 1506.



- Neely, W.B.** 1983. Letter to C.E. **Stephan.** Dow Chemical Co., Midland, HI. June 10.
- Nelson, **C.J.**, J.F. Holson, H.G. Green and **D.W. Gaylor.** 1979. Retrospective study of the relationship between agricultural use of **2,4,5-T** and cleft palate occurrence in Arkansas. *Teratology.* 19: 377-384.
- Nelson, J.O., R.E. **Menzer, P.C.** Kearney and **J.R. Plimmer.** 1977. 2,3,7,8-**Tetrachlorodibenzo-p-dioxin: In** vitro binding to rat liver **microsomes.** *Bull. Environ. Contam. Toxicol.* 18(1): 9-13.
- Nestrlck, T.J., L.L. **Lamparski** and D.I. Townsend. 1980. Identification of **tetrachlorodibenzo-p-dioxin isomers** at the 1 ng level by **photolytic** degradation and pattern recognition techniques. *Anal. Chem.* 52(12): 1865-1874.
- Nestrlck, T.J., L.L. Lamparski, W.B. **Crummet** and **L.A. Shadoff.** 1982. Comments on variations in concentrations of organic compounds including **polychlorinated** dibenzo-p-dioxins and polynuclear aromatic hydrocarbons in fly ash from a municipal incinerator. *Anal. Chem.* 54: 823-824.
- Neubert, D. and I. **Dillmann.** 1972. **Embryotoxic** effects in mice treated with **2,4,5-trichlorophenoxyacetic acid** and **2,3,7,8-tetrachlorodibenzo-p-dioxin.** *Arch. Pharmacol.* 272(3): 243-264.
- Neubert, **D.,** P. Zens, A. **Rothewallner** and H.J. **Merker.** 1973. A survey of the **embryotoxic** effects of TCDD in mammalian species. *Environ. Health Perspect.* 5: 67-79.

Niemann, R.A., W.C. Brumley, D. Firestone and J.A. Sphon. 1983. Analysis of fish for 2,3,7,8-tetrachlorodibenzo-p-dioxin by electron capture gas chromatography. Anal. Chem. 55: 1497-1504.

Nienstedt, W., M. Parkki, P. Uotila and A. Aitio. 1979. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic metabolism of testosterone in the rat. Toxicology. 13(3): 233-236.

Nilsson, C.-A., K. Andersson, C. Rappe and S.-O. Westermark. 1974. Chromatographic evidence for the formation of chlorodioxins from chloro-2-phenoxyphenols. J. Chromatogr. 96: 137-147.

NIOSH (National Institute for Occupational Safety and Health). 1982. Health Hazard Evaluation Determination Report: Long Island Railroad. No. 80-039.

Nisbet, I.C.T. and M.B. Paxton. 1982. Statistical aspects of three-generation studies of the reproductive toxicity of TCDD and 2,4,5-T. Am. Stat. Vol. 36(3): 290-298.

Niwa, A., K. Kumaki and D.W. Nebert. 1975. Induction of aryl hydrocarbon hydroxylase activity in various cell cultures by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol. Pharmacol. 11(4): 399-408.

Nolan, R.J., F.A. Smith and J.G. Hefner. 1979. Elimination and tissue distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female guinea pigs following a single oral dose. Toxicol. Appl. Pharmacol. 48(1): A162.

Norback, D.H. and J.R. Allen. 1973. Biological responses of the **nonhuman primate, chicken, and rat** to chlorinated dibenzo-p-dioxin **ingestion**. Environ. Health Perspect. 5: 233-240.

Norman, **R.L.**, E.F. Johnson and U. **Muller-Eberhard**. 1978a. Identification of the **major cytochrome P-450** form transplacentally induced in neonatal rabbits by **2,3,7,8-tetrachlorodibenzo-p-dioxin**. Fed. Proc. Am. Soc. Exp. Biol. 37(6): 1720.

**Norman**, R.L., E.F. Johnson and U. Muller-Eberhard. 1978b. Identification of the **major cytochrome P-450** form **transplacentally** induced in neonatal rabbits by **2,3,7,8-tetrachlorodibenzo-p-dioxin**. J. Biol. Chem. 253(23): 8640-8647.

**Norris**, L.A. and R.A. Miller. 1974. The **toxicity** of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** in **guppies (Poecilia reticulatus)** Peters). Bull. Environ. Contam. Toxicol. 12(1): 76-80.

Norstrom, **A.**, C. Rappe, R. **Lindahl** and H.R. Buser. 1979. Analysis of some older Scandinavian formulations of **2,4-dichlorophenoxy** acetic acid and 2,4,5-trichlorophenoxy acetic acid for contents of chlorinated **dibenzo-p-dioxins** and **dibenzofurans**. Scand. J. Work Environ. Health. 5(4): 375-378.

**Norstrom, R.J., D.J. Hallett, M. Simon and M.J. Mulvihill.** 1982. Analysis of **Great Lakes** herring gull eggs for **tetrachlorodibenzo-p-dioxins**. In: Chlorinated **Dioxins** and Related Compounds. Impact on the **Environment**, O. **Hutzinger, R.W. Frel, E. Merian** and E. Pocchlarl, Ed. Pergamon Press, NY. p. **173-181**.

NRCC (National Research Council of Canada). 1981a. **Polychlorinated Dibenzo-p-Dioxins: Criteria for their Effects on Man and His Environment**. **Publ.** No. NRCC 18574, ISSN 0316-0114. NRCC/CNRC Associate Committee on Scientific Criteria for Environmental Quality, Ottawa, Canada. 251 p.

NRCC (National Research Council of Canada). 1981b. **Polychlorinated Dibbenzo-p-Dioxins: Limitations to the Current Analytical Techniques**. **Publ.** No. 18576, NRCC/NRC, Ottawa, Canada.

NTP (**National Toxicology Program**). 1980a. **Bioassay of 2,3,7,8-tetrachloro-dibenzo-p-dioxin for possible carcinogenicity** (gavage study). DHHS **Publ.** No. **(NIH) 82-1765**. **Carcinogenesis** Testing Program, NCI, **NIH**, Bethesda, **MD**, and National Toxicology Program, RTP, Box 12233, NC.

NTP (**National Toxicology Program**). 1980b. **Bioassay of 2,3,7,8-tetrachloro-dibenzo-p-dioxin for possible carcinogenicity** (Dermal study). DHHS **Publ.** No. **(NIH) 80-1757**. **Carcinogenesis** Testing Program, NCI, NIH, Bethesda, MO, and National Toxicology Program, RTP, Box 12233, NC.

NTP (National Toxicology Program). 1980c. Bioassay of 1,2,3,6,7,8- and 1,2,3,7,8,9-hexachlorodibenzo-p-dioxin for possible carcinogenicity (dermal study). OHHS Publ. No. (NIH) 80-1758. Carcinogenesis Testing Program, NCI, NIH, Bethesda, MD, and National Toxicology Program, NTP, Box 12233, NC.

NTP (National Toxicology Program). 1980d. Bioassay of 1,2,3,6,7,8- and 1,2,3,7,8,9-hexachlorodibenzo-p-dioxin (gavage) for possible carcinogenicity. DHHS Publ. No. (NIH) 80-1754. Carcinogenesis Testing Program, NCI, NIH, Bethesda, MD, and National Toxicology Program, RTP, Box 12233, NC.

NTP (National Toxicology Program). 1985. Unpublished results. Personal communication from Beth Tainer, NIEHS, Research Triangle Park, NC to Dr. D. Mukerjee, ECAO, U.S. EPA, Cincinnati, OH. March 18.

Ogilvie, D. 1981. Dioxin found in the Great Lakes basin. *Ambio*. 10: 38-39.

O'Keefe, P.W., M.S. Meselson and R.W. Baughman. 1978. Neutral cleanup procedure for 2,3,7,8-tetrachlorodibenzo-p-dioxin residues in bovine fat and milk. *J. Assoc. Off. Anal. Chem.* 61(3): 621-626.

O'Keefe, P., C. Meyer and K. Dillon. 1982. Comparison of concentration techniques for 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Anal. Chem.* 54: 2623-2625.

O'Keefe, P., C. Meyer, D. Hilker, et al. 1983. Analysis of 2,3,7,8-tetrachlorodibenzo-p-dioxin in Great Lakes fish. *Chemosphere*. 12: 325-332.

Okey, **A.G.** 1983. The Ah receptor: A specific **site** for action of chlorinated **dioxins**. In: Human and Environmental Risks of Chlorinated Dioxins and **Related** Compounds, R.E. Tucker, **A.L.** Young and **A.P.** Gray, Ed. Plenum Press, NY. p. 423-440.

Okey, **A.B.** and **L.M. Vella.** 1982. Binding of **3-methylcholanthrene** and **2,3,7,8-tetrachlorodibenzo-p-dioxin** to a common Ah receptor **site** in mouse and rat hepatic **cytosis**. Eur. J. **Biochem.** 127(1): 39-47.

Okey, **A.B.** and **L.M. Vella.** 1984. Elevated binding of **2,3,7,8-tetrachloro-**dibenzo-p-dioxin and 3-methylcholanthrene to the **Ah** receptor in hepatic cytosols from **phenobarbital-treated** rats and **mice**. Biochem. **Pharmacol.** (In press)

Okey, **A.B., G.P.** Bondy, M.E. Mason, et **al.** 1979. **Regulatory** gene product of the Ah locus. J. Biol. Chem. 254: **11636-11648.**

Okey, **A.B., G.P.** Bondy, M.E. Mason, et al. 1980. Temperature-dependent **cytosol-to-nucleus translocation** of the Ah receptor for **2,3,7,8-tetrachloro-**dibenzo-p-dioxin in continuous **cell culture** lines. J. Biol. Chem. 255(23): **11415-11422.**

**Olie, K., J.W.A.** Lustenhouwer and O. **Hutzinger.** 1982. **Polychlorinated** dibenzo-p-dioxins and related compounds **in** Incinerator **effluents**. In: Chlorinated Dioxins and Related Compounds: Impact on the Environment, O. Hutzinger et **al.,** Ed. **Pergamon** Press, NY. p. 227-244.

**Olle, K., M.V.D. Berg and O. Hutzinger.** 1983. Formation and fate of PCDD and PCDF from combustion processes. **Chemosphere.** 12: 627-636.

Oliver. J.E. and **J.M. Ruth.** 1983. Nitration of two TCOOs and their conversion to **1,2,3,6,7,8-HCDD.** Chemosphere. 12: **1497-1503.**

Oliver, **R.M.** 1975. Toxic effects of **2,3,7,8-tetrachlorodibenzo-1,4-dioxin** in laboratory workers. **Br. J. Ind. Med.** 32(1): 49-53.

Olson, J.R. and **W.E. Bittner.** 1983. Comparative metabolism and elimination of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).** **Toxicologist.** 3: 103.

Olson, J.R., **T.A. Gastewicz** and **R.A. Neal.** 1980a. Tissue distribution, excretion, and metabolism of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** in the **Golden Syrian hamster.** **Toxicol. Appl. Pharmacol.** 56: 78-85.

Olson, J.R., **M.A. Holscher** and **R.A. Neal.** 1980b. Toxicity of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the Golden Syrian hamster. **Toxicol. Appl. Pharmacol.** 55: 67-78.

Olson, **J.R., M. Gudzinowicz** and **R.A. Neal.** 1981. The in vitro and in **vivo** metabolism of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** in the rat. **Toxicologist.** 1: 69-70.

Olson, J.R., Gastewicz, T.A., L.E. Geiger and R.A. Neal. 1983. The metabolism of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in mammalian systems. In: Accidental Exposure to **Dioxins**: Human Health Aspects, F. Coulston and F. Pocchiarri, Ed. Academic Press, NY. p. 81-100.

Olsson, H. and L. Brandt. 1981. **Non-Hodgkin's lymphoma** of the **skin** and occupational exposure to herbicides. Lancet. 9/12/81: 579.

Orris, P. 1981. Unjustified conclusion? J. Occup. Med. 23(1): 7-8.

Ott, M.G., B.B. Holder and R.D. Olson. 1980. A mortality analysis of employees engaged in the manufacture of **2,4,5-trichlorophenoxyacetic** add. J. Occup. Med. 22(1): 47-50.

Owens, I.S. 1977. Genetic regulation of UDP-glucuronosyltransferase Induction by **polycyclic** aromatic compounds in mice. J. Biol. Chem. 252: 2827-2833.

Parker, C.E., W.A. Jones, H.B. Matthews, E.E. McConnell and J.R. Hass. 1980. Chronic **toxicity** of technical and **analytical pentachlorophenol** in cattle. II. Chemical analysis of tissues. Toxicol. Appl. Pharmacol. 55(2): 359-369.

Parkinson, A., R. Cockerline and S. Safe. 1980a. **Polychlorinated biphenyl isomers** and congeners as **inducers** of both **3-methylcholanthrene-** and **phenobarbitone-type microsomal** enzyme activity. Chem.-Biol. Interact. 29: 277-289.



Parkinson, **A.**, L. Robertson, L. Safe and S. Safe. 1980b. **Polychlorinated biphenyls** as **inducers** of hepatic **microsomal** enzymes: Structure-activity rules. **Chem.-Biol. Interact.** 30: 271-285.

Parkinson, **A.**, R. Cockerline and S. Safe. 1980c. Induction of both **3-methylcholanthrene-** and **phenobarbitone-type** microsomal enzyme activity by a single **polychlorinated biphenyl isomer**. **Biochem. Pharmacol.** 29: 259-262.

Parkinson, **A.**, L. Robertson, L. Uhlig, **M.A.** Campbell and S. Safe. 1982. **2,3,4,5',5-Pentachlorobiphenyl**: Differential effects on C56BL/6J and DBA/2J Inbred **mice**. **Biochem. Pharmacol.** 31: 2830-2833.

Parkinson, **A.**, S. Safe, L. Robertson, et al. 1983. **Immunochemical quantitation** of **cytochrome P-450 isozymes** and **epoxide** hydrolase in **liver** microsomes from **polychlorinated** and **polybrominated** biphenyls: A study of structure activity relationships. **J. Biol. Chem.** 258: 5967-5976.

Passi, **S., M.** Nazzaro-Porro, L. Boniforti and F. Gianotti. 1981. Analysis of **lipids** and **dioxin** in **chloracne** due to **tetrachloro-2,3,7,8-p-dibenzodioxin**. **Br. J. Dermatol.** 105(2): 137-143.

Pazderova-Vejlukova, **J., M.** Nemcova, J. Pickova, L. Jirasek and E. Lukas. 1981. The development and prognosis of chronic **intoxication** by tetrachloro-dibenzo-p-dioxin in men. **Arch. Environ. Health.** 36(1): 5-11.

Pegg, D.G., W.R. Hewitt, K.M. McCormack and J.B. Hook. 1976. Effect of **2,3,7,8-tetrachlorodibenzo-rho-dioxin** on renal function in the rat. *J. Toxicol. Environ. Health.* 2(1): 55-65.

Peterson, R.E., N. Hamada, K.H. Yang, B.V. Madhukar and F. Matsumura. 1979a. Depression of **adenosine triphosphatase** activities in Isolated **liver** surface membranes of **2,3,7,8-tetrachlorodibenzo-p-dioxin-treated** rats: Correlation **with** effects on **ouabain** biliary excretion and **bile** flow. *J. Pharmacol. Exp. Therap.* 210(2): 275-282.

Peterson, R.E., N. Hamada, K.H. Yang, B.V. Madhukar and F. Matsumura. 1979b. Reversal of **2,3,7,8-tetrachlorodibenzo-p-dioxin-induced** depression of ouabain biliary excretion by **pregnenolone-16alpha-carbonitrile** and **spironolactone** in Isolated perfused rat livers. *Toxicol. Appl. Pharmacol.* 50(3): 407-416.

Peterson, R.E., M.D. Seefeld, B.J. Christian, C.L. Potter, C.K. Kelling and R.E. Keesey. 1984. The wasting syndrome in **2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity**: Basic features and their Interpretation. In: Biological Mechanisms of Dioxin Action. Banbury Report 18. A Poland and R.D. Kimbrough, Ed. Cold Spring Harbor **Laboratory.** p. 291-308.

Phillips, M., V. Krasnobagew, J. Zeyer and R. Huetter. 1981. Fate of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCOD) in **microbial cultures** and **soil** under laboratory conditions. *FEMS Symp.* 12: 2210-233.

**Phillipson, D.W.** and B.J. Puma. 1980. Identification of chlorinated **methoxybiphenyls** as contaminants in **fish** and as potential Interferences in the determination of chlorinated **dibenzo-p-dioxins**. Anal. Chem. 42: 2328-2332.

**Piper, W.N.,** R.Q. Rose and **P.J. Gehring.** 1973. Excretion and tissue distribution of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the rat. Environ. Health Perspect. 5: 241-244.

**Pitot, H.C.,** T. **Goldsworthy** and H. Poland. 1980. Promotion by **2,3,7,8-tetrachlorodibenzo-p-dioxin** of hepatocarcinogenesis from **diethylnitrosamine**. Cancer Res. 40: 3616-3620.

**Plimmer, J.R.** 1978. Photolysis of TCDD and **trifluralin** on silica and soil. Bull. Environ. Contam. Toxicol. 20: 87-92.

**Pummer, J.R.,** J.M. Ruth and **E.A. Woolson.** 1973. Mass spectrometric Identification of the hepta- and **octachlorinated dibenzo-p-dioxins** and **dibenzofurans** in technical **pentachlorophenol**. J. Agric. Food Chem. 21(1): 90-93.

**Pocchiarl, F.,** V. **Silano** and A. **Zampieri.** 1979. Human health effects from accidental release of tetrachlorodibenzo-p-dioxin (TCDD) at Seveso, Italy. Ann. NY Acad. Sci. 320: 311-320.

**Pocchiarl, F., A. DiDomenico, V. Silano and G. Zapponi.** 1983. Environmental Impact of the accidental release of tetrachlorodibenzo-p-dioxin (TCDD) at Seveso (**Italy**). **In:** Accidental Exposure to **Dioxins: Human Health Aspects**, F. Coulston and F. **Pocchiarl**, Ed. Academic Press, NY. p. 5-35.

Pohland, **A.E.** and G.C. Yang. 1972. Preparation and characterization of chlorinated dibenzo-p-dioxins. **J. Agric. Food Chem.** 20: 1093-1099.

**Polger, H.** and C. Schlatter. 1979. Biological degradation of TCDD in rats. **Nature.** 281(5733): 706-707.

Polger, H. and C. **Schlatter.** 1980. Influence of solvents and adsorbents on dermal and Intestinal absorption of TCDD. **Food Cosmet. Toxicol.** 18(5): 477-481.

Polger, **H.,** H. Weber and C. **Schlatter.** 1982a. Special aspects of metabolism and kinetics of TCDD in dogs and rats. Assessment of **toxicity** of TCDD-**metabolite(s)** in guinea pigs. **In:** Chlorinated Dioxins and Related Compounds. Impact on the Environment, O. **Hutzinger, R.W. Frei, E. Merian** and F. Pocchiarl, Ed. Pergamon Press, NY. p. 317-325.

Polger, **H.,** H.R. Buser, H. **Weber, U. Zweifel** and C. Schlatter. 1982b. Structure elucidation of mammalian **TCDD-metabolites.** **Experientia.** 38(4): 484-486.

**Poland, A.** 1984. Reflections on the mechanisms of action of halogenated aromatic hydrocarbons. In: Biological Mechanisms of Dioxin Action. **Banbury Report 18.** A. **Poland** and R.D. **Kimbrough**, Ed. Cold Spring Harbor Laboratory. p. 109-117.

Poland, A. and E. **Glover.** 1973a. Chlorinated dibenzo-p-dioxins: Potent **inducers** of  **$\delta$ -aminolevulinic** acid synthetase and **aryl** hydrocarbon **hydroxylase.** II. A study of the structure activity relationship. **Mol. Pharmacol.** 9: 736.

Poland, A. and E. Glover. 1973b. **2,3,7,8-Tetrachlorodibenzo-p-dioxin.** Potent **inducer** of **delta-aminolevulinic acid** synthetase. **Science.** 179(4072): 476-477.

Poland, A. and E. Glover. 1974. Comparison of **2,3,7,8-tetrachlorodibenzo-p-dioxin**, a potent Inducer of aryl hydrocarbon hydroxylase, **with** Inducer **3-methylcholanthrene.** **Mol. Pharmacol.** 10(2): 349-359.

**Poland, A.** and E. Glover. 1975. Genetic expression of aryl hydrocarbon hydroxylase by **2,3,7,8-tetrachlorodibenzo-p-dioxin:** Evidence for a receptor mutation in **genetically** non-responsive **mice.** **Mol. Pharmacol.** 11(4): 389-398.

Poland, A. and E. Glover. 1979. An estimate of the maximum **in vivo** covalent binding of **2,3,7,8-tetrachlorodibenzo-p-dioxin** to rat liver protein, **ribosomal** RNA and DNA. **Cancer Res.** 39(9): 3341-3344.

- Poland, A. and E. Glover. 1980. **2,3,7,8-Tetrachlorodibenzo-p-dioxin**: Segregation of toxicity with the Ah locus. **Mol. Pharmacol.** 17(1): 86-94.
- Poland, A.** and J.C. Knutson. 1982. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** and related halogenated aromatic hydrocarbons: Examination of the mechanism of **toxicity**. **Ann. Rev. Pharmacol. Toxicol.** 22: 517-554.
- Poland, **A.P.**, D. Smith, G. **Metter** and P. **Possick**. 1971. A health survey of workers in a **2,4-D** and **2,4,5-T** plant with special attention to **chloracne**, **porphyria** cutanea tarda, and **psychologic** parameters. **Arch. Environ. Health.** 22: 316-327.
- Poland, A.P.**, E. Glover, **J.R.** Robinson and **D.W.** Nebert. 1974. Genetic expression of **aryl hydrocarbon hydroxylase** activity. Induction of **mono-oxygenase** activities and cytochrome **P<sub>1</sub>-450** formation by **2,3,7,8-tetra-chlorodibenzo-p-dioxin** in mice genetically "**nonresponsive**" to other aromatic hydrocarbons. **J. Biol. Chem.** 249(17): 5599-5606.
- Poland, **A.**, E. Glover and **A.S. Kende**. 1976. **Stereospecific, high** affinity binding of **2,3,7,8-tetrachlorodibenzo-p-dioxin** by hepatic cytosol. Evidence that the binding species is a receptor for Induction of aryl hydrocarbon hydroxylase. **J. Biol. Chem.** 251(16): 4936-4946.
- Poland, **A.**, **W.F. Greenlee** and **A.S. Kende**. 1979. Studies on the mechanisms of action of the chlorinated dibenzo-p-dioxins and related compounds. **Ann. NY Acad. Sci.** 320: 214-230.

**Poland, A., D. Palen and E. Glover.** 1982. Tumour promotion by TCDD in skin of HRS/J mice. Nature. 300(5889): 271-273.

**Poland, A., J. Knutson and E. Glover.** 1983. A consideration of the mechanism of action of **2,3,7,8-tetrachlorodibenzo-p-dioxin** and related halogenated aromatic hydrocarbons. In: Human and Environmental Risks of Chlorinated Dioxins and Related Compounds, R.E. Rucker, A.L. Young and A.P. Gray, Ed. Plenum Press, NY. p. 539-559.

**Poli, A., G. Grancesini, L. Puglisi and C.R. Sirtori.** 1980. Increased total and high density lipoprotein cholesterol with apoprotein changes resembling streptozotocin diabetes in tetrachlorodibenzodioxin (TCDD) treated rats. Biochem. Pharmacol. 28(5): 835-838.

**Poole, C.** 1983. Statement of Charles Poole before the United States House of Representatives Science and Technology Committee, Subcommittee on Natural Resources, Agricultural Research and Environment. March 23.

Potter, C.L., I.G. Slipes and O.H. Russell. 1982. Inhibition of ornithine decarboxylase activity by **2,3,7,8-tetrachlorodibenzo-p-dioxin**. Biochem. Pharmacol. 31(21): 3367-3371.

Pratt, R.M. 1983. Mechanisms of chemically-induced cleft palate. Trends Pharmacol. Sci. 4: 160-162.

Pratt, **R.M.** and **W.D.** Willis. 1985. In vitro screening assay for teratogens using growth Inhibition of human embryonic cells. Proc. **Natl. Acad. Sci.** USA. (In press, September Issue)

Pratt, **R.M.**, L. Dencker and V.M. **Diewert.** 1984a. TCDD-induced cleft palate In the mouse: Evidence for **alterations in** palatal shelf fusion. **Teratol. Carcinog. Mutagen.** 4: 427-436.

Pratt, **R.M.**, R.I. Grove, C.S. **Kim,** L. Dencker and V.M. Diewert. **1984b.** Mechanism of **TCDD-induced** cleft palate In the mouse. In: Biological Mechanisms of **Dioxin** Action. Banbury Report 18. A. Poland and R.D. **Kimbrough,** Ed. **Cold Spring Harbor Laboratory.** p. 61-71.

Ramsey, **J.C.,** J.G. Hefner, **R.J. Karbowski,** W.H. Braun and **P.J. Gehring.** 1982. The in vitro **biotransformation** of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) In the rat. **Toxicol. Appl. Pharmacol.** 65: 180-184.

Rappe, C., S. Marklund, H.R. Buser and **H.P. Bosshardt.** **1978.** Formation of **polychlorinated** dibenzo-p-dioxins and **dibenzofurans** by burning or heating chlorophenates. **Chemosphere.** 7(3): 269-281.

Rappe, **C.,** H.R. Buser and H.P. Bosshardt. 1979. Dioxins, **dibenzofurans,** and other polyhalogenated **aromatics** production use formation and destruction. Ann. NY Acad. **Sci.** 320: 1-18.



Rappe, C., S. **Marklund**, M. Nygren and A. Garl. 1983a. Parameter for Identification and confirmation **in** trace analyses of **polychlorinated dioxins** and **dibenzofurans**. In: Chlorinated Dioxins and **Dibenzofurans** in the Total Environment, **Vol. I**, L.H. Keith et **al.**, Ed. Butterworth Publishers.

Rappe, **C.**, S. Marklund, **P.A. Bergqvist** and P. Hansson. 1983b. Polychlorinated dioxins, dibenzofurans and other polychlorinated polynuclear **aromatics** formed during Incinerator and PCB fires. **In**: Chlorinated Dioxins and Dibenzofurans in the Total Environment, **Vol. I**, L.H. Keith et **al.**, Ed. Butterworth Publishers.

Rappe, **C.**, P-A. **Bergqvist**, M. Hansson, et al. 1984. Chemistry and analysis of polychlorinated dioxins and dibenzofurans in biological **samples**. in: Biological Mechanisms of **Dioxin** Action. Banbury Report, A. Poland and R.D. **Kimbrough**, Ed. Cold Spring Harbor **Laboratory**. p. 17-25.

Rappe, **C.**, M. Nygren, M. Hansson, et al. 1985. Identification of 2,3,7,8-**substituted** polychlorinated dioxins (**PCDDs**) and dibenzofurans (PCDFs) **in** environmental and human samples. (Submitted for publication)

Regglanl, G. 1980. Acute human exposure to TCDD in Seveso, Italy. **J. Toxicol. Environ. Health. 6(1):** 27-43.

Regglanl, G. 1982. Toxicology of TCDD and related compounds: Observation **in** man. In: Chlorinated Dioxins and Related Compounds. Impact on the Environment. O. **Hutzinger**, R.W. Frel, E. **Merian** and F. Pocchlarl, Ed. Pergamon Press, NY. p. 463-493.

Riihimäki, V., S. Asp, A.M. Seppäläinen and S. Herberg. 1978. **Symptomatology, Morbidity, and Mortality Experience of Chlorinated Phenoxy Acid Herbicide (2,4-D and 2,4,5-T) Sprayers in Finland: A Clinical and Epidemiological Study.** Working paper for an IARC working group meeting on coordination of **epidemiological** studies on the long-term hazards of chlorinated **dibenzodioxins** and chlorinated **dibenzofurans**. Lyon, France. Jan. 10-11.

Riihimäki, V., A. Sisko and S. Hernberg. 1982. **Mortality of 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlorophenoxyacetic acid herbicide applicators in Finland.** Scand. J. Work Environ. Health. 8: 37-42.

Riihimäki, V., S. Asp, E. Pukkala and S. Hernberg. 1983. **Mortality and cancer morbidity among chlorinated phenoxy acid applicators in Finland.** **Chemosphere.** 12(4/5): 779-784.

Rikans, L.E., D.D. Gibson and P.B. McCay. 1979. **Evidence for the presence of cytochrome P-450 in rat mammary gland.** **Biochem. Pharmacol.** 28(19): 3039-3042.

Rizzardi, M., M. Romano, F. Turzi, et al. 1983. **Toxicological evaluation of urban waste incinerator emissions.** **Chemosphere.** 12: 559-564.

Roberts, E.A., N.H. Shear and A.B. Okey. 1985. **The Ah receptor and dioxin toxicity: From rodent to human tissues.** **Chemosphere.** 14(6/7): 661-674.

Robinson, J.R., **J.S. Felton**, R.C. **Levitt**, S.S. **Thorgetrsson** and **D.W. Nebert**. 1975. Relationship between aromatic hydrocarbon responsiveness and the survival times in **mice** treated **with** various drugs and environmental compounds. **Mol. Pharmacol.** 11: 850-865.

**Rogers, A.M., M.E.** Anderson and **K.C.** Back. 1982. **Mutagenicity** of 2,3,7,8-tetrachlorodibenzo-p-dioxin and **perfluoro-n-decanoic** acid in L5178y mouse **lymphoma** cells. **Mutat. Res.** 105: 445-449.

**Roll, R.** 1971. Studies of the **teratogenic** effect of **2,4,5-T** in mice. Food Cosmet. **Toxicol.** 9(5): 671-676.

Rose, J.Q., **J.C.** Ramsey, T.H. **Wentzler**, R.A. Hummel and **P.J. Gehring**. 1976. The fate of **2,3,7,8-tetrachlorodibenzo-p-dioxin** following single and repeated oral doses to the rat. **Toxicol. Appl. Pharmacol.** 36(2): 209-226.

Ryan, **J.J.** and J.C. Pilon. 1980. **High performance liquid chromatography** in the analysis of chlorinated dibenzodioxins and **dibenzofurans** in the chicken liver and wood shaving **samples**. **J. Chromatogr.** 197: 171-180.

Ryan, J.J., J.C. Pilon, H.B.S. Conacher and D. Firestone. 1983. Inter-laboratory study on determination of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in **fish**. **J. Assoc. Off. Anal. Chem.** 66: 700-707.

Ryan, J.J., R. **Lizotte** and B.P-Y. Lau. **1985**. Chlorinated dibenzo-p-dioxins and chlorinated **dibenzofurnas** in Canadian human adipose tissue. **Chemosphere.** 14(6/7): 697-706.

**Safe, S.** 1984. **Polychlorinated biphenyls** (PCBs) and **polybrominated biphenyls** (PBBs): Biochemistry, toxicology and mechanism of action. CRC Critical Reviews. Toxicology. 13: 319-343.

Safe, S. 1985. Personal communication to Dr. O. **Mukerjee**, ECAO, U.S. **EPA**, Cincinnati, OH.

Safe, **S., L.W.** Robertson, L. Safe, et **al.** 1982. Halogenated biphenyls: Molecular toxicology. Can. **J. Physiol. Pharmacol.** 60: 1057-1064.

Safe, **S.,** T. Sawyer, S. **Bandiera**, et al. 1984. Binding to the **2,3,7,8-TCDD** receptor and AHH/EROD Induction: **In vitro** QXAR. **In: Biological** Mechanisms of Oloxin Action. Banbury Report 18. A. Poland and R.D. **Kimbrough**, Ed. Cold Spring Harbor **Laboratory.** p. 135-149.

**SAI** (Systems Applications, Inc.) 1980. Human Exposure to Atmospheric Concentration of Selected **Chemicals.** Vol. I. **NTIS** PB 81-193252.

Sarma, **P.R.** and J. Jacobs. 1981. Thoracic soft-tissue sarcoma in Vietnam veterans exposed to agent orange. Lancet. 306(18): 1109.

Sawahata, **T.,** J.R. Olson and **R.A. Neal.** 1982. Identification of metabolites **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) formed on incubation with isolated rat hepatocytes. **Biochem. Biophys. Res. Commun.** 105(1): 341-346.

Sawyer, T. and S. Safe. 1982. PCB **isomers** and congeners: Induction of **aryl** hydrocarbon hydroxylase and **ethoxyresorufin O-deethylase** enzyme activities in rat **hepatoma** cells. **Toxicol. Lett.** 13: 87-94.

Sawyer, T., S. Bandiera, S. Safe, O. Hutzinger and K. Olie. 1983. Bioanalysis of **polychlorinated dibenzofuran** and dibenzo-p-dioxin mixtures in fly ash. **Chemosphere.** 12: 529-535.

Scarpelli, D.G., M.S. Rao, V. Subbarao, M. Beversluis, D.P. Gurka and P.F. Hollenberg. 1980. Activation of **nitrosamines** to **mutagens** by **post-mitochondrial** fraction of hamster pancreas. **Cancer Res.** 40(1): 67-74.

Schantz, S.L., D.A. Barsotti and J.R. Allen. 1979. **Toxicological** effects produced in nonhuman primates chronically exposed to fifty parts per trillion **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDO). **Toxicol. Appl. Pharmacol.** 48: A180.

Schechter, A., J.J. Ryan, R. Lizotte, et al. 1985. Chlorinated **dibenzo-dioxins** and **dibenzofurans** in human adipose tissue from exposed and control New York State patients. **Chemosphere.** 14(6/7): 933-937.

Schueler, R.L. 1983. Review of Selected **Neoplastic** and **Non-neoplastic** Liver Lesions in Rats Given **Hexachlorodibenzo-p-dioxins**. Prepared for the U.S. EPA under Contract No. 68-02-3763.

Schwetz, B.A., J.M. Norris, G.L. Sparschu, et al. 1973. Toxicology of chlorinated dibenzo-p-dioxins. **Environ. Health Perspect.** 5: 87-99.

Seefeld, M.D. and R.E. Peterson. 1983. **2,3,7,8-Tetrachlorodibenzo-p-dioxin**-induced weight loss: A proposed mechanism. In: Human and Environmental Risks of Chlorinated Dioxins and Related Compounds, R.E. Tucker, A.L. Young and A.P. Gray, Ed. Plenum Press, NY. p. 405-413.

Seefeld, M.D., R.M. Albrecht and R.E. Peterson. 1979. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on indocyanine green blood clearance in rhesus monkeys. Toxicology. 14(3): 263-272.

Seefeld, M.D., R.M. Albrecht, K.W. Gilchrist and R.E. Peterson. 1980. Blood clearance tests for detecting **2,3,7,8-tetrachlorodibenzo-p-dioxin** hepatotoxicity in rats and rabbits. Arch. Environ. Contam. Toxicol. 9(3): 317-327.

Seefeld, M.D., S.W. Corbett, R.E. Keesey and R.E. Peterson. 1984. Characterization of the wasting syndrome in rats treated with **2,3,7,8-tetrachlorodibenzo-p-dioxin**. Toxicol. Appl. Pharmacol. 73: 311-322.

Seller, J.P. 1973. A survey on the mutagenicity of various pesticides. Experientia. 29: 622-623.

Shadoff, L.A., R.A. Hummel, L. Lamparski and J.H. Davidson. 1977. A search for **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) in an environment exposed annually to **2,4,5-trichlorophenoxyacetic** acid ester (**2,4,5-T**) herbicides. Bull. Environ. Contam. Toxicol. 18(4): 478-485.

Sharma, R.P. and P.J. Gehring. 1979. Effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on **splenic lymphocyte** transformation in mice after single and repeated exposures. Ann. NY Acad. Sci. 320: 487-497.

Shaub, W.M. and W. Tsang. 1983. **Physical** and chemical properties of **dioxins** in relation to their disposal. **In:** Human and Environmental Risks of Chlorinated Dioxins and Related Compounds, R. Tucker et al., Ed. Plenum Publishing Corp., NY. p. **731-748**.

Shiverick, K.T. and T.F. Muther. 1982. Effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on serum concentrations and the **uterotrophic** action of exogenous estrone in rats. **Toxicol. Appl. Pharmacol.** 65(1): 170-176.

Shiverick, K.T. and T.F. Muther. 1983. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** (TCDD) effect on hepatic **microsomal** steroid metabolism and serum **estradiol** of pregnant rats. **Biochem. Pharmacol.** 32: 991-995.

Shum, S., N.M. Jensen and D.W. Nebert. 1979. The Ah Locus. In utero toxicity and **teratogenesis** associated with genetic differences in **benzo[a]-pyrene** metabolism. **Teratology.** 20: 365-376.

Silbergeld, E.K. 1984. **Neurotoxicology** of Agent Orange. Training course in neurotoxicology. Johns Hopkins School of Hygiene and Public Health. **November.**

Silkworth, J., D. McMartin, A. DeCaprio, R. Rej, P. O'Keefe and L. Kaminsky. 1982. Acute toxicity in guinea pigs and rabbits of soot from a polychlorinated biphenyl-containing transformer fire. *Toxicol. Appl. Pharmacol.* 65: 425-439.

Singer, R., M. Moses, J. Valciukas, R. Lills and I.J. Selikoff. 1982. Nerve conduction velocity studies of workers employed in the manufacture of phenoxy herbicides. *Environ. Res.* 29: 297-311.

Sirchia, G. 1978. Report to Lombardy Regional Authority (unpublished). (Cited in Pocchiari et al., 1979)

Smith, A.H. 1983. School of Public Health, University of California. Letter to the Carcinogen Assessment Group, U.S. EPA, December 13.

Smith, A.H., J.E. Francis, S.J. Kay and J.B. Greig. 1981. Hepatic toxicity and uroporphyrinogen decarboxylase activity following a single dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin to mice. *Biochem. Pharmacol.* 30(20): 2825-2830.

Smith, A.H., D.O. Fisher, N. Pearce and C.J. Chapman. 1982a. Congenital defects and miscarriages among New Zealand 2,4,5-T sprayers. *Arch. Environ. Health.* 37: 197-200.

Smith, A.H., D.O. Fisher, N. Pearce and C.A. Teague. 1982b. Do agricultural chemicals cause soft-tissue sarcoma? Initial findings of a case-control study in New Zealand. *Community Health Studies.* 6(2): 114-119.



Smith, **A.H.**, D.O. Fisher, H.J. Giles and N. Pearce. 1983a. The New Zealand soft tissue sarcoma **case-control** study: Interview findings concerning **phenoxyacetic acid** exposure. Chemosphere. 12(4/5): 565-571.

Smith, **F.A.**, **B.A.** Schwetz and **K.D.** Nitschke. 1976. **Teratogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin** in CF-1 mice. **Toxicol. Appl. Pharmacol.** 38(3): 517-523.

Smith, J. 1979. EPA halts **most** uses of herbicide **2,4,5-T**. **Science.** 203(4385): 1090-1091.

Smith, **L.M.**, D.L. Stalling and J.L. **Johnson.** 1984. Determination of **parts-per-trillion levels of polychlorinated dibenzofurans and dioxins** in **environmental** samples. **Anal. Chem.** 56(11): 1830-1842.

Smith, **R.M.**, **P.W.** O'Keefe, **K.M.** Aldous, D.R. **Hilker** and J.E. **O'Brian.** 1983b. **2,3,7,8-Tetrachlorodibenzo-p-dioxin** in sediment and samples from Love Canal storm sewers and creeks. **Environ. Sci. Technol.** 17: 6-10.

Sparschu, G.L., Jr., F.L. Dunn, Jr., and **V.K.** Rowe, Jr. 1971a. Study of the **teratogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin** in the rat. **Food Cosmet. Toxicol.** 9: 405-412.

Sparschu, G.L., F.L. Dunn, **R.W.** Lisowe and V.K. Rowe. 1971b. Effects of **high levels of 2,4,5-trichlorophenoxyacetic acid** on fetal development in the rat. **Food Cosmet. Toxicol.** 9(4): 527-530.

Spencer, **H.W.** and **W. Woodrow.** 1979. Memorandum to D. **Reisa.** TDAP review at the University of Wisconsin. TCDD in rats. February 8.

Squire, **R.A.** 1980. Pathologic Evaluations of Selected Tissues from the Dow **Chemical** TCDD and **2,4,5-T** Rat Studies. Submitted to Carcinogen Assessment Group, U.S. EPA on August 15 under contract no. 68-01-5092.

Squire, R.A. 1983. An Assessment of the Experimental Evidence for Potential **Carcinogenicity** of Hexachlorodibenzo-p-dioxins. Report prepared for Vulcan Chemicals and **Reichhold** Chemicals, Inc. June 29, 1983.

SRI (Stanford Research Institute) **International.** 1982. 1982 Directory of Chemical Producers: USA, SRI **International, Menlo** Park, CA.

Stalling, D.L., **L.M.** Smith, J.D. Petty, et **al.** 1983. Residues of polychlorinated dibenzo-p-dioxins and **dibenzofurans** in **Laurentian** Great Lakes **fish.** In: Human and Environmental Risks of Chlorinated Dioxins and **Related** Compounds, R.E. Tucker et **al.**, Ed. Plenum Press, NY. p. 220-240.

Stanley, J., C. Halle, A. Small and E. Olson. 1982. Sampling and Analysis Procedures for Assessing Organic Emissions from Stationary Combustion Sources for EED Studies. **Methods-Manual.** EPA 580/5-82-014. Office of Toxic Substances, U.S. EPA, Washington, DC.

**Stehl,** R.H., R.R. Paperfuss, R.A. Bredeweg and R.W. Roberts. 1973. The stability of **pentachlorophenol** and chlorinated **dioxins** to sunlight, heat and combustion. Adv. **Chem.** Ser. 120, Am. **Chem.** Soc. p. **119.**

Stephan, C.E. 1980. Memorandum to **Jerry**. F. Stara, U.S. EPA, Cincinnati, OH. July.

Stevens, **K.M.** 1981. Agent Orange **toxicity**: A quantitative perspective. Human Toxicol. 1(1): 31-39.

Stohs, S.J., **M.Q.** Hassan and **W.J.** Murray. 1983. Lipid **peroxidation** as a **possible** cause of TCDD **toxicity**. Biochem. Biophys. Res. Commun. 111: 854-859.

**Strik**, J.J. and J.M. de **Wit**. 1980. Health aspects of rabbits in a **low-TCDD** contaminated area. Int. J. Biochem. 12(5-6): 999-1001.

**Sundstrom**, G., S. Jensen, B. Jansson and **K.** Erne. 1979. Chlorinated **phenoxyacetic** acid derivatives and tetrachlorodibenzo-p-dioxin in foliage after **application** of **2,4,5-trichlorophenoxyacetic** acid esters. Arch. Environ. Contam. Toxicol. 8(4): **441-448**.

**Suskind**, R.R. and V.S. Hertzberg. 1984. Human **health** effects of **2,4,5-T** and **its** toxic contaminants. J. Am. Med. Assoc. 251(18): 2372-2380.

Sweeney, G.D. and **K.G.** Jones. 1978. On the mechanism of **porphyria** due to chlorinated hydrocarbons. Int. Congr. Ser. Excerpta Med. 440: 229-231.

**Sweeney, G.G.** and **K.G. Jones.** 1983. Studies of the mechanism of action of **hepatotoxicity** of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** and **related** compounds. In: Human and Environmental Risks of Chlorinated **Dioxins** and Related Compounds, **R.E. Tucker, A.L. Young** and **A.P. Gray,** Ed. Plenum Press, NY. p. 415-422.

**Sweeney, G.D., K.G. Jones, F.M. Cole,** D. Basford and **F. Krestynski.** 1979. Iron deficiency prevents liver **toxicity** of **2,3,7,8-tetrachlorodibenzo-p-dioxin.** Science. 204(4390): 332-335.

**Swift, L.L., T.A. Gastewicz, G.O. Dunn, P.O. Soule** and **R.A. Neal.** 1981. Characterization of the **hyperlipidemia** in guinea **pigs** Induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. **Toxicol. Appl. Pharmacol.** 59(3): 489-499.

**Taylor, J.S.** 1979. Environmental **chloracne:** Update and overview. Ann. NY Acad. Sci. 320: 295-307.

**Taylor, M.L., T.O. Tiernan, J.H. Garrett, G.F. Van Ness** and **J.G. Solch.** 1983. Assessments of Incineration processes as sources of **supertoxic** chlorinated hydrocarbons: Concentrations of **polychlorinated dibenzo-p-dioxins/dibenzofurans** and possible precursor compounds **in** Incinerator effluents. In: Chlorinated Dioxins and Dibenzofurans in the Total Environment, Vol. I, **L.H. Keith et al.,** Ed. Butterworth Publishers, p. 125-164.

**Teitelbaum, P.J.** and **A.P. Poland.** 1978. Studies of the hepatic uptake of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in the mouse. Fed. Proc. Fed. Am. Soc. Exp. Biol. 37(3): 692.

Tenchi, M.L., C. Cirmaudo, G. Simoni, L. Decarli, R. Giorgi and F. Nuzzo. 1979. Approaches to the **evaluation** of genetic damage after a **major** hazard in chemical industry: Preliminary **cytogenetic** findings in TCDD-exposed subjects after the Seveso **accident**. in: Genetic Damage in Man Caused by Environmental Agents, K. Berg, Ed. Academic Press, NY. p. 301-316.

Tenchi, M.L., C. Cirmaudo, G. Pacchetti, A. Motura, S. Agosti and L. DeCarli. 1983. A comparative cytogenetic study on cases of induced abortions in TCDD-exposed and nonexposed women. Environ. Mutagen. 5: 73-85.

Thibodeaux, L.J. 1979. **Chemodynamics-Environmental** Movement of Chemicals in Air, Water and Soil. John Wiley and Sons, Inc., NY. p. 176-177.

Thibodeaux, L. 1983. Off-site transport of **2,3,7,8-tetrachlorodibenzo-p-dioxin** from a production disposal facility. **In: Chlorinated Dioxins and Dibenzofurans** in the Total Environment, Vol. I, L.H. Keith et al., Ed. Butterworth Publishers, Woburn, MA.

Thiess, A.M. and R. Frenzel-Beyme. 1977. Mortality Study of Persons Exposed to **Dioxin** Following an Accident which Occurred in the BASF on 13, November, 1953. Proceedings of MEDICHEM Congress V, San Francisco, Sept. 5.

Thiess, A.M. and R. Frenzel-Beyme. 1978. Mortality Study of Persons Exposed to Dioxin Following an Accident which Occurred in the BASF on 13, November, 1953. Working Papers, Joint **NIEHS/IARC** Working Group Report, Lyon, France, June, 1978.

**Thiess, A.M., R. Frentzel-Beyme and R. Link.** 1982. Mortality study of persons exposed to **dioxin** in a **trichlorophenol-process** accident that occurred in the BASF AG on November **17**, 1953. Am. J. **Ind. Med.** 3: 179-189.

**Thigpen, J.E., R.E. Faith, E.E. McConnell and J.A. Moore.** 1975. Increased susceptibility to bacterial infection as a **sequela** of exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Infect. **Immun.** 12(6): 1319-1324.

Thomas, **N.A.** 1983. Memorandum to C.E. **Stephan**, U.S. EPA, **Duluth**, MN. July 22.

Thomas, **P.E., J.J. Hutton and B.A. Taylor.** 1973. Genetic relationship between **aryl** hydrocarbon hydroxylase inducibility and chemical carcinogen induced **skin ulceration** in **mice**. Genetics. 74: 655-659.

Thomas, **P.T. and R.D. Hindsill.** 1979. The effect of perinatal exposure to **tetrachlorodibenzo-p-dioxin** on the immune response of young **mice**. Drug Chem. **Toxicol.** 2(1,2): 77-98.

Thomas, H.F. 1980a. Internal memo to P. Cohn, Office of Toxic Substances, U.S. EPA, Washington, DC.

Thomas, H.F. 1980b. **2,4,5-T** use and congenital malformation rates in Hungary. Lancet. 11: 214-215.

**Thunberg, T.** 1984. Effects of TCDD on vitamin A and **its** relation to TCDD **toxicity.** In: Biological Mechanisms of Oloxl<sub>n</sub> Action. **Banbury** Report 18. A. Poland and R.D. **Kimbrough,** Ed. Cold Spring Harbor **Laboratory.** p. 333-344.

Thunberg, T. and H. **Häkansson.** 1983. Vitamin A (**retinol**) status in the Gunn rat: The effect of **2,3,7,8-tetrachlorodibenzo-p-dioxin.** Arch. **Toxicol.** 53: 225-233.

Thunberg, **T.,** U.G. Ahlborg and H. Johnsson. 1979. Vitamin A (retinol) status **in** the rat after a **single oral** dose of **2,3,7,8-tetrachlorodibenzo-p-dioxin.** Arch. Toxicol. 42(4): 265-274.

Thunberg, **T.,** U.G. Ahlborg, H. Hakansson, C. **Krantz** and M. **Monier.** 1980. Effect of **2,3,7,8-tetrachlorodibenzo-p-dioxin** on the hepatic storage of **Retinol** in rats **with** different dietary supplies of vitamin A (Retinol). Arch. **Toxicol. (Berl).** 45(4): 273-285.

Thunberg, **T.,** U.G. Ahlborg and B. **Wahlström.** 1984. Comparison between the effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** and **six** other compounds on the vitamin A storage, the **UDP-glucuronosyltransferase** and the **aryl** hydrocarbon hydroxylase activity **in** the rat liver. Arch. Toxicol. 55: 16-19.

**Tiernan,** T.O. 1982. Chlorodibenzodioxins and **chlorodibenzofurans:** An overview. In: Detoxication of Hazardous Wastes, J.H. Exner, Ed. Ann Arbor Science **Publishers,** Inc., Ann Arbor, MI. p. 243-260.

Tiernan, T.O. 1983. Analytical chemistry of polychlorinated dibenzo-p-dioxins and dibenzofurans: A review of the current status. In: Chlorinated Dioxins and Dibenzofurans in the Total Environment, Vol. I, L.H. Keith et al., Ed. Butterworth Publishers. p. 211-237.

Tiernan, T.O., M.L. Taylor, S.D. Erk, J.G. Solch and G. Van Ness. 1980. Dioxins. Vol. II. Analytical Method for Industrial Wastes. Final Report Industrial Environmental Research Lab., Cincinnati, OH. EPA 600/280-57. 80 p.

Tiernan, T.O., M.L. Taylor, J.G. Solch, G.F. Van Ness, J.H. Garrett and M.D. Porter. 1982a. Incineration of chemical wastes containing polychlorinated biphenyls: Assessment of tests conducted at Rollins Environmental Sciences, Deer Park, TX, and Energy Systems Co., El Dorado, AR. In: Detoxification of Hazardous Waste, J.H. Exner, Ed. Ann Arbor Science (Butterworth). p. 143-184.

Tiernan, T.O., M.L. Taylor, J.G. Solch, G.F. Van Ness and J.H. Garrett. 1982b. Characterization of toxic components in the effluent from a refuse-fired incinerator. Resour. Conserv. 9: 343-354.

Tofflon, P.J., P.G. Peters, R.P. Clement, D.M. Hardwicke and W.N. Piper. 1980. Depressed guinea pig testicular microsomal cytochrome P-450 content by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Life Sci. 27(10): 871-876.

Tognoni, G. and A. Bonaccorsi. 1982. Epidemiological problems with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Drug Metab. Rev. 13: 447-469.



**Tosine, H. 1981.** Method used by Ontario Ministry of the Environment primarily for the analysis of **fish** tissues and raw and untreated waters. In: **Polychlorinated Dibenzo-p-Dioxins: Limitations to the Current Analytical Techniques**, NRCC/NRC, **Ottawa, Canada.** p. 129-137.

**Toth, K.,** 3. Sugar, S. **Somfal-Relle** and 3. Bence. 1978. Carcinogenic bio-assay of the herbicide, **2,4,5-trichlorophenoxyethanol** (TCPE) **with** different **2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin)** content in Swiss **mice.** **Prog. Biochem. Pharmacol.** 14: 82-93.

Toth, **K.,** S. Somfal-Relle, 0. Sugar and 3. Bence. **1979. Carcinogenicity** testing of herbicide **2,4,5-trichlorophenoxyethanol** containing dioxin and of pure dioxin in Swiss **mice.** **Nature (Lond).** 278(5704): 548-549.

Townsend, J.C., K.M. Bodner, **P.F.** Van Peenen, R.D. **Olsen** and R.R. Cook. 1982. Survey of reproductive events of wives of employees exposed to chlorinated **dioxins.** **Am. J. Epidemiol.** 115(5): **695-713.**

**Tsushimoto, G.,** F. Matsumura and R. Sago. 1982. Fate of **2,3,7,8-tetra-Chlorodibenzo-p-dioxin (TCDO)** in an outdoor pond and in model aquatic ecosystem. **Environ. Toxicol. Chem.** 1: 61-68.

Tukey, R.H., R.R. Hannah, M. Negishi, **D.W.** Nebert and **H.J. Eisen.** 1982. The Ah locus: Correlation of Intranuclear appearance of **inducer-receptor** complex **with** Induction of cytochrome **P<sub>1</sub>-450 mRNA.** **Cell.** 31: 275-284.

- Tulp, M.T.M. and O. Hutzinger. 1978. Rat metabolism of polychlorinated dibenzo-p-dioxins. Chemosphere. 9: 761-768.
- Turner, J.N. and D.N. Collins. 1983. Liver morphology in guinea pigs administered either pyrolysis products of a polychlorinated biphenyl transformer fluid or 2,3,7,8-tetrachlorodibenzo-p-dioxins. Toxicol. Appl. Pharmacol. 67: 417-429.
- United Kingdom Ministry of Agriculture, Fisheries and Food. 1983. Advisory committee on pesticides: Report on phenoxy acid herbicides. Whitehall Place, London, February 7.
- U.S. EPA. 1978. Report of the ad hoc study group on pentachlorophenol and contaminants. EPA/SAB/78/001. p. 170. (Cited in NRCC, 1981b)
- U.S. EPA. 1979a. Chemistry Laboratory Manual for Bottom Sediments and Elutriate Testing. EPA 903/4-79-014. NTIS PB 294 596, Springfield, VA.
- U.S. EPA. 1979b. Report of the FIFRA Scientific Advisory Panel on Proposed Section 6(b) (2) Notices for 2,4,5-T and Silvex. Memorandum from Dr. H. Wade Fowler, Jr., Executive Secretary FIFRA Scientific Advisory Panel to the Deputy Assistant Administrator for Pesticide Programs. Sept. 27, 1979.
- U.S. EPA. 1979c. Report of Assessment of a Field Investigation of Six-year Spontaneous Abortion Rates in Three Oregon Areas in Relation to Forest 2,4,5-T Spray Practice. OTS, U.S. EPA.

- U.S. EPA. 1980a. Dioxins. Industrial Pollution Control Division, IERL, ORD, U.S. EPA, Cincinnati, OH. EPA 600/2-80-197.
- U.S. EPA. 1980b. Seafood Consumption Data Analysis, SRI **International**, Menlo Park, CA. Final Report, Task 11. EPA Contract No. 68-01-3887.
- U.S. EPA. 1980c. Carcinogen **Assessment** Group's **Risk** Assessment on (2,4,5-Trichlorophenoxy)acetic acid **(2,4,5-T)**, **(2,4,5-Trichlorophenoxy)propionic acid (Silvex)**, and **2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)**. September 12.
- U.S. EPA. 1982a. Test **Method: 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Method 613**. Storet No. 34675. Environmental Monitoring and Support Laboratory, Cincinnati, OH.
- U.S. EPA. 1982b. Environmental Monitoring at Love Canal. Vol. I. EPA **600/4-82-030a**, Office of Research and Development, U.S. EPA, Washington, DC, May, **1982**. **NTIS** PB 82-237330.
- U.S. EPA. 1982c. Tolerances and Exemptions from Tolerances for Pesticide Chemicals in or on Raw Agricultural Commodities. Food Drug Cosmetic Law **Reporter**, 40 CFR 180.302.
- U.S. EPA. **1983a**. Dow Chemical Company - Midland Plant **Wastewater** Characterization Study. Preliminary Summary of Results. March 28.
- U.S. EPA. **1983b**. Memorandum from U.S. EPA Cancer Assessment Group, to Judy **Bellin, OSW**, October 19.

U.S. EPA. 1984. Ambient Water Quality Criteria for **2,3,7,8-Tetrachlorodibenzo-p-dioxin**. Environmental Criteria and Assessment Office, U.S. EPA, Cincinnati, OH. EPA 440/5-84-007.

**USITC** (U.S. International Trade Commission). 1982. Synthetic Organic Chemicals. United States Production and **Sales**, 1981. USITC **Publ.** No. 1292, **Washington, DC**.

Van der Berg, **M., K. Olle and O. Hutzinger**. 1983. Uptake and selective retention **in** rats of orally administered chlorinated **dioxins** and **dibenzofurans** from fly ash and fly ash extract. **Chemosphere**. 12(4/5): 537-544.

van Logten, **M.J., B.N. Gupta, E.E. McConnell and J.A. Moore**. 1980. Role of the endocrine system **in** the action of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on the thymus. **Toxicology**. 15(2): 135-144.

van Logten, M.J., B.N. Gupta, E.E. McConnell and J.A. Moore. 1981. The Influence of **malnutrition** on the **toxicity** of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) **in** rats. **Toxicology**. 21(1): 77-88.

Van Miller, **J.P., R.J. Marlar and J.R. Allen**. 1976. Tissue distribution and excretion of **tritiated** tetrachlorodibenzo-p-dioxin **in** non-human primates and rats. **Food Cosmet. Toxicol.** 14(1): 31-34.

Van Miller, **J.P., J.J. Lalich and J.R. Allen**. 1977a. Increased Incidence of neoplasms **in** rats exposed to low **levels** of **2,3,7,8-tetrachlorodibenzo-p-dioxin**. **Chemosphere**. 6(10): 625-632.

Van **Miller, J.P.**, J.J. **Lalich** and J.R. **Allen**. 1977b. Increased Incidence of neoplasms in rats exposed to low levels of **2,3,7,8-tetrachlorodibenzo-p-dioxin**. **Chemosphere**. 6(9): 537-544.

Van Ness, **G.F.**, J.G. **Solch**, M.L. **Taylor** and T.O. **Tiernan**. 1980. Tetrachlorodibenzo-p-dioxins in chemical wastes, aqueous effluents and soils. **Chemosphere**. 9: 553-563.

**Vecchi, A.**, A. **Mantovani**, M. **Sironi**, W. **Lulni**, F. **Spreafico** and S. **Garattini**. 1980. The effect of acute administration of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) on humoral antibody production and cell-mediated activities in mice. **Arch. Toxicol. (Suppl.)** 4: 163-165.

**Vecchi, A.**, M. **Sironi**, M.A. **Canegrati**, M. **Recchia** and S. **Garattini**. 1983. Immunosuppressive effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in strains of mice with different susceptibility to induction of aryl hydrocarbon hydroxylase. **Toxicol. Appl. Pharmacol.** 68: 434-441.

**Veith, G.D.** and P. **Kosian**. 1983. Estimating bioconcentration potential from octanol/water partition coefficients. In: Physical Behavior of PCBs in the Great Lakes, D. **Mackay** et al., Ed. Ann Arbor Science, Ann Arbor, MI. p. 269.

**Veith, G.D.**, K.J. **Macek**, S.R. **Petrocelli** and J. **Carroll**. 1980. An evaluation of using partition coefficients and water solubility to estimate bioconcentration factors for organic chemicals in fish. In: J.G. **Eaton** et al., Ed., Aquatic Toxicology. **ASTM** STP 707. American Society for Testing and Materials, Philadelphia, PA. p. 116-129.

Villaneuva, E.C., R.W. Jennings and V.W. Burse. 1973. Chlorodibenzo-p-dioxin contamination of two commercially available pentachlorophenols. J. Agric. Food Chem. 21(4): 739.

Vinopal, J.H. and J.E. Casida. 1973. Metabolic stability of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mammalian liver microsomal systems and in living mice. Arch. Environ. Contam. Toxicol. 1(2): 122-132.

Vos, J.G. 1977. Immune suppression as related to toxicology. Crit. Rev. Toxicol. 5(1): 67-101.

Vos, J.G. and R.B. Beems. 1971. Dermal toxicity studies of technical polychlorinated biphenyls and fractions thereof in rabbits. Toxicol. Appl. Pharmacol. 19: 617-633.

Vos, J.G. and J.H. Koeman. 1970. Comparative toxicologic study with polychlorinated biphenyls in chickens with special reference to porphyrin, edema formation, liver necrosis and tissue residues. Toxicol. Appl. Pharmacol. 17: 656-668.

Vos, J.G. and J.A. Moore. 1974. Suppression of cellular immunity in rats and mice by maternal treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Int. Arch. Allergy Appl. Immunol. 47(5): 777-794.

Vos, J.G., J.A. Moore and J.G. Zinkl. 1973. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the immune system of laboratory animals. Environ. Health Perspect. 5: 149-162.

Vos, J.G., **J.A. Moore** and J.G. Zinkl. 1974. Toxicity of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** in C57B1/6 mice. **Toxicol. Appl. Pharmacol.** 29: 229-241.

Vos, J.G., J.G. **Kreeftenberg** and L. **Kater**. 1978a. Immune Suppression by TCDD. **In: Dioxin: Toxicological and Chemical Aspects.** SO Medical and Scientific Books, NY. p. 163-175.

**Vos, J.G., J.G. Kreeftenberg, H.W. Engel, A. Minderhoud** and J.L.M. Van Noorle. 1978b. Studies on **2,3,7,8-tetrachlorodibenzo-p-dioxin** Induced Immune suppression and decreased resistance to Infection: **Endotoxin** hypersensitivity, serum **zinc** concentrations and effect of thymos in treatment. **Toxicology.** 9(1-2): 75-86.

Walker, **A.E.** and J.V. Martin. 1979. **Lipid** profiles in **dioxin-exposed** workers. **Lancet.** 1: 446-447.

Walsh, J. 1977. Seveso: The questions persist where **dioxin** created a wasteland. **Science.** 197(4308): 1064-1067.

**Ward, A.M.** 1982. Investigation of the Immune capability of workers previously exposed to **2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD).** **In: The Chemical Scythe: Lessons of 2,4,5-T and Dioxin,** A. Hay, Ed. Plenum Press, NY. p. 117-118.

Ward, C. and F. Matsumura. 1977. Fate of 2,4,5-T contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in aquatic **environments.** **NTIS PB-264187.** 28 p.

Ward, C.T. and F. **Matsumura**. 1978. Fate of **2,3,7,8-tetrachlorodibenzo-p-dioxin** (TCDD) in a model aquatic environment. Arch. Environ. **Contam. Toxicol.** 7: 349-357.

**Wassom**, J.S., J.E. Huff and N. **Loprieno**. 1978. A review of the genetic toxicology of **chlorinated dibenzo-p-dioxins**. **Mutat. Res.** 47(3,4): 141-160.

Weber, G., P. **Luzi**, L. Resl, P. **Tanganelli**, **M.R. Lovati** and A. **Poli**. 1983. Natural history of **TCDD-induced** liver lesions in rats as observed by transmission electron microscopy during a 32-week period after a single **intra-peritoneal injection**. J. Toxicol. Environ. Health. 12: 533-540.

Weber, H., H. **Potiger** and C. **Schlatter**. 1982. Fate of **2,3,7,8-tetrachloro-dibenzo-p-dioxin** metabolites from dogs in rats. Xenobiotica. 12(6): 353-357.

**Weissberg**, J.B. and J.G. Zinkl. 1973. Effects of **2,3,7,8-tetrachloro-dibenzo-p-dioxin** upon **hemostasis** and **hematologic** function in the rat. Environ. Health Perspect. 5: 119-123.

**Whitlock**, J.P., D.I. Israel, O.R. **Galeazzi** and A.G. Miller. 1984. **2,3,7,8-Tetrachlorodibenzo-2-dioxin** regulates **cytochrome P<sub>1</sub>-450** gene expression. In: Biological Mechanisms of **Dioxin** Action. Banbury Report 18. A. Poland and R.D. **Kimbrough**, Ed. Cold Spring Harbor **Laboratory**. p. 191-200.

Wlplf, H.K. and J. **Schmid**. 1983. Seveso -- An environmental assessment. In: Human and Environmental Risks of Chlorinated Dioxins and Related Compounds, R.E. Tucker et al., Ed. Plenum Publishing Corp., NY. p. 255-274.



Wipf, H.K., E. Homberger, N. Neimer, U.B. Ranalder, W. Vetter and J.P. Vullleumelr. 1982. TCDO levels **in soil** and plant samples from the Seveso area. **In:** Chlorinated **Dioxins** and Related Compounds: Impact on the Environment, O. Hutzinger et al., Ed. **Pergamon** Press, NY. p. 115-126.

Wolfe, W.H., U.E. Michalek, R.A. Albanese, G.D. Lathrop and P.M. Moynahan. 1984. An epdemiologic Investigation of health effects **in Air** Force personnel following exposure to herbicides. Mortality update, 1984. December 10. **USAF** School of Aerospace Medicine (AFSC), **Brooks** Air Force Base, TX.

Wolfe, W.H., G.D. Lathrop, R.A. Albanese and P.M. Moynahan. 1985. An **epidemiologic** Investigation of health effects **in** Air Force personnel following exposure to herbicides and associated **dioxins**. *Chemosphere*. 14(6/7): 707-716.

Woods, J.S. 1973. Studies of the effects **of 2,3,7,8-tetrachlorodibenzo-p-dioxin** on mammalian hepatic  **$\delta$ -aminolevulinic** acid **synthetase**. *Environ. Health Perspect.* 5: 221.

Woolson, E.A., R.F. Thomas and P.D.J. Ensor. 1972. Survey of polychloro-**dibenzo-p-dioxin** content in selected pesticides. 20(2): 350-354.

**Yamagishi**, T., T. Mlyazaki, **K. Akiyama**, et al. 1981. Polychlorinated dibenzo-p-dioxins and dibenzofurans in commercial **diphenyl** ether herbicides, and in freshwater **fish** collected from the application area. *Chemosphere*. 10(10): 1137-1144.

**Yamamoto, H., H. Yoshimura, M. Fujita and T. Yamamoto.** 1976. Metabolic and **toxicologic** evaluation of **2,3,4,4',4'-pentachlorobiphenyl** in rats and mice. **Chem. Pharm. Bull.** 24: 2168-2174.

Yang, **K.H.** and R.E. Peterson. 1977. Differential effects of halogenated aromatic hydrocarbons on pancreatic excretory function in rats. **Fed. Proc. Fed. Am. Soc. Exp. Biol.** 36(3): 356.

Yang, **K.H., W.A. Croft** and R.E. Peterson. 1977. Effects of **2,3,7,8-tetra-chlorodibenzo-p-dioxins** on plasma disappearance and biliary excretion of foreign compounds in rats. **Toxicol. Appl. Pharmacol.** 40: 485-496.

Yang, **K.H., E.J. Choi** and S.Y. Choe. 1983. **Cytotoxicity** of **2,3,7,8-tetra-chlorodibenzo-p-dioxin** on primary cultures of adult rat **hepatocytes**. **Arch. Environ. Contam. Toxicol.** 12: 183-188.

**Yockim, R.S., A.R. Isensee** and G.E. Jones. 1978. Distribution and **toxicity** of TCDD and **2,4,5-T** in an aquatic model ecosystem. **Chemosphere.** 7(3): 215-220.

**Yoshihara, S., K. Nagata, H. Yoshimura, H. Kuroki** and Y. **Masuda.** 1981. Inductive effect on hepatic enzymes and acute toxicity of individual polychlorinated **dibenzofuran** congeners in rats. **Toxicol. Appl. Pharmacol.** 59: 580-588.

**Young, A.L.** 1983. Long-term studies on the persistence and movement of TCDD in a natural ecosystem. **In:** Human and Environmental Risks of Chlorinated **Dioxins** and Related Compounds, R.E. Tucker et **al.**, Ed. Plenum Publishing Corp., NY. p. **173-190**.

**Young, A.L.**, C.E. Thalken and **W.E. Ward.** 1975. Studies of the ecological impact of repetitive aerial applications of herbicides on the ecosystem of test area C-52A, **Eglin** AFB, Florida. **Air** Force Armament Laboratory, **Eglin** Air Force Base, Florida. Air Force Report No. **AFATL-TR-75-142**. 142 p. **NTIS** AD-A032773.

Young, **A.L.**, C.E. **Thalken**, E.L. Arnold, **J.M. Cupello** and L.G. **Cockerham.** 1976. Fate of **2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)** in the environment: Summary and decontamination **recommendations**. Air Force Tech. Report No. **USAFA-TR-76-18**, U.S. **Air** Force Academy, CO. p. 41.

Young, **A.L.**, **H.K. Kang** and **B.M. Shepard.** 1983. Chlorinated **dioxins** as herbicide contaminants. Environ. **Sci. Technol.** **17:** 530A-540A.

Zack, **J.A.** and R.R. **Suskind.** 1980. The mortality experience of workers exposed to **tetrachlorodibenzodioxin** in a **trichlorophenol** process accident. **J. Occup. Med.** **22(1):** 11-14.

**Zimmering, S.**, J.M. Mason, R. Valencia and R.C. Woodruff. 1985. Chemical **mutagenesis** testing in **Drosophila**. II. Results of 20 coded compounds tested for the National Toxicology Program. Environ. Mutagen. **7:** 87-100.

**Zimmermann, E.F. and D. Bowen.** 1972. Distribution and metabolism of **triamcinolone acetonide** in Inbred mice with different **cleft** palate sensitivities. Teratology. 5: 335-344.

**Zinkl, J.G., J.G. Vos, J.A. Moore and B.N. Gupta.** 1973. **Hematologic** and clinical chemistry effects of **2,3,7,8-tetrachlorodibenzo-p-dioxin** in laboratory animals. Environ. Health Perspect. 5: 111-118.

**Zullei, N. and G. Benecke.** 1978. Application of a new **bioassay** to screen the **toxicity** of **polychlorinated biphenyls** on blue-green **algae**. 20(6): 786-792.

APPENDIX A

TABLE A-1  
Cumulative Mortality of Hare Rats<sup>a</sup>

| Time<br>(end of 30-day period)<br>N= | Controls<br>(86) | <u>µg/kg/day 2,3,7,8-TCDO</u> |                         |                         |
|--------------------------------------|------------------|-------------------------------|-------------------------|-------------------------|
|                                      |                  | 0.1<br>(50)                   | 0.01<br>(50)            | 0.001<br>(50)           |
| 1-7                                  | 0.0              | 0.0                           | 0.0                     | 2.0                     |
| 8                                    | 0.0              | 2.0                           | 0.0                     | 2.0                     |
| 9                                    | 0.0              | 4.0                           | 0.0                     | 2.0                     |
| 10                                   | 0.0              | 4.0                           | 0.0                     | 2.0                     |
| 11                                   | 2.3              | 4.0                           | 0.0                     | 2.0                     |
| 12                                   | 5.8              | 8.0                           | 0.0                     | 2.0                     |
| 13                                   | 7.0              | <b>12.0</b>                   | 0.0                     | 2.0                     |
| 14                                   | 10.5             | 18.0                          | 4.0                     | 4.0                     |
| 15                                   | 12.8             | 18.0                          | 14.0                    | 14.0                    |
| 16                                   | 16.3             | 20.0                          | 22.0                    | 14.0                    |
| 17                                   | 18.6             | 28.0                          | 28.0                    | 24.0                    |
| 18                                   | 24.4             | 34.0                          | 34.0                    | <b>44.0<sup>b</sup></b> |
| <b>19</b>                            | 31.4             | 44.0                          | 46.0                    | 50.0                    |
| 20                                   | 41.9             | 46.0                          | 54.0                    | 56.0                    |
| <b>21</b>                            | 48.8             | 62.0                          | 68.0                    | 60.0                    |
| 22                                   | 58.1             | <b>74.0<sup>b</sup></b>       | <b>76.0<sup>b</sup></b> | 68.0                    |
| 23                                   | 69.8             | 78.0                          | 84.0                    | 74.0                    |
| 24                                   | 77.9             | 84.0                          | 88.0                    | 76.0                    |
| 25                                   | 82.6             | 90.0                          | 92.0                    | 78.0                    |

<sup>a</sup>Source: Kociba et al., 1977

<sup>b</sup>Interval of greatest difference, D, in cumulative mortality curves of controls and treatment group. None of the differences were statistically significant (Kolmogorov-Smirnov test,  $p > 0.05$ ).

TABLE A-2  
 Cumulative Mortality of Female Rats<sup>a</sup>

| Time<br>(end of 30-day period)<br>N= | Controls<br>(86) | <u>µg/kg/day 2,3,7,8-TCOO</u> |                         |                         |
|--------------------------------------|------------------|-------------------------------|-------------------------|-------------------------|
|                                      |                  | 0.1<br>(50)                   | 0.01<br>(50)            | 0.001<br>(50)           |
| 0-5                                  | 0.0              | 0.0                           | 0.0                     | 0.0                     |
| 6-8                                  | 1.2              | 0.0                           | 0.0                     | 0.0                     |
| 9                                    | 1.2              | 2.0                           | 0.0                     | 0.0                     |
| 10                                   | 1.2              | 4.0                           | 2.0                     | 0.0                     |
| 11                                   | 1.2              | 8.0                           | 2.0                     | 0.0                     |
| 12                                   | 1.2              | 16.0                          | 4.0                     | 4.0                     |
| 13                                   | 3.5              | 20.0                          | 4.0                     | 4.0                     |
| 14                                   | 3.5              | 26.0                          | 8.0                     | 6.0                     |
| 15                                   | 7.0              | 28.0                          | <b>12.0</b>             | 10.0                    |
| 16                                   | 12.8             | 32.0                          | 18.0                    | 12.0                    |
| 17                                   | 15.1             | 38.0                          | 18.0                    | 18.0                    |
| 18                                   | 18.6             | 44.0                          | 20.0                    | 22.0                    |
| <b>19</b>                            | 25.6             | <b>56.0<sup>b</sup></b>       | 30.0                    | <b>34.0<sup>b</sup></b> |
| 20                                   | 34.9             | 60.0                          | 36.0                    | 36.0                    |
| 21                                   | 40.7             | 66.0                          | <b>46.0<sup>b</sup></b> | 44.0                    |
| 22                                   | 58.1             | 82.0                          | 60.0                    | 52.0                    |
| 23                                   | 64.0             | 86.0                          | 66.0                    | 58.0                    |
| 24                                   | 70.9             | 88.0                          | 72.0                    | 66.0                    |
| 25                                   | 70.9             | 92.0                          | 72.0                    | 68.0                    |

<sup>a</sup>Source: Kociba et al., 1977

<sup>b</sup>Interval of greatest difference, D, in cumulative mortality curves of controls and treatment group. The mortality curve for the rats fed 0.1 µg/kg/day differed significantly from that for controls (D = 30.4, **p<0.01**, Kolmogorov-Smirnov test). The other two groups **did** not differ significantly from controls (**p>0.05**).

TABLE A-8

## Males: Interval Mortality Rates

| Days    | Control |       | 0.1 $\mu\text{g}/\text{kg}/\text{day}$ |       | 0.01 $\mu\text{g}/\text{kg}/\text{day}$ |       | 0.001 $\mu\text{g}/\text{kg}/\text{day}$ |       |
|---------|---------|-------|--|-------|---|-------|--|-------|
|         | d/1     | Rate  | d/1                                    | Rate  | d/1                                     | Rate  | d/1                                      | Rate  |
| 40-30   | 0/86    | 0.000 | 0/50                                   | 0.000 | 0/50                                    | 0.000 | 1/50                                     | 0.020 |
| 31-210  | 0/86    | 0.000 | 0/50                                   | 0.000 | 0/50                                    | 0.000 | 0/49                                     | 0.000 |
| 211-240 | 0/86    | 0.000 | 1/50                                   | 0.020 | 0/50                                    | 0.000 | 0/49                                     | 0.000 |
| 241-270 | 0/86    | 0.000 | 1/49                                   | 0.020 | 0/50                                    | 0.000 | 0/49                                     | 0.000 |
| 271-300 | 0/86    | 0.000 | 0/48                                   | 0.000 | 0/50                                    | 0.000 | 0/49                                     | 0.000 |
| 301-330 | 2/86    | 0.023 | 0/48                                   | 0.000 | 0/50                                    | 0.000 | 0/49                                     | 0.000 |
| 331-360 | 3/84    | 0.036 | 2/48                                   | 0.042 | 0/50                                    | 0.000 | 0/49                                     | 0.000 |
| 391-420 | 3/80    | 0.038 | 3/44                                   | 0.068 | 2/50                                    | 0.040 | 1/49                                     | 0.020 |
| 421-450 | 2/77    | 0.026 | 0/41                                   | 0.000 | 5/48                                    | 0.104 | 5/48                                     | 0.104 |
| 451-480 | 3/75    | 0.040 | 1/41                                   | 0.024 | 4/43                                    | 0.093 | 0/43                                     | 0.000 |
| 481-510 | 2/72    | 0.028 | 4/40                                   | 0.100 | 3/39                                    | 0.077 | 5/43                                     | 0.116 |
| 511-540 | 5/70    | 0.071 | 3/36                                   | 0.083 | 3/36                                    | 0.083 | 10/38                                    | 0.263 |
| 541-570 | 6/65    | 0.092 | 5/33                                   | 0.152 | 6/33                                    | 0.182 | 3/28                                     | 0.107 |
| 571-600 | 9/59    | 0.158 | 1/28                                   | 0.036 | 4/27                                    | 0.148 | 3/25                                     | 0.120 |
| 601-630 | 6/50    | 0.120 | 8/27                                   | 0.296 | 7/23                                    | 0.304 | 2/22                                     | 0.091 |
| 631-660 | 8/44    | 0.182 | 6/19                                   | 0.316 | 4/16                                    | 0.250 | 4/20                                     | 0.200 |
| 661-690 | 10/36   | 0.278 | 2/13                                   | 0.154 | 4/12                                    | 0.333 | 3/16                                     | 0.188 |
| 691-720 | 7/26    | 0.269 | 3/11                                   | 0.273 | 2/8                                     | 0.250 | 1/13                                     | 0.077 |
| 721-726 | 4/19    | 0.211 | 3/8                                    | 0.375 | 2/6                                     | 0.333 | 1/12                                     | 0.083 |

Terminal  
K111

15

5

4

11

Corrected for continuity for combined intervals:

421-510

7/77 vs. 5/41 ( $X^2=0.04$ , n.s.) 12/48 ( $X^2=4.68$ ,  $p<0.05$ )  
10/48 ( $X^2=2.54$ , n.s.)

451-540

10/72 vs. 8/41 ( $X^2=0.87$ , n.s.) 10/48 ( $X^2=1.27$ , n.s.)  
15/48 ( $X^2=6.37$ ,  $p<0.025$ )

481-570

13/72 vs. 12/40 ( $X^2=1.48$ , n.s.) 12/89 ( $X^2=1.67$ , n.s.)  
18/48 ( $X^2=6.59$ ,  $p<0.025$ )

511-600

21/70 vs. 9/36 ( $X^2=0.03$ , n.s.) 13/86 ( $X^2=0.82$ , n.s.)  
10/80 ( $X^2=1/47$ , n.s.)



TABLE A-4

Females: **Interval** Mortality Rates

| Days           | <u>Control</u> |       | <u>0.1 ug/kg/day</u> |       | <u>0.01 ug/kg/day</u> |       | <u>0.001 ug/kg/day</u> |              |
|----------------|----------------|-------|----------------------|-------|-----------------------|-------|------------------------|--------------|
|                | d/1            | Rate  | d/1                  | Rate  | d/1                   | Rate  | d/1                    | Rate         |
| 0-150          | 0/86           | 0.000 | 0/50                 | 0.000 | 0/50                  | 0.000 | 0/50                   | 0.000        |
| 151-180        | 1/86           | 0.012 | 0/50                 | 0.000 | 0/50                  | 0.000 | 0/50                   | 0.000        |
| 181-240        | 0/85           | 0.000 | 0/50                 | 0.000 | 0/50                  | 0.000 | 0/50                   | 0.000        |
| <b>241-270</b> | 0/85           | 0.000 | 1/50                 | 0.020 | 0/50                  | 0.000 | 0/50                   | 0.000        |
| 271-300        | 0/85           | 0.000 | 1/49                 | 0.020 | 1/50                  | 0.020 | 0/50                   | 0.000        |
| 301-330        | 0/85           | 0.000 | 2/48                 | 0.042 | 0/49                  | 0.000 | 0/50                   | 0.000        |
| 331-360        | 0/85           | 0.000 | 4/46                 | 0.087 | 1/49                  | 0.020 | 2/50                   | 0.040        |
| <b>361-390</b> | 2/85           | 0.024 | 2/42                 | 0.048 | 0/48                  | 0.000 | 0/48                   | 0.000        |
| 391-420        | 0/83           | 0.000 | 3/40                 | 0.075 | 2/48                  | 0.042 | <b>1/48</b>            | 0.021        |
| 421-450        | 3/83           | 0.036 | 1/37                 | 0.027 | 2/46                  | 0.044 | 2/47                   | 0.043        |
| 451-480        | 5/80           | 0.063 | 2/36                 | 0.056 | 3/44                  | 0.068 | 1/45                   | 0.022        |
| 481-510        | 2/75           | 0.027 | 3/34                 | 0.088 | 0/41                  | 0.000 | 3/44                   | 0.068        |
| <b>511-540</b> | 3/73           | 0.041 | 3/31                 | 0.097 | 1/41                  | 0.024 | 2/41                   | 0.049        |
| 541-570        | 6/70           | 0.086 | 6/28                 | 0.214 | 5/40                  | 0.125 | 6/39                   | 0.154        |
| 571-600        | 8/64           | 0.125 | 2/22                 | 0.091 | 3/35                  | 0.086 | 1/33                   | 0.030        |
| 601-630        | 5/56           | 0.089 | 3/20                 | 0.150 | 5/32                  | 0.156 | 4/32                   | 0.125        |
| 631-660        | 15/51          | 0.294 | 8/17                 | 0.471 | 7/27                  | 0.259 | 4/28                   | 0.143        |
| 661-690        | 5/36           | 0.139 | 2/9                  | 0.222 | 3/20                  | 0.150 | 3/24                   | <b>0.125</b> |
| 691-720        | 6/31           | 0.194 | 1/7                  | 0.143 | 3/17                  | 0.177 | 4/21                   | 0.191        |
| 721-726        | 0/25           | 0.000 | 2/6                  | 0.333 | 0/14                  | 0.000 | 1/17                   | 0.059        |

Terminal

**Kill**

25

4

14

16

Corrected for continuity for combined **interval**:

421-510 10/83 vs. 6/37 ( $X^2=1.131$  n.s.) **5/46** ( $X^2=0.0$ , n.s.)  
6/47 ( $X^2=0.01$ , n.s.)

451-540 10/80 vs. 8/36 ( $X^2=1.13$ , n.s.) **4/44** ( $X^2=0.8$ , n.s.)  
6/45 ( $X^2=0.01$ , n.s.)

481-570 **11/75** vs. **12/34** ( $X^2=4.80$ ,  $p<0.05$ ) 6/41 ( $X^2=0.0$ , n.s.)  
**11/44** ( $X^2=1.34$ , n.s.)

510-600 17/73 vs. 11/31 ( $X^2=1.08$ , n.s.) **9/41** ( $X^2=0.0$ , n.s.)  
9/41 ( $X^2=0.0$ , n.s.)

APPENDIX B

Tables for **2,3,7,8-TCDD** Quantitative Incremental  
**Unit Cancer Risk** Estimates

Tables for **2,3,7,8-TCDD** Quantitative Incremental  
Unit Cancer Risk Estimates

Tables B-1 through B-5 are the 2,3,7,8-TCDD bioassay results Judged suitable for quantitative estimates of Incremental unit risk. Tables B-1 and B-2 show the results of the Dow rat feeding study for both males and females. The results include both the original (Kociba) analysis and the (Squire) review. Individual organ sites where significantly increased tumors occurred are tabulated separately, then the total number of animals with at least one of these tumors is compiled. Tables B-3, B-4 and B-5 compile similar data for the NCI bioassay. Table B-6 uses the data from Table B-1 to estimate the parameters of the linearized multistage model. The  $\chi^2$  test for goodness-of-fit of the model to the data determines whether or not the highest dose group is retained in the fit. The 95% upper-limit on the linear term  $q_1^*$  is then adjusted by the surface area constant  $(70/W_a)^{1/3}$  to derive the final extrapolated animal-to-human 95% upper-limit incremental unit cancer risk estimate. Tables B-7 through B-12 present the extrapolation procedure for the remaining data sets, with Tables B-8A and B-9A adjusting for high early mortality in the female rat high-dose group. Table B-13 summarizes the estimates derived in Tables B-6 through B-12. The  $q_1^*$  estimates from the female rat data of the Dow feeding study using both the Kociba and Squire readings are averaged to derive the final estimate  $q_1^* = 1.56 \times 10^5 \text{ (mg/kg/day)}^5$ .

Description of the Animal-to-Human Extrapolation Procedure Using the Linearized Multistage Model

Let  $P(d)$  represent the lifetime risk (probability) of cancer at dose  $d$ . The multistage model has the form

$$P(d) = 1 - \exp [-(q_0 + q_1 d + q_2 d^2 + \dots + q_k d^k)]$$

where

$$q_1 > 0, \quad 1 = 0, 1, 2, \dots, k$$

Equivalently,

$$P_t(d) = 1 - \exp [-(q_1 d + q_2 d^2 + \dots + q_k d^k)]$$

where

$$P_t(d) = \frac{P(d) - P(0)}{1 - P(0)}$$

is the extra **risk** over background rate at dose d.

The point estimate of the coefficients  $q_1, 1 = 0, 1, 2, \dots, k$ , and **consequently**, the extra **risk** function,  $P_t(d)$ , at any given dose d, is calculated by maximizing the likelihood function of the data.

The point estimate and the 95% upper confidence limit of the extra **risk**,  $P_t(d)$ , are calculated by using the computer program GLOBAL 79 developed by Crump and Watson (1979). At low doses, upper 95% confidence limits on the extra **risk** and **lower** 95% confidence **limits** on the dose producing a given **risk** are determined from a 95% upper confidence limit,  $q_1^*$  on parameter  $q_1$ . Whenever  $q_1 > 0$ , at low doses the extra **risk**  $P_t(d)$  has approximately the form  $P_t(d) = q_1 x d$ . Therefore,  $q_1^* x d$  is a 95% upper confidence limit on the extra **risk** and  $P_t/q_1^*$  is a 95% lower confidence limit on the dose producing an extra **risk** of  $P_t$ . Let  $L_0$  be the maximum value of the **log-likelihood** function. The upper limit,  $q_1^*$  is calculated by increasing  $q_1$  to a value  $q_1^*$  such that when the **log-likelihood** is **remaximized** subject to **this** fixed value  $q_1^*$  for the linear coefficient, the resulting maximum value of the **log-likelihood**  $L_1$  satisfies the equation

$$2 (L_0 - L_1) = 2.70554$$

where 2.70554 is the **cumulative 90%** point of the **chi-square** distribution **with** one degree of freedom, which corresponds to a **95%** upper limit (one-sided). **This** approach of computing the upper confidence **limit** for the extra **risk**,  $P_t(d)$ , **is** an Improvement on the Crump et al. (1977) model. The upper confidence limit for the extra **risk** calculated at low doses is always linear. **This** is conceptually consistent **with** the linear nonthreshold. The **slope**,  $q_1^*$ , is taken as a plausible upper bound of the potency of the chemical in inducing cancer at low doses. (In the section calculating the **risk** estimates,  $P_t(d)$  is abbreviated as P.)

In fitting the dose-response model, the number of terms in the polynomial is chosen equal to **(h-1)**, where **h** is the number of dose groups in the experiment, including the control group.

Whenever the multistage model does not **fit** the data sufficiently well, data at the highest dose are deleted and the model is refit to the rest of the data. **This** is continued until an acceptable **fit** to the data is obtained. To determine whether or not a **fit** is acceptable, the chi-square

$$X^2 = \sum_{l=1}^h \frac{(R_l - N_l P_l)^2}{N_l P_l (1 - P_l)}$$

statistic is calculated where  $N_l$  is the number of animals in the  $l^{th}$  dose group,  $R_l$  is the number of animals in the  $l^{th}$  dose group with a tumor response,  $P_l$  is the probability of a response in the  $l^{th}$  dose group estimated by fitting the multistage model to the data, and  $h$  is the number of remaining groups. The **fit** is determined to be unacceptable whenever  $X^2$  is larger than the cumulative 9954 point of the **chi-square** distribution **with**  $f$  degrees of freedom, where  $f$  equals the number of dose groups minus the number of nonzero multistage coefficients.

TABLE B-1

DOW (Dr. Kociba) 2,3,7,8-TCDD Oral Rat Study (1978) with Dr. R. Squire's Review  
Hale Sprague-Dawley Rats - Spartan Substrain (2 yrs)\*

| Tissue and Diagnosis  | Dose Levels ( $\mu\text{g}/\text{kg}/\text{day}$ ) |           |           |   |
|---|--|-----------|-----------|---|
|   | 0<br>(control)                                     | 0.001     | 0.01      | 0.1                                       |
| Dow (Kociba) Analysis   |  |           |           |   |
| 1. Tongue   |  |           |           |   |
| Stratified squamous cell carcinoma                              | 0/76 (0%)  | 1/49 (2X) | 1/49 (2X) | 3/42 (7%)<br>( $p=0.043$ )                |
| 2. Nasal turbinates/hard palate                                 |  |           |           |   |
| Squamous cell carcinoma   | 0/51 (0%)  | 1/34 (3X) | 0/27 (0X) | 4/30 (13X)<br>( $p=0.016$ )               |
| Total   | 0/76 (0X)  | 2/49 (4X) | 1/49 (4X) | 7/42 (17X)<br>( $p=5.12 \times 10^{-4}$ ) |
| R. Squire's Review  |  |           |           |   |
| 1. Tongue   |  |           |           |   |
| Squamous cell carcinoma   | 0/77 (0X)  | 1/44 (2X) | 1/49 (2X) | 3/44 (7X)<br>( $p=4.60 \times 10^{-2}$ )  |
| 2. Nasal turbinates/hard palate                                 |  |           |           |   |
| Squamous cell carcinoma   | 0/55 (0X)  | 1/34 (3X) | 0/26 (0X) | 6/30 (20X)<br>( $p=1.36 \times 10^{-3}$ ) |
| Total (1 or 2 above)<br>(each rat had at least one tumor above) | 0/77 (0X)  | 2/44 (5X) | 1/49 (2X) | 9/44 (20X)<br>( $p=6.28 \times 10^{-5}$ ) |

\*Average body weight of male rat = 600 g

TABLE B-2

DOW (Dr. **Kociba**) **2,3,7,8-TCDD** Oral Rat Study (1978) with Dr. R. **Squire's** Review  
 Female Sprague-Dawley Rats - Spartan **Substrain** (2 yrs)\*

| Tissue and Diagnosis   | Dose Levels (yg/kg/day) |                    |   |  |
|--|-------------------------|--------------------|---|--|
|  | 0<br>(control)          | 0.001              | 0.01  | 0.1  |
| Dow (Kociba) Analysis  |                         |                    |   |  |
| 1. Lung<br><b>Keratinizing squamous</b><br>cell carcinoma  | 0/86 (0%)               | 0/50 ( <b>0%</b> ) | 0/49 (0X)   | <b>7/49 (14%)</b><br>( $p=6.21 \times 10^{-4}$ )   |
| CD<br>2. Nasal <b>turbinates/hard</b> palate<br>Stratified squamous cell<br>carcinoma (revised diagnoses<br><b>2/19/79</b> ) | <b>1/54 (2X)</b>        | 0/30 (0%)          | 1/27 (4X)   | <b>5/24 (21%)</b><br>( $p=9.46 \times 10^{-3}$ )   |
| 3. Liver<br>Hepatocellular <b>hyperplastic</b><br><b>nodules/hepatocellular</b><br>carcinoma                                 | 9/86 ( <b>10%</b> )     | 3/50 ( <b>6%</b> ) | <b>18/50 (36%)</b><br>(2 had both)<br>( $p=4.37 \times 10^{-4}$ ) | <b>34/48 (71%)</b><br>( $p=9.53 \times 10^{-13}$ ) |
| Total ( <b>1, 2, or 3</b> above)<br>(each rat had at least one<br>tumor above)   | 9/86 (10%)              | 3/50 ( <b>6%</b> ) | <b>18/50 (36X)</b><br>( $p=4.37 \times 10^{-4}$ )                 | <b>34/49 (69X)</b><br>( $p=2.13 \times 10^{-12}$ ) |

TABLE B-2 (cont.)

| Tissue and Diagnosis   | Dose Levels ( $\mu\text{g}/\text{kg}/\text{day}$ ) |            |  |  |
|--|--|------------|--|--|
|  | 0<br>(control)                                     | 0.001      | 0.01                                       | 0.1  |
| <b>R. Squire's Review</b>  |  |            |  |  |
| 1. Lung<br>Squamous cell carcinoma   | 0/86 (0%)  | 0/50 (0%)  | 0/49 (0X)                                  | 8/47 (17X)<br>( $p=1.61 \times 10^{-4}$ )  |
| 2. Nasal turbinate/hard palate<br>Squamous cell carcinoma                      | 0/54 (0%)  | 0/30 (0%)  | 1/27 (4X)                                  | 5/22 (23X)<br>( $p=1.43 \times 10^{-9}$ )  |
| 3. Liver<br>Neoplastic nodules/hepatocellular carcinoma                        | 16/86 (OX)   | 8/50 (16%) | 27/50 (54X)<br>( $p=2.42 \times 10^{-5}$ ) | 33/47 (70X)<br>( $p=4.92 \times 10^{-9}$ ) |
| Total combined (1, 2 or 3 above)<br>(each animal had at least one tumor above) | 16/86 (19X)  | 8/50 (16X) | 27/50 (54%)<br>( $p=2.42 \times 10^{-5}$ ) | 34/47 (72X)<br>( $p=1.20 \times 10^{-9}$ ) |

\*Average body weight of female rat = 450 g



TABLE B-3

NCI **2,3,7,8-TCDD** (Gavage) **Bioassay** (No. 80-1765)  
Osborne-Mendel Female Rats (2 years; weight = **450** g)

| Tissue and Diagnosis  | Dose Levels ( $\mu\text{g}/\text{kg}/\text{week}$ ) |                   |                   |  |
|---|---|-------------------|-------------------|--|
|   | Vehicle Control<br>0                                | Low<br>0.01       | Medium<br>0.05    | High<br>0.5                            |
| 1. Liver<br><b>Neoplastic</b> nodule or<br>hepatocellular carcinoma | 5/75 (7%)   | 1/49 (2X)         | 3/50 (6X)         | <b>14/49 (28%)</b><br><b>(p=0.001)</b> |
| 2. Adrenal*<br>Cortical adenoma, or<br>carcinoma                    | 11/73 <b>(15%)</b>                                  | 9/49 <b>(18%)</b> | 5/49 <b>(10%)</b> | 14/46 <b>(30%)</b><br><b>(p=0.038)</b> |

\*The biological significance of **this** tumor in old rats **is questionable**, since it **is** commonly observed in control rats and associated **with** the aging process.

TABLE B-4

NCI **2,3,7,8-TCDD** (Gavage) **Bioassay** (No. 80-1765)  
 B6C3F1 Male **Mice** (2 years; weight -- 48 g)

| Tissue and Diagnosis                        | Dose Levels ( $\mu\text{g}/\text{kg}/\text{week}$ )   |                    |                    |  |
|---|---|--------------------|--------------------|--|
|   | Vehicle Control<br>0                                  | Low<br>0.01        | Medium<br>0.05     | High<br>0.5                                    |
| <b>Liver</b>                                |   |                    |                    |  |
| Hepatocellular adenoma<br>or carcinoma      | <b>15/73 (21%)</b><br><b>(p&lt;0.001)<sup>a</sup></b> | <b>12/49 (24%)</b> | <b>13/49 (26%)</b> | 27/50 (54%)<br><b>(p=1.31x10<sup>-4</sup>)</b> |
| Hepatocellular <b>carcinoma<sup>b</sup></b> | 8/73 (11%)<br><b>(p&lt;0.001)<sup>a</sup></b>         | 9/49 (18%)         | 8/49 <b>(16%)</b>  | 17/50 (34%)<br><b>(p=0.002)</b>                |

<sup>a</sup>Cochran-Armitage test for linear trend

<sup>b</sup>Used for Unit Risk Estimate

TABLE B-5

NCI 2,3,7,8-TCDD (Gavage) Bioassay (No. 80-1765)  
B6C3F1 Female Mice (2 years)<sup>a</sup>

| Tissue and Diagnosis   | Dose Levels ( $\mu\text{g}/\text{kg}/\text{week}$ )                 |             |               |  |
|--|---|-------------|---------------|--|
|  | Vehicle Control<br>0  | Low<br>0.04 | Medium<br>0.2 | High<br>2.0                                |
| 1. Subcutaneous tissue<br>Fibrosarcoma                                     | 1/74 (1%)   | 1/50 (2X)   | 1/48 (2X)     | 5/47 (11%)<br>( $p=0.032$ )                |
| 2. Hematopoietic system<br>Lymphoma or leukemia                            | 18/74 (24X)   | 12/50 (24%) | 13/48 (27X)   | 20/47 (43X)<br>( $p=0.028$ )               |
| 3. Liver<br>Hepatocellular adenoma<br>or carcinoma                         | 3/73 (4X)<br>( $p=0.0050$ )   | 6/50 (12%)  | 6/48 (12X)    | 11/47 (23X)<br>( $p=1.84 \times 10^{-3}$ ) |
|  | Hepatocellular carcinoma<br>1/73 (1%)<br>( $p=0.008$ ) <sup>b</sup> | 2/50 (4X)   | 2/48 (4X)     | 6/47 (13X)<br>( $p=0.014$ )                |
| 4. Thyroid<br>Follicular cell adenoma                                      | 0/69  | 3/50 (6X)   | 1/47 (2X)     | 5/46 (11%)<br>( $p=8.93 \times 10^{-3}$ )  |
| Total (1, 2, 3 or 4 above)<br>(each mouse had at least<br>one tumor above) | 22/74 (30%)   | 20/50 (40X) | 19/48 (40X)   | 31/47 (66X)<br>( $p=8.94 \times 10^{-5}$ ) |

<sup>a</sup>Average body weight of female mouse = 40 g

<sup>b</sup>Cochran-Armitage test for trend

TABLE B-6

Curve **Fit** of the **Multistage Model** Parameters to Experimental Data by Study and Pathologist  
 Linear Parameter  $q_1$ , **Maximized** to Give Upper **95%** Limit  $q_1^*$

Compound ..... 2,3,7,8-TCDD  
 Study..... **Kociba** - Dow  
 Sex-species..... Male rat  
 Weight ( $w_a$ )..... 600 g  
 Tumor sites (one or **more**)——Tongue - squamous cell carcinomas  
                                   Nasal **turbinates/hard** palate - stratified squamous cell carcinoma  
                                   (ref. Table **B-1**)

Pathologist - **Kociba**

|                            |      |                    |                    |                    |
|----------------------------|------|--------------------|--------------------|--------------------|
| Exposure level (mg/kg/day) | 0    | $1 \times 10^{-6}$ | $1 \times 10^{-5}$ | $1 \times 10^{-4}$ |
| +r/n                       | 0/76 | 2/49               | 1/49               | 7/42               |

+r = number of animals **with** one or more of the tumors  
 n = total number of animals examined

| Estimated multistage parameters         | $q_0$                            | $q_1$              | $q_2$ | $q_3$                 | $aq_1^*$           | Goodness of fit $\chi^2$ |
|---|----------------------------------|--------------------|-------|-----------------------|--------------------|--------------------------|
| When all dose groups are used           | $1.40 \times 10^{-2}$            | $1.10 \times 10^3$ | 0     | $5.86 \times 10^{10}$ | $3.01 \times 10^3$ | 3.34 (d.f. = 2)          |
| When the highest dose group is not used | Above <b>fit is</b> satisfactory |                    |       |                       |                    |                          |

$aq_1^*$  = the maximum linear component from the model **with** adequate goodness of fit ( $p > 0.01$ ) =  $3.01 \times 10^3$  (mg/kg/day) $^{-1}$

$q_1^*$  =  $aq_1^* (70/w_a)^{1/3}$  =  $1.47 \times 10^3$  (mg/kg/day) $^{-1}$ , the upper **95%** limit slope factor associated with human dose response.



TABLE B-8

Curve Fit of the Multistage Model Parameters to Experimental Data by Study and Pathologist  
 Linear Parameter  $q_1$ , Maximized to Give Upper 95% Limit  $q_1^*$

Compound ..... 2,3,7,8-TCOD  
 Study..... Dow  
 Sex-species..... Female rat  
 Height ( $w_a$ )..... 450 g  
 Tumor sites (one or more)——Liver, lung, hard palate, or nasal turbinates (ref. Table B-2)  
 Pathologist - **Kociba**

|                            |      |                 |                    |                    |
|----------------------------|------|-----------------|--------------------|--------------------|
| Exposure level (mg/kg/day) | 0    | $1 \times 10^*$ | $1 \times 10^{-5}$ | $1 \times 10^{-4}$ |
| +r/n                       | 9/86 | 3/50            | 18/50              | 34/49              |

+r = number of animals **with** one or more of the tumors  
 n = total number of **animals** examined

8-13

| Estimated multistage parameters                | $q_0$                            | $q_1$              | $q_2$   | $q_3$ | $aq_1^*$           | Goodness of fit $\chi^2$                          |
|--|----------------------------------|--------------------|---|-------|--------------------|---|
| When all dose groups are used                  | 0.12                             | $1.23 \times 10^*$ | 0   | 0     | $1.67 \times 10^*$ | 6.67 (d.f. = 2)<br>0.025 < p < 0.05               |
| When the highest dose group <b>is</b> not used | 0.09                             | 0                  | Above <b>fit is</b> satisfactory<br>$3.5 \times 10^*$ |       | 0                  | $4.69 \times 10^*$<br>0.92 (d.f. = 1)<br>p > 0.25 |
| When the two highest dose groups are not used  | Above <b>fit is</b> satisfactory |                    |   |       |                    |   |

$aq_1^* =$  the maximum linear component from the model **with** adequate goodness of fit ( $p > 0.01$ ) =  $1.67 \times 10^*$  -  $4.69 \times 10^*$  (mg/kg/day) $^{-1}$

$q_1^* = aq_1^* (70/w_a)^{1/3} = 8.98 \times 10^*$  -  $2.52 \times 10^5$  (mg/kg/day) $^{-1}$ , the upper 95% limit slope factor associated **with** human dose response depending on Inclusion or exclusion of the highest dose data.

TABLE B-8A

Curve **fit** of the **Multistage** Model Parameters to Experimental Data  
 by Study and **Pathologist**  
 Linear Parameter **q<sub>1</sub>**, Maximized to **Give** Upper 95% Limit **q<sub>1</sub><sup>\*</sup>**

Compound ..... **2,3,7,8-TCDD**  
 Study ..... Dow  
 Sex-species ..... Female rat  
 Weight (**w<sub>a</sub>**) ..... 450 g  
 Tumor sites (one or **more**)—Liver, **lung**, hard palate, or nasal **turbinates**  
 (ref. Table B-2)

Pathologist - **Kociba** (Eliminating first **year's** data to adjust for **high** early  
**mortality in** the high-dose group.)

| Exposure level (mg/kg/day) | 0    | 1 x 10 <sup>-6</sup> | 1 x 10 <sup>-5</sup> | 1 x 10 <sup>-4</sup> |
|----------------------------|------|----------------------|----------------------|----------------------|
| +r/n                       | 9/85 | 3/48                 | <b>18/48</b>         | 34/40                |

+r = number of animals **with** one or more of the tumors  
 n = total number of **animals** examined

| Estimated multistage parameters         | q <sub>0</sub> | q <sub>1</sub>         | q <sub>2</sub> | q <sub>3</sub> | aq <sub>1</sub> <sup>*</sup> | Goodness of fit X <sup>2</sup>     |
|---|----------------|------------------------|----------------|----------------|------------------------------|------------------------------------|
| When all dose groups are used           | 0.11           | 2.08 x 10 <sup>4</sup> | 0              | 0              | 2.82 x 10 <sup>4</sup>       | 3.38 (d.f. = 2)<br>0.25 < p < 0.10 |
| When the highest dose group is not used |                |                        |                |                | Above fit is satisfactory    | p > 0.25                           |

**aq<sub>1</sub><sup>\*</sup>** = the maximum linear component from the model **with** adequate goodness of **fit** (p>0.01) = 2.82x10<sup>4</sup> (mg/kg/day)<sup>-1</sup>  
**q<sub>1</sub><sup>\*</sup>** = **aq<sub>1</sub><sup>\*</sup>** (70/w<sub>a</sub>)<sup>1/3</sup> = 1.51x10<sup>5</sup> (mg/kg/day)<sup>-1</sup>, the upper 95% limit slope factor associated **with** human dose response.

TABLE B-9

Curve Fit of the Multistage Model Parameters to Experimental Data by Study and Pathologist  
Linear Parameter  $q_1$ , Maximized to Give Upper 95% Limit  $q_1^*$

Compound ..... 2,3,7,8-TCDD  
Study..... Kociba - Dow  
Sex-species..... Female rat  
Weight ( $w_a$ )..... 450 g  
Tumor sites (one or more)——Liver, lung, hard palate, or nasal turbinates (ref. Table B-2)  
Pathologist - Squire

| Exposure level (mg/kg/day) | 0     | $1 \times 10^{-6}$ | $1 \times 10^{-5}$ | $1 \times 10^{-4}$ |
|----------------------------|-------|--------------------|--------------------|--------------------|
| +r/n                       | 16/86 | 8/50               | 27/50              | 34/47              |

+r = number of animals with one or more of the tumors  
n = total number of animals examined

| Estimated multistage parameters               | $q_0$ | $q_1$              | $q_2$              | $q_3$ | $aq_1^*$           | Goodness of fit $\chi^2$     |
|---|-------|--------------------|--------------------|-------|--------------------|------------------------------|
| When all dose groups are used                 | 0.26  | $1.25 \times 10^4$ | 0                  | 0     |                    | 9.8 (d.f. = 2)<br>$p < 0.01$ |
| When the highest dose group is not used       | 0.19  | 0                  | $5.83 \times 10^9$ |       | $7.90 \times 10^*$ | 0.209 (d.f. = 1)             |
| When the two highest dose groups are not used |       |                    |                    |       |                    | Above fit is satisfactory    |

$aq_1^*$  = the maximum linear component from the model with adequate goodness of fit ( $p > 0.01$ ) =  $7.90 \times 10^*$  (mg/kg/day) $^{-1}$

$q_1^*$  =  $aq_1^* (70/w_a)^{1/3} = 4.25 \times 10^5$  (mg/kg/day) $^{-1}$ , the upper 95% limit slope factor associated with human dose response.



TABLE B-9A

Curve **Fit** of the Multistage Model Parameters to Experimental **Data**  
 by Study and Pathologist  
 Linear Parameter **q<sub>1</sub>**. Maximized to **Give** Upper 95% **Limit q<sub>1</sub><sup>\*</sup>**

Compound ..... **2,3,7,8-TCDD**  
 Study..... **Kociba** - Dow  
 Sex-species..... Female rat  
 Height (**w<sub>a</sub>**)..... 450 g  
 Tumor sites (one or **more**)—**Liver, lung, hard palate, or nasal turbinates**  
 (ref. Table B-2)

Pathologist - Squire (Eliminating first **year's** data to adjust for **high** early mortality **in** the high-dose group.)

|                            |       |                      |                      |                      |
|----------------------------|-------|----------------------|----------------------|----------------------|
| Exposure level (mg/kg/day) | 0     | 1 x 10 <sup>-6</sup> | 1 x 10 <sup>-5</sup> | 1 x 10 <sup>-4</sup> |
| <b>+r/n</b>                | 16/85 | 8/48                 | 27/48                | 34/40                |

+r = **number** of animals **with** one or more of the tumors  
 n = total number of animals examined

| Estimated multistage parameters | <b>q<sub>0</sub></b> | <b>q<sub>1</sub></b>   | <b>q<sub>2</sub></b> | <b>q<sub>3</sub></b> | <b>aq<sub>1</sub><sup>*</sup></b> | Goodness of <b>fit</b><br><b>X<sup>2</sup></b> |
|---------------------------------|----------------------|------------------------|----------------------|----------------------|-----------------------------------|--|
| When all dose groups are used   | 0.24                 | 2.12 x 10 <sup>4</sup> | 0                    | 0                    | 3.00 x 10 <sup>4</sup>            | 6.41 (d.f. = 2)<br>0.025 < p < 0.05            |

**When** the highest dose group **is** not used  
 Above **fit** is satisfactory

**aq<sub>1</sub><sup>\*</sup>** = the maximum linear component from the model **with** adequate goodness of **fit** (**p**>0.01) = 3.00x10<sup>4</sup> (mg/kg/day)<sup>-1</sup>

**q<sub>1</sub><sup>\*</sup>** = **aq<sub>1</sub><sup>\*</sup>** (70/**w<sub>a</sub>**)<sup>1/3</sup> = 1.61x10<sup>5</sup> (mg/kg/day)<sup>-1</sup>, the upper 95% limit slope factor associated **with** human dose response.

TABLE B-10

Curve **fit** of the Multistage **Model** Parameters to Experimental **Data** by Study and Pathologist  
 Linear Parameter  $q_1$ , Maximized to **Give** Upper **95%** Limit  $q_1^*$

Compound ..... **2,3,7,8-TCDD**  
 Study..... NCI  
 Sex-species..... Female rat  
 Weight ( $w_a$ )..... 450 g  
 Tumor sites (one or **more**)——Liver **neoplastic** nodules or **hepatocellular** carcinoma (ref. Table B-3)  
 Pathologist - NCI Reviewed

|                            |      |                       |                       |                       |
|----------------------------|------|-----------------------|-----------------------|-----------------------|
| Exposure level (mg/kg/day) | 0    | $1.43 \times 10^{-6}$ | $7.14 \times 10^{-6}$ | $7.14 \times 10^{-5}$ |
| <b>+r/n</b>                | 5/75 | 1/49                  | 3/50                  | 14/49                 |

B-17

**+r** = number of animals **with** one or more of the tumors  
**n** = total number of animals examined

| Estimated multistage parameters      | $q_0$ | $q_1$ | $q_2$              | $q_3$ | $aq_1^*$           | Goodness of fit $\chi^2$ |
|--------------------------------------|-------|-------|--------------------|-------|--------------------|--------------------------|
| <b>When</b> all dose groups are used | 0.05  | 0     | $5.65 \times 10^7$ | 0     | $6.09 \times 10^8$ | 1.44 (d.f. = 2)          |

**When** the highest dose group is not used Above **fit** is satisfactory

$aq_1^*$  = the maximum linear component from the model **with** adequate goodness of fit ( $p > 0.01$ ) =  $6.09 \times 10^8$  (mg/kg/day)<sup>-1</sup>

$q_1^*$  =  $aq_1^* (70/w_a)^{1/3} = 3.28 \times 10^8$  (mg/kg/day)<sup>-1</sup>, the upper 95% limit slope factor associated with human dose response.

TABLE B-11

Curve fit of the **Multistage** Model Parameters to Experimental Data by Study and Pathologist  
 Linear Parameter  $q_1$ , **Maximized to Give Upper 95% Limit  $q_1^*$**

Compound ..... **2,3,7,8-TCDD**  
 Study..... NCI  
 Sex-species..... Male mice  
 Height ( $w_a$ )..... 48 g  
 Tumor sites (one or more) \_\_\_ Hepatocellular carcinomas (ref. Table B-4)  
 Pathologist - NCI Review

|                            |      |                       |                       |                       |
|----------------------------|------|-----------------------|-----------------------|-----------------------|
| Exposure level (mg/kg/day) | 0    | $1.43 \times 10^{-6}$ | $7.14 \times 10^{-6}$ | $7.14 \times 10^{-5}$ |
| +r/n                       | 8/73 | 9/49                  | 8/49                  | 17/50                 |

+r = number of animals **with** one or more of the tumors  
 n = total number of animals examined

| Estimated multistage parameters      | $q_0$ | $q_1$              | $q_2$ | $q_3$ | $aq_1^*$           | Goodness of fit $\chi^2$ |
|--------------------------------------|-------|--------------------|-------|-------|--------------------|--------------------------|
| When <b>all</b> dose groups are used | 0.15  | $3.80 \times 10^3$ | 0     | 0     | $6.63 \times 10^3$ | 2.43 (d.f. = 2)          |

When the highest dose group **is** not used Above **fit is** satisfactory

$aq_1^*$  = the maximum linear component from the model **with** adequate goodness of fit ( $p > 0.01$ ) =  $6.63 \times 10^3$  (mg/kg/day) $^{-1}$

$fl_1^*$  =  $aq_1^* (70/w_a)^{1/3} = 7.52 \times 10^4$  (mg/kg/day) $^{-1}$ , the upper **95% limit slope** factor associated with human dose response.



TABLE B-13

## Summary of Human Slope Estimates for 2,3,7,8-TCDD

| Species     | Study | Sex         | Pathologist                           | Human Slope Estimate<br>in (mg/kg/day) <sup>-1</sup> q1* | Ref. Table<br>No. |
|-------------|-------|-------------|---------------------------------------|--|-------------------|
| Rat         | Dow   | <b>Male</b> | <b>Kociba</b>                         | 1.47 x 10 <sup>4</sup>                                   | B6                |
| Rat         |       |             | Squire                                | 1.73 x 10 <sup>4</sup>                                   | B7                |
| Rat         |       | Female      | Kociba - unadjusted                   | 8.98 x 10 <sup>4</sup> - 2.52 x 10 <sup>5</sup>          | B8                |
|             |       |             | - <b>adjusted</b> for<br>early deaths | 1.51 x 10 <sup>5†</sup>                                  | B8A               |
| B-20<br>Rat |       | Female      | Squire - unadjusted                   | 4.25 x 10 <sup>5</sup>                                   | B9                |
|             |       |             | - adjusted for<br>early deaths        | <b>1.61 x 10<sup>5†</sup></b>                            | B9A               |
| Rat         | NCI   | Female      | NCI - <b>Reviewed</b>                 | 3.28 x 10 <sup>4</sup>                                   | <b>B10</b>        |
| <b>Mice</b> | NCI   | Male        | NCI - Reviewed                        | 7.52 x 10 <sup>4</sup>                                   | <b>B11</b>        |
| <b>Mice</b> |       | Female      | NCI - Reviewed                        | 4.56 x 10 <sup>4</sup>                                   | B12               |

†Values used to determine geometric mean of 1.56 x 10<sup>5</sup> (mg/kg/day)<sup>-1</sup>

## APPENDIX C

### COMPARISON OF RESULTS BY VARIOUS EXTRAPOLATION MODELS

The estimate of **unit risk** from animals presented in the body of **this** document **is calculated** by the use of the linearized multistage model, for the reasons given herein. The use of **this** nonthreshold model is part of a methodology that estimates a conservative linear slope at low extrapolation doses that is usually consistent **with** the data at all dose levels in an experiment. The model holds that the most plausible upper limits of **risk** are those predicted by linear **extrapolation** to low **levels** of the dose-response **relationship**.

Other nonthreshold models that have been used for **risk** extrapolation are the one-hit, the **log-Probit**, and the **Welbull models**. The one-hit model is characterized by a continuous downward curvature, but is linear at low doses. Because of its functional form, the one-hit model can be considered the **linear** form or first stage of the multistage **model**. **This** fact, together **with** the downward curvature of the one-hit model, means that it **will** always yield low-level **risk** estimates which are at least as large as those of the multistage model. In addition, whenever the data can be fitted adequately by the one-hit model, estimates based on the one-hit model and the multistage model **will** be comparable.

The **log-Probit** and the Welbull models, because of their general **"S"** curvature, are often used for the interpretation of **toxicological** data in the observable range. The low-dose upward curvatures of these two models usually yield lower low-dose **risk** estimates than those of the one-hit or **multistage models**. The **log-Probit** model was originally used in **biological** assay problems such as potency assessments of toxicants and drugs, and is

generally used to **estimate** such values as **percentile** lethal dose or **percentile** effective dose. The **development** of the model occurred along strictly empirical lines, **i.e.**, it was observed in these studies that several log dose-response relationships followed the cumulative normal probability distribution function,  $\Phi$ . In fitting the cancer **bioassay** data, assuming an Independent background, **this** becomes

$$P(D;a,b,c) = c + (1-c) * (a + b \log_{10} D) \quad a, b > 0 < c < 1$$

where P is the proportion responding at dose **D**, c is an estimate of the background rate, a is an estimate of the standardized mean of Individual tolerances, and b is an estimate of the log **dose-Probit** response slope.

The one-hit model arises from the theory that a single **molecule** of a carcinogen has a probability of transforming a single **normal cell into** a cancer cell. It has the probability distribution function

$$P(D;a,b) = 1 - \exp(-(a+bd)) \quad a, b > 0$$

where a and b are the parameter estimates. The estimate a represents the background or zero dose rate, and the parameter estimated by b represents the linear component or slope of the dose-response model. In discussing the added **risk** over background, Incorporation of **Abbott's** correction leads to

$$P(D;b) = 1 - \exp(-bd) \quad b > 0$$

Finally, a model from the theory of **carcinogenesis** arises from the **multihit** model **applied** to **multiple** target cells. **This** model has been termed here the **Weibull** model. It is of the form

$$P(D;b,k) = 1 - \exp(-bd^k) \quad b, k > 0$$

For the power of dose only, the restriction  $k > 0$  has been placed on **this** model. When  $k > 1$ , **this** model yields low-dose estimates of risks usually significantly lower than either the multistage or one-hit models, which are

**linear** at low doses. When  $0 < k < 1$ , the model yields low-dose estimates of **risk** that are greater than the one-hit and multistage **models**; **this** is generally regarded as biologically **implausible**. All three of these models usually project **risk** estimates that are significantly higher at low exposure levels than those projected by the **log-Probit** model.

The Dow Chemical Company data for female Sprague-Dawley rats were fitted to the above models, after adjusting for early mortality by eliminating all animals dying before 1 year. The results are identical for the multistage and one-hit models, as shown in **Tables C-1** and C-2. The **log-Probit** model yielded by far the lowest estimates at low doses. The **Weibull** model yielded estimates higher (**by** two orders of magnitude) at low levels than either the one-hit or the **multistage** model, since  $k$ , determined by best **fit** to the data, is **<1**. As discussed in the text and shown in Tables B-8 and B-9, dropping the highest dose resulted in a larger upper-limit slope estimate for the multistage model. However, without the highest dose points, neither the **log-Probit** nor the Weibull models could be fitted to the data, for the reason that the control group response was higher than that of the lowest dose group.



TABLE C-1

Estimates of Low-Dose **Risk** to Humans Exposed to **2,3,7,8-TCDD** Based on Female **Sprague-Dawley** Rats  
 From the Dow Chemical Co. Feeding Study Derived from Four Different Models  
 Data - **Kociba** Analysis, Adjusting for Early Mortality (Ref. Table **B-8A**)

| Dose<br>(ng/kg/day) | Maximum Likelihood Estimates of<br>Additional Risks |                               |                       | 95% Upper Confidence Limit of<br>Additional Risks |                      |                       |
|---------------------|---|-------------------------------|-----------------------|---|----------------------|-----------------------|
|                     | Multistage/One-hit<br>Model                         | Weibull<br>Model <sup>a</sup> | Log-Probit<br>Model   | Multistage/One-hit<br>Model                       | Weibull<br>Model     | Log-Probit<br>Model   |
| 10 <sup>-5</sup>    | 1.1x10 <sup>-6</sup>                                | 1.8x10 <sup>-5</sup>          | 0                     | 1.5x10 <sup>-6</sup>                              | 9.7x10 <sup>-5</sup> | 7.7x10 <sup>-10</sup> |
| 10 <sup>-4</sup>    | 1.1x10 <sup>-5</sup>                                | 1.1x10 <sup>-4</sup>          | 1.2x10 <sup>-13</sup> | 1.5x10 <sup>-5</sup>                              | 5.3x10 <sup>-4</sup> | 3.0x10 <sup>-12</sup> |
| 10 <sup>-3</sup>    | 1.1x10 <sup>-4</sup>                                | 7.1x10 <sup>-4</sup>          | 4.9x10 <sup>-9</sup>  | 1.5x10 <sup>-4</sup>                              | 2.9x10 <sup>-3</sup> | 7.5x10 <sup>-8</sup>  |
| 10 <sup>-2</sup>    | 1.1x10 <sup>-3</sup>                                | 4.5x10 <sup>-3</sup>          | 1.7x10 <sup>-5</sup>  | 1.5x10 <sup>-3</sup>                              | 1.5x10 <sup>-2</sup> | 1.5x10 <sup>-4</sup>  |
| 10 <sup>-1</sup>    | 1.1x10 <sup>-2</sup>                                | 2.9x10 <sup>-2</sup>          | 5.2x10 <sup>-3</sup>  | 1.5x10 <sup>-2</sup>                              | 7.2x10 <sup>-2</sup> | 2.3x10 <sup>-2</sup>  |
| 1                   | 1.1x10 <sup>-1</sup>                                | 1.7x10 <sup>-1</sup>          | 1.7x10 <sup>-1</sup>  | 1.4x10 <sup>-1</sup>                              | 3.0x10 <sup>-1</sup> | 3.1x10 <sup>-1</sup>  |

<sup>a</sup>Both models gave Identical results

<sup>b</sup>The value of k, determined by best fit to the data, is <1.

Human equivalent dose (ng/kg/day):                    0            0.186            1.86            18.6  
 Animal tumors/number examined:                    9/85            3/48            18/48            34/40  
 Human equivalence conversion:                    1 ng/kg/day (oral) = 25.0 ng/m<sup>3</sup> 1n air

TABLE C-2

Estimates of Low-Dose Risk to Humans Exposed to 2,3,7,8-TCDD Based on Female Sprague-Dawley Rats  
From the Dow Chemical Co. Feeding Study Derived from Four Different Models  
Data - Squire Analysis, Adjusting for Early Mortality (Ref. Table B-9A)

| Dose<br>(ng/kg/day) | Maximum Likelihood Estimates of<br>Additional Risks |                               |                       | 95% Upper Confidence Limit of<br>Additional Risks |                      |                       |
|---------------------|---|-------------------------------|-----------------------|---|----------------------|-----------------------|
|                     | Multistage/One-hit<br>Model                         | Weibull<br>Model <sup>a</sup> | Log-ProbIt<br>Model   | Multistage/One-hit<br>Model                       | Weibull<br>Model*    | Log-ProbIt<br>Model   |
| 10 <sup>-5</sup>    | 1.1x10 <sup>-6</sup>                                | 3.0x10 <sup>-4</sup>          | 2.2x10 <sup>-12</sup> | 1.6x10 <sup>-6</sup>                              | 1.3x10 <sup>-8</sup> | 4.4x10 <sup>-10</sup> |
| 10 <sup>-4</sup>    | 1.1x10 <sup>-5</sup>                                | 1.2x10 <sup>-3</sup>          | 7.6x10 <sup>-9</sup>  | 1.6x10 <sup>-5</sup>                              | 4.4x10 <sup>-8</sup> | 1.1x10 <sup>-7</sup>  |
| 10 <sup>-3</sup>    | 1.1x10 <sup>-4</sup>                                | 4.9x10 <sup>-3</sup>          | 5.8x10 <sup>-6</sup>  | 1.6x10 <sup>-4</sup>                              | 1.5x10 <sup>-2</sup> | 5.3x10 <sup>-5</sup>  |
| 10 <sup>-2</sup>    | 1.1x10 <sup>-3</sup>                                | 2.0x10 <sup>-2</sup>          | 9.2x10 <sup>-4</sup>  | 1.6x10 <sup>-3</sup>                              | 5.1x10 <sup>-2</sup> | 5.8x10 <sup>-3</sup>  |
| 10 <sup>-1</sup>    | 1.1x10 <sup>-2</sup>                                | 7.8x10 <sup>-2</sup>          | 3.3x10 <sup>-2</sup>  | 1.6x10 <sup>-2</sup>                              | 1.6x10 <sup>-1</sup> | 1.1x10 <sup>-1</sup>  |
| 1                   | 1.1x10 <sup>-1</sup>                                | 2.8x10 <sup>-1</sup>          | 2.9x10 <sup>-1</sup>  | 1.5x10 <sup>-1</sup>                              | 4.3x10 <sup>-1</sup> | 4.8x10 <sup>-1</sup>  |

<sup>a</sup>Both models gave identical results

<sup>b</sup>The value of k, determined by best fit to the data, is <1.

|                                    |  |       |       |       |
|------------------------------------|--|-------|-------|-------|
| Human equivalent dose (ng/kg/day): | 0  | 0.186 | 1.86  | 18.6  |
| Animal tumors/number examined:     | 16/85  | 8/48  | 27/48 | 34/40 |
| Human equivalence conversion:      | 1 ng/kg/day (oral) = 25.0 ng/m <sup>3</sup> in air |       |       |       |

## APPENDIX D

A **toxicity-based risk** assessment has been **calculated** for comparison **with** the cancer-based **risk** assessment in accordance **with** the recommendations by U.S. **EPA's** Science Advisory Board.

**2,3,7,8-TCDD** is an **unusually** toxic compound **with** demonstrated acute, subacute and chronic effects in animals and humans. Acute or **subchronic** exposures to 2,3,7,8-TCDD can adversely affect the **skin**, the liver, the nervous system and the Immune system.

**2,3,7,8-TCDD** displays an unusually **high** degree of reproductive toxicity. It is **teratogenic**, **fetotoxic** and reduces fertility. In a three-generation reproductive study, Murray et al. (1979) reported a reduction in fertility after daily dosing at 0.1 or 0.01 **µg 2,3,7,8-TCDD/kg** in the **F<sub>1</sub>** and **F<sub>2</sub>** generations of Sprague-Dawley rats. Although Murray et al. (1979) considered the lowest dose tested, 0.001 **µg/kg**, to be a NOEL, a re-evaluation of these data by **Nisbet** and Paxton (1982), using different **statistical** methods, indicated that there was a reduction in the gestation index, decreased fetal weight, increased **liver** to body weight ratio, and increased incidence of dilated renal pelvis at the 0.001 **µg/kg** dose. The re-evaluated data would suggest that equivocal adverse effects were seen at the lowest dose (0.001 **µg/kg/day**) and that **this** dose should, therefore, represent a LOAEL. **Schantz** et al. (1979) found reductions in fertility and various other toxic effects in rhesus monkeys fed a 50 ppt 2,3,7,8-TCDD **diet** for 20 months. **This** corresponds to a calculated daily dose of 0.0015 **µg 2,3,7,8-TCDD/kg/day**. These results suggest that monkeys may be somewhat more sensitive than rats, since the effects **in** monkeys were more severe and not equivocal.

A **toxicity-based** criterion has been **calculated** for comparison **with** the cancer-based criterion in accordance **with** public comments. Since the data from the limited study by **Schantz et al.** (1979) are supportive of the findings by Murray et al. (1979), it seems reasonable to determine an ADI based on the LOAEL. If one selects an uncertainty factor of 100 based on the existence of lifetime animal studies and knowledge of effects in man as per U.S. EPA methodologies (**Federal Register, 1980b**), and then an additional 10 because a LOAEL is used as the basis of **this calculation,\*** then the ADI for a 70 kg man would be:

$$\text{ADI} = \frac{10^{-9} \text{ yg/kg/day (LOAEL)}}{100 \times 10} = 7.0 \times 10^{-5} \text{ yg/kg/day.}$$

However, **this** concentration may not be sufficiently protective of human health since it does not take **into** account the demonstrated carcinogenic effects of **2,3,7,8-TCDD** in animals and the probability that **2,3,7,8-TCDD is** a human carcinogen as discussed in Section 11.6.1.

---

\*According to the methods published by U.S. EPA (Federal Register, 1980b), an additional uncertainty factor between 1 and 10 must be used because the calculation is based on a LOAEL. An uncertainty factor of 10 was chosen because of the adverse effects seen in rhesus monkeys at 0.0015 yg/kg/day, despite the equivocal nature of the effects **in** rats seen at the 0.001 yg/kg/day dose level.